UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/499,725	10/12/2021	Nathaniel T. Bradley	DHP-P0001CIP1	9953

133690 7590 06/05/2026

Goodhue, Coleman & Owens, P.C.
7300 Westown Parkway, Suite 110
West Des Moines, IA 50266

EXAMINER	
RAAB, CHRISTOPHER J	

ART UNIT	PAPER NUMBER
2156	

NOTIFICATION DATE	DELIVERY MODE
06/05/2026	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USPTO@dockettrak.com
docketing@goodhue.com
eofficeaction@appcoll.com

Advisory Action Before the Filing of an Appeal Brief	**Application No.** 17/499,725	**Applicant(s)** Bradley et al.	
	Examiner CHRISTOPHER J RAAB	**Art Unit** 2156	**AIA (First Inventor to File) Status** No

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 26 May 2026 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.

NO NOTICE OF APPEAL FILED

1. ☑ The reply was filed after a final rejection. No Notice of Appeal has been filed. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114 if this is a utility or plant application. Note that RCEs are not permitted in design applications. The reply must be filed within one of the following time periods:
   a) ☑ The period for reply expires 3 months from the mailing date of the final rejection.
   b) ☐ The period for reply expires on: (1) the mailing date of this Advisory Action; or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.
   c) ☐ A prior Advisory Action was mailed more than 3 months after the mailing date of the final rejection in response to a first after-final reply filed within 2 months of the mailing date of the final rejection.The current period for reply expires ____ months from the mailing date of *the prior Advisory Action* or SIX MONTHS from the mailing date of the final rejection, whichever is earlier.
   Examiner Note: If box 1 is checked, check either box (a), (b) or (c). ONLY CHECK BOX (b) WHEN THIS ADVISORY ACTION IS THE FIRST RESPONSE TO APPLICANTS FIRST AFTER-FINAL REPLY WHICH WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. ONLY CHECK BOX (c) IN THE LIMITED SITUATION SET FORTH UNDER BOX (c). See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) or (c) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

NOTICE OF APPEAL

2. ☐ The Notice of Appeal was filed on _____. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37CFR 41.37(a).

AMENDMENTS

3. ☐ The proposed amendments filed after a final rejection, but prior to the date of filing a brief, will not be entered because
   a) ☐ They raise new issues that would require further consideration and/or search (see NOTE below);
   b) ☐ They raise the issue of new matter (see NOTE below);
   c) ☐ They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
   d) ☐ They present additional claims without canceling a corresponding number of finally rejected claims.
   NOTE: _____ (See 37 CFR 1.116 and 41.33(a)).
4. ☐ The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).
5. ☐ Applicant's reply has overcome the following rejection(s): _____
6. ☐ Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
7. ☐ For purposes of appeal, the proposed amendment(s):(a)☐will not be entered; or (b)☐will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.

AFFIDAVIT OR OTHER EVIDENCE

8. ☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____
9. ☐ The affidavit or other evidence filed after final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).
10. ☐ The affidavit or other evidence filed after the date of filing the Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing of good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).
11. ☐ The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.

REQUEST FOR RECONSIDERATION/OTHER

12. ☑ The request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.
13. ☐ Note the attached Information *Disclosure Statement*(s). (PTO/SB/08) Paper No(s). _____
14. ☐ Other: _____.

STATUS OF CLAIMS

15. The status of the claim(s) is (or will be) as follows:
    Claim(s) allowed:_____.
    Claim(s) objected to:_____.
    Claim(s) rejected:1-20.
    Claim(s) withdrawn from consideration:_____.

/CHRISTOPHER J RAAB/ Primary Examiner, Art Unit 2156	

Continuation of REQUEST FOR RECONSIDERATION/OTHER 12. The request for reconsideration has been considered but does NOT place the application in condition for allowance because: Applicant argues that Douglas does not teach “assigning each of the clients to one or more of the providers by the server in response to selections from the administrator”. The argument presented by Applicant is that the claims allow for “computer-implemented workflow in which a server programmatically assigns clients to providers in response to discrete selection inputs received from an identified administrator user”, and that the “claim recites a specific server-driven assignment mechanism that links to the downstream automated functions of the claim”. First off, this is a much narrower and more specific embodiment than that which is claimed. The claim merely recites that clients are assigned to providers in response to selections from an administrator. It appears to Examiner that Applicant is arguing that the server is some complex system that is capable of decision making on its own and that the assigning is done by some type of smart system . However, the claims do not appear to recite such an embodiment. Additionally, the assigning is specifically claimed as being done “in response to selections from an administrator”. Given the broadest reasonable interpretation, these selections could simply be the assignments that the administrator wants, and then the system simply allows for them to happen. There is no specific claim language that explains what the selections are, how they affect the system, or what specific actions a server takes and whether or not they can be done on its own.

Applicant argues that the biometric devices are “members of the providers set” and are not “independent measurement instruments”. It is not clear to Examiner what the argument is here exactly. Based on the specification, the biometric devices appear to be physical devices that can be used to monitor a user’s health, such as a smart watch, hearing aid, etc. This is explained in paragraph [0204], and does not appear to be further defined in the specification beyond this rather generic definition. Regardless, it is unclear to Examiner what is means that the biometric devices are providers, at least beyond what paragraph [0204] explains them to be. Based on a reading of the claim language, it follows that a provider is a person (individual) that has biometric devices that can be given to clients. Furthermore, the specification does not appear to disclose that the biometric devices can be “assigned” to clients, but rather just appear to be sensors that a client some how gets and can use. Examiner requests Applicant to provide specific recitations from the specification that explain how a biometric device is a provider, meaning that it is not simply “wearable biometric devices that generate and transmit patient data”, as well as how these biometric devices are assigned to clients.

Applicant argues that Douglas does not teach “goals”, “a baseline for each of the clients”, and “thresholds associated with each of the goals”. Examiner respectfully disagrees. The main argument by Applicant is that the “goals and milestones” taught by Douglas are generic and not patient specific. First off, the claims do not appear to make this distinction, as the claims simply recite that goals and a baseline are established, which are not specifically recited as being tailored to specific clients. Regardless, Douglas teaches that initial patient characteristics are input, such as age, sex, weight, etc. (page 8 lines 1 – 9, Fig. 5), and that the physician determines the goals for the patient (page 8 lines 8 – 11, Fig. 6), which can be a final goal, a 1 month goal, etc. These different goals are specifically assigned to the patients and are based on their current or initial readings. For example, a 1 month goal for a patient may be to weigh 175 pounds, down from 182 pounds, which is clearly not a generic goal assigned to all patients, as not all patients weight 182 pounds at the start or are on the system to lose weight. Therefore Douglas teaches the Applicant’s claimed goals, baseline, and thresholds.

Applicant argues that Douglas and Stenquist do not disclose “automatically compiling, via the server, data associated with each of the clients received from the one or more providers including at least the one or more biometric devices in the server”. With respect to this claim limitation, Applicant argues that the prior art does not teach “server-side automatic aggregation of streaming or periodic data”. However, this specific embodiment is not found in the claim language. Instead, the claim recites the automatic compiling of the received data. Douglas teaches that data is input into the system via different means, and

specifically that is can be done via the biometric sensors. Page 10 lines 10 – 19 and page 20 lines 3 – 34 of Douglas explain how computing devices are used to collect data and then have it stored in the database. Figures 40 – 45 further show how the data is compiled as it collects data over time and is put into various fields, charts, and graphs. Therefore Douglas is understood to teach the aforementioned claim limitation.

Applicant argues that Douglas does not teach "determining whether the goals are being met in response to the baseline and the thresholds for the compiled data". Examiner respectfully disagrees. As previously explained, Douglas teaches that patient data is compared with the goals and parameters residing in the system's database, such that the system can periodically correlate updates to patient health information with the program goals to determine patient progress and compliance (page 11 line 6 – page 12 line 2, Fig . 5, 6, 60). As defined in the Applicant's specification, the baseline is the initial data or evaluation of a patient, which is the same thing Douglas does, as the patient necessarily has to be evaluated in order to determine their state and to develop the program. Although Douglas does not use the specific term of " threshold", the progress of the patient is monitored to make sure it complies with the different steps of the program, which is the same as the claimed thresholds in the Applicant's claims.

Applicant argues that Douglas does not teach "automatically communicating alerts as manage by the server in response to the compiled data varying from one of the thresholds to become significant". Examiner respectfully disagrees. The main argument presented by Applicant appears to stem from the previous argument with respect to goals, baseline, and thresholds. This has been addressed above with respect to those claim limitations. Applicant further argues that Douglas only teaches a general alarm that is not tied to any compiled data. However, Douglas specifically teaches that the alarm is triggered in response to the compiled data varying from the goals (page 11 lines 11 – 17, Fig. 60), and is not limited to a general significance alarm. Therefore, Douglas teaches that the alarm can be triggered based on the compiled data varying from a certain point, which reads on the Applicant's aforementioned claim limitation.

Applicant argues that the combination of Douglas and Stenquist is invalid and states that there is no supporting rational or motivation to combined their teachings. Examiner respectfully disagrees. Douglas teaches a patient monitoring system that uses patient health data in order to manage the patient, ensure they are making progress, and allows for physicians to intervene in order to help patients when their health/data meets a certain criteria. Stenquist, being in the same field of endeavor, allows for health data to be obtained for a patient, which specifically allows for the data to be compiled, which can then be used to trigger a initiation of an emergency call for health personnel to intervene. This makes it clear that both Douglas and Stenquist provide for one of the exact same features, namely the ability of health professionals to be able to intervene in order to help patients, due to posed health risks or problems. Contrary to the Applicant's remarks, both Douglas and Stenquist aim to solve very similar problems and are hence directed towards the same technology or field of endeavor.

OK TO ENTER: /C.J.R/

Attorney Docket No.
DHP-P0001CIP1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of: Bradley et al. **Application No.** 17/499,725 **Filing Date:** October 12, 2021 **For:** SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	**Confirmation No.** 9953 **Group Art Unit:** 2156 **Examiner:** Christopher J RAAB

AMENDMENT AFTER FINAL UNDER 37 C.F.R. § 1.116

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

VIA PATENT CENTER

Commissioner:

In reply to the Final Office Action mailed March 24, 2026, please consider the following remarks in the above-identified application. No amendments to the claims are being made; the claims as currently presented (Claims 1 – 20) remain pending and under examination.

Attorney Docket No.
DHP-P0001CIP1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of: Bradley et al. **Application No.** 17/499,725 **Filing Date:** October 12, 2021 **For:** SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	**Confirmation No.** 9953 **Group Art Unit:** 2156 **Examiner:** Christopher J RAAB

AMENDMENT AFTER FINAL UNDER 37 C.F.R. § 1.116

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

VIA PATENT CENTER

Commissioner:

In reply to the Final Office Action mailed March 24, 2026, please consider the following remarks in the above-identified application. No amendments to the claims are being made; the claims as currently presented (Claims 1 – 20) remain pending and under examination.

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

Claim 1 (Previously presented): A method for tracking goal progression, the method comprising:

receiving input establishing clients, wherein the clients are individuals receiving treatment or assistance, and wherein the data associated with the clients is stored in a server available through one or more networks;

assigning each of the clients to one or more of the providers by the server in response to selections from an administrator, wherein the one or more providers include at least 1) individuals available to treat or assist each of the clients and 2) one or more biometric devices assigned to and worn by each of the clients;

establishing goals and a baseline for each of the clients and thresholds associated with each of the goals;

automatically compiling, via the server, data associated with each of the clients received from the one or more providers including at least the one or more biometric devices in the server;

determining whether the goals are being met in response to the baseline and the thresholds for the compiled data; and

automatically communicating alerts as managed by the server in response to the compiled data varying from one of the thresholds to become significant for one or more of the clients.

Claim 2 (Original): The method according to claim 1, wherein the server is accessed through a

cloud network, and wherein a client management program is executed by communications devices utilized by the one or more providers to receive the data and track progress of the goals.

Claim 3 (Original): The method according to claim 1, further comprising:

intervening with the one or more of the clients in response to the alerts.

Claim 4 (Original): The method according to claim 3, wherein the intervening is performed by the one or more providers.

Claim 5 (Original): The method according to claim 1, wherein each of the goals is associated with a plan of action for achieving each of the goals.

Claim 6 (Original): The method according to claim 1, further comprising:

establishing a baseline for the goals of the clients.

Claim 7 (Original): The method according to claim 1, wherein the goals are established by the clients and the one or more providers.

Claim 8 (Original): The method according to claim 1, further comprising:

determining whether modifications to the goals are required in response to the compiled data.

Claim 9 (Original): The method according to claim 8, further comprising:

modifying the goals in response to the compiled data.

Claim 10 (Original): The method according to claim 8, wherein modifications are determined to be required if the one of the clients is unable to achieve the goals associated with the client.

Claim 11 (Previously presented): A system for tracking goal progression, the system comprising:

a server communicates with communications devices through a transceiver utilizing one or more networks, the server includes a processor that executes a client management program to:

receive input establishing a client, wherein the client is an individual receiving treatment or assistance, and wherein an account associated with the client is stored in a server available through one or more networks;

assign the client to one or more of the providers in response to selections from an administrator, wherein the one or more providers include at least 1) individuals available to treat or assist the client and 2) one or more biometric devices assigned to and worn by the client;

establish goals and a baseline for the client and thresholds associated with each of the goals;

automatically compile data associated with the client received from the one or more providers including at least the one or more biometric devices in the server;

determine whether the goals are being met in response to thresholds for the compiled data; and

automatically communicate alerts as managed by the server in response to the compiled data varying from one of the thresholds to become significant for the client; and

a database in communication with the server configured to store at least the data, goals, and thresholds associated with the client and the one or more providers.

Claim 12 (Original): The system according to claim 11, wherein the communications devices receive the data from the one or more providers.

Claim 13 (Original): The system according to claim 11, wherein the alerts indicate that the one or more providers are to intervene with the client.

Claim 14 (Original): The system according to claim 11, wherein each of the goals is associated with a plan of action for achieving each of the goals.

Claim 15 (Original): The system according to claim 11, wherein the goals are established by the client and the one or more providers.

Claim 16 (Original): The system according to claim 11, wherein the client management program is further executed to:

determine whether modifications to the goals are required in response to the compiled data indicating the goals are not achievable; and

modify the goals in response to the compiled data indicating the goals are not achievable.

Claim 17 (Previously presented): A server comprising:

a processor for executing a set of instructions; and

a memory for storing the set of instructions, wherein the set of instructions are executed by the processor to:

receive input establishing clients receiving assistance, wherein the clients are individuals receiving treatment or assistance, and wherein the accounts are stored in a server available through one or more networks;

assign each of the clients to one or more of the providers in response to selections from an administrator, wherein the one or more providers include at least 1) individuals available to treat or assist each of the clients and 2) one or more biometric devices associated with and worn by each of the clients;

establish goals and a baseline for each of the clients and thresholds associated with each of the goals;

automatically compile data associated with each of the clients received from the one or more providers including at least the one or more biometric devices in the server;

determine whether the goals are being met in response to the baseline and thresholds for the compiled data; and

automatically communicate alerts as managed by the server in response to the compiled data varying from one of the thresholds to become significant for one or more of the clients.

Claim 18 (Original): The server according to claim 17, wherein the set of instructions are further executed to:

physically intervene with the one or more of the clients in response to the alerts, wherein the physical intervention is performed by the one or more providers.

Claim 19 (Original): The server according to claim 17, wherein each of the goals is associated with a plan of action for achieving each of the goals, wherein the goals are established by the client and the one or more providers.

Claim 20 (Previously presented): The server according to claim 17, wherein the set of instructions are further executed to:

determine whether modifications to the goals are required in response to the compiled data; and

modify the goals in response to determining the modifications to the goals are required.

REMARKS

In the Final Office Action, the Examiner took the following actions:

I. Claims 1 – 20 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1 – 20 of U.S. Patent No. 10,061,812 in view of Stenquist (US PGPub 2010/0048159);

II. Claims 1 and 3 – 20 are rejected under 35 U.S.C. § 103 as being unpatentable over Douglas et al. (WO 99/03045), hereinafter "Douglas," in view of Stenquist (US PGPub 2010/0048159), hereinafter "Stenquist"; and

III. Claim 2 is rejected under 35 U.S.C. § 103 as being unpatentable over Douglas in view of Stenquist, in further view of Chitiveli (US PGPub 2013/0179450), hereinafter "Chitiveli."

The Office Action may contain statements characterizing the related art and/or the claims. Regardless of whether any such statement is expressly identified and/or discussed herein, Applicant reserves the right to disagree with any such statement or characterization in the Office Act ion.

Applicant respectfully notes that the prior rejection of Claims 1 – 20 under 35 U.S.C. § 112(a) has been withdrawn, and thanks the Examiner for that consideration. Claims 1 – 20 remain pending and under examination. For at least the following reasons, Applicant respectfully requests reconsideration and withdrawal of the remaining rejections, and entry of these Remarks under 37 C.F.R. § 1.116.

Status of the Claims

Claims 1 – 20 are pending. No amendments are being submitted at this time. Claim 1, Claim 11, and Claim 17 stand as previously presented, and Claims 2 – 10, 12 – 16, and 18 – 20 stand as originally filed.

Response to Examiner's General Comments

The Examiner notes (Office Action, p. 2) that Applicant's prior arguments addressed the same claim limitations addressed in earlier actions, and respectfully requests Applicant to "narrow down" the specific arguments. Applicant respectfully appreciates the Examiner's guidance and addresses each rejection below with point-specific argument tied to particular claim language, particular passages of the cited references, and particular deficiencies in the Office Action's element mapping.

Applicant further notes that the Examiner has now agreed that Douglas does not teach biometric devices that are worn by the clients (Office Action, p. 3). The Office Action relies on Stenquist solely to fill that single limitation. As shown below, however, the limitations of Claim 1 that Douglas was previously cited to teach included substantially more than the "worn by" element alone, and the gaps in Douglas's disclosure of those other elements are not cured by Stenquist or by Chitiveli.

Double Patenting

Claims 1 – 20 stand rejected on the ground of nonstatutory obviousness-type double patenting over claims 1 – 20 of U.S. Patent No. 10,061,812 in view of Stenquist. Applicant remains willing to submit a terminal disclaimer in compliance with 37 C.F.R. § 1.321(c) if and when allowable claims are reached. The terminal disclaimer will be filed at the time the remaining rejections are resolved.

Applicant respectfully notes that, although a terminal disclaimer may be used to overcome the double patenting ground, the underlying patentability of the pending claims is independently maintained for the reasons set forth below with respect to the § 103 rejection. Resolution of the § 103 rejection in Applicant's favor will provide the predicate for the terminal disclaimer.

Claim Rejections – 35 U.S.C. § 103 (Claims 1 and 3 – 20 over Douglas in view of Stenquist)

Claims 1 and 3 – 20 are rejected under 35 U.S.C. § 103 as being unpatentable over Douglas in view of Stenquist. This rejection is respectfully traversed.

The Office Action relies on Douglas as teaching all elements of Claim 1 except "one or more biometric devices assigned to and worn by each of the clients," and relies on Stenquist (paragraphs [0054], [0055]) solely to teach that biometric devices are "assigned to and worn by" patients. Applicant respectfully submits that, even granting Stenquist's wearable biometric devices in arguendo, the proposed combination does not disclose or render obvious each element of Claim 1, and the Office Action's articulated motivation to combine is not supported by rational underpinning.

A. Douglas, even as modified by Stenquist, does not disclose "assigning each of the clients to one or more of the providers by the server in response to selections from an administrator."

Claim 1 recites that the SERVER performs the assignment, and that the assignment occurs IN RESPONSE TO selections from an ADMINISTRATOR. These are two distinct functional requirements. The Office Action maps this limitation to Douglas, page 11, line 6 – page 12, line 2, where "patients are assigned to physicians, wherein the physicians are able to provide help and treatment to the patients." Applicant respectfully submits that the cited passage describes a conventional clinical association between a patient and a treating physician. It does not disclose any computer-implemented workflow in which a server programmatically assigns clients to providers in response to discrete selection inputs received from an identified administrator user.

This distinction is not a matter of wording. The claim recites a specific server-driven assignment mechanism that links to the downstream automated functions of the claim, including compiling data from the assigned providers and monitoring threshold deviations for the assigned clients. Douglas's description of conventional physician–patient assignments does not disclose this server-mediated workflow, and Stenquist does not teach it either. Neither reference, alone or in combination, discloses an administrator interface for selecting provider–client assignments, nor server-side logic that performs those assignments in response to such administrator input.

B. Douglas, even as modified by Stenquist, does not disclose providers that include both "individuals available to treat or assist each of the clients" and "one or more biometric devices assigned to and worn by each of the clients."

Claim 1 recites that "the one or more providers include at least 1) individuals available to treat or assist each of the clients and 2) one or more biometric devices assigned to and worn by each of the clients." The plain language of this language treats biometric devices as members of the "providers" set — not as independent measurement instruments and not as data sources separate from providers. Both "individuals" and "biometric devices" are recited as types of "providers."

Stenquist, as characterized by the Office Action, discloses that "patients are provided with biometric devices that they wear, which provide biometric patient data that can be sent to a server for monitoring" (Office Action, p. 13; Stenquist [0054], [0055]). Stenquist therefore discloses wearable biometric devices that generate and transmit patient data. Stenquist does not, however, disclose treating those biometric devices as members of a "providers" entity that also includes individual treating personnel and that is assigned, as a unit, to particular clients via server logic responsive to administrator selections.

Douglas, in turn, describes physicians and clinical staff as providers but uses medical devices as measurement instruments rather than as members of the "providers" group. The Office Action's combination places Stenquist's wearable devices into Douglas's system as data sources, which is the function for which Stenquist is cited. The Office Action has not identified, and the references do not disclose, any teaching that a wearable biometric device functions as a "provider" alongside human treating personnel, and is "assigned" to a client in the same manner as those personnel. Applicant's claim recites that specific dual-membership "providers" architecture, and the proposed combination does not reach it.

C. Douglas, even as modified by Stenquist, does not disclose the recited combination of "goals," a "baseline for each of the clients," and "thresholds associated with each of the goals."

Claim 1 recites three distinct, related concepts: (i) a baseline for each client, (ii) goals for each client, and (iii) thresholds associated with each goal. The thresholds are tied to specific goals, not to clients generally and not to data values generally. The Office Action maps the entire limitation to Douglas, page 7, line 29 – page 8, line 9, characterizing it as describing "goals and milestones [that] are generated for the patients, which can be modified and updated as needed" (Office Action, p. 12).

Applicant respectfully submits that "goals and milestones" do not disclose the recited three-part structure. The cited Douglas passage does not describe a per-client baseline as a distinct anchor for evaluation; it does not describe thresholds at all; and it certainly does not describe thresholds as being "associated with each of the goals." Stenquist does not disclose this structure either; the Office Action does not cite Stenquist for any element other than the wearable biometric device. Accordingly, even in combination, the references fail to disclose this limitation as recited.

D. Douglas, even as modified by Stenquist, does not disclose "automatically compiling, via the server, data associated with each of the clients received from the one or more providers including at least the one or more biometric devices in the server."

Claim 1 requires automatic compilation, by the server, of client-associated data received from the providers. The data must include data from the biometric devices, and the providers from which data is received must include those biometric devices. The Office Action maps this limitation to Douglas, page 20, lines 3 – 34, where "a patient's characteristics, such as vitals and progress towards goals, are determined, such that updated information about the patients is managed, including a patient's vitals" (Office Action, p. 12).

Determining a patient's characteristics, and managing updated information, is not the same as automatically compiling, via the server, data received from a defined set of providers that includes wearable biometric devices. Douglas describes a clinical record-keeping function. It

does not disclose server-side automatic aggregation of streaming or periodic data from wearable biometric devices that are themselves members of the "providers" set. Stenquist discloses that biometric data "can be sent to a server for monitoring" but is cited only for the wearing of the device, not for the server-side automatic compilation of data from that device alongside data from human providers. The combination, as articulated, therefore does not disclose the recited automatic compilation step.

E. Douglas, even as modified by Stenquist, does not disclose "determining whether the goals are being met in response to the baseline and the thresholds for the compiled data."

Claim 1 recites a specific evaluation step in which goal satisfaction is determined as a function of both the baseline and the thresholds, operating on the compiled data. The Office Action maps this limitation to Douglas, page 11, line 8 – page 12, line 2, where "patient progress is monitored with respect to the goals, which includes determining if a certain level of progress is being made by the patient" (Office Action, p. 12).

Monitoring patient progress and "determining if a certain level of progress is being made" does not disclose the claimed two-input determination. The Douglas passage describes a general progress-monitoring function. It does not disclose that the determination is made "in response to" both the baseline and the thresholds — a determination that requires the prior establishment of both a baseline and threshold values tied to specific goals, neither of which is taught in the cited Douglas passages as discussed in Section C above. Stenquist does not address goal determination at all. The recited limitation is therefore absent from the combination.

F. Douglas, even as modified by Stenquist, does not disclose "automatically communicating alerts as managed by the server in response to the compiled data varying from one of the thresholds to become significant."

Claim 1 recites alerts that are (i) automatically communicated, (ii) managed by the server, and (iii) triggered in response to the compiled data varying from one of the thresholds to become significant. The Office Action maps this limitation to Douglas, page 11, lines 11 – 15, where "an

alarm can be triggered in response to patient data being significant, such as posing a health risk" (Office Action, p. 12).

The Douglas passage describes an alarm triggered by significance generally. It does not disclose that the alert is triggered specifically in response to the compiled data varying from one of the thresholds. Without the threshold structure of Section C above, the recited "vary from one of the thresholds to become significant" trigger is not present. A general "significance" alarm based on a health risk is not the same as a server-managed threshold-deviation alert; the former is open-ended, while the latter is keyed to predefined threshold values associated with established goals. Stenquist does not address the alert mechanism, the threshold logic, or the conditional triggering at all. The combination therefore does not disclose the limitation as recited.

G. The proposed combination of Douglas and Stenquist lacks rational underpinning.

The Office Action's articulated motivation is that it "would have been obvious to one of ordinary skill in the art … to incorporate the worn biometric devices taught by Stenquist into the patient monitoring system taught by Douglas for the purpose of allowing patient data to be obtained quicker and more efficiently, so that the data can be obtained by and reviewed either automatically or by doctors, so they a patient's health can be more accurately determined, which would lead to the ability to intervene quicker in the event the patient needs medical care" (Office Action, pp. 13 – 14).

Applicant respectfully submits that this rationale is a generic, results-based justification of the type cautioned against under *KSR International Co. v. Teleflex Inc.*, 550 U.S. 398, 418 (2007) and MPEP § 2143. The stated rationale (faster, more efficient data; quicker intervention) describes a desirable outcome, not a specific teaching, suggestion, or design problem that would have led a person of ordinary skill in the art to modify Douglas's provider-centric clinical records and assignment system by incorporating wearable biometric devices and treating those devices as members of the "providers" group. Notably, the Office Action's articulated motivation does not address why a person of ordinary skill in the art would have integrated wearable devices into the specific server-driven assignment and compilation architecture recited

in Claim 1, which is materially more than substitution of a wearable sensor for a clinical measurement.

H. The ordered combination of Claim 1 is not disclosed by Douglas and Stenquist.

Obviousness analysis must consider the claim "as a whole," including the recited order and interrelationship of steps. The pending Claim 1 recites an integrated, server-driven architecture in which the server: (i) receives input establishing clients; (ii) assigns clients to providers (including wearable biometric devices) in response to administrator selections; (iii) establishes goals, baselines, and per-goal thresholds; (iv) automatically compiles data from the assigned providers, including the wearable devices; (v) determines goal satisfaction by reference to the baseline and the thresholds; and (vi) automatically communicates threshold-triggered alerts. Each downstream step depends on the prior establishment of the assignment, the baseline, and the threshold-per-goal structure.

Douglas describes a provider-centric clinical and case-management system; Stenquist describes wearable biometric devices that send data to a server for monitoring. Neither, alone or in combination, discloses the recited integrated, server-driven architecture in the recited order and interrelationship. Combining the two as the Office Action proposes does not produce the claimed system; it produces, at best, Douglas with wearable sensors added as additional data sources, which is not what the claim recites.

I. The dependent claims and parallel independent claims are independently allowable.

Claims 3 – 10 depend, directly or indirectly, from Claim 1. Claims 12 – 16 depend from Claim 11. Claims 18 – 20 depend from Claim 17. Claims 11 and 17 recite limitations substantially parallel to those of Claim 1 in system and server form. Because Claim 1, Claim 11, and Claim 17 are patentable for at least the foregoing reasons, the dependent claims are likewise patentable. The Office Action has not identified any teaching in Douglas or Stenquist that, when added to the deficient combination addressed in Sections A – H above, cures those deficiencies.

For at least the foregoing reasons, the rejection of Claims 1 and 3 – 20 under 35 U.S.C. § 103 over Douglas in view of Stenquist is respectfully traversed, and withdrawal of the rejection is respectfully requested.

Claim Rejections – 35 U.S.C. § 103 (Claim 2 over Douglas, Stenquist, and Chitiveli)

Claim 2 is rejected under 35 U.S.C. § 103 as being unpatentable over Douglas in view of Stenquist, in further view of Chitiveli. The Office Action relies on Chitiveli (paragraphs [0031], [0032]) for the cloud network limitation of Claim 2.

Applicant respectfully traverses this rejection. Claim 2 depends from Claim 1 and incorporates all of the limitations of Claim 1. The Office Action does not rely on Chitiveli for any limitation of Claim 1, and Chitiveli's disclosure of a cloud-accessed server does not cure the deficiencies of Douglas and Stenquist with respect to Claim 1 as set forth in Sections A through H above. Because Claim 1 is patentable, Claim 2 is patentable for at least the same reasons, and is further patentable based on its additional limitations.

For at least the foregoing reasons, the rejection of Claim 2 under 35 U.S.C. § 103 over Douglas in view of Stenquist, in further view of Chitiveli, is respectfully traversed, and withdrawal of the rejection is respectfully requested.

CONCLUSION

In view of the foregoing, Applicant respectfully requests reconsideration of this application, entry of these Remarks under 37 C.F.R. § 1.116, and the timely allowance of the pending claims. As stated above, Applicant remains willing to submit a terminal disclaimer in compliance with 37 C.F.R. § 1.321(c) once allowable claims are reached, to dispose of the double patenting rejection. Applicant respectfully requests an interview with the Examiner at the Examiner's convenience to advance prosecution.

This is a request for any necessary extension of time, the small entity fee for which is being paid at the time of filing this response. No additional fees are believed due; however, the Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, to fees to Deposit Account 506801.

Respectfully submitted,

Goodhue, Coleman & Owens, P.C.

Dated: May 26, 2026

By: /Brian D. Owens/
Brian Dean Owens
Reg. No. 55,517
(515) 218-7888

UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
17/499,725	**05/26/2026 05:41:48 PM Z ET**	**DHP-P0001CIP1**

Title of Invention

SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	-
CONFIRMATION #	9953	FILED BY	Ashlyn Nguyen
PATENT CENTER #	76677610	FILING DATE	10/12/2021
CUSTOMER #	133690	FIRST NAMED INVENTOR	Nathaniel T. Bradley
CORRESPONDENCE ADDRESS	-	AUTHORIZED BY	Brian Owens

Documents

TOTAL DOCUMENTS: 3

DOCUMENT		PAGES	DESCRIPTION	SIZE (KB)
DHP-P0001CIP1_17499725_FINAL-OFFICE-ACTION_FILED-RESPONSE_5-26-26.pdf		17	-	281 KB
DHP-P0001CIP1_17499725_FINAL-OFFICE-ACTION_FILED-RESPONSE_5-26-26-A.NE.pdf	(1-1)	1	Response After Final Action	135 KB
DHP-P0001CIP1_17499725_FINAL-OFFICE-ACTION_FILED-	(2-7)	6	Claims	143 KB

RESPONSE_5-26-26-CLM.pdf				
DHP-P0001CIP1_17499725_FINAL-OFFICE-ACTION_FILED-RESPONSE_5-26-26-REM.pdf	(8-17)	10	Applicant Arguments/Remarks Made in an Amendment	266 KB

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)
DHP-P0001CIP1_17499725_FINAL-OFFICE-ACTION_FILED-RESPONSE_5-26-26.pdf	4B77CF395E9710E63B375D90A2CF681BB0C1AEA7D4D4071431E246822BF898C9008E4D40095F8932E323C6D9DCF01D72675E91F7868A7CFAFD360C51A23C8C2B
DHP-P0001CIP1_17499725_FINAL-OFFICE-ACTION_FILED-RESPONSE_5-26-26-A.NE.pdf	AE83ED5AD49219BFB937B9B67740C2441A3905849CE65B0EC0310A4719E394FA33B8BDDF18884FC7DD8F838B1102F5E488D7E4BFDA22FB875ECB1D52DDA21211
DHP-P0001CIP1_17499725_FINAL-OFFICE-ACTION_FILED-RESPONSE_5-26-26-CLM.pdf	B0A38D9E2CAB6DEB3E93453FC900361136D35FEDDA1D2E1313F485DFCAFC7E4C9A2F4874587B0748B61EA9875BE2678E0AA583F5670DE014F432A347B453AAB3
DHP-P0001CIP1_17499725_FINAL-OFFICE-ACTION_FILED-RESPONSE_5-26-26-REM.pdf	F9023B88A1DB529E0B81CA54515E6991DAD7F7D00836F1CF898FB5DA4AC5FF91AEB8A41017171F169212396E0DE9B9744B37FCD8E08E19E2A6994275805CD861

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security,

and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875	Application or Docket Number 17/499,725	Filing Date 10/12/2021	☐ To be Mailed

ENTITY: ☐ LARGE ☑ SMALL ☐ MICRO

APPLICATION AS FILED - PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA		RATE ($)	FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A		N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A		N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A		N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*		x $50 =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*		x $240 =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).				
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))					
* If the difference in column 1 is less than zero, enter "0" in column 2.				TOTAL	

APPLICATION AS AMENDED - PART II

		(Column 1)		(Column 2)	(Column 3)			
AMENDMENT	05/26/2026	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	* 20	Minus	** 20	= 0		x $80 =	0
	Independent (37 CFR 1.16(h))	* 3	Minus	*** 3	= 0		x $240 =	0
	☐ Application Size Fee (37 CFR 1.16(s))							
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							
							TOTAL ADD'L FEE	0

		(Column 1)		(Column 2)	(Column 3)			
AMENDMENT		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	*	Minus	**	=		x $0 =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=		x $0 =	
	☐ Application Size Fee (37 CFR 1.16(s))							
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							
							TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.	LIE
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".	/ROSS W BROWN/
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".	
The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.	

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/499,725	10/12/2021	Nathaniel T. Bradley	DHP-P0001CIP1	9953

133690 7590 03/24/2026

Goodhue, Coleman & Owens, P.C.
7300 Westown Parkway, Suite 110
West Des Moines, IA 50266

EXAMINER	
RAAB, CHRISTOPHER J	

ART UNIT	PAPER NUMBER
2156	

NOTIFICATION DATE	DELIVERY MODE
03/24/2026	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USPTO@dockettrak.com
docketing@goodhue.com
eofficeaction@appcoll.com

Office Action Summary	Application No. 17/499,725	Applicant(s) Bradley et al.	
	Examiner CHRISTOPHER J RAAB	Art Unit 2156	AIA (First Inventor to File) Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTHS FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☑ Responsive to communication(s) filed on 02/04/2026.

☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2a)☑ This action is **FINAL.** 2b) ☐ This action is non-final.

3)☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

4)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims*

5) ☑ Claim(s) 1-20 is/are pending in the application.

5a) Of the above claim(s) _____ is/are withdrawn from consideration.

6) ☐ Claim(s) _____ is/are allowed.

7) ☑ Claim(s) 1-20 is/are rejected.

8) ☐ Claim(s) _____ is/are objected to.

9) ☐ Claim(s) _____ are subject to restriction and/or election requirement

* If any claims have been determined allowable, you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to **PPHfeedback@uspto.gov.**

Application Papers

10)☐ The specification is objected to by the Examiner.

11)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

a)☐ All b)☐ Some** c)☐ None of the:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

** See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☑ Notice of References Cited (PTO-892)

2) ☐ Information Disclosure Statement(s) (PTO/SB/08a and/or PTO/SB/08b) Paper No(s)/Mail Date _____.

3) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date _____.

4) ☐ Other: _____.

DETAILED ACTION

Notice of Pre-AIA or AIA Status

01. The present application is being examined under the pre-AIA first to invent provisions.

Response to Amendment

02. This action is in response to Applicant's amendment filed on **02/04/2026**. **Claims 1 – 20** are pending in the present application. **This action is made FINAL**, as necessitated by amendment.

Response to Arguments

03. Applicant argues that not all claimed limitations are disclosed by the prior art reference Douglas. With respect to the arguments presented, Examiner notes that these are very similar, and often the same, as arguments that have been presented previously multiple times, as the Applicant continues to argue the same claim limitations. Additionally, Examiner has responded to these arguments each time, but Applicant does not appear to address any of the Examiner's arguments in the subsequent responses, including this most recently filed response (February 04, 2026). As a result, Examiner relies on the same rationale provided in the previous office action(s) as a response to the Applicant's current arguments. If the same claim limitations are to be argued by Applicant in further responses, Examiner suggests narrowing down the specific arguments about what specifically is believed to be different with the prior art, as well as address the arguments provided by the Examiner

with respect to both the prior art's teachings as well as how the Applicant's claim limitations are being interpreted by the Examiner.

Applicant argues that Douglas does not teach biometric devices that are worn by the patients. Examiner respectfully agrees that Douglas does not teach the entirety of the Applicant's claim limitation with respect to this one specific limitation. However, a new prior art reference has been relied upon to teach biometric devices that are worn by patients, as explained below with respect to the 35 USC 103 rejections.

Double Patenting

04. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the claims at issue are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the reference application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP §§ 706.02(l)(1) - 706.02(l)(3) for applications not subject to examination under the first inventor to file provisions of the AIA. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).

The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/forms/. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA/25, or PTO/AIA/26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to http://www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp.

05. **Claims 1 – 20** are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over **claims 1 – 20** of **US Patent 10,061,821** in view of **Stenquist (US PGPub 2010/0048159)**. Although the conflicted claims are not identical, they are not patentably distinct from each other because the claims in the instant application recite broader versions of claims that are found in the prior patent. All of the claimed limitations in the instant application (except for the biometric device)

are either broader versions or minor variations of wording of the claim's limitations in the prior patent, as outlined in the table below with respect to claim 1:

Application 17/499,725	**Patent 10,061,812**
1. A method for tracking goal progression, the method comprising:	1. A method for tracking outcome specific data, the method comprising:
receiving input establishing clients, wherein the clients are individuals receiving treatment or assistance, and wherein the data associated with the clients is stored in a server available through one or more networks;	receiving input establishing accounts **for providers serving clients in a client management program**, wherein the clients are individuals receiving treatment or assistance, **wherein the input includes rules for determining progress of the clients**, wherein the accounts are stored in a database of a server, **and wherein the input is received from an administrator utilizing one of a plurality of communications devices in communication with the server by one or more networks;**
assigning each of the clients to one or more of the providers *by the server* in	assigning each of the clients to one or more of the providers in response to

response to selections from an administrator, wherein the one or more providers include at least 1) individuals available to treat or assist each of the clients **and 2) one or more biometric devices assigned to and worn by each of the clients;**	selections from the administrator utilizing one of the plurality of communications devices, wherein the one or more providers are individuals available to treat or assist the clients;
establishing goals and a baseline for each of the clients and thresholds associated with each of the goals;	prompting the providers to provide data associated with each of the clients **that is required and not already received through the client management program**, wherein the one or more providers periodically provide/update the data, and wherein the data relates to the well-being of the clients;
automatically compiling, via the server, data associated with each of the clients received from the one or more providers **including at least the one**	compiling the data associated with each of the clients received from the providers **without input from the clients for the client management program to generate a score**

or more biometric devices in the server;	**utilizing the rules, wherein the score is associated with progress toward mastery of one or more goals;**
determining whether the goals are being met in response to the baseline and the thresholds for the compiled data; and	analyzing the compiled data and the score to automatically determine a status of the clients **within the client management program, wherein the score is compared with previous compiled data** to determine whether a plurality of measurements of the compiled data vary from a threshold to become significant;
automatically communicating alerts as managed by the server in response to the compiled data varying from one of the threshold to become significant for one of the one or more clients.	automatically communicating an alert **including the compiled data and the status** from the server **executing the client management program to the plurality of communications devices associated with the providers assigned to one of the clients that is utilized by the administrator or one or more of the providers to intervene**

	with the client in response to the plurality of measurements of the compiled data varying from the threshold to become significant for one of the clients.

Claim 1 of the instant application recites nearly the same claim embodiments as the prior patent, as seen in the table above. The only difference is that claim 1 in the instant application eliminates some claim limitations and makes some broader. The bolded sections from the prior patent (right side of the chart) are the sections that have either been eliminated or broadened. The bolded section for the instant application (left side of the chart) are the limitations that have been added to the claims, which is specifically a biometric device. However, this is a generic tool used in the technology and industry, and does not add anything significant to the claims. Since the claims in the instant application are merely reworded and abbreviated versions of the claims in the prior patent, they are rejected as such, as shown below.

Claim 1 of **US Patent 10,061,812** substantially discloses the claimed invention but fails to explicitly teach a biometric device. However, Stenquist (US PGPub 2010/0048159) teaches a biometric device that is worn by patients to obtain and transmit biometric data (paragraph [0054]).

Therefore it would have been obvious to one or ordinary skill in the art at the time the invention was made to incorporate the teachings of Stenquist into the invention of the instant application in order to allow for better monitoring of patients' health so that

the data could become available to clinicians quicker so that they could provide the necessary care for their patients in a timelier manner.

Claims 2 and 12 recite that a cloud network is used and that communications devices are utilized. Claim 2 of the prior patent recites both the usage of communications devices and a cloud network.

Claims 3, 4, 13, and 18 recites claim limitations that are present in independent claim 1 of the prior patent. Namely, the prior patent recites that the providers intervene in claims 4, 13, and 18. Therefore these claims are broader versions of claim 1 of the prior patent and they are rejected under the same rationale with respect to claim 1 above.

Claims 5, 14, and 19 recite that a plan of action is determined for achieving the goals. In the prior patent, claim 2 recites the progress of the client towards goals and claim 3 recites goals and their associated masteries and statuses. The determining of a goal status and client progress toward achieving a goal is just different terminology to explain the actions that have been done toward achieving a goal. Additionally, claim 5 of the prior patent recites best practices for the clients, which is also another way of saying the plan of action for the clients.

Claim 6 recites that a baseline and goals are established by the client and providers. These claim limitations are simplifications of parts of claims 2 and 3 of the prior patent, which recites data for the clients (baseline) and goals, which are determined by the providers for the clients.

Claims 7 and 15 recite that goals are established by the clients and the providers. Claim 5 of the prior patent recites that best practices are recommended to

the providers, and claim 3 recites that goals are established for the clients based on the input data. The combination of claims 3 and 5 of the prior patent therefore teach the same embodiments as the Applicant's claims, which is the recommending of goals based on received input.

Claims 8, 9, and 16 recite modifying goals, which can be in response to client progress towards the goals. Claim 10 of the prior patent recites that the status of goals can be determined, which relates to the client progress. Claim 1 of the prior patent recites that a determination of goal status can be used to allow a provider to intervene, which could be used to update or change the goals. Therefore the prior patented claims recite that the goals can be changed based on client progress towards the goals.

Claim 10 recites modifying goals, which can be in response to client not progressing toward the goals. Claim 10 of the prior patent recites that the status of goals can be determined, which relates to the client progress. Claim 1 of the prior patent recites that a determination of goal status can be used to allow a provider to intervene, which could be used to update or change the goals. Therefore the prior patented claims recite that the goals can be changed based on client progress towards the goals.

Claim Rejections - 35 USC § 103

06. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of

rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.

07. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:

> A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.

08. **Claims 1 and 3 – 20** are rejected under 35 U.S.C. 103 as being unpatentable over **Douglas et al. (WO 99/03045)**, hereinafter "Douglas", in view of **Stenquist (US PGPub 2010/0048159)**.

Consider **claim 1**, Douglas discloses a method for tracking goal progression (page 2 line 36 – page 3 line 2), the method comprising:

receiving input establishing clients, wherein the clients are individuals receiving treatment or assistance (page 6 line 28 – page 7 line 16, patients are entered into the system, which includes information about the patient's conditions and what treatment they are to received) **and wherein the data associated with the clients is stored in a server available through one or more networks** (page 8 lines 28 – 31, the patent data is stored on a server that is accessible through a network);

assigning each of the clients to one or more of the providers by the server in response to selections from an administrator, wherein the one or more providers include at least 1) individuals available to treat or assist each of the clients (page 11 line 6 – page 12 line 2, the patients are assigned to physicians,

wherein the physicians are able to provide help and treatment to the patients) **and 2) one or more biometric devices assigned to each of the clients** (page 10 lines 10 – 24, medical devices are used that are able to capture the patients vitals);

establishing goals and a baseline for each of the clients and thresholds associated with each of the goals (page 7 line 29 – page 8 line 9, goals and milestones are generated for the patients, which can be modified and updated as needed);

automatically compiling, via the server, data associated with each of the clients received from the one or more providers including at least the one or more biometric devices in the server (page 20 lines 3 – 34, a patient's characteristics, such as vitals and progress towards goals, are determined, such that updated information about the patients is managed, including a patient's vitals);

determining whether the goals are being met in response to the baseline and the thresholds for the compiled data (page 11 line 8 – page 12 line 2, patient progress is monitored with respect to the goals, which includes determining if a certain level of progress is being made by the patient);

automatically communicating alerts as managed by the server in response to the compiled data varying from a one of the thresholds to become significant for one or more of the clients (page 11 lines 11 – 15, an alarm can be triggered in response to patient data being significant, such as posing a health risk).

Although Douglas teaches using biometric devices to obtain patient data (page 10 lines 10 – 24), Douglas does not specifically teach that the biometric devices are worn by the client.

In the same field of endeavor, Stenquist discloses a method comprising:

one or more biometric devices assigned to and worn by each of the clients (paragraphs [0054], [0055], patients are provided with biometric devices that they wear, which provide biometric patient data that can be sent to a server for monitoring).

Therefore it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to incorporate the worn biometric devices taught by Stenquist into the patient monitoring system taught by Douglas for the purpose of allowing patient data to be obtained quicker and more efficiently, so that the data can be obtained by and reviewed either automatically or by doctors, so they a patient's health can be more accurately determined, which would lead to the ability to intervene quicker in the event the patient needs medical care.

Consider **claim 3**, and **as applied to claim 1 above**, Douglas discloses a method comprising:

intervening with the one or more of the clients in response to the alerts (page 11 lines 11 – 19, an alarm can be triggered in response to a threatening situation with the patient).

Consider **claim 4**, and **as applied to claim 3 above**, Douglas discloses a method comprising:

the intervening is performed by the one or more providers (page 11 lines 11 – 19, the physician for the patient provides the intervening).

Consider **claim 5**, and **as applied to claim 1 above**, Douglas discloses a method comprising:

each of the goals is associated with a plan of action for achieving each of the goals (page 7 line 5 – page 8 line 13, a program is created for the patient to assist in the achieving of goals).

Consider **claim 6**, and **as applied to claim 1 above**, Douglas discloses a method comprising:

establishing a baseline for the goals of the clients (page 7 lines 20 – 32, different goals and baseline values are established for the patients).

Consider **claim 7**, and **as applied to claim 1 above**, Douglas discloses a method comprising:

the goals are established by the clients and the one or more providers (page 7 lines 20 – 32, the goals are determined based on the client and physician input).

Consider **claim 8**, and **as applied to claim 1 above**, Douglas discloses a method comprising:

determining whether modifications to the goals are required in response to the compiled data (page 8 lines 8 – 13, page 11 lines 18 – 34, changes can be made to the goals for the patients).

Consider **claim 9**, and **as applied to claim 8 above**, Douglas discloses a method comprising:

modifying the goals in response to the compiled data (page 8 lines 8 – 13, page 11 lines 18 – 34, changes can be made to the goals for the patients).

Consider **claim 10**, and **as applied to claim 8 above**, Douglas discloses a method comprising:

modifications are determined to be required if the one of the clients is unable to achieve the goals associated with the client (page 8 lines 8 – 13, page 11 lines 18 – 34, changes can be made to the goals for the patients in response to determining that progress is not appropriate for that goals).

Claims 11 – 20, recite nearly identical claim limitations to those found in claims 1 – 10. Claims 11 – 16 recite a system and claims 17 – 20 recite a server, whereas claims 1 – 10 recite a method. However, the same claim limitations are otherwise found, and claims 11 – 20 are rejected under the same rationale as claims 1 – 10.

09. **Claim 2** is rejected under 35 U.S.C. 103 as being unpatentable over **Douglas et al. (WO 99/03045)**, hereinafter "Douglas", in view of **Stenquist (US PGPub 2010/0048159)**, in further view of **Chitiveli (US PGPub 2013/0179450)**, hereinafter "Chitiveli".

Consider **claim 2**, and **as applied to claim 1 above**, Douglas discloses a method comprising:

the server is accessed through a [cloud] network, and wherein a client management program is executed by communications devices utilized by the one or more providers to receive the data and track progress of the goals (page 24 lines 3 – 34, a server is accessed through a network, whereby the programs utilized by different communications devices and hardware/software).

However, Douglas and Stenquist does not specifically disclose a cloud network.

In the same field of endeavor, Chitiveli discloses a method comprising:

the server is accessed through a cloud network (paragraphs [0031], [0032], a cloud network it utilized, which is used to access a server).

Therefore it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to incorporate the cloud network taught by Chitiveli into the patient monitoring system taught by Douglas and Stenquist to allow for a more complex and modern computing infrastructure to be used for the monitoring of patients and their conditions. This would allow for better managing of the patient information which would lead to quicker speeds in being able to respond to patient health issues.

Conclusion

10. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

11. Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Christopher Raab whose telephone number is (571) 270-1090. The Examiner can normally be reached on Monday-Friday from 9:00am to 5:00pm.

Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Ajay Bhatia can be reached on (571) 272-3906. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free) or 703-305-3028.

/CHRISTOPHER J RAAB/
Primary Examiner, Art Unit 2156

March 20, 2026

Notice of References Cited	Application/Control No. 17/499,725	Applicant(s)/Patent Under Reexamination Bradley et al.	
	Examiner CHRISTOPHER J RAAB	Art Unit 2156	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date YYYY-MM-DD	Name	CPC Classification	US Classification
*	A	US-20110161107-A1	2011-06-30	Goldberg; Neal	G16H50/20	705/3
*	B	US-20100048159-A1	2010-02-25	Stenquist; Anna	H04M11/04	455/404.1
	C					
	D					
	E					
	F					
	G					
	H					
	I					
	J					
	K					
	L					
	M					

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date YYYY-MM-DD	Country	Name	CPC Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title, Date, Publisher, Edition or Volume, Pertinent Pages
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in YYYY-MM-DD format are publication dates. Classifications may be US or foreign.

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/499,725	Bradley et al.
	Examiner	Art Unit
	CHRISTOPHER J RAAB	2156

CPC - Searched*		
Symbol	**Date**	**Examiner**
G06Q10/06, limited keyword search	03/25/2023	CJR
G06Q10/0637, limited keyword search	03/25/2023	CJR

CPC Combination Sets - Searched*		
Symbol	**Date**	**Examiner**

US Classification - Searched*			
Class	**Subclass**	**Date**	**Examiner**

* See search history printout included with this form or the SEARCH NOTES box below to determine the scope of the search.

/CHRISTOPHER J RAAB/ Primary Examiner, Art Unit 2156	

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/499,725	Bradley et al.
	Examiner	Art Unit
	CHRISTOPHER J RAAB	2156

Search Notes		
Search Notes	**Date**	**Examiner**
PE2E image and keyword search	03/25/2023	CJR
NPL Search: Google Scholar	03/25/2023	CJR
Inventor Name Search: PALM and PE2E	03/25/2023	CJR
Updated search	10/02/2023	CJR
Updated search	03/20/2024	CJR
IPR2024-00616 Reviewed Petition for Post Grant Review of U.S. Patent No. 11,144,554 on 04/15/2024	04/15/2024	CJR
IPR2024-00617 Reviewed Petition for Post Grant Review of U.S. Patent No. 11,151,142 on 04/15/2024	04/15/2024	CJR
IPR2024-00618 Reviewed Petition for Post Grant Review of U.S. Patent No. 10,061,812 on 04/15/2024	04/15/2024	CJR
Updated search	01/06/2025	CJR
Updated search	07/28/2025	CJR
Updated search	03/20/2026	CJR

Interference Search			
US Class/CPC Symbol	**US Subclass/CPC Group**	**Date**	**Examiner**

/CHRISTOPHER J RAAB/ Primary Examiner, Art Unit 2156	

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/499,725	Bradley et al.
	Examiner	Art Unit
	CHRISTOPHER J RAAB	2156

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

CLAIMS

☐ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIM		DATE								
Final	Original	03/25/2023	10/02/2023	03/20/2024	01/06/2025	07/28/2025	03/20/2026			
	1	✓	✓	✓	✓	✓	✓			
	2	✓	✓	✓	✓	✓	✓			
	3	✓	✓	✓	✓	✓	✓			
	4	✓	✓	✓	✓	✓	✓			
	5	✓	✓	✓	✓	✓	✓			
	6	✓	✓	✓	✓	✓	✓			
	7	✓	✓	✓	✓	✓	✓			
	8	✓	✓	✓	✓	✓	✓			
	9	✓	✓	✓	✓	✓	✓			
	10	✓	✓	✓	✓	✓	✓			
	11	✓	✓	✓	✓	✓	✓			
	12	✓	✓	✓	✓	✓	✓			
	13	✓	✓	✓	✓	✓	✓			
	14	✓	✓	✓	✓	✓	✓			
	15	✓	✓	✓	✓	✓	✓			
	16	✓	✓	✓	✓	✓	✓			
	17	✓	✓	✓	✓	✓	✓			
	18	✓	✓	✓	✓	✓	✓			
	19	✓	✓	✓	✓	✓	✓			
	20	✓	✓	✓	✓	✓	✓			

PE2E SEARCH - Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	British Equivalents	Time Stamp
L331	7	"17499725"	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2026/03/19 04:39 PM
L332	8422	((client OR patient) WITH biometric) AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2026/03/19 04:41 PM
L333	2027	((client OR patient) WITH biometric WITH (vital OR sensor OR monitor$)) AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2026/03/19 04:42 PM
L334	936	(biometric ADJ (sensor OR device) WITH (wear$ OR worn)) AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2026/03/19 04:45 PM

PE2E SEARCH - Search History (Interference)

There are no Interference searches to show.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of: Bradley et al. **Application No.** 17/499,725 **Filing Date:** October 12, 2021 **For:** SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	**Confirmation No.** 9953 **Group Art Unit:** 2156 **Examiner:** Christopher J RAAB

AMENDMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

VIA EFS-WEB

Commissioner:

In reply to the Office Action mailed August 4, 2025, the shortened statutory period for response to which expires on November 4, 2025 and extends through February 4, 2026, please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims in this paper.

Remarks follow the amendments section of this paper.

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

Claim 1 (Currently Amended): A method for tracking goal progression, the method comprising:

receiving input establishing clients, wherein the clients are individuals receiving treatment or assistance, and wherein the data associated with the clients is stored in a server available through one or more networks;

assigning each of the clients to one or more of the providers by the server in response to selections from an administrator, wherein the one or more providers include at least 1) individuals available to treat or assist each of the clients and 2) one or more biometric devices assigned to and worn by each of the clients;

establishing goals and a baseline for each of the clients and thresholds associated with each of the goals;

automatically compiling, via the server, data associated with each of the clients received from the one or more providers including at least the one or more biometric devices in the server;

determining whether the goals are being met in response to the baseline and the thresholds for the compiled data; and

automatically communicating alerts as managed by the server in response to the compiled data varying from one of the thresholds to become significant for one or more of the clients.

Claim 2 (Original): The method according to claim 1, wherein the server is accessed through a cloud network, and wherein a client management program is executed by communications devices utilized by the one or more providers to receive the data and track progress of the goals.

Claim 3 (Original): The method according to claim 1, further comprising:

intervening with the one or more of the clients in response to the alerts.

Claim 4 (Original): The method according to claim 3, wherein the intervening is performed by the one or more providers.

Claim 5 (Original): The method according to claim 1, wherein each of the goals is associated with a plan of action for achieving each of the goals.

Claim 6 (Original): The method according to claim 1, further comprising:

establishing a baseline for the goals of the clients.

Claim 7 (Original): The method according to claim 1, wherein the goals are established by the clients and the one or more providers.

Claim 8 (Original): The method according to claim 1, further comprising:

determining whether modifications to the goals are required in response to the compiled data.

Claim 9 (Original): The method according to claim 8, further comprising:

modifying the goals in response to the compiled data.

Claim 10 (Original): The method according to claim 8, wherein modifications are determined to be required if the one of the clients is unable to achieve the goals associated with the client.

Claim 11 (Currently Amended): A system for tracking goal progression, the system comprising:

a server communicates with communications devices through a transceiver utilizing one or more networks, the server includes a processor that executes a client management program to:

receive input establishing a client, wherein the client is an individual receiving treatment or assistance, and wherein an account associated with the client is stored in a server available through one or more networks;

assign the client to one or more of the providers in response to selections from an administrator, wherein the one or more providers include at least 1) individuals available to treat or assist the client and 2) one or more biometric devices assigned to and worn by the client;

establish goals and a baseline for the client and thresholds associated with each of the goals;

automatically compile data associated with the client received from the one or more

providers including at least the one or more biometric devices in the server;

determine whether the goals are being met in response to thresholds for the compiled data; and

automatically communicate alerts as managed by the server in response to the compiled data varying from one of the thresholds to become significant for the client; and

a database in communication with the server configured to store at least the data, goals, and thresholds associated with the client and the one or more providers.

Claim 12 (Original): The system according to claim 11, wherein the communications devices receive the data from the one or more providers.

Claim 13 (Original): The system according to claim 11, wherein the alerts indicate that the one or more providers are to intervene with the client.

Claim 14 (Original): The system according to claim 11, wherein each of the goals is associated with a plan of action for achieving each of the goals.

Claim 15 (Original): The system according to claim 11, wherein the goals are established by the client and the one or more providers.

Claim 16 (Original): The system according to claim 11, wherein the client management program is further executed to:

determine whether modifications to the goals are required in response to the compiled data indicating the goals are not achievable; and

modify the goals in response to the compiled data indicating the goals are not achievable.

Claim 17 (Currently Amended): A server comprising:

a processor for executing a set of instructions; and

a memory for storing the set of instructions, wherein the set of instructions are executed by the processor to:

receive input establishing clients receiving assistance, wherein the clients are individuals receiving treatment or assistance, and wherein the accounts are stored in a server available through one or more networks;

assign each of the clients to one or more of the providers in response to selections from an administrator, wherein the one or more providers include at least 1) individuals available to treat or assist each of the clients and 2) one or more biometric devices associated with and worn by each of the clients;

establish goals and a baseline for each of the clients and thresholds associated with each of the goals;

automatically compile data associated with each of the clients received from the one or more providers including at least the one or more biometric devices in the server;

determine whether the goals are being met in response to the baseline and thresholds for the compiled data; and

automatically communicate alerts as managed by the server in response to the compiled data varying from one of the thresholds to become significant for one or more of the clients.

Claim 18 (Original): The server according to claim 17, wherein the set of instructions are further executed to:

physically intervene with the one or more of the clients in response to the alerts, wherein the physical intervention is performed by the one or more providers.

Claim 19 (Original): The server according to claim 17, wherein each of the goals is associated with a plan of action for achieving each of the goals, wherein the goals are established by the client and the one or more providers.

Claim 20 (Previously presented): The server according to claim 17, wherein the set of instructions are further executed to:

determine whether modifications to the goals are required in response to the compiled data; and

modify the goals in response to determining the modifications to the goals are required.

REMARKS

In the Office Action, the Examiner took the following actions:

I. Claims 1 – 20 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA), first paragraph, as failing to comply with the written description requirement;
II. Claims 1 – 20 are rejected on the ground of nonstatutory double patenting over claims 1 – 20 of prior U.S. Patent No. 10,061,812;
III. Claims 1 and 3 – 20 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Douglas et al. (WO 99/03045), hereinafter "Douglas"; and
IV. Claim 2 is rejected under 35 U.S.C. 103 as being unpatentable over Douglas et al. (WO 99/03045), hereinafter "Douglas", in view of Chitiveli (US PGPub 2013/0179450), hereinafter "Chitiveli".

The Office Action may contain statements characterizing the related art and/or the claims. Regardless of whether any such statement is expressly identified and/or discussed herein, Applicant reserves the right to disagree with any such statement or characterization in the Office Action.

Applicant amends claims 1, 11, and 17 without prejudice or disclaimer of its subject matter. Support for the amendments may be found in the Claims, Figures, and Specification. Claims 1-20 remain pending and under examination. For at least the following reasons, Applicant respectfully requests reconsideration and withdrawal of the rejections.

Examiner Interview

Attorney Brian Owens would like to thank the Examiner for the courtesy extended during the Telephonic interview of August 28, 2025. The Interview Summary sets forth an accurate and complete record of the Interview.

Claim Rejections – 35 USC § 112

Claims 1 – 20 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claims 1–20 stand rejected under 35 U.S.C. §112(a) as allegedly lacking written description support for the limitation "one or more biometric devices assigned to and worn by each of the clients." Applicant respectfully traverses this rejection because the specification reasonably conveys to one of ordinary skill in the art that the inventors possessed the concept of biometric devices being allocated or designated for use with particular clients, which constitutes the claimed "assignment."

The written description does not require ipsissimis verbis support or the exact term "assigned." Rather, the test is whether the disclosure reasonably conveys possession of the claimed subject matter to those skilled in the art. See MPEP §2163. The specification here repeatedly describes wearable biometric sensors that are provided to, associated with, and used for monitoring specific clients within the server-managed system. Such disclosure inherently teaches that those devices are allocated to particular clients.

The specification expressly teaches that monitoring devices and wearable sensors are used to collect biometric information for each client and transmit that

information to the server. For example, the disclosure explains that wearable sensors or biometric monitoring devices may be utilized to determine metrics of individual clients and provide those metrics to the system for analysis (e.g., Spec. [0024]). Because these sensors collect client-specific data and the server compiles the data on a per-client basis, one of ordinary skill would understand that each device must necessarily be associated with and designated for a particular client in order to correctly attribute the biometric data. In other words, the system cannot function unless the wearable device is allocated to a specific client identity within the server database. That functional relationship is exactly what the claim term "assigned" describes.

The written description also repeatedly describes that client data is tracked, stored, and evaluated on an individual basis within accounts or records maintained by the server. The server receives data "associated with each of the client s," compiles that data, and evaluates goals and thresholds for each client separately. Because the server aggregates device-generated data on a per-client basis, the specification necessarily discloses that the biometric device is linked to a particular client record. A person of ordinary skill in networked health monitoring systems would recognize that such linking or association constitutes assignment of the device to the client. The law does not require a separate step or narrative explaining how a sensor is physically handed to a user; rather, the disclosure of device-client association is sufficient to demonstrate possession.

The Examiner asserts that paragraph [0024] "doesn't explain how this sensor would be assigned to and worn by the client." However, written description does not

require step-by-step instructions for every administrative action. The specification need only describe the invention sufficiently so that one skilled in the art would understand the inventor had possession of it. Here, the disclosure of wearable sensors that gather biometric information for specific clients, combined with server-side compilation of that information on a per-client basis, necessarily implies that the devices are designated for those clients. This is a routine and well-understood implementation detail in the art of remote patient monitoring and therefore does not require further elaboration to satisfy §112(a).

Additionally, the claim language "assigned to and worn by each of the clients" is fully consistent with the specification's description of wearable sensors. A wearable biometric device that is worn by a specific client for the purpose of collecting that client's biometric data is, by its ordinary meaning, assigned to that client. Thus, the claim merely clarifies the relationship already described in the specification and does not introduce new subject matter.

Because the specification clearly describes wearable biometric devices that are associated with, used by, and generate client-specific data for each client within the server-managed system, the disclosure reasonably conveys possession of biometric devices being assigned to clients. Accordingly, the written description requirement of 35 U.S.C. §112(a) is satisfied, and the rejection should be withdrawn.

Double Patenting

Claims 1 – 20 are rejected on the ground of nonstatutory double patenting over claims 1 – 20 of prior U.S. Patent No. 10,061,812. Applicants are willing to submit the

terminal disclaimer if allowable claims are reached.

Claim Rejections - 35 USC § 102

Claims 1 and 3 – 20 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by **Douglas et al. (WO 99/03045)**, hereinafter "Douglas". This rejection is respectfully traversed.

Claims 1 and 3–20 are rejected under 35 U.S.C. §102 as allegedly anticipated by Douglas et al. This rejection is respectfully traversed because Douglas does not disclose each and every element of the language of claim 1 arranged as recited. Anticipation requires a single reference to teach all elements of the claim in the same arrangement and operation. Douglas fails to do so.

Claim 1 first recites "receiving input establishing clients, wherein the clients are individuals receiving treatment or assistance, and wherein the data associated with the clients is stored in a server available through one or more networks." Douglas describes entering or accessing patient information within a medical system; however, Douglas does not disclose the claimed server-based architecture in which client data is expressly stored in a server available through one or more networks as part of the method steps. Rather, Douglas generally discusses provider-side record systems and case management. The cited disclosure does not teach, suggest, or disclose the claimed network-accessible server configuration as a structural component of the method.

Claim 1 next recites "assigning each of the clients to one or more of the providers by the server in response to selections from an administrator." Douglas does not disclose assignment by the server and in response to selections from an administrator. Instead, Douglas describes conventional clinical relationships where physicians or staff treat

patients. Such real-world associations are not the recites a specific computerized workflow in which the server performs the assignment operation. Douglas lacks this server-driven assignment functionality.

Further, the claim expressly recites that "the one or more providers include at least 1) individuals available to treat or assist each of the clients and 2) one or more biometric devices assigned to and worn by each of the clients." This language is not disclosed in Douglas. While Douglas may mention medical devices or vitals measurements, it does not teach that providers include biometric devices assigned to and worn by each client. The claim recites wearable biometric devices that function as providers supplying data to the server. Douglas instead relies primarily on clinical measurements and provider-entered data. A manually operated or stationary clinical device is not a wearable device assigned to and worn by each client. This distinction is substantive and cannot be bridged by inherency or broad interpretation.

Claim 1 further recites "establishing goals and a baseline for each of the clients and thresholds associated with each of the goals." Douglas does not disclose this group of (1) baseline, (2) goals, and (3) thresholds associated with each goal. At most, Douglas discusses general treatment plans or monitoring. It does not teach establishing a measurable baseline for each client nor defining thresholds associated with each goal against which future data is evaluated. The claimed structure requires defined quantitative criteria that are linked to individual goals. Douglas contains no such teaching.

The claim then requires "automatically compiling, via the server, data associated with each of the clients received from the one or more providers including at least the one or more biometric devices in the server." Douglas does not teach this automated server-side compilation. The Douglas system relies heavily on human entry or periodic reporting. Manual entry by physicians or staff is not the same as automatically compiling, via the

server, data streams from multiple providers including wearable biometric devices. The requirement of automatic server-driven aggregation from device sources is absent.

Claim 1 additionally recites "determining whether the goals are being met in response to the baseline and the thresholds for the compiled data." Douglas does not disclose determining goal satisfaction specifically in response to the baseline and the thresholds for the compiled data. Even if Douglas discusses reviewing progress, that is qualitatively different from the claimed algorithmic comparison against predefined baseline-anchored thresholds. The Office Action's reasoning improperly equates general monitoring with the specific decision logic required by the claim. Anticipation cannot be based on such functional generalization.

Finally, the claim requires "automatically communicating alerts as managed by the server in response to the compiled data varying from one of the thresholds to become significant for one or more of the clients." Douglas fails to disclose this language. Any notification or report in Douglas is not shown to be (1) automatic, (2) server-managed, and (3) triggered by deviation from a defined threshold. The claimed alerts are conditional outputs generated by threshold comparisons, whereas Douglas merely describes reporting or alarms in a general clinical sense. The specific automated, threshold-triggered alert mechanism is not present.

Even more importantly, Douglas does not disclose these features in the ordered combination recited by the claim, namely: server-based client establishment, server-executed administrator assignments, wearable biometric devices measuring data, automatic server compilation of device data, evaluation against baseline-defined thresholds, and automatic server-managed alerts. The claims describes an integrated, automated, networked monitoring architecture. Douglas describes a conventional provider-centric medical record and monitoring system. These are not the same.

Because Douglas fails to disclose multiple elements and certainly does not disclose all elements arranged as claimed, Douglas cannot anticipate claim 1. Accordingly, the rejection under 35 U.S.C. §102 should be withdrawn.

CONCLUSION

In view of the foregoing, Applicant respectfully requests reconsideration of this application and the timely allowance of the pending claims.

This is a request for a three month extension of time, the small entity fee of $636 for which is being paid at the time of filing this response. No additional fees are believed due; however, the Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, to fees to Deposit Account 506801.

Respectfully submitted,

Goodhue, Coleman & Owens, P.C.

Dated: February 4, 2026

By: /Brian D. Owens/
Brian Dean Owens
Reg. No. 55517
(515) 218-7888

UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC PAYMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
17/499,725	**02/04/2026 05:42:17 PM Z ET**	**DHP-P0001CIP1**

Title of Invention

SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	-
CONFIRMATION #	9953	FILED BY	Ashlyn Nguyen
PATENT CENTER #	74336371	AUTHORIZED BY	Brian Owens
CUSTOMER #	133690	FILING DATE	10/12/2021
CORRESPONDENCE ADDRESS	-	FIRST NAMED INVENTOR	Nathaniel T. Bradley

Payment Information

PAYMENT METHOD	PAYMENT TRANSACTION ID	PAYMENT AUTHORIZED BY
DA / 506801	**E202624H43009824**	**Ashlyn Nguyen**

FEE CODE	DESCRIPTION	ITEM PRICE($)	QUANTITY	ITEM TOTAL($)
2253	EXTENSION FOR RESPONSE WITHIN THIRD MONTH, EXCEPT PROVISIONAL APPLICATIONS	636.00	1	636.00
			TOTAL AMOUNT:	**$636.00**

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C.

371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
17/499,725	**02/04/2026 05:42:17 PM Z ET**	**DHP-P0001CIP1**

Title of Invention

SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	-
CONFIRMATION #	9953	FILED BY	Ashlyn Nguyen
PATENT CENTER #	74336371	FILING DATE	10/12/2021
CUSTOMER #	133690	FIRST NAMED INVENTOR	Nathaniel T. Bradley
CORRESPONDENCE ADDRESS	-	AUTHORIZED BY	Brian Owens

Documents

TOTAL DOCUMENTS: 3

DOCUMENT		PAGES	DESCRIPTION	SIZE (KB)
DHP-P0001CIP1_17499725_NON-FINAL-OFFICE-ACTION_FILED-RESPONSE_2-4-26.pdf		16	-	245 KB
DHP-P0001CIP1_17499725_NON-FINAL-OFFICE-ACTION_FILED-RESPONSE_2-4-26-A....pdf	(1-1)	1	Amendment/Request for Reconsideration-After Non-Final Rejection	162 KB
DHP-P0001CIP1_17499725_NON-FINAL-OFFICE-ACTION_FILED-	(2-7)	6	Claims	169 KB

RESPONSE_2-4-26-CLM.pdf				
DHP-P0001CIP1_17499725_NON-FINAL-OFFICE-ACTION_FILED-RESPONSE_2-4-26-REM.pdf	(8-16)	9	Applicant Arguments/Remarks Made in an Amendment	230 KB

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)
DHP-P0001CIP1_17499725_NON-FINAL-OFFICE-ACTION_FILED-RESPONSE_2-4-26.pdf	79A25430737A7D1D7B5A774FBE02628BF74DA9ABB4FB56A80EFB0EEF8074BD648E84F2836C76B1C5EB24BF42421DD265841BCEC70A21CF8CA6157E67840D4C29
DHP-P0001CIP1_17499725_NON-FINAL-OFFICE-ACTION_FILED-RESPONSE_2-4-26-A....pdf	26DBE3646DD01E9EBC589DD3E6B63E6811677A765B780C385F072F36F5E629C73E8D940E10E4A8DA0BB98AFC90AB1C9CFB5A8D5639A8667B71DAFF4E970974F6
DHP-P0001CIP1_17499725_NON-FINAL-OFFICE-ACTION_FILED-RESPONSE_2-4-26-CLM.pdf	0A0FCFE83A6BE43334023DF4B983A7FC20CB3D3EC4C792AF9E44FF3402DDCA647A423C6701EA84C612F3C12EE4FEC08F0A765AB06726F4D6B59BCFF08130B238
DHP-P0001CIP1_17499725_NON-FINAL-OFFICE-ACTION_FILED-RESPONSE_2-4-26-REM.pdf	675C76A62D234DD1D33581777731F5F9F1D8AA5B39800BED506BC428A1197AA2293D48244C53C5552BE9EBFF646D6829FBEF954F92DF9B52A7F2D4FAF97DDFCF

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875	Application or Docket Number 17/499,725	Filing Date 10/12/2021	☐ To be Mailed

ENTITY: ☐ LARGE ☑ SMALL ☐ MICRO

APPLICATION AS FILED - PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA		RATE ($)	FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A		N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A		N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A		N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*		x $50 =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*		x $ 240 =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).				
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))					
* If the difference in column 1 is less than zero, enter "0" in column 2.				TOTAL	

APPLICATION AS AMENDED - PART II

		(Column 1)		(Column 2)	(Column 3)			
AMENDMENT	02/04/2026	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	* 20	Minus	** 20	= 0		x $80 =	0
	Independent (37 CFR 1.16(h))	* 3	Minus	*** 3	= 0		x $240 =	0
	☐ Application Size Fee (37 CFR 1.16(s))							
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							
							TOTAL ADD'L FEE	0

		(Column 1)		(Column 2)	(Column 3)			
AMENDMENT		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	*	Minus	**	=		x $0 =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=		x $0 =	
	☐ Application Size Fee (37 CFR 1.16(s))							
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							
							TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.	LIE
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".	/JESSICA T GAYNOR/
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".	
The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.	

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/499,725	10/12/2021	Nathaniel T. Bradley	DHP-P0001CIP1	9953

133690 7590 09/17/2025

Goodhue, Coleman & Owens, P.C.
7300 Westown Parkway, Suite 110
West Des Moines, IA 50266

EXAMINER	
RAAB, CHRISTOPHER J	

ART UNIT	PAPER NUMBER
2156	

NOTIFICATION DATE	DELIVERY MODE
09/17/2025	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USPTO@dockettrak.com
docketing@goodhue.com
eofficeaction@appcoll.com

Applicant-Initiated Interview Summary	**Application No.** 17/499,725	**Applicant(s)** Bradley et al.		
	Examiner CHRISTOPHER J RAAB	**Art Unit** 2156	**AIA (First Inventor to File) Status** No	**Page** 1 of 1

All Participants (applicant, applicants representative, PTO personnel)	**Title**	**Type**
CHRISTOPHER J RAAB	Primary Examiner	Telephonic
Brian D. Owens	Attorney	

Date of Interview: 28 August 2025

Issues Discussed:

35 U.S.C. 102

Applicant's Representative discussed the current prior art rejections and argued that Douglas does not teach assigning biometric devices to the clients. Examiner pointed out that the specification does not support the concept of "assigning" the biometric devices. It was also discussed that an amendment to the claims that would recite what the biometrics devices are, such as a Smartwatch, would differentiate over Douglas, as Douglas is more limited to devices such as a cholesterol kit and a sphygmomanometer . However, no specific agreement was reached with respect to the claims.

/CHRISTOPHER J RAAB/ Primary Examiner, Art Unit 2156	

Applicant is reminded that a complete written statement as to the substance of the interview must be made of record in the application file. It is the applicants responsibility to provide the written statement, unless the interview was initiated by the Examiner and the Examiner has indicated that a written summary will be provided. See MPEP 713.04
Please further see:
MPEP 713.04
Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews, paragraph (b)
37 CFR § 1.2 Business to be transacted in writing

Applicant recordation instructions: The formal written reply to the last Office action must include the substance of the interview. (See MPEP section 713.04). If a reply to the last Office action has already been filed, applicant is given a non-extendable period of the longer of one month or thirty days from this interview date, or the mailing date of this interview summary form, whichever is later, to file a statement of the substance of the interview.

Examiner recordation instructions: Examiners must summarize the substance of any interview of record. A complete and proper recordation of the substance of an interview should include the items listed in MPEP 713.04 for complete and proper recordation including the identification of the general thrust of each argument or issue discussed, a general indication of any other pertinent matters discussed regarding patentability and the general results or outcome of the interview, to include an indication as to whether or not agreement was reached on the issues raised.

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/499,725	10/12/2021	Nathaniel T. Bradley	DHP-P0001CIP1	9953

133690 7590 08/04/2025

Goodhue, Coleman & Owens, P.C.
7300 Westown Parkway, Suite 110
West Des Moines, IA 50266

EXAMINER	
RAAB, CHRISTOPHER J	

ART UNIT	PAPER NUMBER
2156	

NOTIFICATION DATE	DELIVERY MODE
08/04/2025	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USPTO@dockettrak.com
docketing@goodhue.com
eofficeaction@appcoll.com

Office Action Summary	Application No. 17/499,725	Applicant(s) Bradley et al.	
	Examiner CHRISTOPHER J RAAB	Art Unit 2156	AIA (First Inventor to File) Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTHS FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☑ Responsive to communication(s) filed on 07/10/2025.

☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2a)☐ This action is **FINAL.** 2b) ☑ This action is non-final.

3)☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

4)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims*

5) ☑ Claim(s) 1-20 is/are pending in the application.

5a) Of the above claim(s) _____ is/are withdrawn from consideration.

6) ☐ Claim(s) _____ is/are allowed.

7) ☑ Claim(s) 1-20 is/are rejected.

8) ☐ Claim(s) _____ is/are objected to.

9) ☐ Claim(s) _____ are subject to restriction and/or election requirement

* If any claims have been determined allowable, you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to **PPHfeedback@uspto.gov.**

Application Papers

10)☐ The specification is objected to by the Examiner.

11)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

a)☐ All b)☐ Some** c)☐ None of the:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

** See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☑ Notice of References Cited (PTO-892)

2) ☐ Information Disclosure Statement(s) (PTO/SB/08a and/or PTO/SB/08b) Paper No(s)/Mail Date _____.

3) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date _____.

4) ☐ Other: _____.

DETAILED ACTION

Notice of Pre-AIA or AIA Status

01. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA.

Continued Examination Under 37 CFR 1.114

02. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on **07/10/2025** has been entered.

Response to Arguments

03. Applicant argues that not all claimed limitations in claim 1 are disclosed by Douglas. Applicant argues four different limitations, which are generally the 4 limitations that have had amendments made to them. These same limitations were, to some extent, argued in the last response and were responded to by Examiner in the Final Office action that was mailed out on January 1, 2025. However, since the claims have been amended and some different arguments have been presented, Examiner will respond to each of those four arguments.

Applicant argues that Douglas does not disclose that assignment of each client to the providers is performed "by the server in response to selections from an administrator". The main argument presented by Applicant is that assigning of clients to providers is "not performed manually" but instead is "conducted automatically by a server based on administrative output". Examiner respectfully disagrees. First off, the claim recites that the assigning of clients to providers is done "by the server". There is no claim specific claim language that explains that it is "conducted automatically", as is suggested by Applicant. For example, a doctor's (provider's) input could be to enter a physician name along with a client, and then the server stores that information to allow for such an assignment. In such a scenario, the doctor is simply entering data and the server allows for the association to be made. Furthermore, the Applicant's specification does not appear to disclose an embodiment where the server somehow assigns clients to providers, as the specification broadly recites that the assignments are simply based on selections from an administrator.

Applicant argues that Douglas does not teach that the biometric devices are "assigned to each of the clients". Examiner respectfully disagrees. First off, there does not appear to be support for this limitation in the specification. The claims were previously recited as having the biometric devices "associated with" the clients, which is fully supported by the specification. However, there does not appear to be support for assigning the biometric devices to the clients, especially in view of what the Applicant is arguing. Second, Douglas does teach that biometric devices are used for the patients, which includes medical devices that can obtain patient vitals. Page 10 lines 12 – 19 explains how medical device can be used (automatically) to capture a patients' blood

pressure and heart rate. Patients can also be "assigned" a cholesterol kit that they would use to measure their cholesterol level. This reasonably teaches having biometric devices "assigned to each of the clients", as claimed by the Applicant, given there is no claim language present that explains what the biometric devices are or how they are used/obtained.

Applicant argues that Douglas does not teach "automatically compiling, via the server" the data associated with the clients. The argument presented by Applicant is that this claim limitations "confirms that the data aggregation is not reliant on manual input or passive collection but is instead compiled proactively and autonomously by the server". Examiner respectfully disagrees, as this type of claim language is not found in the claims. The claim does not recite data aggregation, that it is not reliant on manual input or passive collection, nor that anything is proactive or autonomously performed. Furthermore, the information entered into the system includes the patient's vitals, which are taken by the medical devices, and that it is compiled by the system and not by a human user. As an example, Douglas disclose that the generation of a report can be triggered based on progress or achievement of a goal (page 20 lines 33 – 37). Douglas also teaches that reports can be generated, which would be a type of automatic compilation, as a person does manually create graphs (page 20 lines 14 – 19). Therefore the aforementioned claim limitation is taught by Douglas.

Applicant argues that Douglas does not teach "automatically communicating alerts as managed by the server in response…" Examiner respectfully disagrees. First off, Applicant argues that the claim allows for "the server's autonomous assessment of data significance in view of thresholds". However, the claim only recites that the alerts

are communicated automatically, as there is nothing relating to the server being autonomous or making any assessments. Applicant then argues that the alarm signals in Douglas "are not dynamically generated based on threshold significance determinations" and that they are "triggered by basic deviations from goals". It is unclear to Examiner what the difference between basic deviations and threshold significance determination is. This is further evidenced by the claim language, which only recites that the data varies from a threshold, which appears to be the same as a deviation from a goal, as taught by Douglas. Page 11 lines 11 – 15 of Douglas explain how an alarm can be triggered in response to data relating to a patient becoming significant, such as by a potential health risk being determined. This allows for alerts to be both generated automatically and transmitted automatically so that intervention can be performed to help a patient with a health issue.

Claim Rejections – 35 USC § 112

04. The following is a quotation of the first paragraph of 35 U.S.C. 112(a):

> (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.

The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:

> The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.

05. **Claims 1 – 20** are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claim 1 recites the limitation "one or more biometric devices assigned to each of the clients". The specification does not appear to support the claimed limitation of "assigning" the biometric devices to the client. The specification does support the use of the language "associated with" (e.g. paragraph [00004]), which is how the claims were previously recited. Paragraph [00204] explains that wearable sensors may be used to determine biometrics, but it doesn't explain how this sensor would be assigned to the client. Furthermore, the claim recites that the providers include the biometric sensors, so it is unclear how the provider would include a biometric device that is then assigned to a client.

Claims 2 – 20 are rejected under the same rationale as claim 1, as they recite the same limitations found in claim 1.

Double Patenting

06. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-

type double patenting rejection is appropriate where the claims at issue are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the reference application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP §§ 706.02(l)(1) - 706.02(l)(3) for applications not subject to examination under the first inventor to file provisions of the AIA. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).

The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/forms/. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA/25, or PTO/AIA/26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all

requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to http://www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp.

07. **Claims 1 – 20** are rejected on the ground of nonstatutory double patenting over claims 1 – 20 of prior U.S. Patent No. 10,061,812. The subject matter claimed in the instant application is fully disclosed in the referenced patent. The instant application recites a broader version of the claims recited in 10,061,812, and it is deemed an obvious variation or simplification of the prior patent. All of the claimed limitations in the instant application are either broader versions or minor variations of wording of the claim's limitations in the prior patent, as outlined in the table below with respect to claim 1:

Application 17/499,725	**Patent 10,061,812**
1. A method for tracking goal progression, the method comprising:	1. A method for tracking outcome specific data, the method comprising:
receiving input establishing clients, wherein the clients are individuals receiving treatment or assistance, and wherein the data associated with the clients is stored in a server available through one or more networks;	receiving input establishing accounts **for providers serving clients in a client management program**, wherein the clients are individuals receiving treatment or assistance, **wherein the input includes rules for determining progress of the clients**, wherein the accounts are stored in a database of a

	server, **and wherein the input is received from an administrator utilizing one of a plurality of communications devices in communication with the server by one or more networks;**
assigning each of the clients to one or more of the providers by the server in response to selections from an administrator, wherein the one or more providers include at least 1) individuals available to treat or assist each of the clients **and 2) one or more biometric devices assigned to each of the clients;**	assigning each of the clients to one or more of the providers in response to selections from the administrator utilizing one of the plurality of communications devices, wherein the one or more providers are individuals available to treat or assist the clients;
establishing goals and a baseline for each of the clients and thresholds associated with each of the goals;	prompting the providers to provide data associated with each of the clients that is required and not already received through the client management program, wherein the one or more providers periodically

	provide/update the data, and wherein the data relates to the well-being of the clients;
automatically compiling, via the server, data associated with each of the clients received from the one or more providers **including at least the one or more biometric devices in the server**;	compiling the data associated with each of the clients received from the providers **without input from the clients for the client management program to generate a score utilizing the rules, wherein the score is associated with progress toward mastery of one or more goals;**
determining whether the goals are being met in response to the baseline and the thresholds for the compiled data; and	analyzing the compiled data and the score to automatically determine a status of the clients within the client management program, wherein the score is compared with previous compiled data to determine whether a plurality of measurements of the compiled data vary from a threshold to become significant;

automatically communicating alerts as managed by the server in response to the compiled data varying from one of the threshold to become significant for one of the one or more clients.	automatically communicating an alert including the compiled data and the status from the server executing the client management program to the plurality of communications devices associated with the providers assigned to one of the clients that is utilized by the administrator or one or more of the providers to intervene with the client in response to the plurality of measurements of the compiled data varying from the threshold to become significant for one of the clients.

Claim 1 of the instant application recites nearly the same claim embodiments as the prior patent, as seen in the table above. The only difference is that claim 1 in the instant application eliminates some claim limitations and makes some broader. There are no new limitations introduced in the claims, with the exception of a biometric device. However, this is a generic tool used in the technology and industry, and does not add anything significant to the claims. Since the claims in the instant application are merely reworded and abbreviated versions of the claims in the prior patent, they are rejected as such.

Claims 2 and 12 recite that a cloud network is used and that communications devices are utilized. Claim 2 of the prior patent recites both the usage of communications devices and a cloud network.

Claims 3, 4, 13, and 18 recites claim limitations that are present in independent claim 1 of the prior patent. Namely, the prior patent recites that the providers intervene in claims 4, 13, and 18. Therefore these claims are broader versions of claim 1 of the prior patent and they are rejected under the same rationale with respect to claim 1 above.

Claims 5, 14, and 19 recite that a plan of action is determined for achieving the goals. In the prior patent, claim 2 recites the progress of the client towards goals and claim 3 recites goals and their associated masteries and statuses. The determining of a goal status and client progress toward achieving a goal is just different terminology to explain the actions that have been done toward achieving a goal. Additionally, claim 5 of the prior patent recites best practices for the clients, which is also another way of saying the plan of action for the clients.

Claim 6 recites that a baseline and goals are established by the client and providers. These claim limitations are simplifications of parts of claims 2 and 3 of the prior patent, which recites data for the clients (baseline) and goals, which are determined by the providers for the clients.

Claims 7 and 15 recite that goals are established by the clients and the providers. Claim 5 of the prior patent recites that best practices are recommended to the providers, and claim 3 recites that goals are established for the clients based on the input data. The combination of claims 3 and 5 of the prior patent therefore teach the

same embodiments as the Applicant's claims, which is the recommending of goals based on received input.

Claims 8, 9, and 16 recite modifying goals, which can be in response to client progress towards the goals. Claim 10 of the prior patent recites that the status of goals can be determined, which relates to the client progress. Claim 1 of the prior patent recites that a determination of goal status can be used to allow a provider to intervene, which could be used to update or change the goals. Therefore the prior patented claims recite that the goals can be changed based on client progress towards the goals.

Claim 10 recites modifying goals, which can be in response to client not progressing toward the goals. Claim 10 of the prior patent recites that the status of goals can be determined, which relates to the client progress. Claim 1 of the prior patent recites that a determination of goal status can be used to allow a provider to intervene, which could be used to update or change the goals. Therefore the prior patented claims recite that the goals can be changed based on client progress towards the goals.

Claim Rejections - 35 USC § 102

08. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.

09. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

> A person shall be entitled to a patent unless –
>
> (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention.

10. **Claims 1 and 3 – 20** are rejected under 35 U.S.C. 102(a)(1) as being anticipated by **Douglas et al. (WO 99/03045)**, hereinafter "Douglas".

Consider **claim 1**, Douglas discloses a method for tracking goal progression (page 2 line 36 – page 3 line 2), the method comprising:

receiving input establishing clients, wherein the clients are individuals receiving treatment or assistance (page 6 line 28 – page 7 line 16, patients are entered into the system, which includes information about the patient's conditions and what treatment they are to received) **and wherein the data associated with the clients is stored in a server available through one or more networks** (page 8 lines 28 – 31, the patent data is stored on a server that is accessible through a network);

assigning each of the clients to one or more of the providers by the server in response to selections from an administrator, wherein the one or more providers include at least 1) individuals available to treat or assist each of the clients (page 11 line 6 – page 12 line 2, the patients are assigned to physicians, wherein the physicians are able to provide help and treatment to the patients) **and 2) one or more biometric devices assigned to each of the clients** (page 10 lines 10 – 24, medical devices are used that are able to capture the patients vitals);

establishing goals and a baseline for each of the clients and thresholds associated with each of the goals (page 7 line 29 – page 8 line 9, goals and

milestones are generated for the patients, which can be modified and updated as needed);

automatically compiling, via the server, data associated with each of the clients received from the one or more providers including at least the one or more biometric devices in the server (page 20 lines 3 – 34, a patient's characteristics, such as vitals and progress towards goals, are determined, such that updated information about the patients is managed, including a patient's vitals);

determining whether the goals are being met in response to the baseline and the thresholds for the compiled data (page 11 line 8 – page 12 line 2, patient progress is monitored with respect to the goals, which includes determining if a certain level of progress is being made by the patient);

automatically communicating alerts as managed by the server in response to the compiled data varying from a one of the thresholds to become significant for one or more of the clients (page 11 lines 11 – 15, an alarm can be triggered in response to patient data being significant, such as posing a health risk).

Consider **claim 3**, and **as applied to claim 1 above**, Douglas discloses a method comprising:

intervening with the one or more of the clients in response to the alerts (page 11 lines 11 – 19, an alarm can be triggered in response to a threatening situation with the patient).

Consider **claim 4**, and **as applied to claim 3 above**, Douglas discloses a method comprising:

the intervening is performed by the one or more providers (page 11 lines 11 – 19, the physician for the patient provides the intervening).

Consider **claim 5**, and **as applied to claim 1 above**, Douglas discloses a method comprising:

each of the goals is associated with a plan of action for achieving each of the goals (page 7 line 5 – page 8 line 13, a program is created for the patient to assist in the achieving of goals).

Consider **claim 6**, and **as applied to claim 1 above**, Douglas discloses a method comprising:

establishing a baseline for the goals of the clients (page 7 lines 20 – 32, different goals and baseline values are established for the patients).

Consider **claim 7**, and **as applied to claim 1 above**, Douglas discloses a method comprising:

the goals are established by the clients and the one or more providers (page 7 lines 20 – 32, the goals are determined based on the client and physician input).

Consider **claim 8**, and **as applied to claim 1 above**, Douglas discloses a method comprising:

determining whether modifications to the goals are required in response to the compiled data (page 8 lines 8 – 13, page 11 lines 18 – 34, changes can be made to the goals for the patients).

Consider **claim 9**, and **as applied to claim 8 above**, Douglas discloses a method comprising:

modifying the goals in response to the compiled data (page 8 lines 8 – 13, page 11 lines 18 – 34, changes can be made to the goals for the patients).

Consider **claim 10**, and **as applied to claim 8 above**, Douglas discloses a method comprising:

modifications are determined to be required if the one of the clients is unable to achieve the goals associated with the client (page 8 lines 8 – 13, page 11 lines 18 – 34, changes can be made to the goals for the patients in response to determining that progress is not appropriate for that goals).

Claims 11 – 20, recite nearly identical claim limitations to those found in claims 1 – 10. Claims 11 – 16 recite a system and claims 17 – 20 recite a server, whereas claims 1 – 10 recite a method. However, the same claim limitations are otherwise found, and claims 11 – 20 are rejected under the same rationale as claims 1 – 10.

Claim Rejections - 35 USC § 103

11. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.

12. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:

> A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole

would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.

13. **Claim 2** is rejected under 35 U.S.C. 103 as being unpatentable over **Douglas et al. (WO 99/03045)**, hereinafter "Douglas", in view of **Chitiveli (US PGPub 2013/0179450)**, hereinafter "Chitiveli".

Consider **claim 2**, and **as applied to claim 1 above**, Douglas discloses a method comprising:

the server is accessed through a [cloud] network, and wherein a client management program is executed by communications devices utilized by the one or more providers to receive the data and track progress of the goals (page 24 lines 3 – 34, a server is accessed through a network, whereby the programs utilized by different communications devices and hardware/software).

However, Douglas does not specifically disclose a cloud network.

In the same field of endeavor, Chitiveli discloses a method comprising:

the server is accessed through a cloud network (paragraphs [0031], [0032], a cloud network it utilized, which is used to access a server).

Therefore it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to incorporate the cloud network taught by Chitiveli into the patient monitoring system taught by Douglas to allow for a more complex and modern computing infrastructure to be used for the monitoring of patients and their conditions. This would allow for better managing of the patient information which would lead to quicker speeds in being able to respond to patient health issues.

Conclusion

14. Any response to this Office Action should be **faxed to** (571) 273-8300 **or mailed to**:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Hand-delivered responses should be brought to

Customer Service Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314

15. Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Christopher Raab whose telephone number is (571) 270-1090. The Examiner can normally be reached on Monday-Friday from 9:00am to 5:00pm.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Ajay Bhatia can be reached on (571) 272-3906. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you

have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free) or 703-305-3028.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist/customer service whose telephone number is (571) 272-2600.

/CHRISTOPHER J RAAB/
Primary Examiner, Art Unit 2156

July 29, 2025

Notice of References Cited	Application/Control No. 17/499,725	Applicant(s)/Patent Under Reexamination Bradley et al.	
	Examiner CHRISTOPHER J RAAB	Art Unit 2156	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date YYYY-MM-DD	Name	CPC Classification	US Classification
*	A	US-20140156292-A1	2014-06-05	Kozicki; Scott	G16H10/20	705/2
	B					
	C					
	D					
	E					
	F					
	G					
	H					
	I					
	J					
	K					
	L					
	M					

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date YYYY-MM-DD	Country	Name	CPC Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title, Date, Publisher, Edition or Volume, Pertinent Pages
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in YYYY-MM-DD format are publication dates. Classifications may be US or foreign.

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/499,725	Bradley et al.
	Examiner	Art Unit
	CHRISTOPHER J RAAB	2156

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

CLAIMS

☐ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIM		DATE								
Final	Original	03/25/2023	10/02/2023	03/20/2024	01/06/2025	07/28/2025				
	1	✓	✓	✓	✓	✓				
	2	✓	✓	✓	✓	✓				
	3	✓	✓	✓	✓	✓				
	4	✓	✓	✓	✓	✓				
	5	✓	✓	✓	✓	✓				
	6	✓	✓	✓	✓	✓				
	7	✓	✓	✓	✓	✓				
	8	✓	✓	✓	✓	✓				
	9	✓	✓	✓	✓	✓				
	10	✓	✓	✓	✓	✓				
	11	✓	✓	✓	✓	✓				
	12	✓	✓	✓	✓	✓				
	13	✓	✓	✓	✓	✓				
	14	✓	✓	✓	✓	✓				
	15	✓	✓	✓	✓	✓				
	16	✓	✓	✓	✓	✓				
	17	✓	✓	✓	✓	✓				
	18	✓	✓	✓	✓	✓				
	19	✓	✓	✓	✓	✓				
	20	✓	✓	✓	✓	✓				

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/499,725	Bradley et al.
	Examiner	Art Unit
	CHRISTOPHER J RAAB	2156

CPC - Searched*		
Symbol	**Date**	**Examiner**
G06Q10/06, limited keyword search	03/25/2023	CJR
G06Q10/0637, limited keyword search	03/25/2023	CJR

CPC Combination Sets - Searched*		
Symbol	**Date**	**Examiner**

US Classification - Searched*			
Class	**Subclass**	**Date**	**Examiner**

* See search history printout included with this form or the SEARCH NOTES box below to determine the scope of the search.

/CHRISTOPHER J RAAB/ Primary Examiner, Art Unit 2156	

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/499,725	Bradley et al.
	Examiner	**Art Unit**
	CHRISTOPHER J RAAB	2156

Search Notes		
Search Notes	**Date**	**Examiner**
PE2E image and keyword search	03/25/2023	CJR
NPL Search: Google Scholar	03/25/2023	CJR
Inventor Name Search: PALM and PE2E	03/25/2023	CJR
Updated search	10/02/2023	CJR
Updated search	03/20/2024	CJR
IPR2024-00616 Reviewed Petition for Post Grant Review of U.S. Patent No. 11,144,554 on 04/15/2024	04/15/2024	CJR
IPR2024-00617 Reviewed Petition for Post Grant Review of U.S. Patent No. 11,151,142 on 04/15/2024	04/15/2024	CJR
IPR2024-00618 Reviewed Petition for Post Grant Review of U.S. Patent No. 10,061,812 on 04/15/2024	04/15/2024	CJR
Updated search	01/06/2025	CJR
Updated search	07/28/2025	CJR

Interference Search			
US Class/CPC Symbol	**US Subclass/CPC Group**	**Date**	**Examiner**

/CHRISTOPHER J RAAB/ Primary Examiner, Art Unit 2156	

PE2E SEARCH - Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	British Equivalents	Time Stamp
L1	2	("20110047404").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 01:24 PM
L2	10	("20090112924"|"20090192825"|"8313433"|"8355925"|"RE42508").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:00 PM
L3	3130	account WITH client WITH provider	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:01 PM
L4	77	data mining WITH goal WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:01 PM
L5	41	data mining WITH best practices	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:01 PM
L6	1	intensive trial teaching	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:01 PM
L7	1	reinforcement recorder	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:06 PM
L8	864	goal WITH achiev$5 WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:24 PM
L9	3158	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:25 PM
L10	1117	L9 AND goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:25 PM
L11	78	L9 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:25 PM
L12	23	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:25 PM
L13	6	Macrosolve$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:30 PM
L14	84	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:30 PM
L15	1753	alert WITH automatic$6 WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2016/07/08 04:34 PM
L16	540	alert NEAR5 automatic$6 NEAR5	(US-PGPUB; USPAT; EPO; JPO;	ADJ	ON	ON	2016/07/08 04:34 PM

		threshold	DERWENT; IBM_TDB)				
L17	1110	(compile OR compiling OR compiled) WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 09:37 PM
L18	27	(compile OR compiling OR compiled) WITH user input WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 09:37 PM
L19	18	(compile OR compiling OR compiled) WITH "without user input"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 09:39 PM
L20	126	(score OR status) WITH "without user input"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 09:41 PM
L21	441	(status) WITH automatic$ WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 09:49 PM
L22	352	status WITH automatic$ WITH (score OR compile OR compiling OR scoring)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 10:01 PM
L23	1161	score WITH client WITH (threshold OR status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/07/09 10:20 PM
L24	125	well-being WITH client	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/07/09 10:21 PM
L25	385	well-being WITH score	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/07/09 10:21 PM
L26	0	well-being WITH client WITH score	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/07/09 10:21 PM
L27	90	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/02/27 11:11 AM
L28	1	"61791218"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/02/27 11:24 AM
L29	1	"15301419"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/02/27 01:30 PM
L30	55	client management program	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2018/03/19 10:14 AM
L31	2008	administrator SAME (client WITH provider)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2018/03/19 10:14 AM
L33	2	("7346545").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2018/04/12 02:12 PM
L34	2710	(track OR tracked OR	(US-PGPUB; USPAT;	ADJ	ON	ON	2018/04/15

		tracking) NEAR2 goal	EPO; JPO; DERWENT; IBM_TDB)				03:10 PM
L35	71	((track OR tracked OR tracking) NEAR2 goal) WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/04/15 03:10 PM
L36	44	((track OR tracked OR tracking) NEAR2 goal) SAME (behavioral OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/04/15 03:20 PM
L37	77	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/04/15 03:23 PM
L38	90	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/06/22 04:37 PM
L39	4499	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/06/22 04:37 PM
L40	6	(administrator SAME (client WITH provider)) AND ((score OR mastery) NEAR5 goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2018/06/22 04:40 PM
L41	24	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/06/22 04:40 PM
L42	714	score WITH measurement WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/06/22 04:40 PM
L43	39585	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/06/22 04:44 PM
L54	4	("10061812").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2019/12/23 01:57 PM
L55	13	("20020065697"|"20020147626"|"20020194046"|"20080141138"|"20080281651"|"20090112924"|"20090192825"|"20100082381"|"20110029521"|"20110047404"|"8313433"|"8355925"|"RE42508").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2019/12/23 02:26 PM
L56	27	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:29 PM
L57	1695	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:30 PM
L58	5898	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:31 PM

L59	46154	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:31 PM
L60	9	L57 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:31 PM
L61	100	L58 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:31 PM
L62	647	(status) WITH automatic$ WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:31 PM
L63	87	data mining WITH goal WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:32 PM
L64	9	(administrator SAME (client WITH provider)) AND ((score OR mastery) NEAR5 goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2019/12/23 02:32 PM
L65	101	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:32 PM
L66	4	L57 AND goal wizard	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:32 PM
L67	4	L58 AND goal wizard	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:32 PM
L68	4	L57 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:33 PM
L69	5	L58 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:33 PM
L70	4	L57 AND (goal WITH alert WITH client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:33 PM
L71	4	L58 AND (goal WITH alert WITH client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:33 PM
L72	2	"16053141"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/07/23 03:16 PM
L73	191357	field WITH (treatment OR assistance)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/07/24 10:31 AM
L74	363	field WITH (treatment OR assistance) WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/07/24 02:37 PM
L75	726	(compile OR compiled OR compiling) WITH	(US-PGPUB; USPAT; EPO; JPO;	ADJ	ON	ON	2020/07/24 03:04 PM

		(client OR patient) WITH (field OR treatment)	DERWENT; IBM_TDB)				
L76	11	(("4237344") or ("5377258") or ("20090048872") or ("20110295613")).PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2020/07/27 02:54 PM
L77	2	("20090048872"|"20110295613").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2020/09/29 09:56 AM
L78	2	("4237344"|"5377258").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2020/09/29 09:56 AM
L79	1	("20030004758").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2020/09/29 09:56 AM
L80	1	"16141471"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 10:19 AM
L81	0	"Platform for Optimizing Goal Progression".TI.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 10:19 AM
L82	43	Bradley, Nathaniel.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 10:19 AM
L83	4	("10061812").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2020/09/29 10:20 AM
L84	88	data mining WITH goal WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L85	60	data mining WITH best practices	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L86	41	(compile OR compiling OR compiled) WITH user input WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L87	115	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L88	95	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L89	2189	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L90	11	L89 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:02 AM
L91	4	L89 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:02 AM
L92	4	L89 AND (goal WITH	(US-PGPUB; USPAT;	ADJ	ON	ON	2020/09/29

		alert WITH client)	EPO; JPO; DERWENT; IBM_TDB)				11:02 AM
L93	10482	threshold WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:23 PM
L94	714	threshold WITH goal WITH (plan OR met)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:23 PM
L95	43	threshold WITH goal WITH (plan OR met) WITH (treatment OR provider OR client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:24 PM
L96	22	threshold WITH goal WITH (plan OR met) WITH (treat$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:28 PM
L97	252	threshold WITH goal WITH (treat$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:46 PM
L98	103	L97 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:46 PM
L99	7	(("20120203092") or ("20080270182") or ("10098584")).PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2021/04/08 09:52 PM
L100	5	L99 AND threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:52 PM
L101	56	(patient OR client) WITH threshold WITH goal WITH (treat$5 OR chang$4 OR modif$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:03 PM
L102	17	L101 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:03 PM
L103	49389	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:05 PM
L104	6924	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:05 PM
L105	297	(L103 OR L104) AND (threshold WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:06 PM
L106	204	L105 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:06 PM
L107	29	(L103 OR L104) AND ((threshold WITH goal) SAME (patient OR client))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:08 PM
L108	9	L107 AND (@AD<"20130315" OR	(US-PGPUB; USPAT; EPO; JPO;	ADJ	ON	ON	2021/04/08 10:08 PM

		@RLAD<"20130315")	DERWENT; IBM_TDB)				
L109	364	(treatment OR evaluation) WITH (goal) WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:39 PM
L110	10	(client OR patient) WITH goal WITH threshold WITH progress$4	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:43 PM
L111	1708	(client OR patient) WITH goal WITH (threshold OR progress$4)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:43 PM
L112	902	(client OR patient) WITH (goal NEAR5 (threshold OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:45 PM
L113	362	L112 AND @AD<"20130315"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:46 PM
L114	238	(client OR patient) WITH (goal NEAR5 (threshold OR progress$4)) WITH (treatment OR assistance OR modify$4 OR plan)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:53 PM
L115	84	L114 AND @AD<"20130315"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:53 PM
L116	327	(client OR patient) WITH goal WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 02:03 PM
L117	121	(client OR patient) WITH goal WITH (progress$4 OR threshold) WITH (modif$5 OR chang$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 02:03 PM
L118	1	"16141471"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 02:27 PM
L119	327	(patient OR client) WITH threshold WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 07:35 PM
L120	153	L119 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 07:44 PM
L121	50097	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/08/12 02:27 PM
L122	2	("8066640").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2021/08/12 02:36 PM
L133	252	patient WITH threshold	(US-PGPUB; USPAT;	ADJ	ON	ON	2022/02/25

		WITH goal	EPO; JPO; DERWENT; IBM_TDB)				09:43 PM
L134	3051	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L135	51231	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L136	7790	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L137	30	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L138	136	L134 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L139	1130	L135 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L140	292	L136 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L141	13	L136 AND ((patient OR client) WITH (threshold) WITH (alert OR goal OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:51 PM
L142	94	L135 AND ((patient OR client) WITH (threshold) WITH (alert OR goal OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:51 PM
L143	13	L134 AND ((patient OR client) WITH (threshold) WITH (alert OR goal OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:51 PM
L144	60	Bradley, Nathaniel.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:51 PM
L145	62	Gaynor, James.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:51 PM
L146	41	Paugh, Joshua.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:52 PM
L147	5	Arena, Paul.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:52 PM
L148	2	("20090192825").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2022/02/25 09:53 PM
L149	4	("11144554").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO;	ADJ	OFF	OFF	2022/02/25 10:10 PM

			DERWENT; IBM_TDB)				
L151	972	(client OR patient) WITH baseline WITH goal	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/07/25 11:43 AM
L152	73	((client OR patient) WITH baseline WITH goal) SAME threshold	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/07/25 11:43 AM
L153	154	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/07/25 11:43 AM
L154	57	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; EPO)	ADJ	ON	ON	2022/07/25 11:43 AM
L155	61	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; EPO)	ADJ	ON	ON	2023/01/13 08:53 PM
L157	139	(client OR patient)	(US-PGPUB; USPAT;	OR	ON	ON	2023/01/13

		WITH goal WITH biometric	USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)				08:53 PM
L158	633	goal WITH threshold WITH rule	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2023/03/24 02:04 PM
L159	23	(client OR patient) WITH goal WITH threshold WITH rule	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/24 02:05 PM
L160	2	("20110047404").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L161	10	("20090112924"|"20090192825"|"8313433"|"8355925"|"RE42508").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L162	7418	account WITH client WITH provider	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L163	112	data mining WITH goal WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L164	61	data mining WITH best practices	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L165	9	intensive trial teaching	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L166	9	reinforcement recorder	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM

L167	1919	goal WITH achiev$5 WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L168	9840	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L169	2100	L9 AND goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L170	155	L9 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L171	31	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L172	6	Macrosolve$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L173	96	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L174	4987	alert WITH automatic$6 WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L175	1324	alert NEAR5 automatic$6 NEAR5 threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L176	2056	(compile OR compiling OR compiled) WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L177	54	(compile OR compiling OR compiled) WITH user input WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L178	50	(compile OR compiling OR compiled) WITH "without user input"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L179	340	(score OR status) WITH "without user input"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L180	992	(status) WITH automatic$ WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L181	853	status WITH automatic$ WITH (score OR compile OR compiling OR scoring)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L182	3702	score WITH client WITH (threshold OR status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L183	223	well-being WITH client	(US-PGPUB; USPAT; EPO; JPO;	ADJ	ON	ON	2023/03/25 07:42 PM

			DERWENT; IBM_TDB)				
L184	962	well-being WITH score	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L185	18	well-being WITH client WITH score	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L186	96	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L187	9	"61791218"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L188	3	"15301419"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L189	69	client management program	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L190	3683	administrator SAME (client WITH provider)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L191	2	("7346545").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L192	4638	(track OR tracked OR tracking) NEAR2 goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L193	133	((track OR tracked OR tracking) NEAR2 goal) WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L194	90	((track OR tracked OR tracking) NEAR2 goal) SAME (behavioral OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L195	178	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L196	96	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L197	9840	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L198	20	(administrator SAME (client WITH provider)) AND ((score OR mastery) NEAR5 goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L199	31	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM

L200	1805	score WITH measurement WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L201	62988	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L202	4	("10061812").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L203	13	("20020065697"|"20020147626"|"20020194046"|"20080141138"|"20080281651"|"20090112924"|"20090192825"|"20100082381"|"20110029521"|"20110047404"|"813433"|"8355925"|"RE42508").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/25 07:42 PM
L204	31	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L205	3722	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L206	9840	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L207	62988	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L208	26	L57 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L209	155	L58 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L210	992	(status) WITH automatic$ WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L211	112	data mining WITH goal WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L212	20	(administrator SAME (client WITH provider)) AND ((score OR mastery) NEAR5 goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L213	178	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L214	9	L57 AND goal wizard	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM

L215	9	L58 AND goal wizard	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L216	92	L57 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L217	12	L58 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L218	10	L57 AND (goal WITH alert WITH client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L219	12	L58 AND (goal WITH alert WITH client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L220	7	"16053141"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L221	327785	field WITH (treatment OR assistance)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L222	490	field WITH (treatment OR assistance) WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L223	933	(compile OR compiled OR compiling) WITH (client OR patient) WITH (field OR treatment)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L224	11	(("4237344") or ("5377258") or ("20090048872") or ("20110295613")).PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L225	2	("20090048872"|"20110295613").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/25 07:42 PM
L226	2	("4237344"|"5377258").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/25 07:42 PM
L227	1	("20030004758").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/25 07:42 PM
L228	4	"16141471"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L229	0	"Platform for Optimizing Goal Progression".TI.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L230	85	Bradley, Nathaniel.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L231	4	("10061812").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L232	112	data mining WITH goal	(US-PGPUB; USPAT;	ADJ	ON	ON	2023/03/25

		WITH status	EPO; JPO; DERWENT; IBM_TDB)				07:42 PM
L233	61	data mining WITH best practices	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L234	54	(compile OR compiling OR compiled) WITH user input WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L235	178	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L236	96	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L237	3722	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L238	26	L89 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L239	92	L89 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L240	10	L89 AND (goal WITH alert WITH client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L241	13185	threshold WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L242	898	threshold WITH goal WITH (plan OR met)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L243	70	threshold WITH goal WITH (plan OR met) WITH (treatment OR provider OR client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L244	45	threshold WITH goal WITH (plan OR met) WITH (treat$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L245	358	threshold WITH goal WITH (treat$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L246	107	L97 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L247	7	(("20120203092") or ("20080270182") or ("10098584")).PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L248	5	L99 AND threshold	(US-PGPUB; USPAT; EPO; JPO;	ADJ	ON	ON	2023/03/25 07:42 PM

			DERWENT; IBM_TDB)				
L249	104	(patient OR client) WITH threshold WITH goal WITH (treat$5 OR chang$4 OR modif$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L250	18	L101 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L251	62988	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L252	9840	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L253	356	(L103 OR L104) AND (threshold WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L254	213	L105 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L255	37	(L103 OR L104) AND ((threshold WITH goal) SAME (patient OR client))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L256	10	L107 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L257	496	(treatment OR evaluation) WITH (goal) WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L258	30	(client OR patient) WITH goal WITH threshold WITH progress$4	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L259	2057	(client OR patient) WITH goal WITH (threshold OR progress$4)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L260	1043	(client OR patient) WITH (goal NEAR5 (threshold OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L261	351	L112 AND @AD<"20130315"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L262	287	(client OR patient) WITH (goal NEAR5 (threshold OR progress$4)) WITH (treatment OR assistance OR modify$4 OR plan)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L263	82	L114 AND	(US-PGPUB; USPAT;	ADJ	ON	ON	2023/03/25

		@AD<"20130315"	EPO; JPO; DERWENT; IBM_TDB)				07:42 PM
L264	434	(client OR patient) WITH goal WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L265	163	(client OR patient) WITH goal WITH (progress$4 OR threshold) WITH (modif$5 OR chang$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L266	4	"16141471"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L267	434	(patient OR client) WITH threshold WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L268	157	L119 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L269	62988	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L270	2	("8066640").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L271	309	patient WITH threshold WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L272	3722	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L273	62988	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L274	9840	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L275	31	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L276	154	L134 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L277	1193	L135 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L278	341	L136 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L279	16	L136 AND ((patient OR client) WITH (threshold) WITH (alert OR goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM

		OR progress$4))					
L280	101	L135 AND ((patient OR client) WITH (threshold) WITH (alert OR goal OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L281	15	L134 AND ((patient OR client) WITH (threshold) WITH (alert OR goal OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L282	85	Bradley, Nathaniel.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L283	66	Gaynor, James.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L284	61	Paugh, Joshua.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L285	6	Arena, Paul.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L286	2	("20090192825").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L287	4	("11144554").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L288	1050	(client OR patient) WITH baseline WITH goal	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L289	80	((client OR patient) WITH baseline WITH goal) SAME threshold	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE,	ADJ	ON	ON	2023/03/25 07:42 PM

			SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)				
L290	167	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L291	64	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; EPO)	ADJ	ON	ON	2023/03/25 07:42 PM
L292	64	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; EPO)	ADJ	ON	ON	2023/03/25 07:42 PM
L293	141	(client OR patient) WITH goal WITH biometric	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2023/03/25 07:42 PM
L294	633	goal WITH threshold WITH rule	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA,	OR	ON	ON	2023/03/25 07:42 PM

			VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)				
L295	23	(client OR patient) WITH goal WITH threshold WITH rule	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/25 07:42 PM
L296	2	"20150205930".PN.	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	OFF	OFF	2023/03/25 08:30 PM
L298	136	Bradley, Nathaniel.INV.	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/10/02 02:08 PM
L299	4	Bradley, Nathaniel.INV. AND goal.TI.	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/10/02 02:09 PM
L300	53	goal WITH biometric device	(US-PGPUB; USPAT; USOCR; FIT (AP, AT,	ADJ	ON	ON	2023/10/02 02:30 PM

			AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)				
L301	31	goal WITH biometric device	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/10/02 02:30 PM
L302	0	"biometric sensors worn by"	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/10/02 02:33 PM
L303	228	"biometric sensors worn"	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/10/02 02:33 PM
L304	29	"biometric sensors worn".CLM.	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/10/02 02:33 PM
L305	2	L304 AND (Bradley.INV. OR Marshall.INV. OR Gaynor.INV.)	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/10/02 02:34 PM
L306	5	99/03045	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2024/03/20 01:51 PM
L308	755	Douglas, Peter.INV.	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA,	ADJ	ON	ON	2024/03/20 01:51 PM

			VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)				
L309	10	Douglas, Peter.INV. AND Dudik, Evan.INV.	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2024/03/20 01:51 PM
L310	8	"20060149589"	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2024/03/20 01:52 PM
L311	1	"achieving goal progression".TI.	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2024/03/20 02:04 PM
L313	4	"optimizing goal progression".TI.	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA,	ADJ	ON	ON	2024/03/20 02:05 PM

			EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)				
L316	11	Parallax Behavioral Health$.AS.	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2024/03/20 02:05 PM
L317	7	"17499725"	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2024/03/20 03:37 PM
L318	17	"20130179450"	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO;	ADJ	ON	ON	2024/03/20 08:10 PM

			JPO; DERWENT; IBM_TDB)				
L321	3	"10061812".PN. OR "11151142".PN. OR "11144554".PN.	(US-PGPUB; USPAT)	OR	ON	ON	2024/04/15 01:40 PM
L323	3530	biometric$ WITH (automat$ OR autonom$ OR assign$) WITH (patient OR client)	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2025/07/29 03:42 PM
L324	26	(biometric$ WITH (automat$ OR autonom$ OR assign$) WITH (patient OR client)) SAME goal	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2025/07/29 04:30 PM
L325	9	(biometric$ WITH (automat$ OR autonom$ OR assign$) WITH (patient OR client)) SAME goal	(US-PGPUB; USPAT)	OR	ON	ON	2025/07/29 04:31 PM
L326	670	(biometric ADJ (sensor OR device)) NEAR5 (assign$ OR automatic$ OR autonomo$)	(US-PGPUB; USPAT)	OR	ON	ON	2025/07/29 04:32 PM
L328	25	((biometric ADJ (sensor OR device)) NEAR5 (assign$ OR automatic$ OR autonomo$)) WITH (client OR patient)	(US-PGPUB; USPAT)	OR	ON	ON	2025/07/29 04:32 PM
L329	179	((biometric ADJ (sensor OR device)) NEAR5 (assign$ OR automatic$ OR autonomo$)) AND	(US-PGPUB; USPAT)	OR	ON	ON	2025/07/29 04:33 PM

L330	28	(@AD<"20130315" OR @RLAD<"20130315") ((biometric ADJ (sensor OR device)) NEAR5 (assign$)) AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT)	OR	ON	ON	2025/07/29 04:34 PM

PE2E SEARCH - Search History (Interference)

There are no Interference searches to show.

PTO/SB/30EFS (01-22)
Approved for use through 05/31/2024. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

REQUEST FOR CONTINUED EXAMINATION(RCE)TRANSMITTAL
(Submitted Only via EFS-Web)

Application Number	17/499,725	Filing Date	2021-10-12	Docket Number (if applicable)	DHP-P0001CIP1	Art Unit	2156
First Named Inventor	Nathaniel T. Bradley			Examiner Name	Christopher J RAAB		

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.
Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. The Instruction Sheet for this form is located at WWW.USPTO.GOV

SUBMISSION REQUIRED UNDER 37 CFR 1.114

Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).

☐ Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.

- ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____
- ☐ Other _____

☒ Enclosed

- ☒ Amendment/Reply
- ☐ Information Disclosure Statement (IDS)
- ☐ Affidavit(s)/ Declaration(s)
- ☐ Other _____

MISCELLANEOUS

☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months _____
(Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)

☐ Other _____

FEES

☒ **The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.**
The Director is hereby authorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No 506801

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

☒ Patent Practitioner Signature

☐ Applicant Signature

PTO/SB/30EFS (01-22)
Approved for use through 05/31/2024. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Signature of Registered U.S. Patent Practitioner			
Signature	/Brian D. Owens/	Date (YYYY-MM-DD)	2025-07-10
Name	Brian Dean Owens	Registration Number	55517

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Attorney Docket No.
DHP-P0001CIP1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of: Bradley et al. **Application No.** 17/499,725 **Filing Date:** October 12, 2021 **For:** SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	**Confirmation No.** 9953 **Group Art Unit:** 2156 **Examiner:** Christopher J RAAB

AMENDMENT ACCOMPANYING A REQUEST FOR CONTINUED EXAMINATION (RCE)

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

VIA EFS-WEB

Commissioner:

In reply to the Final Office Action mailed January 10, 2025, a Request for Continued Examination has been submitted. With due respect, please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims in this paper.

Remarks follow the amendments section of this paper.

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

Claim 1 (Currently Amended): A method for tracking goal progression, the method comprising:

receiving input establishing clients, wherein the clients are individuals receiving treatment or assistance, and wherein the data associated with the clients is stored in a server available through one or more networks;

assigning each of the clients to one or more of the providers by the server in response to selections from an administrator, wherein the one or more providers include at least 1) individuals available to treat or assist each of the clients and 2) one or more biometric devices ~~associated with~~assigned to each of the clients;

establishing goals and a baseline for each of the clients and thresholds associated with each of the goals;

automatically compiling, via the server, data associated with each of the clients received from the one or more providers including at least the one or more biometric devices in the server;

determining whether the goals are being met in response to the baseline and the thresholds for the compiled data; and

automatically communicating alerts as managed by the server in response to the compiled data varying from one of the thresholds to become significant for one or more of the clients.

Claim 2 (Original): The method according to claim 1, wherein the server is accessed through a cloud network, and wherein a client management program is executed by communications devices utilized by the one or more providers to receive the data and track progress of the goals.

Claim 3 (Original): The method according to claim 1, further comprising:

intervening with the one or more of the clients in response to the alerts.

Claim 4 (Original): The method according to claim 3, wherein the intervening is performed by the one or more providers.

Claim 5 (Original): The method according to claim 1, wherein each of the goals is associated with a plan of action for achieving each of the goals.

Claim 6 (Original): The method according to claim 1, further comprising:

establishing a baseline for the goals of the clients.

Claim 7 (Original): The method according to claim 1, wherein the goals are established by the clients and the one or more providers.

Claim 8 (Original): The method according to claim 1, further comprising:

determining whether modifications to the goals are required in response to the compiled data.

Claim 9 (Original): The method according to claim 8, further comprising:

modifying the goals in response to the compiled data.

Claim 10 (Original): The method according to claim 8, wherein modifications are determined to be required if the one of the clients is unable to achieve the goals associated with the client.

Claim 11 (Currently Amended): A system for tracking goal progression, the system comprising:

a server communicates with communications devices through a transceiver utilizing one or more networks, the server includes a processor that executes a client management program to:

receive input establishing a client, wherein the client is ~~a~~ an individual receiving treatment or assistance, and wherein an account associated with the client is stored in a server available through one or more networks;

assign the client to one or more of the providers in response to selections from an administrator, wherein the one or more providers include at least 1) individuals available to treat or assist the client and 2) one or more biometric devices ~~associated with~~assigned to the client;

establish goals and a baseline for the client and thresholds associated with each of the goals;

automatically compile data associated with the client received from the one or more

providers including at least the one or more biometric devices in the server;

determine whether the goals are being met in response to thresholds for the compiled data; and

automatically communicate alerts as managed by the server in response to the compiled data varying from one of the thresholds to become significant for the client; and

a database in communication with the server configured to store at least the data, goals, and thresholds associated with the client and the one or more providers.

Claim 12 (Original): The system according to claim 11, wherein the communications devices receive the data from the one or more providers.

Claim 13 (Original): The system according to claim 11, wherein the alerts indicate that the one or more providers are to intervene with the client.

Claim 14 (Original): The system according to claim 11, wherein each of the goals is associated with a plan of action for achieving each of the goals.

Claim 15 (Original): The system according to claim 11, wherein the goals are established by the client and the one or more providers.

Claim 16 (Original): The system according to claim 11, wherein the client management program is further executed to:

determine whether modifications to the goals are required in response to the compiled data indicating the goals are not achievable; and

modify the goals in response to the compiled data indicating the goals are not achievable.

Claim 17 (Currently Amended): A server comprising:

a processor for executing a set of instructions; and

a memory for storing the set of instructions, wherein the set of instructions are executed by the processor to:

receive input establishing clients receiving assistance, wherein the clients are individuals receiving treatment or assistance, and wherein the accounts are stored in a server available through one or more networks;

assign each of the clients to one or more of the providers in response to selections from an administrator, wherein the one or more providers include at least 1) individuals available to treat or assist each of the clients and 2) one or more biometric devices associated with each of the clients;

establish goals and a baseline for each of the clients and thresholds associated with each of the goals;

automatically compile data associated with each of the clients received from the one or more providers including at least the one or more biometric devices in the server;

determine whether the goals are being met in response to the baseline and thresholds for the compiled data; and

automatically communicate alerts as managed by the server in response to the compiled data varying from one of the thresholds to become significant for one or more of the clients.

Claim 18 (Original): The server according to claim 17, wherein the set of instructions are further executed to:

physically intervene with the one or more of the clients in response to the alerts, wherein the physical intervention is performed by the one or more providers.

Claim 19 (Original): The server according to claim 17, wherein each of the goals is associated with a plan of action for achieving each of the goals, wherein the goals are established by the client and the one or more providers.

Claim 20 (Previously presented): The server according to claim 17, wherein the set of instructions are further executed to:

determine whether modifications to the goals are required in response to the compiled data; and

modify the goals in response to determining the modifications to the goals are required.

REMARKS

In the Final Office Action, the Examiner took the following actions:

I. Claims 1 - 20 are rejected on the ground of nonstatutory double patenting over claims 1 - 20 of prior U.S. Patent No. 10,061,812;

II. Claims 1 and 3 - 20 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Douglas et al. (WO 99/03045), hereinafter "Douglas"; and

III. Claim 2 is rejected under 35 U.S.C. 103 as being unpatentable over Douglas et al. (WO 99/03045), hereinafter "Douglas", in view of Chitiveli (US PGPub 2013/0179450), hereinafter "Chitiveli".

The Final Office Action may contain statements characterizing the related art and/or the claims. Regardless of whether any such statement is expressly identified and/or discussed herein, Applicant reserves the right to disagree with any such statement or characterization in the Final Office Action.

Applicant amends claims 1, 11, and 17 without prejudice or disclaimer of its subject matter. Support for the amendments may be found in the figures, claims, and specification including at least paragraphs [0266, 0294, 0296]. Claims 1-20 remain pending and under examination. For at least the following reasons, Applicant respectfully requests reconsideration and withdrawal of the rejections.

Double Patenting

Claims 1 - 20 are rejected on the ground of nonstatutory double patenting over claims 1 - 20 of prior U.S. Patent No. 10,061,812. Applicants are willing to submit the terminal disclaimer if allowable claims are reached.

Claim Rejections - 35 USC§ 102

Claims 1 and 3 - 20 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by **Douglas et al. (WO 99/03045),** hereinafter "Douglas". This rejection is respectfully traversed. In accordance with 37 C.F.R. § 1.116(b), Applicant submits the following remarks in support of the accompanying amendment to claim 1, which materially advances prosecution and are therefore appropriate for entry after final rejection. The amendments clarify and narrow the scope of the claim to further distinguish the invention from the cited prior art, Douglas et al. (WO 99/03045) ("Douglas").

First, claim 1 has been amended to specify that the assignment of each client to one or more providers is performed *"by the server in response to selections from an administrator."* This makes clear that the step of assigning clients to providers is not performed manually or entirely through human intervention but is instead conducted automatically by a server based on administrative inputs. Douglas does not disclose or suggest such automated assignment. In Douglas, the "case advisor" manually manages patient progress and determines intervention needs. There is no disclosure that a server automatically assigns providers based on selections from an administrator; rather, Douglas centers on static patient participation and manual physician oversight. This distinction introduces an automated workflow absent from Douglas.

Second, claim 1 has been amended to clarify that the "providers include at least

1) individuals available to treat or assist each of the clients and 2) one or more biometric devices *assigned to each of the clients.*" The specific recitation of biometric devices being *assigned to* individual clients imposes a structural relationship that is not found in Douglas. Douglas merely references the collection of various health metrics (e.g., blood pressure, weight, cholesterol), which are manually entered by patients and visualized for review. There is no teaching of uniquely assigned biometric devices tied to individual clients that generate and report data to a server. The claimed system architecture establishes a direct and ongoing data pipeline between assigned biometric devices and the server, a configuration missing in Douglas.

Third, claim 1 now expressly recites that data is "*automatically compiled, via the server,*" from the assigned providers and biometric devices. This language confirms that the data aggregation is not reliant on manual input or passive collection but is instead compiled proactively and autonomously by the server. In contrast, Douglas's system requires patient participation in submitting questionnaires or manually tracking progress, and it does not teach or suggest autonomous server-side compilation of biometric data.

Fourth, the amended claim now clarifies that alerts are "*automatically communicated, as managed by the server,*" in response to data variations that cross defined thresholds. This highlights that alert triggering is not just a generic notification function but one governed by the server's autonomous assessment of data significance in view of thresholds. Douglas lacks any disclosure of a server *managing the alert process* in this manner. While Douglas includes "alarm signals," they are not dynamically generated based on threshold significance determinations made by a

server. Rather, they appear to be predefined and triggered by basic deviations from goals. The recited claim language, particularly "varying from one of the thresholds to become significant," introduces a meaningful evaluation of the data variation beyond a mere absolute deviation.

Accordingly, the amended claim distinguishes over Douglas on at least the following points:

1. Server-automated assignment of providers in response to administrator selections.
2. Structural assignment of biometric devices to clients.
3. Server-side automatic compilation of data from providers and devices.
4. Server-managed alerts based on threshold significance analysis.

These amendments materially narrow the scope of the claim and respond directly to the cited anticipatory disclosures in Douglas. Furthermore, none of these distinguishing limitations are disclosed or suggested in Douglas, either individually or in combination. Therefore, claim 1, as amended, is not anticipated under 35 U.S.C. § 102(a)(1) and is respectfully submitted to be in condition for allowance.

Applicant respectfully requests reconsideration of the rejection and entry of the claim amendments in light of the clear distinctions now presented over the cited art.

Independent claims 11 and 17 are allowable for at least the same reasons as claim 1. Claims 2-10, 12-16, and 18-20 are allowable at least based on their dependence on claims 1, 11, and 17, respectively.

Applicants respectfully request an Examiner interview to move forward prosecution and to discuss the art of record.

CONCLUSION

In view of the foregoing, Applicant respectfully requests reconsideration of this application and the timely allowance of the pending claims.

This is a request for a three month extension of time, the small entity fee of $636 for which is being paid at the time of filing this response. A subsequent RCE request in amount of $1,144 (small entity) is included herewith; however, please grant any extensions of time required to enter this response and charge any additional required fees (including the fees under 37 C.F.R. §1.17(e)(1) for a subsequent Request for Continued Examiner) to Deposit Account 506801.

Respectfully submitted,

Goodhue, Coleman & Owens, P.C.

Dated: July 10, 2025

By: /Brian D. Owens/
Brian Dean Owens
Reg. No. 55517
(515) 218-7888

UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC PAYMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
17/499,725	**07/10/2025 05:14:16 PM Z ET**	**DHP-P0001CIP1**

Title of Invention

SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	-
CONFIRMATION #	9953	FILED BY	Ashlyn Nguyen
PATENT CENTER #	71311649	AUTHORIZED BY	Brian Owens
CUSTOMER #	133690	FILING DATE	10/12/2021
CORRESPONDENCE ADDRESS	-	FIRST NAMED INVENTOR	Nathaniel T. Bradley

Payment Information

PAYMENT METHOD	PAYMENT TRANSACTION ID	PAYMENT AUTHORIZED BY
DA / 506801	**E202570H15079028**	**Ashlyn Nguyen**

FEE CODE	DESCRIPTION	ITEM PRICE($)	QUANTITY	ITEM TOTAL($)
2253	EXTENSION FOR RESPONSE WITHIN THIRD MONTH, EXCEPT PROVISIONAL APPLICATIONS	636.00	1	636.00
2820	REQUEST FOR CONTINUED EXAMINATION (RCE)- 2ND AND SUBSEQUENT REQUEST (SEE 37 CFR 1.114)	1144.00	1	1144.00
			TOTAL AMOUNT:	**$1,780.00**

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d)

and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
17/499,725	**07/10/2025 05:14:16 PM Z ET**	**DHP-P0001CIP1**

Title of Invention

SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	-
CONFIRMATION #	9953	FILED BY	Ashlyn Nguyen
PATENT CENTER #	71311649	FILING DATE	10/12/2021
CUSTOMER #	133690	FIRST NAMED INVENTOR	Nathaniel T. Bradley
CORRESPONDENCE ADDRESS	-	AUTHORIZED BY	Brian Owens

Documents

TOTAL DOCUMENTS: 4

DOCUMENT		PAGES	DESCRIPTION	SIZE (KB)
DHP-P0001CIP1_17499725_FINAL-OFFICE-ACTION_FILED-SUB-RCE-RESPONSE.pdf		12	-	281 KB
DHP-P0001CIP1_17499725_FINAL-OFFICE-ACTION_FILED-SUB-RCE-RESPONSE-AMSB.pdf	(1-1)	1	Amendment Submitted/Entered with Filing of Continued Prosecution Application (CPA)/Request for Continued Examination(RCE)	162 KB
DHP-P0001CIP1_17499725_FINAL-OFFICE-ACTION_FILED-SUB-RCE-RESPONSE-CLM.pdf	(2-7)	6	Claims	169 KB

DHP-P0001CIP1_17499725_FINAL-OFFICE-ACTION_FILED-SUB-RCE-RESPONSE-REM.pdf	(8-12)	5	Applicant Arguments/Remarks Made in an Amendment	265 KB
DHP-P0001CIP1_17499725_FINAL-OFFICE-ACTION_FILED-SUB-RCE-TRANSMITTAL.pdf		3	Request for Continued Examination (RCE)	1642 KB

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)
DHP-P0001CIP1_17499725_FINAL-OFFICE-ACTION_FILED-SUB-RCE-RESPONSE.pdf	B40D99396297471564F931DA4608FD70A4929A268276718F991494992143FC7892E041FF5ADBA317ABECD1CA96F9BF70B82A34075A84CF17AB2654E8569036D7
DHP-P0001CIP1_17499725_FINAL-OFFICE-ACTION_FILED-SUB-RCE-RESPONSE-AMSB.pdf	E1C5926EC93D3837E2313C4E8E9AB181310294541946AA9D41DE74A6BF51BCBB4B629CDC3860522EE0D2D368B50FA6E2A06E15315CD654F4433A83884CD23CFB
DHP-P0001CIP1_17499725_FINAL-OFFICE-ACTION_FILED-SUB-RCE-RESPONSE-CLM.pdf	AF5DF02B91C6ECF5F6F466F9F545F51A950EEE195019772F1212B444809277272A7C3E7CD114048C3E069798942900AFB84566C0F380F4250B318BEFDA544272
DHP-P0001CIP1_17499725_FINAL-OFFICE-ACTION_FILED-SUB-RCE-RESPONSE-REM.pdf	118C9BD42C4A1400E66F55AD51CCDFF95FA9CAFE39634E8E8A7C005B85AD2F102399DC40BBAA7FD34A58D3B47F133BFB6F013BAC57D954918B0030D2FA196B8C
DHP-P0001CIP1_17499725_FINAL-OFFICE-ACTION_FILED-SUB-RCE-TRANSMITTAL.pdf	87AD138D68970EC88D3BC26EBE3FD3F9600F702DDD8E5A9197A2F44F3EE52A74A6C2983568D5658A02D94ADBF1C472FF1A6D5924AE28834EF9AAFDFF8C3A849C

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875	Application or Docket Number 17/499,725	Filing Date 10/12/2021	☐ To be Mailed

ENTITY: ☐ LARGE ☑ SMALL ☐ MICRO

APPLICATION AS FILED - PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA		RATE ($)	FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A		N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A		N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A		N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*		x $50 =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*		x $240 =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).				
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))					
* If the difference in column 1 is less than zero, enter "0" in column 2.				TOTAL	

APPLICATION AS AMENDED - PART II

		(Column 1)		(Column 2)	(Column 3)			
AMENDMENT	07/10/2025	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	* 20	Minus	** 20	= 0		x $80 =	0
	Independent (37 CFR 1.16(h))	* 3	Minus	*** 3	= 0		x $240 =	0
	☐ Application Size Fee (37 CFR 1.16(s))							
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							
							TOTAL ADD'L FEE	0

		(Column 1)		(Column 2)	(Column 3)			
AMENDMENT		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	*	Minus	**	=		x $0 =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=		x $0 =	
	☐ Application Size Fee (37 CFR 1.16(s))							
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							
							TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.	LIE
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".	/PAULA D MCCRAY STANLEY/
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".	
The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.	

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/499,725	10/12/2021	Nathaniel T. Bradley	DHP-P0001CIP1	9953

133690 7590 01/10/2025

Goodhue, Coleman & Owens, P.C.
7300 Westown Parkway, Suite 110
West Des Moines, IA 50266

EXAMINER	
RAAB, CHRISTOPHER J	

ART UNIT	PAPER NUMBER
2156	

NOTIFICATION DATE	DELIVERY MODE
01/10/2025	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USPTO@dockettrak.com
docketing@goodhue.com
eofficeaction@appcoll.com

Office Action Summary	Application No. 17/499,725	Applicant(s) Bradley et al.	
	Examiner CHRISTOPHER J RAAB	Art Unit 2156	AIA (FITF) Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTHS FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☑ Responsive to communication(s) filed on 09/26/2024.

☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2a)☑ This action is **FINAL.** 2b) ☐ This action is non-final.

3)☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

4)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims*

5) ☑ Claim(s) 1-20 is/are pending in the application.

5a) Of the above claim(s) _____ is/are withdrawn from consideration.

6) ☐ Claim(s) _____ is/are allowed.

7) ☑ Claim(s) 1-20 is/are rejected.

8) ☐ Claim(s) _____ is/are objected to.

9) ☐ Claim(s) _____ are subject to restriction and/or election requirement

* If any claims have been determined allowable, you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to **PPHfeedback@uspto.gov.**

Application Papers

10)☐ The specification is objected to by the Examiner.

11)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

a)☐ All b)☐ Some** c)☐ None of the:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

** See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)

2) ☐ Information Disclosure Statement(s) (PTO/SB/08a and/or PTO/SB/08b) Paper No(s)/Mail Date _____.

3) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date _____.

4) ☐ Other: _____.

DETAILED ACTION

Notice of Pre-AIA or AIA Status

01. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA.

Response to Amendment

02. This action is in response to Applicant's amendment filed on **09/26/2024**. **Claims 1 – 20** are pending in the present application.

Applicant's arguments are considered but are not persuasive.

This action is made final.

Response to Arguments

03. Applicant argues that Douglas does not disclose "automatically compiling data associated with each of the clients received from the one or more providers including at least the one or more biometric devices in the server". Examiner respectfully disagrees. It is unclear what exactly Applicant is arguing with respect to this claim limitation, but the Applicant does argue that Douglas does not teach "automatically compiling" and that the information is "patient entered". However, Douglas teaches that the information is entered by a physician/doctor. For example, page 4 lines 28 – 35 explains that the physician enters patient information, such as the patient's baseline vital factors, into the system by way of using a personal computer or by sending the information to a case advisor who sets the patient up on the system. Additionally, the Figures, namely Fig. 1

– Fig. 7 show that a doctor/physician accesses the system in order to enter and/or obtain information. This makes it clear that the information is not necessarily patient entered, as essentially anyone, including doctors, physicians, case works, and patients can enter the information. Furthermore, the information entered into the system includes the patient's vitals, which are taken by medical devices. For example, page 10 lines 10 – 19 explain that the vitals can be entered into the system by way of using medical devices, such as by a device hooked up to a computer in order to automatically obtain the blood pressure or heart rate of a patient. With respect to the Applicant's claimed language of the data being "automatically compiled", this is rather broad and could mean a few things. For example, the system of Douglas that obtains the information from the client and then populates the database or a particular form would be a form of compiling the data, and since that is done by a computer, it would be considered automatic, as a person does not have to fill out all the details of the system. Additionally, the system of Douglas can create a program for the user, such as devising goals and milestones (page 8 lines 6 – 8). Therefore Douglas is understood to the teach the Applicant's aforementioned claimed limitation, which is the use of information entered by way of a physician and biometric device that is then compiled by the system.

Applicant argues that Douglas does not teach the claimed limitation of "assigning each of the clients to one or more of the providers in response to selections from an administrator, wherein the one or more providers include at least individuals available to treat or assist each of the clients and one or more biometric devices associated with each of the clients". Examiner respectfully disagrees. With respect to this claim limitation, Applicant argues that "the word client is not utilized in Douglas as it relates to

being assigned to a provider". However, it is unclear what is being argued here, as a Douglas uses the word "patient", which is equated to the Applicant's claimed client. Additionally, the system in Douglas utilizes input from a physician and/or case advisor, which then allow for a patient to be seen by the physician or another physician/doctor. Applicant also argues that Douglas does not mention biometric devices in this context, but it unclear exactly what is being argued here. As explained above, Douglas teaches that medical devices are used, such as those that can obtain the vitals of a patient and enter them into the system. This reasonably reads on the claimed "biometric devices that are associated with each of the clients".

Applicant argues that Douglas does not disclose "determining whether the goals are being met in response to baseline and the thresholds for the compiled data", in that Douglas does not specifically recite the terminology of "threshold". Examiner agrees that Douglas does not use the term "threshold", but this is something that is inherently taught in Douglas. Douglas teaches that patients have programs assigned to them and that progress towards program goals are monitored. Page 11 line 8 – page 12 line 2 explains how a patient has goals and that progress towards those goals is monitored. This is done so that it can be determined if a certain level of progress has or hasn't been made within a certain time period. Page 20 lines 33 – 37 explains that reports are generated based on patient progress towards goals, and that an achievement of a goal and/or the setting off of an alarm, which would be based on a patient deviating from a goal or certain level of progress, are utilized. Furthermore, page 21 lines 4 – 13 explain that a specific ' threshold' may be to lose a certain amount of weight in a certain time period, and if that is/isn't being met, then an alert can be triggered or a report generated.

Therefore, although Douglas does not explicitly recite the word "threshold", it is clear that thresholds are being utilized for monitoring the patients and their progress towards meeting one or more goals.

Applicant argues that Douglas does not teach "automatically communicating alerts in response to the complied data varying from at least one of the thresholds to become significant for one of the one or more clients". It appears this argument stems from the same argument addressed above about whether or not Douglas teaches thresholds. Therefore, Examiner relies upon the same rational as to how Douglas inherently teaches thresholds to disclose this limitation.

Double Patenting

04. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the claims at issue are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438,

164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the reference application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP §§ 706.02(l)(1) - 706.02(l)(3) for applications not subject to examination under the first inventor to file provisions of the AIA. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).

The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/forms/. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA/25, or PTO/AIA/26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to http://www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp.

05. **Claims 1 – 20** are rejected on the ground of nonstatutory double patenting over claims 1 – 20 of prior U.S. Patent No. 10,061,812. The subject matter claimed in the instant application is fully disclosed in the referenced patent. The instant application recites a broader version of the claims recited in 10,061,812, and it is deemed an

obvious variation or simplification of the prior patent. All of the claimed limitations in the instant application are either broader versions or minor variations of wording of the claim's limitations in the prior patent, as outlined in the table below with respect to claim 1:

Application 17/499,725	**Patent 10,061,812**
1. A method for tracking goal progression, the method comprising: receiving input establishing clients, wherein the clients are individuals receiving treatment or assistance, and wherein the data associated with the clients is stored in a server available through one or more networks;	1. A method for tracking outcome specific data, the method comprising: receiving input establishing accounts for providers serving clients in a client management program, wherein the clients are individuals receiving treatment or assistance, wherein the input includes rules for determining progress of the clients, wherein the accounts are stored in a database of a server, and wherein the input is received from an administrator utilizing one of a plurality of communications devices in communication with the server by one or more networks;

assigning each of the clients to one or more of the providers in response to selections from an administrator, wherein the one or more providers include at least individuals available to treat or assist each of the clients **and one or more biometric devices associated with each of the clients;**	assigning each of the clients to one or more of the providers in response to selections from the administrator utilizing one of the plurality of communications devices, wherein the one or more providers are individuals available to treat or assist the clients;
establishing goals and a baseline for each of the clients and thresholds associated with each of the goals;	prompting the providers to provide data associated with each of the clients that is required and not already received through the client management program, wherein the one or more providers periodically provide/update the data, and wherein the data relates to the well-being of the clients;
automatically compiling data associated with each of the clients received from the one or more	compiling the data associated with each of the clients received from the providers without input from the clients for the client management program to

providers including at least the one or more biometric devices in the server;	generate a score utilizing the rules, wherein the score is associated with progress toward mastery of one or more goals;
determining whether the goals are being met in response to the baseline and the thresholds for the compiled data; and	analyzing the compiled data and the score to automatically determine a status of the clients within the client management program, wherein the score is compared with previous compiled data to determine whether a plurality of measurements of the compiled data vary from a threshold to become significant;
automatically communicating alerts in response to the compiled data varying from one of the threshold to become significant for one of the one or more clients.	automatically communicating an alert including the compiled data and the status from the server executing the client management program to the plurality of communications devices associated with the providers assigned to one of the clients that is utilized by the administrator or one or more of the

	providers to intervene with the client in response to the plurality of measurements of the compiled data varying from the threshold to become significant for one of the clients.

Claim 1 of the instant application recites nearly the same claim embodiments as the prior patent, as seen in the table above. The only difference is that claim 1 in the instant application eliminates some claim limitations and makes some broader. There are no new limitations introduced in the claims, with the exception of a biometric device. However, this is a generic tool used in the technology and industry, and does not add anything significant to the claims. Since the claims in the instant application are merely reworded and abbreviated versions of the claims in the prior patent, they are rejected as such.

Claims 2 and 12 recite that a cloud network is used and that communications devices are utilized. Claim 2 of the prior patent recites both the usage of communications devices and a cloud network.

Claims 3, 4, 13, and 18 recites claim limitations that are present in independent claim 1 of the prior patent. Namely, the prior patent recites that the providers intervene in claims 4, 13, and 18. Therefore these claims are broader versions of claim 1 of the prior patent and they are rejected under the same rationale with respect to claim 1 above.

Claims 5, 14, and 19 recite that a plan of action is determined for achieving the goals. In the prior patent, claim 2 recites the progress of the client towards goals and claim 3 recites goals and their associated masteries and statuses. The determining of a goal status and client progress toward achieving a goal is just different terminology to explain the actions that have been done toward achieving a goal. Additionally, claim 5 of the prior patent recites best practices for the clients, which is also another way of saying the plan of action for the clients.

Claim 6 recites that a baseline and goals are established by the client and providers. These claim limitations are simplifications of parts of claims 2 and 3 of the prior patent, which recites data for the clients (baseline) and goals, which are determined by the providers for the clients.

Claims 7 and 15 recite that goals are established by the clients and the providers. Claim 5 of the prior patent recites that best practices are recommended to the providers, and claim 3 recites that goals are established for the clients based on the input data. The combination of claims 3 and 5 of the prior patent therefore teach the same embodiments as the Applicant's claims, which is the recommending of goals based on received input.

Claims 8, 9, and 16 recite modifying goals, which can be in response to client progress towards the goals. Claim 10 of the prior patent recites that the status of goals can be determined, which relates to the client progress. Claim 1 of the prior patent recites that a determination of goal status can be used to allow a provider to intervene, which could be used to update or change the goals. Therefore the prior patented claims recite that the goals can be changed based on client progress towards the goals.

Claim 10 recites modifying goals, which can be in response to client not progressing toward the goals. Claim 10 of the prior patent recites that the status of goals can be determined, which relates to the client progress. Claim 1 of the prior patent recites that a determination of goal status can be used to allow a provider to intervene, which could be used to update or change the goals. Therefore the prior patented claims recite that the goals can be changed based on client progress towards the goals.

Claim Rejections - 35 USC § 102

06. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.

07. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

> A person shall be entitled to a patent unless –
>
> (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention.

08. **Claims 1 and 3 – 20** are rejected under 35 U.S.C. 102(a)(1) as being anticipated by **Douglas et al. (WO 99/03045)**, hereinafter "Douglas".

Consider **claim 1**, Douglas discloses a method for tracking goal progression (page 2 line 36 – page 3 line 2), the method comprising:

receiving input establishing clients, wherein the clients are individuals receiving treatment or assistance (page 6 line 28 – page 7 line 16, patients are entered into the system, which includes information about the patient's conditions and what treatment they are to received) **and wherein the data associated with the clients is stored in a server available through one or more networks** (page 8 lines 28 – 31, the patent data is stored on a server that is accessible through a network);

assigning each of the clients to one or more of the providers in response to selections from an administrator, wherein the one or more providers include at least individuals available to treat or assist each of the clients (page 11 line 6 – page 12 line 2, the patients are assigned to physicians, wherein the physicians are able to provide help and treatment to the patients) **and one or more biometric devices associated with each of the clients** (page 10 lines 10 – 24, medical devices are used that are able to capture the patients vitals);

establishing goals and a baseline for each of the clients and thresholds associated with each of the goals (page 7 line 29 – page 8 line 9, goals and milestones are generated for the patients, which can be modified and updated as needed);

automatically compiling data associated with each of the clients received from the one or more providers including at least the one or more biometric devices in the server (page 20 lines 3 – 44, a patient's characteristics, such as vitals and progress towards goals, are determined, such that updated information about the patients is managed, including a patient's vitals);

determining whether the goals are being met in response to the baseline and the thresholds for the compiled data (page 11 line 8 – page 12 line 2, patient progress is monitored with respect to the goals, which includes determining if a certain level of progress is being made by the patient);

automatically communicating alerts in response to the compiled data varying from a one of the thresholds to become significant for one or more of the clients (page 11 lines 11 – 15, an alarm can be triggered in response to patient data being significant, such as posing a health risk).

Consider **claim 3**, and **as applied to claim 1 above**, Douglas discloses a method comprising:

intervening with the one or more of the clients in response to the alerts (page 11 lines 11 – 19, an alarm can be triggered in response to a threatening situation with the patient).

Consider **claim 4**, and **as applied to claim 3 above**, Douglas discloses a method comprising:

the intervening is performed by the one or more providers (page 11 lines 11 – 19, the physician for the patient provides the intervening).

Consider **claim 5**, and **as applied to claim 1 above**, Douglas discloses a method comprising:

each of the goals is associated with a plan of action for achieving each of the goals (page 7 line 5 – page 8 line 13, a program is created for the patient to assist in the achieving of goals).

Consider **claim 6**, and **as applied to claim 1 above**, Douglas discloses a method comprising:

establishing a baseline for the goals of the clients (page 7 lines 20 – 32, different goals and baseline values are established for the patients).

Consider **claim 7**, and **as applied to claim 1 above**, Douglas discloses a method comprising:

the goals are established by the clients and the one or more providers (page 7 lines 20 – 32, the goals are determined based on the client and physician input).

Consider **claim 8**, and **as applied to claim 1 above**, Douglas discloses a method comprising:

determining whether modifications to the goals are required in response to the compiled data (page 8 lines 8 – 13, page 11 lines 18 – 34, changes can be made to the goals for the patients).

Consider **claim 9**, and **as applied to claim 8 above**, Douglas discloses a method comprising:

modifying the goals in response to the compiled data (page 8 lines 8 – 13, page 11 lines 18 – 34, changes can be made to the goals for the patients).

Consider **claim 10**, and **as applied to claim 8 above**, Douglas discloses a method comprising:

modifications are determined to be required if the one of the clients is unable to achieve the goals associated with the client (page 8 lines 8 – 13, page 11 lines 18 – 34, changes can be made to the goals for the patients in response to determining that progress is not appropriate for that goals).

Claims 11 – 20, recite nearly identical claim limitations to those found in claims 1 – 10. Claims 11 – 16 recite a system and claims 17 – 20 recite a server, whereas claims 1 – 10 recite a method. However, the same claim limitations are otherwise found, and claims 11 – 20 are rejected under the same rationale as claims 1 – 10.

Claim Rejections - 35 USC § 103

09. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.

10. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:

> A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.

11. **Claim 2** is rejected under 35 U.S.C. 103 as being unpatentable over **Douglas et al. (WO 99/03045)**, hereinafter "Douglas", in view of **Chitiveli (US PGPub 2013/0179450)**, hereinafter "Chitiveli".

Consider **claim 2**, and **as applied to claim 1 above**, Douglas discloses a method comprising:

the server is accessed through a [cloud] network, and wherein a client management program is executed by communications devices utilized by the one or more providers to receive the data and track progress of the goals (page 24 lines 3 – 34, a server is accessed through a network, whereby the programs utilized by different communications devices and hardware/software).

However, Douglas does not specifically disclose a cloud network.

In the same field of endeavor, Chitiveli discloses a method comprising:

The server is accessed through a cloud network (paragraphs [0031], [0032], a cloud network it utilized, which is used to access a server).

Therefore it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to incorporate the cloud network taught by Chitiveli into the patient monitoring system taught by Douglas to allow for a more complex and modern computing infrastructure to be used for the monitoring of patients and their conditions.

Conclusion

12. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any

extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

13. Any response to this Office Action should be **faxed to** (571) 273-8300 **or mailed to**:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Hand-delivered responses should be brought to

Customer Service Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314

14. Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Christopher Raab whose telephone number is (571) 270-1090. The Examiner can normally be reached on Monday-Friday from 9:00am to 5:00pm.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Ajay Bhatia can be reached on (571) 272-3906. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status

information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free) or 703-305-3028.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist/customer service whose telephone number is (571) 272-2600.

/CHRISTOPHER J RAAB/
Primary Examiner, Art Unit 2156

January 06, 2025

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/499,725	Bradley et al.
	Examiner	Art Unit
	CHRISTOPHER J RAAB	2156

CPC - Searched*		
Symbol	**Date**	**Examiner**
G06Q10/06, limited keyword search	03/25/2023	CJR
G06Q10/0637, limited keyword search	03/25/2023	CJR

CPC Combination Sets - Searched*		
Symbol	**Date**	**Examiner**

US Classification - Searched*			
Class	**Subclass**	**Date**	**Examiner**

* See search history printout included with this form or the SEARCH NOTES box below to determine the scope of the search.

/CHRISTOPHER J RAAB/ Primary Examiner, Art Unit 2156	

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/499,725	Bradley et al.
	Examiner	Art Unit
	CHRISTOPHER J RAAB	2156

Search Notes		
Search Notes	**Date**	**Examiner**
PE2E image and keyword search	03/25/2023	CJR
NPL Search: Google Scholar	03/25/2023	CJR
Inventor Name Search: PALM and PE2E	03/25/2023	CJR
Updated search	10/02/2023	CJR
Updated search	03/20/2024	CJR
IPR2024-00616 Reviewed Petition for Post Grant Review of U.S. Patent No. 11,144,554 on 04/15/2024	04/15/2024	CJR
IPR2024-00617 Reviewed Petition for Post Grant Review of U.S. Patent No. 11,151,142 on 04/15/2024	04/15/2024	CJR
IPR2024-00618 Reviewed Petition for Post Grant Review of U.S. Patent No. 10,061,812 on 04/15/2024	04/15/2024	CJR
Updated search	01/06/2025	CJR

Interference Search			
US Class/CPC Symbol	**US Subclass/CPC Group**	**Date**	**Examiner**

/CHRISTOPHER J RAAB/ Primary Examiner, Art Unit 2156	

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/499,725	Bradley et al.
	Examiner	**Art Unit**
	CHRISTOPHER J RAAB	2156

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

CLAIMS

☐ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIM		DATE								
Final	Original	03/25/2023	10/02/2023	03/20/2024	01/06/2025					
	1	✓	✓	✓	✓					
	2	✓	✓	✓	✓					
	3	✓	✓	✓	✓					
	4	✓	✓	✓	✓					
	5	✓	✓	✓	✓					
	6	✓	✓	✓	✓					
	7	✓	✓	✓	✓					
	8	✓	✓	✓	✓					
	9	✓	✓	✓	✓					
	10	✓	✓	✓	✓					
	11	✓	✓	✓	✓					
	12	✓	✓	✓	✓					
	13	✓	✓	✓	✓					
	14	✓	✓	✓	✓					
	15	✓	✓	✓	✓					
	16	✓	✓	✓	✓					
	17	✓	✓	✓	✓					
	18	✓	✓	✓	✓					
	19	✓	✓	✓	✓					
	20	✓	✓	✓	✓					

PE2E SEARCH - Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	British Equivalents	Time Stamp
L1	2	("20110047404").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 01:24 PM
L2	10	("20090112924"|"20090192825"|"8313433"|"8355925"|"RE42508").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:00 PM
L3	3130	account WITH client WITH provider	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:01 PM
L4	77	data mining WITH goal WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:01 PM
L5	41	data mining WITH best practices	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:01 PM
L6	1	intensive trial teaching	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:01 PM
L7	1	reinforcement recorder	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:06 PM
L8	864	goal WITH achiev$5 WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:24 PM
L9	3158	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:25 PM
L10	1117	L9 AND goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:25 PM
L11	78	L9 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:25 PM
L12	23	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:25 PM
L13	6	Macrosolve$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:30 PM
L14	84	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:30 PM
L15	1753	alert WITH automatic$6 WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2016/07/08 04:34 PM
L16	540	alert NEAR5 automatic$6 NEAR5	(US-PGPUB; USPAT; EPO; JPO;	ADJ	ON	ON	2016/07/08 04:34 PM

		threshold	DERWENT; IBM_TDB)				
L17	1110	(compile OR compiling OR compiled) WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 09:37 PM
L18	27	(compile OR compiling OR compiled) WITH user input WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 09:37 PM
L19	18	(compile OR compiling OR compiled) WITH "without user input"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 09:39 PM
L20	126	(score OR status) WITH "without user input"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 09:41 PM
L21	441	(status) WITH automatic$ WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 09:49 PM
L22	352	status WITH automatic$ WITH (score OR compile OR compiling OR scoring)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 10:01 PM
L23	1161	score WITH client WITH (threshold OR status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/07/09 10:20 PM
L24	125	well-being WITH client	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/07/09 10:21 PM
L25	385	well-being WITH score	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/07/09 10:21 PM
L26	0	well-being WITH client WITH score	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/07/09 10:21 PM
L27	90	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/02/27 11:11 AM
L28	1	"61791218"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/02/27 11:24 AM
L29	1	"15301419"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/02/27 01:30 PM
L30	55	client management program	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2018/03/19 10:14 AM
L31	2008	administrator SAME (client WITH provider)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2018/03/19 10:14 AM
L33	2	("7346545").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2018/04/12 02:12 PM
L34	2710	(track OR tracked OR	(US-PGPUB; USPAT;	ADJ	ON	ON	2018/04/15

		tracking) NEAR2 goal	EPO; JPO; DERWENT; IBM_TDB)				03:10 PM
L35	71	((track OR tracked OR tracking) NEAR2 goal) WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/04/15 03:10 PM
L36	44	((track OR tracked OR tracking) NEAR2 goal) SAME (behavioral OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/04/15 03:20 PM
L37	77	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/04/15 03:23 PM
L38	90	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/06/22 04:37 PM
L39	4499	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/06/22 04:37 PM
L40	6	(administrator SAME (client WITH provider)) AND ((score OR mastery) NEAR5 goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2018/06/22 04:40 PM
L41	24	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/06/22 04:40 PM
L42	714	score WITH measurement WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/06/22 04:40 PM
L43	39585	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/06/22 04:44 PM
L54	4	("10061812").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2019/12/23 01:57 PM
L55	13	("20020065697"|"20020147626"|"20020194046"|"20080141138"|"20080281651"|"20090112924"|"20090192825"|"20100082381"|"20110029521"|"20110047404"|"8313433"|"8355925"|"RE42508").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2019/12/23 02:26 PM
L56	27	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:29 PM
L57	1695	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:30 PM
L58	5898	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:31 PM

L59	46154	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:31 PM
L60	9	L57 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:31 PM
L61	100	L58 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:31 PM
L62	647	(status) WITH automatic$ WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:31 PM
L63	87	data mining WITH goal WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:32 PM
L64	9	(administrator SAME (client WITH provider)) AND ((score OR mastery) NEAR5 goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2019/12/23 02:32 PM
L65	101	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:32 PM
L66	4	L57 AND goal wizard	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:32 PM
L67	4	L58 AND goal wizard	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:32 PM
L68	4	L57 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:33 PM
L69	5	L58 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:33 PM
L70	4	L57 AND (goal WITH alert WITH client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:33 PM
L71	4	L58 AND (goal WITH alert WITH client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:33 PM
L72	2	"16053141"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/07/23 03:16 PM
L73	191357	field WITH (treatment OR assistance)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/07/24 10:31 AM
L74	363	field WITH (treatment OR assistance) WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/07/24 02:37 PM
L75	726	(compile OR compiled OR compiling) WITH	(US-PGPUB; USPAT; EPO; JPO;	ADJ	ON	ON	2020/07/24 03:04 PM

		(client OR patient) WITH (field OR treatment)	DERWENT; IBM_TDB)				
L76	11	(("4237344") or ("5377258") or ("20090048872") or ("20110295613")).PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2020/07/27 02:54 PM
L77	2	("20090048872"|"20110295613").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2020/09/29 09:56 AM
L78	2	("4237344"|"5377258").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2020/09/29 09:56 AM
L79	1	("20030004758").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2020/09/29 09:56 AM
L80	1	"16141471"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 10:19 AM
L81	0	"Platform for Optimizing Goal Progression".TI.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 10:19 AM
L82	43	Bradley, Nathaniel.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 10:19 AM
L83	4	("10061812").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2020/09/29 10:20 AM
L84	88	data mining WITH goal WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L85	60	data mining WITH best practices	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L86	41	(compile OR compiling OR compiled) WITH user input WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L87	115	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L88	95	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L89	2189	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L90	11	L89 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:02 AM
L91	4	L89 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:02 AM
L92	4	L89 AND (goal WITH	(US-PGPUB; USPAT;	ADJ	ON	ON	2020/09/29

		alert WITH client)	EPO; JPO; DERWENT; IBM_TDB)				11:02 AM
L93	10482	threshold WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:23 PM
L94	714	threshold WITH goal WITH (plan OR met)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:23 PM
L95	43	threshold WITH goal WITH (plan OR met) WITH (treatment OR provider OR client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:24 PM
L96	22	threshold WITH goal WITH (plan OR met) WITH (treat$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:28 PM
L97	252	threshold WITH goal WITH (treat$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:46 PM
L98	103	L97 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:46 PM
L99	7	(("20120203092") or ("20080270182") or ("10098584")).PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2021/04/08 09:52 PM
L100	5	L99 AND threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:52 PM
L101	56	(patient OR client) WITH threshold WITH goal WITH (treat$5 OR chang$4 OR modif$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:03 PM
L102	17	L101 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:03 PM
L103	49389	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:05 PM
L104	6924	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:05 PM
L105	297	(L103 OR L104) AND (threshold WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:06 PM
L106	204	L105 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:06 PM
L107	29	(L103 OR L104) AND ((threshold WITH goal) SAME (patient OR client))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:08 PM
L108	9	L107 AND (@AD<"20130315" OR	(US-PGPUB; USPAT; EPO; JPO;	ADJ	ON	ON	2021/04/08 10:08 PM

		@RLAD<"20130315")	DERWENT; IBM_TDB)				
L109	364	(treatment OR evaluation) WITH (goal) WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:39 PM
L110	10	(client OR patient) WITH goal WITH threshold WITH progress$4	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:43 PM
L111	1708	(client OR patient) WITH goal WITH (threshold OR progress$4)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:43 PM
L112	902	(client OR patient) WITH (goal NEAR5 (threshold OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:45 PM
L113	362	L112 AND @AD<"20130315"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:46 PM
L114	238	(client OR patient) WITH (goal NEAR5 (threshold OR progress$4)) WITH (treatment OR assistance OR modify$4 OR plan)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:53 PM
L115	84	L114 AND @AD<"20130315"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:53 PM
L116	327	(client OR patient) WITH goal WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 02:03 PM
L117	121	(client OR patient) WITH goal WITH (progress$4 OR threshold) WITH (modif$5 OR chang$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 02:03 PM
L118	1	"16141471"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 02:27 PM
L119	327	(patient OR client) WITH threshold WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 07:35 PM
L120	153	L119 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 07:44 PM
L121	50097	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/08/12 02:27 PM
L122	2	("8066640").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2021/08/12 02:36 PM
L133	252	patient WITH threshold	(US-PGPUB; USPAT;	ADJ	ON	ON	2022/02/25

		WITH goal	EPO; JPO; DERWENT; IBM_TDB)				09:43 PM
L134	3051	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L135	51231	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L136	7790	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L137	30	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L138	136	L134 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L139	1130	L135 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L140	292	L136 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L141	13	L136 AND ((patient OR client) WITH (threshold) WITH (alert OR goal OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:51 PM
L142	94	L135 AND ((patient OR client) WITH (threshold) WITH (alert OR goal OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:51 PM
L143	13	L134 AND ((patient OR client) WITH (threshold) WITH (alert OR goal OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:51 PM
L144	60	Bradley, Nathaniel.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:51 PM
L145	62	Gaynor, James.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:51 PM
L146	41	Paugh, Joshua.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:52 PM
L147	5	Arena, Paul.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:52 PM
L148	2	("20090192825").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2022/02/25 09:53 PM
L149	4	("11144554").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO;	ADJ	OFF	OFF	2022/02/25 10:10 PM

			DERWENT; IBM_TDB)				
L151	972	(client OR patient) WITH baseline WITH goal	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/07/25 11:43 AM
L152	73	((client OR patient) WITH baseline WITH goal) SAME threshold	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/07/25 11:43 AM
L153	154	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/07/25 11:43 AM
L154	57	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; EPO)	ADJ	ON	ON	2022/07/25 11:43 AM
L155	61	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; EPO)	ADJ	ON	ON	2023/01/13 08:53 PM
L157	139	(client OR patient)	(US-PGPUB; USPAT;	OR	ON	ON	2023/01/13

		WITH goal WITH biometric	USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)				08:53 PM
L158	633	goal WITH threshold WITH rule	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2023/03/24 02:04 PM
L159	23	(client OR patient) WITH goal WITH threshold WITH rule	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/24 02:05 PM
L160	2	("20110047404").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L161	10	("20090112924"|"20090192825"|"8313433"|"8355925"|"RE42508").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L162	7418	account WITH client WITH provider	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L163	112	data mining WITH goal WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L164	61	data mining WITH best practices	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L165	9	intensive trial teaching	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L166	9	reinforcement recorder	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM

L167	1919	goal WITH achiev$5 WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L168	9840	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L169	2100	L9 AND goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L170	155	L9 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L171	31	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L172	6	Macrosolve$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L173	96	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L174	4987	alert WITH automatic$6 WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L175	1324	alert NEAR5 automatic$6 NEAR5 threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L176	2056	(compile OR compiling OR compiled) WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L177	54	(compile OR compiling OR compiled) WITH user input WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L178	50	(compile OR compiling OR compiled) WITH "without user input"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L179	340	(score OR status) WITH "without user input"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L180	992	(status) WITH automatic$ WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L181	853	status WITH automatic$ WITH (score OR compile OR compiling OR scoring)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L182	3702	score WITH client WITH (threshold OR status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L183	223	well-being WITH client	(US-PGPUB; USPAT; EPO; JPO;	ADJ	ON	ON	2023/03/25 07:42 PM

			DERWENT; IBM_TDB)				
L184	962	well-being WITH score	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L185	18	well-being WITH client WITH score	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L186	96	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L187	9	"61791218"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L188	3	"15301419"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L189	69	client management program	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L190	3683	administrator SAME (client WITH provider)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L191	2	("7346545").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L192	4638	(track OR tracked OR tracking) NEAR2 goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L193	133	((track OR tracked OR tracking) NEAR2 goal) WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L194	90	((track OR tracked OR tracking) NEAR2 goal) SAME (behavioral OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L195	178	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L196	96	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L197	9840	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L198	20	(administrator SAME (client WITH provider)) AND ((score OR mastery) NEAR5 goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L199	31	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM

L200	1805	score WITH measurement WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L201	62988	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L202	4	("10061812").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L203	13	("20020065697"|"20020147626"|"20020194046"|"20080141138"|"20080281651"|"20090112924"|"20090192825"|"20100082381"|"20110029521"|"20110047404"|"813433"|"8355925"|"RE42508").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/25 07:42 PM
L204	31	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L205	3722	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L206	9840	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L207	62988	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L208	26	L57 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L209	155	L58 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L210	992	(status) WITH automatic$ WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L211	112	data mining WITH goal WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L212	20	(administrator SAME (client WITH provider)) AND ((score OR mastery) NEAR5 goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L213	178	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L214	9	L57 AND goal wizard	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM

L215	9	L58 AND goal wizard	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L216	92	L57 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L217	12	L58 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L218	10	L57 AND (goal WITH alert WITH client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L219	12	L58 AND (goal WITH alert WITH client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L220	7	"16053141"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L221	327785	field WITH (treatment OR assistance)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L222	490	field WITH (treatment OR assistance) WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L223	933	(compile OR compiled OR compiling) WITH (client OR patient) WITH (field OR treatment)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L224	11	(("4237344") or ("5377258") or ("20090048872") or ("20110295613")).PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L225	2	("20090048872"|"20110295613").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/25 07:42 PM
L226	2	("4237344"|"5377258").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/25 07:42 PM
L227	1	("20030004758").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/25 07:42 PM
L228	4	"16141471"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L229	0	"Platform for Optimizing Goal Progression".TI.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L230	85	Bradley, Nathaniel.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L231	4	("10061812").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L232	112	data mining WITH goal	(US-PGPUB; USPAT;	ADJ	ON	ON	2023/03/25

		WITH status	EPO; JPO; DERWENT; IBM_TDB)				07:42 PM
L233	61	data mining WITH best practices	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L234	54	(compile OR compiling OR compiled) WITH user input WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L235	178	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L236	96	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L237	3722	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L238	26	L89 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L239	92	L89 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L240	10	L89 AND (goal WITH alert WITH client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L241	13185	threshold WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L242	898	threshold WITH goal WITH (plan OR met)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L243	70	threshold WITH goal WITH (plan OR met) WITH (treatment OR provider OR client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L244	45	threshold WITH goal WITH (plan OR met) WITH (treat$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L245	358	threshold WITH goal WITH (treat$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L246	107	L97 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L247	7	(("20120203092") or ("20080270182") or ("10098584")).PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L248	5	L99 AND threshold	(US-PGPUB; USPAT; EPO; JPO;	ADJ	ON	ON	2023/03/25 07:42 PM

			DERWENT; IBM_TDB)				
L249	104	(patient OR client) WITH threshold WITH goal WITH (treat$5 OR chang$4 OR modif$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L250	18	L101 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L251	62988	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L252	9840	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L253	356	(L103 OR L104) AND (threshold WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L254	213	L105 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L255	37	(L103 OR L104) AND ((threshold WITH goal) SAME (patient OR client))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L256	10	L107 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L257	496	(treatment OR evaluation) WITH (goal) WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L258	30	(client OR patient) WITH goal WITH threshold WITH progress$4	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L259	2057	(client OR patient) WITH goal WITH (threshold OR progress$4)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L260	1043	(client OR patient) WITH (goal NEAR5 (threshold OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L261	351	L112 AND @AD<"20130315"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L262	287	(client OR patient) WITH (goal NEAR5 (threshold OR progress$4)) WITH (treatment OR assistance OR modify$4 OR plan)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L263	82	L114 AND	(US-PGPUB; USPAT;	ADJ	ON	ON	2023/03/25

		@AD<"20130315"	EPO; JPO; DERWENT; IBM_TDB)				07:42 PM
L264	434	(client OR patient) WITH goal WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L265	163	(client OR patient) WITH goal WITH (progress$4 OR threshold) WITH (modif$5 OR chang$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L266	4	"16141471"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L267	434	(patient OR client) WITH threshold WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L268	157	L119 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L269	62988	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L270	2	("8066640").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L271	309	patient WITH threshold WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L272	3722	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L273	62988	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L274	9840	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L275	31	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L276	154	L134 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L277	1193	L135 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L278	341	L136 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L279	16	L136 AND ((patient OR client) WITH (threshold) WITH (alert OR goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM

		OR progress$4))					
L280	101	L135 AND ((patient OR client) WITH (threshold) WITH (alert OR goal OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L281	15	L134 AND ((patient OR client) WITH (threshold) WITH (alert OR goal OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L282	85	Bradley, Nathaniel.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L283	66	Gaynor, James.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L284	61	Paugh, Joshua.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L285	6	Arena, Paul.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L286	2	("20090192825").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L287	4	("11144554").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L288	1050	(client OR patient) WITH baseline WITH goal	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L289	80	((client OR patient) WITH baseline WITH goal) SAME threshold	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE,	ADJ	ON	ON	2023/03/25 07:42 PM

			SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)				
L290	167	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L291	64	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; EPO)	ADJ	ON	ON	2023/03/25 07:42 PM
L292	64	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; EPO)	ADJ	ON	ON	2023/03/25 07:42 PM
L293	141	(client OR patient) WITH goal WITH biometric	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2023/03/25 07:42 PM
L294	633	goal WITH threshold WITH rule	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA,	OR	ON	ON	2023/03/25 07:42 PM

			VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)				
L295	23	(client OR patient) WITH goal WITH threshold WITH rule	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/25 07:42 PM
L296	2	"20150205930".PN.	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	OFF	OFF	2023/03/25 08:30 PM
L298	136	Bradley, Nathaniel.INV.	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/10/02 02:08 PM
L299	4	Bradley, Nathaniel.INV. AND goal.TI.	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/10/02 02:09 PM
L300	53	goal WITH biometric device	(US-PGPUB; USPAT; USOCR; FIT (AP, AT,	ADJ	ON	ON	2023/10/02 02:30 PM

			AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)				
L301	31	goal WITH biometric device	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/10/02 02:30 PM
L302	0	"biometric sensors worn by"	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/10/02 02:33 PM
L303	228	"biometric sensors worn"	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/10/02 02:33 PM
L304	29	"biometric sensors worn".CLM.	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/10/02 02:33 PM
L305	2	L304 AND (Bradley.INV. OR Marshall.INV. OR Gaynor.INV.)	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/10/02 02:34 PM
L306	5	99/03045	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2024/03/20 01:51 PM
L308	755	Douglas, Peter.INV.	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA,	ADJ	ON	ON	2024/03/20 01:51 PM

			VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)				
L309	10	Douglas, Peter.INV. AND Dudik, Evan.INV.	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2024/03/20 01:51 PM
L310	8	"20060149589"	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2024/03/20 01:52 PM
L311	1	"achieving goal progression".TI.	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2024/03/20 02:04 PM
L313	4	"optimizing goal progression".TI.	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA,	ADJ	ON	ON	2024/03/20 02:05 PM

			EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)				
L316	11	Parallax Behavioral Health$.AS.	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2024/03/20 02:05 PM
L317	7	"17499725"	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2024/03/20 03:37 PM
L318	17	"20130179450"	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO;	ADJ	ON	ON	2024/03/20 08:10 PM

L321	3	"10061812".PN. OR "11151142".PN. OR "11144554".PN.	JPO; DERWENT; IBM_TDB) (US-PGPUB; USPAT)	OR	ON	ON	2024/04/15 01:40 PM

PE2E SEARCH - Search History (Interference)

There are no Interference searches to show.

UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC PAYMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
17/499,725	**09/26/2024 05:12:53 PM Z ET**	**DHP-P0001CIP1**

Title of Invention

SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	-
CONFIRMATION #	9953	FILED BY	Ashlyn Nguyen
PATENT CENTER #	67341737	AUTHORIZED BY	Brian Owens
CUSTOMER #	133690	FILING DATE	10/12/2021
CORRESPONDENCE ADDRESS	-	FIRST NAMED INVENTOR	Nathaniel T. Bradley

Payment Information

PAYMENT METHOD	PAYMENT TRANSACTION ID	PAYMENT AUTHORIZED BY
DA / 506801	**E20249PH13356366**	**Ashlyn Nguyen**

FEE CODE	DESCRIPTION	ITEM PRICE($)	QUANTITY	ITEM TOTAL($)
2253	EXTENSION FOR RESPONSE WITHIN THIRD MONTH -	592.00	1	592.00
			TOTAL AMOUNT:	**$592.00**

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage

submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of: Bradley et al. **Application No.** 17/499,725 **Filing Date:** October 12, 2021 **For:** SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	**Confirmation No.** 9953 **Group Art Unit:** 2156 **Examiner:** Christopher J RAAB

AMENDMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

VIA EFS-WEB

Commissioner:

In reply to the Office Action mailed March 26, 2024, the shortened statutory period for response to which expires on June 26, 2024 and extends through September 26, 2024, please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims in this paper.

Remarks follow the amendments section of this paper.

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

Claim 1 (Previously presented): A method for tracking goal progression, the method comprising:

receiving input establishing clients, wherein the clients are individuals receiving treatment or assistance, and wherein the data associated with the clients is stored in a server available through one or more networks;

assigning each of the clients to one or more of the providers in response to selections from an administrator, wherein the one or more providers include at least individuals available to treat or assist each of the clients and one or more biometric devices associated with each of the clients;

establishing goals and a baseline for each of the clients and thresholds associated with each of the goals;

automatically compiling data associated with each of the clients received from the one or more providers including at least the one or more biometric devices in the server;

determining whether the goals are being met in response to the baseline and the thresholds for the compiled data; and

automatically communicating alerts in response to the compiled data varying from one of the thresholds to become significant for one or more of the clients.

Claim 2 (Original): The method according to claim 1, wherein the server is accessed

through a cloud network, and wherein a client management program is executed by communications devices utilized by the one or more providers to receive the data and track progress of the goals.

Claim 3 (Original): The method according to claim 1, further comprising:

intervening with the one or more of the clients in response to the alerts.

Claim 4 (Original): The method according to claim 3, wherein the intervening is performed by the one or more providers.

Claim 5 (Original): The method according to claim 1, wherein each of the goals is associated with a plan of action for achieving each of the goals.

Claim 6 (Original): The method according to claim 1, further comprising:

establishing a baseline for the goals of the clients.

Claim 7 (Original): The method according to claim 1, wherein the goals are established by the clients and the one or more providers.

Claim 8 (Original): The method according to claim 1, further comprising:

determining whether modifications to the goals are required in response to the compiled data.

Claim 9 (Original): The method according to claim 8, further comprising:

modifying the goals in response to the compiled data.

Claim 10 (Original): The method according to claim 8, wherein modifications are determined to be required if the one of the clients is unable to achieve the goals associated with the client.

Claim 11 (Previously presented): A system for tracking goal progression, the system comprising:

a server communicates with communications devices through a transceiver utilizing one or more networks, the server includes a processor that executes a client management program to:

receive input establishing a client, wherein the client is a individual receiving treatment or assistance, and wherein an account associated with the client is stored in a server available through one or more networks;

assign the client to one or more of the providers in response to selections from an administrator, wherein the one or more providers include at least individuals available to treat or assist the client and one or more biometric devices associated with the client;

establish goals and a baseline for the client and thresholds associated with each of the goals;

automatically compile data associated with the client received from the one or more providers including at least the one or more biometric devices in the server;

determine whether the goals are being met in response to thresholds for the compiled data; and

automatically communicate alerts in response to the compiled data varying from one of the thresholds to become significant for the client; and

a database in communication with the server configured to store at least the data, goals, and thresholds associated with the client and the one or more providers.

Claim 12 (Original): The system according to claim 11, wherein the communications devices receive the data from the one or more providers.

Claim 13 (Original): The system according to claim 11, wherein the alerts indicate that the one or more providers are to intervene with the client.

Claim 14 (Original): The system according to claim 11, wherein each of the goals is associated with a plan of action for achieving each of the goals.

Claim 15 (Original): The system according to claim 11, wherein the goals are established by the client and the one or more providers.

Claim 16 (Original): The system according to claim 11, wherein the client management program is further executed to:

determine whether modifications to the goals are required in response to the compiled data indicating the goals are not achievable; and

modify the goals in response to the compiled data indicating the goals are not achievable.

Claim 17 (Previously presented): A server comprising:

a processor for executing a set of instructions; and

a memory for storing the set of instructions, wherein the set of instructions are executed by the processor to:

receive input establishing clients receiving assistance, wherein the clients are individuals receiving treatment or assistance, and wherein the accounts are stored in a server available through one or more networks;

assign each of the clients to one or more of the providers in response to selections from an administrator, wherein the one or more providers include at least individuals available to treat or assist each of the clients and one or more biometric devices associated with each of the clients;

establish goals and a baseline for each of the clients and thresholds associated with each of the goals;

automatically compile data associated with each of the clients received from the one or more providers including at least the one or more biometric devices in the server;

determine whether the goals are being met in response to the baseline and thresholds for the compiled data; and

automatically communicate alerts in response to the compiled data varying from one of the thresholds to become significant for one or more of the clients.

Claim 18 (Original): The server according to claim 17, wherein the set of instructions are further executed to:

physically intervene with the one or more of the clients in response to the alerts, wherein the physical intervention is performed by the one or more providers.

Claim 19 (Original): The server according to claim 17, wherein each of the goals is associated with a plan of action for achieving each of the goals, wherein the goals are established by the client and the one or more providers.

Claim 20 (Previously presented): The server according to claim 17, wherein the set of instructions are further executed to:

determine whether modifications to the goals are required in response to the compiled data; and

modify the goals in response to determining the modifications to the goals are required.

REMARKS

In the Office Action, the Examiner took the following actions:

I. Claims 1 and 3 - 20 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Douglas et al. (WO 99/03045), hereinafter "Douglas"; and

II. Claim 2 is rejected under 35 U.S.C. 103 as being unpatentable over Douglas et al. (WO 99/03045), hereinafter "Douglas", in view of Chitiveli (US PGPub 2013/0179450), hereinafter "Chitiveli".

The Office Action may contain statements characterizing the related art and/or the claims. Regardless of whether any such statement is expressly identified and/or discussed herein, Applicant reserves the right to disagree with any such statement or characterization in the Office Action.

Claims 1-20 remain pending and under examination. For at least the following reasons, Applicant respectfully requests reconsideration and withdrawal of the rejections.

Claim Rejections - 35 USC§ 102

Claims 1 and 3 - 20 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Douglas et al. (WO 99/03045), hereinafter "Douglas". This rejection is respectfully traversed.

The Examiner bears the burden of establishing a prima facie case of obviousness based on the prior art when rejecting claims under 35 U.S.C. §103. In re

Fritch, 972 F.2d 1260, 23 U.S.P.Q.2d 1780 (Fed. Cir. 1992). When evaluating claims for obviousness under 35 U.S.C. 103, all the limitations of the claims must be considered and given weight. Ex parte Grasselli, 231 USPQ 393 (Bd. App. 1983) aff'd mem. 738 F.2d 453 (Fed. Cir. 1984) (emphasis added).

With regard to claim 1, Douglas does not appear to teach, suggest, or disclose "automatically compiling data associated with each of the clients received from the one or more providers including at least the one or more biometric devices in the server." The recited portion of Douglas teaches the following:

> Furthermore, information as to the total amount of time that the patient has been participating in the program may be given as shown at 246. Column 258 shows the patient's vital signs and other health-related factors, such as blood pressure 250, number of cigarettes smoked per day 252, amount of physical activity 254, weight 256, and cholesterol level 258. Some of these factors may be monitored and reported on a weekly basis, as shown in columns 260-268. Other factors, such as the patient's cholesterol level 258, may be monitored and reported on a bi-weekly basis, as shown in columns 260, 264, and 268. The ultimate goal to be achieved in each of the specified areas is given in column 272.
>
> A list of the risk factors which may affect the patient's recovery may further be pinpointed as shown at 270.
>
> Vital signs may be represented graphically for the patient, physician and case advisor. These may include charts or graphs of the patient's blood pressure 250A (FIG. 41), physical activity 254A (FIG. 42), weight 256A (FIG. 43), and cholesterol level 258A (FIG. 44). These graphs allow the physician/case advisor to review and grasp the patient's progress visually over a period of time, and help him or her determine how the patient is doing in relation to the ultimate goals that are to be achieved in the charted areas. Referring again to FIG. 40, a physician/case advisor is also given an option 274 to assess the patient's behavior. Upon selection of this option, the system provides a behavioral change assessment form 305 like the one shown in FIG. 45. This form 305 is used to determine how inclined the selected patient is toward complying with the recommended program. In the preferred embodiment, on-line questionnaires are submitted to the patients, asking them to rate their behavioral intention 300, self-efficacy 302, and social support 304.
>
> Alternate forms of evaluation may also be used to assess the likelihood of a patient's compliance with the program.
>
> The system periodically assesses and reports the patient's behavioral change as shown in columns 306 and 308. The desired goals 310 are also listed to monitor whether the patient is making progress towards them. If a patient continues to score low on the behavioral change assessment form 305, this may indicate that he or she is

unable to change his or her lifestyle, and lead to the conclusion that the patient should be taken off the system.

The system generates reports on patient progress based on the data shown in FIGS. 40-45, as frequently as the physician desires. These reports can be received via either e-mail or facsimile. The frequency of reports will depend on the needs of the particular patient, and may be triggered by the achievement of goals or the setting off of alarm signals as described above. The system can also generate regularly scheduled reports for a physician's review on a default basis, depending on a patient's needs. For example, patients who are relatively ill can be reviewed twice a week or more, even if no warning signals occur. (Douglas, p. 20, lines 3-37)

As shown, Douglas refers to graphically representing information based on answers to questionnaires and health related data entered by the user. (Douglas, Abstract, FIG. 45) Douglas does not teach "automatically compiling". This language or analogous language does not appear to be used. Douglas also does not teach "automatically compiling data associated with each of the clients received from the one or more providers including at least the one or more biometric devices in the server." Douglas teaches patient entered information. (Douglas, claim 4, Abstract) For at least this reason, claim 1 is allowable over the cited art.

With regard to claim 1, the cited art does not appear to teach, suggest, or disclose "assigning each of the clients to one or more of the providers in response to selections from an administrator, wherein the one or more providers include at least individuals available to treat or assist each of the clients and one or more biometric devices associated with each of the clients." The recited portion of Douglas teaches the following:

Once the patient is set up on the system, it assists him or her in complying with his or her behavior modification program (block 1020, FIG. 60). (p. 8, lines 28-31)

The system automatically correlates the patient's input with the physician's to check for accuracy. In addition, the system automatically provides the physician with reports of patient progress. Depending on the patient's plan requirements, the case advisor periodically reviews the patient-reported and physician-reported input to monitor

whether the patient is complying with program parameters and meeting goals (block 1036, FIG. 60).

As part of the feedback process, the system provides an "alarm" option (block 1040, FIG. 60). The system compares actual data about the patient with the goals and parameters residing in the system's database and automatically notifies the physician or case advisor via e-mail or facsimile (or pager depending upon the severity of the problem), if a health risk is present (block 1042, FIG. 60). For instance, if a patient's current blood pressure is potentially dangerous, the system will automatically send an alarm to the physician or case advisor and require his or her immediate action.

If the difference between current data and goals does not present a threatening situation, the system will simply notify the physician or case advisor that these goals are not being met. For example, if the current data states that the patient has lost 5 pounds instead of 10, the system will notify the physician or case advisor of this fact. This information, although not life-threatening, must nonetheless be addressed by the physician or case advisor. He or she may then contact the patient in order to support and to further motivate him or her to meet the desired goals (block 1044, FIG. 60). In addition, the physician or case advisor may recommend that the program be modified to suit the patient's condition (block 1046, FIG. 60). (p.11, line 6 – p.12, line 2)

There is no mention of assigning each of the clients to one or more of the providers. The word client is not utilized in Douglas as it relates to being assigned to a provider. Likewsie, Douglas also does not mention biometric devices in this context. For at least this reason, claim 1 is allowable over the cited art.

In addition, Douglas does not teach, suggest, or disclose “determining whether the goals are being met in response to the baseline and the thresholds for the compiled data.” Douglas does not teach thresholds for the compiled data. In fact, Douglas does not mention thresholds at all. The cited art talks generically about whether “goals are not being met.” (Douglas, p. 11, 19) There is no mention of “thresholds.” For at least this reason, claim 1 is allowable over Douglas.

Furthermore, Douglas does not teach, suggest, or disclose does not teach, suggest, or disclose “automatically communicating alerts in response to the compiled data varying from at least one of the thresholds to become significant for one of the one

or more clients." As previously mentioned Douglas does not disclose thresholds. In addition, Douglas does not mention the compiled data "varying from at least one of the thresholds to become significant..." This language is distinct from that of Douglas that seems to relate to health risks. (Douglas, p.11, lines 11-15) For at least this reason, claim 1 is allowable over the cited art.

Independent claims 11 and 17 are allowable for at least the same reasons as claim 1. Claims 2-10, 12-16, and 18-20 are allowable at least based on their dependence on claims 1, 11, and 17, respectively.

Applicants respectfully request an Examiner interview to move forward prosecution and to discuss the art of record.

CONCLUSION

In view of the foregoing, Applicant respectfully requests reconsideration of this application and the timely allowance of the pending claims.

This is a request for a three month extension of time, the small entity fee of $592 for which is being paid at the time of filing this response. No additional fees or extensions of time are believed due; however, the Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, to fees to Deposit Account 506801.

Respectfully submitted,

Goodhue, Coleman & Owens, P.C.

Dated: September 26, 2024

By: /Brian D. Owens/
Brian Dean Owens
Reg. No. 55517
(515) 218-7888

UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
17/499,725	**09/26/2024 05:12:53 PM Z ET**	**DHP-P0001CIP1**

Title of Invention

SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	-
CONFIRMATION #	9953	FILED BY	Ashlyn Nguyen
PATENT CENTER #	67341737	FILING DATE	10/12/2021
CUSTOMER #	133690	FIRST NAMED INVENTOR	Nathaniel T. Bradley
CORRESPONDENCE ADDRESS	-	AUTHORIZED BY	Brian Owens

Documents

TOTAL DOCUMENTS: 3

DOCUMENT		PAGES	DESCRIPTION	SIZE (KB)
DHP-P0001CIP1_17499725_FILED-NON-FINAL-OFFICE-ACTION-RESPONSE_9-26-24.pdf		13	-	236 KB
DHP-P0001CIP1_17499725_FILED-NON-FINAL-OFFICE-ACTION-RESPONSE_9-26-24-A....pdf	(1-1)	1	Amendment/Request for Reconsideration-After Non-Final Rejection	162 KB
DHP-P0001CIP1_17499725_FILED-NON-FINAL-OFFICE-ACTION-RESPONSE_9-26-24-CLM.pdf	(2-7)	6	Claims	169 KB

DHP-P0001CIP1_17499725_FILED-NON-FINAL-OFFICE-ACTION-RESPONSE_9-26-24-REM.pdf	(8-13)	6	Applicant Arguments/Remarks Made in an Amendment	224 KB

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)
DHP-P0001CIP1_17499725_FILED-NON-FINAL-OFFICE-ACTION-RESPONSE_9-26-24.pdf	7BEB04F77882FBC63CB2A9CE76B4CC9B7933113FF1475C9D1A2FCB30386A972D9692B12EA9F1C81949B3130DD4432EE9E6582CBDACD53548324C2EA21FC77C2A
DHP-P0001CIP1_17499725_FILED-NON-FINAL-OFFICE-ACTION-RESPONSE_9-26-24-A....pdf	59ABDA520CC5B5A2E5465CC0F3C877428DC5DC3F96C669FF65C4A65F62B8E7E477C4D98F3770E93DFFE66E6A58FF46E1F90AA2B90F800CE08768F50558611A86
DHP-P0001CIP1_17499725_FILED-NON-FINAL-OFFICE-ACTION-RESPONSE_9-26-24-CLM.pdf	DC0EC3DC83218D8AE93774DEA45BFC719B04A8C4845D0B807346866F8CA357E632072043B7997A4325A7906ECC111003B1709CD7558F1044E2835FA57C4CF177
DHP-P0001CIP1_17499725_FILED-NON-FINAL-OFFICE-ACTION-RESPONSE_9-26-24-REM.pdf	B1BB18B8DFB2C2F58505D560668EA021CE1120CD6BD7A53FA5680DF7F15FAC650851FEEF1CE0F729225F66F20F3DAB7229640036953B54ED7DB5FCD9ADB656FE

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875	Application or Docket Number 17/499,725	Filing Date 10/12/2021	☐ To be Mailed

ENTITY: ☐ LARGE ☑ SMALL ☐ MICRO

APPLICATION AS FILED - PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA		RATE ($)	FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A		N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A		N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A		N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*		x $50 =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*		x $240 =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).				
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))					
* If the difference in column 1 is less than zero, enter "0" in column 2.				TOTAL	

APPLICATION AS AMENDED - PART II

		(Column 1)		(Column 2)	(Column 3)			
AMENDMENT	09/26/2024	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	* 20	Minus	** 20	= 0		x $40 =	0
	Independent (37 CFR 1.16(h))	* 3	Minus	*** 3	= 0		x $192 =	0
	☐ Application Size Fee (37 CFR 1.16(s))							
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							
							TOTAL ADD'L FEE	0

		(Column 1)		(Column 2)	(Column 3)			
AMENDMENT		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	*	Minus	**	=		x $0 =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=		x $0 =	
	☐ Application Size Fee (37 CFR 1.16(s))							
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							
							TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.	Program Support Asistant
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".	/DIANIECE M JACOBS/
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".	
The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.	

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR/ PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
17/499,725	10/12/2021	Bradley et al.	DHP-P0001CIP1

	EXAMINER	
Goodhue, Coleman & Owens, P.C. 7300 Westown Parkway, Suite 110 West Des Moines, IA 50266	--	
	ART UNIT	PAPER
	--	20240427-vOBNtz

DATE MAILED: 27 April 2024

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

PTO-90C (Rev.04-03)

Notice of Potential Erroneous Release of Patent Application Titles

On February 5, 2024, the United States Patent and Trademark Office (USPTO), replaced the Electronic Patent Assignment System (EPAS) and Electronic Trademark Assignment System (ETAS) with Assignment Center.

Between February 5, 2024 and March 29, 2024, the USPTO, unintentionally, through a computer programming error, permitted bibliographic information to be viewed by unauthorized individuals with access to registered Assignment Center accounts. This bibliographic information was limited to the application number (the two-digit series code plus the six-digit serial number) and title of the invention.

You are receiving this notification because your application's patent title may have been viewed during that time frame by individual(s) who lacked permission to do so. The software error was first reproduced by USPTO on March 28, 2024, and was corrected on March 29, 2024. Only application numbers and titles were disclosed; it is important to note that your specification and claims were not part of the information made available and were not accessed.

Any improper access of the application information between the dates of February 5, 2024 and March 29, 2024, is not considered a publication of such applications under 35 U.S.C. 122(b). No rights in United States patents are threatened by the access to unpublished applications. It is extremely unlikely that the title could disclose the invention in a way that would constitute patent-defeating prior art in any jurisdiction. To the extent any issue is raised, the USPTO will assist applicants by confirming that the disclosure was erroneous and inadvertent.

We're committed to data security and are taking enhanced steps to prevent incidents such as this from happening in the future. The USPTO sincerely regrets this error and is instituting more testing controls, both manual and automated testing, to prevent similar processing errors in the future.

Inquiries regarding this matter may be directed to Mark Polutta, Senior Legal Advisor, at (571) 272-7709 or Andrew Stclair, Legal Advisor, at (571) 270-0238, both of the Office of Patent Legal Administration or via email addressed to Patent.Practice@uspto.gov.



Henry "Jamie" Holcombe
Chief Information Officer
US Patent and Trademark Office
Office +1 (571) 272-9400

Dated: April 27th, 2024

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/499,725	10/12/2021	Nathaniel T. Bradley	DHP-P0001CIP1	9953

133690 7590 04/19/2024

Goodhue, Coleman & Owens, P.C.
7300 Westown Parkway, Suite 110
West Des Moines, IA 50266

EXAMINER	
RAAB, CHRISTOPHER J	

ART UNIT	PAPER NUMBER
2156	

NOTIFICATION DATE	DELIVERY MODE
04/19/2024	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USPTO@dockettrak.com
docketing@goodhue.com
eofficeaction@appcoll.com

Examiner-Initiated Interview Summary	**Application No.** 17/499,725	**Applicant(s)** Bradley et al.		
	Examiner CHRISTOPHER J RAAB	**Art Unit** 2156	**AIA (First Inventor to File) Status** No	**Page** 1 of 1

All Participants (applicant, applicants representative, PTO personnel)	**Title**	**Type**
CHRISTOPHER J RAAB	Primary Examiner	Telephonic
Brian D. Owens	Attorney	

Date of Interview: 08 April 2024

Issues Discussed:

Other

Examiner contacted Applicant's Representative to discuss the most recent Office Action that was mailed out, the Non-Final Rejection on March 26, 2024. Examiner discussed that the Office Action inadvertently left out a potential double patenting rejection, which had been made of record in previous Office Actions. At the moment, no allowable claims have been identified, and Applicant previously stated that the double patenting rejection(s) would be addressed when allowable claims are found.

/CHRISTOPHER J RAAB/ Primary Examiner, Art Unit 2156	

Applicant is reminded that a complete written statement as to the substance of the interview must be made of record in the application file. It is the applicants responsibility to provide the written statement, unless the interview was initiated by the Examiner and the Examiner has indicated that a written summary will be provided. See MPEP 713.04
Please further see:
MPEP 713.04
Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews, paragraph (b)
37 CFR § 1.2 Business to be transacted in writing

Applicant recordation instructions: It is not necessary for applicant to provide a separate record of the substance of interview.

Examiner recordation instructions: Examiners must summarize the substance of any interview of record. A complete and proper recordation of the substance of an interview should include the items listed in MPEP 713.04 for complete and proper recordation including the identification of the general thrust of each argument or issue discussed, a general indication of any other pertinent matters discussed regarding patentability and the general results or outcome of the interview, to include an indication as to whether or not agreement was reached on the issues raised.

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/499,725	Bradley et al.
	Examiner	Art Unit
	CHRISTOPHER J RAAB	2156

CPC - Searched*		
Symbol	**Date**	**Examiner**
G06Q10/06, limited keyword search	03/25/2023	CJR
G06Q10/0637, limited keyword search	03/25/2023	CJR

CPC Combination Sets - Searched*		
Symbol	**Date**	**Examiner**

US Classification - Searched*			
Class	**Subclass**	**Date**	**Examiner**

* See search history printout included with this form or the SEARCH NOTES box below to determine the scope of the search.

Search Notes		
Search Notes	**Date**	**Examiner**
PE2E image and keyword search	03/25/2023	CJR
NPL Search: Google Scholar	03/25/2023	CJR
Inventor Name Search: PALM and PE2E	03/25/2023	CJR
Updated search	10/02/2023	CJR
Updated search	03/20/2024	CJR
IPR2024-00616 Reviewed Petition for Post Grant Review of U.S. Patent No. 11,144,554 on 04/15/2024	04/15/2024	CJR
IPR2024-00617 Reviewed Petition for Post Grant Review of U.S. Patent No. 11,151,142 on 04/15/2024	04/15/2024	CJR
IPR2024-00618 Reviewed Petition for Post Grant Review of U.S. Patent No. 10,061,812 on 04/15/2024	04/15/2024	CJR

/CHRISTOPHER J RAAB/ Primary Examiner, Art Unit 2156	

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/499,725	Bradley et al.
	Examiner	Art Unit
	CHRISTOPHER J RAAB	2156

Interference Search			
US Class/CPC Symbol	US Subclass/CPC Group	Date	Examiner

/CHRISTOPHER J RAAB/ Primary Examiner, Art Unit 2156	

PTO/SB/08a (01-22)
Approved for use through 05/31/2024. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	18502813
Filing Date	2023-11-06
First Named Inventor	Nathaniel T. Bradley
Art Unit	2156
Examiner Name	Christopher J RAAB
Attorney Docket Number	DHP-P0001CIP3

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1							☐

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	18502813
	Filing Date	2023-11-06
	First Named Inventor	Nathaniel T. Bradley
	Art Unit	2156
	Examiner Name	Christopher J RAAB
	Attorney Docket Number	DHP-P0001CIP3

	1	Petition for Inter Partes Review Under 35U.S.C. §312, TALADOC HEALTH INC., V. DATA HEALTH PARTNERS, INC., CASE IPR2024-00616, Patent 11,144,554 B2. February 28, 2024. 89 pages.	☒
	2	Petition for Inter Partes Review Under 35U.S.C. §312, TALADOC HEALTH INC., V. DATA HEALTH PARTNERS, INC., CASE IPR2024-00617, Patent 11,151,142 B2. March 1, 2024. 87 pages.	☒
	3	Petition for Inter Partes Review Under 35U.S.C. §312, TALADOC HEALTH INC., V. DATA HEALTH PARTNERS, INC., CASE IPR2024-00618, Patent 10,061,812 B2. February 29, 2024. 87 pages.	☒

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	18502813
	Filing Date	2023-11-06
	First Named Inventor	Nathaniel T. Bradley
	Art Unit	2156
	Examiner Name	Christopher J RAAB
	Attorney Docket Number	DHP-P0001CIP3

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☒ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Brian D. Owens/	Date (YYYY-MM-DD)	2024-03-27
Name/Print	Brian Dean Owens	Registration Number	55517

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
17/499,725	**03/27/2024 05:31:35 PM Z ET**	**DHP-P0001CIP1**

Title of Invention

SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	-
CONFIRMATION #	9953	FILED BY	Ashlyn Nguyen
PATENT CENTER #	64863787	FILING DATE	10/12/2021
CUSTOMER #	133690	FIRST NAMED INVENTOR	Nathaniel T. Bradley
CORRESPONDENCE ADDRESS	-	AUTHORIZED BY	Brian Owens

Documents

TOTAL DOCUMENTS: 4

DOCUMENT	PAGES	DESCRIPTION	SIZE (KB)
DHP-P0001CIP3_18502813_FILED-SUPPLEMENTAL-IDS.pdf	4	Information Disclosure Statement (IDS) Form (SB08)	1252 KB
142-Petition-size-reduce.pdf	87	Non Patent Literature	14664 KB
554-Petition-size-reduce.pdf	89	Non Patent Literature	15198 KB
812-Petition-size-reduce.pdf	87	Non Patent Literature	13792 KB

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)
DHP-P0001CIP3_18502813_FILED-	26479402270A1F8C31B875248AD3F52EA6D5A035E6B64E1B2A9774A53900781761A032FBFB0E7DEDC6256EA3629A6AEE55

SUPPLEMENTAL-IDS.pdf	787D7DE0A7F4A090D65646DC087C5A
142-Petition-size-reduce.pdf	2CE5A25321F8E86BE9D449D360F00C5E51CDB448BA019E044F836CA8C656DCA7AC9A9A0769485A3E5B76CE1710BA9770ADC40D007B59AD2A8EB8F83BF5D93712
554-Petition-size-reduce.pdf	B40F65A21C9E95E236983F70380A2D0824F1A542A6EDC0E8603FA134EB6F5C702FAA8C8E25E431D4AE70B4DA09DECE35874A6F617BB769A419E41F611BBFE0B5
812-Petition-size-reduce.pdf	4965522B341841C601E52DDC291EA6B3551CF79B34551F6764F08B69E55CBD3DE521E28DEAF472E3B9B21CE4890B20E67E9C7676FD1E87ADFD290A8D5BCC8600

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/SB/08a (01-22)
Approved for use through 05/31/2024. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	17499725
Filing Date	2021-10-12
First Named Inventor	Nathaniel T. Bradley
Art Unit	2156
Examiner Name	Christopher J RAAB
Attorney Docket Number	DHP-P0001CIP1

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1							☐

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17499725
	Filing Date	2021-10-12
	First Named Inventor	Nathaniel T. Bradley
	Art Unit	2156
	Examiner Name	Christopher J RAAB
	Attorney Docket Number	DHP-P0001CIP1

	1	Petition for Inter Partes Review Under 35U.S.C. §312, TALADOC HEALTH INC., V. DATA HEALTH PARTNERS, INC., CASE IPR2024-00616, Patent 11,144,554 B2. February 28, 2024. 89 pages.	☒
	2	Petition for Inter Partes Review Under 35U.S.C. §312, TALADOC HEALTH INC., V. DATA HEALTH PARTNERS, INC., CASE IPR2024-00617, Patent 11,151,142 B2. March 1, 2024. 87 pages.	☒
	3	Petition for Inter Partes Review Under 35U.S.C. §312, TALADOC HEALTH INC., V. DATA HEALTH PARTNERS, INC., CASE IPR2024-00618, Patent 10,061,812 B2. February 29, 2024. 89 pages.	☒

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17499725
	Filing Date	2021-10-12
	First Named Inventor	Nathaniel T. Bradley
	Art Unit	2156
	Examiner Name	Christopher J RAAB
	Attorney Docket Number	DHP-P0001CIP1

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☒ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Brian D. Owens/	Date (YYYY-MM-DD)	2024-03-27
Name/Print	Brian Dean Owens	Registration Number	55517

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
17/499,725	**03/27/2024 05:18:11 PM Z ET**	**DHP-P0001CIP1**

Title of Invention

SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	-
CONFIRMATION #	9953	FILED BY	Ashlyn Nguyen
PATENT CENTER #	64863074	FILING DATE	10/12/2021
CUSTOMER #	133690	FIRST NAMED INVENTOR	Nathaniel T. Bradley
CORRESPONDENCE ADDRESS	-	AUTHORIZED BY	Brian Owens

Documents

TOTAL DOCUMENTS: 4

DOCUMENT	PAGES	DESCRIPTION	SIZE (KB)
DHP-P0001CIP1_17499725_FILED-SUPPLEMENTAL-IDS_3-27-24.pdf	4	Information Disclosure Statement (IDS) Form (SB08)	1252 KB
142-Petition-size-reduce.pdf	87	Non Patent Literature	14664 KB
554-Petition-size-reduce.pdf	89	Non Patent Literature	15198 KB
812-Petition-size-reduce.pdf	87	Non Patent Literature	13792 KB

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)
DHP-	F5D2A40B1E32569F9AF3B55ADBF0C85BE0F9BD03DD9610DD

P0001CIP1_17499725_FILED-SUPPLEMENTAL-IDS_3-27-24.pdf	7654441B29778B08BE143657233CDF240313FD929041CA43530B1140943176086C4800897497D51B
142-Petition-size-reduce.pdf	2CE5A25321F8E86BE9D449D360F00C5E51CDB448BA019E044F836CA8C656DCA7AC9A9A0769485A3E5B76CE1710BA9770ADC40D007B59AD2A8EB8F83BF5D93712
554-Petition-size-reduce.pdf	B40F65A21C9E95E236983F70380A2D0824F1A542A6EDC0E8603FA134EB6F5C702FAA8C8E25E431D4AE70B4DA09DECE35874A6F617BB769A419E41F611BBFE0B5
812-Petition-size-reduce.pdf	4965522B341841C601E52DDC291EA6B3551CF79B34551F6764F08B69E55CBD3DE521E28DEAF472E3B9B21CE4890B20E67E9C7676FD1E87ADFD290A8D5BCC8600

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC PAYMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
17/499,725	**03/27/2024 05:18:11 PM Z ET**	**DHP-P0001CIP1**

Title of Invention

SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	-
CONFIRMATION #	9953	FILED BY	Ashlyn Nguyen
PATENT CENTER #	64863074	AUTHORIZED BY	Brian Owens
CUSTOMER #	133690	FILING DATE	10/12/2021
CORRESPONDENCE ADDRESS	-	FIRST NAMED INVENTOR	Nathaniel T. Bradley

Payment Information

PAYMENT METHOD	PAYMENT TRANSACTION ID	PAYMENT AUTHORIZED BY
DA / 506801	**E20243QH21029701**	**Ashlyn Nguyen**

FEE CODE	DESCRIPTION	ITEM PRICE($)	QUANTITY	ITEM TOTAL($)
2806	SUBMISSION OF AN INFORMATION DISCLOSURE STATEMENT	104.00	1	104.00
			TOTAL AMOUNT:	**$104.00**

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C.

371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI124693

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Order Granting Plaintiff/Judgment Creditor's Motion for an Assignment Order in Aid of Enforcement of Judgment

CONVEYING PARTY DATA

Name	Execution Date
Parallax Behavioral Health Inc.	09/21/2023
Parallax Health Sciences, Inc.	09/21/2023

RECEIVING PARTY DATA

Individual Name:	Shahla Melamed
Street Address:	3209 Hutton Drive
City:	Beverly Hills
State/Country:	CALIFORNIA
Postal Code:	90210

PROPERTY NUMBERS Total: 6

Property Type	Number
Patent Number:	10061812
Patent Number:	11144554
Patent Number:	11151142
Application Number:	17499725
Application Number:	17505166
Application Number:	17546594

CORRESPONDENCE DATA

Fax Number: 6197449994

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6197449992
Email: mvivoli@vivolilaw.com
Correspondent Name: Michael W. Vivoli
Address Line 1: 3104 Fourth Avenue
Address Line 4: San Diego, CALIFORNIA 92103

NAME OF SUBMITTER:	Theodore Gregor
SIGNATURE:	Theodore Gregor
DATE SIGNED:	03/27/2024
	This document serves as an Oath/Declaration (37 CFR 1.63).

Total Attachments: 72

source=Order Granting Plaintiff-Judgment Creditor's Motion for an Assignment Order in Aid of Enforcement of Judgment filed 9-21-23 (00249351xAB189)#page1.tif

source=Order Granting Plaintiff-Judgment Creditor's Motion for an Assignment Order in Aid of Enforcement of Judgment filed 9-21-23 (00249351xAB189)#page2.tif

source=IP Agreement and Declaration#page1.tif

source=IP Agreement and Declaration#page2.tif

source=IP Agreement and Declaration#page3.tif

source=IP Agreement and Declaration#page4.tif

source=IP Agreement and Declaration#page5.tif

source=IP Agreement and Declaration#page6.tif

source=IP Agreement and Declaration#page7.tif

source=IP Agreement and Declaration#page8.tif

source=IP Agreement and Declaration#page9.tif

source=IP Agreement and Declaration#page10.tif

source=IP Agreement and Declaration#page11.tif

source=IP Agreement and Declaration#page12.tif

source=IP Agreement and Declaration#page13.tif

source=IP Agreement and Declaration#page14.tif

source=IP Agreement and Declaration#page15.tif

source=IP Agreement and Declaration#page16.tif

source=IP Agreement and Declaration#page17.tif

source=IP Agreement and Declaration#page18.tif

source=IP Agreement and Declaration#page19.tif

source=IP Agreement and Declaration#page20.tif

source=IP Agreement and Declaration#page21.tif

source=IP Agreement and Declaration#page22.tif

source=IP Agreement and Declaration#page23.tif

source=IP Agreement and Declaration#page24.tif

source=IP Agreement and Declaration#page25.tif

source=IP Agreement and Declaration#page26.tif

source=IP Agreement and Declaration#page27.tif

source=IP Agreement and Declaration#page28.tif

source=IP Agreement and Declaration#page29.tif

source=IP Agreement and Declaration#page30.tif

source=IP Agreement and Declaration#page31.tif

source=IP Agreement and Declaration#page32.tif

source=IP Agreement and Declaration#page33.tif

source=IP Agreement and Declaration#page34.tif

source=IP Agreement and Declaration#page35.tif

source=IP Agreement and Declaration#page36.tif

source=IP Agreement and Declaration#page37.tif

source=IP Agreement and Declaration#page38.tif

source=IP Agreement and Declaration#page39.tif

source=IP Agreement and Declaration#page40.tif

source=IP Agreement and Declaration#page41.tif

source=IP Agreement and Declaration#page42.tif

source=IP Agreement and Declaration#page43.tif

source=IP Agreement and Declaration#page44.tif
source=IP Agreement and Declaration#page45.tif
source=IP Agreement and Declaration#page46.tif
source=IP Agreement and Declaration#page47.tif
source=IP Agreement and Declaration#page48.tif
source=IP Agreement and Declaration#page49.tif
source=IP Agreement and Declaration#page50.tif
source=IP Agreement and Declaration#page51.tif
source=IP Agreement and Declaration#page52.tif
source=IP Agreement and Declaration#page53.tif
source=IP Agreement and Declaration#page54.tif
source=IP Agreement and Declaration#page55.tif
source=IP Agreement and Declaration#page56.tif
source=IP Agreement and Declaration#page57.tif
source=IP Agreement and Declaration#page58.tif
source=IP Agreement and Declaration#page59.tif
source=IP Agreement and Declaration#page60.tif
source=IP Agreement and Declaration#page61.tif
source=IP Agreement and Declaration#page62.tif
source=IP Agreement and Declaration#page63.tif
source=IP Agreement and Declaration#page64.tif
source=IP Agreement and Declaration#page65.tif
source=IP Agreement and Declaration#page66.tif
source=IP Agreement and Declaration#page67.tif
source=IP Agreement and Declaration#page68.tif
source=IP Agreement and Declaration#page69.tif
source=IP Agreement and Declaration#page70.tif

Electronically Received 05/01/2023 09:28 AM

FILED
Superior Court of California
County of Los Angeles
09/21/2023
David W. Slayton, Executive Officer / Clerk of Court
By: K. Meloyer Deputy

SUPERIOR COURT OF THE STATE OF CALIFORNIA

FOR THE COUNTY OF LOS ANGELES, WESTERN JUDICIAL DISTRICT

SHAHLAH MELAMED, an individual Plaintiff, vs. PARALLAX HEALTH SCIENCES, INC., a Nevada corporation; ROXSAN PHARMACY, INC. a California corporation, nominally; J. MICHAEL REDMOND, an individual; EDWARD WITHROW, III, an individual; HUNTINGTON CHASE FINANCIAL, an entity of unknown form and citizenship; CALLI BUCCI, an individual; DAVE ENGERT, an individual; 1st PMF BANCORP, a corporation of unknown citizenship; and DOES 1 through 50, Inclusive. Defendants.	LEAD CASE NO.: SC 124873 (Related to Case Nos. SC124898, SC125702 and SC125142) ~~[PROPOSED]~~ **ORDER GRANTING PLAINTIFF/JUDGMENT CREDITOR'S MOTION FOR AN ASSIGNMENT ORDER IN AID OF ENFORCEMENT OF JUDGMENT** Date: September 21, 2023 Time: 8:30 a.m. Dept.: M Judge: Hon. Mark A. Young **Reservation ID: 074489123010** Complaint Filed: October 15, 2015 Trial Date: Vacated After Settlement

Based on the motion by Plaintiff/Judgment Creditor Shahla Melamed ("Melamed") for an Assignment Order in aid of enforcement of Melamed's judgment herein, assigning to Plaintiff all of the rights to payment held by Parallax Health Sciences, Inc. ("Parallax") under that certain Senior Secured Corporate Promissory Note dated May 11, 2022 ("the Note"), as well as that

Royalty Agreement bearing the same date ("Royalty Agreement"), the memorandum of points and authorities filed in support thereof, the Declaration of Michael W. Vivoli and attached exhibits filed therewith, all papers filed in support of and in reply to the opposition to the motion, the complete court record and file herein and the arguments presented at the hearing on the motion, and good cause appearing therefrom, IT IS HEREBY ODERED that Melamed's motion is GRANTED.

As such, any and all rights to payment held Parallax Health Sciences, Inc. in the Note and the Royalty Agreement are hereby assigned to Plaintiff/Judgment Creditor Shahla Melamed.

Any payments received by Melamed shall be credited against the payment obligation owed by Parallax under its judgment to Melamed herein.

IT IS SO ORDERED.

Dated: 09/21/2023

HON. MARK A. YOUNG
JUDGE OF THE SUPERIOR COURT

MICHAEL W. VIVOLI (Bar No. 184366)
JASON P. SACCUZZO (Bar No. 221837)
VIVOLI SACCUZZO, LLP
3104 Fourth Avenue
San Diego, California 92103
(619) 744-9992 (Tel)
(619) 744-9994 (Fax)

Attorneys for Plaintiff/Judgment Creditor,
SHAHLA MELAMED

SUPERIOR COURT OF THE STATE OF CALIFORNIA

FOR THE COUNTY OF LOS ANGELES, WESTERN JUDICIAL DISTRICT

SHAHLA MELAMED, an individual Plaintiff, vs. PARALLAX HEALTH SCIENCES, INC., a Nevada corporation; ROXSAN PHARMACY, INC. a California corporation, nominally; J. MICHAEL REDMOND, an individual; EDWARD WITHROW, III, an individual; HUNTINGTON CHASE FINANCIAL, an entity of unknown form and citizenship; CALLI BUCCI, an individual; DAVE ENGERT, an individual; 1st PMF BANCORP, a corporation of unknown citizenship; and DOES 1 through 50, Inclusive. Defendants.	LEAD CASE NO.: SC 124873 (Related to Case Nos. SC124898, SC125702 and SC125142) **DECLARATION OF MICHAEL W. VIVOLI & ATTACHED EXHIBITS INS SUPPORT OF PLAINTIFF/JUDGMENT CREDITOR'S MOTION FOR AN ASSIGNMENT ORDER** Date: September 21, 2023 Time: 8:30 a.m. Dept.: M Judge: Hon. Mark A. Young **Reservation ID: 074489123010** Complaint Filed: October 15, 2015 Trial Date: Vacated After Settlement

I, MICHAEL W. VIVOLI, declare as follows:

1. I am an attorney duly licensed to practice law before all courts of the state of California and am a partner in the law firm of Vivoli Saccuzzo, LLP, attorneys of record for Plaintiff herein, Shahla "Shana" Melamed ("Melamed"). I have been directly involved in all aspects of this case since it was filed in October of 2015, and I served as Plaintiff's sole trial

counsel in the trial of the Lead Case herein, to which three other cases were then deemed "related" to this one. As such, and by virtue of my personal participation in the matters herein averred, I have personal knowledge of the facts contained herein and, if called upon to testify with respect thereto, I could and would competently do so.

2. On August 14, 2020, this Court entered judgment in favor of Melamed in the sum of $20,000,000 on the stipulated judgment previously submitted to the Court, signed by the parties. Attached hereto as **Exhibit "1"** is a true and correct copy of the Judgment entered that day and which was thereafter mailed to the parties together with a Notice of Entry of Judgment. The stipulated judgment that led to **Exhibit "1"** was executed after a settlement meeting that I attended, during which Parallax represented, by and through Paul Arena, its CEO, that Parallax had "lined up investors" willing to fund a settlement payment to Melamed, provided the settlement resolved all claims against Parallax and its assets, against which Melamed held a lien.

3. In or after May of 2022, I learned that Parallax had purported to sell all of its intellectual property to "Data Health Partners, Inc." and I accessed a copy of the Form 8-k filed with the SEC by Parallax in connection with that purported sale. Attached hereto as **Exhibit "3"** is a true and correct copy of the 8-K that I located, and which Calli Bucci later authenticated during her deposition taken in the case of *Shahla Melamed v. Parallax Health Sciences, Inc., et al.*, LASC Case No. 21SMCV00532 (the "Fraudulent Conveyance Action").

4. Attached hereto as **Exhibit "2"** are true and correct copies of relevant pages from the transcript of the deposition of Calli Bucci, produced as Parallax's "person most qualified" to testify in response to a deposition notice requesting that Parallax produce a witness authorized to testify on its behalf. In Ms. Bucci's deposition, she refers to "Paul," referring to Paul Arena, Parallax's long-term CEO and the individual largely responsible for defrauding Melamed into signing the settlement agreement in this case, and to "Ted," which refers to Edward "Ted" Withrow, III, who originally formed Parallax and has controlled it since then. I know that because I have deposed Mr. Withrow and I examined him under oath during the trial of the Lead Case herein.

////

5. On April 28, 2023, this Court denied, without prejudice, Melamed's motion to amend her judgment to name Data Health Partners, Inc. ("DHP") as a co-debtor on Melamed's judgment, based on its determination more evidence is needed to demonstrate the alter ego relationship between DHP and Parallax. On April 28, 2023, I noticed the deposition of DHP in the case currently pending between Melamed and, among others, DHP, for DHP's person most knowledgeable to secure the information this Court found missing. In the meantime, Melamed requests this Court grant this motion for an assignment order, assigning to Melamed the payment rights owed to Parallax under the secured corporate Promissory Note given by DHP to Parallax on its "purchase" of Parallax's IP, as well as Parallax's payment rights on the Royalty Agreement also given in Parallax's favor.

I declare, under penalty of perjury under the laws of the State of California the foregoing is true and correct and that this Declaration was executed on this 28th day of April, 2023, in San Diego, California.

MICHAEL W. VIVOLI

SUPERIOR COURT OF CALIFORNIA COUNTY OF LOS ANGELES	Reserved for Clerk's File Stamp FILED Superior Court of California County of Los Angeles 08/14/2020 Sherri R. Carter, Executive Officer / Clerk of Court By: P. Anyankor Deputy
COURTHOUSE ADDRESS: Santa Monica Courthouse 1725 Main Street, Santa Monica, CA 90401	
PLAINTIFF(S): Shahlah Melamed	
DEFENDANT(S): Parallax Health Services, Inc et al	
JUDGMENT	CASE NUMBER: SC125702

It is hereby ordered that judgment be entered as follows by: [X] The court [ ] The clerk

Date:08/14/2020 [ ] By Default [X] By Stipulation [ ] After Court Trial [ ] After Jury Trial

Judgment is for: Melamed, Shahlah
and against Parallax Health Services, Inc

[ ] Joint and several

Principal:	$20,000,000.00	Damages:	$0.00
Punitive Damages:	$0.00	Attorney Fees:	$0.00
Costs:	$0.00	Interest:	$0.00
Recovery Costs:	$0.00	Other:	$0.00

Total Judgment amount: $20,000,000.00

[X] See written stipulation for further terms and conditions.
[ ] Execution stayed pursuant to written stipulation.
[ ] Written stipulation filed and copy of stipulation given/mailed to each party.

Sherri R. Carter, Executive Officer / Clerk of Court
P. Anyankor
Deputy Clerk

SUPERIOR COURT OF THE STATE OF CALIFORNIA
FOR THE COUNTY OF LOS ANGELES, WESTERN JUDICIAL DISTRICT

SHAHLAH MELAMED, an individual,

Plaintiff,

vs.

CASE NO.
21SMCV00532

PARALLAX HEALTH SCIENCES, INC., a, Nevada corporation; PAUL ARENA, an individual; AIM GROUP, INC., a corporation of unknown citizenship; DAVID APPELL, an individual; EDWARD WITHROW, III, an individual; HUNTINGTON CHASE FINANCIAL, an entity of unknown form and citizenship; MONTECITO BIOSCIENCES, LTD., an entity of unknown form and citizenship; CALLI BUCCI, an individual; MJ MANAGEMENT, INC., a California corporation; NATHANIEL BRADLEY, an individual; DAVE ENGERT, an individual; DOES 1-3, licensed attorneys to be named with leave of court; and DOES 4 through 100, Inclusive,

Defendants.

DEPOSITION OF CALLI BUCCI
VOLUME I, PAGES 1 THROUGH 78
DEPOSITION CONDUCTED REMOTELY
JULY 19, 2022

Reported by: Lorraine E. Mesker, RPR
CSR License No. 6499

there, as well.
Q. You said he resides in a structure -- adjacent structure in the back?
A. It was a garage they converted to, like, a little apartment.
Q. Okay.
A. Yeah.
Q. With regard to, for instance -- by the way, why did Mr. Arena cease to serve as CEO of Parallax?
A. He was forced to resign because of the SEC settlement.
Q. What SEC settlement?
A. I'm sorry. What?
Q. What SEC settlement?
A. Okay. So in March, around the time COVID started, the company got excited about what they could provide for COVID relief, including testing and so forth. And several press releases were sent out. I'm not quite sure when it started.
Sometime in early '21 we got a halt on the stock because, I guess, the SEC was halting a bunch of companies saying -- claiming they could provide COVID relief of some kind. So the SEC performed an extensive investigation of the company. I provided tons of discovery. We did interviews with the SEC.

And in the end, Paul and Nate Bradley were -- entered into settlement agreements, not claiming any guilt or innocence. I don't know exactly what the term is. But each one of them was sanctioned with fines and bans on -- Paul was sanctioned on a ban from being a director or officer of a public company for -- I am not -- I don't know if it's for a period of years or --
Q. Permanent?
A. Permanent, yeah.
Nate had different restrictions, but he didn't have that officer/director ban. And they were each fined, and the company, Parallax, was fined, as well.
Q. How much was Parallax fined?
A. I think $100,000. I am not sure, but I think $100,000.
Q. Was that fine paid?
A. Yes.
Q. When?
A. There were payments made. There was a payment arrangement. I can look in one of the printouts and give you the exact dates because it's in the use of funds.
Q. Do you know what Mr. Bradley's current address is?
A. That's the address: 95 Main Street, Matawan,

New Jersey.
Q. Do you know that's a good and valid address for him?
A. Well, it was the most recent I had. I know he and his girlfriend or fiancée moved around a lot, but I think that was -- the last one they had was Matawan.
Q. You don't know of any others?
A. I know others, but this was the most recent one that I knew about, yeah.
Q. Do you know any other more recent address than that --
A. No.
Q. -- for Mr. Bradley?
A. Sorry. No.
The final payment to the SEC was made in December of '21.
Q. And you were just looking at?
A. The use-of-funds document that I printed out so I don't have to search for anything.
Q. Okay. Let me see if I can show you that document.
Can you see what's on the screen?
A. Yes.
Q. This purports to be -- well, it is.
A. Yeah.

Q. This is the document production we received this morning.
A. Correct.
Q. One of the documents that's in here, under 6 and 7, is entitled "Use of Funds." Is that what you are referring to?
A. Yes.
Q. So if we open that, can you tell me what it is we have depicted here?
A. Are we going to wait for it to open?
Q. Oh, it's open.
A. Oh, I can't see it open.
First you have to extract them all. You're in a zip file. I don't know if that makes a difference.
Q. I have the open document on my screen. Let me try it again.
Do you see it?
A. There we go. Yes. Okay. So this is a printout from QuickBooks. I took all of the bank accounts, all of the debits from the bank accounts -- sorry -- credits, which would be withdrawals, and sorted them by vendor. So you could see every payment and who it was paid to and the total paid to them.
Q. So this -- is this from the general ledger?
A. Yes.

Q. This is a sorting of the general ledger by vendor?
A. Correct. Only the -- only through the -- only the bank account activity, which is what the use of funds would be.
Q. And, for instance, the first vendor that's listed there is ABT Medical Supply?
A. Correct.
Q. And then is there a vendor that is delineated as the SEC on this document?
A. Yes. It was "Securities." There you go. Go next. There you go.
Okay. So the last payment, 12/6, right there.
Q. A check written to the SEC for $66,000?
A. Correct.
Q. Out of what account?
A. It would be paid out of the City National Bank account.
Wait, wait. I take that back. Okay. So we will get to this through all your questions. This would have been paid out of the proceeds from one of the sales in December of '21. And all of the money during that sale went into the Wells Fargo account.
I am not a signer on that account, so the funds that went in were paid out by Nate Bradley, who's a

signer on the account, or his assistant. They were in control of all of the funds in that account.
Q. When you are referring to funds from a sale, are you talking a sale of stock?
A. A sale of the patents under Parallax Health Management.
Q. So which entity sold those patents?
A. Parallax Health Management.
Q. To whom?
A. Nate Bradley, one of his companies.
Q. That's not the Data Health entity, is it?
A. No.
Q. So in -- what was the date of that sale?
A. I believe it was December 1st or 2nd, 2021.
Q. You believe that was the sale by Parallax Health Management?
A. Correct.
Q. To Mr. Bradley's company?
A. Yeah, Data Donate, which is a different company.
Q. And specifically what patents were sold?
A. The remote patient monitoring patent. When we acquired Qualcomm, which was Nate Bradley's company, in 2016, these were included in that acquisition of that company. So he wanted to buy them back.

Q. And what did he pay for those patents?
A. $450,000.
Q. And other than the money sent to the SEC, how was that money spent?
A. I printed out a use of funds that filters it from August of 2021 instead of the report -- you don't have the printout, but I can provide it to you -- where -- the information on this doesn't go back so far to 2015 so you can focus on August '21 to present. And the total out -- cash-out was $454,000. So this report would show you exactly what that 450 was spent on, basically.
Q. How many pages is that document?
A. Five.
Q. And you have it before you right now?
A. Yeah. I can -- do you want me to --
THE WITNESS: Is that okay, Lisbeth? Can I e-mail it to him?
MS. MERRILL: E-mail it to me. E-mail it to me and I'll get it to the -- as part of today's production.
THE WITNESS: Okay. How do I get back to my -- hold on just a second. Give me a second here.
MS. MERRILL: You want her to just do it on a break, Michael?
MR. VIVOLI: I'd like to get it sooner than

later.
MS. MERRILL: Okay.
BY MR. VIVOLI:
Q. And while you're looking at it, Ms. Bucci, the information that's on the five-page document that you have, is it contained within this document? It's just more difficult to find?
A. Yes, yes.
Q. Okay. Just let me know when you've had a chance to e-mail it to Ms. Merrill.
A. Give me a second. The funds -- 2021 and 2022. Okay.
THE WITNESS: Okay. Lisbeth, it's on its way.
BY MR. VIVOLI:
Q. Ms. Bucci, the top of the document reads "Parallax Health Sciences, Inc., and Subsidiaries." Do you see that?
A. Yes.
Q. What subsidiaries are included within this report?
A. Parallax Diagnostics, Inc.; Parallax Health Management -- those two because Parallax Health Sciences, Parallax Diagnostics, and Parallax Health Management have bank accounts, so those would be the only sources of "use of funds."

Q. And Parallax Diagnostics and Parallax Health Management are subsidiaries of Parallax Health Sciences, Inc.?
A. Correct.
Q. Do all three entities maintain bank accounts?
A. Just recently the Wells Fargo account was closed by me, but Parallax Health Sciences and Parallax Diagnostics maintain accounts that are pretty much zero now. Been zero for a while.
Q. Did you say Nate caused the accounts to be closed?
A. Yes. When he was terminated, he emptied the bank account of $10,000 and closed the account.
Q. When did he do that?
A. March 28, 2022. Those -- the payments will be to Intellectual Property Network on the report I just sent you.
Q. Do you know what Paul Arena is doing currently?
A. I believe he's doing several things.
Q. What is he doing?
A. He's also a part of Data Health Partners.
Q. What is Data Health Partners?
A. It's the company that acquired some of the Parallax patents, the company you addressed in your discovery subpoena.

Q. What is your relationship to that entity?
A. Okay. So let's just get this out. It's me, Paul, and Ted; a private company incorporated in Delaware.
Q. When was Data Health Partners incorporated?
A. Sometime this year.
Q. What was the purpose for which it was formed?
A. To expand and monetize patents, assets.
Q. Expand and monetize patents and assets owned by Parallax Health Sciences?
A. Well, it was formed to acquire the assets so that they could be monetized. And in that transaction -- well, Parallax is in pretty bad shape. You know, there's really -- there's -- no money can be raised. The stock is still halted. So this provides --
Q. Still halted --
A. I'm sorry.
Q. Still halted as a result of the SEC situation?
A. Yes. Well, when your stock gets halted, to get relisted or active again, you have to catch up all your financials. You have to then go through a review process with FINRA and file a 15c2-11, which is a pretty big job. And the company didn't have the funds to get the audits done. So there was no way the company could move forward. And there's no way the company could get

any money in because the investors are -- no investor will invest. Nobody will invest.
Q. When is the last time, to your knowledge, Parallax repaid money owed to an investor?
A. Okay. There's a difference between an investor and a lender.
MS. MERRILL: Objection. The question is somewhat vague, but you can answer the question.
THE WITNESS: Okay.
In the discovery there will be a document called -- can I look at your list?
MR. VIVOLI: I can put it on the screen if you want.
THE WITNESS: Yeah, that would be great.
BY MR. VIVOLI:
Q. Can you see it?
A. Yeah. Okay. So payments to lenders. That would be the report that shows every payment to lender.
Q. Is this chronological? No.
A. I don't -- hold on a second. I'll have to explain it to you. I want it to be as thorough as possible.
So payments include not just cash payments but, for example, if I said you can take $100,000 of my compensation that's owed to me and instead give me

stock. So that would be a repayment as well.
And you'll see in this report there's a cash column and a non-cash column that shows you how, perhaps, the accrued compensation was reduced by a non-cash item but also any cash that went out to the lender.
Okay. There's a separate report that shows you payments to board members. It's all kind of the same -- comes from the same data, but it's just displayed differently for you, so it separates out just the board members. So --
Q. This document is entitled "Payment to Lenders." What is this intended to reflect?
A. Okay. Hold on just a second. Let me -- I'll -- I'm trying to -- here we go. Okay.
So this is sorted by lender, and it shows you all the payments, for example, any payment that went to Paul for accrued compensation, for -- if it was cash, then it would be assigned to the cash column. So in essence, Paul was paid a total of $594,000 over the period August 15th to July 20 -- August 2015 to July 2022. He received cash in the amount of $594,000.
Q. To be clear, it looks like the last cash payment to him was on May 14, 2021, in the amount of $2,000?

A. Do you -- I didn't know you wanted it. I'm sorry.
Q. When did the sale take place?
A. December of '21. I'll get everything to Lisbeth, and she can put it --
Q. Please. And so when was -- I'm sorry. Continue, please.
A. Okay. So --
MS. MERRILL: Is there a question pending?
MR. VIVOLI: She's explaining to me the background underlining how Mr. Bradley became involved, and now it sounds like segueing into how he became disassociated.
THE WITNESS: Correct.
MS. MERRILL: Objection to how did Nate become disassociated.
BY MR. VIVOLI:
Q. Go ahead.
A. Okay. So it all --
MS. MERRILL: Just let me -- just stop, Calli, please. You know we need to have a question and answer. We are not doing narratives. So you can ask her questions about it.
BY MR. VIVOLI:
Q. Ms. Bucci, please continue with your

explanation as to how it is that Mr. Bradley became, apparently, removed from the company by majority shareholder vote.
A. Okay. So after the settlement, Paul left. Nate was now one of three board members. Oh, and Jorn Gorlach, who had left when Paul came on, who was -- Jorn Gorlach was a board member before Paul, and Paul came on and Jorn went off the board. Jorn came back.
So the board consisted then of Jorn, Nate, myself, and John Ogden, and it was a bit contentious, you know.
Anyways, I was getting ready to leave the company. I was preparing to leave the company because of all this. And, basically, Nate was in charge. Nate and Sonia were in charge of the company. They controlled the cash; they controlled the bank account; they controlled who got paid; they controlled all negotiations with lenders.
Q. When did Sonia Choi come into the picture?
A. She came on board in July of '21, but her -- her agreement wasn't signed until, I believe, September of '21. That's what it will -- it will show where we announced her coming on board.
Q. Okay.
A. So as we became aware of this, you know,

inexperience and potential for having Nate take over everything, the shareholders got together and decided to take back the company, myself included.
Q. When you say "the shareholders," who are you referring to specifically?
A. There were quite a few. It included Ted and Paul, who have the most shares, but it also included investors across the board.
Q. Such as?
A. I can give you -- it's posted online on the SEC website. I think -- if not, I can -- I don't know if I posted -- oh, it should be in discovery. No? Yeah.
Q. Discovery that you've produced here today?
A. Yes. Hold on a second. I want to make sure I put it in there.
Okay. Because it was a -- I didn't put it in, but I will provide you with a copy.
It's a majority shareholder consent, and since it was not a board resolution -- because this was an action done by the shareholders separate from Parallax. It wasn't a proxy initiated by Parallax. This was just shareholders getting together going, "We don't like where this is going." And there -- with the majority shareholder consent that I provide you with, it has a list of all the shareholders that were involved.

Q. Can you just send that to Ms. Merrill.
A. I will right now.
Q. Let me know when you've sent it.
A. Bear with me. I've got to find it on my computer. Here we go.
THE WITNESS: Okay. Lisbeth, I just sent it to you.
BY MR. VIVOLI:
Q. And while she is turning that around to me, can you just tell me generally what it is that the shareholder resolution accomplished?
A. It replaced the board of directors of Parallax. It removed Nate and Jorn, and it added David Stark. I think -- did it? Yeah, it added David Stark.
Q. Who's David Stark?
A. David Stark is a very smart guy. He's a doctor. He works, I believe, with the FDA or in connection with the FDA.
And he's -- he was brought on to be Parallax's president and board -- one of the board members.
Q. Is he affiliated with Data Health Partners?
A. Only as a shareholder. So as part of the sale of the -- to Data Health Partners, every shareholder in Parallax got shares in Data Health Partners. So the shareholder list will basically mirror -- mirror that of

Parallax.
Q. Is it your general understanding that the purpose of selling assets to Data Health Partners was to take its assets out of the hands of a public company and place it into a private company?
MS. MERRILL: Again, I –
THE WITNESS: No. I'm sorry.
MS. MERRILL: Go ahead. That's fine.
THE WITNESS: No. I don't believe that's what it was.
BY MR. VIVOLI:
Q. Okay. What was the purpose?
A. To help monetize the patents that were going – were unable to do anything in Parallax because of the condition of the company. So this was actually – it really was for the benefit of the shareholders of Parallax.
Q. What, if anything, has Data Health Partners done to monetize those assets?
A. Nothing has been finalized as of yet. I mean, it's not my job duty, per se, but it's being worked on.
Q. By whom?
A. By Paul Arena. And the agreements connected with the sale will spell out the financial commitment made to Parallax.

42

Q. And speaking of that, let me put on the screen – are you familiar with a reporting of this transaction that was made to the SEC?
A. Yes.
Q. In what fashion?
A. What fashion was it made to the SEC?
Q. Yeah.
A. Oh, in the form of an 8-K.
Q. Okay. And I have on the screen – do you see that?
A. Yup.
Q. A copy of what was downloaded from the SEC website and the Form 8-K dated May 11, 2022. Are you familiar with this?
A. Yes, I prepared it.
Q. Is this, in fact, a true and correct copy of the agreement that was ultimately entered into between Data Health Partners and Parallax?
A. Yes.
MS. MERRILL: Are you going to mark this as an exhibit?
MR. VIVOLI: Yes. This will be Exhibit 3.
(Exhibit 3 was marked for identification.)
BY MR. VIVOLI:
Q. And you signed this on behalf of Data Health

43

Partners?
A. Did I? I believe I did.
Q. Do you see under "Buyer" it says "Data Health Partners, Inc., Calli R. Bucci, Director, Chief Financial Officer"?
A. Yes.
Q. And what, generally, do you understand to be the consideration that was provided to Parallax in exchange for that reassignment?
A. A promissory note for $20 million.
Q. And how was that figure arrived upon?
A. Good question.
Q. Do you know the answer?
A. Well, we wanted to make sure that all of Parallax's debt was taken care of. I think that is the honest answer.
Q. What is Parallax's existing debt?
A. Including the stipulated judgment or not?
Q. Including that, yes.
A. Probably 36 million or something like that.
Q. Some 20 million of which is the judgment held by Melamed?
A. Yes.
Q. And what's the other 16 million? What does that consist of? Or is that document somewhere in

44

something you produced here?
A. It consists of promissory notes, unpaid compensation, accounts payable, and that is just an estimate, so – but I do recall that, a 36-million figure. So it could be less.
Q. What other third-party debt exists?
A. It will be in the documents.
Q. What would it be? What would that be –
A. The documents. Sorry. Go on.
Q. What documents produced today would reflect that?
A. You would actually have to do the math. That's where it's kind of difficult because I provided you with "Loans to Parallax" in one document and payments against the debt in another document. So to get the exact amount that's owed net, it's not in here. I would have to do the math.
Q. Would I at least find the debt owed by Parallax in the document that's entitled "Loans to Parallax"?
A. Yes.
Q. Would that include the three creditors to whom Parallax owes money?
A. No. It wouldn't include the accounts payable, like, the bills that are not loans, they're actually for services or whatever. It would include all of the

45

third-party cash loans to the company that were acquired from some lending institution or company. It would include that.

And it would include any cash loans from any individual. And it would include any cash loans from any -- like, a board member, what have you.

And it would include any compensated -- accrued non-cash loans, which would be like if I wasn't paid my salary in a month, say $10,000; that would be a loan to Parallax that they would owe me. You see, but it's a non-cash. I didn't give them the cash, but it would be like me giving them the cash because they didn't pay me.

Q. And I would find that where within these documents?

A. "Loans to Parallax."

Q. What is the investments document?

A. Okay. Your discovery asked for a list of any investments. I took it back from the beginning of 2000 -- August of 2015.

This is a summary of every cash and non-cash investment into Parallax. So the holder graph is basically the shareholder abbreviated and the shares they acquired and whether they paid cash for those shares or whether it was offset against patents. Like, for example, the third line down, Qualcomm, that was

5 million shares of which they paid 500 -- $5,000 cash, and we recorded the valuation of the patents at $220,000.

Q. Were those the patents that were then sold to Mr. Bradley for 450,000?

A. Yes, they are.

Q. Okay. To be clear, was it all the exact same patents or portions of it?

A. The way I recorded it -- and I assumed that it was all of them.

There's several patents that came in a group, but when you do a valuation of those patents, the valuation will include intangibles such as noncompete or -- it's all related to the patents, but they are broken down into different categories of the valuation.

So we received valuation at the time of $225,000, and it was broken down via patents, trademarks, marketing, customer lists, and noncompete.

Q. So is it your understanding that all of these patents that were owned by Parallax Health Sciences at the time it settled with Ms. Melamed are now owned by Data Health Partners?

A. Actually, no, that's not correct.

Q. Okay. Where did I go wrong?

A. Well, if you take Parallax Health Sciences as

a -- including it's subsidiaries, so say consolidated, there were certain patents that were terminated. The license agreement was terminated.

There were certain patents that were acquired by Nate Bradley's company Data Donate. And then the third subsidiary is Parallax Behavioral Health, and that's the subsidiary that held the patents that were acquired by Data Health Partners.

Q. Okay. What other patents continue to be owned by Parallax Health Sciences?

A. None.

Can we take a pause? I need to go to the ladies' room.

MR. VIVOLI: Yeah. Let's take a ten-minute break.

THE WITNESS: Okay. Thank you.

THE REPORTER: Off the record.

(Recess taken.)

BY MR. VIVOLI:

Q. Ms. Bucci, I have -- you can't see it yet.

I have on the screen the document that you sent today. Do you see that?

A. Yes.

Q. And that's "Parallax Health Sciences, Inc., and Subsidiaries Use of Funds-All," August 15th through

July 15, 2022.

Do you see that?

A. Yes.

Q. This is an accounting of the $454,000 that was spent from the proceeds generated by the sale to Mr. Bradley?

A. Correct. But that would be the assumption. It just happens to work out to 450,000, which basically accounts for pretty much how the company has worked over the last couple of years, which is zero money and -- yeah.

Q. Obviously the first category is account fees at $1,307. Do you see that?

A. Yes.

Q. There's then a bill paid on December 6, 2021, to -- I can't see the name. The last name is Alston, A-L-S-T-O-N, & Bird for $102,179.05.

Do you see that?

A. Right. So if you see bill payment parentheses "CHE," that means check. It's just a quick reference. So you just start from Alston & Bird. Yes, I know that payment, yes.

Q. What is that payment?

A. Alston & Bird is an attorney -- patent attorney.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

EXHIBIT 3
C. BUCCI
7/19/2022
LORRAINE MESKER, CSR, RPR

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **May 11, 2022**

Parallax Health Sciences

PARALLAX HEALTH SCIENCES, INC.

(Exact name of Company as specified in its charter)

Nevada	000-52534	46-4733512
(State or other jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)

3415 S. Sepulveda Blvd, Suite 1100-6592
Los Angeles, CA 90034
(Address of principal executive offices)

(888) 263-9799
(Registrant's Telephone Number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

EXHIBIT 3

As used in this current report and unless otherwise indicated, the terms "we", "us", "our", "Company", and "Parallax" mean Parallax Health Sciences, Inc., a Nevada corporation, and its subsidiaries, unless otherwise indicated.

ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

On May 11, 2022, pursuant to a unanimous resolution of the Company's Board of Directors, the Company and its wholly owned subsidiary, Parallax Behavioral Health, Inc. ("PBH" or "Seller"), executed an Intellectual Property Purchase Agreement (the "Purchase Agreement") for the sale of certain intellectual property (the "Intellectual Property"), as defined within the Purchase Agreement, to Data Health Partners, Inc., a privately held Delaware corporation ("DHPI" or "Buyer"). The Purchase Agreement is effective April 13, 2022, and includes the following consideration to Seller for the transfer of all rights, title and interest in and to the Intellectual Property to Buyer:

An aggregate of 3,960,344 shares of Buyer's common stock to be issued to the Company's shareholders of record on the Record Date of April 13, 2022 (the "Parallax Shareholders"); and

An Anti-Dilution Agreement providing for certain protections for the Parallax Shareholders; and

A corporate Promissory Note in the principal sum of twenty million dollars ($20,0000,000), bearing interest at a rate of three percent (3%) per annum, and maturing in ten (10) years (the "Note"). The Note is secured by the Intellectual Property, as defined within the Intellectual Property Pledge and Security Agreement; and

A royalty of two and one-half percent (2.5%) of Net Proceeds from the monetization of the Intellectual Property, as defined within the Royalty Agreement.

The foregoing disclosure set forth in this Section 1.01 does not purport to be complete, and is qualified in its entirety by reference to the Intellectual Property Purchase Agreement filed herewith as Exhibit 10.1 of this Current Report and incorporated by reference herein.

Purpose and Consideration

Parallax has entered into this transaction to help the Company meet its financial obligations and generate value for its shareholders.

DHPI has entered into this transaction in an effort to monetize the Intellectual Property through licensing and joint ventures, and to prosecute possible infringement through litigation.

The consideration provided to Parallax has been based upon potential sources of revenues for the Intellectual Property from prospective licensing and recovery of financial damages from infringement.

About Data Health Partners

The primary focus of the Data Health Partners, Inc. business is in the commercialization of intellectual property through business development, licensing endeavors, and enforcement of intellectual property services and products. Ms. Calli Bucci serves as DHPI's Chief Financial Officer and is a member of its Board of Directors, and is also Parallax's Chief Financial Officer and Corporate Secretary, and a member of Parallax's Board of Directors.

COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS

The disclosures set forth in Item 1.01 are incorporated into this Item 2.01 by reference.

FINANCIAL STATEMENTS AND EXHIBITS

(b) ***Pro Forma Financial Information.***

Pro forma financial information relative to the disposition transaction is not included in this Current Report on Form 8-K. Such pro forma financial information will be filed within 71 calendar days after the date on which this Current Report on Form 8-K is required to be filed.

(d) ***Exhibits.***

Exhibit Number	Description of Exhibit	Filing Reference
10.1	Intellectual Property Purchase Agreement	Filed herewith.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PARALLAX HEALTH SCIENCES, INC.

Dated: May 11, 2022

/s/ David L. Stark
David L. Stark
President

EXHIBIT 10.1

Note: Certain Exhibits to the Intellectual Property Purchase Agreement may make reference to Agreements as Exhibits, all of which are included herein. Redundant Exhibits are omitted.

Hyperlinks *have been added for ease of navigation.*

CONTENTS

INTELLECTUAL PROPERTY PURCHASE AGREEMENT

PURCHASED ASSETS

SENIOR SECURED CORPORATE PROMISSORY NOTE

INTELLECTUAL PROPERTY PLEDGE AND SECURITY AGREEMENT

ANTI-DILUTION AGREEMENT

ROYALTY AGREEMENT

PATENT ASSIGNMENT

TRADEMARK ASSIGNMENT

INTELLECTUAL PROPERTY PURCHASE AGREEMENT

by and among

PARALLAX BEHAVIORAL HEALTH, INC.,

PARALLAX HEALTH SCIENCES, INC., and

DATA HEALTH PARTNERS, INC.

This **INTELLECTUAL PROPERTY PURCHASE AGREEMENT** (the "Agreement"), executed this 11th day of May, 2022, is effective as of April 13, 2022 (the "Effective Date"), by and among Parallax Behavioral Health, Inc., a Delaware corporation ("Seller"), and Parallax Health Sciences, Inc., a Nevada corporation and sole shareholder of Seller ("Parallax"), on the one hand, and Data Health Partners, Inc., a Delaware corporation ("Buyer"), on the other hand, hereinafter collectively referred to as the "Parties".

WHEREAS, Buyer is a newly formed company engaged in the business of intellectual property commercialization through the licensing and enforcement of intellectual property services and products (the "Business"); and

WHEREAS, Seller desires to sell, and Buyer desires to purchase, the Purchased Assets, as set forth in Exhibit A attached herewith, upon the terms and subject to the conditions set forth in this Agreement.

NOW, THEREFORE, in consideration of the foregoing, of the mutual covenants and agreements herein contained, and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Parties hereby agree as follows:

PURCHASE AND SALE OF ASSETS

Purchase and Sale of Assets. On and subject to the terms and conditions of this Agreement, at the Closing, Seller shall sell, assign, transfer, convey and deliver to Buyer, and Buyer shall purchase and acquire from Seller, free and clear of all Encumbrances (other than Permitted Encumbrances), all of Seller's right, title and interest, as of the Closing, in and to the intellectual properties and rights set forth in Exhibit A attached herewith (collectively, the "Purchased Assets").

Excluded Liabilities and Assets. Seller is not selling any of its assets to Buyer other than the Purchased Assets. Buyer does not assume any liability or obligation of Seller, in connection with Buyer's purchase of the Purchased Assets pursuant to this Agreement.

Purchase Consideration. The Parties agree to the following as good and sufficient consideration for the sale by Seller of the Purchased Assets to Buyer:

Corporate Promissory Note. Buyer shall issue a ten (10) year interest-bearing Corporate Promissory Note to Seller, in the form attached herewith as Exhibit B-1, providing for the payment to Seller of twenty million dollars ($20,000,000), plus accrued interest at a rate of three percent (3%) per annum, on the terms and conditions set forth therein.

Intellectual Property Pledge and Security Agreement. Buyer shall enter into an Intellectual Property Pledge and Security Agreement with the Seller, in the form attached herewith as Exhibit B-2, that will pledge the Purchased Assets as collateral for the Corporate Promissory Note.

To Exhibits Index

Equity. At Closing, Buyer shall issue to the Parallax shareholders of record (the "Parallax Shareholders") on the record date of April 13, 2022 (the "Record Date"), an aggregate of three million nine hundred sixty thousand three hundred forty-four (3,960,344) shares of the Buyer's Common Stock.

Buyer shall enter into an Anti-Dilution Agreement with the Seller, in the form attached herewith as Exhibit C, providing for dilution protection for the common stock issued by the Buyer to the Parallax Shareholders.

Royalty Agreement. Buyer shall enter into a Royalty Agreement with Seller ("Royalty Agreement"), in the form attached herewith as Exhibit D providing for payment to the Seller by the Buyer of two and one-half percent (2.5%) of the Adjusted Gross Revenues generated from the Purchased Assets on the terms and conditions set forth therein.

Closing Transactions.

Closing. Unless this Agreement shall have been terminated in accordance with Section 8.1, and subject to the satisfaction or, if permissible, waiver of the conditions set forth in Article VII, the closing of the Transactions (the "Closing") will take place at 12:00 p.m., Los Angeles, California time, on a date to be specified by the Parties (the "Closing Date"), which shall be not later than the second Business Day after the satisfaction or, if permissible, waiver of the conditions set forth in Article VII (other than those that by their terms are to be satisfied or waived at the Closing), at the offices of Parallax Health Sciences, Inc., at 3415 S. Sepulveda Blvd., Suite 1100-6592, Los Angeles, CA 90034, or via virtual electronic meeting whereby all Parties are present, unless another time, date or place is agreed to in writing by the Parties; provided, however, that the Parties shall use reasonable efforts to conduct the Closing by mail, electronic mail, and overnight delivery so as not to require the personal attendance of the parties at the Closing.

Actions and Deliveries by Seller. At the Closing, Seller shall deliver to Buyer:

the Patent Assignment dated as of the Closing Date and duly executed by Seller, in the form attached herewith as Exhibit E; and

the Trademark Assignment dated as of the Closing Date and duly executed by Seller, in the form attached herewith as Exhibit F; and

a NOBO (non-objecting beneficial owners) list of the publicly traded securities of Parallax, identifying the Parallax Shareholders as of the Record Date; and

the certificates and documents required to be delivered by Seller pursuant to Sections 7.1 and 7.2; and

all such other instruments of assignment and transfer as are reasonably required to effect the transfer to Buyer all of Seller's right, title and interest in and to the Purchased Assets in accordance with this Agreement, in form and substance reasonably satisfactory to Buyer and Seller.

Actions and Deliveries by Buyer. At the Closing, Buyer shall deliver to Seller:

the Corporate Promissory Note dated as of the Closing Date and duly executed by Buyer. in the form attached herewith as Exhibit B-1; and

Return to Top | To Exhibits Index

the Intellectual Property Pledge and Security Agreement dated as of the Closing and duly executed by the Buyer, in the form attached herewith as Exhibit B-2; and

the Anti-Dilution Agreement dated as of the Closing Date and duly executed by Buyer, in the form attached herewith as Exhibit C; and

the Royalty Agreement dated as of the Closing Date and duly executed by Buyer, in the form attached herewith as Exhibit D; and

the certificates and documents required to be delivered by Buyer pursuant to Sections 7.1 and 7.3.

REPRESENTATIONS AND WARRANTIES OF SELLER

Seller hereby represents and warrants to Buyer that, to the best of "Seller's Knowledge" (as hereinafter defined) and except as set forth in the disclosure schedule delivered by Seller to Buyer and attached hereto and made a part hereof (the "Seller Disclosure Schedule"):

Organization. Seller is duly incorporated, validly existing and in good standing under the Laws of the jurisdiction of its incorporation and has the requisite corporate power and authority to own, operate or lease the properties that it purports to own, operate or lease and to carry on its business as it is now being conducted.

Authority Relative to this Agreement and Related Matters. Seller has all necessary corporate power and authority to enter into this Agreement and to carry out its obligations hereunder. The execution and delivery by Seller of this Agreement and the consummation by Seller of the transactions contemplated hereby (the "Transactions") have been duly authorized by all necessary corporate action on the part of Seller. This Agreement has been duly executed and delivered by Seller and, assuming the due authorization, execution and delivery hereof by Buyer, no further action or approval, corporate or otherwise, is required in order to constitute this Agreement as a valid and binding obligation of Seller enforceable in accordance with its terms.

No Conflict; Required Filings and Consents. The execution and delivery of this Agreement by Seller do not, and the consummation by Seller of the Transactions will not, (a) conflict with or violate the certificate of incorporation or bylaws, each as amended to date, of Seller, (b) conflict with or violate any Law or Order applicable to Seller or by which Seller or any of its properties is bound, (c) result in a breach of or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or give rise to any right of termination, acceleration or cancellation under, or result in the creation of an Encumbrance on any of the Purchased Assets pursuant to, any note, bond, mortgage, indenture, contract, agreement, lease, license or other instrument or obligation to which Seller is a party or by which Seller or any of its properties is bound, or (d) require Seller to obtain any consent, approval, authorization or permit of, or to make any filing with or notification to, any Governmental Authority, except (i) as set forth in Section 2.3 of the Seller Disclosure Schedule, or (ii) for any filings required pursuant to the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the "Exchange Act").

Absence of Litigation. Except as disclosed in Section 2.4 of the Seller Disclosure Schedule and disclosed in Parallax's last Form 10-K filed with the US Securities and Exchange Commission for period ended December 31, 2019, as of the date hereof, (a) there is no private or governmental action, suit, proceeding, litigation, arbitration or investigation ("Action") pending or, to the knowledge of Seller, threatened against Seller before any Governmental Authority that, if adversely determined, would prohibit, prevent, enjoin, restrict or materially impair or delay any of the Transactions, and (b) there is no legally binding judgment, decree, order, injunction, decision or

Return to Top | To Exhibits Index

award of any Governmental Authority ("Order") against Seller that would prohibit, prevent, enjoin, restrict or materially impair or delay any of the Transactions.

Purchased Assets. Section 2.5 of the Seller Disclosure Schedule sets forth a list of all registrations and applications for registration in respect of the Purchased Assets. Except as set forth in Section 2.5 of the Seller Disclosure Schedule, Seller owns (beneficially and of record) all right, title and interest in and to all Purchased Assets, free and clear of all Encumbrances, other than Permitted Encumbrances. Except as set forth in Section 2.5 of the Seller Disclosure Schedule, the Purchased Assets and all of the pending Letters Patent and trademark applications (if any) related to the Purchased Assets have been duly filed in the jurisdiction named in each such application, are being actively prosecuted and have not been abandoned or allowed to lapse. Except as set forth in Section 2.5 of the Seller Disclosure Schedule, there is no Action that is pending or, to the knowledge of Seller, threatened that challenges the rights of Seller in respect of any Purchased Assets or the validity, enforceability or effectiveness thereof. Seller has not received any written communication alleging that it has infringed the Intellectual Property rights of any third party and there are no Actions that are pending or, to the knowledge of Seller, threatened against Seller with respect thereto. Except as set forth in Section 2.5 of the Seller Disclosure Schedule, to the knowledge of Seller, there is no unauthorized use, infringement or misappropriation of the Purchased Assets by any third party and there is no Action that is pending or threatened by Seller with respect thereto. Notwithstanding anything to the contrary, this representation shall not limit or restrict the transfer to Buyer pursuant to this Agreement of all right, title and interest in and to the Purchased Assets owned by Seller throughout the world; provided, however, that Seller does not represent, warrant or covenant that any rights in or to the Purchased Assets exist anywhere outside of the United States of America.

REPRESENTATIONS AND WARRANTIES OF BUYER

Buyer hereby represents and warrants to Seller that, except as set forth in the disclosure schedule delivered by Buyer to Seller and attached hereto and made a part hereof (the "Buyer Disclosure Schedule"):

Organization. Buyer is duly organized, validly existing and in good standing under the Laws of its jurisdiction of organization and has the requisite limited liability company or corporate power and authority (as the case may be) to own, operate or lease the properties that it purports to own, operate or lease and to carry on its business as it is now being conducted.

Authority Relative to this Agreement and Related Matters. Buyer has all necessary corporate power and authority, as the case may be, to enter into this Agreement and to carry out its obligations hereunder. The execution and delivery by Buyer of this Agreement and the consummation by the Buyer of the Transactions has been duly authorized by all necessary corporate action on the part of the Buyer. This Agreement has been duly executed and delivered by the Buyer, and, assuming the due authorization, execution and delivery hereof by Seller, constitutes the legal, valid and binding obligation of the Buyer, enforceable against the Buyer in accordance with its terms.

No Conflict; Required Filings and Consents. The execution and delivery of this Agreement by Buyer does not, and the consummation of the Transactions will not, (a) conflict with or violate the organizational or governing documents of Buyer, (b) conflict with or violate any Law or Order applicable to Buyer or by which Buyer has any of their respective properties is bound, (c) result in a breach of or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or give rise to any right of termination, acceleration or cancellation under, any note, bond, mortgage, indenture, contract, agreement, lease, license or other instrument or obligation to which Buyer is a party or by which Buyer or any of their respective properties is bound, or (d) require Buyer to obtain any consent, approval, authorization or permit of, or to make any filing with or notification

Return to Top | To Exhibits Index

to, any Governmental Authority, except (i) as set forth in Section 3.3 of the Buyer Disclosure Schedule, or (ii) for any filings required pursuant to the Exchange Act.

Absence of Litigation. Except as disclosed in Section 3.4 of the Buyer Disclosure Schedule, as of the date hereof, (a) there is no Action pending or, to the knowledge of Buyer, threatened against Buyer or before any Governmental Authority that, if adversely determined, would prohibit, prevent, enjoin, restrict or materially impair or delay any of the Transactions, and (b) there is no Order against Buyer that would prohibit, prevent, enjoin, restrict or materially impair or delay any of the Transactions.

Data. Buyer agrees that it shall not, nor permit others to, use any data or information relating to "personal health information" as that term is defined under the Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), as amended, or any other Data (as defined in Article XI of this Agreement) obtained through the acquisition of the Purchased Assets, and Buyer agrees it shall not, nor permit others to, disclose or disseminate such information to any Person without the prior written consent of the Seller, and, in all such cases, subject to applicable Law.

COVENANTS OF SELLER

Conduct of Seller Pending the Closing. Seller shall not, between the date of this Agreement and the Closing Date or the earlier termination of this Agreement, do or agree to do any of the following without the prior written consent of Buyer:

take or fail to take, or agree to take or fail to take, any action which would make any representation or warranty made by Seller herein untrue or incorrect in any material respect;

sell, lease, license, encumber, transfer or otherwise dispose of any Purchased Assets; and

agree to do any of the foregoing.

Notification of Certain Events. Seller shall give prompt notice to Buyer if any of the following occurs after the date of this Agreement: (i) there has been a material failure of Seller to comply with or satisfy any covenant, condition or agreement to be complied with or satisfied by it hereunder; (ii) receipt by Seller of any material notice or other communication from any Governmental Authority in connection with the Transactions; (iii) the occurrence of an event which would cause a condition in Section 7.2 not to be satisfied; or (iv) the commencement or threat, in writing, of any Action against Seller, or any of its properties, with respect to the Transactions and/or any of the Purchased Assets. No such notice to Buyer shall have any effect on the determination of whether or not any of the conditions to Closing or to the consummation of the Transactions have been satisfied or in determining whether or not any of the representations, warranties or covenants contained in this Agreement have been breached.

COVENANTS OF BUYER

Representations and Warranties. Buyer covenants and agrees that, except as otherwise contemplated by this Agreement or unless Seller shall give its prior written consent, Buyer shall not, between the date of this Agreement and the Closing Date or the earlier termination of this Agreement, take or fail to take, or agree to take or fail to take, any action which would make any representation or warranty made by Buyer herein untrue or incorrect in any material respect.

Notification of Certain Events. Buyer shall give prompt notice to Seller if any of the following occurs after the date of this Agreement: (i) there has been a material failure of Buyer to comply with or satisfy any covenant, condition or agreement to be complied with or satisfied by it hereunder; (ii) receipt by Buyer of any material notice

Return to Top | To Exhibits Index

or other communication from any Governmental Authority in connection with the Transactions; (iii) the occurrence of an event which would cause a condition in Section 7.3 not to be satisfied; or (iv) the commencement or threat, in writing, of any Action against Buyer, or any of its properties, with respect to the Transactions. No such notice to Seller shall have any effect on the determination of whether or not any of the conditions to Closing or to the consummation of the Transactions have been satisfied or in determining whether or not any of the representations, warranties or covenants contained in this Agreement have been breached.

Condition of Purchased Assets. BUYER ACKNOWLEDGES THAT IT IS A SOPHISTICATED INVESTOR IN ASSET PURCHASES OF THE TYPE CONTEMPLATED BY THIS AGREEMENT AND THAT ITS VALUATION OF AND DECISION TO PURCHASE THE PURCHASED ASSETS IS BASED UPON ITS OWN INDEPENDENT EXPERT EVALUATIONS OF SUCH FACTS AND MATERIALS DEEMED RELEVANT BY BUYER. BUYER ACKNOWLEDGES AND AGREES THAT, EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN SECTION 2 ABOVE, SELLER HAS NOT MADE, AND SELLER HEREBY SPECIFICALLY DISCLAIMS, ANY REPRESENTATION, WARRANTY, GUARANTY, PROMISE, COVENANT OR AGREEMENT, IN EACH CASE WHETHER EXPRESS OR IMPLIED, ORAL OR WRITTEN, PAST, PRESENT OR FUTURE, OF, AS TO, CONCERNING, OR WITH RESPECT TO THE PURCHASED ASSETS. BUYER ACKNOWLEDGES AND AGREES THAT, HAVING BEEN GIVEN THE OPPORTUNITY TO INSPECT THE PURCHASED ASSETS, BUYER IS RELYING SOLELY ON ITS OWN INVESTIGATION OF THE PURCHASED ASSETS, AND NOT ON ANY MATERIALS AND OTHER INFORMATION PROVIDED OR TO BE PROVIDED BY SELLER. BUYER FURTHER ACKNOWLEDGES THAT ANY INFORMATION PROVIDED AND TO BE PROVIDED WITH RESPECT TO THE PURCHASED ASSETS WAS OBTAINED FROM A VARIETY OF SOURCES AND SELLER (i) HAS NOT MADE ANY INDEPENDENT INVESTIGATION OR VERIFICATION OF SUCH INFORMATION; AND (ii) MAKES NO REPRESENTATIONS OR WARRANTIES AS TO THE ACCURACY OR COMPLETENESS OF SUCH INFORMATION. EXCEPT AS OTHERWISE EXPRESSLY SPECIFIED HEREIN, BUYER AGREES TO ACCEPT THE PURCHASED ASSETS AND ACKNOWLEDGES THAT THE SALE OF THE PURCHASED ASSETS AS PROVIDED FOR HEREIN IS CONDITIONED ON THE FACT THAT THE PROPERTY IS "AS IS", WHERE IS AND WITH ALL FAULTS". WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, BUYER EXPRESSLY ACKNOWLEDGES THAT, EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN SECTION 3 ABOVE, SELLER MAKES NO WARRANTY OR REPRESENTATION OF ANY KIND OR CHARACTER WHATSOEVER, WHETHER EXPRESS OR IMPLIED, ORAL OR WRITTEN, PAST, PRESENT OR FUTURE, OF, AS TO, CONCERNING OR WITH RESPECT TO (A) THE VALUE, NATURE, QUALITY OR CONDITION OF THE PURCHASED ASSETS (OR ANY PORTION THEREOF), (B) THE INCOME TO BE DERIVED FROM THE PURCHASED ASSETS (OR ANY PORTION THEREOF), (C) THE SUITABILITY OF THE PURCHASED ASSETS (OR ANY PORTION THEREOF) FOR ANY AND ALL ACTIVITIES AND USES WHICH BUYER MAY CONDUCT THEREWITH, (D) THE COMPLIANCE OF OR BY THE PURCHASED ASSETS (OR ANY PORTION THEREOF) OR ITS USE WITH ANY LAWS, RULES, ORDINANCES OR REGULATIONS OF ANY APPLICABLE GOVERNMENTAL AUTHORITY OR BODY, (E) THE MERCHANTABILITY, MARKETABILITY, PROFITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE PURCHASED ASSETS (OR ANY PORTION THEREOF), (F) THE MANNER OR QUALITY OF THE OPERATIONS ENABLED BY THE PURCHASED ASSETS (OR ANY PORTION THEREOF), (G) THE MANNER, QUALITY, OR STATE OF THE PURCHASED ASSETS (OR ANY PORTION THEREOF), (H) THE PAST, PRESENT OR FUTURE USE OF THE PURCHASED ASSETS (OR ANY PORTION THEREOF), (I) THE RELIABILITY, ACCURACY OR COMPLETENESS OF ANY OF THE PURCHASED ASSETS FOR THE USES INTENDED BY BUYER; AND BUYER HEREBY WAIVES ANY RIGHT TO MAKE ANY CLAIM BASED ON ANY OF THE FOREGOING.

Return to Top | To Exhibits Index

ADDITIONAL AGREEMENTS OF THE PARTIES

Commercially Reasonable Efforts.

Upon the terms and subject to the conditions hereof, each of the Parties agrees to use its commercially reasonable efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary, proper or advisable to consummate and make effective as promptly as practicable the Transactions and to vest in Buyer (and any transferee of Buyer) good and marketable title to the Purchased Assets, including obtaining all consents, waivers, authorizations and approvals from Governmental Authorities and other third parties required for the consummation of the Transactions.

From time to time after the Closing, at the request of Buyer (or any transferee of Buyer) and at such requesting party's expense, and without further consideration, Seller agrees on its own behalf, as well as on behalf of its subsidiaries, affiliates, successors, assigns and legal representatives, to execute and deliver to Buyer any further documents or instruments and perform any further acts that may reasonably be deemed necessary to vest, record, perfect, support and/or confirm the rights herein conveyed, or intended so to be, to Buyer (and any transferee of Buyer) with respect to the Purchased Assets, including without limitation such assignments, agreements and limited powers of attorney as may be needed for recording or effectuating the transfer of the Purchased Assets in the United States. Nothing herein shall be deemed a waiver by Buyer of its right to receive at the Closing an effective assignment of such rights by Seller as otherwise set forth in this Agreement. Without limiting the generality of the foregoing, Seller shall execute and deliver to Buyer or obtain for delivery to Buyer, at the request of Buyer and at Buyer's expense, and without further consideration, any documents required to update record title to the owned Purchased Assets to reflect Buyer (and any transferee of Buyer) as the record owner in each jurisdiction in which such Purchased Assets exists. At the request of Buyer and at Buyer's expense, and without further consideration, Seller shall reasonably cooperate with Buyer (and any transferee of Buyer) in connection with the registration of the Purchased Assets in jurisdictions outside of the United States.

From time to time after the Closing, at the request of Buyer and at Buyer's expense, and without further consideration, Seller shall assist Buyer (and any transferee of Buyer) to the extent reasonably necessary for the defense or prosecution of any claim by or against any third party with respect to the ownership, validity, enforceability, infringement or other violation of or by the Purchased Assets, so long as Seller is not named as a party adverse to the Buyer in any such proceeding.

Public Announcements. Each of the Parties agrees that no press release or announcement concerning this Agreement or the Transactions shall be issued by it or any of its Affiliates without the prior written consent of the other Party (which consent shall not be unreasonably withheld or delayed), except as such release or announcement may be required by applicable Law or the rules or regulations of any securities exchange, in which case such Party shall use its commercially reasonable efforts to allow the other Party reasonable time to comment on such release or announcement in advance of such issuance.

CONDITIONS TO THE CLOSING

Conditions to Obligations of Each Party. The respective obligations of each Party to consummate the Transactions shall be subject to the condition that no Governmental Authority shall have enacted, issued, promulgated, enforced or entered any Law or Order (whether temporary, preliminary or permanent) that is then in effect and has the effect of making the Transactions illegal or otherwise preventing or prohibiting consummation of the Transactions.

Return to Top | To Exhibits Index

Additional Conditions to Obligations of Buyer. The obligation of Buyer to consummate the Transactions shall also be subject to the satisfaction or waiver (where permissible), on or prior to the Closing Date, of each of the following conditions:

The representations and warranties of Seller set forth in Article II of this Agreement (i) that are qualified by the words "material" or "material adverse effect" shall be true and correct in all respects on and as of the Closing Date as if made on and as of such date and (ii) that are not so qualified shall be true and correct in all material respects on and as of the Closing Date as if made on and as of such date, except in any such case (x) for changes contemplated by this Agreement and by the Seller Disclosure Schedule, and (y) to the extent that any such representation or warranty is made as of a specified date, in which case such representation or warranty shall remain true and correct (in all material respects, as the case may be) as of such date.

Seller shall in all material respects have performed or complied with each obligation and covenant to be performed or complied with by Seller hereunder on or prior to the Closing Date, including the deliveries under Section 1.4(b).

Buyer shall have received a certificate of Seller, dated the Closing Date, signed by an officer of Seller, to the effect that the conditions specified in Sections 7.2(a) and (b) have been satisfied.

Additional Conditions to Obligations of Seller. The obligation of Seller to consummate the Transactions shall also be subject to the satisfaction or waiver (where permissible), on or prior to the Closing Date, of each of the following conditions:

The representations and warranties of Buyer set forth in Article III of this Agreement shall be true and correct in all respects on and as of the Closing Date as if made on and as of such date, except in any such case (x) for changes contemplated by this Agreement and by the Buyer Disclosure Schedule, and (y) to the extent that any such representation or warranty is made as of a specified date, in which case such representation or warranty shall remain true and correct (in all material respects, as the case may be) as of such date.

Buyer shall in all material respects have performed or complied with each obligation and covenant to be performed or complied with by it hereunder on or prior to the Closing Date, including the deliveries under Section 1.4(c).

Seller shall have received a certificate of Buyer, dated the Closing Date, signed by an executive officer of Buyer, to the effect that the conditions specified in Sections 7.3(a) and (b) have been satisfied.

TERMINATION

Termination. This Agreement may not be terminated at any time prior to the Closing Date except:

by mutual written consent of Buyer and Seller;

either Seller or Buyer, if the Closing shall not have occurred on or before May 15, 2022 (the "Outside Date"); provided, however, that the right to terminate this Agreement under this Section 8.1(b) shall not be available to any Party whose failure to fulfill any obligation under this Agreement has been the cause of, or resulted in, the failure of the Transactions to be consummated on or before the Outside Date;

by either Seller or Buyer if any Governmental Authority shall have enacted, issued, promulgated, enforced or entered any Law or Order that is, in each case, then in effect and is final and non-appealable and has the effect of making the Transactions illegal or otherwise preventing or prohibiting

Return to Top | To Exhibits Index

consummation of the Transactions; provided, however, that the right to terminate this Agreement under this Section 8.1(c) shall not be available to any Party whose failure to fulfill any obligation under this Agreement has been the cause of, or resulted in, any such Law or Order to have been enacted, issued, promulgated, enforced or entered;

by Buyer (if Buyer is not in material breach of any of the terms or conditions of this Agreement), if there has been a material breach by Seller of any terms or conditions of this Agreement, or if any representation or warranty of Seller shall have become inaccurate, in either case that would result in a failure of a condition set forth in Section 7.2(a) or 7.2(b) (a "Terminating Seller Breach"); provided, that if such Terminating Seller Breach is reasonably curable by Seller, within 30 days after Seller has received written notice from Buyer of such Terminating Seller Breach, through the exercise of its commercially reasonable efforts and for as long as Seller continues to exercise such commercially reasonable efforts, Buyer may not terminate this Agreement under this Section 8.1(d) until the earlier of the expiration of such 30-day period and the Outside Date; and

by Seller (if Seller is not in material breach of any of its representations, warranties, covenants or agreements under this Agreement), if there has been a material breach by Buyer of any of terms or conditions of this Agreement, or if any representation or warranty of Buyer shall have become inaccurate, in either case that would result in a failure of a condition set forth in Section 7.3(a) or 7.3(b) (a "Terminating Buyer Breach"); provided, that if such Terminating Buyer Breach is reasonably curable by Buyer, within 30 days after Buyer has received written notice from Seller of such Terminating Buyer Breach, through the exercise of its commercially reasonable efforts and for as long as Buyer continues to exercise such commercially reasonable efforts, Seller may not terminate this Agreement under this Section 8.1(e) until the earlier of the expiration of such 30-day period and the Outside Date.

Effect of Termination. In the event of the termination of this Agreement pursuant to Section 8.1, this Agreement shall forthwith become void, and there shall be no liability on the part of any Party hereto or any of their respective Affiliates or the directors, officers, partners, members, managers, employees, agents or other representatives of any of them, and all rights and obligations of each Party hereto shall cease, except that nothing herein shall relieve any Party from liability for any breach of this Agreement committed before such termination. Without limiting the foregoing, Section 6.2, this Section 8.2 and Article X shall survive the termination of this Agreement. Notwithstanding anything to the contrary contained in this Agreement, nothing shall limit or prevent any Party from exercising any rights or remedies it may have under Section 10.9 hereof in lieu of terminating this Agreement pursuant to Section 8.1. Notwithstanding anything to the contrary contained in this Agreement, nothing shall limit or prevent any Party from exercising any rights or remedies it may have under any of the agreements attached as Exhibits to this Agreement, whether or not this Agreement has been terminated.

INDEMNIFICATION PROVISIONS

Seller's Indemnification Obligation. Seller agrees that, from and after the Closing, it shall indemnify, defend and hold harmless Buyer, its officers, directors, Affiliates, partners, members, managers, employees, agents and other representatives ("Buyer Indemnified Parties") from and against any damages, claims, losses, liabilities, costs and expenses (including, without limitation, reasonable attorneys' fees) (each, a "Liability" and, collectively, "Liabilities") incurred by any of the foregoing Persons arising out of (a) any misrepresentation in or breach of any representation or warranty of Seller contained in Article II of this Agreement and/or (b) any breach of any covenant or agreement of Seller contained in this Agreement.

Buyer's Indemnification Obligation. Buyer agrees that, from and after the Closing, it shall indemnify, defend and hold harmless Seller and its officers, directors, Affiliates, partners, members, managers, employees, agents and other representatives ("Seller Indemnified Parties") from and against any Liabilities incurred by any of the foregoing Persons arising out of (a) any misrepresentation in or breach of any representation or warranty of

Return to Top | To Exhibits Index

Buyer contained in Article III of this Agreement, (b) any breach of any covenant or agreement of Buyer contained in this Agreement, and (c) any action, suit, litigation, proceeding at law or in equity, arbitration or governmental investigation against, or threatened against, Seller relating to any matter regarding the Purchased Assets, this Agreement and the Transactions entered into under the terms of this Agreement, except in all cases to the extent any Liabilities arise out of any breach of the Seller's representations, warranties, covenants or agreements set forth in this Agreement.

Procedures for Indemnification for Third Party Claims. For purposes of this Article IX, any Party entitled to be indemnified under Article IX is referred to herein as an "Indemnified Party," and any Party obligated to provide indemnification under Article IX is referred to herein as an "Indemnifying Party." The obligations and liabilities of the Parties under this Article IX with respect to, relating to or arising out of claims of third parties (individually, a "Third Party Claim" and, collectively, the "Third Party Claims") shall be subject to the following terms and conditions:

The Indemnified Party shall give the Indemnifying Party prompt written notice of any Liability regarding which it seeks indemnification. In the event a Liability is the result of a Liability asserted against the Indemnified Party by a third-party to this Agreement (a "Third Party Claim"), the Indemnifying Party may undertake the defense of that claim by representatives chosen by it with the written consent of the Indemnified Party, provided, that, in such event, the Indemnified Party will have the right to participate in such defense through counsel of its own choice. Any such notice of a Liability shall identify with reasonable specificity the basis for the indemnification claimed, the facts giving rise to the Liability and the amount of the Liability (or, if such amount is not yet known, a reasonable estimate of the amount of the Liability). The Indemnified Party shall make available to the Indemnifying Party copies of all relevant documents and records in its possession at the expense of the Indemnifying Party. Failure of an Indemnified Party to give prompt notice shall not relieve the Indemnifying Party of its obligation to indemnify, except to the extent that the failure to so notify materially prejudices the Indemnifying Party's ability to defend such claim against a third party.

If the Indemnifying Party, within 20 days after notice from the Indemnified Party of any such Liability, notifies the Indemnified Party in writing of its election not to, or fails to, assume the defense thereof in accordance with Section 9.3(a) of this Agreement, the Indemnified Party shall have the right (but not the obligation) to undertake the defense of the Liability. Any failure on the part of the Indemnifying Party to notify the Indemnified Party within the time period provided above regarding its election shall be deemed an election by the Indemnifying Party not to assume and control the defense of the Liability.

Anything in this Section 9.3 to the contrary notwithstanding, the Indemnifying Party shall not, and does not have any authority to, without the prior written consent of the Indemnified Party, settle or compromise any Liability or consent to the entry of judgment which does not include as an unconditional term thereof the unconditional release of the Indemnified Party from all liability with respect to the Liability. The Indemnified Party shall not settle, compromise, pay or consent to the entry of judgment with respect thereto, any Liability regarding which it has delivered notice of a claim for indemnification to the Indemnifying Party, without first obtaining the written consent of the Indemnifying Party (which shall not be unreasonably withheld or delayed). An Indemnifying Party shall be deemed to have consented to a settlement, compromise, payment or judgment by the Indemnified Party if it does not respond to written notice from the Indemnified Party seeking such consent within ten (10) days after delivery of such notice to the Indemnifying Party.

Indemnification Limitations.

Time Limits On Indemnification. No claim on account of a breach or inaccuracy of a representation or warranty shall be made after the expiration of the survival periods referred to in Section 10.1 of

Return to Top | To Exhibits Index

this Agreement. Notwithstanding the foregoing, if a written claim or written notice is given under Article IX with respect to any representation or warranty prior to the expiration of its survival period, the claim with respect to such representation or warranty shall continue until such claim is finally resolved.

Limitations on Damages.

In no event shall Seller be liable for indemnification pursuant to Section 9.1(a) unless and until the aggregate of all Liabilities which are incurred or suffered by the Buyer Indemnified Parties exceeds $50,000 (the "Basket"), in which case the Buyer Indemnified Parties shall be entitled to indemnification for all such Liabilities including the Basket (subject to Section 9.4(b)(ii)). Buyer shall be liable for indemnification pursuant to Section 9.2(a) for all Liabilities which are incurred or suffered by the Seller Indemnified Parties (subject to Section 9.4(b)(ii)).

Notwithstanding anything to the contrary in this Agreement, the maximum aggregate liability of Seller pursuant to Section 9.1(a) shall not exceed (1) the amount of money actually paid to and received by the Seller from the Buyer, Buyer's Shareholder or their Affiliates pursuant to the terms of this Agreement and any of the Agreements attached as Exhibits hereto as of the date the notice of requested indemnification is delivered to the Seller, less (2) any amounts of money due to the Seller from the Buyer, Buyer's shareholders or their Affiliates pursuant to the terms of this Agreement and any of the Agreements attached as Exhibits hereto.

Notwithstanding anything to the contrary contained in this Agreement or otherwise, no Party to this Agreement shall be liable to any Indemnified Party for any special, incidental, punitive, consequential or similar damages except, in the event a Third-Party Claim results in a judgment against an Indemnified Party by the third-party claimant, then such damages shall be included in the amount of indemnification due the Indemnified Party.

Exclusive Remedy. The remedies provided in this Article IX shall be the sole and exclusive remedies of the Parties with respect to the matters arising from or related to this Agreement or the Transactions, except that nothing herein shall prevent a Party from seeking specific performance pursuant to Section 10.9, subject to the provisions thereof, including with respect to the obligations in Section 6.1.

GENERAL PROVISIONS

Survival of Representations and Warranties. The representations and warranties made by Seller in Article II of this Agreement shall survive until the date that is fifteen (15) months after the Closing Date. The representations and warranties made by Buyer in Article III of this Agreement shall survive until the date that is fifteen (15) months after the Closing Date.

Notices. All notices and other communications under this Agreement shall be in writing and shall be deemed given (a) when delivered personally by hand (with written confirmation of receipt) or (b) when delivered by electronic mail or (c) one Business Day following the day sent by nationally-recognized overnight courier (with written confirmation of receipt), in each case at the following addresses (or to such other address as a Party may have specified by notice given to the other Party pursuant to this provision):

Data Health Partners, Inc.
10586 W Pico Blvd., #1096
Los Angeles, CA 90064
Attention: Calli R. Bucci, CFO
Email: calli.bucci@datahpi.com

Return to Top | To Exhibits Index

Parallax Behavioral Health, Inc.
3415 S. Sepulveda Blvd., Suite 1100-6592
Los Angeles, CA 90034
Attention: Dr. David Stark, President
Email: davidstark@parallaxhealthsciences.com

Parallax Health Sciences, Inc.
3415 S. Sepulveda Blvd., Suite 1100-6592
Los Angeles, CA 90034
Attention: Dr. David Stark, President
Email: davidstark@parallaxhealthsciences.com

Any notice or other communication that has been given or made as of a date that is not a Business Day shall be deemed to have been given or made on the next succeeding day that is a Business Day.

Headings. The headings contained in this Agreement and the disclosure schedules are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement or the disclosure schedules. Unless the context of this Agreement otherwise requires, words of any gender are deemed to include each other gender and words using the singular or plural number also include the plural or singular number, respectively.

Entire Agreement. This Agreement, together with the Schedules and Exhibits attached hereto, constitutes the entire agreement, and supersede all prior agreements and undertakings, both written and oral, between the Parties with respect to the subject matter hereof.

Assignment: Parties in Interest. Neither this Agreement nor any rights or obligations hereunder shall be assigned by any Party without the prior written consent of the other Party. This Agreement shall be binding upon and inure solely to the benefit of each Party hereto and its successors and permitted assigns, and nothing in this Agreement, express or implied, is intended to confer upon any other Person any rights or remedies of any nature whatsoever under this Agreement, other than Article IX hereof (which is intended to be for the benefit of the Persons covered thereby and may be enforced by such Persons).

Governing Law; Consent to Jurisdiction. This Agreement shall be governed by, and construed in accordance with, the Laws of the State of California applicable to contracts executed in and to be performed entirely in that State, without regard to conflicts of Laws principles thereof to the extent that the general application of the Laws of another jurisdiction would be required thereby.

Binding Arbitration. All claims and disputes arising under or relating to this Royalty Agreement are to be settled by binding arbitration in the state of California or another location mutually agreeable to the parties. The arbitration shall be conducted on a confidential basis pursuant to the Commercial Arbitration Rules of the American Arbitration Association. Any decision or award as a result of any such arbitration proceeding shall be in writing and shall provide an explanation for all conclusions of law and fact and shall include the assessment of costs, expenses, and reasonable attorneys' fees. Any such arbitration shall be conducted by an arbitrator experienced in the area of intellectual property and shall include a written record of the arbitration hearing. The parties reserve the right to object to any individual who shall be employed by or affiliated with a competing organization or entity. An award of arbitration may be confirmed in a court of competent jurisdiction.

Return to Top | To Exhibits Index

Counterparts. This Agreement may be executed and delivered (including by facsimile transmission or .pdf) in one or more counterparts, and by the Parties hereto in separate counterparts, each of which when executed shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement.

Severability. In case any provision in this Agreement shall be held invalid, illegal or unenforceable in a jurisdiction, such provision shall be modified or deleted, as to the jurisdiction involved, only to the extent necessary to render the same valid, legal and enforceable, and the validity, legality and enforceability of the remaining provisions hereof shall not in any way be affected or impaired thereby nor shall the validity, legality or enforceability of such provision be affected thereby in any other jurisdiction.

Specific Performance. The Parties hereto agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. Accordingly, the Parties further agree that each Party shall be entitled to seek an injunction or restraining order to prevent breaches of this Agreement and to seek to enforce specifically the terms and provisions hereof, this being in addition to any other right or remedy to which such Party may be entitled under this Agreement, at law or in equity.

Fees and Expenses. All fees, costs and expenses incurred in connection with this Agreement and the Transactions shall be paid by the Party incurring the same, regardless of the termination, if any, of this Agreement pursuant to Section 8.1. Notwithstanding the foregoing, in the event the Parties engage in litigation relating to or arising out of this Agreement or the performance thereof, the Parties agree that the Court shall be asked to determine which Party is the prevailing Party to the proceeding or proceedings, and the non-prevailing Party or Parties shall, jointly and severally, be liable to the prevailing Party in the amount of all reasonable attorney's fees, court costs, and all other expenses, incurred by the prevailing Party to the proceeding in addition to any other relief to which the prevailing Party may be entitled.

Amendment. This Agreement may not be modified, amended, altered or supplemented except upon the execution and delivery of a written agreement executed by Buyer, Parallax, and Seller.

Waiver. At any time prior to the Closing Date, any Party hereto may (a) extend the time for the performance of any of the obligations or other acts of the other Party hereto, (b) waive any inaccuracies in the representations and warranties contained herein or in any document delivered pursuant hereto and (c) waive compliance with any of the agreements or conditions contained herein. Any such extension or waiver shall be valid if set forth in an instrument in writing signed by the Parties hereto. The failure of any Party hereto to assert any of its rights hereunder shall not constitute a waiver of such rights.

CERTAIN DEFINITIONS

For purposes of this Agreement, the term:

"Action" shall have the meaning ascribed to it in Section 2.4.

"Adjusted Gross Revenues" shall mean the gross revenues generated from the Purchased Assets, less all costs of goods sold, direct and indirect, as defined within the Royalty Agreement.

"Affiliate(s)" of a Person means a Person that directly or indirectly, through one or more intermediaries, Controls, is Controlled by, or is under common Control with, the first mentioned Person.

"Agreement" shall have the meaning ascribed to it in the preamble.

Return to Top | To Exhibits Index

"Business Day" means any calendar day which is not a Saturday, Sunday or federal holiday.

"Buyer" shall have the meaning ascribed to it in the Preamble.

"Buyer Disclosure Schedule" shall have the meaning ascribed to it in the preamble to Article III.

"Closing" shall have the meaning ascribed to it in Section 1.4(a).

"Closing Date" shall have the meaning ascribed to it in Section 1.4(a).

"Control" (including the terms "Controlled by" and "under common Control with") means the possession, directly or indirectly or as trustee or executor, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, as trustee or executor, by contract or credit arrangement or otherwise.

"Data" means all information gathered in the use or operation of any of the Purchased Assets that identifies or describes an individual or an individual's record of behavior or action, including without limitation, name, telephone, postal address, phone number, email, date of birth, gender, or any other information identifiable to a specific person, including "personal health information" as that term is defined in the Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), as amended, to the extent such information exists as of the Closing Date.

"Encumbrance" means any charge, claim, community property interest, condition, easement, covenant, warrant, demand, encumbrance, equitable interest, lien, mortgage, option, purchase right, pledge, security interest, right of first refusal or other right of third parties or restriction of any kind, including any restriction on use, voting, transfer, receipt of income or exercise of any other attribute of ownership.

"Exchange Act" shall have the meaning ascribed to it in Section 2.3.

"Governmental Authority" means any United States federal, state or local government, governmental, regulatory or administrative authority, agency, self-regulatory body, instrumentality or commission, and any court, tribunal or judicial or arbitral body (including private bodies) and any political or other subdivision, department or branch of any of the foregoing.

"Indemnified Party" shall have the meaning ascribed to it in Section 9.3.

"Indemnifying Party" shall have the meaning ascribed to it in Section 9.3.

"Intellectual Property" means all United States and foreign intellectual property and all other similar proprietary rights, including all (i) patents and patent applications, including divisionals, continuations, continuations-in-part, reissues, reexaminations and extensions thereof and counterparts claiming priority therefrom; utility models; invention disclosures; and statutory invention registrations and certificates; (ii) registered, pending and unregistered trademarks, service marks, trade dress, logos, trade names, corporate names and other source identifiers, domain names, Internet sites and web pages; and registrations and applications for registration for any of the foregoing, together with all of the goodwill associated therewith; (iii) registered copyrights, and registrations and applications for registration thereof; rights of publicity; and copyrightable works; (iv) all inventions and design rights (whether patentable or unpatentable) and all categories of trade secrets as defined in the Uniform Trade Secrets Act, including business, technical and financial information; and (v) confidential and proprietary information, including know-how.

Return to Top | To Exhibits Index

"Seller's Knowledge" shall have the meaning ascribed to it in Section 2.6.

"Laws" means any federal, state or local statute, law, rule, ordinance, code or regulation of any Governmental Authority.

"Liability" and, collectively, "Liabilities" shall have the meaning ascribed to it in Section 9.1.

"Order" shall have the meaning ascribed to it in Section 2.4.

"Outside Date" shall have the meaning ascribed to it in Section 8.1(b).

"Parties" shall have the meaning ascribed to it in the preamble.

"Patent Assignment" means Seller's Patent Assignment, attached herewith as Exhibit E, whereby, as part of this Agreement, Seller assigns to Buyer all of Seller's right, title and interest in and to the Purchased Assets, as forth in attached herewith as Exhibit A, in the United States or worldwide.

"Patent Application" means all Applications for Letters Patent of the United States and worldwide, as set forth in Exhibit A of this Agreement, and any application for letters patent to be filed in the United States or worldwide in the future, in connection with inventions and improvements in and to the Intellectual Property set forth in Exhibit A of this Agreement.

"Permitted Encumbrance" means (i) statutory liens for Taxes, assessments and governmental charges or levies not yet due and payable or that are being contested in good faith by appropriate proceedings; (ii) mechanics', materialmen's, carriers', warehousemen's or similar statutory liens for amounts not yet due or being diligently contested in good faith in appropriate proceedings; and (iii) pledges or deposits to secure obligations under workers' compensation laws or similar legislation or to secure public or statutory obligations.

"Person" means an individual, corporation, partnership, limited liability company, association, trust, unincorporated organization or other entity.

"Purchase Consideration" shall mean the purchase price for the Purchased Assets, and have the same meaning ascribed to it in Section 1.3.

"Purchased Assets" shall have the meaning ascribed to it in Section 1.1.

"R.E.B.O.O.T." R.E.B.O.O.T. is an acronym for "Reliable Evidence Based Outcomes Optimization Technologies" and is a structured, scalable and sustainable software system used to identify, monitor, and evaluate a single user or an entire organization's progress towards mastery of any achievable task, objective or goal.

"Seller" shall have the meaning ascribed to it in the Preamble.

"Seller Disclosure Schedule" shall have the meaning ascribed to it in the preamble to Article II.

"Shareholder(s)" means any individual or entity owning, directly or indirectly, shares of a corporation's common stock.

"Subsidiary" means any Person with respect to which a specified Person directly or indirectly (A) owns a majority of the equity interests, (B) has the power to elect a majority of that Person's board of directors or

Return to Top | To Exhibits Index

similar governing body, or (C) otherwise has the power, directly or indirectly, to direct the business and policies of that Person.

"Tax" or "Taxes" means any and all taxes, fees, levies, duties, tariffs, imposts and other charges of any kind (together with any and all interest, penalties, additions to tax and additional amounts imposed with respect thereto) imposed by any Governmental Authority, including: taxes or other charges on or with respect to income, franchise, windfall or other profits, gross receipts, property, sales, use, equity interests, payroll, employment, social security, workers' compensation, unemployment compensation or net worth; taxes or other charges in the nature of excise, withholding, ad valorem, stamp, transfer, value-added or gains taxes; license, registration and documentation fees; and customers' duties, tariffs and similar charges.

"Terminating Buyer Breach" shall have the meaning ascribed to it in Section 8.1(e).

"Terminating Seller Breach" shall have the meaning ascribed to it in Section 8.1(d).

"Third Party Claim" and, collectively, "Third Party Claims" shall have the meaning ascribed to it in Section 9.3.

"Trademark Assignment Agreement" shall have the meaning ascribed to it in Section 1.4(b)(i).

"Transactions" shall have the meaning ascribed to it in Section 2.2.

IN WITNESS WHEREOF, each of the parties hereto has caused this Agreement to be duly executed this 11th day of May, to be effective as of April 13, 2022.

SELLER:
Parallax Behavioral Health, Inc.

/s/ David L. Stark
By: Dr. David L. Stark
Title: Chairman, President

BUYER:
Data Health Partners, Inc.

/s/ Calli R. Bucci
By: Calli R. Bucci
Title: Director, Chief Financial Officer

SELLER:
Parallax Health Sciences, Inc.

/s/ David L. Stark
By: Dr. David L. Stark
Title: Chairman, President

* * * * *

Return to Top | To Exhibits Index

SCHEDULES AND EXHIBITS

SCHEDULES

SCHEDULE 1	SELLER DISCLOSURE SCHEDULE
SCHEDULE 2	BUYER DISCLOSURE SCHEDULE

EXHBITS

EXHIBIT A	PURCHASED ASSETS
EXHIBIT B-1	CORPORATE PROMISSORY NOTE
EXHIBIT B-2	INTELLECTUAL PROPERTY PLEDGE AND SECURITY AGREEMENT
EXHIBIT C	ANTI-DILUTION AGREEMENT
EXHIBIT D	ROYALTY AGREEMENT
EXHIBIT E	PATENT ASSIGNMENT
EXHIBIT F	TRADEMARK ASSIGNMENT

Return to Top

SCHEDULE 1

SELLER DISCLOSURE SCHEDULE

These Disclosure Schedules are made pursuant to that certain Intellectual Property Purchase Agreement executed May 11, 2022, and effective as of April 13, 2022 (the "Agreement"), by and among Parallax Behavioral Health, Inc., a Delaware corporation ("Seller"), and Parallax Health Sciences, Inc., a Nevada corporation and sole shareholder of Seller ("Parallax"), on the one hand, and Data Health Partners, Inc., a Delaware corporation ("Buyer"), on the other hand, hereinafter collectively referred to as the "Parties".

The representations and warranties of Seller in Section 2 of the Agreement are made subject to the exceptions and qualifications set forth herein. These Disclosure Schedules are qualified in their entirety by reference to specific provisions of the Agreement and are not intended to constitute separate or additional representations or warranties of Seller.

The inclusion of any information (including dollar amounts) in any section of these Disclosure Schedules is not an admission by Seller that such information is required to be listed in that section or that it is material to or outside the ordinary course of business of Seller. Further, the inclusion of such information may not be used to establish a standard of materiality (and the actual standard of materiality may be higher or lower than the matters disclosed by such information).

Matters reflected in these Disclosure Schedules are not necessarily limited to matters that are required to be reflected in these Disclosure Schedules per the Agreement. Such additional matters are included for informational purposes only and do not necessarily include other matters of a similar nature.

The information in these Disclosure Schedules is provided solely to make the disclosures to Buyer under the Agreement. Seller does not assume any responsibility for the accuracy of any information herein to any Person that is not a party to the Agreement. The information was not prepared or disclosed with a view to its potential disclosure to others. Subject to applicable law, this information is disclosed in confidence for the purposes contemplated in the Agreement and is subject to any confidentiality provisions between the Parties. In disclosing this information, Seller expressly reserves any attorney-client privilege associated with such information or any protection afforded by the work-product doctrine concerning any of the matters disclosed herein.

[Schedule shared between Buyer and Seller Only - Omitted due to Confidentiality]

Return to Top | To Exhibits Index

SCHEDULE 2

BUYER DISCLOSURE SCHEDULE

These Disclosure Schedules are made pursuant to that certain Intellectual Property Purchase Agreement executed May 11, 2022, and effective as of April 13, 2022 (the "Agreement"), by and among Parallax Behavioral Health, Inc., a Delaware corporation ("Seller"), and Parallax Health Sciences, Inc., a Nevada corporation and sole shareholder of Seller ("Parallax"), on the one hand, and Data Health Partners, Inc., a Delaware corporation ("Buyer"), on the other hand, hereinafter collectively referred to as the "Parties".

The representations and warranties of Buyer in Section 3 of the Agreement are made subject to the exceptions and qualifications set forth herein. These Disclosure Schedules are qualified in their entirety by reference to specific provisions of the Agreement and are not intended to constitute separate or additional representations or warranties of Buyer.

The inclusion of any information (including dollar amounts) in any section of these Disclosure Schedules is not an admission by Buyer that such information is required to be listed in that section or that it is material to or outside the ordinary course of business of Buyer. Further, the inclusion of such information may not be used to establish a standard of materiality (and the actual standard of materiality may be higher or lower than the matters disclosed by such information).

Matters reflected in these Disclosure Schedules are not necessarily limited to matters that are required to be reflected in these Disclosure Schedules per the Agreement. Such additional matters are included for informational purposes only and do not necessarily include other matters of a similar nature.

The information in these Disclosure Schedules is provided solely to make the disclosures to Seller under the Agreement. Buyer does not assume any responsibility for the accuracy of any information herein to any Person that is not a party to the Agreement. The information was not prepared or disclosed with a view to its potential disclosure to others. Subject to applicable law, this information is disclosed in confidence for the purposes contemplated in the Agreement and is subject to any confidentiality provisions between the Parties. In disclosing this information, Buyer expressly reserves any attorney-client privilege associated with such information or any protection afforded by the work-product doctrine concerning any of the matters disclosed herein.

[Schedule shared between Buyer and Seller Only - Omitted due to Confidentiality]

Return to Top | To Exhibits Index

EXHIBIT A

PURCHASED ASSETS

Letters Patent of the United States

United States Patent No. 10,061,812 (Family ID 51533139) issued August 28, 2018, and all related worldwide patents:

Platform For Optimizing Data Driven Outcomes

Abstract: A system, method, server, and computer readable medium for tracking outcome specific data. Input establishing accounts for providers serving clients is received. The accounts are stored in a server. Each of the clients is assigned to one or more of the providers in response to selections from an administrator. Data associated with each of the clients received from the providers is compiled utilizing computing or communications devices in communication with the server. The compiled data is presented visually in response to a user request.

United States Patent No. 11,144,554 (Family ID 65038812) issued October 12, 2021, and all related worldwide patents:

Platform For Optimizing Goal Progression

Abstract: A system, method, server, and computer readable medium for tracking goal progression. Input establishing accounts for providers serving a client is received. The client is an individual receiving treatment or assistance. The accounts are stored in a server available through one or more networks. The client is assigned to one or more of the providers in response to selections from an administrator. Goals and a plan of action are established for the client in response to treatments and assistance required. Data associated with the client received from the providers is compiled. A determination is made whether thresholds associated with the goals are being met based on the compiled data.

United States Patent No. 11,151,142 (Family ID 51533139) granted October 12, 2021, and all related worldwide patents:

Platform For Optimizing Goal Progression

Abstract: A system, method, server, and computer readable medium for tracking goal progression. Input establishing accounts for providers serving clients is received. Each of the clients is assigned to one or more of the providers in response to selections from an administrator. Goals are established for each of the clients in response to treatments and assistance required. Data associated with each of the clients received from the providers is compiled. A determination is made whether the goals are being met in response to rules based on the compiled data. Alerts are automatically communicated in response to the compiled data varying from a threshold to become significant for one or more of the clients.

All related patents filed or to be filed in connection with the aforementioned patents and patent applications, as well as those provided in the Global Dossier included herewith.

Return to Top | To Exhibits Index

Applications for Letters Patent of the United States

United States Patent Application No. 17/499,725 (Family ID 65038812) filed October 12, 2021, and all related worldwide patent applications:

System And Method For Achieving Goal Progression

Abstract: A system, method, server, and computer readable medium for tracking goal progression. Input is received establishing clients. The clients are individuals receiving treatment or assistance. Each of the clients are assigned to one or more providers in response to selections from an administrator. The one or more providers include at least individuals available to treat or assist each of the clients and one or more biometric devices associated with the clients. Goals are established for each of the clients. Data associated with each of the clients is compiled as received from the one or more providers in the server. A determination is made where the goals are being met in response to the thresholds for the compiled data. Alerts are automatically communicated in response to the compiled data varying from a threshold to become significant for one or more of the clients.

United States Patent Application No. 17/505,166 (Family ID 51533139) filed October 19, 2021, and all related worldwide patent applications:

System And Method For Tracking Progression Toward A Customized Goal

Abstract: A system, method, server, and computer readable medium for tracking progression toward a customized goal. Input establishing accounts for clients is received. Each of the clients is assigned to one or more of the providers in response to selections from an administrator. Customized goals are established for each of the clients based on treatment or assistance required. Data associated with each of the clients is received from the one or more providers. Data associated with each of the clients received from the providers is compiled. A determination is made whether the customized goals are being met in response one or more thresholds for the compiled data. Alerts are automatically communicated to at least the one or more providers in response to the compiled data varying from the one or more thresholds to become significant for one or more of the clients.

United States Patent Application No. 17/546,594 (Family ID 1000006016644) filed December 9, 2021, and all related worldwide patent applications:

System And Method For Achieving Goals

Abstract: A system, method, server, and computer readable medium for tracking goal progression. Input is received establishing one or more clients. The one or more clients are individuals receiving treatment or assistance. Each of the one or more clients are assigned to one or more providers in response to selections from an administrator. The one or more providers include at least individuals available to treat or assist each of the one or more clients and one or more biometric devices associated with the one or more clients. Goals are established for each of the one or more clients. Data associated with each of the one or more clients is compiled as received from the one or more providers in the server. A determination is made where the goals are being met in response to the thresholds for the compiled data. Alerts are automatically communicated in response to the compiled data varying from a threshold to become significant for one of the one or more clients.

All related patent applications filed or to be filed in connection with the aforementioned patents and patent applications, as well as those provided in the Global Dossier included herewith.

Return to Top | To Exhibits Index

Trademarks And Copyrights

"R.E.B.O.O.T." "R.E.B.O.O.T." is an acronym for "Reliable Evidence Based Outcomes Optimization Technologies" and is a structured, scalable and sustainable software system used to identify, monitor, and evaluate a single user or an entire organization's progress towards mastery of any achievable task, objective or goal.

The "COMPASS Application." The COMPASS Application is a software program which features evidence-based content, decision support and real-time status updates for multiple stakeholders, all aimed at improving physical and behavioral health and wellness. The wealth of data collected through use of the software fuels machine learning algorithms that can be used to establish best practice predictive models to drive value-based health care and reduce lifetime health care spend.

Other Intellectual Property

COMPASS, development work papers, Code, Master Software.

Confidentiality and Invention Assignment Agreements with employees and consultants.

Trademarks and service marks related to R.E.B.O.O.T. and COMPASS.

Key trade secrets and proprietary know-how.

Technology licenses from third parties to the selling company, if any.

Software and databases.

Contracts providing for indemnification of third-parties for IP matters, if any.

Open-source software used in (or used to create) the seller's products or services, if any.

Source Code or object code escrows.

Patents and Patent Applications contained within the Global Dossier immediately following.

Return to Top | To Exhibits Index

GLOBAL DOSSIER

IP Office	Application	Applicant	Title	Application Date	Priority Number	Publication Number	Publication Date
AU	2014229758	1)Grafton School Inc	Platform for optimizing data driven outcomes	03/14/2014	US 14212429 US PCT/US14/29287 US 61791218	AU 2014229758 A1	10/01/2015
US	14212429	1)Marshall Lisa A 2)Gaynor James	PLATFORM FOR OPTIMIZING DATA DRIVEN OUTCOMES	03/14/2014	US 14212429 US 61791218	US 20140280136 A1 US 10061812 B2	09/18/2014 08/28/2018
US	PCT/US14/29287	1)GRAFTON SCHOOL INC	PLATFORM FOR OPTIMIZING DATA DRIVEN OUTCOMES	03/14/2014	US 14212429 US 61791218	WO 2014144749 A1	09/18/2014
GB	2015173 71			03/14/2014	US 14212429 US PCT/US14/29287 US 61791218	GB 2015173 71 D0 GB 2526749 A	11/18/2015 12/02/2015
US	16053141	1)Marshall Lisa A 2)Gaynor James	PLATFORM FOR OPTIMIZING GOAL PROGRESSION	08/02/2018	US 14212429 US 16053141 US 61791218	US 20180373763 A1 US 11151142 B2	12/27/2018 10/19/2021
US	16141471	1)Bradley Nathaniel T 2)Gaynor James 3)Paugh Joshua S 4)Arena Paul	PLATFORM FOR OPTIMIZING GOAL PROGRESSION	09/25/2018	US 16141471 US 61791218 US 14212429 US 16053141	US 20190034494 A1 US 11144554 B2	01/31/2019 10/12/2021
AU	2020100161	1)Parallax Behavioral Health Inc	Platform for optimizing data driven outcomes	01/31/2020	US PCT/US14/29287 US 61791218 AU 2014229758 US 14212429 AU 2020100161	AU 2020100161 A4	09/05/2020
US	17499725	1)Bradley Nathaniel T 2)Gaynor James 3)Paugh Joshua S. 4)Arena Paul	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	10/12/2021	US 16141471 US 61791218 US 17499725 US 14212429 US 16053141	US 20220037013 A1	02/03/2022
US	17505166	1)Marshall, Lisa A., 2)Gaynor, James	SYSTEM AND METHOD FOR TRACKING PROGRESSION TOWARD A CUSTOMIZED GOAL	10/19/2021	US 61791218 US 14212429 US 16053141 US 17505166	US 20220035855 A1	02/03/2022
US	17546594	1)Bradley Nathaniel T 2)Gaynor James 3)Paugh Joshua S 4)Arena Paul	SYSTEM AND METHOD FOR ACHIEVING GOALS	12/09/2021	US 16141471 US 61791218 US 17499725 US 14212429 US 16053141 US 17546594	US 20220100754 A1	03/31/2022

Return to Top | To Exhibits Index

EXHIBIT B-1

SENIOR SECURED CORPORATE PROMISSORY NOTE

Los Angeles, California

This **SENIOR SECURED CORPORATE PROMISSORY NOTE** (the "Note) executed this 11th day of May, 2022, is being issued effective April 13, 2022 (the "Issuance Date") in connection with the Intellectual Property Purchase Agreement (the "Purchase Agreement") and Intellectual Property Pledge and Security Agreement (the "Security Agreement") of the same date, attached herewith as Exhibit A and B, respectively. All capitalized terms contained in this Note shall have the meaning set forth in the Security Agreement. In the event there is an inconsistency in the terms contained in the Security Agreement and the terms contained in this Note, then the terms of the Security Agreement shall control.

FOR VALUE RECEIVED, Data Health Partners, Inc., a Delaware corporation (the "Company") promises to pay to Parallax Behavioral Health, Inc., a Delaware corporation (the "Holder"), in lawful money of the United States, the principal amount of Twenty Million Dollars ($20,000,000.00) (the "Principal Sum"), together with Interest thereon calculated from the Issuance Date.

Interest. Interest on the Principal Sum of the Note outstanding from time to time, shall accrue at the rate of three percent (3%) per annum from thirty-six months after the Issuance Date, calculated on the basis of a 365-day year, and continue until the Note is paid in full, whether at maturity or upon acceleration or otherwise (the "Interest").

The Company shall make Interest-only cash payments to the Holder in the amount of two hundred thousand dollars ($200,000) annually, to be applied to, and thereby reducing, accrued and unpaid Interest accordingly (the "Annual Interest Payment(s)").

The initial Annual Interest Payment shall be made within thirty (30) days of the Company securing initial funding to litigate and license the Intellectual Property, and shall continue every twelve (12) month period until the Note and any accrued but unpaid Interest has been paid in full.

Maturity Date. The Company shall pay to the Holder the Principal Sum and all accrued Interest one hundred twenty (120) months from the Issuance Date (the "Maturity Date"). Interest shall accrue on the Principal Sum, or any portion thereof, under this Note until such time as payment therefor is delivered to the Note Holder, or, as the case may be, on any Prepayment date pursuant to Section 3.1.

Payments. On or before the Maturity Date, the Company shall pay the Principal Sum outstanding under this Note and accrued and unpaid Interest thereon to the Holder in lawful money of the United States of America by bank wire transfer of immediately available funds to the account specified by the Holder in writing to the Company at least five Business Days before such payment is to be made, without the presentation or surrender of this Note or the making of any notation thereon.

Prepayments. The Company may make prepayments ("Prepayments") on this Note in whole or in part at any time without the prior written consent of the Holder. Unless otherwise specified in Section 3.1.(i) and 3.1.(ii), any payment pursuant to this Note, including Annual Interest Payments, shall be applied first to Interest that has become due pursuant to this Note and remains unpaid and then to the outstanding Principal Sum of this Note.

To Exhibits Index

In the event the Company receives monies during the first twenty-four months from the Issuance Date, in connection with the intellectual property monetization efforts from litigation and/or licensing (the "IP Monetization"), payments to the Holder shall include:

10% of all Net Proceeds from $1 to $10,000,000 shall be paid to Holder and applied towards the Principal Sum, up to a maximum of $1,000,000 applied towards the Principal Sum; and

20% of all Net Proceeds from $10,000,001 to $20,000,000 shall be paid to Holder and applied towards the Principal Sum, up to a maximum of $2,000,000 applied towards the Principal Sum; and

30% of all Net Proceeds from $20,000,001 to $30,000,000 shall be paid to Holder and applied towards the Principal Sum, up to a maximum of $3,000,000 applied towards the Principal Sum; and

40% of all Net Proceeds from $30,000,001 to $40,000,000 shall be paid to Holder and applied towards the Principal Sum, up to a maximum of $4,000,000 applied towards the Principal Sum; and

50% of all Net Proceeds from $40,000,001 to $50,000,000 shall be paid to Holder and applied towards the Principal Sum, up to a maximum of $5,000,000 applied towards the Principal Sum.

60% of all Net Proceeds from $50,000,001 to $60,000,000 shall be paid to Holder and applied towards the Principal Sum, up to a maximum of $5,000,000 applied towards the Principal Sum.

The Prepayments in Section 3.1.(i)(a) through 3.1.(i)(f), shall be based upon cumulative Net Proceeds during the twenty-four-month period, and represent an aggregate of $20,000,000 in Principal, as illustrated in the table below:

Net Proceeds		To Holder	Principal Reduction		Note
Minimum	Maximum	%	Amount	Cumulative	Balance
					$20,000,000
$0	$10,000,000	10%	$1,000,000	$1,000,000	$19,000,000
$10,000,001	$20,000,000	20%	$2,000,000	$3,000,000	$17,000,000
$20,000,001	$30,000,000	30%	$3,000,000	$6,000,000	$14,000,000
$30,000,001	$40,000,000	40%	$4,000,000	$10,000,000	$10,000,000
$40,000,001	$50,000,000	50%	$5,000,000	$15,000,000	$5,000,000
$50,000,001	$60,000,000	60%	$5,000,000	$20,000,000	$0
			$20,000,000		

In the event the Company receives monies between the twenty-fifth month through the one hundred twentieth month from the Issuance Date, in connection with the IP Monetization, payments to the Holder shall include:

50% of all Net Proceeds from $1 to $10,000,000 shall be paid to Holder and applied towards the Principal Sum, up to a maximum of $5,000,000 applied towards the Principal Sum; and

EXHIBIT B-1

Return to Top | To Exhibits Index

60% of all Net Proceeds from $10,000,001 to $20,000,000 shall be paid to Holder and applied towards the Principal Sum, up to a maximum of $6,000,000 applied towards the Principal Sum; and

70% of all Net Proceeds from $20,000,001 to $30,000,000 shall be paid to Holder and applied towards the Principal Sum, up to a maximum of $7,000,000 applied towards the Principal Sum; and

80% of all Net Proceeds from $30,000,001 to $40,000,000 shall be paid to Holder and applied towards the Principal Sum, up to a maximum of $2,000,000 applied towards the Principal Sum.

The Prepayments in Section 3.1.(ii)(a) through 3.1.(ii)(d), shall be based upon cumulative Net Proceeds during the ninety-six-month period, and represent an aggregate of $20,000,000 in Principal, as illustrated in the table below:

Net Proceeds		To Holder	Principal Reduction		Note
Minimum	Maximum	%	Amount	Cumulative	Balance
					$20,000,000
$0	$10,000,000	50%	$5,000,000	$5,000,000	$15,000,000
$10,000,001	$20,000,000	60%	$6,000,000	$11,000,000	$9,000,000
$20,000,001	$30,000,000	70%	$7,000,000	$18,000,000	$2,000,000
$30,000,001	$40,000,000	80%	$2,000,000	$20,000,000	$0
			$20,000,000		

Net Proceeds. Net Proceeds shall be defined as all gross monies received by the Company in connection with the IP Monetization ("Gross Receipts"), less all direct costs reasonably incurred by the Company in connection with the IP Monetization ("Direct Costs"), including, but not limited to, legal and other professional fees.

Business Days. If any payment is due, or any time period for giving notice or taking action expires, on a day which is a Saturday, Sunday or legal holiday in the State of California, the payment shall be due and payable on, and the time period shall automatically be extended to, the next business day immediately following such Saturday, Sunday or legal holiday, and Interest shall continue to accrue at the required rate hereunder until any such payment is made.

Grace Period. Payments pursuant to this Section 3 are subject to a 10-day grace period, as provided herein and in the Purchase Agreement, attached herewith as Exhibit A.

Accounting. The Company shall provide Holder with semi-annual reports of Net Proceeds. The Company agrees to provide Holder, within forty (40) days after the end of each semi-annual period, except seventy-five (75) days after the last day of the Company's fiscal year, a report of the Net Proceeds of Company ("Semi-Annual Reports"). The Company shall commence providing Holder such Semi-Annual Reports within forty (40) days following the end of the first semi-annul period after the Effective Date of this Note. The Semi-Annual Reports will quantify the Gross Receipts, less all Direct Costs during the previous semi-annual period.

The Company shall keep a permanent, accurate set of books and records ("Books and Records") in gross monies received and direct costs incurred shall be recorded. All Books and Records reflecting the Gross Receipts and/or the calculation of Net Proceeds shall be retained and preserved for a period of five (5) years.

EXHIBIT B-1

Return to Top | To Exhibits Index

The Books and Records shall be open to inspection and audit by Holder and/or its duly authorized representatives, at all reasonable times during business hours upon not less than ten (10) days prior written notice. The cost of such audit shall be determined on a time and expense basis at the rate per hour which shall not exceed that charged for similar personnel by a national firm of independent certified public accountants.

If the Holder conducts an audit of the Books and Records, and if the audit determines that Company has understated the Gross Receipts or calculation of Net Proceeds by more than three (3%) percent, in addition to such other rights and remedies available to the Holder at law or equity, the Company shall, within thirty (30) business days thereafter, pay any deficiency in the Net Proceeds due on account of such understatement and the reasonable cost of such audit.

If the Holder conducts an audit of the Books and Records, and if the audit determines that Company has not understated the Gross Receipts or calculation of Net Proceeds, the cost of the audit shall be borne by the Holder.

If Company fails to submit the required statement of Gross Receipts or calculation of Net Proceeds, as required, the Company shall pay the cost thereof, irrespective of the results of such audit.

The Books and Records shall include: (i) as soon as available, and in any event within thirty (30) calendar days after the close of each quarter, quarterly financial statements, all in reasonable detail and prepared in accordance with generally accepted accounting principles applied on a consistent basis; (ii) as soon as available, and in any event within seventy-five (75) calendar days after the close of each year, annual financial statements, all in reasonable detail and prepared in accordance with generally accepted accounting principles applied on a consistent basis.

In the event any Government Authorities imposes any taxes on any part of the payments required hereunder and the Company's auditors or tax advisors advise the Company that it is required to withhold taxes from such payment, the Company may withhold such taxes from such payments or pay same as required. Tax receipts indicating such payments or withholding of taxes shall be promptly submitted to Holder. The Company shall cooperate with Holder in a determination of the propriety of, or imposition of, any such tax and shall permit Holder to challenge such tax by all lawful means.

In the event any national government imposes any exchange restriction prohibiting payments as required under this Agreement, an account in the name of Holder shall be established in a financial institution of Holder's choice in such country (or permitted place of payment) and all monies due Holder shall be paid into such account, or at Holder's election, payment shall be made to any account designated by Holder that complies with such restriction(s)/prohibition.

Seniority. The Note ranks senior in right of payment with all indebtedness of the Company, whether currently existing or issued in the future, and its seniority can only be changed by written approval by the Holder.

Security. As collateral security for the due and punctual payment of the Principal Sum and accrued but unpaid Interest due under the Note, the Company hereby collaterally assigns, transfers, sets over and delivers to Holder and hereby grants to Holder a continuing first interest in and to an aggregate of one hundred percent (100%) of the Intellectual Property of the Company. as set forth in Exhibit A of the Security Agreement. subject to the terms and conditions of the Security Agreement, attached herewith as Exhibit B (the "Pledged Collateral").

EXHIBIT B-1

Return to Top | To Exhibits Index

Events of Default. The occurrence of any of the following shall constitute an Event of Default under this Note:

Failure to Pay. The Company fails to pay any sum when due under this Note, whether at maturity or by acceleration or otherwise.

Voluntary Bankruptcy or Insolvency Proceedings. The Company shall (i) apply for or consent to the appointment of a receiver, trustee, liquidator or custodian of itself or of all or a substantial part of its property, (ii) makes a general assignment for the benefit of creditors or admits in writing its inability to pay its debts generally as they become due, (iii) commence a voluntary case or other proceeding seeking liquidation, reorganization or other relief with respect to itself or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or consent to any such relief or to the appointment of or taking possession of its property by any official in an involuntary case or other proceeding commenced against it, or (iv) take any action for the purpose of effecting any of the foregoing.

Involuntary Bankruptcy or Insolvency Proceedings. If proceedings for the appointment of a receiver, trustee, liquidator or custodian of the Company or of all or a substantial part of the property thereof, or an involuntary case or other proceedings seeking liquidation, reorganization or other relief with respect to the Company or the debts thereof under any bankruptcy, insolvency or other similar law or hereafter in effect shall be commenced, and an order for relief entered in such proceeding shall not be dismissed or discharged within thirty (30) days of the entry of such an order.

Judgment. Any money judgment, writ or similar process shall be entered or filed against the Company or any subsidiary of the Company or any of its property or other assets for more than $250,000, and shall remain unvacated, unbonded or unstayed for a period of sixty (60) days.

Maintain Assets. The Company fails to maintain any material intellectual property rights, personal, real property or other assets which are necessary to conduct its business (whether now or in the future) of the Company.

Covenants. The Company fails to observe or perform any material covenant or agreement set forth in this Note (except a default in the payment of money) within thirty (30) days after written notice thereof is received by the Company.

Rights of Holder Upon Default. Upon the occurrence or existence of any Event of Default and at any time thereafter during the continuance of such Event of Default, then the aggregate Principal Sum (together with all accrued but unpaid Interest thereon), shall become immediately due and payable without any notice, demand, presentment, demand or protest of any kind, each of which is hereby expressly waived by the Company.

In addition to the foregoing remedies, upon the occurrence or existence of any Event of Default, the Holder may exercise its rights expressly provided under the Security Agreement, attached herewith as Exhibit B, for the Pledged Collateral, or any other right, power or remedy granted to it or otherwise permitted to it by law, either by suit in equity or by action at law.

Miscellaneous.

Replacement. Upon receipt of evidence reasonably satisfactory to Company of the loss, theft, destruction or mutilation of this Note, and in the case of any such loss, theft, or destruction of this Note, upon receipt of an indemnity reasonably satisfactory to the Company, or in the case of mutilation of this Note, upon surrender and cancellation of the Note, the Company shall execute and deliver to the Holder, in lieu thereof, a new Note of like tenor and date of this Note.

EXHIBIT B-1

Return to Top | To Exhibits Index

Covenants The Company shall be subject to the covenants contained in the Note.

Notices. Any notice, request or other communication required or permitted hereunder shall be to the addresses set forth in, and in accordance with, the Purchase Agreement, attached herewith as Exhibit A, or any other addresses designated by the parties from time to time in writing.

Amendment. This Note may only be amended by an instrument in writing signed by the Company and the Holder.

Remedies Not Waived. No course of dealing between the Company and the Holders or any delay on the part of the Holders or Company in exercising any of their respective rights hereunder shall operate as a waiver of any such right.

Governing Law. This Note and all actions arising out of or in connection with this Note shall be governed by and construed in accordance with the laws of the state of California, without regard to the conflicts of law provisions of the state of California, or of any other state. If any term or provision of this Note shall be held invalid, illegal or unenforceable, the validity of all other terms and provisions hereof shall in no way be affected thereby.

Binding Arbitration. All claims and disputes arising under or relating to this Royalty Agreement are to be settled by binding arbitration in the state of California or another location mutually agreeable to the parties. The arbitration shall be conducted on a confidential basis pursuant to the Commercial Arbitration Rules of the American Arbitration Association. Any decision or award as a result of any such arbitration proceeding shall be in writing and shall provide an explanation for all conclusions of law and fact and shall include the assessment of costs, expenses, and reasonable attorneys' fees. Any such arbitration shall be conducted by an arbitrator experienced in the area of intellectual property and shall include a written record of the arbitration hearing. The parties reserve the right to object to any individual who shall be employed by or affiliated with a competing organization or entity. An award of arbitration may be confirmed in a court of competent jurisdiction.

Expenses of Enforcement. The Company agrees to pay all reasonable fees and expenses incurred by the Holder in connection with any amendments, modifications, extensions, renewals, renegotiations, waivers, collection or protection of Holder's rights in connection with this Note or in connection with any pending or threatened action, proceeding, or investigation relating to the foregoing, including but not limited to the reasonable fees and disbursements of counsel for the Holder, unless such action is without merit.

Assignment. This Note is subject to the assignment restrictions as provided in the Purchase Agreement, attached herewith as Exhibit A.

Cancellation. After the Principal Sum and accrued but unpaid Interest at any time owed on this Note have been finally, fully and indefeasibly paid in full, this Note shall be surrendered to the Company for cancellation.

Severability. If any provision of this Note is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this Note shall remain in full force and effect. Any provision of this Note held invalid or unenforceable only in part shall remain in full force and effect to the extent not held invalid or unenforceable.

EXHIBIT B-1

Return to Top | To Exhibits Index

Headings. The descriptive headings of the several sections and paragraphs of this Note are inserted for convenience only and do not constitute a part of this Note.

Applicable Interest Rate. If it shall be found that any Interest or other amount deemed Interest due hereunder violates the applicable law governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum rate of interest permitted under applicable law. In no event shall Interest pursuant to this Note be payable at a rate in excess of the maximum rate permitted by applicable law and solely to the extent necessary to result in such interest not being payable at a rate in excess of such maximum rate, any amount that would be treated as part of such interest under a final judicial interpretation of applicable law shall be deemed to have been a mistake and automatically canceled, and, if received by the Holder, shall be refunded to the Company, it being the intention of the Holder and of the Company that such Interest not be payable at a rate in excess of such maximum rate. All rights and remedies available to the Holder pursuant to the provisions of applicable law and otherwise are cumulative, not exclusive and enforceable alternatively, successively and/or concurrently after default by the Company pursuant to the provisions of this Note. No delay or failure on the part of the Holder in exercising any right, privilege or option hereunder shall operate as a waiver thereof or of any event of default, nor shall any single or partial exercise of any such right, privilege or option preclude any further exercise thereof, or the exercise of any other right, privilege or option.

Counterparts. This Note may be executed and delivered (including by facsimile transmission, electronic mail or .pdf) in one or more counterparts, and by the Parties hereto in separate counterparts, each of which when executed shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement.

IN WITNESS WHEREOF, the Company has caused this Note to be duly executed this 11th day of May, to be effective as of April 13, 2022.

NOTE ISSUER:	**NOTE HOLDER:**
Data Health Partners, Inc.	**Parallax Behavioral Health, Inc.**
/s/ Calli R. Bucci	*/s/ David L. Stark*
By: Calli R. Bucci	By: Dr. David L. Stark
Title: Director, Chief Financial Officer	Title: Chairman, President

EXHIBIT B-1

Return to Top | To Exhibits Index

EXHIBITS TO
SENIOR SECURED CORPORATE PROMISSORY NOTE

EXHIBIT	**INTELLECTUAL PROPERTY PURCHASE AGREEMENT**
EXHIBIT	**INTELLECTUAL PROPERTY PLEDGE AND SECURITY AGREEMENT**

* * * * *

EXHIBIT B-1

Return to Top | To Exhibits Index

EXHIBIT B-2

INTELLECTUAL PROPERTY PLEDGE AND SECURITY AGREEMENT

This **INTELLECTUAL PROPERTY PLEDGE AND SECURITY AGREEMENT** (the "Security Agreement") executed this 11th day of May, 2022, is effective as of April 13, 2022, by and between Data Health Partners, Inc., a Delaware corporation ("Pledgor"), and Parallax Behavioral Health, Inc., a Delaware corporation ("Pledgee"), hereinafter collectively referred to as the Parties.

WHEREAS, contemporaneous with the execution of this Security Agreement, Pledgor has issued a promissory note to Pledgee in the principal sum of twenty million dollars ($20,000,000), as evidenced by that certain Senior Secured Corporate Promissory Note (the "Note"), attached herewith as Exhibit B; and

WHEREAS, Pledgor is the rightful holder of all rights, title and interest in and to the Intellectual Property set forth in Exhibit A attached herewith (the "Intellectual Property"); and

WHEREAS, Pledgor desires to pledge the Intellectual Property to Pledgee, and Pledgee desires to accept such Pledge, to secure repayment of the Note.

NOW THEREFORE, in consideration of the foregoing, of the mutual covenants and agreements herein contained, and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Parties hereby agree as follows:

Pledge. As collateral security for the due and punctual payment of all principal due under the Note, Pledgor hereby collaterally assigns, assigns, sets over, delivers and grants to Pledgee a one hundred percent (100%) continuing first interest in and to the Intellectual Property set forth in Exhibit A of this Security Agreement, (the "Pledged Collateral"), herewith delivered to Pledgee.

Pledgor appoints Pledgee, or its attorney, to arrange for the assignment of the Pledged Collateral to the name of Pledgee on the books and records of the Company.

Pledgee shall hold the Pledged Collateral to secure the repayment of the Note and shall not encumber or dispose of the Intellectual Property, except as provided in Paragraph 8 herein.

Royalties. During the term of this Security Agreement, any and all royalties and other amounts received by Pledgee in connection with the Pledged Collateral prior to the Maturity Date of the Note, if any, as a result of Pledgee's interest in the Pledged Collateral, shall be applied as a Prepayment on the Note, to be applied to the Note in accordance with Section 3.1 of the Note.

Representations of Pledgor.

With the exception of the security interest granted to Pledgee pursuant to this Security Agreement, Pledgor is the sole beneficial and record owner of the Pledged Collateral, having good and valid title thereto, free, and clear of any and all liens, claims, encumbrances, security interests, attachments, charges or rights of others, except for those disclosed to the Pledgor and Pledgee.

Pledgor has the right to assign to Pledgee the Pledged Collateral, free of any encumbrances and without restriction, and without obtaining the consents of any other party.

Release of Pledged Collateral/Repayment of Note. Upon full satisfaction of the Note at or before the Maturity Date of the Note, inclusive of amounts theretofore received and applied by Pledgee in accordance with paragraph 3 herein, Pledgee shall assign back to Pledgor all rights received by Pledgee in and to the Pledged Collateral under this Security Agreement.

Return to Top | To Exhibits Index

Default. In any Event of Default, as defined within the Note, or in the default in performance of any terms of this Security Agreement, Pledgee shall have the rights and remedies provided in the Uniform Commercial Code in force in the state of California on the date of this Security Agreement.

In addition to and in conjunction with such rights and remedies, Pledgee may, by giving thirty (30) days prior notice to Pledgor in writing, either by registered mail or electronic mail, and without liability for any diminution in price that may have occurred, sell all of the Pledged Collateral in any manner and for any price Pledgee reasonably determines. Out of the proceeds of any such sale, Pledgee may retain an amount equal to the unpaid Principal Sum and accrued Interest then due on the Note, and shall return the surplus, if any, to the Pledgor.

At any such bona fide public sale by Pledgee of the Pledged Collateral, Pledgor shall have the right, but not the obligation, to repurchase all or any part of the Pledged Collateral in exchange for payment to Pledgee of the balance owed under the Note.

If Pledgee has received Prepayments on the Note, Pledgee is not obligated to return any such Prepayments to Pledgor as part of taking full custody, ownership and assignment of the Pledged Collateral.

Non-Recourse. Notwithstanding any other provision in this Security Agreement to the contrary, the obligation of Pledgor to pay the indebtedness evidenced by the Note and secured hereby shall not be enforced by any action or proceeding wherein or whereby damages or any money judgment (including any deficiency judgment) shall be sought against Pledgor. It being, expressly understood and agreed by Pledgee that its sole and exclusive remedy for the default of Pledgor shall be to effect the remedies provided under this Security Agreement.

Termination. This Security Agreement shall terminate upon the earlier of (i) the satisfaction of the Note; or (ii) the Pledgee's completion of the exercise of its remedies hereunder.

General Provisions.

Entire Agreement. This Security Agreement supersedes all agreements previously made between the parties hereto relating to its subject matter. There are no other understandings or agreements between them.

Notices. All notices and other communications hereunder shall be deemed to have duly given if mailed by first class mail, or via electronic mail, to the applicable party at the address indicated below, or such other address as a party may so designate in the future, in writing to the other party.

Data Health Partners, Inc.
10586 W Pico Blvd #1096
Los Angeles, CA 90064
Attention: Calli R. Bucci, CFO
Email: calli.bucci@datahpi.com

Parallax Behavioral Health, Inc.
3415 S. Sepulveda Blvd., Suite 1100-6592
Los Angeles, CA 90034
Attention: Dr. David Stark, President
Email: davidstark@parallaxhealthsciences.com

Return to Top | To Exhibits Index

Amendment. This Security Agreement may not be modified, amended, altered or supplemented except upon the execution and delivery of a written agreement executed by parties.

Governing Law; Consent to Jurisdiction. This Security Agreement shall be governed by, and construed in accordance with, the Laws of the State of California applicable to contracts executed in and to be performed entirely in that State, without regard to conflicts of Laws principles thereof to the extent that the general application of the Laws of another jurisdiction would be required thereby.

Assignment: Parties in Interest. Neither this Security Agreement nor any rights or obligations hereunder shall be assigned by any Party without the prior written consent of the other Parties. This Security Agreement shall be binding upon and inure solely to the benefit of each Party hereto and its successors and permitted assigns, and nothing in this Security Agreement, express or implied, is intended to confer upon any other person any rights or remedies of any nature whatsoever under this Agreement.

Severability. In case any provision in this Security Agreement shall be held invalid, illegal or unenforceable, such provision shall be modified or deleted, only to the extent necessary to render the same valid, legal and enforceable, and the validity, legality and enforceability of the remaining provisions hereof shall not in any way be affected or impaired thereby.

Non-Waiver. No delay or failure by either party to exercise any right under this Security Agreement, and no partial or single exercise of that right, shall constitute a waiver of that or any other right, unless otherwise expressly provided herein.

Necessary Acts. Each party agrees to take such further action and execute, deliver and/or file such documents or instruments as are reasonably necessary to carry out the terms and purposes of this Security Agreement.

Headings. The headings contained in this Security Agreement are for reference purposes only, and shall not affect in any way the meaning or interpretation of this Security Agreement. Unless the context of this Security Agreement otherwise requires, words of any gender are deemed to include each other gender and words using the singular or plural number also include the plural or singular number, respectively.

Counterparts. This Agreement may be executed and delivered (including by facsimile transmission, electronic mail or .pdf) in one or more counterparts, and by the Parties hereto in separate counterparts, each of which when executed shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement.

IN WITNESS WHEREOF, each of the parties hereto has caused this Security Agreement to be duly executed this 11th day of May, to be effective as of April 13, 2022.

PLEDGOR:	**PLEDGEE:**
Data Health Partners, Inc.	**Parallax Behavioral Health, Inc.**
/s/ Calli R. Bucci	*/s/ David L. Stark*
By: Calli R. Bucci	By: Dr. David L. Stark
Title: Director, Chief Financial Officer	Title: Chairman, President

Return to Top | To Exhibits Index

EXHIBITS TO
INTELLECTUAL PROPERTY PLEDGE AND SECURITY AGREEMENT

EXHIBIT	**INTELLECTUAL PROPERTY PURCHASE AGREEMENT**
EXHIBIT	**SENIOR SECURED CORPORATE PROMISSORY NOTE**

* * * * *

Return to Top | To Exhibits Index

EXHIBIT C

ANTI-DILUTION AGREEMENT

This **ANTI-DILUTION AGREEMENT** (the "Agreement") executed this 11th day of May, 2022, is effective as of April 13, 2022, by and between Parallax Health Sciences, Inc., a Nevada corporation ("Parallax"), Parallax Behavior Health, Inc., a Delaware corporation ("Seller"), and Data Health Partners, Inc. a Delaware corporation ("DHPI" or the "Buyer"), hereinafter collectively referred to as the "Parties."

WHEREAS, the Parties have entered into a certain Intellectual Property Purchase Agreement (the "Purchase Agreement"), attached herewith as Exhibit I, and other related agreements, pursuant to which the Buyer is acquiring from the Seller all right, title, and interest in and to certain intellectual property and related assets (the "Intellectual Property"), as set forth in Exhibit A of the Purchase Agreement; and

WHEREAS, as partial consideration for the Intellectual Property under the Purchase Agreement, Buyer is issuing to Seller a Corporate Promissory Note in the principal sum of twenty million dollars ($20,000,000) (the "Note"), which is secured through an Intellectual Property Pledge and Security Agreement, as set forth in Exhibit B-1 and Exhibit B-2, respectively, of the Purchase Agreement; and

WHEREAS, as partial consideration for the Intellectual Property under the Purchase Agreement, at Closing, Buyer shall issue to the Parallax shareholders of record (the "Parallax Shareholders") on the record date of April 13, 2022 (the "Record Date"), an aggregate of three million nine hundred sixty thousand three hundred forty-four (3,960,344) shares of the Buyer's Common Stock (the "DHPI Shares"); and

WHEREAS, as of the Record Date, no other Person or Affiliate, other than the Parallax Shareholders, has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the DHPI Shares; and

WHEREAS, the Parties desire to provide the Parallax Shareholders certain protections against dilution with respect to the DHPI Shares.

NOW, THEREFORE, in consideration of the foregoing, of the mutual covenants and agreements herein contained, and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Parties hereby agree as follows:

Definitions:

"Affiliate" means with respect to any Person, each other Person that directly or indirectly, through one or more intermediaries, owns or controls, is controlled by or is under common control with, such Person. For the purpose of this Agreement, "control" means the possession, directly or indirectly, of the power to direct or cause the direction of management and policies, whether through the ownership of voting securities, by contract or otherwise.

"Additional Shares" means the number of shares of Common Stock issued by the Buyer after the Record Date resulting from a Dilutive Transaction.

"Adjustment Shares" means the number of shares of Common Stock issuable by the Buyer to the Parallax Shareholders resulting from a Dilutive Transaction to maintain the Percentage Interest, or from any transaction, including an Exempt Transaction, that would result in the DHPI Shares equaling less than the Minimum Percentage.

"Anti-Dilution Percentage" means forty-five percent (45%).

Parallax Behavioral Health, Inc.

Return to Top | To Exhibits Index

"Asset Acquisition" means acquiring some or all of a target company's assets in exchange for consideration, which can be cash, equity, or a combination of both.

"Common Stock" means the securities or shares that represent the Buyer's share capital, inclusive of any shares of common stock underlying any convertible securities, such as convertible preferred stock.

"DHPI Outstanding Shares" means the number of shares of Common Stock issued and outstanding by the Buyer, exclusive of (i) the DHPI Shares, (ii) any shares reserved for an equity-based incentive plan, (iii) any Adjustment Shares issued in connection with a Dilutive Transaction, and (iv) any shares issued in connection with an Exempt Transaction.

"Dilutive Transaction" means an Asset Acquisition or Merger, as defined herein, by the Buyer that would result in a reduction of the Percentage Interest.

"Exempt Transaction" means (i) any equity financing or similar transaction effected by the Buyer, excluding the Initial Equity Financing; (ii) any acquisition or merger that is accretive to the DHPI shareholders; or (iii) any other transaction not otherwise defined herein that results in the issuance of shares of DHPI Common Stock.

"Initial Equity Financing" means the Buyer's initial equity financing in connection with the pending litigation for a minimum commitment of seven million five hundred thousand dollars ($7,500,000).

"Merger" means the process in which one entity merges with and into another entity with only one entity surviving, for which the consideration can be cash, equity, or a combination of both.

"Minimum Percentage" means thirty percent (30%) of the total issued and outstanding shares of DHPI.

"Note" means the Corporate Promissory Note, attached herewith as Exhibit B-1 to the Purchase Agreement.

"Percentage Interest" means the aggregate number of shares of the Buyer's Common Stock held by Parallax Shareholders that represents the Anti-Dilution Percentage of (i) the DHPI Outstanding Shares; and (ii) any Additional Shares issued in connection with a Dilutive Transaction, in accordance with the provisions of this Agreement. The Percentage Interest and Adjustment Shares shall be calculated pursuant to the formula set forth in Schedule A attached herewith.

"Person" means any natural person, corporation, limited liability company, partnership, association, trust, organization, Governmental Authority or other legal entity.

Capitalization.

Capitalization of the Buyer. The Buyer has twenty million (20,000,000) authorized shares of Common Stock for issuance, of which (i) three million nine hundred sixty thousand three hundred forty-four (3,960,344) shares, or forty-five percent (45%), have been reserved for issuance to the Parallax Shareholders; (ii) 440,038 shares, or five percent (5%), have been reserved for issuance under an equity-based incentive plan to be established in the future; and (iii) four million four hundred thousand three hundred eighty-two (4,400,382), or fifty percent (50%), have been reserved for issuance to investors in the Initial Equity Financing and founders of DHPI. Collectively, the reserved shares represent eight million eight hundred thousand seven hundred sixty-four (8,800,764) shares to be issued and outstanding, or one hundred percent (100%).

Parallax Behavioral Health, Inc.

Return to Top | To Exhibits Index

Term. The rights provided under this Agreement shall commence on the Record Date, and shall expire on the later of (i) the date on which the Buyer has satisfied the Note in accordance with its terms and conditions; (ii) the completion of proposed litigation in connection with the Intellectual Property; or (iii) the acquisition of the Buyer.

Anti-Dilution Rights.

To the extent that, during the Term of the Agreement, the Buyer issues any Additional Shares of Common Stock as a result of a Dilutive Transaction, contemporaneously with the Dilutive Transaction, the Buyer shall issue the Parallax Shareholders the number of Adjustment Shares required to maintain the Percentage Interest in the DHPI Outstanding Shares.

In no event shall the DHPI Shares equal less than the Minimum Percentage of the total issued and outstanding shares of DHPI. If any issuance of DHPI Common Stock, whether in connection with a Dilutive Transaction or an Exempt Transaction, would result in the DHPI Shares equaling less than the Minimum Percentage, the Buyer shall issue Adjustment Shares to the Parallax Shareholders that will maintain the Minimum Percentage.

Any shares issued by the Buyer during the Term of the Agreement in connection with an Exempt Transaction are not subject to the anti-dilution provisions provided herein, and shall not be treated as DHPI Outstanding Shares for the purposes of calculating Percentage Interest, or result in the issuance of any Adjustment Shares to the Parallax Shareholders, except in accordance with Section 4.2 herein.

No further approval or authorization of any shareholder, the board of directors of any Party, or any other Person or Affiliate is required for the issuance of the Adjustment Shares issuable to the Parallax Shareholders under this Agreement.

Confidentiality. The Parties to this Agreement agree to keep its terms strictly confidential, and not to disclose the terms hereof to any third-party other than the shareholders of the Parties, without the consent of the majority of the board of directors of each Party; provided, however, that this provision shall not apply to information which, at the time of disclosure, is already part of the public domain (except by breach of this Agreement) and information which is required to be disclosed by law or by the regulations of the SEC.

General Provisions.

Entire Agreement. This Agreement supersedes all agreements previously made between the parties hereto relating to its subject matter. There are no other understandings or agreements between them.

Notices. Any notice, request or other communication required or permitted hereunder shall be to the addresses set forth in, and in accordance with, the Purchase Agreement, attached herewith as Exhibit I, or any other addresses designated by the parties from time to time in writing

Amendment. This Agreement may not be modified, amended, altered or supplemented except upon the execution and delivery of a written agreement executed by Parent, Seller and Buyer.

Governing Law; Consent to Jurisdiction. This Agreement shall be governed by, and construed in accordance with, the Laws of the State of California applicable to contracts executed in and to be performed entirely in that State, without regard to conflicts of Laws principles thereof to the extent that the general application of the Laws of another jurisdiction would be required thereby.

Parallax Behavioral Health, Inc.

Return to Top | To Exhibits Index

Binding Arbitration. All claims and disputes arising under or relating to this Agreement are to be settled by binding arbitration in the state of California or another location mutually agreeable to the parties. The arbitration shall be conducted on a confidential basis pursuant to the Commercial Arbitration Rules of the American Arbitration Association. Any decision or award as a result of any such arbitration proceeding shall be in writing and shall provide an explanation for all conclusions of law and fact and shall include the assessment of costs, expenses, and reasonable attorneys' fees. Any such arbitration shall be conducted by an arbitrator experienced in the area of intellectual property and shall include a written record of the arbitration hearing. The parties reserve the right to object to any individual who shall be employed by or affiliated with a competing organization or entity. An award of arbitration may be confirmed in a court of competent jurisdiction

Fees and Expenses. All fees, costs and expenses incurred in connection with this Agreement shall be paid by the Party incurring the same. Notwithstanding the foregoing, in the event the Parties engage in binding arbitration relating to or arising out of this Agreement or the performance thereof, the Parties agree that the arbitrator shall be asked to determine which Party is the prevailing Party to the proceeding or proceedings, and the non-prevailing Party or Parties shall, jointly and severally, be liable to the prevailing Party in the amount of all reasonable attorney's fees, court costs, and all other expenses, incurred by the prevailing Party to the proceeding in addition to any other relief to which the prevailing Party may be entitled.

Assignment: Parties in Interest. Neither this Agreement nor any rights or obligations hereunder shall be assigned by any Party without the prior written consent of the other Parties. This Agreement shall be binding upon and inure solely to the benefit of each Party hereto and its successors and permitted assigns, and nothing in this Agreement, express or implied, is intended to confer upon any other Person any rights or remedies of any nature whatsoever under this Agreement.

Severability. In case any provision in this Agreement shall be held invalid, illegal or unenforceable in a jurisdiction, such provision shall be modified or deleted, as to the jurisdiction involved, only to the extent necessary to render the same valid, legal and enforceable, and the validity, legality and enforceability of the remaining provisions hereof shall not in any way be affected or impaired thereby nor shall the validity, legality or enforceability of such provision be affected thereby in any other jurisdiction.

Non-Waiver. No delay or failure by either party to exercise any right under this Agreement, and no partial or single exercise of that right, shall constitute a waiver of that or any other right, unless otherwise expressly provided herein.

Necessary Acts. Each party agrees to take such further action and execute, deliver and/or file such documents or instruments as are reasonably necessary to carry out the terms and purposes of this Agreement.

Headings. The headings contained in this Agreement are for reference purposes only, and shall not affect in any way the meaning or interpretation of this Agreement. Unless the context of this Agreement otherwise requires, words of any gender are deemed to include each other gender and words using the singular or plural number also include the plural or singular number, respectively.

Counterparts. This Agreement may be executed and delivered (including by facsimile transmission, electronic mail or .pdf) in one or more counterparts, and by the Parties hereto in separate counterparts, each of which when executed shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement.

The remainder of this page intentionally left blank

Parallax Behavioral Health, Inc.

Return to Top | To Exhibits Index

IN WITNESS WHEREOF, each of the parties hereto has caused this Agreement to be duly executed this 11th day of May, to be effective as of April 13, 2022.

Parallax Health Sciences, Inc.

/s/ David L. Stark
By: Dr. David L. Stark
Title: Chairman, President

Data Health Partners, Inc.

/s/ Calli R. Bucci
By: Calli R. Bucci
Title: Director, Chief Financial Officer

Parallax Behavioral Health, Inc.

/s/ David L. Stark
By: Dr. David L. Stark
Title: Chairman, President

The remainder of this page intentionally left blank

Parallax Behavioral Health, Inc.

Return to Top | To Exhibits Index

SCHEDULE A

CALCULATION OF PERCENTAGE INTEREST

Capitalized terms refer to definitions ascribed to them in paragraph 1 of this Agreement.

The Percentage Interest and Adjustment Shares, as defined in paragraph 1 of this Agreement, shall be calculated using the following formula:

$$((Y / 55\%) \times P) - A = X$$

whereby:
- A = DHPI Shares
- S = Additional Shares
- P = Anti-Dilution Percentage
- Y = DHPI Outstanding Shares
- X = Adjustment Shares

For illustration purposes only, and without limiting or altering the Agreement to which this Schedule is attached, the following example is provided with respect to Percentage Interest and the calculation of Adjustment Shares.

EXAMPLE:

Assume that DHPI enters into a Dilutive Transaction that includes the issuance of 2,000,000 shares of DHPI Common Stock.

Assume that, prior to the Dilutive Transaction, the capitalization of DHPI is as follows:

DHPI Shares	3,960,344	45%
DHPI Outstanding Shares	4,400,392	55%
Total DHPI Common Stock issued and outstanding	8,360,726	100%

Assume that DHPI also enters into an Exempt Transaction that includes the issuance of 1,500,000 shares of DHPI Common Stock.

The capitalization of DHPI immediately preceding the calculation of Percentage Interest is as follows:

	Beginning Shares	Transactions	Ending Shares
DHPI Shares	3,960,344 (a)		3,960,344
DHPI Outstanding Shares	4,400,392 (b)	2,000,000 (c)	7,900,392
		1,500,000 (d)	
Total DHPI Common Stock issued and outstanding	8,360,726	3,500,000	11,860,736

The Parallax Shareholders would be entitled to Adjustment Shares in connection with the Dilutive Transaction, using the following information:

$$((Y / 55\%) \times P) - A - X$$

whereby: A = DHPI Shares	=	3,960,344 = (a)
P = Anti-Dilution Percentage	=	45%
S = Additional Shares	=	2,000.000 = (c)
Y = DHPI Outstanding Shares	=	4,400,392 + 2,000,000 = (b) + (c)
X = Adjustment Shares	=	To Be Determined

Parallax Behavioral Health, Inc.

Return to Top | To Exhibits Index

Applying the formula, the Adjustment Shares to be issued to the Parallax Shareholders is calculated by solving for X, as follow:

X

Adjustment Shares

The resulting capitalization after Adjustment Shares would be as follows:

DHPI Shares	5,236,684	40% (e)
DHPI Outstanding Shares-Dilutive Transactions	6,400,392	49%
DHPI Outstanding Shares-Exempt Transactions	1,500,000	11%
Total DHPI Common Stock issue and outstanding	13,137,076	100%

For the purposes of determining X, only shares issued in connection with Dilutive Transactions are treated as Additional Shares. The 1,500,000 shares resulting from the Exempt Transaction are excluded from the calculation.

Pursuant to paragraph 4.2 of this Agreement, in no event shall this percentage equal less than thirty percent (30%).

Parallax Behavioral Health, Inc.

Return to Top | To Exhibits Index

EXHIBITS TO
ANTI-DILUTION AGREEMENT

EXHIBIT	INTELLECTUAL PROPERTY PURCHASE AGREEMENT

* * * * *

Parallax Behavioral Health, Inc.

Return to Top | To Exhibits Index

EXHIBIT D

ROYALTY AGREEMENT

This **ROYALTY AGREEMENT** (the "Agreement") executed this 11th day of May, 2022, is effective as of April 13, 2022, by and between Data Health Partners, Inc., a Delaware corporation ("Data Health"), and Parallax Behavioral Health, Inc., a Delaware corporation ("Parallax"), hereinafter collectively referred to as the "Parties."

WHEREAS, the Parties have entered into a certain Intellectual Property Purchase Agreement (the "Purchase Agreement"), attached herewith as Exhibit I, and other related agreements, pursuant to which Data Health acquiring from Parallax all right, title, and interest in and to certain intellectual property and related assets (the "Intellectual Property"), as set forth in Exhibit A of the Purchase Agreement; and

WHEREAS, as partial consideration for the Intellectual Property under the Purchase Agreement, the Parties desire to enter into an agreement whereby Parallax is acquiring the the right to receive certain payments from Data Health in connection with the Intellectual Property, on the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the foregoing, of the mutual covenants and agreements herein contained, and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Parties hereby agree as follows:

Definitions. Capitalized terms shall have the meaning set forth in this section. Unless the context requires otherwise, words in the singular include the plural, words in the plural include the singular, and words importing any gender shall be applicable to all genders. If a term is defined as one part of speech (such as a noun), it shall have a corresponding meaning when used as another part of speech (such as a verb).

"Affiliate" means with respect to any Person, each other Person that directly or indirectly, through one or more intermediaries, owns or controls, is controlled by or is under common control with, such Person. For the purpose of this Agreement, "control" means the possession, directly or indirectly, of the power to direct or cause the direction of management and policies, whether through the ownership of voting securities, by contract or otherwise.

"Assigned Patents" means the transfer from Parallax to Data Health of all of rights, title, and interest in and to the Patents, as set forth in Exhibit A to the Purchase Agreement attached herewith as Exhibit I.

"Assigned Patent Application(s)" means the transfer from Parallax to Data Health of all of rights, title, and interest in and to the Patent Applications, as set forth in Exhibit A to the Purchase Agreement attached herewith as Exhibit I, and any patent application to be filed in the future in connection with the Assigned Patents and Assigned Patent Applications.

"Business Day" means any day other than Saturday, Sunday or a day on which banks in the state of California are authorized or required to be closed.

"Corporate Promissory Note" means the Corporate Promissory Note attached herewith as Exhibit II.

"Direct Costs" means all expenses incurred by Data Health in connection with the generation of Gross Receipts, including, but not limited to, legal and other professional fees, as well as taxes, if any, imposed pursuant to Section 3.4 herein.

"Government Authority" means any nation or government, any state or other political subdivision thereof and any entity exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to government.

Return to Top | To Exhibits Index

"Intellectual Property" means (i) the Intellectual Property as set forth in Exhibit A of the Purchase Agreement, attached herewith as Exhibit I; (ii) all inventions, patents, patent applications, trade secrets, know-how, technical data, laboratory results, clinical results, manufacturing methods, copyrights, trademarks and other data, know-how and intellectual property owned, licensed or controlled by Data Health, whenever acquired, that are necessary to develop, manufacture, have manufactured, use, promote, distribute, import, sell and offer for sale any Data Health product; and (iii) any "Patents," "Patent Applications" or "Know-How" not otherwise included in subsection (i) and (ii) of this definition.

"Know-How" means everything that would constitute ideas, concepts, schemes, information, knowledge, techniques, methodology, and anything else in the nature of know-how relating to the Intellectual Property.

"Gross Receipts" means all monies received by Data Health from any sale, use, derivation, license, grant or transfer of any rights in, to or regarding the Assigned Patent and Assigned Patent Application, any subsequently issued patent resulting from the Assigned Patent or Assigned Patent Application (as may be modified or amended from time to time by Data Health), the commercial exploitation of the Assigned Patent and Assigned Patent Application, and any technological applications or processes enabled by the use of the information contained in the same.

"Note" shall have the same meaning as "Corporate Promissory Note," defined herein.

"Net Proceeds" means Gross Receipts less Direct Costs.

"Person" means any natural person, corporation, limited liability company, partnership, association, trust, organization, Governmental Authority or other legal entity.

"Purchase Agreement" means the Intellectual Property Purchase Agreement attached herewith as Exhibit I, whereby Parallax has assigned all rights, title and interest in and to the Intellectual Property, subject to the conditions set forth in Section 2.3 of this Royalty Agreement and pursuant to the terms of the Assigned Patents and Assigned Patent Applications.

"Royalty Agreement" shall have the meaning set forth in the introductory paragraph.

"Royalty Payments" means the amounts due from Data Health to Parallax in accordance with Section 2 of this Royalty Agreement.

"Royalty Term" shall commence on the date of this Royalty Agreement and end at such time as Data Health is no longer able to generate revenues from (i) the sale, use, derivation, license, grant or transfer of any rights in or to the Assigned Patent and/or Assigned Patent Application, or any subsequently issued patent resulting from the Assigned Patent and/or Assigned Patent Application (as may be modified or amended from time to time by Data Health), or (ii) the commercial exploitation of the Assigned Patent and/or Assigned Patent Application or any subsequently issued patent resulting therefrom, and any technological applications or processes enabled by use of the information contained in the same. Notwithstanding anything in the foregoing to the contrary, Data Health's obligation to pay the Royalty to Parallax shall expire with the expiration or termination of any Assigned Patent, or subsequently issued patent resulting from the Assigned Patent and/or Assigned Patent Application (as may be amended).

Royalty.

Royalty Amount. As partial consideration for the rights acquired by Data Health in and to the Intellectual Property under the Purchase Agreement, Data Health shall pay to Parallax a royalty equal to two and one-half percent (2.5%) of Net Proceeds generated during the Royalty Term (the "Royalty").

Return to Top | To Exhibits Index

Royalty Payments. All Royalty Payments shall be made according to the following:

Royalty Payments due and payable under this Royalty Agreement during the Royalty Term shall be treated as IP Monetization Prepayments, as defined and in accordance with Section 3.1 of the Corporate Promissory Note, and thereafter, shall be applied towards any accrued and unpaid Interest, as defined within the Note, until such time as the Note is satisfied in full.

Thereafter during the Royalty Term, and upon full satisfaction of the Note, Royalty Payments shall be distributed to Parallax in lawful money of the United States of America by bank wire transfer of immediately available funds to the account specified by Parallax in writing to the Data Health at least five Business Days before such payment is to be made.

Royalty Payments Following Termination. The termination of this Royalty Agreement, including termination due to the expiration of the Royalty Term, shall not terminate the obligation of Data Health, or its Affiliates, licensees or assignees, to pay any Royalty accrued prior to termination. Upon termination of this Agreement, Parallax shall have the right to retain any Royalty already paid by Data Health under this Agreement.

Accounting. Data Health shall provide Parallax with semi-annual reports of Net Proceeds. Data Health agrees to provide Parallax, within forty (40) days after the end of each semi-annual period, except seventy-five (75) days after the last day of Data Health's fiscal year, a report of the Net Proceeds of Data Health ("Semi-Annual Reports"). Data Health shall commence providing Parallax such Semi-Annual Reports within forty (40) days following the end of the first semi-annul period after the Effective Date of this Royalty Agreement. The Semi-Annual Reports will detail all Gross Receipts and Direct Costs during the previous semi-annual period.

Data Health shall keep a permanent, accurate set of books and records ("Books and Records") in which Gross Receipts and Direct Costs shall be recorded. All Books and Records reflecting the Gross Receipts and/or the calculation of Net Proceeds shall be retained and preserved for a period of five (5) years.

The Books and Records shall be open to inspection and audit by Parallax and/or its duly authorized representatives, at all reasonable times during business hours upon not less than ten (10) days prior written notice. The cost of such audit shall be determined on a time and expense basis at the rate per hour which shall not exceed that charged for similar personnel by a national firm of independent certified public accountants.

If Parallax conducts an audit of the Books and Records, and if the audit determines that Data Health has understated the Gross Receipts or calculation of Net Proceeds by more than three (3%) percent, in addition to such other rights and remedies available to the Parallax at law or equity, Data Health shall, within thirty (30) business days thereafter, pay any deficiency in the Net Proceeds due on account of such understatement and the reasonable cost of such audit.

If Parallax conducts an audit of the Books and Records, and if the audit determines that Data Health has not understated the Gross Receipts or calculation of Net Proceeds, the cost of the audit shall be borne by the Parallax.

If Data Health fails to submit the required statement of Gross Receipts or calculation of Net Proceeds, as required, Data Health shall pay the cost thereof, irrespective of the results of such audit.

The Books and Records shall include: (i) as soon as available, and in any event within thirty (30) calendar days after the close of each quarter, quarterly financial statements, all in reasonable detail and prepared in accordance with generally accepted accounting principles applied on a consistent basis; (ii) as soon as available, and in any event within seventy-five (75) calendar days after the close of each year, annual financial statements, all

Return to Top | To Exhibits Index

in reasonable detail and prepared in accordance with generally accepted accounting principles applied on a consistent basis.

In the event any Government Authorities imposes any taxes on any part of the payments required hereunder and Data Health's auditors or tax advisors advise Data Health that it is required to withhold taxes from such payment, Data Health may withhold such taxes from such payments or pay same as required. Tax receipts indicating such payments or withholding of taxes shall be promptly submitted to Parallax. Data Health shall cooperate with Parallax in a determination of the propriety of, or imposition of, any such tax and shall permit Parallax to challenge such tax by all lawful means.

In the event any national government imposes any exchange restriction prohibiting payments as required under this Agreement, an account in the name of Parallax shall be established in a financial institution of Parallax's choice in such country (or permitted place of payment) and all monies due Parallax shall be paid into such account, or at Parallax's election, payment shall be made to any account designated by Parallax that complies with such restriction(s)/prohibition.

Representations and Warranties.

Representations and Warranties of Parallax. Parallax represents and warrants that (a) it is a corporation duly organized, validly existing, and in good standing under the laws of the state of Delaware; (b) it has full power and authority to enter into this Royalty Agreement and perform its obligations hereunder; (c) immediately prior to the execution of the Purchase Agreement (and subject to such licenses as have been disclosed to Data Health in writing), it owned all right, title and interest in and to the Assigned Patent and Assigned Patent Applications; and (d) it has the legal right and is entitled to the Royalty Payments pursuant to Section 2 above.

Representations and Warranties of Data Health. Data Health represents and warrants that (a) it is a corporation duly organized, validly existing, and in good standing under the laws of the state of Delaware; (b) it has full power and authority to enter into this Royalty Agreement and perform its obligations hereunder, and (c) immediately subsequent to the execution of the Purchase Agreement (and subject to such licenses as have been disclosed by Parallax in writing), it owns all right, title and interest in and to the Assigned Patent and Assigned Patent Applications.

Covenants.

Maintenance of Rights. Neither Party shall take any action, or fail to take any action or enforce any right, that is intended to, or would have the effect of, reducing Gross Receipts.

Maintenance of Rights Under Purchase Agreement. Neither Party shall take any action that would, or fail to take any action if such failure would, (i) modify, relinquish, diminish or terminate, or provide any Person with the right to modify, relinquish, diminish or terminate, any of Party's rights under the Purchase Agreement or (ii) modify or terminate, or provide any Person with the right to modify or terminate the Purchase Agreement.

General Provisions.

Entire Agreement. This Royalty Agreement, together with the Exhibits attached hereto, constitutes the entire agreement, and supersede all prior agreements and undertakings, both written and oral, between the Parties with respect to the subject matter hereof.

Notices. Any notice, request or other communication required or permitted hereunder shall be to the addresses set forth in, and in accordance with, the Purchase Agreement, attached herewith as Exhibit I, or any other addresses designated by the parties from time to time in writing.

Return to Top | To Exhibits Index

Amendment. This Royalty Agreement shall not be amended or otherwise modified except by a written agreement dated after the date of this Royalty Agreement and signed on behalf of Data Health and Parallax by their respective duly authorized representatives.

Limitation of Liability. To the maximum extent permitted by applicable law, in no event shall any party be liable for any special, incidental or consequential damages whatsoever arising out of or in any way related to this Royalty Agreement, even if the party has been advised of the possibility of such damages. The immediately preceding sentence shall have no applicability to any legal cause of action arising from any party's activities outside the scope of this Royalty Agreement.

Governing Law; Consent to Jurisdiction. This Royalty Agreement shall be governed by, and construed in accordance with, the Laws of the State of California applicable to contracts executed in and to be performed entirely in that State, without regard to conflicts of Laws principles thereof to the extent that the general application of the Laws of another jurisdiction would be required thereby.

Binding Arbitration. All claims and disputes arising under or relating to this Royalty Agreement are to be settled by binding arbitration in the state of California or another location mutually agreeable to the parties. The arbitration shall be conducted on a confidential basis pursuant to the Commercial Arbitration Rules of the American Arbitration Association. Any decision or award as a result of any such arbitration proceeding shall be in writing and shall provide an explanation for all conclusions of law and fact and shall include the assessment of costs, expenses, and reasonable attorneys' fees. Any such arbitration shall be conducted by an arbitrator experienced in the area of intellectual property and shall include a written record of the arbitration hearing. The parties reserve the right to object to any individual who shall be employed by or affiliated with a competing organization or entity. An award of arbitration may be confirmed in a court of competent jurisdiction.

Fees And Expenses. All fees, costs and expenses incurred in connection with this Royalty Agreement shall be paid by the Party incurring the same. Notwithstanding the foregoing, in the event the Parties engage in binding arbitration relating to or arising out of this Royalty Agreement or the performance thereof, the Parties agree that the arbitrator shall be asked to determine which Party is the prevailing Party to the proceeding or proceedings, and the non-prevailing Party or Parties shall, jointly and severally, be liable to the prevailing Party in the amount of all reasonable attorney's fees, court costs, and all other expenses, incurred by the prevailing Party to the proceeding in addition to any other relief to which the prevailing Party may be entitled.

Assignment: Parties in Interest. Neither this Royalty Agreement nor any rights or obligations hereunder shall be assigned by any Party without the prior written consent of the other Parties. This Royalty Agreement shall be binding upon and inure solely to the benefit of each Party hereto and its successors and permitted assigns, and nothing in this Royalty Agreement, express or implied, is intended to confer upon any other person any rights or remedies of any nature whatsoever under this Agreement.

Severability. In case any provision in this Royalty Agreement shall be held invalid, illegal or unenforceable in a jurisdiction, such provision shall be modified or deleted, as to the jurisdiction involved, only to the extent necessary to render the same valid, legal and enforceable, and the validity, legality and enforceability of the remaining provisions hereof shall not in any way be affected or impaired thereby nor shall the validity, legality or enforceability of such provision be affected thereby in any other jurisdiction.

Non-Waiver. No waiver of any breach of any provision of this Royalty Agreement shall constitute a waiver of any prior, concurrent or subsequent breach of the same or any other provisions hereof, and no waiver shall be effective unless made in writing and signed by an authorized representative of the waiving party.

Return to Top | To Exhibits Index

Necessary Acts. Each party agrees to take such further action and execute, deliver and/or file such documents or instruments as are reasonably necessary to carry out the terms and purposes of this Royalty Agreement.

Headings. The headings contained in this Royalty Agreement, together with the Exhibits attached hereto, are for reference purposes only and shall not affect in any way the meaning or interpretation of this Royalty Agreement or the Exhibits. Unless the context of this Royalty Agreement otherwise requires, words of any gender are deemed to include each other gender and words using the singular or plural number also include the plural or singular number, respectively.

Counterparts. This Royalty Agreement may be executed and delivered (including by facsimile transmission, electronic mail or .pdf) in one or more counterparts, and by the Parties hereto in separate counterparts, each of which when executed shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement.

IN WITNESS WHEREOF, each of the parties hereto has caused this Royalty Agreement to be duly executed this 11th day of May, and effective as of April 13, 2022.

Data Health Partners, Inc.	**Parallax Behavioral Health, Inc.**
/s/ Calli R. Bucci	*/s/ David L. Stark*
By: Calli R. Bucci	By: Dr. David L. Stark
Title: Director, Chief Financial Officer	Title: Chairman, President

The remainder of this page intentionally left blank

Return to Top | To Exhibits Index

EXHIBITS TO
ROYALTY AGREEMENT

EXHIBIT	**INTELLECTUAL PROPERTY PURCHASE AGREEMENT**
EXHIBIT	**SENIOR SECURED CORPORATE PROMISSORY NOTE**

* * * * *

Return to Top | To Exhibits Index

EXHIBIT E

PATENT ASSIGNMENT

WHEREAS, Parallax Behavioral Health, Inc., a Delaware corporation, with an address 3415 S. Sepulveda Blvd., Suite 1100-6592, Los Angeles, CA 90034 ("Assignor"), owns all right, title and interest in and to the patents and/or patent applications identified in Exhibit A attached hereto, including the inventions described therein and the patents issued and reissued thereon (collectively, the "Patents"), the renewals therefor and all claims for past or future infringement thereof; and

WHEREAS, Data Health Partners, Inc., a Delaware corporation with an address at 10586 W. Pico Blvd., #1096, Los Angeles, CA 90064 ("Assignee"), and Assignor have entered into an Intellectual Property Purchase Agreement (the "Agreement") effective April 13, 2022, under which Assignor agreed to sell and Assignee agreed to purchase certain assets of Assignor, including the aforesaid Patents, and the applications and renewals therefor and all claims for past or future infringement thereof.

NOW THEREFORE, for valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor does hereby sell, assign, convey and transfer unto Assignee, its successors and assigns, free and clear of any and all liens, restrictions, claims and encumbrances, Assignor's entire right, title, and interest in and to the Patents and divisions, continuations or continuations-in-part thereof, together with all rights of registration, maintenance, and protection thereof in any form, all rights to income, royalties, damages and payments now due or hereafter due or payable in respect thereto, and all rights of recovery and of legal action for past or future infringements and of interference proceedings and reexaminations involving such Patents.

This Assignment is deemed to be executed and delivered within the State of California, and it is the intention of the parties that it shall be construed, interpreted and applied in accordance with the laws of the State of California without regard to its conflicts of law principles.

IN WITNESS WHEREOF, Assignor has duly executed this Assignment this 11th day of May, 2022, to be effective as of April 13, 2022.

ASSIGNOR:		**ASSIGNEE:**	
Parallax Behavioral Health, Inc.		**Data Health Partners, Inc.**	
	/s/ David L. Stark		*/s/ Calli R. Bucci*
By:	Dr. David L. Stark	By:	Calli R. Bucci
Title:	Chairman, President	Title:	Director, Chief Financial Officer

Return to Top | To Exhibits Index

EXHIBIT A

PATENTS AND PATENT APPLICATIONS

United States Patent No. 10,061,812 (Family ID 51533139) issued August 28, 2018, and all related worldwide patents: *Platform For Optimizing Data Driven Outcomes*.

United States Patent No. 11,144,554 (Family ID 65038812) issued October 12, 2021, and all related worldwide patents: *Platform For Optimizing Goal Progression*.

United States Patent No. 11,151,142 (Family ID 51533139) granted October 12, 2021, and all related worldwide patents: *Platform For Optimizing Goal Progression*.

United States Patent Application No. 17/499,725 (Family ID 65038812) filed October 12, 2021, and all related worldwide patent applications: *System And Method For Achieving Goal Progression*.

United States Patent Application No. 17/505,166 (Family ID 51533139) filed October 19, 2021, and all related worldwide patent applications: *System And Method For Tracking Progression Toward A Customized Goal*

United States Patent Application No. 17/546,594 (Family ID 1000006016644) filed December 9, 2021, and all related worldwide patent applications: *System And Method For Achieving Goals*.

All related patent and patent applications filed or to be filed in connection with the aforementioned patents and patent applications, as well as those provided in the Global Dossier attached herewith as Exhibit B.

The remainder of this page intentionally left blank

Return to Top | To Exhibits Index

EXHIBIT F

TRADEMARK ASSIGNMENT

WHEREAS, Parallax Behavioral Health, Inc., a Delaware corporation, with an address 3415 S. Sepulveda Blvd., Suite 1100-6592, Los Angeles, CA 90034 ("Assignor"), owns all right, title and interest in and to the federal trademark registrations of the marks identified in Exhibit A hereto (the "Marks") and all foreign registrations everywhere in the world; and

WHEREAS, Data Health Partners, Inc., a Delaware corporation with an address at 10586 W. Pico Blvd., #1096, Los Angeles, CA 90064 ("Assignee"), and Assignor have entered into an Intellectual Property Purchase Agreement (the "Agreement") effective April 13, 2022, under which Assignor agreed to sell and Assignee agreed to purchase certain assets of Assignor, including the aforesaid Marks, the registrations thereof, and the goodwill associated therewith.

NOW THEREFORE, for valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor does hereby sell, assign, convey and transfer unto Assignee, its successors and assigns, free and clear of any and all liens, restrictions, claims and encumbrances, Assignor's entire right, title, and interest in and to the Marks together with all goodwill of the business represented and symbolized thereby with all rights of registration, maintenance, and protection thereof in any form, all rights to income, royalties, damages and payments now due or hereafter due or payable in respect thereto, and all rights of recovery and of legal action for past or future infringements and of interference proceedings and reexaminations involving such Marks.

This Assignment is deemed to be executed and delivered within the State of California, and it is the intention of the parties that it shall be construed, interpreted and applied in accordance with the laws of the State of California without regard to its conflicts of law principles.

IN WITNESS WHEREOF, Assignor has duly executed this Assignment this 11th day of May, 2022, to be effective as of April 13, 2022.

ASSIGNOR:		**ASSIGNEE:**	
Parallax Behavioral Health, Inc.		**Data Health Partners, Inc.**	
	/s/ David L. Stark		*/s/ Calli R. Bucci*
By:	Dr. David L. Stark	By:	Calli R. Bucci
Title:	Director, Chief Financial Officer	Title:	Director, Chief Financial Officer

Return to Top | To Exhibits Index

EXHIBIT A

TRADEMARKS AND SERVICE MARKS

The Assignment refers to the Trademarks and service marks related to R.E.B.O.O.T. and COMPASS, as further described below:

"R.E.B.O.O.T." "R.E.B.O.O.T." is an acronym for "Reliable Evidence Based Outcomes Optimization Technologies" and is a structured, scalable and sustainable software system used to identify, monitor, and evaluate a single user or an entire organization's progress towards mastery of any achievable task, objective or goal.

The "COMPASS Application." The COMPASS Application is a software program which features evidence-based content, decision support and real-time status updates for multiple stakeholders, all aimed at improving physical and behavioral health and wellness. The wealth of data collected through use of the software fuels machine learning algorithms that can be used to establish best practice predictive models to drive value-based health care and reduce lifetime health care spend.

The remainder of this page intentionally left blank

Return to Top | To Exhibits Index

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/499,725	10/12/2021	Nathaniel T. Bradley	DHP-P0001CIP1	9953

133690 7590 03/26/2024

Goodhue, Coleman & Owens, P.C.
7300 Westown Parkway, Suite 110
West Des Moines, IA 50266

EXAMINER	
RAAB, CHRISTOPHER J	

ART UNIT	PAPER NUMBER
2156	

NOTIFICATION DATE	DELIVERY MODE
03/26/2024	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USPTO@dockettrak.com
docketing@goodhue.com
eofficeaction@appcoll.com

Office Action Summary	Application No. 17/499,725	Applicant(s) Bradley et al.	
	Examiner CHRISTOPHER J RAAB	Art Unit 2156	AIA (FITF) Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTHS FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☑ Responsive to communication(s) filed on 03/06/2024.

☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2a)☐ This action is **FINAL.** 2b) ☑ This action is non-final.

3)☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

4)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims*

5) ☑ Claim(s) 1-20 is/are pending in the application.

5a) Of the above claim(s) _____ is/are withdrawn from consideration.

6) ☐ Claim(s) _____ is/are allowed.

7) ☑ Claim(s) 1-20 is/are rejected.

8) ☐ Claim(s) _____ is/are objected to.

9) ☐ Claim(s) _____ are subject to restriction and/or election requirement

* If any claims have been determined allowable, you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to **PPHfeedback@uspto.gov.**

Application Papers

10)☐ The specification is objected to by the Examiner.

11)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

a)☐ All b)☐ Some** c)☐ None of the:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

** See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☑ Notice of References Cited (PTO-892)

2) ☐ Information Disclosure Statement(s) (PTO/SB/08a and/or PTO/SB/08b) Paper No(s)/Mail Date _____.

3) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date _____.

4) ☐ Other: _____.

DETAILED ACTION

Notice of Pre-AIA or AIA Status

01. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA.

Continued Examination Under 37 CFR 1.114

02. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on **03/06/2024** has been entered.

Response to Arguments

03. Applicant's arguments with respect to claims 1 – 20 have been considered, but are moot in view of the new ground(s) of rejection.

Claim Rejections - 35 USC § 102

04. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of

rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.

05. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

> A person shall be entitled to a patent unless –
>
> (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention.

06. **Claims 1 and 3 – 20** are rejected under 35 U.S.C. 102(a)(1) as being anticipated by **Douglas et al. (WO 99/03045)**, hereinafter "Douglas".

Consider **claim 1**, Douglas discloses a method for tracking goal progression (page 2 line 36 – page 3 line 2), the method comprising:

receiving input establishing clients, wherein the clients are individuals receiving treatment or assistance (page 6 line 28 – page 7 line 16, patients are entered into the system, which includes information about the patient's conditions and what treatment they are to received) and wherein the data associated with the clients is stored in a server available through one or more networks (page 8 lines 28 – 31, the patent data is stored on a server that is accessible through a network);

assigning each of the clients to one or more of the providers in response to selections from an administrator, wherein the one or more providers include at least individuals available to treat or assist each of the clients (page 11 line 6 – page 12 line 2, the patients are assigned to physicians, wherein the physicians are able to provide help and treatment to the patients) and one or more biometric devices associated with

each of the clients (page 10 lines 10 – 24, devices are used that are able to capture the patients vitals);

establishing goals and a baseline for each of the clients and thresholds associated with each of the goals (page 7 line 29 – page 8 line 9, goals and milestones are generated for the patients, which can be modified and updated as needed);

automatically compiling data associated with each of the clients received from the one or more providers including at least the one or more biometric devices in the server (page 20 lines 3 – 44, the patient's characteristics, such as vitals and progress towards goals, are determined, such that updated information about the patients is managed, including the patient's vitals);

determining whether the goals are being met in response to the baseline and the thresholds for the compiled data (page 11 line 8 – page 12 line 2, patient progress is monitored with respect to the goals, which includes determining if a certain level of progress is being made by the patient);

automatically communicating alerts in response to the compiled data varying from a one of the thresholds to become significant for one or more of the clients (page 11 lines 11 – 15, an alarm can be triggered in response to patient data being significant, such as posing a health risk).

Consider **claim 3**, and **as applied to claim 1 above**, Douglas discloses a method comprising:

intervening with the one or more of the clients in response to the alerts (page 11 lines 11 – 19, an alarm can be triggered in response to a threatening situation with the patient).

Consider **claim 4**, and **as applied to claim 3 above**, Douglas discloses a method comprising:

the intervening is performed by the one or more providers (page 11 lines 11 – 19, the physician for the patient provides the intervening).

Consider **claim 5**, and **as applied to claim 1 above**, Douglas discloses a method comprising:

each of the goals is associated with a plan of action for achieving each of the goals (page 7 line 5 – page 8 line 13, a program is created for the patient to assist in the achieving of goals).

Consider **claim 6**, and **as applied to claim 1 above**, Douglas discloses a method comprising:

establishing a baseline for the goals of the clients (page 7 lines 20 – 32, different goals and baseline values are established for the patients).

Consider **claim 7**, and **as applied to claim 1 above**, Douglas discloses a method comprising:

the goals are established by the clients and the one or more providers (page 7 lines 20 – 32, the goals are determined based on the client and physician input).

Consider **claim 8**, and **as applied to claim 1 above**, Douglas discloses a method comprising:

determining whether modifications to the goals are required in response to the compiled data (page 8 lines 8 – 13, page 11 lines 18 – 34, changes can be made to the goals for the patients).

Consider **claim 9**, and **as applied to claim 8 above**, Douglas discloses a method comprising:

modifying the goals in response to the compiled data (page 8 lines 8 – 13, page 11 lines 18 – 34, changes can be made to the goals for the patients).

Consider **claim 10**, and **as applied to claim 8 above**, Douglas discloses a method comprising:

modifications are determined to be required if the one of the clients is unable to achieve the goals associated with the client (page 8 lines 8 – 13, page 11 lines 18 – 34, changes can be made to the goals for the patients in response to determining that progress is not appropriate for that goals).

Claims 11 – 20, recite nearly identical claim limitations to those found in claims 1 – 10. Claims 11 – 16 recite a system and claims 17 – 20 recite a server, whereas claims 1 – 10 recite a method. However, the same claim limitations are otherwise found, and claims 11 – 20 are rejected under the same rationale as claims 1 – 10.

Claim Rejections - 35 USC § 103

07. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.

08. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:

> A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.

09. **Claim 2** is rejected under 35 U.S.C. 103 as being unpatentable over **Douglas et al. (WO 99/03045)**, hereinafter "Douglas", in view of **Chitiveli (US PGPub 2013/0179450)**, hereinafter "Chitiveli".

Consider **claim 2**, and **as applied to claim 1 above**, Douglas discloses a method comprising:

the server is accessed through a [cloud] network, and wherein a client management program is executed by communications devices utilized by the one or more providers to receive the data and track progress of the goals (page 24 lines 3 – 34, a server is accessed through a network, whereby the programs utilized by different communications devices and hardware/software).

However, Douglas does not specifically disclose a cloud network.

In the same field of endeavor, Chitiveli discloses a method comprising:

The server is accessed through a cloud network (paragraphs [0031], [0032], a cloud network it utilized, which is used to access a server).

Therefore it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to incorporate the cloud network taught by Chitiveli into the patient monitoring system taught by Douglas to allow for a more

complex and modern computing infrastructure to be used for the monitoring of patients and their conditions.

Conclusion

10. Any response to this Office Action should be **faxed to** (571) 273-8300 **or mailed to**:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Hand-delivered responses should be brought to

Customer Service Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314

11. Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Christopher Raab whose telephone number is (571) 270-1090. The Examiner can normally be reached on Monday-Friday from 9:00am to 5:00pm.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Ajay Bhatia can be reached on (571) 272-3906. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status

information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free) or 703-305-3028.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist/customer service whose telephone number is (571) 272-2600.

/CHRISTOPHER J RAAB/
Primary Examiner, Art Unit 2156

March 20, 2024

Notice of References Cited	Application/Control No. 17/499,725	Applicant(s)/Patent Under Reexamination Bradley et al.	
	Examiner CHRISTOPHER J RAAB	Art Unit 2156	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date YYYY-MM-DD	Name	CPC Classification	US Classification
*	A	US-20130179450-A1	2013-07-11	CHITIVELI; Srinivas	G06F16/27	707/E17.089
	B					
	C					
	D					
	E					
	F					
	G					
	H					
	I					
	J					
	K					
	L					
	M					

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date YYYY-MM-DD	Country	Name	CPC Classification
	N	WO-9903045-A1	1999-01-21	WO	DOUGLAS P	A61B5/4833
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in YYYY-MM-DD format are publication dates. Classifications may be US or foreign.

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/499,725	Bradley et al.
	Examiner	Art Unit
	CHRISTOPHER J RAAB	2156

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

CLAIMS

☐ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIM		DATE								
Final	Original	03/25/2023	10/02/2023	03/20/2024						
	1	✓	✓	✓						
	2	✓	✓	✓						
	3	✓	✓	✓						
	4	✓	✓	✓						
	5	✓	✓	✓						
	6	✓	✓	✓						
	7	✓	✓	✓						
	8	✓	✓	✓						
	9	✓	✓	✓						
	10	✓	✓	✓						
	11	✓	✓	✓						
	12	✓	✓	✓						
	13	✓	✓	✓						
	14	✓	✓	✓						
	15	✓	✓	✓						
	16	✓	✓	✓						
	17	✓	✓	✓						
	18	✓	✓	✓						
	19	✓	✓	✓						
	20	✓	✓	✓						

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/499,725	Bradley et al.
	Examiner	Art Unit
	CHRISTOPHER J RAAB	2156

CPC - Searched*		
Symbol	**Date**	**Examiner**
G06Q10/06, limited keyword search	03/25/2023	CJR
G06Q10/0637, limited keyword search	03/25/2023	CJR

CPC Combination Sets - Searched*		
Symbol	**Date**	**Examiner**

US Classification - Searched*			
Class	**Subclass**	**Date**	**Examiner**

* See search history printout included with this form or the SEARCH NOTES box below to determine the scope of the search.

Search Notes		
Search Notes	**Date**	**Examiner**
PE2E image and keyword search	03/25/2023	CJR
NPL Search: Google Scholar	03/25/2023	CJR
Inventor Name Search: PALM and PE2E	03/25/2023	CJR
Updated search	10/02/2023	CJR
Updated search	03/20/2024	CJR

Interference Search			
US Class/CPC Symbol	**US Subclass/CPC Group**	**Date**	**Examiner**

/CHRISTOPHER J RAAB/ Primary Examiner, Art Unit 2156	

PE2E SEARCH - Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	British Equivalents	Time Stamp
L1	2	("20110047404").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 01:24 PM
L2	10	("20090112924"|"20090192825"|"8313433"|"8355925"|"RE42508").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:00 PM
L3	3130	account WITH client WITH provider	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:01 PM
L4	77	data mining WITH goal WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:01 PM
L5	41	data mining WITH best practices	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:01 PM
L6	1	intensive trial teaching	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:01 PM
L7	1	reinforcement recorder	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:06 PM
L8	864	goal WITH achiev$5 WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:24 PM
L9	3158	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:25 PM
L10	1117	L9 AND goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:25 PM
L11	78	L9 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:25 PM
L12	23	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:25 PM
L13	6	Macrosolve$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:30 PM
L14	84	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:30 PM
L15	1753	alert WITH automatic$6 WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2016/07/08 04:34 PM
L16	540	alert NEAR5 automatic$6 NEAR5	(US-PGPUB; USPAT; EPO; JPO;	ADJ	ON	ON	2016/07/08 04:34 PM

		threshold	DERWENT; IBM_TDB)				
L17	1110	(compile OR compiling OR compiled) WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 09:37 PM
L18	27	(compile OR compiling OR compiled) WITH user input WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 09:37 PM
L19	18	(compile OR compiling OR compiled) WITH "without user input"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 09:39 PM
L20	126	(score OR status) WITH "without user input"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 09:41 PM
L21	441	(status) WITH automatic$ WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 09:49 PM
L22	352	status WITH automatic$ WITH (score OR compile OR compiling OR scoring)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 10:01 PM
L23	1161	score WITH client WITH (threshold OR status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/07/09 10:20 PM
L24	125	well-being WITH client	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/07/09 10:21 PM
L25	385	well-being WITH score	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/07/09 10:21 PM
L26	0	well-being WITH client WITH score	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/07/09 10:21 PM
L27	90	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/02/27 11:11 AM
L28	1	"61791218"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/02/27 11:24 AM
L29	1	"15301419"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/02/27 01:30 PM
L30	55	client management program	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2018/03/19 10:14 AM
L31	2008	administrator SAME (client WITH provider)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2018/03/19 10:14 AM
L33	2	("7346545").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2018/04/12 02:12 PM
L34	2710	(track OR tracked OR	(US-PGPUB; USPAT;	ADJ	ON	ON	2018/04/15

		tracking) NEAR2 goal	EPO; JPO; DERWENT; IBM_TDB)				03:10 PM
L35	71	((track OR tracked OR tracking) NEAR2 goal) WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/04/15 03:10 PM
L36	44	((track OR tracked OR tracking) NEAR2 goal) SAME (behavioral OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/04/15 03:20 PM
L37	77	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/04/15 03:23 PM
L38	90	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/06/22 04:37 PM
L39	4499	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/06/22 04:37 PM
L40	6	(administrator SAME (client WITH provider)) AND ((score OR mastery) NEAR5 goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2018/06/22 04:40 PM
L41	24	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/06/22 04:40 PM
L42	714	score WITH measurement WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/06/22 04:40 PM
L43	39585	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/06/22 04:44 PM
L54	4	("10061812").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2019/12/23 01:57 PM
L55	13	("20020065697"|"20020147626"|"20020194046"|"20080141138"|"20080281651"|"20090112924"|"20090192825"|"20100082381"|"20110029521"|"20110047404"|"8313433"|"8355925"|"RE42508").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2019/12/23 02:26 PM
L56	27	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:29 PM
L57	1695	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:30 PM
L58	5898	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:31 PM

L59	46154	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:31 PM
L60	9	L57 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:31 PM
L61	100	L58 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:31 PM
L62	647	(status) WITH automatic$ WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:31 PM
L63	87	data mining WITH goal WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:32 PM
L64	9	(administrator SAME (client WITH provider)) AND ((score OR mastery) NEAR5 goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2019/12/23 02:32 PM
L65	101	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:32 PM
L66	4	L57 AND goal wizard	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:32 PM
L67	4	L58 AND goal wizard	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:32 PM
L68	4	L57 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:33 PM
L69	5	L58 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:33 PM
L70	4	L57 AND (goal WITH alert WITH client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:33 PM
L71	4	L58 AND (goal WITH alert WITH client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:33 PM
L72	2	"16053141"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/07/23 03:16 PM
L73	191357	field WITH (treatment OR assistance)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/07/24 10:31 AM
L74	363	field WITH (treatment OR assistance) WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/07/24 02:37 PM
L75	726	(compile OR compiled OR compiling) WITH	(US-PGPUB; USPAT; EPO; JPO;	ADJ	ON	ON	2020/07/24 03:04 PM

		(client OR patient) WITH (field OR treatment)	DERWENT; IBM_TDB)				
L76	11	(("4237344") or ("5377258") or ("20090048872") or ("20110295613")).PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2020/07/27 02:54 PM
L77	2	("20090048872"|"20110295613").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2020/09/29 09:56 AM
L78	2	("4237344"|"5377258").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2020/09/29 09:56 AM
L79	1	("20030004758").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2020/09/29 09:56 AM
L80	1	"16141471"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 10:19 AM
L81	0	"Platform for Optimizing Goal Progression".TI.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 10:19 AM
L82	43	Bradley, Nathaniel.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 10:19 AM
L83	4	("10061812").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2020/09/29 10:20 AM
L84	88	data mining WITH goal WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L85	60	data mining WITH best practices	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L86	41	(compile OR compiling OR compiled) WITH user input WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L87	115	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L88	95	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L89	2189	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L90	11	L89 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:02 AM
L91	4	L89 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:02 AM
L92	4	L89 AND (goal WITH	(US-PGPUB; USPAT;	ADJ	ON	ON	2020/09/29

		alert WITH client)	EPO; JPO; DERWENT; IBM_TDB)				11:02 AM
L93	10482	threshold WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:23 PM
L94	714	threshold WITH goal WITH (plan OR met)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:23 PM
L95	43	threshold WITH goal WITH (plan OR met) WITH (treatment OR provider OR client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:24 PM
L96	22	threshold WITH goal WITH (plan OR met) WITH (treat$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:28 PM
L97	252	threshold WITH goal WITH (treat$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:46 PM
L98	103	L97 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:46 PM
L99	7	(("20120203092") or ("20080270182") or ("10098584")).PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2021/04/08 09:52 PM
L100	5	L99 AND threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:52 PM
L101	56	(patient OR client) WITH threshold WITH goal WITH (treat$5 OR chang$4 OR modif$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:03 PM
L102	17	L101 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:03 PM
L103	49389	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:05 PM
L104	6924	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:05 PM
L105	297	(L103 OR L104) AND (threshold WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:06 PM
L106	204	L105 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:06 PM
L107	29	(L103 OR L104) AND ((threshold WITH goal) SAME (patient OR client))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:08 PM
L108	9	L107 AND (@AD<"20130315" OR	(US-PGPUB; USPAT; EPO; JPO;	ADJ	ON	ON	2021/04/08 10:08 PM

		@RLAD<"20130315")	DERWENT; IBM_TDB)				
L109	364	(treatment OR evaluation) WITH (goal) WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:39 PM
L110	10	(client OR patient) WITH goal WITH threshold WITH progress$4	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:43 PM
L111	1708	(client OR patient) WITH goal WITH (threshold OR progress$4)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:43 PM
L112	902	(client OR patient) WITH (goal NEAR5 (threshold OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:45 PM
L113	362	L112 AND @AD<"20130315"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:46 PM
L114	238	(client OR patient) WITH (goal NEAR5 (threshold OR progress$4)) WITH (treatment OR assistance OR modify$4 OR plan)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:53 PM
L115	84	L114 AND @AD<"20130315"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:53 PM
L116	327	(client OR patient) WITH goal WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 02:03 PM
L117	121	(client OR patient) WITH goal WITH (progress$4 OR threshold) WITH (modif$5 OR chang$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 02:03 PM
L118	1	"16141471"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 02:27 PM
L119	327	(patient OR client) WITH threshold WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 07:35 PM
L120	153	L119 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 07:44 PM
L121	50097	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/08/12 02:27 PM
L122	2	("8066640").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2021/08/12 02:36 PM
L133	252	patient WITH threshold	(US-PGPUB; USPAT;	ADJ	ON	ON	2022/02/25

		WITH goal	EPO; JPO; DERWENT; IBM_TDB)				09:43 PM
L134	3051	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L135	51231	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L136	7790	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L137	30	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L138	136	L134 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L139	1130	L135 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L140	292	L136 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L141	13	L136 AND ((patient OR client) WITH (threshold) WITH (alert OR goal OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:51 PM
L142	94	L135 AND ((patient OR client) WITH (threshold) WITH (alert OR goal OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:51 PM
L143	13	L134 AND ((patient OR client) WITH (threshold) WITH (alert OR goal OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:51 PM
L144	60	Bradley, Nathaniel.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:51 PM
L145	62	Gaynor, James.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:51 PM
L146	41	Paugh, Joshua.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:52 PM
L147	5	Arena, Paul.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:52 PM
L148	2	("20090192825").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2022/02/25 09:53 PM
L149	4	("11144554").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO;	ADJ	OFF	OFF	2022/02/25 10:10 PM

			DERWENT; IBM_TDB)				
L151	972	(client OR patient) WITH baseline WITH goal	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/07/25 11:43 AM
L152	73	((client OR patient) WITH baseline WITH goal) SAME threshold	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/07/25 11:43 AM
L153	154	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/07/25 11:43 AM
L154	57	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; EPO)	ADJ	ON	ON	2022/07/25 11:43 AM
L155	61	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; EPO)	ADJ	ON	ON	2023/01/13 08:53 PM
L157	139	(client OR patient)	(US-PGPUB; USPAT;	OR	ON	ON	2023/01/13

		WITH goal WITH biometric	USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)				08:53 PM
L158	633	goal WITH threshold WITH rule	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2023/03/24 02:04 PM
L159	23	(client OR patient) WITH goal WITH threshold WITH rule	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/24 02:05 PM
L160	2	("20110047404").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L161	10	("20090112924"|"20090192825"|"8313433"|"8355925"|"RE42508").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L162	7418	account WITH client WITH provider	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L163	112	data mining WITH goal WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L164	61	data mining WITH best practices	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L165	9	intensive trial teaching	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L166	9	reinforcement recorder	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM

L167	1919	goal WITH achiev$5 WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L168	9840	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L169	2100	L9 AND goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L170	155	L9 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L171	31	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L172	6	Macrosolve$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L173	96	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L174	4987	alert WITH automatic$6 WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L175	1324	alert NEAR5 automatic$6 NEAR5 threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L176	2056	(compile OR compiling OR compiled) WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L177	54	(compile OR compiling OR compiled) WITH user input WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L178	50	(compile OR compiling OR compiled) WITH "without user input"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L179	340	(score OR status) WITH "without user input"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L180	992	(status) WITH automatic$ WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L181	853	status WITH automatic$ WITH (score OR compile OR compiling OR scoring)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L182	3702	score WITH client WITH (threshold OR status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L183	223	well-being WITH client	(US-PGPUB; USPAT; EPO; JPO;	ADJ	ON	ON	2023/03/25 07:42 PM

			DERWENT; IBM_TDB)				
L184	962	well-being WITH score	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L185	18	well-being WITH client WITH score	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L186	96	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L187	9	"61791218"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L188	3	"15301419"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L189	69	client management program	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L190	3683	administrator SAME (client WITH provider)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L191	2	("7346545").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L192	4638	(track OR tracked OR tracking) NEAR2 goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L193	133	((track OR tracked OR tracking) NEAR2 goal) WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L194	90	((track OR tracked OR tracking) NEAR2 goal) SAME (behavioral OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L195	178	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L196	96	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L197	9840	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L198	20	(administrator SAME (client WITH provider)) AND ((score OR mastery) NEAR5 goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L199	31	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM

L200	1805	score WITH measurement WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L201	62988	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L202	4	("10061812").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L203	13	("20020065697"|"20020147626"|"20020194046"|"20080141138"|"20080281651"|"20090112924"|"20090192825"|"20100082381"|"20110029521"|"20110047404"|"813433"|"8355925"|"RE42508").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/25 07:42 PM
L204	31	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L205	3722	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L206	9840	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L207	62988	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L208	26	L57 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L209	155	L58 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L210	992	(status) WITH automatic$ WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L211	112	data mining WITH goal WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L212	20	(administrator SAME (client WITH provider)) AND ((score OR mastery) NEAR5 goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L213	178	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L214	9	L57 AND goal wizard	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM

L215	9	L58 AND goal wizard	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L216	92	L57 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L217	12	L58 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L218	10	L57 AND (goal WITH alert WITH client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L219	12	L58 AND (goal WITH alert WITH client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L220	7	"16053141"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L221	327785	field WITH (treatment OR assistance)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L222	490	field WITH (treatment OR assistance) WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L223	933	(compile OR compiled OR compiling) WITH (client OR patient) WITH (field OR treatment)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L224	11	(("4237344") or ("5377258") or ("20090048872") or ("20110295613")).PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L225	2	("20090048872"|"20110295613").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/25 07:42 PM
L226	2	("4237344"|"5377258").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/25 07:42 PM
L227	1	("20030004758").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/25 07:42 PM
L228	4	"16141471"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L229	0	"Platform for Optimizing Goal Progression".TI.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L230	85	Bradley, Nathaniel.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L231	4	("10061812").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L232	112	data mining WITH goal	(US-PGPUB; USPAT;	ADJ	ON	ON	2023/03/25

		WITH status	EPO; JPO; DERWENT; IBM_TDB)				07:42 PM
L233	61	data mining WITH best practices	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L234	54	(compile OR compiling OR compiled) WITH user input WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L235	178	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L236	96	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L237	3722	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L238	26	L89 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L239	92	L89 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L240	10	L89 AND (goal WITH alert WITH client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L241	13185	threshold WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L242	898	threshold WITH goal WITH (plan OR met)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L243	70	threshold WITH goal WITH (plan OR met) WITH (treatment OR provider OR client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L244	45	threshold WITH goal WITH (plan OR met) WITH (treat$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L245	358	threshold WITH goal WITH (treat$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L246	107	L97 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L247	7	(("20120203092") or ("20080270182") or ("10098584")).PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L248	5	L99 AND threshold	(US-PGPUB; USPAT; EPO; JPO;	ADJ	ON	ON	2023/03/25 07:42 PM

			DERWENT; IBM_TDB)				
L249	104	(patient OR client) WITH threshold WITH goal WITH (treat$5 OR chang$4 OR modif$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L250	18	L101 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L251	62988	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L252	9840	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L253	356	(L103 OR L104) AND (threshold WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L254	213	L105 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L255	37	(L103 OR L104) AND ((threshold WITH goal) SAME (patient OR client))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L256	10	L107 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L257	496	(treatment OR evaluation) WITH (goal) WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L258	30	(client OR patient) WITH goal WITH threshold WITH progress$4	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L259	2057	(client OR patient) WITH goal WITH (threshold OR progress$4)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L260	1043	(client OR patient) WITH (goal NEAR5 (threshold OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L261	351	L112 AND @AD<"20130315"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L262	287	(client OR patient) WITH (goal NEAR5 (threshold OR progress$4)) WITH (treatment OR assistance OR modify$4 OR plan)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L263	82	L114 AND	(US-PGPUB; USPAT;	ADJ	ON	ON	2023/03/25

		@AD<"20130315"	EPO; JPO; DERWENT; IBM_TDB)				07:42 PM
L264	434	(client OR patient) WITH goal WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L265	163	(client OR patient) WITH goal WITH (progress$4 OR threshold) WITH (modif$5 OR chang$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L266	4	"16141471"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L267	434	(patient OR client) WITH threshold WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L268	157	L119 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L269	62988	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L270	2	("8066640").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L271	309	patient WITH threshold WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L272	3722	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L273	62988	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L274	9840	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L275	31	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L276	154	L134 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L277	1193	L135 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L278	341	L136 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L279	16	L136 AND ((patient OR client) WITH (threshold) WITH (alert OR goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM

		OR progress$4))					
L280	101	L135 AND ((patient OR client) WITH (threshold) WITH (alert OR goal OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L281	15	L134 AND ((patient OR client) WITH (threshold) WITH (alert OR goal OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L282	85	Bradley, Nathaniel.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L283	66	Gaynor, James.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L284	61	Paugh, Joshua.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L285	6	Arena, Paul.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L286	2	("20090192825").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L287	4	("11144554").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L288	1050	(client OR patient) WITH baseline WITH goal	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L289	80	((client OR patient) WITH baseline WITH goal) SAME threshold	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE,	ADJ	ON	ON	2023/03/25 07:42 PM

			SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)				
L290	167	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L291	64	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; EPO)	ADJ	ON	ON	2023/03/25 07:42 PM
L292	64	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; EPO)	ADJ	ON	ON	2023/03/25 07:42 PM
L293	141	(client OR patient) WITH goal WITH biometric	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2023/03/25 07:42 PM
L294	633	goal WITH threshold WITH rule	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA,	OR	ON	ON	2023/03/25 07:42 PM

			VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)				
L295	23	(client OR patient) WITH goal WITH threshold WITH rule	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/25 07:42 PM
L296	2	"20150205930".PN.	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	OFF	OFF	2023/03/25 08:30 PM
L298	136	Bradley, Nathaniel.INV.	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/10/02 02:08 PM
L299	4	Bradley, Nathaniel.INV. AND goal.TI.	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/10/02 02:09 PM
L300	53	goal WITH biometric device	(US-PGPUB; USPAT; USOCR; FIT (AP, AT,	ADJ	ON	ON	2023/10/02 02:30 PM

			AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)				
L301	31	goal WITH biometric device	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/10/02 02:30 PM
L302	0	"biometric sensors worn by"	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/10/02 02:33 PM
L303	228	"biometric sensors worn"	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/10/02 02:33 PM
L304	29	"biometric sensors worn".CLM.	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/10/02 02:33 PM
L305	2	L304 AND (Bradley.INV. OR Marshall.INV. OR Gaynor.INV.)	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/10/02 02:34 PM
L306	5	99/03045	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2024/03/20 01:51 PM
L308	755	Douglas, Peter.INV.	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA,	ADJ	ON	ON	2024/03/20 01:51 PM

			VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)				
L309	10	Douglas, Peter.INV. AND Dudik, Evan.INV.	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2024/03/20 01:51 PM
L310	8	"20060149589"	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2024/03/20 01:52 PM
L311	1	"achieving goal progression".TI.	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2024/03/20 02:04 PM
L313	4	"optimizing goal progression".TI.	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA,	ADJ	ON	ON	2024/03/20 02:05 PM

			EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)				
L316	11	Parallax Behavioral Health$.AS.	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2024/03/20 02:05 PM
L317	7	"17499725"	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2024/03/20 03:37 PM
L318	17	"20130179450"	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO;	ADJ	ON	ON	2024/03/20 08:10 PM

			JPO; DERWENT; IBM_TDB)				

PE2E SEARCH - Search History (Interference)

There are no Interference searches to show.

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : G06F 15/00	A1	(11) International Publication Number: WO 99/03045
		(43) International Publication Date: 21 January 1999 (21.01.99)

(21) International Application Number: PCT/US98/14147

(22) International Filing Date: 10 July 1998 (10.07.98)

(30) Priority Data:

60/052,222	11 July 1997 (11.07.97)	US
08/962,238	31 October 1997 (31.10.97)	US

(71) Applicant *(for all designated States except US)*: SALUS MEDIA INC. [US/US]; 14529 Dickens Street, Sherman Oaks, CA 91403 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: DOUGLAS, Peter [US/US]; 1946 East Valley Road, Montecito, CA 93108 (US). DUDIK, Evan [US/US]; 9304 N.E. 82nd Court, Vancouver, WA 98662 (US). EVANS, John [US/US]; 60 Upper Kingston Road, Pittstown, NJ 08867 (US). KRITZER, Alan [US/US]; 5648 Costello Avenue, Van Nuys, CA 91401 (US).

(74) Agent: HASAN, Art, S.; Christie, Parker & Hale, LLP, P.O. Box 7068, Pasadena, CA 91109–7068 (US).


(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: THERAPEUTIC BEHAVIOR MODIFICATION PROGRAM, COMPLIANCE MONITORING AND FEEDBACK SYSTEM

(57) Abstract

A therapeutic behavior modification program, compliance monitoring and feedback system includes a server based relational database, and one or more microprocessors electronically coupled to the server. The system enables development of a therapeutic behavior modification program having a series of milestones for an individual to achieve lifestyle changes necessary to maintain his or her health of recovering from ailments of medical procedures. The program may be modified (1012) by a physician or trained case advisor prior to implementation. The system monitors the individual's compliance (1050) with the program by prompting the individual to enter health–elated data (1030), correlating the individual's entered data with the milestones in the behavior modification program, and generating compliance data indicative of the individual's progress toward achievement of the program milestones. The entire system is designed around a community of support motif including a graphical electronic navigator operable by the individual to control the microprocessor for accessing different parts of the system.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

THERAPEUTIC BEHAVIOR MODIFICATION PROGRAM, COMPLIANCE MONITORING AND FEEDBACK SYSTEM

FIELD OF THE INVENTION

The present invention relates generally to a computer-implemented system for promoting wellness and improving health, and more particularly to a therapeutic behavior modification program, compliance monitoring and feedback system.

BACKGROUND OF THE INVENTION

One of the most difficult and costly areas of health care, education, and rehabilitation involves the need for individuals to modify their behavior to prevent or recover from medical ailments. Heart disease, stroke, diabetes, asthma, chronic pain, depression, addiction, cancer and a wide variety of other ailments have been clinically shown to respond well to lifestyle modification, including changes to diet, exercise patterns, and stress levels. Patients who are recovering from a surgical procedure such as heart bypass surgery or are suffering from diabetes, for example, must often make lifestyle changes in order to survive.

When individuals are successful in making and adhering to positive lifestyle changes, they frequently require fewer physician visits, go to the hospital less often, and have fewer surgeries. Long term medical costs go down accordingly.

At present, many programs for helping patients make lifestyle changes involve a doctor's visit and distribution of a brochure describing the health benefits of behavior modification and lifestyle change. This method is often ineffective in modifying behavior because there is little or nothing in the way of an on-going support mechanism to assist the patient in complying with recommendations, insufficient means for motivating the patient to make recommended changes, and insufficient means for monitoring compliance with such recommendations. Participation in an on-going support program is often effective for patients who have undergone surgery and must make subsequent lifestyle changes, but currently available in-person programs involve costly medical staff and facilities. It can also be inconvenient for the patient to travel to such programs on a regular basis. Because of their cost and the potential for inconvenience, many support programs last for only a limited time, which is often insufficient for the patient to modify behavior thoroughly and effectively.

Another disadvantage of existing lifestyle modification programs is the lack of information readily available to the physician regarding the patient's compliance with the program. With the present push toward low cost yet high quality health care, a system by which a physician could readily access information on patient compliance has clear benefits.

The development of a therapeutic program that could effectively motivate patients to modify their behavior and change their lifestyles to prevent or recover from ailments, and could be delivered to them electronically at home, work, or while traveling, would be highly desirable. It would also be desirable for such a system to enable physicians and their staffs to receive frequent feedback regarding patients' compliance with their programs. It would be further desirable if such a system allowed for aggregate reviews of such information by health plan payors, such as HMOs, insurance companies, and large self-insured employers, for the purpose of enhancing the efficiency of managed health care.

SUMMARY OF THE INVENTION

The present invention therefore provides for an integrated, computer-implemented, electronically deliverable patient therapeutic behavior modification program, compliance, monitoring, and feedback system which supports the design of customized therapeutic behavior and lifestyle modification programs for subscribers; accepts the input of current health data for these patients; enables the review of these health records by a physician; enables the performance of aggregate reviews of such records by health plan payors, such as HMOs, insurance companies, and large self-insured employers; and motivates the patient to comply with the program and make the necessary lifestyle changes through an integrated system of interactive graphical interfaces.

In an exemplary scenario, a physician prescribes parameters and goals for a such a therapeutic behavior modification program to help a patient recover from an ailment or surgical procedure, and these are input into the computer-implemented system. Alternately, one of several established behavior modification programs that have been designed for patient recovery from particular ailments or procedures can be utilized. The system provides a novel interface that allows immediate patient access to the behavior modification program and helps monitor compliance with the program by prompting the patient to input data relating to his or her adherence to the program's parameters. These parameters may relate, for example, to diet, exercise, and other factors pertinent to the behavior modification program. The patient, physician, case manager or members of the physician's staff may also input information relating to blood pressure, medication, and the results of other medical tests on a computer linked to the system. Using this input, the system can recommend a plan (also referred to as a therapeutic program) and goals based on established medical protocols. The physician can modify the program to customize it for the patient. Once the patient has begun to follow the program, the

system recommends modifications and updates to both physician and patient by correlating the patient's progress with previously established goals.

The system provides ongoing multimedia (audio, video, and e-mail) feedback to the patient through a novel, user-friendly interface designed around an interactive "village" or "community of support" motif that allows him or her to navigate electronically through different parts of the system. The interface provides access to pertinent medical information, an on-line journal that enables the patient to write down his or her feelings on a regular basis, an electronic calendar which integrates events mandated by the program with the patient's daily schedule, on-line interactive group support sessions with patients on similar programs, and motivational multimedia presentations. The system can make specific diet and exercise suggestions based on the patient's overall program. This data is monitored by a professional case advisor--a nurse trained in the protocols of the system's software--as well as electronically by the system's protocols themselves. The system provides specific feedback to the physician so that he or she can modify or update the program as the patient progresses; and in the aggregate to the health plan payor to assess management and cost factors. The health plan payor can also view individual records which are obtainable after receiving the proper medical release from the patient. By providing several channels of continuous feedback among the patient, physician, professional case advisor, and health plan payor through custom designed interfaces, the system helps enhance patient compliance with the behavior modification program, and can help make the overall health care system more efficient.

BRIEF DESCRIPTION OF THE DRAWINGS

These and other aspects of the present invention will become more apparent from the following Detailed Description of a presently preferred embodiment of the present invention read in conjunction with the accompanying drawings and exhibits, in which:

FIG. 1 is a block diagram illustrating how feedback and monitoring is used in the current embodiment of the therapeutic behavior modification program's compliance monitoring and feedback system

FIG. 2 is an exemplary prescription form for inputting a patient's baseline vital factors;

FIG. 3 is a graphical representation of a set of files for patients for whom recovery programs may be designed or modified;

FIG. 4 is a graphical representation of an exemplary patient file taken from among those represented in FIG. 3;

FIG. 5 is a graphical representation corresponding to the program Design option of FIG.4;

FIG. 6 is a graphical representation corresponding to the Program Detail option of FIG. 5;

FIG. 7 is an exemplary patient progress report;

FIG. 8 is a graphical representation of various interface tools, organized around a village motif, available to a clinical group patient;

FIG. 9 is a graphical representation of the system's Inner Core option;

FIG. 10 is a graphical representation of the system's Schedule Book option;

FIG. 11 is an expanded graphical representation of the Schedule Book;

FIG. 12 is a graphical representation of the system's Journal option;

FIG. 13 is an expanded graphical representation of the Journal;

FIG. 14 is a graphical representation of the system's Meeting Room option;

FIG. 15 is a graphical representation of the system's Coffee Shop option;

FIG. 16 is a graphical representation of the system's Post-office option;

FIG. 17 is a graphical representation of the system's Note option;

FIG. 18 is a graphical representation of the system's Postcard option;

FIG. 19 is a graphical representation of the system's Telegram option;

FIG. 20 is a graphical representation of the system's Audio E-mail option;

FIG. 21 is a graphical representation of the system's Kitchen option;

FIG. 22 is an expanded graphical representation of the Kitchen option;

FIG. 23 is a graphical representation of the system's Recipes option;

FIG. 24 is an expanded graphical representation of a Shopping List option;

FIG. 25 is an expanded graphical representation of an educational topic available through a pull-down menu in FIG. 22;

FIG. 26 is a graphical representation of the system's Gym option;

FIG. 27 is a graphical representation of a Stretching option of FIG. 26;

FIG. 28 is a graphical representation of a Strength Training option of FIG. 27;

FIG. 29 is a graphical representation of the system's Tranquility Park option;

FIG. 30 is a graphical representation of the system's Relaxation option;

FIG. 31 is a graphical representation of the system's Yoga option;

FIG. 32 is a graphical representation of the system's Library option;

FIG. 33 is a graphical representation of the system's Articles option;

FIG. 34 is a graphical representation of a World Wide Web access option;

FIG. 35 is a graphical representation of an educational topic available through a pull down menu in FIG. 32;

FIG. 36 is a graphical representation of the system's Travel Agency option;

FIG. 37 is an alternative user interface screen provided by the system;

FIG. 38 is a graphical representation of a log-on screen for a physician or case manager in accordance with another aspect of the present invention;

FIG. 39 is a graphical representation of a main menu available to a physician or case manager;

FIG. 40 is a graphical representation of an exemplary patient file;

FIG. 41 is a graphical representation of a blood pressure chart for an exemplary patient;

FIG. 42 is a graphical representation of a physical activity chart for an exemplary patient;

FIG. 43 is a graphical representation of a weight chart for an exemplary patient;

FIG. 44 is a graphical representation of a cholesterol chart for an exemplary patient;

FIG. 45 is a graphical representation of the system's Behavior option;

FIG. 46 is a graphical representation of the system's Recommend option;

FIG. 47 is an expanded graphical representation of the system's Communicate option;

FIG. 48 is a graphical representation of the system's Video Conferencing option;

FIG. 49 is a graphical representation of a main menu available to a health plan payor or employer;

FIG. 50 is a graphical representation of a View Compliance Status option;

FIG. 51 is a graphical representation of a View Comparative Costs option;

FIG. 52 is a graphical representation through which the system indicates whether the patient has executed a limited waiver of confidentiality;

FIG. 53 is another graphical representation of an excmplary patient record;

FIG. 54 is a graphical representation of the system's Review Costs option;

FIG. 55 is a graphical representation of the system's Review Outcomes option;

FIG. 56 is a graphical representation of the system's Perform Utilization Review option;

FIG. 57 is a graphical representation upon selection of an exemplary physician group of FIG. 55;

FIG. 58 is an expanded graphical representation of a Communicate option of FIG. 48;

FIG. 59 is a block diagram of the therapeutic behavior modification program's compliance monitoring and feedback system; and

FIG. 60 is a flow diagram illustrating certain aspects of the therapeutic behavior modification program's compliance monitoring and feedback system.

To facilitate description of the present invention, reference is made in numerous instances to the flow diagram of FIG. 60. For convenience, the blocks in the flow diagram are numbered beginning at 1000.

DETAILED DESCRIPTION OF THE INVENTION

Referring to FIG. 1, in a presently preferred embodiment of the invention, the patient 10, physician 12, case advisor 14, and health plan payor 16 (such as an HMO, insurance company or self-insured employer), all provide input to and/or receive output from the therapeutic behavior modification program's compliance monitoring and feedback system. The case advisor may be a doctor, nurse, and/or other trained medical professional experienced in case management protocols and practices. Patients electronically interact with the system, the case

advisor and their doctor through the system interface 18. The behavior modification program is customized to fit the health care and recovery needs of individual patients. The system provides at least two separate benefits: it helps the patient comply with the program through an electronically-implemented support mechanism; and further assists in monitoring such compliance.

A wide range of individuals can benefit from the system. By way of example only, these individuals include those with chronic ailments such as coronary artery disease, diabetes, chronic pain, depression, addiction, arthritis, cancer and asthma, as well as patients who are recovering from medical procedures such as angioplasty or by-pass surgery (the "clinical group").

Individuals who simply want to maintain their health and prevent or reduce the risk of such ailments (the "wellness group") can also benefit from the program. For these individuals, the program may be focused on stress management, diet, and exercise. The wellness group may further include family members of the clinical group who may need group support and/or counseling in dealing with the family member's chronic illness.

The members of the wellness group may not need all the features available to members of the clinical group. Furthermore, access to certain areas within the system may be limited and/or customized to meet the individual user's needs. However, wellness group members may choose to use the case management functions as a "virtual coach." For example, an individual may want to have a case advisor assist them in losing weight by helping the individual change his or her nutrition, exercise and stress management habits. The "virtual coach" or case advisor, can provide ongoing feedback and encouragement throughout the process. Wellness participants may also choose to join an on-line support group to help them achieve their health and wellness goals.

In an exemplary scenario, a physician diagnoses an individual with an ailment. The physician may then recommend a health care maintenance or recovery program which requires the patient to: take certain medications; participate in a support group; and control risk factors by altering his or her diet, following an exercise program, and managing stress levels.

The physician can then place the patient on the system to help him or her make these desirable or necessary lifestyle and behavior modifications. In order to subscribe the patient to the system, his or her baseline vital factors are entered. Such factors may include blood pressure readings, heart rate, height, weight, and cholesterol levels. Depending on whether the doctor is on-line (block 1000, FIG. 60), The doctor may input these vital factors into the system directly via his or her personal computer (block 1002, FIG. 60). Alternatively, the physician may fill out a prescription form and send the information to a case advisor, who then sets the patient up on the system (blocks 1004, 1006 and 1008, FIG. 60).

Referring to FIG. 2, an exemplary prescription form 22 contains identification information 23 such as the patient's name and identification. Using the form, the physician selects a diagnostic category 24 and prescribes a recovery program level 26. In the exemplary

embodiment, eight separate diagnostic categories exist that correspond to the state of the patient's health. Category I, for example, includes patients who have suffered from a heart attack within the current year, while Category VIII includes patients who suffer from no particular ailment but are on the plan simply to promote wellness. Other categories may also be added as necessary.

Depending on the diagnosis, the physician may recommend that the patient cease smoking or that he or she lose a targeted amount of weight within a certain period by circling the appropriate response in field 30. The physician may also enter other information, such as the patient's medications 32. The physician then circles or fills in desired 3-month targets 34 relating to, among other things, daily calorie intake, percent daily intake of saturated fat, maximum heart rate, and cholesterol level.

Referring to FIG. 3, the case administrator sets up a new patient based on information contained in the patient prescription form or accesses the records of existing patients through patient files 40. In this example, the patient files 40 are identified by the patient's name and social security number. To create or modify the program for a particular patient, the administrator creates a new folder or selects a preexisting folder 42 corresponding to the patient in question.

Once the physician or case administrator enters the patient into the system, either the system or case advisor recommends a default set of goals based on the patient's needs and existing medical protocols that may be modified by the physician (blocks 1010 and 1012, FIG. 60). FIG. 4 illustrates an exemplary patient record after selection of the desired patient file 42 in FIG. 3. The record includes, among other things, the patient's current status and program goals. The first column 44 of the record sets forth fields for pertinent patient information including the patient's vital signs (e.g., weight, cholesterol level, blood pressure), other baseline characteristics (e.g., patient's smoking habit, physical activity, alcohol and eating habits, depression and stress levels, seat belt use), and information relating to any medications used by the patient. The second column 46 of the record sets forth the baseline values corresponding to the vital signs and patient characteristics at the beginning of his or her participation in the program. As shown in the third column 48, the record may be updated on an ongoing basis by taking data from the patient on-line and from subsequent office visits. Based on the patient's initial evaluation and/or short-term progress, the physician or case advisor can design a new program or modify an existing program for the patient by selecting the system's Design option 50.

Referring to FIG. 5, upon selection of the Design option 50 in FIG. 4, the system prompts the physician or case advisor to assign intensity levels 51 corresponding to the patient's diet, exercise, stress management, need for group support, anticipated compliance, and pharmaceutical requirements. The intensity levels in this example range from a lowest level of 1 to a highest level of 5. Other measures of program intensity may also be included.

Based on the input information, the system, case advisor or physician generates a set of goals 52 or milestones for the patient. This is done by correlating patient information such as age, sex, weight and information relating to the health, life situation and diagnostic category of the patient to established medical protocols for that type of patient. Other pertinent information that may be taken into account includes the patient's medication and other health conditions. Based on the correlation, the system suggests a therapeutic program including goals relating to intake of calories from fat, exercise level, stress management counseling, and group support and compliance management frequency. The physician or case advisor may view details as to how the suggested goals may be implemented by selecting the system's Program Detail option 54.

Referring to FIG. 6, upon selection of the Program Detail option 54, the patient record 60 is presented along with the recommended one month goals 61 and final goals 62. The physician or case advisor may confirm 63 or edit 64 the suggested program to modify the goals by making appropriate selections (block 1012, FIG. 60).

The content of the patient records and the generated goals vary depending on the patient's diagnostic category. For example, some of the information shown on the patient record may not be necessary for an individual belonging to the wellness group. Information regarding calories, cholesterol level, blood pressure, and seat belt use, for instance, may not pertain to a person who is on the system to get support to help deal with a family member who suffers from a chronic ailment.

Referring to FIG. 7, the system also sends an exemplary patient status report 70 to physicians who do not have direct access to the system. The status report may include information regarding a patient's current status 66, suggested next steps 67, and target goals 68. Other information may also be included in the status report as desired by the physician. The physician has the option to agree with the suggested next steps 69 or indicate changes to the program. The physician then sends the report 70 back to the case advisor for modification of the program as necessary. Communication may take place via e-mail, facsimile, or any other method of transferring data.

Once the patient is set up on the system, it assists him or her in complying with his or her behavior modification program (block 1020, FIG. 60). To use the program, the patient logs into the system network via telephone line, cable modem, cellular connection, satellite link or other communication method that allows for a connection into a network server.

Referring to FIG. 8, in a presently preferred embodiment of the invention, the user interface for patients in the clinical and wellness groups is organized around a village motif. The user progresses through the system by following paths through a graphically represented town square to destinations including the village gymnasium 71, tranquility park 72, post office 74, coffee shop 76, store 78, library 80, travel agency 82, as well as the user's own "home" 84. The village motif presents the patient with an image of a community of support. The entire on-line community revolves around his or her recovery and well-being, and this helps bolster the

patient's confidence and motivation. Furthermore, the village motif provides an easy-to-understand representation of the system's structure. The patient learns to navigate the system more quickly and easily because of the intuitive town layout.

Another benefit of the village motif is its familiarity. A patient afraid of technology will be reassured through the symbolic images of home and neighbor, street and store. Finally, the patient may find navigating an electronic "neighborhood" more enjoyable than a traditional text-menu-driven system. Other user interfaces, such as the one described in conjunction with FIG. 37, are available.

Referring to FIG. 9, the inner core 86 of the village provides the user with a schedule book icon 90, a journal icon 94, a meeting room icon 96, a mail icon 98, and a rewards icon 92. These give the user access to additional tools that assist with complying with his or her health program, and further help the physician or case advisor monitor such compliance.

Referring to FIG. 10, upon selection the schedule book icon 90 from the interface of FIG 9, the system displays a graphical representation of a schedule book 90A. As shown in FIG. 11, the schedule book presents the user with a list of meetings that the user can participate in via his or her computer. The list of meetings varies for each user depending on his or her specific health recovery program. The schedule book also presents general information on the meetings, including time 100, date (not shown), and meeting profile 104, with a notation of how may people have signed up for the meeting 106. The system also sets a limit on the maximum number of individuals that may sign up for a meeting.

Based on this information, a user may then sign up for the meeting that best fits his or her schedule. Other factors, such as the city in which the other members are located 108 may also influence the user's choice. A user may decide to join a group whose members are located in his or her home city if he or she wants to meet these people face-to-face someday.

The system integrates the user's schedule book 90A with the user's personal electronic daily calendar. For example, after a patient signs up for a meeting, the system downloads the day and time of the meeting to the user's calendar. The calendar may be any suitable commercial calendar or organizer program, such as Organizer ™ available from Lotus Development Corp.

In an alternate embodiment, the user may make a further request via the schedule book for automated reminders to sent to him or her by e-mail.

Referring again to FIG. 9, the system also enables the user to access an integrated patient journal 94 from the village's inner core and self-report their progress and describe their feelings. Selection of a journal icon leads the user to a journal 94A like one shown in FIG. 12. Upon entering the journal 94A, the user has the option to view the personal goals that have been set for him or her by the physician or case administrator. The journal also provides a diary used to make a daily record of information pertinent to accomplishing the user's goals. The journal 94A provides an important tool that lets the patient express his or her feelings and fears in a

context other than that of a support group. By journaling, the patient can identify fears concretely, and thus begin to address them. Goal setting is also often more meaningful when it is written down. Instead of merely thinking about ambiguous hopes, patients can define in written form the concrete milestones they plan to attain. These notes can also help remind the patient of matters he or she might wish to discuss in support group meetings. The system also uses certain notations in the journal to assist in generating reports to the physician or case advisor regarding the patient's progress. As part of its overall security measures, the system separates those journal entries which the patient wishes to keep private from those which are to be used in generating reports.

FIG. 13 exemplifies the type of information which may be contained in the journal. For instance, a heart patient belonging to a clinical group may need to monitor his or her emotions 100 as well as the exercises he or she has been doing 104 by means of the journal. Depending on the patient's program, the system might also prompt the patient to input his or her vital signs 102, such as blood pressure and heart rate, in the journal. This can be done manually or automatically. For example, devices can be hooked into the computer's serial port for automatic input of blood pressure and heart rate into the system. Depending on the particular program, patients might be required to weigh themselves on a weekly basis and/or measure their cholesterol level with a home cholesterol kit on a relatively less frequent basis. This information is stored in the system's database and is accessible to the physician and case advisor.

The kind of information required of a person in the wellness group may differ from this. For example, if a user is in the wellness group because a family member is suffering from a chronic illness, it will not be necessary for him or her to input vital signs into the journal. Rather, information as to how he or she is doing emotionally, as well as information as to how much group support he or she is getting, may be solicited.

The user may also record his or her personal comments in the journal. This information may only be viewed by the individual user, and is not available to the case advisor or physician.

The journal is also integrated with the user's daily calendar. The user may, for example, input information as to his or her exercise schedule (such as 30 minutes walking on Tuesdays, Thursdays, and Saturdays) or meditation schedule into the journal. The system then downloads this information into the user's daily calendar. Previous journal entries may also be viewed.

In addition to allowing the patient to electronically enter his or her updated health information, the journal also provides the physician or case advisor with a means of getting feedback on the patient's progress. The information recorded in the journal is electronically forwarded to the case advisor. Alternatively, the case advisor has direct access to portions of the journal stored in the system's database. The physician or case advisor can use the information provided in the journal to update the program on an on-going basis.

The system also accepts additional patient data obtained during office visits or directly from the patient via e-mail or other means of communication. The physician may also input additional data, such as that derived from laboratory tests, into the system. Accordingly, the system accepts updated patient data directly from the patient and through data entered by the physician during office visits (blocks 1030, 1032 and 1034, FIG. 60).

The system automatically correlates the patient's input with the physician's to check for accuracy. In addition, the system automatically provides the physician with reports of patient progress. Depending on the patient's plan requirements, the case advisor periodically reviews the patient-reported and physician-reported input to monitor whether the patient is complying with program parameters and meeting goals (block 1036, FIG. 60).

As part of the feedback process, the system provides an "alarm" option (block 1040, FIG. 60). The system compares actual data about the patient with the goals and parameters residing in the system's database and automatically notifies the physician or case advisor via e-mail or facsimile (or pager depending upon the severity of the problem), if a health risk is present (block 1042, FIG. 60). For instance, if a patient's current blood pressure is potentially dangerous, the system will automatically send an alarm to the physician or case advisor and require his or her immediate action.

If the difference between current data and goals does not present a threatening situation, the system will simply notify the physician or case advisor that these goals are not being met. For example, if the current data states that the patient has lost 5 pounds instead of 10, the system will notify the physician or case advisor of this fact. This information, although not life-threatening, must nonetheless be addressed by the physician or case advisor. He or she may then contact the patient in order to support and to further motivate him or her to meet the desired goals (block 1044, FIG. 60). In addition, the physician or case advisor may recommend that the program be modified to suit the patient's condition (block 1046, FIG. 60).

Regardless of whether an alarm condition exists, the system periodically correlates the updated patient health information with the program goals to determine the patient's progress and compliance with the program (block 1050). If the patient is progressing in accordance with his or her program, the system informs the physician and/or case advisor (block 1052, FIG. 60). The physician or case advisor may then provide positive reinforcement to the patient. Depending on the patient's progress, the case advisor or physician can also determine whether to modify the program by altering the goals or moving the patient into a different diagnostic category. The patient may even be removed from the system if he or she has met program end goals (blocks 1054, 1056, FIG. 60).

The system also notifies the physician or case advisor if the patient is not progressing toward program goals or is not using the system (block 1060, FIG. 60). The case advisor along with the physician then determines whether to modify the patient's therapeutic program,

provide the patient with additional support, or remove the patient from the system (blocks 1064, 1066 and 1068, FIG. 60).

The system also enables direct feedback to the individual user. As one of the features of the journal, users may view their levels of compliance and achievement of goals. Patients may not recognize they are making progress until presented with reminders of how much they have improved. System generated charts and summaries, discussed below with respect to FIGS. 41 to 44, provide patients with an overview of how far they have come.

Referring again to FIG. 9, as another tool to assist patients to comply with their programs, the system offers an electronic meeting room and group support room interfaces via meeting room icon 96 through which a patient receives on-going, on-line group support. Putting a patient in contact with people with the same or similar problems through group counseling has clinically-proven therapeutic benefits. The system facilitates this process through the use of electronic and on-line technologies. On-line group counseling solves many of the logistical difficulties encountered in bringing together, on a regular basis, a large group of people with different schedules who live in different places. Instead of requiring patients to travel physically to a single location, the system enables them to attend group meetings by simply logging on to their computers. As the burden on the individual patient decreases, group attendance increases, and this enhances the overall practical, therapeutic value of group counseling and support.

On-line counseling also brings a patient into contact with a wider pool of people with similar problems than traditional counseling can. When desirable or necessary, group membership can be drawn from people in a wide variety of regions, instead of being limited to a single vicinity.

Furthermore, the relative anonymity of electronic communication benefits patients who are reserved or possibly embarrassed by their situations. These patients may be more willing to share their feelings in an on-line environment than they would be face-to-face.

Patients have access to the meeting room interface via a meeting room icon 96. Upon selection of the meeting room icon 96, patients are presented with meeting rules and regulations. They may then proceed to a pre-scheduled meeting. Only those scheduled for a meeting will be permitted to attend. The scheduling of meetings is part of the schedule book interface explained above in conjunction with FIGS. 10 and 11.

Referring to FIG. 14, each participant 112 may chose to represent him or herself in one of two different ways in the meeting room. The participant 112 may have his or her photo scanned to represent him or her in the system. Alternatively, if anonymity is desired, the patient may choose to be represented by a non-photographic icon, or "avatar," accompanied by either his or her own name or a pseudonymous screen name. The patient will then be represented by that avatar in group meetings and private mentoring sessions. In some cases, patients may choose to design and construct their own avatars.

A trained, experienced leader or chairperson 114 is an important part of these group counseling sessions. It is the chairperson's responsibility to guide the discussion and encourage participation from all members. To enhance the beneficial aspects of group counseling, the system allows the chairperson 114 to access selectively certain parts of the patient's on-line journals and electronically display the selected portion in an anonymous manner to the on-line group. The chairperson can also cut somebody off electronically if he or she is saying things that are inappropriate.

In the preferred embodiment, a participant 112 "speaks" during the meeting by entering text at 122. Upon hitting the enter key, this text appears as "bubble-talk" 116 above the representation of the participant 112 who entered the corresponding text. In an alternate embodiment, instead of using a "bubble-talk" format, each participant 112 may participate at the meetings by talking into a microphone connected to his or her PC, and listening to other participants via speakers also connected to the PC.

A log window 110 keeps a running or scrolling record of the conversations during the meeting. Thus, if a participant 112 loses track of the conversation, or wants to comment on something said earlier, he or she has access to the entire conversation as reference.

During group counseling meetings, a chairperson 114 may play on-line multimedia presentations featuring other patients or well-known figures who have made positive lifestyle changes. In the presently preferred embodiment, each participant has access to the multimedia presentation, such as a video clip, via CD-ROM or DVD received by mail on a regularly updated basis. Alternatively, if the user has access to the appropriate software and hardware, and has a connection of sufficient bandwidth to the server, the multimedia presentation may be streamed to him or her over the network. In addition to CD-ROM, the system can also use DVD disk, downloads to the user's computer hard drive, or any other method or medium capable of storing or transmitting audio and video data.

When it is time to view the multimedia presentation, the chairperson selects, for instance, a particular video clip from a menu of video clips available on his or her CD-ROM or DVD. This sends a signal via the network to each participant's PC. The signal received matches a code on each participant's CD-ROM or DVD, which triggers the playing of the selected video by the PC. If the video is stored on DVD disk or on the user's computer hard drive, or some other storage medium, the video could be triggered to play from that medium as well.

The participants may not play the video prior to the meeting because only the chairperson has access to the code which releases the video. Thus, prior to a meeting, users may view a list of videos in his or her CD-ROM, DVD disk, hard drive, or other storage medium, but videos which have not been shown already at meetings will be inaccessible for viewing. Once a video is released by a chairperson and played for the first time at a meeting, the participants may access it any time thereafter.

The case administrator or advisor knows in advance who the chairperson for a meeting will be and will give him or her access to the video clip to be shown at that meeting.

The multimedia presentations shown at the meetings may feature well-known or public figures and other patients who may have dealt with the same issues that the participants are facing. For example, in a meeting for patients who have suffered heart attacks, a video clip of a celebrity who recovered from a similar problem may be shown. In the clip, the celebrity would talk about his or her own heart attack, the bypass surgery that he or she underwent, and the depression that followed. The celebrity would also describe other struggles that he or she faced, and how these struggles were overcome during the recovery process. Likewise, video clips of program participants may also be used to provide motivational examples of success stories, or to express deep-felt emotions (e.g., anger, depression, etc.) that must be dealt with by that individual and other members of the group in order to be successful in his or her recovery.

Such presentations may act as a source of motivation to the participants, giving them a sense of hope. If someone else was able to overcome the same obstacles, they can too.

The presentations may stimulate further discussion during the meeting, and allow participants to open up about the issues and struggles that they are facing during their recovery process.

Another function provided by the meeting room 96A interface is electronic telephone dialing. Each participant has a phone icon 118 in front of his or her avatar. If a participant wants to talk to any other person in the meeting, he or she may click on the phone icon and the telephone number to that person is dialed automatically. This allows the members to contact each other after meetings to talk further via regular phone lines if desired. The conference room participants also have direct access to a more private mentoring area by clicking on a coffee shop icon 76B. Users of the system may also gain access to this private mentoring area by selecting the coffee shop 76 from the village as shown in FIG. 8.

FIG. 15 is an exemplary illustration of the inside of the coffee shop 76B. Conversation here occurs much like in the meeting room 96A, except for the fact that the conversation is not monitored and structured by a chairperson. Text is inputted at 132 and appears as bubble talk at 134. A record of the conversation is also kept at the log window 130.

In the preferred embodiment, the system allows a maximum of four people into a single coffee shop at a time. Such a restriction is desirable given that the purpose of the coffee shop is for one-on-one mentoring. In the private setting of a coffee shop, more experienced individuals can pass on their experiences to less experienced ones as well as advice as to how to overcome the obstacles that they may be facing.

The group support room 96A and coffee shop 76B applications are implemented by means of third-party chat room applications such as Palace, commercially available from The Palace, Inc., Beaverton, Oregon. The chat room applications may be integrated into the

system and modified to provide additional functionality. Triggering of multimedia presentations during group meetings and the monitoring of attendance are separately programmed into the system.

Through on-line group meetings and private mentoring rooms, the system allows patients to maintain contact with other people who have the same or similar problems, all in entertaining ways that encourage and assist the patient to adhere to program parameters and achieve program goals.

The communications feature of the system further allows users to keep in constant contact with their physician, case advisor, or other users of the system. Although in the presently preferred embodiment of the invention communication is done via e-mail, other methods of communication may also be used. For instance, it is envisioned that the system will allow instant messaging, conference calls, and/or video conferencing as alternate means of communication.

Referring again to FIG. 9, the mail icon 98 gives a user access to the e-mail feature. A user may also access his or her e-mail by selecting the village post office 74 shown in FIG. 8.

Referring to FIG. 16, the system includes four different types of e-mail options: letters 140, postcards 142, telegrams 144, and audio e-mail 146.

FIG. 17 is an example of a letter 140A, which functions as standard e-mail.

FIG. 18 is an example of a postcard 142B, which may be used to send short notes. For instance, postcards may be sent to users to survey the level of satisfaction with the service provided by the system. The postcard would contain questions on this issue, and users would be asked to send the postcard back after having answered the questions.

FIG. 19 is an example of a telegram 144A, which has the highest priority among the types of e-mail provided by the system. The telegram may be used, for instance, to alert a user that he or she has missed a meeting, or just as a short note of encouragement by the case advisor or group leader to an individual user.

FIG. 20 is an example of an audio e-mail 146A notification. Upon clicking this icon, users can hear a recording of the message sent to them via speakers attached to their PCs.

The communications functionality may be implemented by integrating any one of a number of conventional e-mail programs with the system.

As will become more apparent from a detailed description of the system's other interfaces, the system takes a two-pronged approach to behavior modification: education and motivation. Entertainment is used as a means of both educating and motivating a user to make the sometimes difficult changes required for recovery or even for maintaining a healthy lifestyle.

Motivation is one approach to behavior modification. It is the path from education to compliance, which is a goal of the system as a whole. The support group and case advisor described above add a human element to this motivational component. Patients are more likely to respond positively to the encouraging words of others than they would be to a program which must be followed in isolation.

The system's multimedia capabilities allow it to use graphics, videos, and music to communicate and educate. These features provide a refreshing boost to the patient's endeavor to modify his or her behavior, replacing the drudgery typically associated with clinical medical rehabilitation programs. Segments featuring celebrities, medical experts, motivational speakers and successful program participants delivering motivational speeches and personal testimonials further inspire the user. Humor is integrated throughout the system, for example in the whimsical artwork. The entertainment derived from these features of the system is used to spark and maintain the patient's interest in the unfolding drama of his or her recovery and lifestyle change.

The rewards feature is yet another motivational tool provided by the system. Referring again to FIG. 9, the reward "apples" icon 92 allows a user to view information on the rewards point system and how it works, as well as the user's own personal rewards account. Users may earn points by good participation in the program and by reaching certain milestones. For instance, points may be earned for good attendance at meetings, good participation during the meetings, chairing a meeting, or losing a certain amount of weight, if this was a goal to be accomplished.

Rewards range from the symbolic kind, such as getting "gold stars" that commend a user for his or her progress, to reward points and frequent flier miles which may be exchanged for goods in the village store 78 or plane tickets in the village travel agency 82, respectively.

Education is a complementary behavior modification approach offered by the system. Education is provided through informative on-line multimedia presentations and the interactive areas of the village devoted to diet, exercise, and stress management. For example, the recipes provided in the village kitchen, discussed below in conjunction with FIGS. 21-24, are designed to improve patients' diets without forcing them to take on impossible austerities or give up their love for food.

Exercise and stress management programs, discussed below in conjunction with FIGS. 26-31, are designed both to allow for variety and to lie within the individual patient's ability range. By making exercise and a healthy diet both feasible and interesting, the system enables patients to stick with their new lifestyles.

The system also provides relevant articles and includes hyperlinks to other, reputable Internet sites devoted to providing medical and health-related information, as discussed below in conjunction with FIGS. 32-35.

Referring again to FIG. 8, the system encompasses a "home" 84 interface as part of the village motif. Upon its selection, a screen showing the inside of the user's "home" 84 follows, as depicted in FIG. 21. Once inside his "home" 84, the user may access the kitchen by selecting the kitchen icon 150.

FIG. 22 illustrates the interior of the user's kitchen 155. Once in the kitchen 150A, users have the option to get nutritional and dieting information from low-fat cookbooks 153, or view and print recipes from a recipe book 154. FIG. 23 gives an example of a recipe which may be contained in the recipe book 154.

Referring again to FIG. 22, users also have the option to prepare and print a shopping list 156. A user may chose several recipes from the recipe book 154, and the system can automatically enter the ingredients into the user's shopping list 156. The user can also manually enter items into the shopping list 156 via his or her PC keyboard. FIG. 24 gives an example of a user's shopping list.

The system can also indicate which recipes are allowable under the particular patient's program. For example, the system might recommend certain low-fat items that meet the criteria of a patient's program as well as suitable foods he or she might consider when eating out. The system is also capable of generating weekly shopping lists based on program parameters. According to personal preference, users may choose to substitute certain allowable foods for other.

Moreover, users have access to a pull-down computer menu by selecting the computer menu icon 152. From this computer menu, users can access various educational topics related to food, nutrition, and diet. One such topic may, for instance, relate to the basic food groups and may provide information as to the suggested amount of servings for each category of food, as shown in FIG. 25.

The guest chef 158 option shown in FIG. 21 further allows users to view audio or video clips of a chef showing how to prepare a certain recipe. In the presently preferred embodiment, these clips are contained in the user's CD-ROM or DVD, but with proper technology could be sent via streaming audio or video.

From the kitchen, a user may substitute foods (e.g., asparagus for broccoli); access and print food related articles; view new recipes or articles by selecting the "what's new" button (not shown); or join a discussion group via a bulletin board (not shown).

Referring again to FIG. 8, another part of the village motif is the village gymnasium 71, which is used by the system to make recommendations or supply information regarding suitable exercise routines. Each exercise program is generated according to individualized parameters and needs, with progress being regularly charted by user input via the journal 94A (FIGS. 12-13).

Upon entering the gymnasium 71, a user may view featured video clips or listen to audio clips; do key-word searches to access and print exercise related articles; read and print exercise manuals; or join a discussion group via a bulletin board.

FIG. 26 illustrates the inside of a gymnasium 71 shown in FIG. 9. Shown here are various exercise topics 160 that a user may access. For instance, selecting the stretching topic 162 gives the user information on recommended exercises for stretching different muscle groups. FIG. 27 illustrates one such stretching exercise.

Similarly, selecting the strength training topic 164 gives the user information on recommended exercises to help strengthen various muscle groups. FIG. 28 illustrates one such strength training exercise.

Referring again to FIG. 9, the village tranquility park 72 focuses on stress management strategies, including relaxation techniques, biofeedback, yoga, and meditation. Upon entering the park 72, a user may access and print articles on stress management subjects; view video clips or listen to audio clips on these subjects; and join discussion groups via a bulletin board.

An expanded illustration of the tranquility park 72 is shown in FIG. 29. Upon selection of the relaxation option 170, an instructional article on the subject is invoked, as shown in FIG. 30. Similarly, upon selection of the yoga option 172, an instructional article about yoga is invoked, as shown in FIG. 31.

Referring back to FIG. 8, the system also gives access to a village library 80 which allows users to do research germane topics. Thus, patients interested in learning more about their medial condition may access the library 80 in order to educate themselves on the topic.

FIG. 32 illustrates the interior of the library 80. From here, a user may select an Articles option 180 to gain access to an available list of articles 186 via his or her CD-ROM, as shown in FIG. 33. The kind of articles 186 available to a user will vary depending on the type of user. For instance, if the user suffers from a chronic cardiac condition, the articles 186 will all relate to such topic. The list of articles 186 is updated on an ongoing basis to reflect new developments and research on the topic.

Users are also provided with hypertext links 188 to other reputable Internet sites devoted to providing medical and health-related information. These Internet sites may also be accessed by selecting the world wide web option 182 as shown in FIG. 32.

Once linked to an Internet article, a user is taken to a separate web browser from which he or she may navigate the web. FIG. 34 is an example of an Internet site to which a user might get connected upon selection of the world wide web option 182 of FIG. 32.

Furthermore, users have access to a pull-down menu by clicking the menu icon 184. From this menu, users can select various educational topics germane to the user's condition. For instance, an article available through the pull-down menu may teach a user suffering from a chronic cardiac condition how to determine his or her target heart rate zone, as shown in FIG. 35.

Users may also do key word searches to access and print articles of interest, to view featured video clips, or listen to audio clips.

Referring again to FIG. 8, the village store 78 and travel agency 82 are two additional interfaces accessible to users. Upon entering the store 78, users are taken to an in-house or third-party web site through which they may order relevant items, either on-line or by telephone.

Users may also search the store database and view product information, including pictures, descriptions, and prices of products. Moreover, users may view the status of their orders and contact customer service via e-mail or telephone.

Similarly, when a user enters the travel agency 82, he or she is linked to a third-party co-branded reservation system. FIG. 36 illustrates the inside of travel agency 82. From here, a user may make on-line travel reservations by selecting a Reservations option 202. A user may also view the frequent flier miles he or she has accrued so far by selecting a Check Reward Points option 200. As discussed above, a user may gain frequent flier miles by good participation in the program and reaching certain milestones.

Although the user-interface for clinical and wellness group members has been described in terms of a village motif, an alternative user-interface could incorporate another alternate embodiment of the system interface shown in FIG. 37. A multi-frame screen is shown which includes: a main navigation area 210; content area 212; message or video screen area 214; and an instructions area 216. The message or video screen area 214 may be used to show advertisements. The instructions area 216 may be used as a "What's New" area or for the bulletin board functionality discussed above for the kitchen 150A (FIG. 22), gymnasium 71 (FIG. 26), and tranquility park 72 (FIG. 29) interfaces.

FIGS. 38-47 and 49-58 illustrate user interfaces for the case advisor and HMO, some of which are also accessible by the patient. Unlike the user interface for patients, the navigation for the physician/case advisor is generally less graphical and more chart oriented.

Referring now to FIG. 38, a log-on screen 220 for the user interface for a physician/case advisor is shown. The screen 220 requires the physician or case advisor to input their name 222 and corresponding password 224. Screen 220 thus acts as a security measure by ensuring that only legitimate users are able to gain access to the system.

Referring to FIG. 39, an initial screen containing a main menu 230 of the options available to the physician/case advisor follows the log-on screen 220. A Design Program For Patient option 232 allows a physician/case advisor to create a new program or modify an existing program for a patient, as described above in conjunction with FIGS. 3-6.

A second option within the main menu 230 is a Review Patient Record option 234 which allows a physician/case advisor to review the health record of a particular patient.

A list of current patients (not shown), substantially similar to the list shown in FIG. 4 follows upon selection of a Review Patient Record option 234.

Referring now to FIG. 40, a health record of an exemplary patient is shown. The record may provide identifying information, including the patient's name 240, subscription ID 242, and social security number 244. Furthermore, information as to the total amount of time that the patient has been participating in the program may be given as shown at 246.

Column 258 shows the patient's vital signs and other health-related factors, such as blood pressure 250, number of cigarettes smoked per day 252, amount of physical activity 254, weight 256, and cholesterol level 258. Some of these factors may be monitored and reported on a weekly basis, as shown in columns 260-268. Other factors, such as the patient's cholesterol level 258, may be monitored and reported on a bi-weekly basis, as shown in columns 260, 264, and 268. The ultimate goal to be achieved in each of the specified areas is given in column 272.

A list of the risk factors which may affect the patient's recovery may further be pin-pointed as shown at 270.

Vital signs may be represented graphically for the patient, physician and case advisor. These may include charts or graphs of the patient's blood pressure 250A (FIG. 41), physical activity 254A (FIG. 42), weight 256A (FIG. 43), and cholesterol level 258A (FIG. 44). These graphs allow the physician/case advisor to review and grasp the patient's progress visually over a period of time, and help him or her determine how the patient is doing in relation to the ultimate goals that are to be achieved in the charted areas.

Referring again to FIG. 40, a physician/case advisor is also given an option 274 to assess the patient's behavior. Upon selection of this option, the system provides a behavioral change assessment form 305 like the one shown in FIG. 45. This form 305 is used to determine how inclined the selected patient is toward complying with the recommended program. In the preferred embodiment, on-line questionnaires are submitted to the patients, asking them to rate their behavioral intention 300, self-efficacy 302, and social support 304. Alternate forms of evaluation may also be used to assess the likelihood of a patient's compliance with the program.

The system periodically assesses and reports the patient's behavioral change as shown in columns 306 and 308. The desired goals 310 are also listed to monitor whether the patient is making progress towards them. If a patient continues to score low on the behavioral change assessment form 305, this may indicate that he or she is unable to change his or her lifestyle, and lead to the conclusion that the patient should be taken off the system.

The system generates reports on patient progress based on the data shown in FIGS. 40-45, as frequently as the physician desires. These reports can be received via either e-mail or facsimile. The frequency of reports will depend on the needs of the particular patient, and may be triggered by the achievement of goals or the setting off of alarm signals as described above.

The system can also generate regularly scheduled reports for a physician's review on a default basis, depending on a patient's needs. For example, patients who are relatively ill can be reviewed twice a week or more, even if no warning signals occur.

Upon receiving feedback from the system regarding changes to a patient's behavior modification program, a physician or case adviser may want to make recommendations about the program. FIG. 46 shows an exemplary recommendation screen which follows the selection of a Recommend 276 option of FIG. 40. If, for example, a patient initially placed on a program of walking 15 minutes three times a week loses 5 pounds and lowers his or her blood pressure, the system might generate a report to the physician recommending an increase in the patient's walking time to 45 minutes per session as shown at 322. The system may further make recommendations as to the frequency and duration of stress reduction exercises 328 as well as on other areas of the program as shown at 326. The physician reading the report can accept 330 or modify 332 the recommendations.

The system's reporting features enable a physician to handle more patients in the same amount of time without decreasing the quality of care. The system also allows for a patient feedback loop independent of this self-monitoring capability. If the patient has a difficult night, for example, he or she can send an e-mail through the system directly to the case advisor or the physician via the mail 98 (FIGS. 9, 16-20) or post office 74 (FIG. 8) interfaces.

Once the physician/case advisor is satisfied with the recommendations, he or she may electronically communicate 334 program changes to the subscriber.

FIG. 46 also shows an example of a patient who has earned reward points 324 for not having smoked for 60 days. The reward points shown here are to be cashed in at the village store 78 shown in FIG. 8.

Referring to FIG. 47, the system presents a message screen upon the selection of a communications 334 option of FIG. 46. The case advisor may send the recommendation 346 made by the system and reviewed and/or modified by the physician, to the subscriber 340 with an attached audio e-mail message 344, or alternately via text e-mail or facsimile. A copy of the recommendation 346 and message 344 may also be stored in the system's database 342.

Physicians/case advisors may further communicate with patients by video conferencing. An existing third-party video conferencing package may be integrated to the system to allow the video conferencing feature. The minimal requirements for a PC to support the video conferencing capability is a clock cycle of 90 megahertz, 24 megabytes of random access memory, a color camera, a video capture board, an audio board, a video input capture board, and an ISDN line. The technical specification may change as technology affecting bandwidth and/or data compression changes.

As shown in FIG. 47, the video conferencing feature may be accessed upon selection of a video conferencing option 347. A video conferencing manager, like one illustrated in FIG. 48 may then be used to conduct the video conference.

A health plan payor, such as an HMO, insurance company, or self-insured employer, may also access the system. Information that is released by a patient may also be sent electronically to the health plan payor. The information can then be combined with the provider's information to analyze individual patients or aggregate results of all people on the program. The analysis may include, for example, cost per patient, cost for patients in each category or group, and physician utilization. The system's relational database that allows for the custom gathering of data, depending upon the requirements of the health plan. The system may also provide aggregate reports to the health plan payor for management review and cost control purposes. A health plan payor may be less interested in looking at individual patient files and more interested in looking at information as to the number of subscribers on the system, the cost of keeping the subscribers on the system, and how this cost compares to that incurred by patients who are not on the system. At the same time, several layers of electronic security measures insure the individual patient's privacy by strictly segregating the type of information available to the various parties who have access to the system.

The user interface for the health plan payor is similar to the user interface used by a physician/case advisor. When the health plan payor signs onto the system, a main menu screen with a list of options available is provided, as shown in FIG. 49. From here, the payor may choose to view overall compliance status 350, perform case management review 352, perform an utilization review 356, review outcomes 354, or communicate 358, each of which options is described in further detail below.

Upon selection of a view compliance status 350 option, the health payor views current compliance status based on pre-determined categories 360, as shown in FIG. 50. For each category, information as to the total number of eligible patients 364, number of participating patients 366, participating patients complying with the program 368, participating patients put on probation due to lack of compliance 372, and patients terminated 376, may be displayed.

A comparative cost analysis screen is also invoked via a view comparative costs option 362. FIG. 51 shows an example of the cost of maintaining patients on the system. The total cost 380 may be compared against costs incurred by a control group of patients who have not subscribed to the system 382. Comparative savings achieved by use of the system are shown in column 384.

Referring back to FIG. 49, the main menu 348 also includes a perform a case management review 352 option. A list of current patients (not shown), substantially similar to the list shown in FIG. 4, follows selection of this option.

Once a patient file has been selected, a confidentiality waiver information 390 is displayed, as shown in FIG. 52. A patient will be assured confidentiality and privacy in the areas where waiver has not been given. For instance, portions of the patient's journal will be kept confidential and unavailable to the health plan payor, ensuring that patients remain open and honest in making daily journal entries.

Upon selection of a continue option 392, a screen similar in content to the screen shown in FIG. 40 is shown in FIG. 53. As with the user interface for physicians/case advisors, indications of the patient's blood pressure level 404, physical activity 406, weight 408, and cholesterol levels 410 over time, are given. These may also be represented graphically to the health plan payor in a form substantially similar to FIGS. 41, 42, 43, and 44 respectively.

A health plan payor, however, has a review costs option 400 which is not available to a physician/case advisor.

FIG. 54 illustrates an exemplary screen viewable upon selection of the review costs option 400 of FIG. 53. Shown here is information as to the costs incurred to date in maintaining the selected patient on the system. The system costs 410, health service costs 412, and total costs 414 are represented in a bar graph format in this particular example. The cost incurred by a control group patient who is not on the system is also shown 418. This cost is compared to the total costs 414 and the amount of savings 416 thus achieved, and is also displayed in a bar graph format.

Referring back to FIG. 49, another option provided by the main menu 348 is a review outcomes 354 option, which provides a screen like the one shown in FIG. 55 with information as to the various patient outcomes, based on various pre-determined categories. For instance, information as to the percent of compliant subscribers who had an emergency room ("ER") visit 420 is shown. This information may be compared against ER visits made by non-compliant subscribers 422 and control group patients who have not subscribed to the system 424.

Referring back to FIG. 49, the main menu 348 also provides for a utilization review 356 option. As shown in FIG. 56, upon making this selection, a screen appears with information including the name of the group or facility using the system, this group or facility's specialty 432, the number of cases to date 434, the percentage of cases referred to the system 436, and how this percentage compares 438 to the targeted utilization percentage 440.

Upon selection of a particular group or facility 442, the same type of information for the doctors within the selected group or facility 442 may be obtained, as shown in FIG. 57.

The main menu 348 in FIG. 49 further provides a communicate 358 option leading to FIG. 58. The health plan payor may send an audio e-mail 456, text e-mail 458, or fax 460 to the case advisor 450, responsible physician 452, or subscriber 454 as shown here.

In this way, the system provides an on-going loop of compliance monitoring and feedback to help the patient make difficult lifestyle changes. Once the patient has achieved the desired goals, he or she can continue to use the system as a health maintenance or wellness program. An aim of the system is to educate and motivate patients to take control

of their lives and improve their health by modifying their behavior and changing their lifestyles.

FIG. 59 is a block diagram of the present system. It will be apparent to those skilled in the art that the invention described herein may be implemented on various platforms. In a preferred embodiment, however, patients, physicians, case advisors, and health plan payors have access to a PC 500 with a Pentium microprocessor. The PC 500 contains audio and CD-ROM 502 capabilities. However, a PC 500 may have other multimedia capabilities including video display and capture capabilities, microphones, etc. The PC 500 is further connected to a printer 504 for generating hard copies of any data accessible by the computer.

In a preferred embodiment, the operating system utilized by the PC 500 is a windows-based operating system, preferably Windows 95.

In the preferred embodiment of the invention, each PC 500 is electronically linked to network server 508 via the Internet 518. Contained in each server 508 is a transaction server 510, meeting server 512, "inner circle" server 514, and "outer circle" server 516. The transaction server 510 is utilized to handle secure purchases via the store 78 (FIG. 9) or travel agency (FIG. 36) interfaces.

The secure meeting server 512 is dedicated to implementing the meeting room 96 and coffee shop functionalities discussed in reference to FIGS. 9, 14, and 15. The secure "inner circle" server 514 is dedicated to handle sensitive data, such as medical records.

Other servers may be added as needed. For instance, there may be a separate media server to handle the audio and video functionalities of the system.

Communication via the Internet 518 is achieved in the preferred embodiment of the invention through telephone lines by means of a high-speed modem 506 connected to the PC 500. Alternatively, satellites, television cable systems, and ISDN lines may be utilized to access the Internet 518. Standard TCP/IP is utilized as the protocol to communicate between the servers 508 and a PC 500 via the Internet 518.

The network server 508 may be located at a health plan payor facility with an independent third party that acts as an Internet Service Provider or elsewhere. The servers 510-516 have access to one or more relational databases 522 (such as SQL) that contain all the health plan data, including information input to the journal and schedule book information. For example, pertinent information from a patient's journal will be uploaded to the server and downloaded to the physician and case advisor. Information provided by the physician will also be uploaded to the same server. System data will be downloaded to the case advisor on a periodic basis for review.

All the information needed by a user of the system is located in the databases 522 or on CD-ROM and/or DVD distributed to the users on a periodic basis, or, as technology permits, via streaming audio and video. For instance, in the presently preferred embodiment, the video and audio clips available to a chairperson 114 for conducting meetings (FIG. 14), or

via the kitchen (FIGS. 21, 22), gym (FIG. 26), tranquility park (FIG. 29), and library (FIG. 32) interfaces is located on CD-ROM or DVD. However, with the emergence of ISDN, cable modem, XDSL, and direct satellite delivery, it is anticipated that the system will be capable of sending streaming video and audio over the network.

There are three levels of security implementation to help achieve secure transmission of data to and from the servers 510-516, as well as to ensure that only authorized users may access the databases 522. User security for patients, physicians/case advisors, and health plan payors is assured by a two tier (user id and password) system. An example of such log-on screen is shown in FIG. 36.

Furthermore, a "cookie"-based code is used to monitor when users log in and out, and to keep track of how each user uses the system. This will, for example, allow the system to keep attendance at group meetings. If a user has missed a group meeting, the case advisor would then be able to follow up with him or her about the absence.

Referring back to FIG. 59, a firewall 520 is also provided at the server level to protect confidentiality of health plan data. Furthermore, encryption is furnished to ensure that communication between servers 510-516 and PCs 500 is secure.

A network administrator 524, who may be the case administrator or an independent third party, is also attached to the server 508. The network administrator subscribes all users to the system except for clinical or wellness group participants. Physicians or case advisors are responsible for subscribing clinical or wellness members. The network administrator is also in charge of maintaining the system's databases 522.

In the preferred embodiment, the system is constructed using the C++ programming language in conjunction with SQL 6.5, Cold Fusion, commercially available from Alaire Company, Visual Basic, commercially available from Microsoft Corporation), and HTML. Active X and Java components may also be invoked to handle the multimedia functions of the system.

It will be understood that the foregoing is merely illustrative of the principles of the invention, and that various modifications can be made by those skilled in the art without departing from the spirit and scope of the invention as defined by the following claims. For example, the system can be programmed in any number of programming languages besides C++ code to achieve the underlying principles of the present invention. The screens can be reformatted to change their appearance, and many different data sets can be used for various patients with different chronic diseases.

CLAIMS

1. A method for monitoring compliance with a therapeutic behavior modification program, the method comprising the steps of:

providing a therapeutic behavior modification program having a series of milestones for a patient;

inputting patient data at prescribed times; and

correlating the patient's data using a microprocessor with the milestones in the therapeutic behavior modification program to determine whether the patient is complying with the program.

2. The method of claim 1 further comprising the steps of grouping particular data using the microprocessor and linking the data to a remote computer.

3. The method of claim 1 further comprising the step of using the microprocessor to provide graphical screens for encouraging the patient to comply with the therapeutic behavior modification program.

4. A therapeutic behavior modification program, compliance monitoring and feedback system comprising:

means, comprising a relational database and a microprocessor coupled to the database, for developing a therapeutic behavior modification program having a series of milestones for an individual;

means for monitoring the individual's compliance with the program including:

means for prompting the individual to enter health-related data;

means for correlating the individual's entered data with the milestones in the behavior modification program and generating compliance data indicative of the individual's progress toward achievement of the program milestones;

means, accessible to the relational database and microprocessor, for motivating the individual to comply with the program comprising an integrated system of graphical system interfaces, the motivating means including:

means for enabling the individual to review the compliance data;

means for providing health information to the individual from a remote source;

an electronic calendar integrated with the behavior modification program for signaling the individual to take action pursuant to the behavior modification program wherein the calendar accesses the relational database and integrates requirements of the program with the individual's daily schedule;

an electronic journal for enabling the individual to enter personal health-related information;

an electronic meeting room for linking the individual to a plurality of other individuals having related behavior modification programs for facilitating group peer support sessions for compliance with the program; and

means for providing motivational media presentations to the individual for encouraging the individual to comply with the program; and

a graphical electronic navigator operable by the individual to control the microprocessor for accessing different parts of the system.

5. The system of claim 4 wherein the means for developing the therapeutic behavior modification program comprises:

means for inputting preliminary health information relating to the individual;

means for presenting a plurality of suggested behavior modification programs containing suggested milestones generated as a function of the preliminary health information;

means for selecting one of the suggested behavior modification programs and altering the milestones to generate the individual's behavior modification program; and

means for loading the behavior modification program into the relational database.

6. The system of claim 4 further comprising means for providing the motivational media presentations to the individuals in the electronic meeting room as part of the group support sessions, thereby facilitating interactive group discussion about the presentations.

7. The system of claim 4 further comprising means for enabling the individual to select an avatar to represent himself or herself in the electronic meeting room.

8. A method for assisting an individual to comply with a therapeutic behavior modification program, the method comprising the steps of:

providing the therapeutic behavior modification program having a series of milestones for the individual;

inputting health data relating to the individual at prescribed times;

correlating the individual's health data with the milestones in the behavior modification program using a relational database and generating compliance data indicative of whether the individual is complying with the program;

grouping particular compliance data using a microprocessor and linking the data to a remote computer; and

motivating the individual to comply with the behavior modification program by:

providing medical information to the individual relating to the program;

presenting the individual with the compliance data to allow the individual to personally monitor compliance with the program;

signaling the individual to take action according to the program through an electronic interface integrated with the individual's daily schedule;

providing remotely accessible group support sessions and motivational media directed toward encouraging the individual to achieve the program milestones; and

enabling the individual to retrieve the medical information, compliance data, and scheduling signals, and participate in the group support sessions and view the motivational media through a graphical electronic interface.

9. The method of claim 8 wherein the step of providing remotely accessible group support sessions and motivational media comprises presenting the motivational media during the group support sessions to facilitate interactive group discussion about the presentations.

10. The method of claim 8 further comprising the step of selecting an avatar to represent the individual during the group support sessions.

11. A method for assisting an individual to comply with a computer implemented behavior modification program, the method comprising the steps of:

providing milestones in the behavior modification program to be achieved by the individual;

monitoring the individual's compliance with the program by:

obtaining health-related data of the individual at prescribed times;

comparing the health-related data with the milestones for generating compliance data indicative of whether the individual is complying with the program, and encouraging the individual to comply with the program if the compliance data indicates lack of compliance; and

comparing the health-related data against accepted medical protocols and alerting the individual's physician or case advisor when a health-risk is present;

educating the individual electronically on health topics germane to the individual's condition and behavior modification program; and

motivating the individual to comply with the behavior modification program by:

providing group support for the individual by electronically linking the individual to a plurality of other individuals having related behavior modification programs;

providing a reward to the individual when certain of the milestones are reached;

presenting the individual with the compliance data for enabling the individual to personally monitor compliance with the program;

enabling the individual to enter comments germaine to the behavior modification program in a computer-implemented journal; and

providing motivational multi-media presentations for encouraging the individual to comply with the program.

12. The method of claim 11 wherein the step of obtaining the health-related data comprises the user providing the data through a computer-implemented journal.

13. The method of claim 12 wherein portions of the data in the journal are accessible to a physician.

14. The method of claim 11 wherein the step of obtaining the health-related data comprises a physician obtaining the data from office visits by the individual to the physician.

15. The method of claim 11 wherein the step of educating comprises providing recipes, stress management strategies, and nutritional, dieting, and exercise information to the individual.

16. The method of claim 15 wherein ingredients appearing on the recipes are downloaded automatically to an on-line shopping list.

17. The method of claim 11 wherein the group support is provided by a computer-implemented meeting room wherein the individual and the plurality of other individuals participate in on-line group meetings, the meetings comprising:

a chairperson for monitoring discussions and triggering multi-media presentations; and

a means of representing the individual and the plurality of other individuals in the group meetings.

18. The method of claim 17 wherein a computer-implemented schedule book enables the individual to:

view a list of on-line group meetings;

sign-up for a particular group meeting from the list of group meetings; and

request automated reminders for reminding the individual of group meetings for which the individual has signed-up.

19. The method of claim 17 wherein the meetings further comprise a means for the individual for contacting the plurality of other individuals via telephone directly from the computer-implemented meeting room.

20. The method of claim 11 wherein the group support is provided by a computer-implemented mentoring area for mentoring and giving support to the individual by other more experienced individuals.

21. The method of claim 20 wherein no more than a predetermined number of the more experienced individuals may be present in the mentoring area at a single time with the individual.

22. The method of claim 11 wherein the group support is provided through electronic mail for facilitating communication with the physician, case advisor, or the plurality of other individuals having related behavior modification programs.

23. The method of claim 11 wherein the group support is provided through an electronic bulletin board wherein the individual posts messages and read messages posted by the other individuals having related behavior modification programs.

24. The method of claim 11 wherein the reward is rewards points for being redeemed for goods, frequent flier miles, or a symbolic reward commending the individual for good work.

25. A therapeutic behavior modification program, compliance monitoring and feedback system comprising:

means, comprising a relational database and a microprocessor coupled to the database, for developing a therapeutic behavior modification program having a series of milestones for an individual;

means for subscribing an individual to the behavior modification program;

means for monitoring the individual's compliance with the program including:

means for obtaining health-related data of the individual at prescribed times for input into a relational database;

means for comparing the health-related data with the milestones in the behavior modification program for generating compliance data indicative of whether the individual is complying with the program, and encouraging the individual to comply with the program if the compliance data indicates lack of compliance; and

means for comparing the health-related data against accepted medical protocols and alerting the individual's physician or case advisor when a health-risk is present;

means for educating the individual electronically on health and medical topics germane to the individual's condition and behavior modification program;

means, accessible to the relational database and microprocessor, for motivating the individual to comply with the program including:

means for providing group support for the individual by electronically linking the individual to a plurality of other individuals having related behavior modification programs;

means for providing a reward to the individual when certain of the milestones are reached;

means for presenting the individual with the compliance data for enabling the individual to personally monitor compliance with the program;

means for enabling the individual to enter personal feelings and comments germaine to the behavior modification program into a computer-implemented journal; and

means for providing motivational multi-media presentations for encouraging the individual to comply with the program;

means for modifying the program based on the individual's progress; and

a graphical user interface for controlling the microprocessor for accessing different parts of the system.

26. The system of claim 25 wherein the means for developing the therapeutic behavior modification program comprises:

means for inputting preliminary health information relating to the individual;

means for presenting a suggested behavior modification program containing suggested milestones generated as a function of the preliminary health information and accepted medical protocols;

means for modifying the suggested behavior modification program to generate the individual's behavior modification program;

means for loading the behavior modification program into the relational database; and

means for giving access to the individual to the graphical user interface for controlling the microprocessor for accessing different parts of the system.

27. The system of claim 25 wherein the means for obtaining the health-related data comprises means of prompting the individual to input health-related information into a computer-implemented journal.

28. The system of claim 25 wherein the means of educating comprises means for providing recipes, stress management strategies, and nutritional, dieting, and exercise information to the individual.

29. The system of claim 28 wherein the means for providing recipes includes means for downloading recipe ingredients to a computer-implemented shopping list.

30. The system of claim 25 wherein the means for providing group support comprises means for providing on-line group meetings comprising:

means for electronically viewing a list of group meetings available for participation;

means for electronically registering for a particular group meeting;

means for sending automated reminders for reminding the individual about the particular group meeting for which the individual is registered;

means for providing an electronic meeting room for the group meetings;

means for monitoring discussion during the group meetings;

means for triggering multi-media presentations during the group meetings;

means for electronically representing the individual and the plurality of other individuals in the group meetings; and

means for contacting the plurality of other individuals via a telephone directly from the computer-implemented meeting room.

31. The system of claim 25 wherein the means for providing group support comprises a means for providing a computer-implemented mentoring area for mentoring and giving support to the individual by other more experienced individuals.

32. The system of claim 25 wherein the means for providing group support comprises electronic mail means for facilitating communication with the plurality of other individuals.

33. The system of claim 25 wherein the means for providing group support comprises electronic bulletin board means for posting messages and reading messages posted by the other individuals having related behavior modification programs.

34. The system of claim 25 further comprising a means for providing security from unauthorized access to the system.

35. The system of claim 25 further comprising a means for health plan payors for monitoring usage of the system.



PATIENT
10
PHYSICIAN
12
PRESCRIPTION
BASELINE DATA AND GOALS ESTABLISHED
CASE ADVISOR
14
HEARTLAND CASE MANAGEMENT
• ONGOING REVIEW
SYSTEM INTERFACE
18
• DIET
• EXERCISE
• GROUP SUPPORT, ETC.
• SELF REPORTING
PHYSICIAN
12
• REPORT DATA CHANGE
• PRESCRIPTION / GOALS
HMO
16
PATIENT
• RECOVERY
• HEALTH MAINTENANCE

Fig 1

Fig 2

22

HeartLand Prescription Form

23

Patient Name	Patient ID	Date	Physician Name	Physician ID

1. Fill in diagnosis:

Patient Diagnosis	Co-morbid Diagnosis
	26

2 Circle a diagnostic category:

24

Category	Diagnosis	Level 1 (mos.)	Level 2 (mos.)	Level 3 (mos.)	Health and Wellness
I	Current year MI survivor	3	3	6	Contin.>12th month
II	Current year alt. to PTCA or CABG	3	3	6	Contin.>12th month
III	Current year diagnosed CAD	3	3	6	Contin.>12th month
IV	All diagnosed Angina	3	3	6	Contin.>12th month
V	Prior years' post MI/surgical--High Risk	3	3	6	Contin.>12th month
VI	Prior years' post MI/surgical--Low Risk	1	1	10	Contin.>12th month
VII	2 or more Risk factors	0	2	4	Contin.>6th month
VIII	Health and Wellness	0	0	0	Continuous

3. Please circle as appropriate:

30

Does the patient need smoking cessation? Yes No
Have you prescribed nicotine patch or gum? Yes No
Does the patient need weight reduction? Yes No If yes, target weight: _____

32

4. What are patient's current and prescribed medications?

Medication	Standard Dosage	Comments/Changes
HCTZ	25 mg	
Atenolol	50 mg	
Lisinopril	20 mg	
Atorvastatin	20 mg	
Lovastatin	20 mg	
Antioxidant: Vitamin E	400 IU	
Antioxidant: Vitamin C	500 mg	
Other:		
Other:		
Other:		
Other:		

34

5. Circle or fill in desired 3-month targets:


Daily calories	1200	1500	2000	2500	3000
Sat Fat Grams	<15	15	18	20	25
Pct Fat Cal	10%	15%	20%	25%	30%
Exercise (Freq/wk/RPE)	20/5x/3	30/5x/4	45/5x/5	50/5x/6	60/5x/7
Max Heart Rate					
Stress Reduction Needs	Low Need	Some	Definite	High	Very High
Lipid Level Target					
Total Cholesterol	140	150	175	200	<225
LDL	60	70	80	<100	<125
HDL	35	37	39	41	>42

Physician's Signature:_____ Telephone:_____


FAX THIS FORM TO SALUS MEDIA: (805) 969-3601

You will receive Fax confirmation within 24 Hours. For Assistance please call: (805) 969-2234


HeartLand 67 Fig 3




HeartLand 68 Fig 4



HeartLand 69 Fig 5



HeartLand 70 Fig 6



PATIENT STATUS & GOALS: DETAILS			Now 2/10/98	1 month Goal	GOALS
Name / D.O.B.	Fred Smith	2-5-49			
Starting Date	2/1/98				
Heartland I.D.	23-642				
Height / Sex	6'9"	Male			
Weight	183		182	175	170
BMI	28.28		28.28	25.64	25.00
Smoke	.5	Packs/Day	.5	0	0
Physical Activity	0 / 0 / 0	minutes / x-week / RPE	20 / 3 / 3	25 / 6 / 4	4 / 6 / 6
Alcohol	2	Average Drinks per Day	2	1	1
Eating Habits	40	%Fiber/Cmplx Carb Intake	60	70	80
	40	%Fatty Food Intake	20	20	15
	40	%Fatty Dairy Intake	20	10	5
Calories	3,600		3,300	3,100	2,800
Fat Calories & %	45%		45%	20%	15%
Cholesterol - LDL	142		140 mg/dl	125 mg/dl	100 mg/dl
Cholesterol - HDL	35		37 mg/dl	39 mg/dl	45 mg/dl
Cholesterol	246	ml/dl	226	210	190
Resting Pulse Rate	88	Beats Per Minute	88	85	79
Stress	8.5	Scale of 1 to 10 (10 being high stress)	7.0	6.0	3.5
Depression		Scale of 1 to 10 (10 being greatest)	10	6	0
Blood Pressure	140/100	systolic/diastolic	140/100	130/90	130/90
Seatbelt Use	30	percent of time	50	75	100
Back Pain		Incidents per month	3	2	0
Pharmaceuticals					
- aspirin	325	mg	325 mg/da	325 mg/da	325 mg/da
- hydrochlorathzd.	12.5	mg	12.5 mg/da	12.5 mg/da	0 mg/da
- Lovastatin	20	mg	20 mg/da	20 mg/da	0 mg/da

70 Fig 7

HeartLand Patient Progress Report

Date: April 2, 1997

Dear Doctor **Cavello**:

This is a status report on your patient, **Fred Smith**, SSN: **565-76-2334**, Plan No. **011-066754**

Your diagnosis was: **non-complicated anterior MI** and co-morbid diagnosis **none**,

Patient entered the HeartLand program on . **March 12, 1997**. He/she has been on the program 3 weeks.

Progress toward goals:

Parameter	Current Status (66)	Suggested Next steps (67)	Target (68)
Blood Pressure	146/92	144/90	140/90
Weight	172	170	170
Resting Pulse	67	65	65
Exercise Program	35 min/4x-wk/4 RPE	45 min/4x-wk/5 RPE	45 min/6x-wk/6 RPE
Total Cholesterol	210 mg/dl	200 mg/dl	190 mg/dl
LDL Cholesterol	125mg/dl	115mg/dl	100mg/dl
HDL Cholesterol	39mg/dl	42mg/dl	45mg/dl
Diet: Cal/day	3100	3000	2800
Sat Fat grams/day	20 g	15 g	10 g
Smoking Status	0 was:.5 pack/day	0	0
Aspirin	325 mg - missed 1/wk	325 mg - missed 0/wk	325 mg - missed 0/wk
HCTZ	12.5 mg. - missed 0/wk	1205 mg. - missed 0/wk	12.5 mg. - missed 0/wk
Lovastatin	20 mg. - missed 0/wk.	20 mg. - missed 0/wk.	20 mg. - missed 0/wk.
Other			
Other			
Other			

Please initial here to indicate you have reviewed this Status Report: _____

69 ~ Please initial here to indicate you agree with suggested next step targets: _____

Indicate any changes desired in Next Step Goals and Medications:

_____

_____

Physician's Signature: _____

Thank you,

Mary Quinn
HeartLand Case Advisor

FAX THIS FORM TO SALUS MEDIA: FAX NO. (805) 969-3601
You will receive Fax confirmation within 24 Hours. For Assistance please call (805) 969-2234




Fig 8




Fig 4




Fig 10



Heartland
Heartland 05
TIME
GROUP
#
CITY
ACTIVITY
7:30 A.M. Movies 4 LA, CA Low
7:30 A.M. Dog Lovers 15 LA, CA High
7:30 AM Purr-fectionist 18 NYC, NY High
7:45 AM Just for Laughs 10 NYC, NY Med.
8:00 AM. Spartans 12 Chicgo, IL Med.
7:30 AM Travelers 5 LA, CA Low
7:45 A.M. Cool Set 8 LA, CA Low
7:45 A.M. Country Bumkins 12 Ithaca, NY Med.
7:30 A.M. City Slickers 8 NYC, NY Low
7:45 A.M. K9's 18 NYC, NY High
8:00 A.M. Water Babies 7 Dallas, Tx Med.

Fig 11




Fig 12




HeartLand 07
HeartLand
EMOTICONS ~ 100
Happy
Comprehending
More confident
confident
committed
Worried
anxious
Scared
Aware
Growing
Falling
Drifting
Angry
Sad
Depressed
VITAL SIGNS ~ 102
Heart Rate 82
Blood Pressure 160/98
Cholesterol 230
Diet
Y N
EXERCISE ~ 104
Y N
Walking
Stretching
Stress Mgmt.

Fig 13


Heartland
Log Window
CHAIRPERSON Good morning
CHAIRPERSON It's now 7:30 and the meeting should start Is there any business before I introduce the speaker?
It's now 7:30 and the meeting should start. Is there any business before I introduce the speaker?
CHAIR
96A
HeartLand 13
Fig 14
110
112
114
122
74
116



Heartland 36
Fig 15
136
Log Window
FRED: Hi Jean
FRED: What you shared in the meeting was very familiar to me
FRED: You see my wife thought that 'supporting' me was 'looking after' me.
NAVIGATOR
You see my wife thought that 'supporting' me was 'looking after' me.
134
132



Fig 16


Heartland
mail service
FROM: Bill
DATE: 06-27-99
TIME: 9:00 am
Dear Martha,
You spoke about a book which had helped you in dealing with the problem of maintaining a diet while traveling. I am not able to find it in the Library or in the travel agents. Would you please send me the title and author?
I was distressed to hear that your dog is not well. I have had doggy friends all my adult life and know just how attached one becomes. I will say a little prayer for "Patches" tonight and hope that by tomorrow's meeting he is improved.
warmest regards
Bill

Fig 17




Heartland
mail service
FROM: Harry
DATE: 06-27-99
TIME: 9:00 am
Dear Fred,
Thanks for the voice mail regarding the info. I spoke in today's meeting. Attached to this letter is a list of articles, books and videos I read regarding stress management. All of the information is available in the Heartland Village Library. If you have difficulties don't hesitate to call or write.
Best
Harry


Fig 18


HeartLand
HeartLand 11
Heartland
express mail
TO: Fred
FROM: Susan
DATE: 06-27-99
TIME: 9:00 am
Congratulations on your first 100 days in
the program. You sound great!

144A

Fig 19


Heartland
a mail
TO: Fred
FROM: Susan
DATE: 06-27-99
TIME: 9:00 am
Heartland
1464
Fig 20


Kitchen
HeartLand 23
Fig 21
150





HeartLand 24
HeartLand
SHOPPING LIST
low FaT
RECIPES
GUEST CHEF
152
154
156
158

Fig 22


Heartland 25 Fig 23



Heartland 30 Fig 24



HeartLand 27 Fig 25




WALKING
STRETCHING
STRENGTH TRAINING
HeartLand - 4
HeartLand
160
162
164

Fig 26

HeartLand : 8
Fig 27
Heartland
INNER THIGH, QUADRICEPS, AND HIP MUSCLES
Hip muscles need to be stretched to help avoid low back pain.
Quadriceps Stretch
Bring foot back toward gluteals
Standing Lunge
Keep knee in line with toe
Butterfly
Lean forward gently



HeartLand
Wall Push-Up
Push your body away from the wall
Chair Push-Up
Position chair so it won't slide
Knee Push-Up
Keep body straight from knees to shoulders
Toe Push-Up
Don't arch your back or lift your hips
Reverse Fly
Use shoulder and upper back muscles to lift weight to the side and up
Single Arm Row
Pull weight to shoulders, then ease to floor

Fig 28



Heartland 29
Heartland
Tranquility Park
Relaxation
Biofeedback
Yoga
140
142

Fig 29



Creating Your Sanctuary

One of the first things you should do when you start using creative visualization is to create a sanctuary within yourself where you can go anytime you want to. Your sanctuary is your ideal place of relaxation, tranquility, and safety and you can create it exactly as you want it.

Close your eyes and relax in a comfortable position. Imagine yourself in some beautiful natural environment. It can be anyplace that appeals to you . . . in a meadow, on a mountaintop, in the forest, beside the sea. It could even be under the ocean, or on another planet. Wherever it is, it should feel comfortable, pleasant, and peaceful to you. Explore your environment, noticing the visual details, the sounds and smells, any particular feelings or impressions you get about it.

Now do anything you would like to do to make the place more homelike and comfortable. You might want to build some type of house or shelter there, perhaps just surround the whole area with a golden light of protection and safety, create and arrange things there for your convenience and enjoyment, or do a ritual to establish it as your special place.

From now on this is your own personal inner sanctuary, to which you can return anytime just by closing your eyes and desiring to be there. You will always find it healing and relaxing to be there. It is also a place of special power for you, and you may wish to go there every time you do creative visualization.

You may find that your sanctuary spontaneously changes from time to time, or that you want to make changes and additions to it. You can be very creative in your sanctuary and have a lot of fun there . . . just remember to retain the primary qualities of peacefulness, tranquillity, and a feeling of absolute safety.

WO 99/03045

PCT/US98/14147

HeartLand 20 Fig 31





Fig 32

HeartLand 33 Fig 33



HeartLand 34 Fig 34

HeartLand 35 Fig 35



DETERMINING YOUR TARGET HEART RATE ZONE

1. Take your pulse on your neck or wrist.

2. Subtract your age from 220.

	220
	-40 Sample Age
Maximum heart rate	180

3. Multiply maximum heart rate by .55

	x.55
Lower heart rate limit	99


4. Multiply maximum heart rate by .85

	180
	x.85
Upper heart rate limit	153

5. Your target heart rate zone is definined by lower and upper heart rate limits.

TO SEE IF YOU ARE IN YOUR TARGET HEART RATE ZONE

Take your pulse for :10 seconds
and multiply that number by six.
This should be in your
Target Heart Rate Zone.



HeartLand 47 Fig 36





HELP
Journal
E-Mail
Group Meeting
Coffee Shop
Kitchen
Gym
Library
Tranquility Park
Travel Agency
Shopping
Video Conference
Ticker Tape...
Ticker Tape....
Ticker Tape....
Ticker Tape....
Instructions/Data Screen/Controls
(Click To Make Full Size)
Message or Video Screen
(Click To Make Full Size)
MAIN SCREEN
(Click To Make Full Size)
216
214
210
212

Fig 37


HeartLand 66 Fig 38



HeartLand 79 Fig 39



HeartLand 72 Fig 40



HeartLand 75 Fig 41







Fig 42


HeartLand 78
Administration — HeartLand
Provider/Case Advisor
File Edit View Insert Format Tools Table Window Help
MAIN MENU
BACK
HINT: CLICK ON CATEGORY SEE DETAIL
Graphic View: Patient Record Exercise
EXERCISE - Minutes
EXERCISE - # of times/week
RPE
Date - Weekly
2/10/98 2/17/98 2/24/98 3/2/98 3/9/98


HeartLand 76 Fig 43




HeartLand 77 Fig 44




HeartLand 73 Fig 45



HeartLand '74 Fig 46




HeartLand 60 Fig 47






HeartLand 49 Fig 48



NAVIGATOR
VC
PP
Payor/Employer
Provider/Case
Administration — HeartLand
HealthPlan Payor/Employer
File Edit View Insert Format Tools Table Window Help
HeartLand Payor/Employer Main Menu
BACK
TENET
Administration — HeartLand
VIEW COMPLIANCE STATUS
PERFORM CASE MANAGEMENT REVIEW
PERFORM UTILIZATION REVIEW
REVIEW OUTCOMES
COMMUNICATE
348
350
352
354
356
358

HeartLand 52 Fig 50




Category	Description	Total Eligible	Participating No. eligible	Participating Pct. eligible	Compliant No.	Compliant Pct.	Probation No.	Probation Pct.	Terminated No.	Terminated Pct.
Category I	Current-Year MI Survivors	1,009	105	10.4%	87	82.9%	13	12.4%	5	4.8%
Category II	Current-Year Bypass & Angioplasty	733	76	10.4%	59	77.6%	10	13.2%	7	9.2%
Category III	Current-Year Diagnosed CAD, Surgery Rec	740	71	9.6%	63	88.7%	5	7.0%	3	4.2%
Category IV	All Diagnosed Angina	6,726	708	10.5%	553	78.1%	84	11.9%	71	10.0%
Category V	Prior-Years' MI & Post-Surgical - High Risk	2,183	680	31.1%	585	86.0%	38	5.6%	57	8.4%
Category VI	Prior-Years' MI & Post-Surgical - Low Risk	6,547	227	3.5%	187	82.4%	22	9.7%	18	7.9%
Category VII	(2 or more factors)	75,826	3,191	4.2%	2,765	86.6%	148	4.6%	278	8.7%
Category VIII	Wellness Program	125,714	7,920	6.3%	6,267	79.1%	1,359	17.2%	294	3.7%
Grand Totals & Percent Averages			12,978		10,566	81.4%	1,679	12.9%	733	5.6%

HeartLand 53 Fig 51



Category	Description	Number on Program	Heartland Group Medical Costs	Heartland Program Costs	TOTAL HEARTLAND COSTS	Control Group Medical Costs	Heartland Savings
Category I	Current-Year MI Survivors	105	253,385	181,850	435,015	589,221	154,208
Category II	Current-Year Bypass & Angioplasty	76	140,678	122,360	263,036	327,153	64,117
Category III	Current-Year Diagnosed CAD, Surgery Rec	77	240,702	133,210	373,912	559,772	185,860
Category IV	All Diagnosed Angina	708	1,139,172	1,047,840	2,187,012	2,649,237	462,225
Category V	Prior-Years' MI & Post-Surgical - High Risk	680	1,640,840	1,006,400	2,647,240	3,815,907	1,168,867
Category VI	Prior-Years' MI & Post-Surgical - Low Risk	227	420,177	197,490	617,667	977,158	359,489
Category VII	(2 or more factors)	3,191	2,003,948	717,975	2,721,923	4,680,344	1,938,421
Category VIII	Wellness Program	7,920	2,304,720	-	2,304,720	5,359,814	3,055,094
TOTALS		12,984	8,143,600	3,406,925	11,550,525	18,938,605	7,388,080


HeartLand 55
Fig 52
Administration — HeartLand
NAVIGATOR
VC PP Payor/Employer Provider/Case
HealthPlan Payor/Employer
File Edit View Insert Fgmail Tools Table Window Help
MAIN MENU
BACK
HINT: CLICK ON CATEGORY SEE DETAIL
HeartLand Case Review
390
Administration — Heartland
The patient you have chosen for review
HAS
HAS NOT
signed a limited waiver of confidentiality.
The following information reflects this choice.
CONTINUE...
392

HeartLand 56 Fig 53 400







Fig 54


HeartLand 60
Administration — HeartLand
NAVIGATOR
VC PP Payor/Employer Provider/Case
HealthPlan Payor/Employer
File Edit View Insert Format Tools Table Window Help
MAIN MENU
BACK
HeartLand Case Management Review
HINT: CLICK ON CATEGORY SEE DETAIL
Chosen case for review: Fred Smith
Date: 3/10/98
HeartLand I.D. #: 23-642
Social Security #: 213-48-3947
CASE vs. NORM
Case Number 23-642
Last Updated 2/27/98
Weeks on HeartLand 4
Dollars
$9,000
$8,000
$7,000
$6,000
$5,000
$4,000
$3,000
$2,000
$1,000
0
923
1380
6573
6876
Heartland Costs
Health Service Costs
Total Case Costs
Savings
Control Costs
Costs to Date

HeartLand 62 Fig 55




HeartLand 65 Fig 56



Group or Facility	ID No.	Specialty	YTD CAD Cases	Percent referred to Heartland	Percent Heartland vs. norm
Central Valley IPA	8224	Primary	28	22.90%	-0.10%
Baywatch Phys & Sur	9732	Cardio	127	16.70%	-6.30%
Fulton Cty. Cardiolog.	5376	Cardio	89	24.50%	1.50%
Care Fndn of Clovis	8479	Primary	52	23.50%	0.50%
Riverside Primary Care	6745	Primary	77	18.80%	-4.20%

HeartLand 64 Fig 57



Perform Healthplan Utilization Review

Physician	ID No.	Specialty	YTD CAD Cases	YTD norm is 17.3% Percent Heartland	Percent Heartland vs. norm
Moeller, J	66537	Cardio	30	15.6%	-2.2%
King, S	29873	Cardio	38	32.6%	+1.4%
Carvell, C	89721	Primary	16	12.0%	-4.3%
Richards, B	52983	Primary	42	18.7%	+1.4%

HeartLand 63 Fig 58





Fig 59


524
Network Administrator
508
512
Internet
Code Manager PC
Printer
CD-ROM
modem
Database
516
Outer circle server
514
Inner circle server
520
Health Plan Payor PC
Internet
Firewall
517
Meeting Server
510
Transaction Server
Database
504
502
506
Internet
518
Patient/Subscriber PC
500



START
PHYSICIAN ON-LINE
1000
YES
NO
PHYSICIAN ENTER PATIENT HEALTH INFO ON-LINE
1002
FILL OUT PRESCRIPTION FORM
1004
FAX FORM TO CASE ADMIN.
1006
CASE ADMIN. ENTER PATIENT HEALTH INFO. ON-LINE
1008
SET UP THERAPEUTIC PROGRAM/PROTOCOLS FOR PATIENT
1010
PHYSICIAN VERIFY/MODIFY PROGRAM
1012
PROGRAM O.K.
SYSTEM MOTIVATE COMPLIANCE WITH PROGRAM
1020
PATIENT ENTER UPDATED HEALTH INFO.
1032
PERIODICALLY ENTER UPDATED PATIENT HEALTH INFO.
1030
PHYSICIAN/ CASE ADVISOR ENTER UPDATED PAT. HEALTH INFO
1034
CASE ADVISOR PERIOD. REVIEW PATIENT DATA
1036
ALARM VALUE?
1040
YES
1042
NOTIFY PHYSICIAN CASE ADVISOR IMMEDIATELY
NO.
PATIENT COMPLYING WITH PROGRAM
1050
1044
PHYSICIAN/ CASE ADVISOR NOTIFY PATIENT
MODIFY PROGRAM
NO
YES
YES
NO.
INFORM PHYSICIAN, CASE ADVISOR/ HEALTH PLAN PRIOR
1052
1062
1054
PATIENT MET PROGRAM END GOALS
NOTIFY PHYSICIAN/ CASE ADVISOR
1064
PATIENT REMAIN ON SYSTEM?
YES
1066
MODIFY PROGRAM/ PROVIDE ADDITIONAL SUPPORT
NO
YES
NO
1068
END PROGRAM
END PROGRAM/ MOVE PATIENT TO DIFF. DIAG. CATEGORY
1056

FIG. 60

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/14147

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :G06F 15/00
US CL :128/920; 600/300

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 128/897, 898, 920, 921, 923; 600/300, 301; 704/251, 501, 504; 705/2-4

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	US 5,673,691 A (ABRAMS et al) 07 October 1997, col. 3 line 34 to col. 6 line 56.	1, 3
A	US 5,612,869 A (LETZT et al) 18 March 1997, entire document.	1-35
A	US 5,301,105 A (CUMMINGS, JR.) 05 April 1994, entire document.	1-35
A	US 5,377,258 A (BRO) 27 December 1994, entire document.	1-35

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search
11 SEPTEMBER 1998

Date of mailing of the international search report
15OCT1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer
ERIC F. WINAKUR

Telephone No. (703) 308-3940

Form PCT/ISA/210 (second sheet)(July 1992)★

UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC PAYMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
17/499,725	**03/06/2024 05:22:43 PM Z ET**	**DHP-P0001CIP1**

Title of Invention

SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	-
CONFIRMATION #	9953	FILED BY	Ashlyn Nguyen
PATENT CENTER #	64578866	AUTHORIZED BY	Brian Owens
CUSTOMER #	133690	FILING DATE	10/12/2021
CORRESPONDENCE ADDRESS	-	FIRST NAMED INVENTOR	Nathaniel T. Bradley

Payment Information

PAYMENT METHOD	PAYMENT TRANSACTION ID	PAYMENT AUTHORIZED BY
DA / 506801	**E202436H23546213**	**Ashlyn Nguyen**

FEE CODE	DESCRIPTION	ITEM PRICE($)	QUANTITY	ITEM TOTAL($)
2252	EXTENSION FOR RESPONSE WITHIN SECOND MONTH -	256.00	1	256.00
2801	REQUEST FOR CONTINUED EXAMINATION (RCE) - 1ST REQUEST (SEE 37 CFR 1.114)	544.00	1	544.00
			TOTAL AMOUNT:	**$800.00**

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
17/499,725	**03/06/2024 05:22:43 PM Z ET**	**DHP-P0001CIP1**

Title of Invention

SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	-
CONFIRMATION #	9953	FILED BY	Ashlyn Nguyen
PATENT CENTER #	64578866	FILING DATE	10/12/2021
CUSTOMER #	133690	FIRST NAMED INVENTOR	Nathaniel T. Bradley
CORRESPONDENCE ADDRESS	-	AUTHORIZED BY	Brian Owens

Documents

TOTAL DOCUMENTS: 4

DOCUMENT		PAGES	DESCRIPTION	SIZE (KB)
DHP-P0001CIP1_17499725_FILED-RCE-RESPONSE_3-6-24.pdf		11	-	232 KB
DHP-P0001CIP1_17499725_FILED-RCE-RESPONSE_3-6-24-AMSB.pdf	(1-1)	1	Amendment Submitted/Entered with Filing of Continued Prosecution Application (CPA)/Request for Continued Examination(RCE)	162 KB
DHP-P0001CIP1_17499725_FILED-RCE-RESPONSE_3-6-24-CLM.pdf	(2-7)	6	Claims	169 KB
DHP-	(8-11)	4	Applicant Arguments/Remarks	220 KB

P0001CIP1_17499725_FILED-RCE-RESPONSE_3-6-24-REM.pdf		Made in an Amendment	
DHP-P0001CIP1_17499725_FILED-RCE-TRANSMITTAL_3-6-24.pdf	3	Request for Continued Examination (RCE)	1642 KB

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)
DHP-P0001CIP1_17499725_FILED-RCE-RESPONSE_3-6-24.pdf	E69560446643D3618B037FE01160C10DEE28D65D592A9A067257AEF64B08D5B883991BAC52DA855F456F57A71A78C5A5BE1C2D846C7E5E6B3D76B1129A886113
DHP-P0001CIP1_17499725_FILED-RCE-RESPONSE_3-6-24-AMSB.pdf	13C751157CE430574BE650541F9C1D61B6E81A63858BF1808D4A77323A051062132163DD668B3469BF4C338183CC6E8A5E10223E2AF5E98EE6B2878ADE3C8833
DHP-P0001CIP1_17499725_FILED-RCE-RESPONSE_3-6-24-CLM.pdf	4541CFD0185C46868B307D0EFFEC2089404E910D1E7097C31CEB3C336007C90A550A10F899ABC487F9C2DF3DE8C89D345D04CC1F6390950E657FD6DCFEDF0400
DHP-P0001CIP1_17499725_FILED-RCE-RESPONSE_3-6-24-REM.pdf	AF2F9B8AE0FA01258827A53C780DB14E255DAF6C6B060FC37BC5912D3707B4D6DF11BDCDF693D90E1A1BF88DEE127EBA9A36A77CA7802F15624F5BF20D194371
DHP-P0001CIP1_17499725_FILED-RCE-TRANSMITTAL_3-6-24.pdf	83D600534C1BEBC3582E9CFC121569F6AF1F8A4F6DD2B536BDD24D57D56C9A309E73EC0C803E0AE16C102DA77FDB054C12D012B134B4A6CC8E8A4108C1E90ECB

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Attorney Docket No.
DHP-P0001CIP1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of: Bradley et al. **Application No.** 17/499,725 **Filing Date:** October 12, 2021 **For:** SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	**Confirmation No.** 9953 **Group Art Unit:** 2156 **Examiner:** Christopher J RAAB

AMENDMENT ACCOMPANYING A REQUEST FOR CONTINUED EXAMINATION (RCE)

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

VIA EFS-WEB

Commissioner:

In reply to the Final Office Action mailed October 6, 2023, a Request for Continued Examination has been submitted. With due respect, please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims in this paper.

Remarks follow the amendments section of this paper.

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

Claim 1 (Currently Amended): A method for tracking goal progression, the method comprising:

receiving input establishing clients, wherein the clients are individuals receiving treatment or assistance, and wherein the data associated with the clients is stored in a server available through one or more networks;

assigning each of the clients to one or more of the providers in response to selections from an administrator, wherein the one or more providers include at least individuals available to treat or assist each of the clients and one or more biometric devices associated with each of the clients;

establishing goals and a baseline for each of the clients and thresholds associated with each of the goals;

automatically compiling data associated with each of the clients received from the one or more providers including at least the one or more biometric devices in the server;

determining whether the goals are being met in response to the baseline and the thresholds for the compiled data; and

automatically communicating alerts in response to the compiled data varying from ~~a~~ one of the thresholds to become significant for one or more of the clients.

Claim 2 (Original): The method according to claim 1, wherein the server is accessed

through a cloud network, and wherein a client management program is executed by communications devices utilized by the one or more providers to receive the data and track progress of the goals.

Claim 3 (Original): The method according to claim 1, further comprising:

intervening with the one or more of the clients in response to the alerts.

Claim 4 (Original): The method according to claim 3, wherein the intervening is performed by the one or more providers.

Claim 5 (Original): The method according to claim 1, wherein each of the goals is associated with a plan of action for achieving each of the goals.

Claim 6 (Original): The method according to claim 1, further comprising:

establishing a baseline for the goals of the clients.

Claim 7 (Original): The method according to claim 1, wherein the goals are established by the clients and the one or more providers.

Claim 8 (Original): The method according to claim 1, further comprising:

determining whether modifications to the goals are required in response to the compiled data.

Claim 9 (Original): The method according to claim 8, further comprising:

modifying the goals in response to the compiled data.

Claim 10 (Original): The method according to claim 8, wherein modifications are determined to be required if the one of the clients is unable to achieve the goals associated with the client.

Claim 11 (Currently Amended): A system for tracking goal progression, the system comprising:

a server communicates with communications devices through a transceiver utilizing one or more networks, the server includes a processor that executes a client management program to:

receive input establishing a client, wherein the client is a individual receiving treatment or assistance, and wherein an account associated with the client is stored in a server available through one or more networks;

assign the client to one or more of the providers in response to selections from an administrator, wherein the one or more providers include at least individuals available to treat or assist the client and one or more biometric devices associated with the client;

establish goals and a baseline for the client and thresholds associated with each of the goals;

automatically compile data associated with the client received from the one or more providers including at least the one or more biometric devices in the server;

determine whether the goals are being met in response to thresholds for the compiled data; and

automatically communicate alerts in response to the compiled data varying from ~~a~~one of the threshold~~s~~ to become significant for the client; and

a database in communication with the server configured to store at least the data, goals, and thresholds associated with the client and the one or more providers.

Claim 12 (Original): The system according to claim 11, wherein the communications devices receive the data from the one or more providers.

Claim 13 (Original): The system according to claim 11, wherein the alerts indicate that the one or more providers are to intervene with the client.

Claim 14 (Original): The system according to claim 11, wherein each of the goals is associated with a plan of action for achieving each of the goals.

Claim 15 (Original): The system according to claim 11, wherein the goals are established by the client and the one or more providers.

Claim 16 (Original): The system according to claim 11, wherein the client management program is further executed to:

determine whether modifications to the goals are required in response to the compiled data indicating the goals are not achievable; and

modify the goals in response to the compiled data indicating the goals are not achievable.

Claim 17 (Currently Amended): A server comprising:

a processor for executing a set of instructions; and

a memory for storing the set of instructions, wherein the set of instructions are executed by the processor to:

receive input establishing clients receiving assistance, wherein the clients are individuals receiving treatment or assistance, and wherein the accounts are stored in a server available through one or more networks;

assign each of the clients to one or more of the providers in response to selections from an administrator, wherein the one or more providers include at least individuals available to treat or assist each of the clients and one or more biometric devices associated with each of the clients;

establish goals and a baseline for each of the clients and thresholds associated with each of the goals;

automatically compile data associated with each of the clients received from the one or more providers including at least the one or more biometric devices in the server;

determine whether the goals are being met in response to the baseline and thresholds for the compiled data; and

automatically communicate alerts in response to the compiled data varying from ~~a~~one of the threshold**s** to become significant for one or more of the clients.

Claim 18 (Original): The server according to claim 17, wherein the set of instructions are further executed to:

physically intervene with the one or more of the clients in response to the alerts, wherein the physical intervention is performed by the one or more providers.

Claim 19 (Original): The server according to claim 17, wherein each of the goals is associated with a plan of action for achieving each of the goals, wherein the goals are established by the client and the one or more providers.

Claim 20 (Previously presented): The server according to claim 17, wherein the set of instructions are further executed to:

determine whether modifications to the goals are required in response to the compiled data; and

modify the goals in response to determining the modifications to the goals are required.

REMARKS

In the Final Office Action, the Examiner took the following actions:

I. Claims 1 – 20 are rejected on the ground of nonstatutory double patenting over claims 1 – 20 of prior U.S. Patent No. 10,061,812; and

II. Claims 1 – 20 are rejected under 35 U.S.C. 103 as being unpatentable over Luttrell (US PGPub 2003/0004758), in view of Shaanan et al. (US PGPub 2015/0205930), hereinafter "Shaanan".

The Final Office Action may contain statements characterizing the related art and/or the claims. Regardless of whether any such statement is expressly identified and/or discussed herein, Applicant reserves the right to disagree with any such statement or characterization in the Final Office Action.

Applicant amends claims 1, 11, and 17 without prejudice or disclaimer of its subject matter. Support for the amendments may be found in at least the specification, Figures, and at least paragraphs [0237-238, 0254]. Claims 1-20 remain pending and under examination. For at least the following reasons, Applicant respectfully requests reconsideration and withdrawal of the rejections.

Double Patenting

Claims 1 – 20 are rejected on the ground of nonstatutory double patenting over claims 1 – 20 of prior U.S. Patent No. 10,061,812. Applicants are willing to address this rejection once allowable subject matter is reached.

Claim Rejections - 35 USC § 103

Claims 1 – 20 are rejected under 35 U.S.C. 103 as being unpatentable over Luttrell (US PGPub 2003/0004758), in view of Shaanan et al. (US PGPub 2015/0205930), hereinafter "Shaanan". This rejection is respectfully traversed.

The Examiner bears the burden of establishing a prima facie case of obviousness based on the prior art when rejecting claims under 35 U.S.C. §103. In re Fritch, 972 F.2d 1260, 23 U.S.P.Q.2d 1780 (Fed. Cir. 1992). When evaluating claims for obviousness under 35 U.S.C. 103, all the limitations of the claims must be considered and given weight. Ex parte Grasselli, 231 USPQ 393 (Bd. App. 1983) aff'd mem. 738 F.2d 453 (Fed. Cir. 1984) (emphasis added).

With regard to claim 1, Luttrell and Shaanan does not teach, suggest, or disclose "automatically compiling data associated with each of the clients received from the one or more providers including at least the one or more biometric devices in the server." The recited portion of Luttrell teaches the following:

[0058] A processor (102) and associated storage (101) and memory (102) are employed in communication with suitable interactive interface (such as client display 103, keyboard 104, mouse 105, scanner 106, and pen/touch-sensitive screen 108 at the host location 100) or other interface such as laser terminal, diskette-, CD-, or tape-drive, or other interface for accepting electronic data from temporary storage or temporary memory of portable computer 94C at the treatment location, for entry of data into designated searchable data fields for automatic compilation of current treatment session data with any prior treatment information to create records for each patient for which biographical-type information has been entered. The technique and system of the invention incorporate the unique features embodied especially within and between 99, 100, 110, for automatically generating reports requested by a multitude of separate payors from whom payment is eventually sought by the provider once treatment has been rendered. As a result of each treatment session, each identified goal (whether generated at this treatment session or as a result of a prior session) will have a Treatment Record 96A-96C generated therefor (such as those depicted in FIG. 3) interconnecting all progress made by the patient associated with a respective identified

goal during the current treatment session. A diagrammatic representation 80 of sample records generated in association with a treatment session, or visit, is shown in FIG. 7B. FIG. 1 graphically illustrates the interconnection of displays and reports which one may generate and submit, automatically (such as by way of LAN, WAN, modem into and through the Internet, etc.) to an entity such as a prospective payor for payment, whether as a hardcopy for filing with the provider's patient records or as electronic data. (Luttrell, [0058], emphasis added)

Luttrell appears to teach the manual process of "entry of data into designated searchable data fields for automatic compilation of current treatment session data." Luttrell does not appear to teach "automatically compiling" as included in the claim language. For at least this reason, the rejection of claim 1 is allowable over Luttrell and Shaanan.

The independent claims are also further amended to distinguish the claims from the cited art.

Independent claims 11 and 17 are allowable for at least the same reasons as claim 1. Claims 2-10, 12-16, and 18-20 are allowable at least based on their dependence on claims 1, 11, and 17, respectively.

Applicants respectfully request an Examiner interview to move forward prosecution and to discuss the art of record.

CONCLUSION

In view of the foregoing, Applicant respectfully requests reconsideration of this application and the timely allowance of the pending claims.

This amendment accompanies the filing of a first Request for Continued Examination (RCE). Please charge Deposit Account No. 506801 the amount of $544 (small) for the RCE per the attached transmittal. This is a request for a two month extension of time, the small entity fee of $256 for which is being paid at the time of filing this response. Please grant any extensions of time required to enter this response. No additional fees are believed due; however, the Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, to fees to Deposit Account 506801.

Respectfully submitted,

Goodhue, Coleman & Owens, P.C.

Dated: March 6, 2024

By: /Brian D. Owens/
Brian Dean Owens
Reg. No. 55517
(515) 218-7888

PTO/SB/30EFS (01-22)
Approved for use through 05/31/2024. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

REQUEST FOR CONTINUED EXAMINATION(RCE)TRANSMITTAL
(Submitted Only via EFS-Web)

Application Number	17/499,725	Filing Date	2021-10-12	Docket Number (if applicable)	DHP-P0001CIP1	Art Unit	2156
First Named Inventor	Nathaniel T. Bradley			Examiner Name	Christopher J RAAB		

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.
Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. The Instruction Sheet for this form is located at WWW.USPTO.GOV

SUBMISSION REQUIRED UNDER 37 CFR 1.114

Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).

☐ Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.

- ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____
- ☐ Other _____

☒ Enclosed

- ☒ Amendment/Reply
- ☐ Information Disclosure Statement (IDS)
- ☐ Affidavit(s)/ Declaration(s)
- ☐ Other _____

MISCELLANEOUS

☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months _____ (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)

☐ Other _____

FEES

☒ **The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.**
The Director is hereby authorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No 506801

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

☒ Patent Practitioner Signature

☐ Applicant Signature

PTO/SB/30EFS (01-22)
Approved for use through 05/31/2024. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Signature of Registered U.S. Patent Practitioner			
Signature	/Brian D. Owens/	Date (YYYY-MM-DD)	2024-03-06
Name	Brian Dean Owens	Registration Number	55517

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875	Application or Docket Number 17/499,725	Filing Date 10/12/2021	☐ To be Mailed

ENTITY: ☐ LARGE ☑ SMALL ☐ MICRO

APPLICATION AS FILED - PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA		RATE ($)	FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A		N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A		N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A		N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*		x $50 =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*		x $240 =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).				
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))					
* If the difference in column 1 is less than zero, enter "0" in column 2.				TOTAL	

APPLICATION AS AMENDED - PART II

		(Column 1)		(Column 2)	(Column 3)			
AMENDMENT	03/06/2024	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	* 20	Minus	** 20	= 0		x $40 =	0
	Independent (37 CFR 1.16(h))	* 3	Minus	*** 3	= 0		x $192 =	0
	☐ Application Size Fee (37 CFR 1.16(s))							
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							
							TOTAL ADD'L FEE	0

		(Column 1)		(Column 2)	(Column 3)			
AMENDMENT		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	*	Minus	**	=		x $0 =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=		x $0 =	
	☐ Application Size Fee (37 CFR 1.16(s))							
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							
							TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.	LIE
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".	/BRENDA V HARRISON/
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".	
The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.	

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
17/499,725	10/12/2021	2156	830	DHP-P0001CIP1	20	3

CONFIRMATION NO. 9953

CORRECTED FILING RECEIPT

133690
Goodhue, Coleman & Owens, P.C.
12951 University Ave
Suite 201
Clive, IA 50325

OC000000064830639

Date Mailed: 11/21/2023

Receipt is acknowledged of this non-provisional utility patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF FIRST INVENTOR, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection.

Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a corrected Filing Receipt, including a properly marked-up ADS showing the changes with strike-through for deletions and underlining for additions. If you received a "Notice to File Missing Parts" or other Notice requiring a response for this application, please submit any request for correction to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections provided that the request is grantable.

Inventor(s)

Nathaniel T. Bradley, Tucson, AZ;
James Gaynor, Winchester, VA;
Joshua S. Paugh, Tucson, AZ;
Paul Arena, Malibu, CA;
Lisa A. Marshall, Richmond, VA;

Applicant(s)

Data Health Partners, Inc., Beverly Hills, CA;

Assignment For Published Patent Application

Data Health Partners, Inc., Beverly Hills, CA

Power of Attorney: The patent practitioners associated with Customer Number 133690

Domestic Priority data as claimed by applicant

This application is a CON of 16/141,471 09/25/2018 PAT 11,144,554
which is a CIP of 16/053,141 08/02/2018 PAT 11,151,142
which is a CON of 14/212,429 03/14/2014 PAT 10,061,812
which claims benefit of 61/791,218 03/15/2013

Foreign Applications for which priority is claimed (You may be eligible to benefit from the Patent Prosecution Highway program at the USPTO. Please see http://www.uspto.gov for more information.) - None.
Foreign application information must be provided in an Application Data Sheet in order to constitute a claim to foreign priority. See 37 CFR 1.55 and 1.76.

Permission to Access Application via Priority Document Exchange: Yes

Permission to Access Search Results: Yes

Applicant may provide or rescind an authorization for access using Form PTO/SB/39 or Form PTO/SB/69 as appropriate.

If Required, Foreign Filing License Granted: 11/20/2023

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 17/499,725**

Projected Publication Date: 02/03/2022

Non-Publication Request: No

Early Publication Request: No

**** SMALL ENTITY ****

Title

SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION

Preliminary Class

707

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4258).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to promote and facilitate business investment. SelectUSA provides information assistance to the international investor

community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states, and regions competing for global investment; and counsels U.S. economic development organizations on investment attraction best practices. To learn more about why the United States is the best country in the world to develop technology, manufacture products, deliver services, and grow your business, visit http://www.SelectUSA.gov or call +1-202-482-6800.

UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
17/499,725	**11/17/2023 03:56:26 PM Z ET**	**DHP-P0001CIP1**

Title of Invention

SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	-
CONFIRMATION #	9953	FILED BY	Ashlyn Nguyen
PATENT CENTER #	63302369	FILING DATE	10/12/2021
CUSTOMER #	133690	FIRST NAMED INVENTOR	Nathaniel T. Bradley
CORRESPONDENCE ADDRESS	-	AUTHORIZED BY	Brian Owens

Documents

TOTAL DOCUMENTS: 1

DOCUMENT	PAGES	DESCRIPTION	SIZE (KB)
CorrectedADS.pdf	3	Application Data Sheet to update/correct info	75 KB

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)
CorrectedADS.pdf	2F2454ED0CCAE60C0931EDB31AB993D783D85621C59363F76EC2DD63BC7333A83BC75106A16497432D21DC1F2EDA81E0F7C4A700F989E5731D21EC7FE86750B3

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized

by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC PAYMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
17/499,725	**11/17/2023 03:56:26 PM Z ET**	**DHP-P0001CIP1**

Title of Invention

SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	-
CONFIRMATION #	9953	FILED BY	Ashlyn Nguyen
PATENT CENTER #	63302369	AUTHORIZED BY	Brian Owens
CUSTOMER #	133690	FILING DATE	10/12/2021
CORRESPONDENCE ADDRESS	-	FIRST NAMED INVENTOR	Nathaniel T. Bradley

Payment Information

PAYMENT METHOD	PAYMENT TRANSACTION ID	PAYMENT AUTHORIZED BY
DA / 506801	**E2023AGG01026528**	**Brian Owens**

FEE CODE	DESCRIPTION	ITEM PRICE($)	QUANTITY	ITEM TOTAL($)
2830	PROCESSING FEE, EXCEPT IN PROVISIONAL APPLICATIONS	56.00	1	56.00
			TOTAL AMOUNT:	**$56.00**

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

Corrected Application Data Sheet

17499725 : SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION

~~Strike through~~ indicates removal of data from existing record Underline indicates new data being added to the application If no data is shown, no data has been corrected

Inventor Information

Data of record	Updated Data

No data change in this section

Application Information

Title of Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION
Attorney Docket Number	DHP-P0001CIP1
Entity Status	Small

Domestic Benefit/National Stage Information

This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, or 365(c), 386(c), or indicate National Stage entry from a PCT application. Providing benefit claim information in the Application Data Sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78(a)(2) or CFR 1.78(a)(4), and need not otherwise be made part of the specification.

	Updated Data

Data of record

No data change in this section

Foreign Priority Information

This section allows for the applicant to claim benefit of foreign priority and to identify any prior foreign application for which priority is not claimed. Providing this information in the Application Data Sheet constitutes the claim for priority as required by 35 U.S.C. 119 (b) and 37 CFR 1.55. When priority is claimed to a foreign application that is eligible for retrieval under the priority document exchange program (PDX) the information will be used by the Office to automatically attempt retrieval pursuant to 37 CFR 1.55(i)(1) and (2). Under the PDX program, applicant bears the ultimate responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1).

Data of record	Updated Data

No data change in this section

Applicant Information

The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR 1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46.

Data of record	Updated Data
Data Health Partners, Inc. --- --- ~~Los Angeles, CA 90064~~ UNITED STATES Phone : --- Email : --- Fax : --- Organization Applicant type : Assignee	8549 Wilshire Blvd Suite 2403 Beverly Hills, CA 90211

Assignee Information including Non-Applicant Assignee Information

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

Data of record	Updated Data
Data Health Partners, Inc. --- --- ~~Los Angeles, CA 90064~~ UNITED STATES Phone : --- Email : --- Fax : --- Organization	8549 Wilshire Blvd Suite 2403 Beverly Hills, CA 90211

Signature

NOTE:

This Application Data Sheet must be signed in accordance with 37 CFR 1.33(b).

This Application Data Sheet **must** be signed by a patent practitioner if one or more of the applicants is a **juristic entity** (e.g., corporation or association). If the applicant is two or more joint inventors, this form must be signed by a patent practitioner, **all** joint inventors who are the applicant, or one or more joint inventor-applicants who have been given power of attorney (e.g., see USPTO Form PTO/AIA/81) on behalf of **all** joint inventor-applicants.

See CFR 1.4(d) for the manner of making signatures and certifications.

Signature	First name	Last name	Registration #	Date
/Brian D. Owens/	Brian	Owens	55517	11/17/2023

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/499,725	10/12/2021	Nathaniel T. Bradley	DHP-P0001CIP1	9953

133690 7590 10/06/2023

Goodhue, Coleman & Owens, P.C.
12951 University Ave
Suite 201
Clive, IA 50325

EXAMINER	
RAAB, CHRISTOPHER J	

ART UNIT	PAPER NUMBER
2156	

NOTIFICATION DATE	DELIVERY MODE
10/06/2023	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USPTO@dockettrak.com
docketing@goodhue.com
eofficeaction@appcoll.com

Office Action Summary	Application No. 17/499,725	Applicant(s) Bradley et al.	
	Examiner CHRISTOPHER J RAAB	Art Unit 2156	AIA (FITF) Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTHS FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☑ Responsive to communication(s) filed on 09/28/2023.

☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2a)☑ This action is **FINAL.** 2b) ☐ This action is non-final.

3)☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

4)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims*

5) ☑ Claim(s) 1-20 is/are pending in the application.

5a) Of the above claim(s) _____ is/are withdrawn from consideration.

6) ☐ Claim(s) _____ is/are allowed.

7) ☑ Claim(s) 1-20 is/are rejected.

8) ☐ Claim(s) _____ is/are objected to.

9) ☐ Claim(s) _____ are subject to restriction and/or election requirement

* If any claims have been determined allowable, you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to **PPHfeedback@uspto.gov.**

Application Papers

10)☐ The specification is objected to by the Examiner.

11)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

a)☐ All b)☐ Some** c)☐ None of the:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

** See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)

2) ☐ Information Disclosure Statement(s) (PTO/SB/08a and/or PTO/SB/08b) Paper No(s)/Mail Date _____.

3) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date _____.

4) ☐ Other: _____.

DETAILED ACTION

Notice of Pre-AIA or AIA Status

01. The present application is being examined under the pre-AIA first to invent provisions.

Response to Amendment

02. This action is in response to Applicant's amendment filed on **09/28/2023**. **Claims 1 – 20** are pending in the present application.

Applicant's arguments and amendments are considered but are not persuasive.

This action is made final.

Response to Arguments

03. Applicant argues that not all claimed limitations are disclosed by the prior art references, Luttrell and Shaanan. Namely, Applicant argues that the prior art does not teach the newly amended claim limitation of "baseline" for each of the clients. Examiner respectfully disagrees. First off, the only argument made by Applicant is that the prior art does "not appear to teach a baseline for each of the clients as recited by Applicants". There is no specific argument presented as to why the prior art doesn't teach this limitation, so there is no specific argument to respond to. Secondly, Examiner contends that the prior art does teach this claim limitation.

The claims have been amended to recite that a baseline is established for the clients. There is no definition in the claims as to what a baseline is, so it is assumed

that this word is taking on a generally known definition in this context, which would be where the client starts or what their initial state is. As an example, if the client is wishing to be able to reach a specific goal, this "baseline" would be the starting point for the client. This is something that is taught by both Luttrell and Shaanan. Luttrell teaches that when a patient comes in to receive health services, that an evaluation is performed on the patient. This includes the current condition or state of the patient, which could include their medical conditions and what level they are at. This is seen throughout Luttrell, as a patient is assigned a patient condition by way of a (initial) evaluation. For example, paragraph [0003] discusses how a patient is evaluated, either initially and/or at different times; paragraph [0007] explains that an evaluation is performed for a client based on their current condition; Figure 2A shows that the evaluation record is stored for the patient; and paragraph [0027] explains how an evaluation is performed on a patient either initially or at each session. Furthermore, and although not specifically relied upon in the rejection of the claims, Shaanan teaches that initial information about the patient, such as medical conditions, is determined and stored for the patients (paragraph [0062]). Therefore the prior art discloses all of the Applicant's claimed limitations, and specifically a "baseline" for the client. If "baseline" is taking on a more specific or different definition then that which Examiner has relied upon it to take, Examiner requests clarification as to what baseline means, as well as where support for that definition is in the specification.

Double Patenting

04. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the claims at issue are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the reference application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP §§ 706.02(l)(1) - 706.02(l)(3) for applications not subject to examination under the first inventor to file provisions of the AIA. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).

The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/forms/. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA/25, or PTO/AIA/26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to http://www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp.

05. **Claims 1 – 20** are rejected on the ground of nonstatutory double patenting over claims 1 – 20 of prior U.S. Patent No. 10,061,812. The subject matter claimed in the instant application is fully disclosed in the referenced patent. The instant application recites a broader version of the claims recited in 10,061,812, and it is deemed an obvious variation or simplification of the prior patent. All of the claimed limitations in the instant application are either broader versions or minor variations of wording of the claim's limitations in the prior patent, as outlined in the table below with respect to claim 1:

Application 17/499,725	**Patent 10,061,812**
1. A method for tracking goal progression, the method comprising: receiving input establishing clients, wherein the clients are individuals receiving treatment or assistance, and	1. A method for tracking outcome specific data, the method comprising: receiving input establishing accounts for providers serving clients in a client

wherein the data associated with the clients is stored in a server available through one or more networks;	management program, wherein the clients are individuals receiving treatment or assistance, wherein the input includes rules for determining progress of the clients, wherein the accounts are stored in a database of a server, and wherein the input is received from an administrator utilizing one of a plurality of communications devices in communication with the server by one or more networks;
assigning each of the clients to one or more of the providers in response to selections from an administrator, wherein the one or more providers include at least individuals available to treat or assist each of the clients **and one or more biometric devices associated with of the clients;**	assigning each of the clients to one or more of the providers in response to selections from the administrator utilizing one of the plurality of communications devices, wherein the one or more providers are individuals available to treat or assist the clients;

establishing goals and a baseline for each of the clients and thresholds associated with each of the goals;	prompting the providers to provide data associated with each of the clients that is required and not already received through the client management program, wherein the one or more providers periodically provide/update the data, and wherein the data relates to the well-being of the clients;
compiling data associated with each of the clients received from the one or more providers in the server;	compiling the data associated with each of the clients received from the providers without input from the clients for the client management program to generate a score utilizing the rules, wherein the score is associated with progress toward mastery of one or more goals;
determining whether the goals are being met in response to thresholds for the compiled data; and	analyzing the compiled data and the score to automatically determine a status of the clients within the client management program, wherein the

	score is compared with previous compiled data to determine whether a plurality of measurements of the compiled data vary from a threshold to become significant;
automatically communicating alerts in response to the compiled data varying from a threshold to become significant for one of the one or more clients.	automatically communicating an alert including the compiled data and the status from the server executing the client management program to the plurality of communications devices associated with the providers assigned to one of the clients that is utilized by the administrator or one or more of the providers to intervene with the client in response to the plurality of measurements of the compiled data varying from the threshold to become significant for one of the clients.

Claim 1 of the instant application recites nearly the same claim embodiments as the prior patent, as seen in the table above. The only difference is that claim 1 in the instant application eliminates some claim limitations and makes some broader. There

are no new limitations introduced in the claims, with the exception of a biometric device. However, this is a generic tool used in the technology and industry, and does not add anything significant to the claims. Since the claims in the instant application are merely reworded and abbreviated versions of the claims in the prior patent, they are rejected as such.

Claims 2 and 12 recite that a cloud network is used and that communications devices are utilized. Claim 2 of the prior patent recites both the usage of communications devices and a cloud network.

Claims 3, 4, 13, and 18 recites claim limitations that are present in independent claim 1 of the prior patent. Namely, the prior patent recites that the providers intervene in claims 4, 13, and 18. Therefore these claims are broader versions of claim 1 of the prior patent and they are rejected under the same rationale with respect to claim 1 above.

Claims 5, 14, and 19 recite that a plan of action is determined for achieving the goals. In the prior patent, claim 2 recites the progress of the client towards goals and claim 3 recites goals and their associated masteries and statuses. The determining of a goal status and client progress toward achieving a goal is just different terminology to explain the actions that have been done toward achieving a goal. Additionally, claim 5 of the prior patent recites best practices for the clients, which is also another way of saying the plan of action for the clients.

Claim 6 recites that a baseline and goals are established by the client and providers. These claim limitations are simplifications of parts of claims 2 and 3 of the

prior patent, which recites data for the clients (baseline) and goals, which are determined by the providers for the clients.

Claims 7 and 15 recite that goals are established by the clients and the providers. Claim 5 of the prior patent recites that best practices are recommended to the providers, and claim 3 recites that goals are established for the clients based on the input data. The combination of claims 3 and 5 of the prior patent therefore teach the same embodiments as the Applicant's claims, which is the recommending of goals based on received input.

Claims 8, 9, and 16 recite modifying goals, which can be in response to client progress towards the goals. Claim 10 of the prior patent recites that the status of goals can be determined, which relates to the client progress. Claim 1 of the prior patent recites that a determination of goal status can be used to allow a provider to intervene, which could be used to update or change the goals. Therefore the prior patented claims recite that the goals can be changed based on client progress towards the goals.

Claim 10 recites modifying goals, which can be in response to client not progressing toward the goals. Claim 10 of the prior patent recites that the status of goals can be determined, which relates to the client progress. Claim 1 of the prior patent recites that a determination of goal status can be used to allow a provider to intervene, which could be used to update or change the goals. Therefore the prior patented claims recite that the goals can be changed based on client progress towards the goals.

Claim Rejections - 35 USC § 103

06. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.

07. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:

> A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.

08. **Claims 1 – 20** are rejected under 35 U.S.C. 103 as being unpatentable over **Luttrell (US PGPub 2003/0004758)**, in view of **Shaanan et al. (US PGPub 2015/0205930)**, hereinafter "Shaanan".

Consider **claim 1**, Luttrell discloses a method for tracking progression toward goals, the method comprising:

receiving input establishing clients, wherein the clients are individuals receiving treatment or assistance (paragraphs [0003], [0014], [0019], providers treat patients, such that there are records for the patient data), wherein the data associated with the clients is stored in a server available through one or more networks storing the compiled data associated with each of the one or more clients in a server available through one

or more networks (paragraphs [0003], [0014], [0019], the records are stored on and accessible through a network);

assigning each of the one or more clients to one or more providers in response to selections from an administrator, wherein the one or more providers include at least individuals available to treat or assist each of the clients (paragraphs [0051], [0054], the patients are assigned to particular providers based on information input into the system);

establishing goals and a baseline for each of the clients (paragraphs [0003], [0027], [0048], goals are identified for the patients, which can be based on the patient data and the treatment received, which includes an evaluation of the patient, which could be an initial evaluation of the patient's condition and/or health status);

compiling data associated with each of the clients received from the one or more providers in the server (paragraph [0058], the data received by the providers is associated with the patients, and is compiled for the system);

determining whether the goals are being met… for the compiled data (paragraphs [0019], [0048], progress towards the goals is tracked, which is based on the patient data in the system);

However, Luttrell does not specifically mention a biometric device or that a threshold is set for the data varying in order to communicate alerts.

In the same field of endeavor, Shaanan discloses a method comprising:

one or more biometric devices associated with each of the clients (paragraph [0080], biometric devices are used to obtain health related information about clients);

thresholds associated with each of the goals (paragraphs [0058], [0070], thresholds for the goals are established);

in response to thresholds for the compiled data (paragraphs [0058], [0070], thresholds for the goals are established and are compared against both the initial patient data as well as the current patient's health data);

automatically communicating alerts in response to the compiled data varying from a thresholds to become significant for one of the clients (paragraphs [0007], [0063], thresholds are monitored for the patient goals, such that alerts can be generating and sent out based on thresholds being or not being met for a client).

Therefore it would have been obvious to one of ordinary skill in the art before the effective filing date of the invention to incorporate the thresholds for data taught by Shaanan into the tracking of goal progression taught by Luttrell for the purpose of allowing additional data reporting options which can be used to determine the state of a patient that may need assistance, which would provide the patient with better and/or faster treatment.

Consider **claim 2**, and **as applied to claim 1 above**, Luttrell discloses a method comprising:

the server is accessed through a cloud network, and wherein a client management program is executed by communications devices utilized by the one or more providers to receive the data and track progress of the goals (paragraphs [0005], [0024], [0026], [0037], [0039], the server is accessed through a cloud network, wherein various types of networks are utilized to transmit input from the providers for the clients).

Consider **claim 3**, and **as applied to claim 1 above**, Luttrell discloses a method comprising:

intervening with one of the one or more clients in response to the alerts (paragraphs [0021], [0056], interventions are performed on the patients).

Consider **claim 4**, and **as applied to claim 1 above**, Luttrell discloses a method comprising:

the intervening is performed by the one or more providers (paragraphs [0021], [0056], interventions are performed on the patients by the providers).

Consider **claim 5**, and **as applied to claim 1 above**, Luttrell discloses a method comprising:

each of the goals is associated with a plan of action for achieving each of the goals (paragraphs [0021], [0027], plans are established for the goals, which include a way of achieving the goals).

Consider **claim 6**, and **as applied to claim 1 above**, Luttrell discloses a method comprising:

establishing a baseline for the goals of the clients (paragraphs [0003], [0019], goals are established that include functions, activities, and what is to be expected from progress on the goal).

Consider **claim 7**, and **as applied to claim 1 above**, Luttrell discloses a method comprising:

the goals are established by the clients and the one or more providers (paragraphs [0003], [0019], goals are established that include functions, activities, and what is to be expected from progress on the goal).

Consider **claim 8**, and **as applied to claim 1 above**, Luttrell discloses a method comprising:

determining whether modifications to the goals are required in response to the compiled data (paragraphs [0021], [0027], the goals can be changed or updated based on the different data supplied to the system).

Consider **claim 9** and **as applied to claim 8 above**, Luttrell discloses a method comprising:

modifying the goals in response to the complied data (paragraphs [0021], [0027], the goals can be changed or updated based on the different data supplied to the system).

Consider **claim 10**, and **as applied to claim 8 above**, Luttrell discloses a method comprising:

modifications are determined to be required if the one of the one or more clients is unable to achieve the goals associated with the client (paragraphs [0026], [0029], progress made towards the goals by the patients is analyzed, which may trigger the need to change the goals).

Claims 11 – 16 are rejected under the same rational as provided with respect to claims 1 – 10 above. Claim 11 corresponds to claim 1, claim 12 corresponds to claim 2, claim 13 corresponds to claim 3, claim 14 corresponds to claim 5, claim 15 corresponds to claim 7, and claim 16 corresponds to claims 8 and 9. The only difference is claims 11 – 16 are system claims, whereas claims 1 – 10 are method claims. Since the same claim limitations are being claimed, they are therefore the same rejections are applied therein.

Claims 17 – 20 are rejected under the same rational as provided with respect to claims 1 – 10 above. Claim 17 corresponds to claim 1, claim 18 corresponds to claim 3, claim 19 corresponds to claim 5, and claim 20 corresponds to claims 8 and 9. The only difference is claims 17 – 20 are system claims, whereas claims 1 – 10 are method claims. Since the same claim limitations are being claimed, they are therefore the same rejections are applied therein.

Conclusion

09. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

10. Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Christopher Raab whose telephone number is (571) 270-1090. The Examiner can normally be reached on Monday-Friday from 9:00am to 5:00pm.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Tamara Kyle can be reached on (571) 272-4241. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free) or 703-305-3028.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist/customer service whose telephone number is (571) 272-2600.

/CHRISTOPHER J RAAB/
Primary Examiner, Art Unit 2156

October 02, 2023

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/499,725	Bradley et al.
	Examiner	Art Unit
	CHRISTOPHER J RAAB	2156

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

CLAIMS

☐ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIM		DATE								
Final	Original	03/25/2023	10/02/2023							
	1	✓	✓							
	2	✓	✓							
	3	✓	✓							
	4	✓	✓							
	5	✓	✓							
	6	✓	✓							
	7	✓	✓							
	8	✓	✓							
	9	✓	✓							
	10	✓	✓							
	11	✓	✓							
	12	✓	✓							
	13	✓	✓							
	14	✓	✓							
	15	✓	✓							
	16	✓	✓							
	17	✓	✓							
	18	✓	✓							
	19	✓	✓							
	20	✓	✓							

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/499,725	Bradley et al.
	Examiner	Art Unit
	CHRISTOPHER J RAAB	2156

CPC - Searched*		
Symbol	**Date**	**Examiner**
G06Q10/06, limited keyword search	03/25/2023	CJR
G06Q10/0637, limited keyword search	03/25/2023	CJR

CPC Combination Sets - Searched*		
Symbol	**Date**	**Examiner**

US Classification - Searched*			
Class	**Subclass**	**Date**	**Examiner**

* See search history printout included with this form or the SEARCH NOTES box below to determine the scope of the search.

Search Notes		
Search Notes	**Date**	**Examiner**
PE2E image and keyword search	03/25/2023	CJR
NPL Search: Google Scholar	03/25/2023	CJR
Inventor Name Search: PALM and PE2E	03/25/2023	CJR
Updated search	10/02/2023	CJR

Interference Search			
US Class/CPC Symbol	**US Subclass/CPC Group**	**Date**	**Examiner**

/CHRISTOPHER J RAAB/ Primary Examiner, Art Unit 2156	

PE2E SEARCH - Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	British Equivalents	Time Stamp
L1	2	("20110047404").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 01:24 PM
L2	10	("20090112924"|"20090192825"|"8313433"|"8355925"|"RE42508").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:00 PM
L3	3130	account WITH client WITH provider	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:01 PM
L4	77	data mining WITH goal WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:01 PM
L5	41	data mining WITH best practices	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:01 PM
L6	1	intensive trial teaching	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:01 PM
L7	1	reinforcement recorder	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:06 PM
L8	864	goal WITH achiev$5 WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:24 PM
L9	3158	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:25 PM
L10	1117	L9 AND goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:25 PM
L11	78	L9 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:25 PM
L12	23	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:25 PM
L13	6	Macrosolve$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:30 PM
L14	84	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:30 PM
L15	1753	alert WITH automatic$6 WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2016/07/08 04:34 PM
L16	540	alert NEAR5 automatic$6 NEAR5 threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2016/07/08 04:34 PM

L17	1110	(compile OR compiling OR compiled) WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 09:37 PM
L18	27	(compile OR compiling OR compiled) WITH user input WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 09:37 PM
L19	18	(compile OR compiling OR compiled) WITH "without user input"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 09:39 PM
L20	126	(score OR status) WITH "without user input"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 09:41 PM
L21	441	(status) WITH automatic$ WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 09:49 PM
L22	352	status WITH automatic$ WITH (score OR compile OR compiling OR scoring)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 10:01 PM
L23	1161	score WITH client WITH (threshold OR status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/07/09 10:20 PM
L24	125	well-being WITH client	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/07/09 10:21 PM
L25	385	well-being WITH score	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/07/09 10:21 PM
L26	0	well-being WITH client WITH score	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/07/09 10:21 PM
L27	90	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/02/27 11:11 AM
L28	1	"61791218"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/02/27 11:24 AM
L29	1	"15301419"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/02/27 01:30 PM
L30	55	client management program	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2018/03/19 10:14 AM
L31	2008	administrator SAME (client WITH provider)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2018/03/19 10:14 AM
L33	2	("7346545").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2018/04/12 02:12 PM
L34	2710	(track OR tracked OR tracking) NEAR2 goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/04/15 03:10 PM

L35	71	((track OR tracked OR tracking) NEAR2 goal) WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/04/15 03:10 PM
L36	44	((track OR tracked OR tracking) NEAR2 goal) SAME (behavioral OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/04/15 03:20 PM
L37	77	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/04/15 03:23 PM
L38	90	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/06/22 04:37 PM
L39	4499	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/06/22 04:37 PM
L40	6	(administrator SAME (client WITH provider)) AND ((score OR mastery) NEAR5 goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2018/06/22 04:40 PM
L41	24	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/06/22 04:40 PM
L42	714	score WITH measurement WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/06/22 04:40 PM
L43	39585	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/06/22 04:44 PM
L54	4	("10061812").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2019/12/23 01:57 PM
L55	13	("20020065697"|"20020147626"|"20020194046"|"20080141138"|"20080281651"|"20090112924"|"20090192825"|"20100082381"|"20110029521"|"20110047404"|"8313433"|"8355925"|"RE42508").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2019/12/23 02:26 PM
L56	27	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:29 PM
L57	1695	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:30 PM
L58	5898	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:31 PM
L59	46154	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO;	ADJ	ON	ON	2019/12/23 02:31 PM

			DERWENT; IBM_TDB)				
L60	9	L57 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:31 PM
L61	100	L58 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:31 PM
L62	647	(status) WITH automatic$ WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:31 PM
L63	87	data mining WITH goal WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:32 PM
L64	9	(administrator SAME (client WITH provider)) AND ((score OR mastery) NEAR5 goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2019/12/23 02:32 PM
L65	101	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:32 PM
L66	4	L57 AND goal wizard	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:32 PM
L67	4	L58 AND goal wizard	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:32 PM
L68	4	L57 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:33 PM
L69	5	L58 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:33 PM
L70	4	L57 AND (goal WITH alert WITH client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:33 PM
L71	4	L58 AND (goal WITH alert WITH client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:33 PM
L72	2	"16053141"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/07/23 03:16 PM
L73	191357	field WITH (treatment OR assistance)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/07/24 10:31 AM
L74	363	field WITH (treatment OR assistance) WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/07/24 02:37 PM
L75	726	(compile OR compiled OR compiling) WITH (client OR patient) WITH (field OR treatment)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/07/24 03:04 PM

L76	11	(("4237344") or ("5377258") or ("20090048872") or ("20110295613")).PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2020/07/27 02:54 PM
L77	2	("20090048872"|"20110295613").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2020/09/29 09:56 AM
L78	2	("4237344"|"5377258").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2020/09/29 09:56 AM
L79	1	("20030004758").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2020/09/29 09:56 AM
L80	1	"16141471"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 10:19 AM
L81	0	"Platform for Optimizing Goal Progression".TI.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 10:19 AM
L82	43	Bradley, Nathaniel.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 10:19 AM
L83	4	("10061812").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2020/09/29 10:20 AM
L84	88	data mining WITH goal WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L85	60	data mining WITH best practices	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L86	41	(compile OR compiling OR compiled) WITH user input WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L87	115	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L88	95	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L89	2189	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L90	11	L89 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:02 AM
L91	4	L89 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:02 AM
L92	4	L89 AND (goal WITH alert WITH client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:02 AM
L93	10482	threshold WITH goal	(US-PGPUB; USPAT;	ADJ	ON	ON	2021/04/08

			EPO; JPO; DERWENT; IBM_TDB)				09:23 PM
L94	714	threshold WITH goal WITH (plan OR met)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:23 PM
L95	43	threshold WITH goal WITH (plan OR met) WITH (treatment OR provider OR client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:24 PM
L96	22	threshold WITH goal WITH (plan OR met) WITH (treat$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:28 PM
L97	252	threshold WITH goal WITH (treat$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:46 PM
L98	103	L97 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:46 PM
L99	7	(("20120203092") or ("20080270182") or ("10098584")).PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2021/04/08 09:52 PM
L100	5	L99 AND threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:52 PM
L101	56	(patient OR client) WITH threshold WITH goal WITH (treat$5 OR chang$4 OR modif$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:03 PM
L102	17	L101 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:03 PM
L103	49389	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:05 PM
L104	6924	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:05 PM
L105	297	(L103 OR L104) AND (threshold WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:06 PM
L106	204	L105 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:06 PM
L107	29	(L103 OR L104) AND ((threshold WITH goal) SAME (patient OR client))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:08 PM
L108	9	L107 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:08 PM
L109	364	(treatment OR evaluation) WITH (goal) WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:39 PM

L110	10	(client OR patient) WITH goal WITH threshold WITH progress$4	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:43 PM
L111	1708	(client OR patient) WITH goal WITH (threshold OR progress$4)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:43 PM
L112	902	(client OR patient) WITH (goal NEAR5 (threshold OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:45 PM
L113	362	L112 AND @AD<"20130315"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:46 PM
L114	238	(client OR patient) WITH (goal NEAR5 (threshold OR progress$4)) WITH (treatment OR assistance OR modify$4 OR plan)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:53 PM
L115	84	L114 AND @AD<"20130315"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:53 PM
L116	327	(client OR patient) WITH goal WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 02:03 PM
L117	121	(client OR patient) WITH goal WITH (progress$4 OR threshold) WITH (modif$5 OR chang$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 02:03 PM
L118	1	"16141471"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 02:27 PM
L119	327	(patient OR client) WITH threshold WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 07:35 PM
L120	153	L119 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 07:44 PM
L121	50097	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/08/12 02:27 PM
L122	2	("8066640").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2021/08/12 02:36 PM
L133	252	patient WITH threshold WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:43 PM
L134	3051	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO;	ADJ	ON	ON	2022/02/25 09:50 PM

			DERWENT; IBM_TDB)				
L135	51231	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L136	7790	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L137	30	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L138	136	L134 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L139	1130	L135 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L140	292	L136 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L141	13	L136 AND ((patient OR client) WITH (threshold) WITH (alert OR goal OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:51 PM
L142	94	L135 AND ((patient OR client) WITH (threshold) WITH (alert OR goal OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:51 PM
L143	13	L134 AND ((patient OR client) WITH (threshold) WITH (alert OR goal OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:51 PM
L144	60	Bradley, Nathaniel.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:51 PM
L145	62	Gaynor, James.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:51 PM
L146	41	Paugh, Joshua.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:52 PM
L147	5	Arena, Paul.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:52 PM
L148	2	("20090192825").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2022/02/25 09:53 PM
L149	4	("11144554").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2022/02/25 10:10 PM
L151	972	(client OR patient) WITH baseline WITH goal	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU,	ADJ	ON	ON	2022/07/25 11:43 AM

			CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)				
L152	73	((client OR patient) WITH baseline WITH goal) SAME threshold	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/07/25 11:43 AM
L153	154	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/07/25 11:43 AM
L154	57	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; EPO)	ADJ	ON	ON	2022/07/25 11:43 AM
L155	61	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; EPO)	ADJ	ON	ON	2023/01/13 08:53 PM
L157	139	(client OR patient) WITH goal WITH biometric	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB,	OR	ON	ON	2023/01/13 08:53 PM

			HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)				
L158	633	goal WITH threshold WITH rule	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2023/03/24 02:04 PM
L159	23	(client OR patient) WITH goal WITH threshold WITH rule	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/24 02:05 PM
L160	2	("20110047404").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L161	10	("20090112924"|"20090192825"|"8313433"|"8355925"|"RE42508").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L162	7418	account WITH client WITH provider	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L163	112	data mining WITH goal WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L164	61	data mining WITH best practices	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L165	9	intensive trial teaching	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L166	9	reinforcement recorder	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L167	1919	goal WITH achiev$5 WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L168	9840	G06Q10/0637.CPC.	(US-PGPUB; USPAT;	ADJ	ON	ON	2023/03/25

			EPO; JPO; DERWENT; IBM_TDB)				07:42 PM
L169	2100	L9 AND goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L170	155	L9 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L171	31	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L172	6	Macrosolve$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L173	96	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L174	4987	alert WITH automatic$6 WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L175	1324	alert NEAR5 automatic$6 NEAR5 threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L176	2056	(compile OR compiling OR compiled) WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L177	54	(compile OR compiling OR compiled) WITH user input WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L178	50	(compile OR compiling OR compiled) WITH "without user input"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L179	340	(score OR status) WITH "without user input"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L180	992	(status) WITH automatic$ WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L181	853	status WITH automatic$ WITH (score OR compile OR compiling OR scoring)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L182	3702	score WITH client WITH (threshold OR status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L183	223	well-being WITH client	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L184	962	well-being WITH score	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM

L185	18	well-being WITH client WITH score	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L186	96	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L187	9	"61791218"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L188	3	"15301419"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L189	69	client management program	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L190	3683	administrator SAME (client WITH provider)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L191	2	("7346545").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L192	4638	(track OR tracked OR tracking) NEAR2 goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L193	133	((track OR tracked OR tracking) NEAR2 goal) WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L194	90	((track OR tracked OR tracking) NEAR2 goal) SAME (behavioral OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L195	178	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L196	96	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L197	9840	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L198	20	(administrator SAME (client WITH provider)) AND ((score OR mastery) NEAR5 goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L199	31	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L200	1805	score WITH measurement WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L201	62988	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO;	ADJ	ON	ON	2023/03/25 07:42 PM

			DERWENT; IBM_TDB)				
L202	4	("10061812").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L203	13	("20020065697"|"20020147626"|"20020194046"|"20080141138"|"20080281651"|"20090112924"|"20090192825"|"20100082381"|"20110029521"|"20110047404"|"8313433"|"8355925"|"RE42508").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/25 07:42 PM
L204	31	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L205	3722	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L206	9840	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L207	62988	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L208	26	L57 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L209	155	L58 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L210	992	(status) WITH automatic$ WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L211	112	data mining WITH goal WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L212	20	(administrator SAME (client WITH provider)) AND ((score OR mastery) NEAR5 goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L213	178	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L214	9	L57 AND goal wizard	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L215	9	L58 AND goal wizard	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L216	92	L57 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO;	ADJ	ON	ON	2023/03/25 07:42 PM

			DERWENT; IBM_TDB)				
L217	12	L58 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L218	10	L57 AND (goal WITH alert WITH client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L219	12	L58 AND (goal WITH alert WITH client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L220	7	"16053141"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L221	327785	field WITH (treatment OR assistance)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L222	490	field WITH (treatment OR assistance) WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L223	933	(compile OR compiled OR compiling) WITH (client OR patient) WITH (field OR treatment)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L224	11	(("4237344") or ("5377258") or ("20090048872") or ("20110295613")).PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L225	2	("20090048872"|"20110295613").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/25 07:42 PM
L226	2	("4237344"|"5377258").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/25 07:42 PM
L227	1	("20030004758").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/25 07:42 PM
L228	4	"16141471"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L229	0	"Platform for Optimizing Goal Progression".TI.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L230	85	Bradley, Nathaniel.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L231	4	("10061812").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L232	112	data mining WITH goal WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L233	61	data mining WITH best practices	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM

L234	54	(compile OR compiling OR compiled) WITH user input WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L235	178	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L236	96	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L237	3722	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L238	26	L89 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L239	92	L89 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L240	10	L89 AND (goal WITH alert WITH client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L241	13185	threshold WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L242	898	threshold WITH goal WITH (plan OR met)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L243	70	threshold WITH goal WITH (plan OR met) WITH (treatment OR provider OR client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L244	45	threshold WITH goal WITH (plan OR met) WITH (treat$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L245	358	threshold WITH goal WITH (treat$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L246	107	L97 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L247	7	(("20120203092") or ("20080270182") or ("10098584")).PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L248	5	L99 AND threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L249	104	(patient OR client) WITH threshold WITH goal WITH (treat$5 OR chang$4 OR modif$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L250	18	L101 AND	(US-PGPUB; USPAT;	ADJ	ON	ON	2023/03/25

		(@AD<"20130315" OR @RLAD<"20130315")	EPO; JPO; DERWENT; IBM_TDB)				07:42 PM
L251	62988	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L252	9840	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L253	356	(L103 OR L104) AND (threshold WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L254	213	L105 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L255	37	(L103 OR L104) AND ((threshold WITH goal) SAME (patient OR client))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L256	10	L107 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L257	496	(treatment OR evaluation) WITH (goal) WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L258	30	(client OR patient) WITH goal WITH threshold WITH progress$4	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L259	2057	(client OR patient) WITH goal WITH (threshold OR progress$4)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L260	1043	(client OR patient) WITH (goal NEAR5 (threshold OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L261	351	L112 AND @AD<"20130315"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L262	287	(client OR patient) WITH (goal NEAR5 (threshold OR progress$4)) WITH (treatment OR assistance OR modify$4 OR plan)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L263	82	L114 AND @AD<"20130315"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L264	434	(client OR patient) WITH goal WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L265	163	(client OR patient)	(US-PGPUB; USPAT;	ADJ	ON	ON	2023/03/25

		WITH goal WITH (progress$4 OR threshold) WITH (modif$5 OR chang$5)	EPO; JPO; DERWENT; IBM_TDB)				07:42 PM
L266	4	"16141471"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L267	434	(patient OR client) WITH threshold WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L268	157	L119 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L269	62988	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L270	2	("8066640").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L271	309	patient WITH threshold WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L272	3722	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L273	62988	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L274	9840	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L275	31	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L276	154	L134 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L277	1193	L135 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L278	341	L136 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L279	16	L136 AND ((patient OR client) WITH (threshold) WITH (alert OR goal OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L280	101	L135 AND ((patient OR client) WITH (threshold) WITH (alert OR goal OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L281	15	L134 AND ((patient OR client) WITH (threshold)	(US-PGPUB; USPAT; EPO; JPO;	ADJ	ON	ON	2023/03/25 07:42 PM

		WITH (alert OR goal OR progress$4))	DERWENT; IBM_TDB)				
L282	85	Bradley, Nathaniel.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L283	66	Gaynor, James.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L284	61	Paugh, Joshua.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L285	6	Arena, Paul.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L286	2	("20090192825").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L287	4	("11144554").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L288	1050	(client OR patient) WITH baseline WITH goal	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L289	80	((client OR patient) WITH baseline WITH goal) SAME threshold	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L290	167	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY,	ADJ	ON	ON	2023/03/25 07:42 PM

			CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)				
L291	64	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; EPO)	ADJ	ON	ON	2023/03/25 07:42 PM
L292	64	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; EPO)	ADJ	ON	ON	2023/03/25 07:42 PM
L293	141	(client OR patient) WITH goal WITH biometric	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2023/03/25 07:42 PM
L294	633	goal WITH threshold WITH rule	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2023/03/25 07:42 PM
L295	23	(client OR patient) WITH goal WITH threshold WITH rule	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/25 07:42 PM
L296	2	"20150205930".PN.	(US-PGPUB; USPAT; USOCR; FIT (AU, AP,	OR	OFF	OFF	2023/03/25 08:30 PM

			AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)				
L298	136	Bradley, Nathaniel.INV.	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/10/02 02:08 PM
L299	4	Bradley, Nathaniel.INV. AND goal.TI.	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/10/02 02:09 PM
L300	53	goal WITH biometric device	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE,	ADJ	ON	ON	2023/10/02 02:30 PM

			SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)				
L301	31	goal WITH biometric device	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/10/02 02:30 PM
L302	0	"biometric sensors worn by"	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/10/02 02:33 PM
L303	228	"biometric sensors worn"	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/10/02 02:33 PM
L304	29	"biometric sensors worn".CLM.	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/10/02 02:33 PM
L305	2	L304 AND (Bradley.INV. OR Marshall.INV. OR Gaynor.INV.)	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/10/02 02:34 PM

PE2E SEARCH - Search History (Interference)

There are no Interference searches to show.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of: Bradley et al. **Application No.** 17/499,725 **Filing Date:** October 12, 2021 **For:** SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	**Confirmation No.** 9953 **Group Art Unit:** 2156 **Examiner:** Christopher J RAAB

AMENDMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

VIA EFS-WEB

Commissioner:

In reply to the Office Action mailed March 31, 2023, the shortened statutory period for response to which expires on June 30, 2023 and extends through September 30, 2023, please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims in this paper.

Remarks follow the amendments section of this paper.

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

Claim 1 (Currently Amended): A method for tracking goal progression, the method comprising:

receiving input establishing clients, wherein the clients are individuals receiving treatment or assistance, and wherein the data associated with the clients is stored in a server available through one or more networks;

assigning each of the clients to one or more of the providers in response to selections from an administrator, wherein the one or more providers include at least individuals available to treat or assist each of the clients and one or more biometric devices associated with each of the clients;

establishing goals and a baseline for each of the clients and thresholds associated with each of the goals;

compiling data associated with each of the clients received from the one or more providers in the server;

determining whether the goals are being met in response to thresholds for the compiled data; and

automatically communicating alerts in response to the compiled data varying from a threshold to become significant for one or more of the clients.

Claim 2 (Original): The method according to claim 1, wherein the server is accessed through a cloud network, and wherein a client management program is executed by

communications devices utilized by the one or more providers to receive the data and track progress of the goals.

Claim 3 (Original): The method according to claim 1, further comprising:

intervening with the one or more of the clients in response to the alerts.

Claim 4 (Original): The method according to claim 3, wherein the intervening is performed by the one or more providers.

Claim 5 (Original): The method according to claim 1, wherein each of the goals is associated with a plan of action for achieving each of the goals.

Claim 6 (Original): The method according to claim 1, further comprising:

establishing a baseline for the goals of the clients.

Claim 7 (Original): The method according to claim 1, wherein the goals are established by the clients and the one or more providers.

Claim 8 (Original): The method according to claim 1, further comprising:

determining whether modifications to the goals are required in response to the compiled data.

Claim 9 (Original): The method according to claim 8, further comprising:

modifying the goals in response to the compiled data.

Claim 10 (Original): The method according to claim 8, wherein modifications are determined to be required if the one of the clients is unable to achieve the goals associated with the client.

Claim 11 (Currently Amended): A system for tracking goal progression, the system comprising:

a server communicates with communications devices through a transceiver utilizing one or more networks, the server includes a processor that executes a client management program to:

receive input establishing a client, wherein the client is a individual receiving treatment or assistance, and wherein an account associated with the client is stored in a server available through one or more networks;

assign the client to one or more of the providers in response to selections from an administrator, wherein the one or more providers include at least individuals available to treat or assist the client and one or more biometric devices associated with the client;

establish goals and a baseline for the client and thresholds associated with each of the goals;

compile data associated with the client received from the one or more providers in the server;

determine whether the goals are being met in response to thresholds for the compiled

data; and

automatically communicate alerts in response to the compiled data varying from a threshold to become significant for the client; and

a database in communication with the server configured to store at least the data, goals, and thresholds associated with the client and the one or more providers.

Claim 12 (Original): The system according to claim 11, wherein the communications devices receive the data from the one or more providers.

Claim 13 (Original): The system according to claim 11, wherein the alerts indicate that the one or more providers are to intervene with the client.

Claim 14 (Original): The system according to claim 11, wherein each of the goals is associated with a plan of action for achieving each of the goals.

Claim 15 (Original): The system according to claim 11, wherein the goals are established by the client and the one or more providers.

Claim 16 (Original): The system according to claim 11, wherein the client management program is further executed to:

determine whether modifications to the goals are required in response to the compiled data indicating the goals are not achievable; and

modify the goals in response to the compiled data indicating the goals are not

achievable.

Claim 17 (Currently Amended): A server comprising:

a processor for executing a set of instructions; and

a memory for storing the set of instructions, wherein the set of instructions are executed by the processor to:

receive input establishing clients receiving assistance, wherein the clients are individuals receiving treatment or assistance, and wherein the accounts are stored in a server available through one or more networks;

assign each of the clients to one or more of the providers in response to selections from an administrator, wherein the one or more providers include at least individuals available to treat or assist each of the clients and one or more biometric devices associated with each of the clients;

establish goals and a baseline for each of the clients and thresholds associated with each of the goals;

compile data associated with each of the clients received from the one or more providers in the server;

determine whether the goals are being met in response to the baseline and thresholds for the compiled data; and

automatically communicate alerts in response to the compiled data varying from a threshold to become significant for one or more of the clients.

Claim 18 (Original): The server according to claim 17, wherein the set of instructions

are further executed to:

physically intervene with the one or more of the clients in response to the alerts, wherein the physical intervention is performed by the one or more providers.

Claim 19 (Original): The server according to claim 17, wherein each of the goals is associated with a plan of action for achieving each of the goals, wherein the goals are established by the client and the one or more providers.

Claim 20 (Currently Amended): The server according to claim 17, wherein the set of instructions are further executed to:

~~Determine~~ determine whether modifications to the goals are required in response to the compiled data; and

~~Modify~~ modify the goals in response to determining the modifications to the goals are required.

REMARKS

In the Office Action, the Examiner took the following actions:

I. Claims 1 – 20 are rejected on the ground of nonstatutory double patenting over claims 1 – 20 of prior U.S. Patent No. 10,061,812; and
II. Claims 1 – 20 are rejected under 35 U.S.C. 103 as being unpatentable over Luttrell (US PGPub 2003/0004758), in view of Shaanan et al. (US PGPub 2015/0205930), hereinafter "Shaanan".

The Office Action may contain statements characterizing the related art and/or the claims. Regardless of whether any such statement is expressly identified and/or discussed herein, Applicant reserves the right to disagree with any such statement or characterization in the Office Action.

Applicant amends claims 1, 11, 17, and 20 without prejudice or disclaimer of its subject matter. Support for the amendments may be found in at least the specification, Figures, and at least paragraphs [0009, 0055,]. Claims 1-20 remain pending and under examination. For at least the following reasons, Applicant respectfully requests reconsideration and withdrawal of the rejections.

Claim Rejections - 35 USC § 103

Claims 1 – 20 are rejected on the ground of nonstatutory double patenting over claims 1 – 20 of prior U.S. Patent No. 10,061,812. This rejection is respectfully traversed. Applicant will address the double patenting rejection when we are able to reach allowable content.

Claim Rejections - 35 USC § 103

Claims 1 – 20 are rejected under 35 U.S.C. 103 as being unpatentable over Luttrell (US PGPub 2003/0004758), in view of Shaanan et al. (US PGPub 2015/0205930), hereinafter "Shaanan". This rejection is respectfully traversed. The Examiner bears the burden of establishing a prima facie case of obviousness based on the prior art when rejecting claims under 35 U.S.C. §103. In re Fritch, 972 F.2d 1260, 23 U.S.P.Q.2d 1780 (Fed. Cir. 1992). When evaluating claims for obviousness under 35 U.S.C. 103, all the limitations of the claims must be considered and given weight. Ex parte Grasselli, 231 USPQ 393 (Bd. App. 1983) aff'd mem. 738 F.2d 453 (Fed. Cir. 1984) (emphasis added).

With regard to claim 1, Luttrell and Shaanan does not teach, suggest, or disclose "establishing goals and a baseline for each of the clients and thresholds associated with each of the goals." Luttrell and Shaanan to not appear to teach a baseline for each of the clients as recited by Applicants. For at least this reason, the rejection of claim 1 is allowable over Luttrell and Shaanan.

Independent claims 11 and 17 are allowable for at least the same reasons as claim 1. Claims 2-10, 12-16, and 18-20 are allowable at least based on their dependence on claims 1, 11, and 17, respectively.

Applicants respectfully request an Examiner interview to move forward prosecution and to discuss the art of record.

CONCLUSION

In view of the foregoing, Applicant respectfully requests reconsideration of this application and the timely allowance of the pending claims.

This is a request for a three month extension of time, the small entity fee of $592 for which is being paid at the time of filing this response. Please grant any extensions of time required to enter this response. No additional fees are believed due; however, the Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, to fees to Deposit Account 506801.

Respectfully submitted,

Goodhue, Coleman & Owens, P.C.

Dated: September 28, 2023

By: /Brian D. Owens/
Brian Dean Owens
Reg. No. 55517
(515) 218-7888

UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
17/499,725	**09/28/2023 05:55:28 PM ET**	**DHP-P0001CIP1**

Title of Invention

SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	-
CONFIRMATION #	9953	FILED BY	Ashlyn Nguyen
PATENT CENTER #	62894281	FILING DATE	10/12/2021
CUSTOMER #	133690	FIRST NAMED INVENTOR	Nathaniel T. Bradley
CORRESPONDENCE ADDRESS	-	AUTHORIZED BY	Brian Owens

Documents

TOTAL DOCUMENTS: 3

DOCUMENT		PAGES	DESCRIPTION	SIZE (KB)
DHP-P0001CIP1_17499725_FILED-NON-FINAL-OFFICE-ACTION-RESPONSE_9-28-23.pdf		10	-	229 KB
DHP-P0001CIP1_17499725_FILED-NON-FINAL-OFFICE-ACTION-RESPONSE_9-28-23-A....pdf	(1-1)	1	Amendment/Request for Reconsideration-After Non-Final Rejection	162 KB
DHP-P0001CIP1_17499725_FILED-NON-FINAL-OFFICE-	(2-7)	6	Claims	169 KB

ACTION-RESPONSE_9-28-23-CLM.pdf				
DHP-P0001CIP1_17499725_FILED-NON-FINAL-OFFICE-ACTION-RESPONSE_9-28-23-REM.pdf	(8-10)	3	Applicant Arguments/Remarks Made in an Amendment	217 KB

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)
DHP-P0001CIP1_17499725_FILED-NON-FINAL-OFFICE-ACTION-RESPONSE_9-28-23.pdf	B05029671932BDC08E3A4F336230249DD177300262CFECD71DF79526B478349D6C24417D9D72C6A1BEE48A07BBB4B5D9D828D3422E6D8D889971CB17D18967F2
DHP-P0001CIP1_17499725_FILED-NON-FINAL-OFFICE-ACTION-RESPONSE_9-28-23-A....pdf	0DADD413B6338D2C1B2A0539791F68EC295FCF1C0C1770CCF884008371B93F873D26DE22D7555A777AB4C50B73BE4DFBBD1B96B232D7CCDE320BC0174E8A3005
DHP-P0001CIP1_17499725_FILED-NON-FINAL-OFFICE-ACTION-RESPONSE_9-28-23-CLM.pdf	72EC4F9ACAA4461634BB0C99AF6FB6E19D343B2F8D3FE15E5FAC2FBBBDC72574D18C2F2FE17C2F0B094397272D8EDE6D462C3529040408F65CFFBFF493B05AFC
DHP-P0001CIP1_17499725_FILED-NON-FINAL-OFFICE-ACTION-RESPONSE_9-28-23-REM.pdf	C21A4E8BE22EACDEDDC8092662909D81BE1F91A4C75EC639D191459FE1E4BD88186E5EA70828BC32A32275007CAD6C4AE7C1C20F8869AFE8FE7A9D750AD5C2AE

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement

Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC PAYMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
17/499,725	**09/28/2023 05:55:28 PM ET**	**DHP-P0001CIP1**

Title of Invention

SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	-
CONFIRMATION #	9953	FILED BY	Ashlyn Nguyen
PATENT CENTER #	62894281	AUTHORIZED BY	Brian Owens
CUSTOMER #	133690	FILING DATE	10/12/2021
CORRESPONDENCE ADDRESS	-	FIRST NAMED INVENTOR	Nathaniel T. Bradley

Payment Information

PAYMENT METHOD	PAYMENT TRANSACTION ID	PAYMENT AUTHORIZED BY
DA / 506801	**E20239RH56129329**	**Ashlyn Nguyen**

FEE CODE	DESCRIPTION	ITEM PRICE($)	QUANTITY	ITEM TOTAL($)
2253	EXTENSION FOR RESPONSE WITHIN THIRD MONTH -	592.00	1	592.00
			TOTAL AMOUNT:	**$592.00**

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875	Application or Docket Number 17/499,725	Filing Date 10/12/2021	☐ To be Mailed

ENTITY: ☐ LARGE ☑ SMALL ☐ MICRO

APPLICATION AS FILED - PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA		RATE ($)	FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A		N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A		N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A		N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*		x $50 =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*		x $240 =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).				
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))					
* If the difference in column 1 is less than zero, enter "0" in column 2.				TOTAL	

APPLICATION AS AMENDED - PART II

		(Column 1)		(Column 2)	(Column 3)			
AMENDMENT	09/28/2023	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	* 20	Minus	** 20	= 0		x $40 =	0
	Independent (37 CFR 1.16(h))	* 3	Minus	*** 3	= 0		x $192 =	0
	☐ Application Size Fee (37 CFR 1.16(s))							
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							
							TOTAL ADD'L FEE	0

		(Column 1)		(Column 2)	(Column 3)			
AMENDMENT		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	*	Minus	**	=		x $0 =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=		x $0 =	
	☐ Application Size Fee (37 CFR 1.16(s))							
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							
							TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.	LIE
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".	/CAROL A BARNES/
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".	
The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.	

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/499,725	10/12/2021	Nathaniel T. Bradley	DHP-P0001CIP1	9953

133690 7590 03/31/2023

Goodhue, Coleman & Owens, P.C.
12951 University Ave
Suite 201
Clive, IA 50325

EXAMINER	
RAAB, CHRISTOPHER J	

ART UNIT	PAPER NUMBER
2156	

NOTIFICATION DATE	DELIVERY MODE
03/31/2023	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USPTO@dockettrak.com
docketing@goodhue.com
eofficeaction@appcoll.com

Office Action Summary	Application No. 17/499,725	Applicant(s) Bradley et al.	
	Examiner CHRISTOPHER J RAAB	Art Unit 2156	AIA (FITF) Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTHS FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☑ Responsive to communication(s) filed on 10/12/2021.

☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2a)☐ This action is **FINAL.** 2b) ☑ This action is non-final.

3)☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

4)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims*

5) ☑ Claim(s) 1-20 is/are pending in the application.

5a) Of the above claim(s) _____ is/are withdrawn from consideration.

6) ☐ Claim(s) _____ is/are allowed.

7) ☑ Claim(s) 1-20 is/are rejected.

8) ☐ Claim(s) _____ is/are objected to.

9) ☐ Claim(s) _____ are subject to restriction and/or election requirement

* If any claims have been determined allowable, you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to **PPHfeedback@uspto.gov.**

Application Papers

10)☐ The specification is objected to by the Examiner.

11)☑ The drawing(s) filed on 10/12/2021 is/are: a)☑ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

a)☐ All b)☐ Some** c)☐ None of the:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

** See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☑ Notice of References Cited (PTO-892)

2) ☑ Information Disclosure Statement(s) (PTO/SB/08a and/or PTO/SB/08b) Paper No(s)/Mail Date _____.

3) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date _____.

4) ☐ Other: _____.

DETAILED ACTION

Notice of Pre-AIA or AIA Status

01. The present application is being examined under the pre-AIA first to invent provisions.

Information Disclosure Statement

02. The information disclosure statement (IDS) filed on **10/12/2021, 03/07/2022** has been considered by the examiner and made of record in the application file.

Priority

03. Applicant's claim for domestic priority under 35 U.S.C. 119(e) is acknowledged.

Drawings

04. The drawings were received on **10/12/2021**. These drawings are accepted.

Double Patenting

05. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the claims at issue are not identical, but at least one examined application claim is not patentably distinct from the

reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the reference application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP §§ 706.02(l)(1) - 706.02(l)(3) for applications not subject to examination under the first inventor to file provisions of the AIA. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).

The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/forms/. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA/25, or PTO/AIA/26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more

information about eTerminal Disclaimers, refer to

http://www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp.

06. **Claims 1 – 20** are rejected on the ground of nonstatutory double patenting over claims 1 – 20 of prior U.S. Patent No. 10,061,812. The subject matter claimed in the instant application is fully disclosed in the referenced patent. The instant application recites a broader version of the claims recited in 10,061,812, and it is deemed an obvious variation or simplification of the prior patent. All of the claimed limitations in the instant application are either broader versions or minor variations of wording of the claim's limitations in the prior patent, as outlined in the table below with respect to claim 1:

Application 17/499,725	**Patent 10,061,812**
1. A method for tracking goal progression, the method comprising:	1. A method for tracking outcome specific data, the method comprising:
receiving input establishing clients, wherein the clients are individuals receiving treatment or assistance, and wherein the data associated with the clients is stored in a server available through one or more networks;	receiving input establishing accounts for providers serving clients in a client management program, wherein the clients are individuals receiving treatment or assistance, wherein the input includes rules for determining progress of the clients, wherein the accounts are stored in a database of a server, and wherein the input is

	received from an administrator utilizing one of a plurality of communications devices in communication with the server by one or more networks;
assigning each of the clients to one or more of the providers in response to selections from an administrator, wherein the one or more providers include at least individuals available to treat or assist each of the clients and one or more biometric devices associated with of the clients;	assigning each of the clients to one or more of the providers in response to selections from the administrator utilizing one of the plurality of communications devices, wherein the one or more providers are individuals available to treat or assist the clients;
establishing goals for each of the clients;	prompting the providers to provide data associated with each of the clients that is required and not already received through the client management program, wherein the one or more providers periodically provide/update the data, and wherein the data relates to the well-being of the clients;

compiling data associated with each of the clients received from the one or more providers in the server;	compiling the data associated with each of the clients received from the providers without input from the clients for the client management program to generate a score utilizing the rules, wherein the score is associated with progress toward mastery of one or more goals;
determining whether the goals are being met in response to thresholds for the compiled data; and	analyzing the compiled data and the score to automatically determine a status of the clients within the client management program, wherein the score is compared with previous compiled data to determine whether a plurality of measurements of the compiled data vary from a threshold to become significant;
automatically communicating alerts in response to the compiled data varying	automatically communicating an alert including the compiled data and the

from a threshold to become significant for one of the one or more clients.	status from the server executing the client management program to the plurality of communications devices associated with the providers assigned to one of the clients that is utilized by the administrator or one or more of the providers to intervene with the client in response to the plurality of measurements of the compiled data varying from the threshold to become significant for one of the clients.

Claim 1 of the instant application recites nearly the same claim embodiments as the prior patent, as seen in the table above. The only difference is that claim 1 in the instant application eliminates some claim limitations and makes some broader. There are no new limitations introduced in the claims, with the exception of a biometric device. However, this is a generic tool used in the technology and industry, and does not add anything significant to the claims. Since the claims in the instant application are merely reworded and abbreviated versions of the claims in the prior patent, they are rejected as such.

Claims 2 and 12 recite that a cloud network is used and that communications devices are utilized. Claim 2 of the prior patent recites both the usage of communications devices and a cloud network.

Claims 3, 4, 13, and 18 recites claim limitations that are present in independent claim 1 of the prior patent. Namely, the prior patent recites that the providers intervene in claims 4, 13, and 18. Therefore these claims are broader versions of claim 1 of the prior patent and they are rejected under the same rationale with respect to claim 1 above.

Claims 5, 14, and 19 recite that a plan of action is determined for achieving the goals. In the prior patent, claim 2 recites the progress of the client towards goals and claim 3 recites goals and their associated masteries and statuses. The determining of a goal status and client progress toward achieving a goal is just different terminology to explain the actions that have been done toward achieving a goal. Additionally, claim 5 of the prior patent recites best practices for the clients, which is also another way of saying the plan of action for the clients.

Claim 6 recites that a baseline and goals are established by the client and providers. These claim limitations are simplifications of parts of claims 2 and 3 of the prior patent, which recites data for the clients (baseline) and goals, which are determined by the providers for the clients.

Claims 7 and 15 recite that goals are established by the clients and the providers. Claim 5 of the prior patent recites that best practices are recommended to the providers, and claim 3 recites that goals are established for the clients based on the input data. The combination of claims 3 and 5 of the prior patent therefore teach the

same embodiments as the Applicant's claims, which is the recommending of goals based on received input.

Claims 8, 9, and 16 recite modifying goals, which can be in response to client progress towards the goals. Claim 10 of the prior patent recites that the status of goals can be determined, which relates to the client progress. Claim 1 of the prior patent recites that a determination of goal status can be used to allow a provider to intervene, which could be used to update or change the goals. Therefore the prior patented claims recite that the goals can be changed based on client progress towards the goals.

Claim 10 recites modifying goals, which can be in response to client not progressing toward the goals. Claim 10 of the prior patent recites that the status of goals can be determined, which relates to the client progress. Claim 1 of the prior patent recites that a determination of goal status can be used to allow a provider to intervene, which could be used to update or change the goals. Therefore the prior patented claims recite that the goals can be changed based on client progress towards the goals.

Claim Rejections - 35 USC § 103

07. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.

08. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:

> A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.

09. **Claims 1 – 20** are rejected under 35 U.S.C. 103 as being unpatentable over **Luttrell (US PGPub 2003/0004758)**, in view of **Shaanan et al. (US PGPub 2015/0205930)**, hereinafter "Shaanan".

Consider **claim 1**, Luttrell discloses a method for tracking progression toward goals, the method comprising:

receiving input establishing clients, wherein the clients are individuals receiving treatment or assistance (paragraphs [0003], [0014], [0019], providers treat patients, such that there are records for the patient data), wherein the data associated with the clients is stored in a server available through one or more networks storing the compiled data associated with each of the one or more clients in a server available through one or more networks (paragraphs [0003], [0014], [0019], the records are stored on and accessible through a network);

assigning each of the one or more clients to one or more providers in response to selections from an administrator, wherein the one or more providers include at least individuals available to treat or assist each of the clients (paragraphs [0051], [0054], the patients are assigned to particular providers based on information input into the system);

establishing goals for each of the clients (paragraphs [0027], [0048], goals are identified for the patients, which can be based on the patient data and the treatment received);

compiling data associated with each of the clients received from the one or more providers in the server (paragraph [0058], the data received by the providers is associated with the patients, and is compiled for the system);

determining whether the goals are being met… for the compiled data (paragraphs [0019], [0048], progress towards the goals is tracked, which is based on the patient data in the system);

However, Luttrell does not specifically mention a biometric device or that a threshold is set for the data varying in order to communicate alerts.

In the same field of endeavor, Shaanan discloses a method comprising:

one or more biometric devices associated with each of the clients (paragraph [0080], biometric devices are used to obtain health related information about clients);

in response to thresholds for the compiles data (paragraphs [0058], [0070], thresholds for the goals are established and are compared against both the initial patient data as well as the current patient's health data);

automatically communicating alerts in response to the compiled data varying from a thresholds to become significant for one of the clients (paragraphs [0007], [0063], thresholds are monitored for the patient goals, such that alerts can be generating and sent out based on thresholds being or not being met for a client).

Therefore it would have been obvious to one of ordinary skill in the art before the effective filing date of the invention to incorporate the thresholds for data taught by

Shaanan into the tracking of goal progression taught by Luttrell for the purpose of allowing additional data reporting options which can be used to determine the state of a patient that may need assistance.

Consider **claim 2**, and **as applied to claim 1 above**, Luttrell discloses a method comprising:

the server is accessed through a cloud network, and wherein a client management program is executed by communications devices utilized by the one or more providers to receive the data and track progress of the goals (paragraphs [0005], [0024], [0026], [0037], [0039], the server is accessed through a cloud network, wherein various types of networks are utilized to transmit input from the providers for the clients).

Consider **claim 3**, and **as applied to claim 1 above**, Luttrell discloses a method comprising:

intervening with one of the one or more clients in response to the alerts (paragraphs [0021], [0056], interventions are performed on the patients).

Consider **claim 4**, and **as applied to claim 1 above**, Luttrell discloses a method comprising:

the intervening is performed by the one or more providers (paragraphs [0021], [0056], interventions are performed on the patients by the providers).

Consider **claim 5**, and **as applied to claim 1 above**, Luttrell discloses a method comprising:

each of the goals is associated with a plan of action for achieving each of the goals (paragraphs [0021], [0027], plans are established for the goals, which include a way of achieving the goals).

Consider **claim 6**, and **as applied to claim 1 above**, Luttrell discloses a method comprising:

establishing a baseline for the goals of the clients (paragraphs [0003], [0019], goals are established that include functions, activities, and what is to be expected from progress on the goal).

Consider **claim 7**, and **as applied to claim 1 above**, Luttrell discloses a method comprising:

the goals are established by the clients and the one or more providers (paragraphs [0003], [0019], goals are established that include functions, activities, and what is to be expected from progress on the goal).

Consider **claim 8**, and **as applied to claim 1 above**, Luttrell discloses a method comprising:

determining whether modifications to the goals are required in response to the compiled data (paragraphs [0021], [0027], the goals can be changed or updated based on the different data supplied to the system).

Consider **claim 9** and **as applied to claim 8 above**, Luttrell discloses a method comprising:

modifying the goals in response to the complied data (paragraphs [0021], [0027], the goals can be changed or updated based on the different data supplied to the system).

Consider **claim 10**, and **as applied to claim 8 above**, Luttrell discloses a method comprising:

modifications are determined to be required if the one of the one or more clients is unable to achieve the goals associated with the client (paragraphs [0026], [0029], progress made towards the goals by the patients is analyzed, which may trigger the need to change the goals).

Claims 11 – 16 are rejected under the same rational as provided with respect to claims 1 – 10 above. Claim 11 corresponds to claim 1, claim 12 corresponds to claim 2, claim 13 corresponds to claim 3, claim 14 corresponds to claim 5, claim 15 corresponds to claim 7, and claim 16 corresponds to claims 8 and 9. The only difference is claims 11 – 16 are system claims, whereas claims 1 – 10 are method claims. Since the same claim limitations are being claimed, they are therefore the same rejections are applied therein.

Claims 17 – 20 are rejected under the same rational as provided with respect to claims 1 – 10 above. Claim 17 corresponds to claim 1, claim 18 corresponds to claim 3, claim 19 corresponds to claim 5, and claim 20 corresponds to claims 8 and 9. The only difference is claims 17 – 20 are system claims, whereas claims 1 – 10 are method claims. Since the same claim limitations are being claimed, they are therefore the same rejections are applied therein.

Relevant Prior Art Directed to State of Art

10. Metzler (US PGPub 2011/0047404) discloses a method of determining a user's state, such that the behavior and actions of the user are used to determine the user's condition, which allows for others to be alerted if the user is determined to be in a state which may require intervention or help.

Conclusion

11. Any response to this Office Action should be **faxed to** (571) 273-8300 **or mailed to**:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Hand-delivered responses should be brought to

Customer Service Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314

12. Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Christopher Raab whose telephone number is (571) 270-1090. The Examiner can normally be reached on Monday-Friday from 9:00am to 5:00pm.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Tamara Kyle can be reached on (571) 272-4241. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you

have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free) or 703-305-3028.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist/customer service whose telephone number is (571) 272-2600.

/CHRISTOPHER J RAAB/
Primary Examiner, Art Unit 2156

March 25, 2023

Notice of References Cited	Application/Control No. 17/499,725	Applicant(s)/Patent Under Reexamination Bradley et al.	
	Examiner CHRISTOPHER J RAAB	Art Unit 2156	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	CPC Classification	US Classification
*	A	US-20150205930-A1	07-2015	Shaanan; Jessica	G06Q10/00	705/2
*	B	US-20030004758-A1	01-2003	Luttrell, Tammy C.	G06Q40/08	705/2
*	C	US-20140372138-A1	12-2014	Chari; Ravi S.	G16H40/20	705/2
*	D	US-20140280136-A1	09-2014	Marshall; Lisa A.	G06Q10/0637	707/736
*	E	US-20130144646-A1	06-2013	Loncar; Srdjan	G16H20/10	705/2
*	F	US-20120253834-A1	10-2012	Tracy; Carrie L.	G16H10/60	705/2
	G					
	H					
	I					
	J					
	K					
	L					
	M					

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	CPC Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/499,725	Bradley et al.
	Examiner	Art Unit
	CHRISTOPHER J RAAB	2156

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

CLAIMS

☐ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIM		DATE								
Final	Original	03/25/2023								
	1	✓								
	2	✓								
	3	✓								
	4	✓								
	5	✓								
	6	✓								
	7	✓								
	8	✓								
	9	✓								
	10	✓								
	11	✓								
	12	✓								
	13	✓								
	14	✓								
	15	✓								
	16	✓								
	17	✓								
	18	✓								
	19	✓								
	20	✓								

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/499,725	Bradley et al.
	Examiner	Art Unit
	CHRISTOPHER J RAAB	2156

CPC - Searched*		
Symbol	**Date**	**Examiner**
G06Q10/06, limited keyword search	03/25/2023	CJR
G06Q10/0637, limited keyword search	03/25/2023	CJR

CPC Combination Sets - Searched*		
Symbol	**Date**	**Examiner**

US Classification - Searched*			
Class	**Subclass**	**Date**	**Examiner**

* See search history printout included with this form or the SEARCH NOTES box below to determine the scope of the search.

Search Notes		
Search Notes	**Date**	**Examiner**
PE2E image and keyword search	03/25/2023	CJR
NPL Search: Google Scholar	03/25/2023	CJR
Inventor Name Search: PALM and PE2E	03/25/2023	CJR

Interference Search			
US Class/CPC Symbol	**US Subclass/CPC Group**	**Date**	**Examiner**

/CHRISTOPHER J RAAB/ Primary Examiner, Art Unit 2156	

Bibliographic Data

Application No: 17/499,725

Foreign Priority claimed: ○ Yes ◉ No

35 USC 119 (a-d) conditions met: ☐ Yes ☑ No ☐ Met After Allowance

Verified and Acknowledged: /CHRISTOPHER J RAAB/ Examiner's Signature | Initials

Title: SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION

FILING or 371(c) DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
10/12/2021	707	2156	DHP-P0001CIP1
RULE			

APPLICANTS

Data Health Partners, Inc., Los Angeles, CA, UNITED STATES

INVENTORS

Nathaniel T. Bradley, Tucson, AZ, UNITED STATES

James Gaynor, Winchester, VA, UNITED STATES

Joshua S. Paugh, Tucson, AZ, UNITED STATES

Paul Arena, Malibu, CA, UNITED STATES

Lisa A. Marshall, Richmond, VA, UNITED STATES

CONTINUING DATA

This application is a CON of 16141471 09/25/2018 PAT 11144554 okay - CJR

16141471 is a CIP of 16053141 08/02/2018 PAT 11151142 okay - CJR

16053141 is a CON of 14212429 03/14/2014 PAT 10061812 okay - CJR

14212429 has PRO of 61791218 03/15/2013 okay - CJR

FOREIGN APPLICATIONS

IF REQUIRED, FOREIGN LICENSE GRANTED**

**** SMALL ENTITY ****

STATE OR COUNTRY

UNITED STATES

ADDRESS

Goodhue, Coleman & Owens, P.C.
12951 University Ave
Suite 201
Clive, IA 50325
UNITED STATES

FILING FEE RECEIVED

$830

Doc code: IDS
Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (02-18)
Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	17/499725
Filing Date	
First Named Inventor	Nathaniel T. Bradley
Art Unit	2156
Examiner Name	Christopher Raab
Attorney Docket Number	PBH-P0001CIP1

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	4237344	A	1980-12-02	Moore	Entire Document
	2	5377258	A	1994-12-27	Bro	Entire Document
	3	8066640	B2	2011-11-29	Angelides	Entire Document
	4	8313433	B2	2012-11-20	Cohen et al.	Entire Document
	5	8355925	B2	2013-01-15	Rothman et al.	Entire Document
	6	RE42508		2011-06-28	Lewis et al.	Entire Document

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.J.R/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	
	Filing Date	
	First Named Inventor	Nathaniel T. Bradley
	Art Unit	
	Examiner Name	
	Attorney Docket Number	PBH-P0001CIP1

	1	20020065697	A1	2002-05-30	Cautley et al.	Entire Document
	2	20020147626	A1	2002-10-10	Zagotta et al.	Entire Document
	3	20020194046	A1	2002-12-19	Sullivan et al.	Entire Document
	4	20030004758	A1	2003-01-02	Luttrell	Entire Document
	5	20030014279	A1	2003-01-16	Roman et al.	Entire Document
	6	20080141138	A1	2008-06-12	Kalaboukis et al.	Entire Document
	7	20080270182	A1	2008-10-30	Lowney	Entire Document
	8	20080281651	A1	2008-11-13	Brennan et al.	Entire Document
	9	20090048872	A1	2009-02-19	Toy et al.	Entire Document
	10	20090112924	A1	2009-04-30	Harris et al.	Entire Document
	11	20090192825	A1	2009-07-30	Hunt et al.	Entire Document

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.J.R/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	
	Filing Date	
	First Named Inventor	Nathaniel T. Bradley
	Art Unit	
	Examiner Name	
	Attorney Docket Number	PBH-P0001CIP1

	12	20100082381	A1	2010-04-01	Merrifield Jr. et al.	Entire Document
	13	20110029521	A1	2011-02-03	Thayne et al.	Entire Document
	14	20110047404	A1	2011-02-24	Metzler et al.	Entire Document
	15	20110161107	A1	2011-06-30	Goldberg et al.	Entire Document
	16	20110295613	A1	2011-12-01	Coyne	Entire Document

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2]	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1							

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]
	1	"International Application No PCT/US2014/029287 International Search Report and Written Opinion", 08/22/2014, 7 pages.	X

If you wish to add additional non-patent literature document citation information please click the Add button Add

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.J.R/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	
	Filing Date	
	First Named Inventor	Nathaniel T. Bradley
	Art Unit	
	Examiner Name	
	Attorney Docket Number	PBH-P0001CIP1

EXAMINER SIGNATURE			
Examiner Signature	/CHRISTOPHER J RAAB/	Date Considered	03/25/2023

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.J.R/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (**Not for submission under 37 CFR 1.99**)	Application Number	
	Filing Date	
	First Named Inventor	Nathaniel T. Bradley
	Art Unit	
	Examiner Name	
	Attorney Docket Number	PBH-P0001CIP1

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Brian D. Owens/	Date (YYYY-MM-DD)	2021-10-12
Name/Print	Brian Dean Owens	Registration Number	55517

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.J.R/

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.J.R/

Doc code: IDS
Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (01-22)
Approved for use through 05/31/2024. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	17499725
Filing Date	2021-10-12
First Named Inventor	Nathaniel T. Bradley
Art Unit	OPAP 2156
Examiner Name	Docket CENTRAL Christopher Raab
Attorney Docket Number	PBH-P0001CIP1

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20150205930	A1	2015-07-23	Shaanan; Jessica	Entire Document

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2]	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1							

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.J.R/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17499725
	Filing Date	2021-10-12
	First Named Inventor	Nathaniel T. Bradley
	Art Unit	OPAP
	Examiner Name	Docket CENTRAL
	Attorney Docket Number	PBH-P0001CIP1

	1		

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature	/CHRISTOPHER J RAAB/	Date Considered	03/25/2023

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.J.R/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	17499725
Filing Date	2021-10-12
First Named Inventor	Nathaniel T. Bradley
Art Unit	OPAP
Examiner Name	Docket CENTRAL
Attorney Docket Number	PBH-P0001CIP1

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Brian D. Owens/	Date (YYYY-MM-DD)	2022-03-07
Name/Print	Brian Dean Owens	Registration Number	55517

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.J.R/

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.J.R/

Google Scholar | progress towards patient goals

Articles | About 1,700,000 results (0.21 sec) | My profile | My library

Any time
Since 2023
Since 2022
Since 2019
Custom range...

Sort by relevance
Sort by date

Any type
Review articles

include patents
include citations

Create alert

[HTML] **Progress towards** elimination **goals** for viral hepatitis — [HTML] nature.com Full Text @ USPTO-STIC

AL Cox, MH El-Sayed, JH Kao, JV Lazarus... - Nature Reviews ..., 2020 - nature.com

... **progress** has been made **towards** elimination, there are still some important gaps in terms of policy and **progress**... is feasible, what the key areas of **progress** are and what the focus for the ...

Save Cite Cited by 98 Related articles All 10 versions

Tuberculosis control in South Africa: successes, challenges and recommendations: tuberculosis control-**Progress towards** the Millennium Development **Goals** — [PDF] journals.co.za

GJ Churchyard, LD Mametja, L Mvusi... - South African Medical ..., 2014 - journals.co.za

... Although SA has made notable **progress** in reducing TB prevalence and deaths and ... are required to further accelerate **progress towards** improved TB control in SA and beyond. ...

Save Cite Cited by 181 Related articles All 20 versions

[HTML] **Progress towards** the 2030 sustainable development **goals**: direct and indirect impacts on neurological disorders — [HTML] springer.com Full View

EJ Mateen - Journal of Neurology, 2022 - Springer

... Priority lists must be developed for neurological disorders, including targeting the number of **patients** treated, vaccines distributed, cases rehabilitated, and drugs delivered. **Goals** must ...

Save Cite Related articles All 3 versions

A brief history of South Africa's response **to** AIDS: history of HIV in SA-**Progress towards** the Millennium Development **Goals** — [PDF] journals.co.za

NP Simelela, WDF Venter - South African medical journal, 2014 - journals.co.za

The story of the AIDS response in South Africa over the past 4 years is one of great **progress** after almost a decade of complex and tragic denialism that united the world and civil society ...

Save Cite Cited by 173 Related articles All 19 versions

[HTML] Sustainable development **goals** relevant **to** kidney health: an update on **progress** — [HTML] nature.com Full Text @ USPTO-STIC

VA Luyckx, Z Al-Aly, AK Bello, E Bellorin-Font ... - Nature Reviews ..., 2021 - nature.com

... When kidney disease is not detected and treated early, **patient** care requires specialized resources that drive up cost, place many people at risk of catastrophic health expenditure and ...

Save Cite Cited by 74 Related articles All 21 versions

Ensuring that the diagnosis of tuberculosis accelerates **progress towards** the Millennium Development **Goals** — [PDF] ersjournals.com Full View

C Hanson, G Sotgiu... - European Respiratory ..., 2014 - Eur Respiratory Soc

... If the final **goal** is to reach zero deaths due to tuberculosis, it should be unanimously accepted that no **patient** can go undiagnosed. We are still waiting for the shining star, a point-of-care ...

Save Cite Cited by 9 Related articles All 4 versions

[HTML] Improving lives by accelerating **progress towards** the UN Sustainable Development **Goals** for adolescents living with HIV: a prospective cohort study — [HTML] sciencedirect.com

LD Cluver, FM Orkin, L Campeau, E Toska... - The Lancet Child & ..., 2019 - Elsevier

... that can lead to **progress** across multiple Sustainable Development **Goals** (SDG) and ... explicitly tested for combinations of provisions that affect multiple SDG targets and **goals**. ...

Save Cite Cited by 96 Related articles All 13 versions

[HTML] **Progress towards** the integration of pharmacogenomics in practice [HTML] springer.com Full View

SD Mooney - Human genetics, 2015 - Springer

... area of research with the **goal** of common clinical use. This **goal** has developed into today's ... Finally, what and when to return data to a **patient** is an area under constant debate. New ...

Save Cite Cited by 50 Related articles All 8 versions

Consequences of delaying **progression to** optimal therapy in **patients** with type 2 diabetes not achieving glycemic **goals**. Full Text @ USPTO-STIC

WC Hsu - Southern medical journal, 2009 - europepmc.org

... **patients'** long-term prognosis, stems partly from clinical inertia and psychological factors affecting both **patients** ... modern delivery devices, can help **patients** take advantage of this effect, ...

Save Cite Cited by 43 Related articles All 3 versions

Poor availability of essential medicines for women and children threatens **progress towards** Sustainable Development **Goal** 3 in Africa [PDF] bmj.com Free from Publisher

B Droti, KP O'Neill, M Mathai, DYT Doyle... - BMJ Global ..., 2019 - gh.bmj.com

... **Patient** and public involvement **Patients** and the public are not involved in SARA surveys. With WHO technical support, each of the countries has produced comprehensive SARA reports ...

Save Cite Cited by 23 Related articles All 8 versions

Related searches

optimal therapy in patients **glycemic** goals

update on progress **sustainable development** goals

PE2E SEARCH - Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	British Equivalents	Time Stamp
L1	2	("20110047404").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 01:24 PM
L2	10	("20090112924"|"20090192825"|"8313433"|"8355925"|"RE42508").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:00 PM
L3	3130	account WITH client WITH provider	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:01 PM
L4	77	data mining WITH goal WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:01 PM
L5	41	data mining WITH best practices	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:01 PM
L6	1	intensive trial teaching	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:01 PM
L7	1	reinforcement recorder	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:06 PM
L8	864	goal WITH achiev$5 WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:24 PM
L9	3158	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:25 PM
L10	1117	L9 AND goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:25 PM
L11	78	L9 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:25 PM
L12	23	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:25 PM
L13	6	Macrosolve$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:30 PM
L14	84	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2015/12/01 02:30 PM
L15	1753	alert WITH automatic$6 WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2016/07/08 04:34 PM
L16	540	alert NEAR5 automatic$6 NEAR5 threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2016/07/08 04:34 PM

L17	1110	(compile OR compiling OR compiled) WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 09:37 PM
L18	27	(compile OR compiling OR compiled) WITH user input WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 09:37 PM
L19	18	(compile OR compiling OR compiled) WITH "without user input"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 09:39 PM
L20	126	(score OR status) WITH "without user input"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 09:41 PM
L21	441	(status) WITH automatic$ WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 09:49 PM
L22	352	status WITH automatic$ WITH (score OR compile OR compiling OR scoring)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/01/08 10:01 PM
L23	1161	score WITH client WITH (threshold OR status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/07/09 10:20 PM
L24	125	well-being WITH client	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/07/09 10:21 PM
L25	385	well-being WITH score	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/07/09 10:21 PM
L26	0	well-being WITH client WITH score	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2017/07/09 10:21 PM
L27	90	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/02/27 11:11 AM
L28	1	"61791218"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/02/27 11:24 AM
L29	1	"15301419"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/02/27 01:30 PM
L30	55	client management program	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2018/03/19 10:14 AM
L31	2008	administrator SAME (client WITH provider)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2018/03/19 10:14 AM
L33	2	("7346545").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2018/04/12 02:12 PM
L34	2710	(track OR tracked OR tracking) NEAR2 goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/04/15 03:10 PM

L35	71	((track OR tracked OR tracking) NEAR2 goal) WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/04/15 03:10 PM
L36	44	((track OR tracked OR tracking) NEAR2 goal) SAME (behavioral OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/04/15 03:20 PM
L37	77	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/04/15 03:23 PM
L38	90	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/06/22 04:37 PM
L39	4499	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/06/22 04:37 PM
L40	6	(administrator SAME (client WITH provider)) AND ((score OR mastery) NEAR5 goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2018/06/22 04:40 PM
L41	24	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/06/22 04:40 PM
L42	714	score WITH measurement WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/06/22 04:40 PM
L43	39585	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2018/06/22 04:44 PM
L54	4	("10061812").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2019/12/23 01:57 PM
L55	13	("20020065697"|"20020147626"|"20020194046"|"20080141138"|"20080281651"|"20090112924"|"20090192825"|"20100082381"|"20110029521"|"20110047404"|"8313433"|"8355925"|"RE42508").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2019/12/23 02:26 PM
L56	27	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:29 PM
L57	1695	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:30 PM
L58	5898	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:31 PM
L59	46154	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO;	ADJ	ON	ON	2019/12/23 02:31 PM

			DERWENT; IBM_TDB)				
L60	9	L57 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:31 PM
L61	100	L58 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:31 PM
L62	647	(status) WITH automatic$ WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:31 PM
L63	87	data mining WITH goal WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:32 PM
L64	9	(administrator SAME (client WITH provider)) AND ((score OR mastery) NEAR5 goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2019/12/23 02:32 PM
L65	101	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:32 PM
L66	4	L57 AND goal wizard	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:32 PM
L67	4	L58 AND goal wizard	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:32 PM
L68	4	L57 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:33 PM
L69	5	L58 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:33 PM
L70	4	L57 AND (goal WITH alert WITH client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:33 PM
L71	4	L58 AND (goal WITH alert WITH client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2019/12/23 02:33 PM
L72	2	"16053141"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/07/23 03:16 PM
L73	191357	field WITH (treatment OR assistance)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/07/24 10:31 AM
L74	363	field WITH (treatment OR assistance) WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/07/24 02:37 PM
L75	726	(compile OR compiled OR compiling) WITH (client OR patient) WITH (field OR treatment)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/07/24 03:04 PM

L76	11	(("4237344") or ("5377258") or ("20090048872") or ("20110295613")).PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2020/07/27 02:54 PM
L77	2	("20090048872"|"20110295613").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2020/09/29 09:56 AM
L78	2	("4237344"|"5377258").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2020/09/29 09:56 AM
L79	1	("20030004758").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2020/09/29 09:56 AM
L80	1	"16141471"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 10:19 AM
L81	0	"Platform for Optimizing Goal Progression".TI.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 10:19 AM
L82	43	Bradley, Nathaniel.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 10:19 AM
L83	4	("10061812").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2020/09/29 10:20 AM
L84	88	data mining WITH goal WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L85	60	data mining WITH best practices	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L86	41	(compile OR compiling OR compiled) WITH user input WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L87	115	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L88	95	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L89	2189	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:01 AM
L90	11	L89 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:02 AM
L91	4	L89 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:02 AM
L92	4	L89 AND (goal WITH alert WITH client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2020/09/29 11:02 AM
L93	10482	threshold WITH goal	(US-PGPUB; USPAT;	ADJ	ON	ON	2021/04/08

			EPO; JPO; DERWENT; IBM_TDB)				09:23 PM
L94	714	threshold WITH goal WITH (plan OR met)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:23 PM
L95	43	threshold WITH goal WITH (plan OR met) WITH (treatment OR provider OR client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:24 PM
L96	22	threshold WITH goal WITH (plan OR met) WITH (treat$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:28 PM
L97	252	threshold WITH goal WITH (treat$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:46 PM
L98	103	L97 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:46 PM
L99	7	(("20120203092") or ("20080270182") or ("10098584")).PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2021/04/08 09:52 PM
L100	5	L99 AND threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 09:52 PM
L101	56	(patient OR client) WITH threshold WITH goal WITH (treat$5 OR chang$4 OR modif$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:03 PM
L102	17	L101 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:03 PM
L103	49389	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:05 PM
L104	6924	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:05 PM
L105	297	(L103 OR L104) AND (threshold WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:06 PM
L106	204	L105 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:06 PM
L107	29	(L103 OR L104) AND ((threshold WITH goal) SAME (patient OR client))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:08 PM
L108	9	L107 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/04/08 10:08 PM
L109	364	(treatment OR evaluation) WITH (goal) WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:39 PM

L110	10	(client OR patient) WITH goal WITH threshold WITH progress$4	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:43 PM
L111	1708	(client OR patient) WITH goal WITH (threshold OR progress$4)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:43 PM
L112	902	(client OR patient) WITH (goal NEAR5 (threshold OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:45 PM
L113	362	L112 AND @AD<"20130315"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:46 PM
L114	238	(client OR patient) WITH (goal NEAR5 (threshold OR progress$4)) WITH (treatment OR assistance OR modify$4 OR plan)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:53 PM
L115	84	L114 AND @AD<"20130315"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 01:53 PM
L116	327	(client OR patient) WITH goal WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 02:03 PM
L117	121	(client OR patient) WITH goal WITH (progress$4 OR threshold) WITH (modif$5 OR chang$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 02:03 PM
L118	1	"16141471"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 02:27 PM
L119	327	(patient OR client) WITH threshold WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 07:35 PM
L120	153	L119 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/07/21 07:44 PM
L121	50097	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2021/08/12 02:27 PM
L122	2	("8066640").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2021/08/12 02:36 PM
L133	252	patient WITH threshold WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:43 PM
L134	3051	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO;	ADJ	ON	ON	2022/02/25 09:50 PM

			DERWENT; IBM_TDB)				
L135	51231	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L136	7790	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L137	30	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L138	136	L134 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L139	1130	L135 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L140	292	L136 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:50 PM
L141	13	L136 AND ((patient OR client) WITH (threshold) WITH (alert OR goal OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:51 PM
L142	94	L135 AND ((patient OR client) WITH (threshold) WITH (alert OR goal OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:51 PM
L143	13	L134 AND ((patient OR client) WITH (threshold) WITH (alert OR goal OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:51 PM
L144	60	Bradley, Nathaniel.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:51 PM
L145	62	Gaynor, James.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:51 PM
L146	41	Paugh, Joshua.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:52 PM
L147	5	Arena, Paul.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/02/25 09:52 PM
L148	2	("20090192825").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2022/02/25 09:53 PM
L149	4	("11144554").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2022/02/25 10:10 PM
L151	972	(client OR patient) WITH baseline WITH goal	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU,	ADJ	ON	ON	2022/07/25 11:43 AM

			CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)				
L152	73	((client OR patient) WITH baseline WITH goal) SAME threshold	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/07/25 11:43 AM
L153	154	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2022/07/25 11:43 AM
L154	57	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; EPO)	ADJ	ON	ON	2022/07/25 11:43 AM
L155	61	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; EPO)	ADJ	ON	ON	2023/01/13 08:53 PM
L157	139	(client OR patient) WITH goal WITH biometric	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB,	OR	ON	ON	2023/01/13 08:53 PM

			HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)				
L158	633	goal WITH threshold WITH rule	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2023/03/24 02:04 PM
L159	23	(client OR patient) WITH goal WITH threshold WITH rule	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/24 02:05 PM
L160	2	("20110047404").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L161	10	("20090112924"|"20090192825"|"8313433"|"8355925"|"RE42508").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L162	7418	account WITH client WITH provider	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L163	112	data mining WITH goal WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L164	61	data mining WITH best practices	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L165	9	intensive trial teaching	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L166	9	reinforcement recorder	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L167	1919	goal WITH achiev$5 WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L168	9840	G06Q10/0637.CPC.	(US-PGPUB; USPAT;	ADJ	ON	ON	2023/03/25

			EPO; JPO; DERWENT; IBM_TDB)				07:42 PM
L169	2100	L9 AND goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L170	155	L9 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L171	31	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L172	6	Macrosolve$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L173	96	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L174	4987	alert WITH automatic$6 WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L175	1324	alert NEAR5 automatic$6 NEAR5 threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L176	2056	(compile OR compiling OR compiled) WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L177	54	(compile OR compiling OR compiled) WITH user input WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L178	50	(compile OR compiling OR compiled) WITH "without user input"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L179	340	(score OR status) WITH "without user input"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L180	992	(status) WITH automatic$ WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L181	853	status WITH automatic$ WITH (score OR compile OR compiling OR scoring)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L182	3702	score WITH client WITH (threshold OR status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L183	223	well-being WITH client	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L184	962	well-being WITH score	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM

L185	18	well-being WITH client WITH score	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L186	96	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L187	9	"61791218"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L188	3	"15301419"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L189	69	client management program	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L190	3683	administrator SAME (client WITH provider)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L191	2	("7346545").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L192	4638	(track OR tracked OR tracking) NEAR2 goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L193	133	((track OR tracked OR tracking) NEAR2 goal) WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L194	90	((track OR tracked OR tracking) NEAR2 goal) SAME (behavioral OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L195	178	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L196	96	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L197	9840	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L198	20	(administrator SAME (client WITH provider)) AND ((score OR mastery) NEAR5 goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L199	31	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L200	1805	score WITH measurement WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L201	62988	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO;	ADJ	ON	ON	2023/03/25 07:42 PM

			DERWENT; IBM_TDB)				
L202	4	("10061812").PN.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L203	13	("20020065697"|"20020147626"|"20020194046"|"20080141138"|"20080281651"|"20090112924"|"20090192825"|"20100082381"|"20110029521"|"20110047404"|"8313433"|"8355925"|"RE42508").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/25 07:42 PM
L204	31	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L205	3722	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L206	9840	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L207	62988	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L208	26	L57 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L209	155	L58 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L210	992	(status) WITH automatic$ WITH user input	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L211	112	data mining WITH goal WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L212	20	(administrator SAME (client WITH provider)) AND ((score OR mastery) NEAR5 goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L213	178	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L214	9	L57 AND goal wizard	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L215	9	L58 AND goal wizard	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L216	92	L57 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO;	ADJ	ON	ON	2023/03/25 07:42 PM

			DERWENT; IBM_TDB)				
L217	12	L58 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L218	10	L57 AND (goal WITH alert WITH client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L219	12	L58 AND (goal WITH alert WITH client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L220	7	"16053141"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L221	327785	field WITH (treatment OR assistance)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L222	490	field WITH (treatment OR assistance) WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L223	933	(compile OR compiled OR compiling) WITH (client OR patient) WITH (field OR treatment)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L224	11	(("4237344") or ("5377258") or ("20090048872") or ("20110295613")).PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L225	2	("20090048872"|"20110295613").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/25 07:42 PM
L226	2	("4237344"|"5377258").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/25 07:42 PM
L227	1	("20030004758").PN.	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/25 07:42 PM
L228	4	"16141471"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L229	0	"Platform for Optimizing Goal Progression".TI.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L230	85	Bradley, Nathaniel.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L231	4	("10061812").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L232	112	data mining WITH goal WITH status	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L233	61	data mining WITH best practices	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM

L234	54	(compile OR compiling OR compiled) WITH user input WITH (status OR score)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L235	178	((track OR tracked OR tracking) NEAR2 goal) SAME (provider OR hospital)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L236	96	Grafton$.AS.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L237	3722	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L238	26	L89 AND (goal WITH status)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L239	92	L89 AND (client WITH provider WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L240	10	L89 AND (goal WITH alert WITH client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L241	13185	threshold WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L242	898	threshold WITH goal WITH (plan OR met)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L243	70	threshold WITH goal WITH (plan OR met) WITH (treatment OR provider OR client)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L244	45	threshold WITH goal WITH (plan OR met) WITH (treat$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L245	358	threshold WITH goal WITH (treat$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L246	107	L97 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L247	7	(("20120203092") or ("20080270182") or ("10098584")).PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L248	5	L99 AND threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L249	104	(patient OR client) WITH threshold WITH goal WITH (treat$5 OR chang$4 OR modif$5)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L250	18	L101 AND	(US-PGPUB; USPAT;	ADJ	ON	ON	2023/03/25

		(@AD<"20130315" OR @RLAD<"20130315")	EPO; JPO; DERWENT; IBM_TDB)				07:42 PM
L251	62988	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L252	9840	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L253	356	(L103 OR L104) AND (threshold WITH goal)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L254	213	L105 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L255	37	(L103 OR L104) AND ((threshold WITH goal) SAME (patient OR client))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L256	10	L107 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L257	496	(treatment OR evaluation) WITH (goal) WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L258	30	(client OR patient) WITH goal WITH threshold WITH progress$4	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L259	2057	(client OR patient) WITH goal WITH (threshold OR progress$4)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L260	1043	(client OR patient) WITH (goal NEAR5 (threshold OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L261	351	L112 AND @AD<"20130315"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L262	287	(client OR patient) WITH (goal NEAR5 (threshold OR progress$4)) WITH (treatment OR assistance OR modify$4 OR plan)	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L263	82	L114 AND @AD<"20130315"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L264	434	(client OR patient) WITH goal WITH threshold	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L265	163	(client OR patient)	(US-PGPUB; USPAT;	ADJ	ON	ON	2023/03/25

		WITH goal WITH (progress$4 OR threshold) WITH (modif$5 OR chang$5)	EPO; JPO; DERWENT; IBM_TDB)				07:42 PM
L266	4	"16141471"	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L267	434	(patient OR client) WITH threshold WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L268	157	L119 AND (@AD<"20130315" OR @RLAD<"20130315")	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L269	62988	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L270	2	("8066640").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L271	309	patient WITH threshold WITH goal	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L272	3722	G06F16/2457.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L273	62988	G06Q10/06.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L274	9840	G06Q10/0637.CPC.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L275	31	Marshall, Lisa.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L276	154	L134 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L277	1193	L135 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L278	341	L136 AND (goal WITH (status OR progress OR threshold))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L279	16	L136 AND ((patient OR client) WITH (threshold) WITH (alert OR goal OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L280	101	L135 AND ((patient OR client) WITH (threshold) WITH (alert OR goal OR progress$4))	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L281	15	L134 AND ((patient OR client) WITH (threshold)	(US-PGPUB; USPAT; EPO; JPO;	ADJ	ON	ON	2023/03/25 07:42 PM

		WITH (alert OR goal OR progress$4))	DERWENT; IBM_TDB)				
L282	85	Bradley, Nathaniel.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L283	66	Gaynor, James.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L284	61	Paugh, Joshua.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L285	6	Arena, Paul.INV.	(US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L286	2	("20090192825").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L287	4	("11144554").PN.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB)	ADJ	OFF	OFF	2023/03/25 07:42 PM
L288	1050	(client OR patient) WITH baseline WITH goal	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L289	80	((client OR patient) WITH baseline WITH goal) SAME threshold	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)	ADJ	ON	ON	2023/03/25 07:42 PM
L290	167	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; FIT (AP, AT, AU, BE, BG, BR, BY,	ADJ	ON	ON	2023/03/25 07:42 PM

			CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, MC, MD, MY, NL, NO, NZ, OA, PH, PL, PT, RO, RS, RU, SE, SG, SI, SK, SU, TH, TN, TR, TW, UA, VN, WO); FPRS; EPO; JPO; DERWENT; IBM_TDB)				
L291	64	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; EPO)	ADJ	ON	ON	2023/03/25 07:42 PM
L292	64	((client OR patient) NEAR5 baseline NEAR5 goal)	(US-PGPUB; USPAT; USOCR; EPO)	ADJ	ON	ON	2023/03/25 07:42 PM
L293	141	(client OR patient) WITH goal WITH biometric	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2023/03/25 07:42 PM
L294	633	goal WITH threshold WITH rule	(US-PGPUB; USPAT; USOCR; FIT (AU, AP, AT, BE, BG, BR, BY, CA, CH, CN, CS, CU, CZ, DD, DE, DK, EA, EE, EP, ES, FI, FR, GB, HR, HU, ID, IE, IL, IS, IT, JP, KR, LT, LU, LV, MA, OA, RU, SU, WO, MC, MD, MY, NL, NO, NZ, PH, PL, PT, RO, RS, SE, SG, SI, SK, TH, TN, TR, TW, UA, VN); FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2023/03/25 07:42 PM
L295	23	(client OR patient) WITH goal WITH threshold WITH rule	(US-PGPUB; USPAT)	ADJ	ON	ON	2023/03/25 07:42 PM

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	British Equivalents	Time Stamp
N44	5	client management program.CLM.	(US-PGPUB; USPAT)	ADJ	OFF	OFF	2018/06/22 04:37 PM
N45	0	(administrator SAME (client WITH provider)) AND ((score OR mastery) NEAR5 goal).CLM.	(US-PGPUB; USPAT)	ADJ	OFF	OFF	2018/06/22 04:37 PM
N46	1	((track OR tracked OR tracking) NEAR2 goal) SAME (behavioral OR hospital).CLM.	(US-PGPUB; USPAT)	ADJ	ON	ON	2018/06/22 04:37 PM
N47	14	data mining WITH best practices.CLM.	(US-PGPUB; USPAT)	ADJ	ON	ON	2018/06/22 04:37 PM
N48	108	score WITH measurement WITH threshold.CLM.	(US-PGPUB; USPAT)	ADJ	ON	ON	2018/06/22 04:40 PM
N49	3	score WITH measurement WITH threshold WITH (well-being OR health).CLM.	(US-PGPUB; USPAT)	ADJ	ON	ON	2018/06/22 05:04 PM
N50	0	periodically (provide OR update) WITH well-being.CLM.	(US-PGPUB; USPAT)	ADJ	ON	ON	2018/06/22 05:04 PM
N51	0	mastery WITH goal WITH compile.CLM.	(US-PGPUB; USPAT)	ADJ	ON	ON	2018/06/22 05:04 PM
N52	2	mastery WITH goal WITH status.CLM.	(US-PGPUB; USPAT)	ADJ	ON	ON	2018/06/22 05:04 PM
N53	79	score WITH threshold WITH (very OR significant).CLM.	(US-PGPUB; USPAT)	ADJ	ON	ON	2018/06/22 05:05 PM
N123	8	client management program.CLM.	(US-PGPUB; USPAT)	ADJ	OFF	OFF	2021/08/12 02:19 PM
N124	0	(administrator SAME (client WITH provider)) AND ((score OR mastery) NEAR5 goal).CLM.	(US-PGPUB; USPAT)	ADJ	OFF	OFF	2021/08/12 02:19 PM
N125	2	((track OR tracked OR tracking) NEAR2 goal) SAME (behavioral OR hospital).CLM.	(US-PGPUB; USPAT)	ADJ	ON	ON	2021/08/12 02:19 PM
N126	19	data mining WITH best practices.CLM.	(US-PGPUB; USPAT)	ADJ	ON	ON	2021/08/12 02:19 PM
N127	207	score WITH measurement WITH threshold.CLM.	(US-PGPUB; USPAT)	ADJ	ON	ON	2021/08/12 02:19 PM
N128	12	score WITH measurement WITH threshold WITH (well-being OR health).CLM.	(US-PGPUB; USPAT)	ADJ	ON	ON	2021/08/12 02:19 PM

N129	0	periodically (provide OR update) WITH well-being.CLM.	(US-PGPUB; USPAT)	ADJ	ON	ON	2021/08/12 02:19 PM
N130	1	mastery WITH goal WITH compile.CLM.	(US-PGPUB; USPAT)	ADJ	ON	ON	2021/08/12 02:19 PM
N131	3	mastery WITH goal WITH status.CLM.	(US-PGPUB; USPAT)	ADJ	ON	ON	2021/08/12 02:19 PM
N132	107	score WITH threshold WITH (very OR significant).CLM.	(US-PGPUB; USPAT)	ADJ	ON	ON	2021/08/12 02:19 PM

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	DHP-P0001CIP1
	Application Number	17/499,725
Title of Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	

The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.
This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.

Secrecy Order 37 CFR 5.2:

☐ Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)

Inventor Information:

Inventor 1 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Nathaniel	T.	Bradley	

Residence Information (Select One) ◉ US Residency ○ Non US Residency ○ Active US Military Service

City	Tucson	State/Province	AZ	Country of Residence	US

Mailing Address of Inventor:

Address 1	7450 S Sandbar Willow Place		
Address 2			
City	Tucson	State/Province	AZ
Postal Code	85747	Country	US

Inventor 2 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	James		Gaynor	

Residence Information (Select One) ◉ US Residency ○ Non US Residency ○ Active US Military Service

City	Winchester	State/Province	VA	Country of Residence	US

Mailing Address of Inventor:

Address 1	216 Cotton Ridge Road		
Address 2			
City	Winchester	State/Province	VA
Postal Code	22603	Country	US

Inventor 3 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Joshua	S.	Paugh	

Residence Information (Select One) ◉ US Residency ○ Non US Residency ○ Active US Military Service

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	DHP-P0001CIP1
	Application Number	17/499,725
Title of Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	

City	Tucson	State/Province	AZ	Country of Residence	US

Mailing Address of Inventor:

Address 1	7501 E Mary Dr.		
Address 2			
City	Tucson	State/Province	AZ
Postal Code	85730	Country	US

Inventor 4 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Paul		Arena	

Residence Information (Select One) (•) US Residency ( ) Non US Residency ( ) Active US Military Service

City	Malibu	State/Province	CA	Country of Residence	US

Mailing Address of Inventor:

Address 1	600 Schueren Rd		
Address 2			
City	Malibu	State/Province	CA
Postal Code	90265	Country	US

Inventor 5 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Lisa	A.	Marshall	

Residence Information (Select One) (•) US Residency ( ) Non US Residency ( ) Active US Military Service

City	Richmond	State/Province	VA	Country of Residence	US

Mailing Address of Inventor:

Address 1	4016 Northrop St.		
Address 2			
City	Richmond	State/Province	VA
Postal Code	23225	Country	US

All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the **Add** button. Add

Correspondence Information:

Enter either Customer Number or complete the Correspondence Information section below.
For further information see 37 CFR 1.33(a).

☐ **An Address is being provided for the correspondence Information of this application.**

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	DHP-P0001CIP1
	Application Number	17/499,725
Title of Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	

Customer Number	133690		
Email Address	docketing@goodhue.com	Add Email	Remove Email

Application Information:

Title of the Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION		
Attorney Docket Number	DHP-P0001CIP1	Small Entity Status Claimed	☒
Application Type	Nonprovisional		
Subject Matter	Utility		
Total Number of Drawing Sheets (if any)		Suggested Figure for Publication (if any)	

Filing By Reference:

Only complete this section when filing an application by reference under 35 U.S.C. 111(c) and 37 CFR 1.57(a). Do not complete this section if application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be provided in the appropriate section(s) below (i.e., "Domestic Benefit/National Stage Information" and "Foreign Priority Information").

For the purposes of a filing date under 37 CFR 1.53(b), the description and any drawings of the present application are replaced by this reference to the previously filed application, subject to conditions and requirements of 37 CFR 1.57(a).

Application number of the previously filed application	Filing date (YYYY-MM-DD)	Intellectual Property Authority or Country

Publication Information:

☐ Request Early Publication (Fee required at time of Request 37 CFR 1.219)

☐ **Request Not to Publish.** I hereby request that the attached application not be published under 35 U.S.C. 122(b) and certify that the invention disclosed in the attached application **has not and will not** be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.

Representative Information:

Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32).
Either enter Customer Number or complete the Representative Name section below. If both sections are completed the customer Number will be used for the Representative Information during processing.

Please Select One:	◉ Customer Number	○ US Patent Practitioner	○ Limited Recognition (37 CFR 11.9)
Customer Number	133690		

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	DHP-P0001CIP1
	Application Number	17/499,725
Title of Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	

Domestic Benefit/National Stage Information:

This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, 365(c), or 386(c) or indicate National Stage entry from a PCT application. Providing benefit claim information in the Application Data Sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.
When referring to the current application, please leave the "Application Number" field blank.

Prior Application Status	Patented			Remove	
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)	Patent Number	Issue Date (YYYY-MM-DD)
17499725	Continuation of	16141471	2018-09-25	11144554	2021-10-12
Prior Application Status	Patented			Remove	
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)	Patent Number	Issue Date (YYYY-MM-DD)
16141471	Continuation in part of	16053141	2018-08-02	11151142	2021-10-19
Prior Application Status	Patented			Remove	
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)	Patent Number	Issue Date (YYYY-MM-DD)
16053141	Continuation of	14212429	2014-03-14	10061812	2018-08-28
Prior Application Status	Expired			Remove	
Application Number	Continuity Type		Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)	
14212429	Claims benefit of provisional		61791218	2013-03-15	

Additional Domestic Benefit/National Stage Data may be generated within this form by selecting the **Add** button.

Foreign Priority Information:

This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55. When priority is claimed to a foreign application that is eligible for retrieval under the priority document exchange program (PDX)[i] the information will be used by the Office to automatically attempt retrieval pursuant to 37 CFR 1.55(i)(1) and (2). Under the PDX program, applicant bears the ultimate responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1).

			Remove
Application Number	Country[i]	Filing Date (YYYY-MM-DD)	Access Code[i] (if applicable)

Additional Foreign Priority Data may be generated within this form by selecting the **Add** button.

PTO/AIA/14 (01-22)
Approved for use through 05/31/2024. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	DHP-P0001CIP1
	Application Number	17/499,725
Title of Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications

☐ This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March 16, 2013.
NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March 16, 2013, will be examined under the first inventor to file provisions of the AIA.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	DHP-P0001CIP1
	Application Number	17/499,725
Title of Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	

Authorization or Opt-Out of Authorization to Permit Access:

When this Application Data Sheet is properly signed and filed with the application, applicant has provided written authority to permit a participating foreign intellectual property (IP) office access to the instant application-as-filed (see paragraph A in subsection 1 below) and the European Patent Office (EPO) access to any search results from the instant application (see paragraph B in subsection 1 below).

Should applicant choose not to provide an authorization identified in subsection 1 below, applicant **must opt-out** of the authorization by checking the corresponding box A or B or both in subsection 2 below.

NOTE: This section of the Application Data Sheet is **ONLY** reviewed and processed with the **INITIAL** filing of an application. After the initial filing of an application, an Application Data Sheet cannot be used to provide or rescind authorization for access by a foreign IP office(s). Instead, Form PTO/SB/39 or PTO/SB/69 must be used as appropriate.

1. Authorization to Permit Access by a Foreign Intellectual Property Office(s)

A. Priority Document Exchange (PDX) - Unless box A in subsection 2 (opt-out of authorization) is checked, the undersigned hereby **grants the USPTO authority** to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the State Intellectual Property Office of the People's Republic of China (SIPO), the World Intellectual Property Organization (WIPO), and any other foreign intellectual property office participating with the USPTO in a bilateral or multilateral priority document exchange agreement in which a foreign application claiming priority to the instant patent application is filed, access to: (1) the instant patent application-as-filed and its related bibliographic data, (2) any foreign or domestic application to which priority or benefit is claimed by the instant application and its related bibliographic data, and (3) the date of filing of this Authorization. See 37 CFR 1.14(h)(1).

B. Search Results from U.S. Application to EPO - Unless box B in subsection 2 (opt-out of authorization) is checked, the undersigned hereby **grants the USPTO authority** to provide the EPO access to the bibliographic data and search results from the instant patent application when a European patent application claiming priority to the instant patent application is filed. See 37 CFR 1.14(h)(2).

The applicant is reminded that the EPO's Rule 141(1) EPC (European Patent Convention) requires applicants to submit a copy of search results from the instant application without delay in a European patent application that claims priority to the instant application.

2. Opt-Out of Authorizations to Permit Access by a Foreign Intellectual Property Office(s)

☐ A. Applicant **DOES NOT** authorize the USPTO to permit a participating foreign IP office access to the instant application-as-filed. If this box is checked, the USPTO will not be providing a participating foreign IP office with any documents and information identified in subsection 1A above.

☐ B. Applicant **DOES NOT** authorize the USPTO to transmit to the EPO any search results from the instant patent application. If this box is checked, the USPTO will not be providing the EPO with search results from the instant application.

NOTE: Once the application has published or is otherwise publicly available, the USPTO may provide access to the application in accordance with 37 CFR 1.14.

PTO/AIA/14 (01-22)
Approved for use through 05/31/2024. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	DHP-P0001CIP1
	Application Number	17/499,725
Title of Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	

Applicant Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

Applicant 1

If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed. The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR 1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be identified in this section.

Clear

◉ Assignee	○ Legal Representative under 35 U.S.C. 117	○ Joint Inventor
○ Person to whom the inventor is obligated to assign.	○ Person who shows sufficient proprietary interest	

If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:

Name of the Deceased or Legally Incapacitated Inventor:

If the Applicant is an Organization check here. ☒

Organization Name	Data Health Partners, Inc.		
Mailing Address Information For Applicant:			
Address 1	~~10586 W Pico Blvd #1096~~ 8549 Wilshire Blvd		
Address 2	Suite 2403		
City	~~Los Angeles~~ Beverly Hills	**State/Province**	CA
Country	US	Postal Code	~~90064~~ 90211
Phone Number		Fax Number	
Email Address			

Additional Applicant Data may be generated within this form by selecting the Add button.

Assignee Information including Non-Applicant Assignee Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	DHP-P0001CIP1
	Application Number	17/499,725
Title of Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	

Assignee 1

Complete this section if assignee information, including non-applicant assignee information, is desired to be included on the patent application publication. An assignee-applicant identified in the "Applicant Information" section will appear on the patent application publication as an applicant. For an assignee-applicant, complete this section only if identification as an assignee is also desired on the patent application publication.

If the Assignee or Non-Applicant Assignee is an Organization check here. ☒

Organization Name	Data Health Partners, Inc.

Mailing Address Information For Assignee including Non-Applicant Assignee:

Address 1	~~10586 W Pico Blvd #1096~~ 8549 Wilshire Blvd		
Address 2	Suite 2403		
City	~~Los Angeles~~ Beverly Hills	**State/Province**	CA
Country	US	Postal Code	~~90064~~ 90211
Phone Number		Fax Number	
Email Address			

Additional Assignee or Non-Applicant Assignee Data may be generated within this form by selecting the Add button.

Signature:

NOTE: This Application Data Sheet must be signed in accordance with 37 CFR 1.33(b). **However, if this Application Data Sheet is submitted with the INITIAL filing of the application and either box A or B is not checked in subsection 2 of the "Authorization or Opt-Out of Authorization to Permit Access" section, then this form must also be signed in accordance with 37 CFR 1.14(c).**

This Application Data Sheet **must** be signed by a patent practitioner if one or more of the applicants is a **juristic entity** (e.g., corporation or association). If the applicant is two or more joint inventors, this form must be signed by a patent practitioner, **all** joint inventors who are the applicant, or one or more joint inventor-applicants who have been given power of attorney (e.g., see USPTO Form PTO/AIA/81) on behalf of **all** joint inventor-applicants.

See 37 CFR 1.4(d) for the manner of making signatures and certifications.

Signature	/Brian D. Owens/			Date (YYYY-MM-DD)	2023-02-21
First Name	Brian	Last Name	Owens	Registration Number	55517

Additional Signature may be generated within this form by selecting the Add button.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	DHP-P0001CIP1
	Application Number	17/499,725
Title of Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1 The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3 A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent CooperationTreaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
17/499,725	**02/21/2023 03:06:39 PM ET**	**DHP-P0001CIP1**

Title of Invention

SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	-
CONFIRMATION #	9953	FILED BY	Ashlyn Nguyen
PATENT CENTER #	61626174	FILING DATE	10/12/2021
CUSTOMER #	133690	FIRST NAMED INVENTOR	Nathaniel T. Bradley
CORRESPONDENCE ADDRESS	-	AUTHORIZED BY	Brian Owens

Documents

TOTAL DOCUMENTS: 1

DOCUMENT	PAGES	DESCRIPTION	SIZE (KB)
DHP-P0001CIP1_17499725_FILED-CORRECTED-APPLICATION-DATA-SHEET_2-21-23.pdf	10	Application Data Sheet	3184 KB

Warning: This is not a USPTO supplied ADS fillable form. Data in the form cannot be automatically loaded to other USPTO systems.

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)

DHP-P0001CIP1_17499725_FILED-CORRECTED-APPLICATION-DATA-SHEET_2-21-23.pdf	AB130BDBAC699D7A70746432C42EBCFD5DD18D102B2B32B708CD39F6F539D6E055783C2BEE15F51D56884C2A09832E2C4B6EEF80CC730FB9603C39573148B0E9

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
17/499,725	10/12/2021	Nathaniel T. Bradley	DHP-P0001CIP1

CONFIRMATION NO. 9953

133690
Goodhue, Coleman & Owens, P.C.
12951 University Ave
Suite 201
Clive, IA 50325

37 CFR 1.48 ACKNOWLEDGEMENT LETTER

OC000000137160739

Date Mailed: 01/11/2023

NOTICE OF ACCEPTANCE OF REQUEST UNDER 37 CFR 1.48(a)

This is in response to the applicant's request under 37 CFR 1.48(a) submitted on 01/05/2023.

The request under 37 CFR 1.48(a) to correct the inventorship, to correct or update the name of an inventor, or to correct the order of names of joint inventors is accepted.

Questions about the contents of this notice and the requirements it sets forth should be directed to the Office of Data Management, Application Assistance Unit, at **(571) 272-4000** or **(571) 272-4200** or **1-888-786-0101**.

/lqchau/

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
17/499,725	10/12/2021	2156	830	DHP-P0001CIP1	20	3

CONFIRMATION NO. 9953

UPDATED FILING RECEIPT

133690
Goodhue, Coleman & Owens, P.C.
12951 University Ave
Suite 201
Clive, IA 50325

OC000000137160738

Date Mailed: 01/11/2023

Receipt is acknowledged of this non-provisional utility patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF FIRST INVENTOR, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection.

Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a corrected Filing Receipt, including a properly marked-up ADS showing the changes with strike-through for deletions and underlining for additions. If you received a "Notice to File Missing Parts" or other Notice requiring a response for this application, please submit any request for correction to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections provided that the request is grantable.

Inventor(s)

Nathaniel T. Bradley, Tucson, AZ;
James Gaynor, Winchester, VA;
Joshua S. Paugh, Tucson, AZ;
Paul Arena, Malibu, CA;
Lisa A. Marshall, Richmond, VA;

Applicant(s)

Data Health Partners, Inc., Los Angeles, CA;

Assignment For Published Patent Application

Data Health Partners, Inc., Los Angeles, CA

Power of Attorney: The patent practitioners associated with Customer Number 133690

Domestic Priority data as claimed by applicant

This application is a CON of 16/141,471 09/25/2018 PAT 11144554
which is a CIP of 16/053,141 08/02/2018 PAT 11151142
which is a CON of 14/212,429 03/14/2014 PAT 10061812
which claims benefit of 61/791,218 03/15/2013

Foreign Applications for which priority is claimed (You may be eligible to benefit from the **Patent Prosecution Highway** program at the USPTO. Please see http://www.uspto.gov for more information.) - None.
Foreign application information must be provided in an Application Data Sheet in order to constitute a claim to foreign priority. See 37 CFR 1.55 and 1.76.

Permission to Access Application via Priority Document Exchange: Yes

Permission to Access Search Results: Yes

Applicant may provide or rescind an authorization for access using Form PTO/SB/39 or Form PTO/SB/69 as appropriate.

Projected Publication Date: Not Applicable
Non-Publication Request: No
Early Publication Request: No
** **SMALL ENTITY** **
Title

SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION

Preliminary Class

707

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific

countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4258).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to promote and facilitate business investment. SelectUSA provides information assistance to the international investor community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states, and regions competing for global investment; and counsels U.S. economic development organizations on investment attraction best practices. To learn more about why the United States is the best country in the world to develop

technology, manufacture products, deliver services, and grow your business, visit http://www.SelectUSA.gov or call +1-202-482-6800.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
17/499,725	10/12/2021	Nathaniel T. Bradley	DHP-P0001CIP1

CONFIRMATION NO. 9953

133690
Goodhue, Coleman & Owens, P.C.
12951 University Ave
Suite 201
Clive, IA 50325

POA ACCEPTANCE LETTER

OC000000137160736

Date Mailed: 01/11/2023

NOTICE OF ACCEPTANCE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 01/05/2023.

The Power of Attorney in this application is accepted. Correspondence in this application will be mailed to the above address as provided by 37 CFR 1.33.

Questions about the contents of this notice and the requirements it sets forth should be directed to the Office of Data Management, Application Assistance Unit, at **(571) 272-4000** or **(571) 272-4200** or **1-888-786-0101**.

/lqchau/



United States Patent and Trademark Office

Office of the Chief Financial Officer

Document Code:WFEE

User :My-Hoa Nguyen

Refund Accounting Date:01/06/2023

Effective Date	Sale Item Reference Number	Refund Total
01/05/2023	17499725	$256.00

Document Number	Fee Code	Fee Code Description	Amount Paid	Payment Method	Account Number
I202316D04144752	2819	CORRECTION OF INVENTORSHIP ON MERITS	$256.00	DA	506801



United States Patent and Trademark Office

Office of the Chief Financial Officer

Document Code:WFEE

User :My-Hoa Nguyen

Sale Adjustment Accounting Date:01/06/2023

Effective Date	Sale Accounting Date	Sale Item Reference Number
01/05/2023	01/06/2023	17499725

Document Number	Fee Code	Fee Code Description	Amount Paid	Payment Method
I202316D04144752	2819	CORRECTION OF INVENTORSHIP ON MERITS	$256.00	DA

PTO/AIA/82A (07-13)
Approved for use through 03/31/2021. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FOR POWER OF ATTORNEY TO ONE OR MORE REGISTERED PRACTITIONERS

NOTE: This form is to be submitted with the Power of Attorney by Applicant form (PTO/AIA/82B) to identify the application to which the Power of Attorney is directed, in accordance with 37 CFR 1.5, unless the application number and filing date are identified in the Power of Attorney by Applicant form. If neither form PTO/AIA/82A nor form PTO/AIA82B identifies the application to which the Power of Attorney is directed, the Power of Attorney will not be recognized in the application.

Application Number	17/499,725
Filing Date	2021-10-12
First Named Inventor	Nathaniel T. Bradley
Title	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION
Art Unit	OPAP
Examiner Name	
Attorney Docket Number	DHP-P0001CIP1

SIGNATURE of Applicant or Patent Practitioner

Signature	/Brian D. Owens/	Date (Optional)	
Name	Brian D. Owens	Registration Number	55517
Title (if Applicant is a juristic entity)			
Applicant Name (if Applicant is a juristic entity)	Data Health Partners, Inc.		

NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4(d) for signature requirements and certifications. If more than one applicant, use multiple forms.

☐ *Total of _____ forms are submitted.

This collection of information is required by 37 CFR 1.131, 1.32, and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Doc Code: PA..
Document Description: Power of Attorney

PTO/AIA/82B (07-13)
Approved for use through 03/31/2021. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

POWER OF ATTORNEY BY APPLICANT

I hereby revoke all previous powers of attorney given in the application identified in either the attached transmittal letter or the boxes below.

Application Number	Filing Date

(Note: The boxes above may be left blank if information is provided on form PTO/AIA/82A.)

☑ I hereby appoint the Patent Practitioner(s) associated with the following Customer Number as my/our attorney(s) or agent(s), and to transact all business in the United States Patent and Trademark Office connected therewith for the application referenced in the attached transmittal letter (form PTO/AIA/82A) or identified above: 133690

OR

☐ I hereby appoint Practitioner(s) named in the attached list (form PTO/AIA/82C) as my/our attorney(s) or agent(s), and to transact all business in the United States Patent and Trademark Office connected therewith for the patent application referenced in the attached transmittal letter (form PTO/AIA/82A) or identified above. (Note: Complete form PTO/AIA/82C.)

Please recognize or change the correspondence address for the application identified in the attached transmittal letter or the boxes above to:

☑ The address associated with the above-mentioned Customer Number

OR

☐ The address associated with Customer Number:

OR

☐ Firm or Individual Name					
Address					
City		State		Zip	
Country					
Telephone		Email			

I am the Applicant (if the Applicant is a juristic entity, list the Applicant name in the box):

Data Health Partners, Inc.

☐ Inventor or Joint Inventor (title not required below)

☐ Legal Representative of a Deceased or Legally Incapacitated Inventor (title not required below)

☑ Assignee or Person to Whom the Inventor is Under an Obligation to Assign (provide signer's title if applicant is a juristic entity)

☐ Person Who Otherwise Shows Sufficient Proprietary Interest (e.g., a petition under 37 CFR 1.46(b)(2) was granted in the application or is concurrently being filed with this document) (provide signer's title if applicant is a juristic entity)

SIGNATURE of Applicant for Patent

The undersigned (whose title is supplied below) is authorized to act on behalf of the applicant (e.g., where the applicant is a juristic entity).

Signature	Paul R. Arena	Date (Optional)	
Name	Paul R. Arena		
Title	CEO, Data Health Partners, Inc.		

NOTE: Signature - This form must be signed by the applicant in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and certifications. If more than one applicant, use multiple forms.

☐ Total of forms are submitted.

This collection of information is required by 37 CFR 1.131, 1.32, and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC PAYMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
17/499,725	01/05/2023 07:31:46 PM ET	DHP-P0001CIP1

Title of Invention

SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	-
CONFIRMATION #	9953	FILED BY	Ashlyn Nguyen
PATENT CENTER #	61395889	AUTHORIZED BY	Brian Owens
CUSTOMER #	133690	FILING DATE	10/12/2021
CORRESPONDENCE ADDRESS	-	FIRST NAMED INVENTOR	Nathaniel T. Bradley

Payment Information

PAYMENT METHOD	PAYMENT TRANSACTION ID	PAYMENT AUTHORIZED BY
DA / 506801	E202315J32371751	Ashlyn Nguyen

FEE CODE	DESCRIPTION	ITEM PRICE($)	QUANTITY	ITEM TOTAL($)
2830	PROCESSING FEE, EXCEPT IN PROVISIONAL APPLICATIONS	56.00	1	56.00
2819	CORRECTION OF INVENTORSHIP AFTER FIRST ACTION ON MERITS	256.00	1	256.00
			TOTAL AMOUNT:	$312.00

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d)

and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Attorney Docket No.
DHP-P0001CIP1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bradley et al. **Application No.** 17/499,725 **Filing Date:** October 12, 2021 **For:** SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	**Confirmation No.** 9953 **Group Art Unit:** 2156 **Examiner:** Christopher J RAAB

REQUEST TO ADD INVENTOR UNDER CFR 1.48

Dear Commissioner:

This is a request to correct inventorship to add the following inventor to the above-identified application:

Lisa A. Marshall

This request accompanies:

- A statement from each person being added as an inventor (Lisa A. Marshall) that the error in inventorship occurred without deceptive intention on her part.
- An oath or declaration by Lisa A. Marshall.
- Written consent of the assignee.

- A corrected application data sheet
- The processing fee set forth in § 1.17(i) (small entity $56) and the fee set forth in § 1.17(d) (small entity $256) are being paid at the time of filing this request.

No other fees or extensions of time are believed to be due in connection with this brief; however, consider this a request for any extension inadvertently omitted, and charge any additional fees to Deposit Account No. 506801.

Respectfully submitted,

/Brian D. Owens/

January 05, 2023
Brian D. Owens, Reg. No. 55517
Goodhue, Coleman, & Owens P.C.
CUSTOMER NO. 133690

12951 University Avenue, Suite 201
Clive, Iowa 50325
515-218-7888

Doc Code: R46C.REQ
Document Description: Request under 37 CFR 1.46(c) to correct, update or change the applicant.

PTO/AIA/41 (04-15)
Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST TO CORRECT OR UPDATE THE NAME OF THE APPLICANT UNDER 37 CFR 1.46(c)(1), OR CHANGE THE APPLICANT UNDER 37 CFR 1.46(c)(2)
(FOR USE ONLY IN APPLICATIONS FILED ON OR AFTER SEPTEMBER 16, 2012)

Application Number	17/499,725
Filing Date	2021-10-12
First Named Inventor	Nathaniel T. Bradley
Art Unit	OPAP
Examiner Name	
Practitioner Docket Number	DHP-P0001CIP1

To: Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Applicant hereby **requests that the name of the applicant be corrected or updated under 37 CFR 1.46(c)(1), or that the applicant be changed under 37 CFR 1.46(c)(2),** in the above-identified application. **Requests under 37 CFR 1.46(c)(1) or (c)(2) cannot be submitted after payment of the issue fee or if the application has been patented.**

Please check the applicable box(es) below.

☐ 1. This request is to **correct or update the name of the applicant** (**under 37 CFR 1.46(c)(1)**) and includes:

☐ An application data sheet (ADS) in accordance with 37 CFR 1.76(c) with the corrected or updated information shown with markings (*e.g.*, underlining for insertions, strikethrough for deletions). A Corrected Web-based ADS may be used.

Note: Requests under 37 CFR 1.46(c)(1) may be filed to correct typographical errors in the name of the § 1.46 applicant, or for updating the name of the § 1.46 applicant (*i.e.*, where there is no change in the applicant itself but just in the applicant's name). See the Manual of Patent Examining Procedure (MPEP) section 605.01.

☒ 2. This request is to **change the applicant** (**under 37 CFR 1.46(c)(2)**) and includes:

☒ An application data sheet (ADS) in accordance with 37 CFR 1.76(c) that identifies the changes with proper markings (underlining for insertions and strikethrough for deletions). A Corrected Web-based ADS may be used.

☒ A Statement Under 37 CFR 3.73(c) (Form PTO/AIA/96 or equivalent). See MPEP 325.

I am the

☐ applicant* ☒ attorney or agent of record Registration number 55517 ☐ attorney or agent acting under 37 CFR 1.34 Registration number _____

Signature /Brian D. Owens/
Typed or printed name Brian D. Owens
Date January 5, 2023

NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and certifications. *Juristic entities must be represented by a patent practitioner (See 37 CFR 1.31, applicable to any paper filed on or after September 16, 2012 that is presented on behalf of a juristic entity, regardless of application filing date). Submit multiple forms if more than one signature is required, see below**.

☐ ** Total of _____ forms are submitted.

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

PTO/AIA/01 (06-12)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

☒ United States application or PCT international application number 17/499,725 filed on 2021-10-12.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Lisa A. Marshall Date (Optional): 1/2/2023

Signature: Lisa A. Marshall

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
17/499,725	**01/05/2023 07:31:46 PM ET**	**DHP-P0001CIP1**

Title of Invention

SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	-
CONFIRMATION #	9953	FILED BY	Ashlyn Nguyen
PATENT CENTER #	61395889	FILING DATE	10/12/2021
CUSTOMER #	133690	FIRST NAMED INVENTOR	Nathaniel T. Bradley
CORRESPONDENCE ADDRESS	-	AUTHORIZED BY	Brian Owens

Documents

TOTAL DOCUMENTS: 9

DOCUMENT	PAGES	DESCRIPTION	SIZE (KB)
DHP-P0001CIP1_17499725_FILED-CORRECTED-APPLICATION-DATA-SHEET_1-5-23.pdf	10	Application Data Sheet	3170 KB
Warning: This is not a USPTO supplied ADS fillable form. Data in the form cannot be automatically loaded to other USPTO systems.			
DHP-P0001CIP1_17499725_FILED-NEW-APPLICANT-NAME-REQUEST_1-5-23.pdf	2	Request under 37CFR1.46(c) to correct, update, change applicant	191 KB
DHP-	2	Power of Attorney	644 KB

P0001CIP1_17499725_FILED-NEW-POWER-OF-ATTORNEY_1-5-23.pdf			
DHP-P0001CIP1_17499725_FILED-ASSIGNEES-STATEMENT_1-5-23.pdf	3	Assignee showing of ownership per 37 CFR 3.73	120 KB
DHP-P0001CIP1_17499725_LISA-MARSHALL_FILED-CONSENT-OF-ASSIGNEE.pdf	1	Request under Rule 48 correcting inventorship	168 KB
DHP-P0001CIP1_17499725_LISA-MARSHALL_FILED-CONSENT-OF-INVENTORSHIP.pdf	1	Request under Rule 48 correcting inventorship	101 KB
DHP-P0001CIP1_17499725_LISA-MARSHALL_FILED-INVENTOR-DECLARATION.pdf	1	Oath or Declaration filed	387 KB
DHP-P0001CIP1_17499725_LISA-MARSHALL_FILED-INVENTOR-ASSIGNMENT.pdf	2	Miscellaneous Incoming Letter	820 KB
DHP-P0001CIP1_17499725_LISA-MARSHALL_FILED-REQUEST-TO-ADD-INVENTOR.pdf	2	Request under Rule 48 correcting inventorship	169 KB

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)
DHP-P0001CIP1_17499725_FILED-CORRECTED-APPLICATION-DATA-SHEET_1-5-23.pdf	061BA2FF9452840D54ABB6440DB323933B6360134808FC6FD9BD1C1C42D89DB3D07AD3D4C195C0D7BE2525631A86BF64F2E7F334D60DE52C437B2F2C2EF98689
DHP-P0001CIP1_17499725_FILED-NEW-APPLICANT-NAME-REQUEST_1-5-23.pdf	58A764102FB298313795567CCFE112D4168F7770AC30474BB8F3E5CE8479517CA023960683656FC594C2A34D7456664E762607FDCE9BFB6B5A8C5CE725363C97
DHP-P0001CIP1_17499725_FILED-NEW-POWER-OF-ATTORNEY_1-5-23.pdf	8F4C969A86B4F6DF72BAA646DBF9AFEA10E28564C5DDB8B803F9C5C6FA7ABCA4D68A3D8AC282FFE27B4F789052AFC246423513828F92A660117B4FB864E33340
DHP-P0001CIP1_17499725_FILED-ASSIGNEES-STATEMENT_1-5-23.pdf	7528632311EF6609854655AA2E224D461B43372771CD709A9D22B3399C60212649EFCC16CF2FB05CF026F2D6455DC0296DFAF91092A102F728A32BC1BD6FBD42
DHP-P0001CIP1_17499725_LISA-MARSHALL_FILED-CONSENT-OF-ASSIGNEE.pdf	F04EAC1A26C12A53ABA53D44CBE5F6BBBF89430566AD884C7C987DC6C8CEED26300DCFCC0D34D0CF60A991F940446FEBBC2E562FDA99322522EADD8E1680B986
DHP-P0001CIP1_17499725_LISA-MARSHALL_FILED-CONSENT-OF-INVENTORSHIP.pdf	9E392039CD9270919158BD83C2E2F82CF8C361A7864A9A039DF767D35510D3C09586F00F0462BC7DF870F59E03ED8E2024323ADF61877EFAC9607BA418AFA4A7
DHP-P0001CIP1_17499725_LISA-MARSHALL_FILED-INVENTOR-DECLARATION.pdf	23474F9B494EEE679DE54239E537519B3D75D21A1039864OB44AECDDDDE1E10976919149704016481 8D15A1C8FDBC870C519BEF2EE42594CEA5A123CF768917F

DHP-P0001CIP1_17499725_LISA-MARSHALL_FILED-INVENTOR-ASSIGNMENT.pdf	6C5EEDB90BB63D7C165A051F984AE3A9A89E8405F3F663EE90EC793B8C35993CEA1304A18BEEBFDD3A5A18B4EAD685B8507F29E93819E46908341 5CC8F350BA0
DHP-P0001CIP1_17499725_LISA-MARSHALL_FILED-REQUEST-TO-ADD-INVENTOR.pdf	AC33E946932CD60BF0B14DB65E381F643E11096ABF88B62A355EC6A7D24C7E28C9A52605AEBD7E4C148BB710CD4EC6A3642098446CCC8834DB29630B977AE2E8

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	DHP-P0001CIP1
	Application Number	17/499,725
Title of Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	

The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.
This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.

Secrecy Order 37 CFR 5.2:

☐ Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)

Inventor Information:

Inventor 1 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Nathaniel	T.	Bradley	

Residence Information (Select One) ◉ US Residency ○ Non US Residency ○ Active US Military Service

City	Tucson	State/Province	AZ	Country of Residence	US

Mailing Address of Inventor:

Address 1	7450 S Sandbar Willow Place		
Address 2			
City	Tucson	State/Province	AZ
Postal Code	85747	Country	US

Inventor 2 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	James		Gaynor	

Residence Information (Select One) ◉ US Residency ○ Non US Residency ○ Active US Military Service

City	Winchester	State/Province	VA	Country of Residence	US

Mailing Address of Inventor:

Address 1	216 Cotton Ridge Road		
Address 2			
City	Winchester	State/Province	VA
Postal Code	22603	Country	US

Inventor 3 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Joshua	S.	Paugh	

Residence Information (Select One) ◉ US Residency ○ Non US Residency ○ Active US Military Service

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	DHP-P0001CIP1
	Application Number	17/499,725
Title of Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	

City	Tucson	State/Province	AZ	Country of Residence	US

Mailing Address of Inventor:

Address 1	7501 E Mary Dr.		
Address 2			
City	Tucson	State/Province	AZ
Postal Code	85730	Country	US

Inventor 4 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Paul		Arena	

Residence Information (Select One) (•) US Residency ( ) Non US Residency ( ) Active US Military Service

City	Malibu	State/Province	CA	Country of Residence	US

Mailing Address of Inventor:

Address 1	600 Schueren Rd		
Address 2			
City	Malibu	State/Province	CA
Postal Code	90265	Country	US

Inventor 5 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Lisa	A.	Marshall	

Residence Information (Select One) (•) US Residency ( ) Non US Residency ( ) Active US Military Service

City	Richmond	State/Province	VA	Country of Residence	US

Mailing Address of Inventor:

Address 1	4016 Northrop St.		
Address 2			
City	Richmond	State/Province	VA
Postal Code	23225	Country	US

All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the **Add** button. Add

Correspondence Information:

Enter either Customer Number or complete the Correspondence Information section below.
For further information see 37 CFR 1.33(a).

☐ **An Address is being provided for the correspondence Information of this application.**

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	DHP-P0001CIP1
	Application Number	17/499,725
Title of Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	

Customer Number	133690		
Email Address	docketing@goodhue.com	Add Email	Remove Email

Application Information:

Title of the Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION		
Attorney Docket Number	DHP-P0001CIP1	Small Entity Status Claimed	☒
Application Type	Nonprovisional		
Subject Matter	Utility		
Total Number of Drawing Sheets (if any)		Suggested Figure for Publication (if any)	

Filing By Reference:

Only complete this section when filing an application by reference under 35 U.S.C. 111(c) and 37 CFR 1.57(a). Do not complete this section if application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be provided in the appropriate section(s) below (i.e., "Domestic Benefit/National Stage Information" and "Foreign Priority Information").

For the purposes of a filing date under 37 CFR 1.53(b), the description and any drawings of the present application are replaced by this reference to the previously filed application, subject to conditions and requirements of 37 CFR 1.57(a).

Application number of the previously filed application	Filing date (YYYY-MM-DD)	Intellectual Property Authority or Country

Publication Information:

☐ Request Early Publication (Fee required at time of Request 37 CFR 1.219)

☐ **Request Not to Publish.** I hereby request that the attached application not be published under 35 U.S.C. 122(b) and certify that the invention disclosed in the attached application **has not and will not** be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.

Representative Information:

Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32).
Either enter Customer Number or complete the Representative Name section below. If both sections are completed the customer Number will be used for the Representative Information during processing.

Please Select One:	◉ Customer Number	○ US Patent Practitioner	○ Limited Recognition (37 CFR 11.9)
Customer Number	133690		

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	DHP-P0001CIP1
	Application Number	17/499,725
Title of Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	

Domestic Benefit/National Stage Information:

This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, 365(c), or 386(c) or indicate National Stage entry from a PCT application. Providing benefit claim information in the Application Data Sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.
When referring to the current application, please leave the "Application Number" field blank.

Prior Application Status	Patented			Remove	
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)	Patent Number	Issue Date (YYYY-MM-DD)
17499725	Continuation of	16141471	2018-09-25	11144554	2021-10-12
Prior Application Status	Patented			Remove	
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)	Patent Number	Issue Date (YYYY-MM-DD)
16141471	Continuation in part of	16053141	2018-08-02	11151142	2021-10-19
Prior Application Status	Patented			Remove	
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)	Patent Number	Issue Date (YYYY-MM-DD)
16053141	Continuation of	14212429	2014-03-14	10061812	2018-08-28
Prior Application Status	Expired			Remove	
Application Number	Continuity Type		Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)	
14212429	Claims benefit of provisional		61791218	2013-03-15	

Additional Domestic Benefit/National Stage Data may be generated within this form by selecting the **Add** button.

Foreign Priority Information:

This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55. When priority is claimed to a foreign application that is eligible for retrieval under the priority document exchange program (PDX)[i] the information will be used by the Office to automatically attempt retrieval pursuant to 37 CFR 1.55(i)(1) and (2). Under the PDX program, applicant bears the ultimate responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1).

			Remove
Application Number	Country[i]	Filing Date (YYYY-MM-DD)	Access Code[i] (if applicable)

Additional Foreign Priority Data may be generated within this form by selecting the **Add** button.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	DHP-P0001CIP1
	Application Number	17/499,725
Title of Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications

☐ This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March 16, 2013.
NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March 16, 2013, will be examined under the first inventor to file provisions of the AIA.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	DHP-P0001CIP1
	Application Number	17/499,725
Title of Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	

Authorization or Opt-Out of Authorization to Permit Access:

When this Application Data Sheet is properly signed and filed with the application, applicant has provided written authority to permit a participating foreign intellectual property (IP) office access to the instant application-as-filed (see paragraph A in subsection 1 below) and the European Patent Office (EPO) access to any search results from the instant application (see paragraph B in subsection 1 below).

Should applicant choose not to provide an authorization identified in subsection 1 below, applicant **must opt-out** of the authorization by checking the corresponding box A or B or both in subsection 2 below.

NOTE: This section of the Application Data Sheet is **ONLY** reviewed and processed with the **INITIAL** filing of an application. After the initial filing of an application, an Application Data Sheet cannot be used to provide or rescind authorization for access by a foreign IP office(s). Instead, Form PTO/SB/39 or PTO/SB/69 must be used as appropriate.

1. Authorization to Permit Access by a Foreign Intellectual Property Office(s)

A. Priority Document Exchange (PDX) - Unless box A in subsection 2 (opt-out of authorization) is checked, the undersigned hereby **grants the USPTO authority** to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the State Intellectual Property Office of the People's Republic of China (SIPO), the World Intellectual Property Organization (WIPO), and any other foreign intellectual property office participating with the USPTO in a bilateral or multilateral priority document exchange agreement in which a foreign application claiming priority to the instant patent application is filed, access to: (1) the instant patent application-as-filed and its related bibliographic data, (2) any foreign or domestic application to which priority or benefit is claimed by the instant application and its related bibliographic data, and (3) the date of filing of this Authorization. See 37 CFR 1.14(h)(1).

B. Search Results from U.S. Application to EPO - Unless box B in subsection 2 (opt-out of authorization) is checked, the undersigned hereby **grants the USPTO authority** to provide the EPO access to the bibliographic data and search results from the instant patent application when a European patent application claiming priority to the instant patent application is filed. See 37 CFR 1.14(h)(2).

The applicant is reminded that the EPO's Rule 141(1) EPC (European Patent Convention) requires applicants to submit a copy of search results from the instant application without delay in a European patent application that claims priority to the instant application.

2. Opt-Out of Authorizations to Permit Access by a Foreign Intellectual Property Office(s)

☐ A. Applicant **DOES NOT** authorize the USPTO to permit a participating foreign IP office access to the instant application-as-filed. If this box is checked, the USPTO will not be providing a participating foreign IP office with any documents and information identified in subsection 1A above.

☐ B. Applicant **DOES NOT** authorize the USPTO to transmit to the EPO any search results from the instant patent application. If this box is checked, the USPTO will not be providing the EPO with search results from the instant application.

NOTE: Once the application has published or is otherwise publicly available, the USPTO may provide access to the application in accordance with 37 CFR 1.14.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	DHP-P0001CIP1
	Application Number	17/499,725
Title of Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	

Applicant Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

Applicant 1

If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed. The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR 1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be identified in this section.

Clear

◉ Assignee	○ Legal Representative under 35 U.S.C. 117	○ Joint Inventor
○ Person to whom the inventor is obligated to assign.	○ Person who shows sufficient proprietary interest	

If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:

Name of the Deceased or Legally Incapacitated Inventor:

If the Applicant is an Organization check here. ☒

Organization Name	~~Parallax Behavioral Health, Inc.,~~ Data Health Partners, Inc.		
Mailing Address Information For Applicant:			
Address 1	~~1327 Ocean Avenue~~ 10586 W Pico Blvd #1096		
Address 2	~~Suite B~~		
City	~~Santa Monica~~ Los Angeles	**State/Province**	~~CA~~ CA
Country	~~US~~ US	Postal Code	~~90401~~ 90064
Phone Number		Fax Number	
Email Address			

Additional Applicant Data may be generated within this form by selecting the Add button.

Assignee Information including Non-Applicant Assignee Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	DHP-P0001CIP1
	Application Number	17/499,725
Title of Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	

Assignee 1

Complete this section if assignee information, including non-applicant assignee information, is desired to be included on the patent application publication. An assignee-applicant identified in the "Applicant Information" section will appear on the patent application publication as an applicant. For an assignee-applicant, complete this section only if identification as an assignee is also desired on the patent application publication.

If the Assignee or Non-Applicant Assignee is an Organization check here. ☒

Organization Name	~~Parallax Behavioral Health, Inc.,~~ Data Health Partners, Inc.

Mailing Address Information For Assignee including Non-Applicant Assignee:

Address 1	~~1327 Ocean Avenue~~ 10586 W Pico Blvd #1096		
Address 2	~~Suite B~~		
City	~~Santa Monica~~ Los Angeles	**State/Province**	~~CA~~ CA
Country	~~US~~ US	Postal Code	~~90401~~ 90064
Phone Number		Fax Number	
Email Address			

Additional Assignee or Non-Applicant Assignee Data may be generated within this form by selecting the Add button.

Signature:

NOTE: This Application Data Sheet must be signed in accordance with 37 CFR 1.33(b). **However, if this Application Data Sheet is submitted with the INITIAL filing of the application and either box A or B is not checked in subsection 2 of the "Authorization or Opt-Out of Authorization to Permit Access" section, then this form must also be signed in accordance with 37 CFR 1.14(c).**

This Application Data Sheet **must** be signed by a patent practitioner if one or more of the applicants is a **juristic entity** (e.g., corporation or association). If the applicant is two or more joint inventors, this form must be signed by a patent practitioner, **all** joint inventors who are the applicant, or one or more joint inventor-applicants who have been given power of attorney (e.g., see USPTO Form PTO/AIA/81) on behalf of **all** joint inventor-applicants.

See 37 CFR 1.4(d) for the manner of making signatures and certifications.

Signature	/Brian D. Owens/			Date (YYYY-MM-DD)	2023-01-05
First Name	Brian	Last Name	Owens	Registration Number	55517

Additional Signature may be generated within this form by selecting the Add button.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	DHP-P0001CIP1
	Application Number	17/499,725
Title of Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1 The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3 A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent CooperationTreaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Attorney Docket No.
DHP-P0001CIP1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bradley et al. **Application No.** 17/499,725 **Filing Date:** October 12, 2021 **For:** SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	**Confirmation No.** 9953 **Group Art Unit:** 2156 **Examiner:** Christopher J RAAB

CONSENT OF ASSIGNEE TO ADD INVENTOR

The ASSIGNEE of the above-identified application, Data Health Partners, Inc., hereby consents to the addition of **Lisa A. Marshall** as an inventor in the above-identified application.

Data Health Partners, Inc.

By _____

Name: Paul Arena

Title: CEO

Date: Jan 1, 2023

Attorney Docket No.
DHP-P001CIP1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bradley et al. **Application No.** 17/499,725 **Filing Date:** October 12, 2021 **For:** SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	**Confirmation No.** 9953 **Group Art Unit:** 2156 **Examiner:** Christopher J RAAB

STATEMENT FROM PERSON BEING ADDED AS AN INVENTOR

The error in inventorship arose without any deceptive intention on my part.

By Lisa A. Marshall
Lisa A. Marshall | Jan 2, 2023 08:34 EST)

Name: Lisa A. Marshall

Date: Jan 2, 2023

PTO/AIA/96 (08-12)
Approved for use through 01/31/2013. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(c)

Applicant/Patent Owner: Data Health Partners, Inc.

Application No./Patent No.: 17/499,725 Filed/Issue Date: 2021-10-12

Titled: SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION

Data Health Partners, Inc., a corporation

(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that, for the patent application/patent identified above, it is (choose **one** of options 1, 2, 3 or 4 below):

1. [x] The assignee of the entire right, title, and interest.

2. [ ] An assignee of less than the entire right, title, and interest (check applicable box):

   [ ] The extent (by percentage) of its ownership interest is _____%. Additional Statement(s) by the owners holding the balance of the interest must be submitted to account for 100% of the ownership interest.

   [ ] There are unspecified percentages of ownership. The other parties, including inventors, who together own the entire right, title and interest are:

   Additional Statement(s) by the owner(s) holding the balance of the interest must be submitted to account for the entire right, title, and interest.

3. [ ] The assignee of an undivided interest in the entirety (a complete assignment from one of the joint inventors was made). The other parties, including inventors, who together own the entire right, title, and interest are:

   Additional Statement(s) by the owner(s) holding the balance of the interest must be submitted to account for the entire right, title, and interest.

4. [ ] The recipient, via a court proceeding or the like (*e.g.*, bankruptcy, probate), of an undivided interest in the entirety (a complete transfer of ownership interest was made). The certified document(s) showing the transfer is attached.

The interest identified in option 1, 2 or 3 above (not option 4) is evidenced by either (choose **one** of options A or B below):

A. [ ] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

B. [x] A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: Nathaniel T. Bradley, James Gaynor, Joshua S. Paugh, Paul Arena To: PARALLAX BEHAVIORAL HEALTH INC

   The document was recorded in the United States Patent and Trademark Office at
   Reel 057934, Frame 0063, or for which a copy thereof is attached.

2. From: PARALLAX BEHAVIORAL HEALTH INC To: Data Health Partners, Inc.

   The document was recorded in the United States Patent and Trademark Office at
   Reel 060786, Frame 0867, or for which a copy thereof is attached.

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/96 (08-12)
Approved for use through 01/31/2013. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(c)

3. From: Lisa A. Marshall To: Data Health Partners, Inc.

The document was recorded in the United States Patent and Trademark Office at

Reel _____, Frame _____, or for which a copy thereof is attached.

4. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at

Reel _____, Frame _____, or for which a copy thereof is attached.

5. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at

Reel _____, Frame _____, or for which a copy thereof is attached.

6. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at

Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet(s).

☑ As required by 37 CFR 3.73(c)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

/Brian D. Owens/	January 05, 2023
Signature	Date
Brian D. Owens	55517
Printed or Typed Name	Title or Registration Number

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

ASSIGNMENT BY INVENTOR

In consideration of good and valuable consideration, the receipt and sufficiency whereof are hereby acknowledged, the undersigned hereby assigns to Data Health Partners, Inc., having an address of 10586 W Pico Blvd #1096, Los Angeles, CA 90064, United States, its successors and assigns the entire right, title and interest in the invention or improvements of the undersigned disclosed in an application for Letters Patent of the United States, Serial No. **17/499,725** filed in the United States Patent and Trademark Office on **October 12, 2021**, entitled **SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION**, and in said application and any and all other applications for United States Letters Patent, which the undersigned may file, either solely or jointly with others, on said invention and improvements, and in any and all Letters Patent, applications, and in any reissue or extension thereof.

The undersigned hereby authorizes and requests the Commissioner of Patents to issue said Letters Patent to said **Data Health Partners, Inc.**.

For said consideration the undersigned hereby agrees, upon the request, and at the expense of said assignee, its successors and assigns, to execute any and all divisional, continuation and substitute applications for said invention or improvements, and any necessary oath or affidavit relating thereto, and any application for the reissue or extension of any Letters Patent that may be granted upon said application, and for the said considerations the undersigned further agrees upon the request of said assignee, its successors or assigns, in the event of any application or Letters Patent assigned herein becoming involved in an interference, derivation proceeding, opposition, or post-grant review, to cooperate to the best of the ability of the undersigned with said assignee, its successors or assigns in the matters of preparing and executing any statements and giving and producing evidence in support thereof, the undersigned hereby agreeing to perform, upon request, any and all affirmative acts to obtain said Letters Patent of the United States and vest all rights therein hereby conveying in the said assignee, its successors and assigns whereby said Letters Patent will be held and enjoyed by the said assignee, its successors and assigns to the full end of the term for which said Letters Patent may be granted as fully and entirely as the same would have been held and enjoyed by the undersigned if this assignment and sale had not been made.

And for said considerations the undersigned hereby assigns to said assignee, its successors and assigns, the entire right, title and interest in said invention or improvements for any and all foreign countries including the right of priority and agrees upon request of assignee, its successors and assigns to execute any and all documents that undersigned shall be requested

to execute in connection with any and all applications for foreign Letters Patent therefor, including the prosecution thereof, and to execute any and all documents necessary to vest title in said foreign applications and patents in assignee.

Date: Jan 2, 2023

Signature: Lisa A. Marshall
Lisa A. Marshall (Jan 2, 2023 09:04 EST)

Lisa A. Marshall

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7481532

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
PARALLAX BEHAVIORAL HEALTH INC	04/13/2022

RECEIVING PARTY DATA

Name:	DATA HEALTH PARTNERS INC
Street Address:	10586 W PICO BLVD #1096
City:	LOS ANGELES
State/Country:	CALIFORNIA
Postal Code:	90064

PROPERTY NUMBERS Total: 6

Property Type	Number
Patent Number:	10061812
Patent Number:	11144554
Patent Number:	11151142
Application Number:	17499725
Application Number:	17505166
Application Number:	17546594

CORRESPONDENCE DATA

Fax Number: (888)899-1443

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 3105929235
Email: CALLIB@DATAHPI.COM
Correspondent Name: CALLI BUCCI
Address Line 1: 10586 W PICO BLVD #1096
Address Line 2: DATA HEALTH PARTNERS INC
Address Line 4: LOS ANGELES, CALIFORNIA 90064

NAME OF SUBMITTER:	CALLI BUCCI
SIGNATURE:	/calli bucci/
DATE SIGNED:	08/11/2022
	This document serves as an Oath/Declaration (37 CFR 1.63).

Total Attachments: 3
source=2022-04-13 DHP-PBH Patent Assignment (vfinal)-FE#page1.tif
source=2022-04-13 DHP-PBH Patent Assignment (vfinal)-FE#page2.tif
source=2022-04-13 DHP-PBH Patent Assignment (vfinal)-FE#page3.tif

PATENT ASSIGNMENT

WHEREAS, Parallax Behavioral Health, Inc., a Delaware corporation, with an address 3415 S. Sepulveda Blvd., Suite 1100-6592, Los Angeles, CA 90034 ("Assignor"), owns all right, title and interest in and to the patents and/or patent applications identified in Exhibit A attached hereto, including the inventions described therein and the patents issued and reissued thereon (collectively, the "Patents"), the renewals therefor and all claims for past or future infringement thereof; and

WHEREAS, Data Health Partners, Inc., a Delaware corporation with an address at 10586 W. Pico Blvd., #1096, Los Angeles, CA 90064 ("Assignee"), and Assignor have entered into an Intellectual Property Purchase Agreement (the "Agreement") effective April 13, 2022, under which Assignor agreed to sell and Assignee agreed to purchase certain assets of Assignor, including the aforesaid Patents, and the applications and renewals therefor and all claims for past or future infringement thereof.

NOW THEREFORE, for valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor does hereby sell, assign, convey and transfer unto Assignee, its successors and assigns, free and clear of any and all liens, restrictions, claims and encumbrances, Assignor's entire right, title, and interest in and to the Patents and divisions, continuations or continuations-in-part thereof, together with all rights of registration, maintenance, and protection thereof in any form, all rights to income, royalties, damages and payments now due or hereafter due or payable in respect thereto, and all rights of recovery and of legal action for past or future infringements and of interference proceedings and reexaminations involving such Patents.

This Assignment is deemed to be executed and delivered within the State of California, and it is the intention of the parties that it shall be construed, interpreted and applied in accordance with the laws of the State of California without regard to its conflicts of law principles.

IN WITNESS WHEREOF, Assignor has duly executed this Assignment this 11th day of May, 2022, to be effective as of April 13, 2022.

ASSIGNOR:

Parallax Behavioral Health, Inc.

By: Dr. David L. Stark
Title: Chairman, President

ASSIGNEE:

Data Health Partners, Inc.

By: Calli R. Bucci
Title: Director, Chief Financial Officer

EXHIBIT A

PATENTS AND PATENT APPLICATIONS

1. United States Patent No. 10,061,812 (Family ID 51533139) issued August 28, 2018, and all related worldwide patents: *Platform For Optimizing Data Driven Outcomes*

2. United States Patent No. 11,144,554 (Family ID 65038812) issued October 12, 2021, and all related worldwide patents: *Platform For Optimizing Goal Progression*

3. United States Patent No. 11,151,142 (Family ID 51533139) granted October 12, 2021, and all related worldwide patents: *Platform For Optimizing Goal Progression*

4. United States Patent Application No. 17/499,725 (Family ID 65038812) filed October 12, 2021, and all related worldwide patent applications: *System And Method For Achieving Goal Progression*

5. United States Patent Application No. 17/505,166 (Family ID 51533139) filed October 19, 2021, and all related worldwide patent applications: *System And Method For Tracking Progression Toward A Customized Goal*

6. United States Patent Application No. 17/546,594 (Family ID 1000006016644) filed December 9, 2021, and all related worldwide patent applications: *System And Method For Achieving Goals.*

7. All related patent and patent applications filed or to be filed in connection with the aforementioned patents and patent applications, as well as those provided in the Global Dossier attached herewith as Exhibit B.

The remainder of this page intentionally left blank

EXHIBIT B

GLOBAL DOSSIER

IP Office	Application	Applicant	Title	Application Date	Priority Number	Publication Number	Publication Date
AU	2014228758	1)Gratton School, Inc.,	Platform for optimizing data driven outcomes	03/14/2014	US 14212429 US PCT/US14/29287 US 61791218	AU 2014228758 A1	10/01/2015
US	14212429	1)Marshall, Lisa A., 2)Gaynor, James	PLATFORM FOR OPTIMIZING DATA DRIVEN OUTCOMES	03/14/2014	US 14212429 US 61791218	US 20140280136 A1 US 10061812 B2	09/18/2014 08/28/2018
US	PCT/US14/29287	1)GRAFTON SCHOOL, INC.,	PLATFORM FOR OPTIMIZING DATA DRIVEN OUTCOMES	03/14/2014	US 14212429 US 61791218	WO 2014144749 A1	09/18/2014
GB	2015173711			03/14/2014	US 14212429 US PCT/US14/29287 US 61791218	GB 201517371 D0 GB 2526749 A	11/18/2015 12/02/2015
US	16053141	1)Marshall, Lisa A., 2)Gaynor, James	PLATFORM FOR OPTIMIZING GOAL PROGRESSION	08/02/2018	US 14212429 US 16053141 US 61791218	US 20180373763 A1 US 11151142 B2	12/27/2018 10/19/2021
US	16141471	1)Bradley, Nathaniel T., 2)Gaynor, James, 3)Paugh, Joshua S., 4)Arena, Paul	PLATFORM FOR OPTIMIZING GOAL PROGRESSION	09/25/2018	US 16141471 US 61791218 US 14212429 US 16053141	US 20190034494 A1 US 11144554 B2	01/31/2019 10/12/2021
AU	2020100161	1)Parallax Behavioral Health, Inc.,,	Platform for optimizing data driven outcomes	01/31/2020	US PCT/US14/29287 US 61791218 AU 2014228758 US 14212429 AU 2020100161	AU 2020100161 A4	03/05/2020
US	17499725	1)Bradley, Nathaniel T., 2)Gaynor, James, 3)Paugh, Joshua S., 4)Arena, Paul	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	10/12/2021	US 16141471 US 61791218 US 17499725 US 14212429 US 16053141	US 20220037013 A1	02/03/2022
US	17505166	1)Marshall, Lisa A., 2)Gaynor, James	SYSTEM AND METHOD FOR TRACKING PROGRESSION TOWARD A CUSTOMIZED GOAL	10/19/2021	US 61791218 US 14212429 US 16053141 US 17505166	US 20220035805 A1	02/03/2022
US	17546594	1)Bradley, Nathaniel T., 2)Gaynor, James, 3)Paugh, Joshua S., 4)Arena, Paul	SYSTEM AND METHOD FOR ACHIEVING GOALS	12/09/2021	US 16141471 US 61791218 US 17499725 US 14212429 US 16053141 US 17546594	US 20220100754 A1	03/31/2022

PTO/SB/08a (01-22)
Approved for use through 05/31/2024. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	17499725
Filing Date	2021-10-12
First Named Inventor	Nathaniel T. Bradley
Art Unit	OPAP
Examiner Name	Docket CENTRAL
Attorney Docket Number	PBH-P0001CIP1

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20150205930	A1	2015-07-23	Shaanan; Jessica	Entire Document

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1							

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17499725
	Filing Date	2021-10-12
	First Named Inventor	Nathaniel T. Bradley
	Art Unit	OPAP
	Examiner Name	Docket CENTRAL
	Attorney Docket Number	PBH-P0001CIP1

	1		

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17499725
	Filing Date	2021-10-12
	First Named Inventor	Nathaniel T. Bradley
	Art Unit	OPAP
	Examiner Name	Docket CENTRAL
	Attorney Docket Number	PBH-P0001CIP1

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Brian D. Owens/	Date (YYYY-MM-DD)	2022-03-07
Name/Print	Brian Dean Owens	Registration Number	55517

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Acknowledgement Receipt

EFS ID:	45161309
Application Number:	17499725
International Application Number:	
Confirmation Number:	9953
Title of Invention:	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION
First Named Inventor/Applicant Name:	Nathaniel T. Bradley
Customer Number:	133690
Filer:	Brian Dean Owens/Ashlyn Nguyen
Filer Authorized By:	Brian Dean Owens
Attorney Docket Number:	PBH-P0001CIP1
Receipt Date:	07-MAR-2022
Filing Date:	12-OCT-2021
Time Stamp:	14:44:44
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement (IDS) Form (SB08)	PARALLAX_PBH-P0001CIP1_17499725_FILED-SUPPLEMENTAL-IDS_3-7-22.pdf	1282166 1bb60bbe56ed6fea0b18e0232ee18f6b2f568398	no	4

Warnings:

Information:	
Total Files Size (in bytes):	1282166

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
17/499,725	10/12/2021	Nathaniel T. Bradley	PBH-P0001CIP1

CONFIRMATION NO. 9953

133690
Goodhue, Coleman & Owens, P.C.
12951 University Ave
Suite 201
Clive, IA 50325

PUBLICATION NOTICE

OC000000131585988

Title:SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION

Publication No.US-2022-0037013-A1
Publication Date:02/03/2022

NOTICE OF PUBLICATION OF APPLICATION

The above-identified application will be electronically published as a patent application publication pursuant to 37 CFR 1.211, et seq. The patent application publication number and publication date are set forth above.

The publication may be accessed through the USPTO's publically available Searchable Databases via the Internet at www.uspto.gov. The direct link to access the publication is currently http://www.uspto.gov/patft/.

The publication process established by the Office does not provide for mailing a copy of the publication to applicant. A copy of the publication may be obtained from the Office upon payment of the appropriate fee set forth in 37 CFR 1.19(a)(1). Orders for copies of patent application publications are handled by the USPTO's Public Records Division. The Public Records Division can be reached by telephone at (571) 272-3150 or (800) 972-6382, by facsimile at (571) 273-3250, by mail addressed to the United States Patent and Trademark Office, Public Records Division, Alexandria, VA 22313-1450 or via the Internet.

In addition, information on the status of the application, including the mailing date of Office actions and the dates of receipt of correspondence filed in the Office, may also be accessed via the Internet through the Patent Electronic Business Center at www.uspto.gov using the public side of the Patent Application Information and Retrieval (PAIR) system. The direct link to access this status information is currently https://portal.uspto.gov/pair/PublicPair. Prior to publication, such status information is confidential and may only be obtained by applicant using the private side of PAIR.

Further assistance in electronically accessing the publication, or about PAIR, is available by calling the Patent Electronic Business Center at 1-866-217-9197.

Office of Data Managment, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875	Application or Docket Number 17/499,725

APPLICATION AS FILED - PART I

	(Column 1)	(Column 2)	SMALL ENTITY		OR	OTHER THAN SMALL ENTITY	
FOR	NUMBER FILED	NUMBER EXTRA	RATE($)	FEE($)		RATE($)	FEE($)
BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A	80		N/A	
SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A	N/A	350		N/A	
EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A	400		N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	20 minus 20 =	*	x 50 =	0.00	OR		
INDEPENDENT CLAIMS (37 CFR 1.16(h))	3 minus 3 =	*	x 240 =	0.00			
APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).			0.00			
MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))				0.00			
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL	830		TOTAL	

APPLICATION AS AMENDED - PART II

		(Column 1)		(Column 2)	(Column 3)	SMALL ENTITY		OR	OTHER THAN SMALL ENTITY	
		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE($)	ADDITIONAL FEE($)		RATE($)	ADDITIONAL FEE($)
AMENDMENT A	Total (37 CFR 1.16(i))	*	Minus	**	=	x =		OR	x =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x =		OR	x =	
	Application Size Fee (37 CFR 1.16(s))									
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	

		(Column 1)		(Column 2)	(Column 3)					
		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE($)	ADDITIONAL FEE($)		RATE($)	ADDITIONAL FEE($)
AMENDMENT B	Total (37 CFR 1.16(i))	*	Minus	**	=	x =		OR	x =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x =		OR	x =	
	Application Size Fee (37 CFR 1.16(s))									
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".
The "Highest Number Previously Paid For" (Total or Independent) is the highest found in the appropriate box in column 1.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
17/499,725	10/12/2021	2447	830	PBH-P0001CIP1	20	3

CONFIRMATION NO. 9953

FILING RECEIPT

133690
Goodhue, Coleman & Owens, P.C.
12951 University Ave
Suite 201
Clive, IA 50325

OC000000129285938

Date Mailed: 10/25/2021

Receipt is acknowledged of this non-provisional utility patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF FIRST INVENTOR, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection.

Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a corrected Filing Receipt, including a properly marked-up ADS showing the changes with strike-through for deletions and underlining for additions. If you received a "Notice to File Missing Parts" or other Notice requiring a response for this application, please submit any request for correction to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections provided that the request is grantable.

Inventor(s)

Nathaniel T. Bradley, Tucson, AZ;
James Gaynor, Winchester, VA;
Joshua S. Paugh, Tucson, AZ;
Paul Arena, Malibu, CA;

Applicant(s)

Parallax Behavioral Health, Inc.,, Santa Monica, CA;

Assignment For Published Patent Application

Parallax Behavioral Health, Inc.,, Santa Monica, CA

Power of Attorney: The patent practitioners associated with Customer Number 133690

Domestic Priority data as claimed by applicant

This application is a CON of 16/141,471 09/25/2018 PAT 11144554
which is a CIP of 16/053,141 08/02/2018 PAT 11151142
which is a CON of 14/212,429 03/14/2014 PAT 10061812
which claims benefit of 61/791,218 03/15/2013

Foreign Applications for which priority is claimed (You may be eligible to benefit from the **Patent Prosecution Highway** program at the USPTO. Please see http://www.uspto.gov for more information.) - None.
Foreign application information must be provided in an Application Data Sheet in order to constitute a claim to foreign priority. See 37 CFR 1.55 and 1.76.

Permission to Access Application via Priority Document Exchange: Yes

Permission to Access Search Results: Yes

Applicant may provide or rescind an authorization for access using Form PTO/SB/39 or Form PTO/SB/69 as appropriate.

If Required, Foreign Filing License Granted: 10/21/2021

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 17/499,725**

Projected Publication Date: 02/03/2022

Non-Publication Request: No

Early Publication Request: No

**** SMALL ENTITY ****

Title

SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION

Preliminary Class

709

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4258).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to promote and facilitate business investment. SelectUSA provides information assistance to the international investor

community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states, and regions competing for global investment; and counsels U.S. economic development organizations on investment attraction best practices. To learn more about why the United States is the best country in the world to develop technology, manufacture products, deliver services, and grow your business, visit http://www.SelectUSA.gov or call +1-202-482-6800.

PTO/SB/08a (02-18)
Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (**Not for submission under 37 CFR 1.99)**		
	Application Number	
	Filing Date	
	First Named Inventor	Nathaniel T. Bradley
	Art Unit	
	Examiner Name	
	Attorney Docket Number	PBH-P0001CIP1

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	4237344	A	1980-12-02	Moore	Entire Document
	2	5377258	A	1994-12-27	Bro	Entire Document
	3	8066640	B2	2011-11-29	Angelides	Entire Document
	4	8313433	B2	2012-11-20	Cohen et al.	Entire Document
	5	8355925	B2	2013-01-15	Rothman et al.	Entire Document
	6	RE42508		2011-06-28	Lewis et al.	Entire Document
If you wish to add additional U.S. Patent citation information please click the Add button.						Add

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	
	Filing Date	
	First Named Inventor	Nathaniel T. Bradley
	Art Unit	
	Examiner Name	
	Attorney Docket Number	PBH-P0001CIP1

	1	20020065697	A1	2002-05-30	Cautley et al.	Entire Document
	2	20020147626	A1	2002-10-10	Zagotta et al.	Entire Document
	3	20020194046	A1	2002-12-19	Sullivan et al.	Entire Document
	4	20030004758	A1	2003-01-02	Luttrell	Entire Document
	5	20030014279	A1	2003-01-16	Roman et al.	Entire Document
	6	20080141138	A1	2008-06-12	Kalaboukis et al.	Entire Document
	7	20080270182	A1	2008-10-30	Lowney	Entire Document
	8	20080281651	A1	2008-11-13	Brennan et al.	Entire Document
	9	20090048872	A1	2009-02-19	Toy et al.	Entire Document
	10	20090112924	A1	2009-04-30	Harris et al.	Entire Document
	11	20090192825	A1	2009-07-30	Hunt et al.	Entire Document

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	
	Filing Date	
	First Named Inventor	Nathaniel T. Bradley
	Art Unit	
	Examiner Name	
	Attorney Docket Number	PBH-P0001CIP1

	12	20100082381	A1	2010-04-01	Merrifield Jr. et al.	Entire Document
	13	20110029521	A1	2011-02-03	Thayne et al.	Entire Document
	14	20110047404	A1	2011-02-24	Metzler et al.	Entire Document
	15	20110161107	A1	2011-06-30	Goldberg et al.	Entire Document
	16	20110295613	A1	2011-12-01	Coyne	Entire Document

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2]	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1							

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]
	1	"International Application No PCT/US2014/029287 International Search Report and Written Opinion", 08/22/2014, 7 pages.	X

If you wish to add additional non-patent literature document citation information please click the Add button Add

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	
	Filing Date	
	First Named Inventor	Nathaniel T. Bradley
	Art Unit	
	Examiner Name	
	Attorney Docket Number	PBH-P0001CIP1

EXAMINER SIGNATURE			
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	
	Filing Date	
	First Named Inventor	Nathaniel T. Bradley
	Art Unit	
	Examiner Name	
	Attorney Docket Number	PBH-P0001CIP1

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Brian D. Owens/	Date (YYYY-MM-DD)	2021-10-12
Name/Print	Brian Dean Owens	Registration Number	55517

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

PATENT COOPERATION TREATY

ADVANCE E-MAIL

PCT

From the INTERNATIONAL BUREAU

NOTIFICATION CONCERNING TRANSMITTAL OF COPY OF INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (CHAPTER I OF THE PATENT COOPERATION TREATY)
(PCT Rule 44bis.1(c))

To:

COLEMAN, Kyle, S.
MCKEE, VOORHEES & SEASE, P.L.C.
801 Grand Avenue, Suite 3200
Des Moines, Iowa 50309-2721
ETATS-UNIS D'AMERIQUE

Date of mailing *(day/month/year)* 24 September 2015 (24.09.2015)	
Applicant's or agent's file reference P11260WO00	**IMPORTANT NOTICE**

International application No.	International filing date *(day/month/year)*	Priority date *(day/month/year)*
PCT/US2014/029287	14 March 2014 (14.03.2014)	15 March 2013 (15.03.2013)

Applicant
GRAFTON SCHOOL, INC.

The International Bureau transmits herewith a copy of the international preliminary report on patentability (Chapter I of the Patent Cooperation Treaty)

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No. +41 22 338 82 70

Authorized officer
Philippe Bécamel

e-mail: pt03.pct@wipo.int

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY
(Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44*bis*)

Applicant's or agent's file reference P11260WO00	**FOR FURTHER ACTION**	See item 4 below
International application No. PCT/US2014/029287	International filing date *(day/month/year)* 14 March 2014 (14.03.2014)	Priority date *(day/month/year)* 15 March 2013 (15.03.2013)
International Patent Classification (8th edition unless older edition indicated) See relevant information in Form PCT/ISA/237		
Applicant GRAFTON SCHOOL, INC.		

1. This international preliminary report on patentability (Chapter I) is issued by the International Bureau on behalf of the International Searching Authority under Rule 44 *bis*.1(a).

2. This REPORT consists of a total of 6 sheets, including this cover sheet.

   In the attached sheets, any reference to the written opinion of the International Searching Authority should be read as a reference to the international preliminary report on patentability (Chapter I) instead.

3. This report contains indications relating to the following items:

☒	Box No. I	Basis of the report
☐	Box No. II	Priority
☐	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
☐	Box No. IV	Lack of unity of invention
☒	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
☐	Box No. VI	Certain documents cited
☐	Box No. VII	Certain defects in the international application
☐	Box No. VIII	Certain observations on the international application

4. The International Bureau will communicate this report to designated Offices in accordance with Rules 44*bis*.3(c) and 93*bis*.1 but not, except where the applicant makes an express request under Article 23(2), before the expiration of 30 months from the priority date (Rule 44*bis* .2).

	Date of issuance of this report 15 September 2015 (15.09.2015)
The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No. +41 22 338 82 70	Authorized officer Philippe Bécamel e-mail: pt03.pct@wipo.int

Form PCT/IB/373 (January 2004)

PATENT COOPERATION TREATY

From the
INTERNATIONAL SEARCHING AUTHORITY

To: Brian D. Owens
15201 Mason Road, Suite 1000-312
Cypress, Texas 77433
United States of America

PCT

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43*bis*.1)

Date of mailing *(day/month/year)*	22 AUG 2014
Applicant's or agent's file reference 126-103WO	FOR FURTHER ACTION See paragraph 2 below

International application No.	International filing date *(day/month/year)*	Priority date *(day/month/year)*
PCT/US14/29287	14 March 2014 (14.03.2014)	15 March 2013 (15.03.2013)

International Patent Classification (IPC) or both national classification and IPC
IPC(8) - G06Q 50/22 (2014.01)
USPC - 705/2

Applicant GRAFTON SCHOOL, INC.

1. This opinion contains indications relating to the following items:

- ☒ Box No. I Basis of the opinion
- ☐ Box No. II Priority
- ☐ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- ☐ Box No. IV Lack of unity of invention
- ☒ Box No. V Reasoned statement under Rule 43*bis*.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- ☐ Box No. VI Certain documents cited
- ☐ Box No. VII Certain defects in the international application
- ☐ Box No. VIII Certain observations on the international application

2. **FURTHER ACTION**

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1*bis*(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

Name and mailing address of the ISA/US	Date of completion of this opinion	Authorized officer:
Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-3201	21 July 2014 (21.07.2014)	Shane Thomas PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774

Form PCT/ISA/237 (cover sheet) (July 2011)

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/US14/29287

Box No. I Basis of this opinion

1. With regard to the **language**, this opinion has been established on the basis of:

☒ the international application in the language in which it was filed.

☐ a translation of the international application into _____ which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).

2. ☐ This opinion has been established taking into account the **rectification of an obvious mistake** authorized by or notified to this Authority under Rule 91 (Rule 43*bis*.1(a))

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, this opinion has been established on the basis of a sequence listing filed or furnished:

a. (means)

☐ on paper

☐ in electronic form

b. (time)

☐ in the international application as filed

☐ together with the international application in electronic form

☐ subsequently to this Authority for the purposes of search

4. ☐ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

5. Additional comments:

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/US14/29287

Box No. V **Reasoned statement under Rule 43*bis*.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)	Claims	5, 7-10, 12-13, 15, 18-19	YES
	Claims	1-4, 6, 11, 14, 16-17, 20	NO
Inventive step (IS)	Claims	8, 15, 19	YES
	Claims	1-7, 9-14, 16-18, 20	NO
Industrial applicability (IA)	Claims	1-20	YES
	Claims	None	NO

2. Citations and explanations:

Claims 1-4, 6, 11, 14, 16-17 and 20 lack novelty under PCT Article 33(2) as being anticipated by US 2011/0047404 A1 to Metzler et al. (hereinafter "Metzler").

As to claims 1 and 16, Metzler discloses method for tracking outcome specific data (clinical outcomes in the backend provide data to the front end (tracking the status and progress (outcome specific data) of the user), paragraph [0037]); and a controller (software program executing on a server (and a controller), paragraphs [0024], [0121]) comprising: a processor for executing a set of instructions (a processor executing a software module (a processor for executing a set of instructions), paragraph [0121]); and a memory for storing the set of instructions (a storage medium (memory) where the software module resides (for instructions), paragraph [0101]), wherein the set of instructions are executed by the processor to (the software module is executed by the processor (the software module is executed by the processor, (paragraph [0121]); to perform the method of: receiving input establishing accounts for providers serving clients (logon module provides the features and tools that allow a user to register for an account (receiving input establishing accounts) for healthcare professionals (for providers) to observe and interact with users (serving clients), paragraphs [0036], [0037]) wherein the accounts are stored in a server (accounts are stored in a database that is in communication with the server, paragraphs [0025], [0033], [0036]); assigning each of the clients to one or more of the providers in response to selections from an administrator (each patient (client) is assigned to a clinical professional (providers) and is set up and approved by (in response to) the administrator, paragraphs [0036], [0047]); compiling data associated with each of the clients received from the providers utilizing computing or communications devices in communication with the server (data is collected regarding a user (compiling data associated with each of the clients) from treatment professionals (providers) using any network device (utilizing computing devices) interacting with web pages on the server (in communication with the server), paragraphs [0025], [0032], [0071]); and presenting the compiled data visually in response to a user request (the content module can display (presenting visually) the user's progress in completing the achievements (the compiled data), in response to the requests, the hosting device can transfer content to the requesting devices (in response to a user request), figure 9, paragraphs [0025], [0065], [0094]).

As to claim 11, Metzler discloses a system for tracking goal achievement of individuals (tracking a user's goals and performance, paragraphs [0094], [0098]), the system comprising: computing and communications devices in communication with a server through one or more networks (using any network device (computing and communications devices) interacting with web pages (in communication) on the server over the internet (through one or more networks), paragraphs [0025], [0117]); the server configured to receive input establishing accounts for a plurality of providers serving the individuals (the system (the server) includes a logon module provides the features and tools that allow a user to register for an account (establishing accounts) for healthcare professionals (providers) to observe and interact with users (serving the individuals), paragraphs [0036], [0037]), assign each of the individuals to one or more of the providers in response to selections from administrator (each patient (individual) is assigned to a clinical professional (providers) and is set up and approved (in response to selections) by the administrator, paragraphs [0036], [0047]), compile data associated with each of the individuals received from the providers utilizing the computing or communications devices in communication with the server (data can be accumulated (compile data) regarding a user (client) from treatment professionals (received from the providers) using any network device (utilizing computing or communications devices) interacting with web pages on the server (in communication with the server), paragraphs [0025], [0032], [0071], [0092]), and present the compiled data visualizing in response to a user request (the content module can display (presenting visually) the user's progress in completing the achievements (the compiled data), in response to the requests, the hosting device can transfer content to the requesting devices (in response to a user request), figure 9, paragraphs [0025], [0065], [0094]); and a database in communication with the server (the application stores and retrieves data from the database that is in communication with the server, paragraphs [0025], [0033]), the database configured to store the accounts, permissions, settings, and data (the database stores user accounts (store the accounts), privacy settings (permissions), notification settings (settings) and events and activities (data), paragraphs [0036], [0073], [0068], [0078]).

As to claim 2, Metzler disclose the method according to claim 1. Metzler further disclose a method wherein the server is accessed through a cloud network (the server is accessed through the internet (a cloud network), figure 1, paragraph [0024]), and wherein an application executed by the computing or communications devices is utilized to receive user input from the providers (an application executed on a computer data is collected (receive user input) from treatment professionals (from the providers), figure 1, paragraphs [0025], [0071]).

As to claim 3, Metzler discloses the method according to claim 1. Metzler further discloses a method further comprising: establishing goals for the clients, wherein the data indicates a status of the goals (the professionals can set goals (establishing goals) in the account of the user (clients) and have the site assist in the monitoring and support of those goals where the user can report their progress (status of the goals), paragraph [0063]).

-***-Continued Within the Next Supplemental Box-***-

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/US14/29287

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.
Continuation of:
-***-Continued from Box V: Citations and Explanations-***-

As to claim 4, Metzler discloses the method according to claim 3. Metzler further discloses a method comprising: data mining the data to determine best practices (the data can be used for statistical analysis (data mining) by healthcare providers to compare to other treatment centers to determine comparable outcomes (best practices), paragraph [0092]).

As to claim 6, Metzler discloses the method according to claim 1. Metzler further discloses a method wherein the data includes at least intervention plans, goals and objectives, recorded activities, and general notes (events and activities are captured and stored (recorded activities), paragraph [0068]).

As to claim 14, Metzler discloses the system according to claim 11. Metzler further discloses a system wherein the one or more networks are a cloud network (the server is accessed through a local area network, wide area network, virtual private network, or the internet (the server is accessed through a cloud network), figure 1, paragraph [0024]).

As to claim 17, Metzler discloses the server according to claim 16. Metzler further discloses wherein the data includes at least intervention plans, goals and objectives, recorded activities, and general notes (the activities of the patients are captured and stored in the database (recorded activities), paragraph [0068]).

As to claim 20, Metzler discloses the controller according to claim 16. Metzler further discloses a controller wherein the controller is accessible by a plurality of mobile devices, a plurality of computing devices, and a web interface (the software operating on the server (the controller) accessed (accessible) by mobile devices such as a mobile telephone or personal digital assistant (mobile devices); a patient and clinical professional device including a personal computer (computing devices), where the content may be displayed on a mobile device in the form of a webpage (a web interface), paragraphs [0025], [0026], [0121]).

Claim 5 lacks an inventive step under PCT Article 33(3) as being obvious over Metzler in view of US RE42508 E to Lewis et al. (hereinafter "Lewis").

As to claim 5, Metzler disclose the method according to claim 3. However, Metzler fails to disclose a method further comprising: recommending the best practices to the providers in response to the best practices being associated with a client assigned to the providers. Lewis discloses a method comprising: recommending the best practices to the providers in response to the best practices being associated with a client assigned to the providers (recommending an alternative ancillary medical procedure (best practices) to the physicians (providers) for an identified patient (client) treated by the physician that is not being treated per guidelines of ancillary medical procedures, column 5 lines 52-64, column 12, lines 5-12). It would have been obvious to one of ordinary skill in the art, at the time the invention was made, to modify the method of Metzler to include recommending the best practices to the providers in response to the best practices being associated with a client assigned to the providers, as taught by Lewis, for the benefit of providing updated recommendations to the providers so they can determine the best treatment for the client.

Claims 7 lacks an inventive step under PCT Article 33(3) as being obvious over Metzler in view of US 2009/0192825 A1 to Hunt et al. (hereinafter "Hunt").

As to claim 7, Metzler discloses the method according to claim 1. However, Metzler fails to disclose a method further comprising: communicating an alert in response to the data for each of the clients reaching a threshold associated with the alert. Hunt discloses a method comprising: communicating an alert in response to the data for each of the clients reaching a threshold associated with the alert (the communication includes an email (communicating) of an alert (an alert) based on essential data (in response to the data) available for a patient), when a threshold of the user triggers the alert (reaching a threshold), paragraphs [0055], [0057], claim 9). It would have been obvious to one of ordinary skill in the art, at the time the invention was made, to modify the method of Metzler to include communicating an alert in response to the data for each of the clients reaching a threshold associated with the alert, as taught by Hunt, for the benefit of alerting clients of situations that may require attention or contact with the provider.

Claim 9 lacks an inventive step under PCT Article 33(3) as being obvious over Metzler in view of US 2009/0112924 A1 to Harris et al. (hereinafter "Harris").

As to claim 9, Metzler discloses the method according to claim 1. Metzler further discloses a system comprising: indicating a status of goals for the clients in response to the data (each goal and the user's progress in completing the goals (status) are shown (indicating) based on the data (in response to the data), figure 9, paragraphs [0065], [0094]). However, Metzler fails to disclose a method further comprising: tracking a time and occurrence number of client actions in response to input from the providers. Harris discloses a method comprising: tracking a time and occurrence number of client actions in response to input from the providers (each record includes a record number (occurrence number) and a timestamp (tracking a time) of an action performed by the client (of client actions) in response to a request or other reporting event (in response to input), from the provider, paragraphs [0090], [0098]). It would have been obvious to one of ordinary skill in the art, at the time the invention was made, to modify the method of Metzler to include tracking a time and occurrence number of client actions in response to input from the providers, as taught by Harris, for the benefit of storing records with timestamps so queries can be preformed in the database on historical data.

-***-Continued Within the Next Supplemental Box-***-

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/US14/29287

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.
Continuation of:
-***-Continued from Previous Supplemental Box-***-

Claim 10 lacks an inventive step under PCT Article 33(3) as being obvious over Metzler in view of US 8355925 B2 to Rothman et al. (hereinafter "Rothman").

As to claim 10, Metzler discloses the method according to claim 1. However, Metzler fails to disclose a method further comprising reporting outcomes in response to data compared against a minimum growth line. Rothman discloses a method comprising reporting outcomes in response to data compared against a minimum growth line (the comparison module may include a statistical reference curve so that the health score (reporting outcomes in response to data) may be easily compared to a baseline reference (minimum growth line), column 21, lines 52-55, column 22, lines 14-16). It would have been obvious to one of ordinary skill in the art, at the time the invention was made, to modify the method of Metzler to include reporting outcomes in response to data compared against a minimum growth line, as taught by Rothman, for the benefit of giving the data more meaning by comparing against a target or baseline.

Claims 12-13 and 18 lack an inventive step under PCT Article 33(3) as being obvious over Metzler in view of US 8313433 B2 to Cohen et al. (hereinafter "Cohen").

As to claim 12, Metzler discloses the system according to claim 11. Metzler further discloses the system wherein the data is from the providers (data is collected regarding a user from treatment professionals (providers), paragraph [0071]). However, Metzler fails to disclose a system wherein the database is a relational database management system performing data mining to analyze the data to associate best practices with each of the individuals. Cohen discloses a system wherein the database performing data mining to analyze the data to associate best practices with each of the individuals (data may be stored in the database; the data may be made available (performing data mining) and analyzed based on the historical information of the subject (individuals) associated with the beneficial practices (best practices), column 11, lines 25-36). Although neither Metzler nor Cohen specifically disclose a relational database management system, it would have been obvious to one of ordinary skill in the art at the time of the invention to use a relational database for the benefit of comparing larger amounts of data with varied relationships faster, as relational databases are old and well known in the art. Further, it would have been obvious to one of ordinary skill in the art, at the time the invention was made, to modify the system of Metzler to include wherein the database performing data mining to analyze the data to associate best practices with each of the individuals, as taught by Cohen, for the benefit of analyzing historic data to ensure the patients receive the proper and best practices recommended.

As to claim 13, Metzler and Cohen disclose the system according to claim 12. However, Metzler fails to disclose a method wherein the server is configured to recommend one or more best practices to the plurality of providers in response to the data of the individuals being associated with the best practices. Cohen discloses a method wherein the server is configured to recommend one or more best practices to the plurality of providers in response to the data of the individuals being associated with the best practices (the database stores recommendations that may be accessed by the healthcare provider (recommend) and access beneficial practices (one or more best practices) where information may be made generally available for health care providers for analyzing data based on the historical information of the subject (in response to the data of the individuals) associated with the beneficial practices, column 2, lines 60-65, column 11, lines 25-36, column 29, lines 20-24). It would have been obvious to one of ordinary skill in the art, at the time the invention was made, to modify the system of Metzler to include wherein the server is configured to recommend one or more best practices to the plurality of providers in response to the data of the individuals being associated with the best practices, as taught by Cohen, for the benefit of using the individual client data to recommend best practices to multiple providers.

As to claim 18, Metzler discloses the server according to claim 16. However, Metzler fails to disclose a server wherein the set of instructions are further executed to: recommend best practices to the providers in response to historic success with the clients. Cohen discloses a server wherein the set of instructions are further executed to: recommend best practices to the providers in response to historic success with the clients (recommendations may be accessed by the healthcare provider (recommend best practices to the providers); aggregate data of many subject sources may allow the healthcare provider to recognize beneficial practices (in response to historic success), column 2, lines 60-65, column 29, lines 20-24). It would have been obvious to one of ordinary skill in the art, at the time the invention was made, to modify the server of Metzler to include wherein the set of instructions are further executed to: recommend best practices to the providers in response to historic success with the clients, as taught by Cohen, for the benefit of using the historic data of a plurality of clients to develop best practices for future clients.

Claims 8, 15 and 19 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest: receiving the data through a plurality of collection methods including task analysis, intensive trial teaching, interval recording, frequency, percentage data, and a reinforcement recorder. In the closest prior art, Metzler discloses a method and a system comprising: receiving the data through time recording (data is collected (receiving the data) that is tracked over time (through time recording), paragraphs [0072]). However, the prior art fails to disclose the limitations as discussed above.

Claims 1-20 have industrial applicability as defined by PCT Article 33(4) because the subject matter can be made or used in industry.

Electronic Patent Application Fee Transmittal

Application Number:	
Filing Date:	
Title of Invention:	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION
First Named Inventor/Applicant Name:	Nathaniel T. Bradley
Filer:	Brian Dean Owens/Ashlyn Nguyen
Attorney Docket Number:	PBH-P0001CIP1

Filed as Small Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
UTILITY FILING FEE (ELECTRONIC FILING)	4011	1	80	80
UTILITY SEARCH FEE	2111	1	350	350
UTILITY EXAMINATION FEE	2311	1	400	400
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				
Miscellaneous:				
			Total in USD ($)	**830**

Electronic Acknowledgement Receipt

EFS ID:	44012889
Application Number:	17499725
International Application Number:	
Confirmation Number:	9953
Title of Invention:	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION
First Named Inventor/Applicant Name:	Nathaniel T. Bradley
Customer Number:	133690
Filer:	Brian Dean Owens/Ashlyn Nguyen
Filer Authorized By:	Brian Dean Owens
Attorney Docket Number:	PBH-P0001CIP1
Receipt Date:	12-OCT-2021
Filing Date:	
Time Stamp:	19:19:27
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	DA
Payment was successfully received in RAM	$830
RAM confirmation Number	E20210BJ20290280
Deposit Account	
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Application Data Sheet	PARALLAX_PBH-P0001CIP1_CONTINUATION-PATENT-APPLICATION_FILED-ADS.pdf	1874485 0671d0295ed0a79bf300202d7328fdce72fe1283	no	9
Warnings:					
Information:					
2		PARALLAX_PBH-P0001CIP1_CONTINUATION-PATENT-APPLICATION_FILED-SPECIFICATION.pdf	584933 704a948abbbf53e1cfe166d539b94a7bf9a8e011	yes	64

Multipart Description/PDF files in .zip description

Document Description	Start	End
Specification	1	59
Claims	60	63
Abstract	64	64

Warnings:					
Information:					
3	Oath or Declaration filed	PARALLAX_PBH-P0001CIP1_CONTINUATION-PATENT-APPLICATION_FILED-DECLARATIONS.pdf	487710 9a37ccc870499e064c034f6945c73ff8f274abae	no	4
Warnings:					
Information:					
4	Power of Attorney	PARALLAX_PBH-P0001CIP1_CONTINUATION-PATENT-APPLICATION_FILED-POA.pdf	679997 1a8a160b169e16815ef60dfb4c6bcafbc0dc638a	no	2
Warnings:					
Information:					
5	Drawings-only black and white line drawings	PARALLAX_PBH-P0001CIP1_CONTINUATION-PATENT-APPLICATION_FILED-DRAWINGS.pdf	633992 fe5c9b7f9d4c80d6248cfe9d11fff599bf98a417	no	15

Warnings:					
Information:					
6	Information Disclosure Statement (IDS) Form (SB08)	PARALLAX_PBH-P0001CIP1_CONTINUATION-PATENT-APPLICATION_FILED-IDS.pdf	1054011 17ef0ceee97edfb34d54fccca2782d77574ffa9d	no	6
Warnings:					
Information:					
7	Other Reference-Patent/App/Search documents	PCTUS2014029287_ISRWO_8-22-2014.pdf	422922 5d1bce68388d4232c4bc13fd77f1318c5282aff0	no	7
Warnings:					
Information:					
8	Fee Worksheet (SB06)	fee-info.pdf	44036 4bab5d4105edc8c24b68a1cd3d9e68c7b44a9589	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	5782086		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	PBH-P0001CIP1
	Application Number	
Title of Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	

The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.
This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.

Secrecy Order 37 CFR 5.2:

☐ Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)

Inventor Information:

Inventor 1 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Nathaniel	T.	Bradley	

Residence Information (Select One) ● US Residency ○ Non US Residency ○ Active US Military Service

City	State/Province	Country of Residence
Tucson	AZ	US

Mailing Address of Inventor:

Address 1	7450 S Sandbar Willow Place
Address 2	
City	Tucson
State/Province	AZ
Postal Code	85747
Country	US

Inventor 2 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	James		Gaynor	

Residence Information (Select One) ◉ US Residency ○ Non US Residency ○ Active US Military Service

City	State/Province	Country of Residence
Winchester	VA	US

Mailing Address of Inventor:

Address 1	216 Cotton Ridge Road
Address 2	
City	Winchester
State/Province	VA
Postal Code	22603
Country	US

Inventor 3 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Joshua	S.	Paugh	

Residence Information (Select One) ◉ US Residency ○ Non US Residency ○ Active US Military Service

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	PBH-P0001CIP1
	Application Number	
Title of Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	

City	Tucson	State/Province	AZ	Country of Residence	US

Mailing Address of Inventor:

Address 1	7501 E Mary Dr.		
Address 2			
City	Tucson	State/Province	AZ
Postal Code	85730	Country	US

Inventor 4 — Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Paul		Arena	

Residence Information (Select One) ◉ US Residency ○ Non US Residency ○ Active US Military Service

City	Malibu	State/Province	CA	Country of Residence	US

Mailing Address of Inventor:

Address 1	600 Schueren Rd		
Address 2			
City	Malibu	State/Province	CA
Postal Code	90265	Country	US

All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the **Add** button. Add

Correspondence Information:

Enter either Customer Number or complete the Correspondence Information section below.
For further information see 37 CFR 1.33(a).

☐ **An Address is being provided for the correspondence Information of this application.**

Customer Number	133690		
Email Address	docketing@goodhue.com	Add Email	Remove Email

Application Information:

Title of the Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION		
Attorney Docket Number	PBH-P0001CIP1	Small Entity Status Claimed	☒
Application Type	Nonprovisional		
Subject Matter	Utility		
Total Number of Drawing Sheets (if any)		Suggested Figure for Publication (if any)	

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	PBH-P0001CIP1
	Application Number	
Title of Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	

Filing By Reference:

Only complete this section when filing an application by reference under 35 U.S.C. 111(c) and 37 CFR 1.57(a). Do not complete this section if application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be provided in the appropriate section(s) below (i.e., "Domestic Benefit/National Stage Information" and "Foreign Priority Information").

For the purposes of a filing date under 37 CFR 1.53(b), the description and any drawings of the present application are replaced by this reference to the previously filed application, subject to conditions and requirements of 37 CFR 1.57(a).

Application number of the previously filed application	Filing date (YYYY-MM-DD)	Intellectual Property Authority or Country

Publication Information:

☐ Request Early Publication (Fee required at time of Request 37 CFR 1.219)

☐ **Request Not to Publish.** I hereby request that the attached application not be published under 35 U.S.C. 122(b) and certify that the invention disclosed in the attached application **has not and will not** be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.

Representative Information:

Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32).
Either enter Customer Number or complete the Representative Name section below. If both sections are completed the customer Number will be used for the Representative Information during processing.

Please Select One:	● Customer Number	US Patent Practitioner	○ Limited Recognition (37 CFR 11.9)
Customer Number	133690		

Domestic Benefit/National Stage Information:

This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, 365(c), or 386(c) or indicate National Stage entry from a PCT application. Providing benefit claim information in the Application Data Sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.
When referring to the current application, please leave the "Application Number" field blank.

Prior Application Status	Pending		Remove
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)
	Continuation of	16141471	2018-09-25

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	PBH-P0001CIP1
	Application Number	
Title of Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	

Prior Application Status	Pending		Remove
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)
16141471	Continuation in part of	16053141	2018-08-02
Prior Application Status	Patented		Remove

Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)	Patent Number	Issue Date (YYYY-MM-DD)
16053141	Continuation of	14212429	2014-03-14	10061812	2018-08-28

Prior Application Status	Expired		Remove
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)
14212429	Claims benefit of provisional	61791218	2013-03-15

Additional Domestic Benefit/National Stage Data may be generated within this form by selecting the **Add** button. Add

Foreign Priority Information:

This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55. When priority is claimed to a foreign application that is eligible for retrieval under the priority document exchange program (PDX)[i] the information will be used by the Office to automatically attempt retrieval pursuant to 37 CFR 1.55(i)(1) and (2). Under the PDX program, applicant bears the ultimate responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1).

Remove

Application Number	Country[i]	Filing Date (YYYY-MM-DD)	Access Code[i] (if applicable)

Additional Foreign Priority Data may be generated within this form by selecting the **Add** button. Add

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications

☐ This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March 16, 2013.
NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March 16, 2013, will be examined under the first inventor to file provisions of the AIA.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	PBH-P0001CIP1
	Application Number	
Title of Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	

Authorization or Opt-Out of Authorization to Permit Access:

When this Application Data Sheet is properly signed and filed with the application, applicant has provided written authority to permit a participating foreign intellectual property (IP) office access to the instant application-as-filed (see paragraph A in subsection 1 below) and the European Patent Office (EPO) access to any search results from the instant application (see paragraph B in subsection 1 below).

Should applicant choose not to provide an authorization identified in subsection 1 below, applicant **must opt-out** of the authorization by checking the corresponding box A or B or both in subsection 2 below.

NOTE: This section of the Application Data Sheet is **ONLY** reviewed and processed with the **INITIAL** filing of an application. After the initial filing of an application, an Application Data Sheet cannot be used to provide or rescind authorization for access by a foreign IP office(s). Instead, Form PTO/SB/39 or PTO/SB/69 must be used as appropriate.

1. Authorization to Permit Access by a Foreign Intellectual Property Office(s)

A. Priority Document Exchange (PDX) - Unless box A in subsection 2 (opt-out of authorization) is checked, the undersigned hereby **grants the USPTO authority** to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the State Intellectual Property Office of the People's Republic of China (SIPO), the World Intellectual Property Organization (WIPO), and any other foreign intellectual property office participating with the USPTO in a bilateral or multilateral priority document exchange agreement in which a foreign application claiming priority to the instant patent application is filed, access to: (1) the instant patent application-as-filed and its related bibliographic data, (2) any foreign or domestic application to which priority or benefit is claimed by the instant application and its related bibliographic data, and (3) the date of filing of this Authorization. See 37 CFR 1.14(h)(1).

B. Search Results from U.S. Application to EPO - Unless box B in subsection 2 (opt-out of authorization) is checked, the undersigned hereby **grants the USPTO authority** to provide the EPO access to the bibliographic data and search results from the instant patent application when a European patent application claiming priority to the instant patent application is filed. See 37 CFR 1.14(h)(2).

The applicant is reminded that the EPO's Rule 141(1) EPC (European Patent Convention) requires applicants to submit a copy of search results from the instant application without delay in a European patent application that claims priority to the instant application.

2. Opt-Out of Authorizations to Permit Access by a Foreign Intellectual Property Office(s)

☐ A. Applicant **DOES NOT** authorize the USPTO to permit a participating foreign IP office access to the instant application-as-filed. If this box is checked, the USPTO will not be providing a participating foreign IP office with any documents and information identified in subsection 1A above.

☐ B. Applicant **DOES NOT** authorize the USPTO to transmit to the EPO any search results from the instant patent application. If this box is checked, the USPTO will not be providing the EPO with search results from the instant application.

NOTE: Once the application has published or is otherwise publicly available, the USPTO may provide access to the application in accordance with 37 CFR 1.14.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	PBH-P0001CIP1
	Application Number	
Title of Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	

Applicant Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

Applicant 1 — Remove

If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed. The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR 1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be identified in this section.

Clear

● Assignee	Legal Representative under 35 U.S.C. 117	Joint Inventor
Person to whom the inventor is obligated to assign.	Person who shows sufficient proprietary interest	

If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:

Name of the Deceased or Legally Incapacitated Inventor:

If the Applicant is an Organization check here. ☒

Organization Name	Parallax Behavioral Health, Inc.,		
Mailing Address Information For Applicant:			
Address 1	1327 Ocean Avenue		
Address 2	Suite B		
City	Santa Monica	**State/Province**	CA
Country	US	Postal Code	90401
Phone Number		Fax Number	
Email Address			

Additional Applicant Data may be generated within this form by selecting the Add button. Add

Assignee Information including Non-Applicant Assignee Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	PBH-P0001CIP1
	Application Number	
Title of Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	

Assignee 1

Complete this section if assignee information, including non-applicant assignee information, is desired to be included on the patent application publication. An assignee-applicant identified in the "Applicant Information" section will appear on the patent application publication as an applicant. For an assignee-applicant, complete this section only if identification as an assignee is also desired on the patent application publication.

Remove

If the Assignee or Non-Applicant Assignee is an Organization check here. ☒

Organization Name	Parallax Behavioral Health, Inc.,

Mailing Address Information For Assignee including Non-Applicant Assignee:

Address 1	1327 Ocean Avenue		
Address 2	Suite B		
City	Santa Monica	**State/Province**	CA
Country i	US	Postal Code	90401
Phone Number		Fax Number	
Email Address			

Additional Assignee or Non-Applicant Assignee Data may be generated within this form by selecting the Add button. Add

Signature:

Remove

NOTE: This Application Data Sheet must be signed in accordance with 37 CFR 1.33(b). **However, if this Application Data Sheet is submitted with the INITIAL filing of the application and either box A or B is not checked in subsection 2 of the "Authorization or Opt-Out of Authorization to Permit Access" section, then this form must also be signed in accordance with 37 CFR 1.14(c).**

This Application Data Sheet **must** be signed by a patent practitioner if one or more of the applicants is a **juristic entity** (e.g., corporation or association). If the applicant is two or more joint inventors, this form must be signed by a patent practitioner, **all** joint inventors who are the applicant, or one or more joint inventor-applicants who have been given power of attorney (e.g., see USPTO Form PTO/AIA/81) on behalf of **all** joint inventor-applicants.

See 37 CFR 1.4(d) for the manner of making signatures and certifications.

Signature	/Brian D. Owens/			Date (YYYY-MM-DD)	2021-10-12
First Name	Brian	Last Name	Owens	Registration Number	55517

Additional Signature may be generated within this form by selecting the Add button. Add

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	PBH-P0001CIP1
	Application Number	
Title of Invention	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION	

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1 The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3 A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent CooperationTreaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION

RELATED APPLICATIONS

[0001] This application is a continuation of U.S. Application Serial No. 16/141,471 filed on September 25, 2018 which is a continuation-in-part of U.S. Application Serial No. 16/053,141 filed on Aug. 2, 2018 which claims the priority benefit of U.S. Application Serial No. 61/791,218 filed Mar 15, 2013 and U.S. Application Serial No. 14/212,429 issued as patent number 10,061,812 and filed on March 14, 2014.

BACKGROUND

[0002] The ability of organizations, hospitals, schools, businesses, individuals, and others to meet goals is, and always will be, a significant challenge. In particular, it is important to recognize and treat problems and issues that prevent goals and other objectives from being achieved. For example, organizations and institutions that help individuals with disabilities and significant emotional or behavioral challenges have improved their processes in recent years. In particular, more individuals with physical disabilities, autism, chemical imbalances, mental disorders, behavioral problems, drug addictions, and other conditions are being served each year. Improved assessment, medications, training, treatment processes, and education, have provided solutions for addressing the concerns of individuals with special needs.

[0003] However, electronic systems, equipment, software, and processes for tracking, treating, and recording results, such as for individuals with special needs, have not improved as significantly. For example, some organizations still use paper documents and charts to track individuals' information or a single computing system available from only one location to enter and review data. As a result, viewing, updating, managing, and sharing, relevant information may be more difficult than it should be.

SUMMARY

[0004] Illustrative embodiments provide a system, method, server, and computer readable medium for tracking goal progression. Input is received establishing clients. The clients are individuals receiving treatment or assistance. The data associated with the clients is stored in a

server available through one or more networks. Each of the clients are assigned to one or more providers in response to selections from an administrator. The one or more providers include at least individuals available to treat or assist each of the clients and one or more biometric devices associated with the clients. Goals are established for each of the clients. Data associated with each of the clients is compiled as received from the one or more providers in the server. A determination is made where the goals are being met in response to the thresholds for the compiled data. Alerts are automatically communicated in response to the compiled data varying from a threshold to become significant for one or more of the clients.

[0005] Another embodiment provides a system, method, server, and computer readable medium for tracking goal progression. Input establishing accounts for providers serving a client is received. The client is an individual receiving treatment or assistance. The accounts are stored in a server available through one or more networks. The client is assigned to one or more of the providers in response to selections from an administrator. Goals and a plan of action are established for the client in response to treatments and assistance required. Data associated with the client received from the providers is compiled. A determination is made whether thresholds associated with the goals are being met based on the compiled data. The illustrative embodiments also provide a computer or server including a processor and memory for performing the process herein described and a computer readable medium including a non-transitory memory for tracking outcome specific data.

[0006] Another illustrative embodiment provides a system, method, server, and computer readable medium for tracking goal progression. Input establishing accounts for providers serving clients is received. Each of the clients is assigned to one or more of the providers in response to selections from an administrator. Goals are established for each of the clients in response to treatments and assistance required. Data associated with each of the clients received from the providers is compiled. A determination is made whether the goals are being met in response to rules based on the compiled data. Alerts are automatically communicated in response to the compiled data varying from a threshold to become significant for one or more of the clients. The illustrative embodiments also provide a computer, server, or controller including a processor and memory for performing the processes herein described and a computer readable medium including a non-transitory memory for tracking outcome specific data. The illustrative embodiments also provide a computer or server including a processor and memory for

performing the process herein described and a computer readable medium including a non-transitory memory for tracking outcome specific data.

[0007] Another illustrative embodiment provides a system, method, server, controller, and computer readable medium for tracking outcome specific data. Input establishing accounts for providers serving clients is received. The accounts are stored in a server. Each of the clients is assigned to one or more of the providers in response to selections from an administrator. Data associated with each of the clients received from the providers is compiled utilizing computing or communications devices in communication with the server. The compiled data is presented visually, in graph form, in response to a user request. The illustrative embodiments also provide a computer or server including a processor and memory for performing the process herein described and a computer readable medium including a non-transitory memory for tracking outcome specific data.

[0008] Another embodiment provides a system for tracking goal achievement of individuals. The system may include computing and communications devices in communication with a server through one or more networks. The server may be configured to receive input establishing accounts for a plurality of providers serving the individuals, assign each of the individuals to one or more of the providers in response to selections from an administrator, compile data associated with each of the individuals received from the providers utilizing the computing or communications devices in communication with the server, and present the compiled data visually in graph form in response to a user request. The system may also include a database in communication with the server configured to store the accounts, permissions, settings, and data.

[0009] In other embodiments, the server may be accessed through a cloud network. A client management program may be executed by computing devices or communications devices utilized by the one or more providers to receive the data and track progress of the goals. An intervention may be performed with the one or more clients in response to the alerts. The intervention may be performed by the one or more providers. Each of the goals may be associated with a plan of action for achieving each of the goals. A baseline of goals and/or data of the clients may be established. The goals may be established by the clients and the one or more providers. A determination may be made whether modifications to the goals are required

in response to the compiled data. The goals may be modified in response to the compiled data indicating the goals are not achievable.

[0010] In some embodiments, a method for tracking outcome specific data, the method comprises receiving input establishing accounts for providers serving clients, wherein the accounts are stored in a server; assigning each of the clients to one or more of the providers in response to selections from an administrator; compiling data associated with each of the clients received from the providers utilizing computing or communications devices in communication with the server; and presenting the compiled data visually in response to a user request.

[0011] In some embodiments, the server is accessed through a cloud network, and wherein an application executed by the computing or communications devices is utilized to receive user input from the providers.

[0012] In some embodiments, the method further comprises: establishing goals for the clients, wherein the data indicates a status of the goals.

[0013] In some embodiments, the method further comprises: data mining the data to determine best practices.

[0014] In some embodiments, the method further comprises: recommending the best practices to the providers in response to the best practices being associated with a client assigned to the providers.

[0015] In some embodiments, the data includes at least intervention plans, goals and objectives, recorded activities, and general notes.

[0016] In some embodiments, the method further comprises: communicating an alert in response to the data for each of the clients reaching a threshold associated with the alert.

[0017] In some embodiments, the method further comprises: receiving the data through a plurality of collection methods including task analysis, intensive trial teaching, interval recording, time recording, frequency, percentage data, and a reinforcement recorder.

[0018] In some embodiments, the method further comprises: tracking a time and occurrence number of client actions in response to input from the providers; and indicating a status of goals for the clients in response to the data.

[0019] In some embodiments, the method further comprises: reporting outcomes in response to data compared against a minimum growth line.

[0020] In some embodiments, a system for tracking goal achievement of individuals, the system comprising: computing and communications devices in communication with a server through one or more networks, the server configured to receive input establishing accounts for a plurality of providers serving the individuals, assign each of the individuals to one or more of the providers in response to selections from an administrator, compile data associated with each of the individuals received from the providers utilizing the computing or communications devices in communication with the server, and present the compiled data visualizing in response to a user request, and a database in communication with the server, the database configured to store the accounts, permissions, settings, and data.

[0021] In some embodiments, the database is a relational database management system performing data mining to analyze the data from the providers to associate best practices with each of the individuals.

[0022] In some embodiments, the server is configured to recommend one or more best practices to the plurality of providers in response to the data of the individuals being associated with the best practices.

[0023] In some embodiments, the one or more networks are a cloud network.

[0024] In some embodiments, the computing and communications devices are utilized by users to receive the data through a plurality of collection methods including task analysis, intensive trial teaching, interval recording, duration recording, frequency, recording, and percentage recording.

[0025] In some embodiments, a controller comprises a processor for executing a set of instructions; and a memory for storing the set of instructions, wherein the set of instructions are executed by the processor to receive input establishing user accounts for providers serving

clients; assign each of the clients to one or more of the providers in response to selections from an administrator; compile data associated with each of the clients received from the providers utilizing computing or communications devices in communication with the server; and present the compiled data visually in response to a user request.

[0026] In some embodiments, the data includes at least intervention plans, goals and objectives, recorded activities, and general notes.

[0027] In some embodiments, the set of instructions are further executed to recommend best practices to the providers in response to historic success with the clients.

[0028] In some embodiments, the set of instructions are further executed to receive the data through a plurality of collection methods includes task analysis, intensive trial teaching, interval recording, time recording, frequency, percentage data, and a reinforcement recorder.

[0029] In some embodiments, the controller is accessible by a plurality of mobile devices, a plurality of computing devices, and a web interface.

BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Illustrative embodiments of the present invention are described in detail below with reference to the attached drawing figures, which are incorporated by reference herein and wherein:

[0031] FIG. 1 is a pictorial representation of a health system in accordance with an illustrative embodiment;

[0032] FIG. 2 is a block diagram of a controller in accordance with an illustrative embodiment;

[0033] FIG. 3 is a block diagram of a recorded data module in accordance with an illustrative embodiment;

[0034] FIG. 4 provides a chart illustrating data collection in accordance with an illustrative embodiment;

[0035] FIG. 5 is a flowchart of a process for generating a goal in accordance with an illustrative embodiment;

[0036] FIG. 6 is a pictorial representation of a monitoring environment in accordance with an illustrative embodiment;

[0037] FIG. 7 is a flowchart of a process for utilizing data in accordance with an illustrative embodiment;

[0038] FIGs. 8 and 9 illustrate pictorial representations of outcome-based paths and scoring for depression in accordance with illustrative embodiments;

[0039] FIG. 10 is a pictorial representation of a user interface 1000 in accordance with an illustrative embodiment; and

[0040] FIGs. 11-15 are pictorial representations of user interfaces of a mobile application in accordance with an illustrative embodiment.

DETAILED DESCRIPTION OF THE DRAWINGS

[0041] The illustrative embodiments provide systems, methods, servers, techniques, platforms, instruction sequences, computer program products, and networks for optimizing, managing, and tracking data driven outcomes. In one embodiment, a multi-dimensional platform is provided to facilitate data-driven outcomes processes through assessment, goal development, data tracking, graphing, and re-evaluation. In the embodiments, best practices, successful actions, and plans are identified through automatic data-mining and analysis as well as user specified parameters, algorithms, and analytics.

[0042] The illustrative embodiments are applicable to more than just behavioral management. The illustrative embodiments may be adapted to any number of fields, systems, or environments for which an outcome process is identified. The recipient or focus of the outcome process is a subject, the subject may be a client, patient, student, service provider, program, product, service, device, organization, business, department, or so forth. The subject may also be referred to herein as a client.

[0043] The illustrative embodiments may be applied to distinct outcome processes and content that involve the same or similar steps as described herein, such as client behavior management, educational instruction, school improvement activities, program evaluation, organizational key performance indicators, financial management, weight management, tracking insurance claims, or so forth. As used herein the term "or" is not mutually exclusive.

[0044] The illustrative embodiments may include a health network and system utilized to record, manage, and track progress data. One or more system administrators may manage the system for multiple service providers. As referred to herein a provider is an organization, business, group, school, facility, user, or caregiver, working toward specific goals or objectives. The users may specify goals or objectives. In some instances, goals and objectives are referred to simply as goals. Individuals being cared for may be referred to as clients, patients, students, individuals, or recipients.

[0045] Illustrative embodiments allow for full customization of different variables, such as hierarchical structure, subject title, roles, goal content, assessment variables, strategies and interventions, and underlying rules governing data analysis as needed by the user. In another embodiment of the system, the different users may be program administrators, providers, caregivers, IT support, and so forth. The labels specified for different variables and users may be assigned based on roles, levels of function, permissions within the system, and so forth. The illustrative embodiments may be customized to a desired level of functionality and for specific hierarchies.

[0046] The illustrative embodiments may be utilized to manage organizational quality improvement efforts and activities. As a result, organizations may more easily record and track progress to meeting individual, group, or institutional goals. In one embodiment, the described system is applicable to a behavioral health system, but is equally applicable to different conditions, environments, and situations. The ongoing behavioral health example is given for purposes of further illustrating the concepts.

[0047] In one example, the described embodiments may be utilized to assist and serve children and adults with disabilities, or significant emotional or behavioral challenges. The embodiments may be utilized in a patient-centered model, to provide continuous and coordinated services from early intervention, short-term stabilization, and residential services to substance

abuse treatment, outpatient services, educational, and career and technical training. The illustrative embodiments may also be utilized for program or organization evaluation.

[0048] In one embodiment, a health network and system may be utilized to provide software as a service (SaaS). For example, a health network provider may make server-level applications, local applications, web programs, and mobile applications available to a number of providers. Individual users may then enter, retrieve, manage, and view information and data through any number of wired or wireless computing and communications devices. The different software may be updated as new versions are released. As a result, comprehensive systems and software services may be quickly rolled out to the providers. The individuals may be added, deleted, or managed from a number of remote locations. In one embodiment, the existing medical records including files and databases may be integrated with the health network and system to ease any transition concerns. In other embodiments, existing paper records may be digitized for utilization with the health network. Information from existing electronic medical records and systems may be uploaded for immediate utilization. The illustrative embodiments may be utilized to communicate with external databases including importing and exporting medical, financial, or other sensitive records if the correct authorizations are verified.

[0049] In one embodiment, the health network may utilize a cloud network to provide access. The cloud network may allow the system provider to license the system and software more efficiently. The system provider may control the system hosts, client profiles, security access, permissions, key access, and other controls.

[0050] In one embodiment, the described systems and method may be utilized to assess client outcomes to provide data to evaluate a variety of diagnostic, cultural, treatment, and regulatory priorities. Shared and collaborative information may result in team sharing of information for providing automated processes for real-time monitoring of progress and outcomes. The illustrative embodiments provide a systematic data collection and analysis system and process.

[0051] The embodiments may utilize a highly structured outcomes analytics program that assists users in collecting, graphing, and analyzing client-related outcome data. In one embodiment, a provider-defined Analysis of Influences Matrix (AIM) is considered to assess factors associated with a lack of progress to substantiate changes to service methodology. The

AIM process may be used to determine needs, propose goals to address, and better match service components to optimize outcomes. In one embodiment, the illustrative embodiments may be referred to as Reliable Evidence Based Outcomes Optimization Technologies (REBOOT). The embodiments may be available to professionals, doctors, teachers, and clinicians as well as family members to facilitate the effectiveness of care and service plans. The data may be collected at the client, service, program, and organization levels to drive comprehensive quality improvement efforts. The illustrative embodiments provide a systematic method of pinpointing staff training needs, identifying departmental resources and programming needs, and developing processes to evaluate the utilization of best practices to improve outcomes.

[0052] The illustrative embodiments may be effective for addictions (e.g., drug abuse, gambling, sex addiction, etc.), mental health/disorders, and other recoveries, diseases, or conditions for which people seek treatment or help. The illustrative embodiments may be utilized to score a client's progress (positive, negative, neutral) based on numerous factors, values, conditions, and goals. The progress may be recorded utilizing a score. The score and other information may be communicated to any number of parties. As needed, the client information may be utilized to match providers with clients based on applicable information and data.

[0053] In one example of a health system, goal mastery rates across programs that utilize the described processes and embodiments have improved from 35%-81% and have sustained above 80%. At the same time, coercive behavior management interventions have been reduced dramatically. The resulting increases in both client and staff safety indices correlate significantly with associated cost reductions to the organization. The illustrative embodiments decrease delivery costs despite the increases in sophistication over the existing systems.

[0054] The illustrative embodiments may improve client functioning, reduce client and staff injuries, reduce program costs, and mobilize a trans-disciplinary wrap-around system and process that "owns" the actualization of sustainable positive outcomes. The positive results indicate that it is possible to make gains in the independence and quality of life for clients with disabilities, while improving the viability of both the organization and the naturalistic support community as well.

[0055] The following paragraphs provide information that help understand the illustrative embodiments and the processes utilized to measure and achieve goals. As used herein, a baseline may be initial data obtained when the identified goal is first implemented. For example, an initial score and date may be obtained as part of the baseline. A mastery level may be the score, or achievement required to master a goal or objective. For example, a measurable activity may need to be performed at the mastery level a number of times over a duration of time before the goal is considered achieved.

[0056] The duration may be a length measure in time or a number of times an activity is performed at the mastery level or goal is reached. A projected closure date is the date at which the goal will end. The projected closure date is utilized to keep users and clients focused on reaching a designated goal in a reasonable time period. For example, depending upon procedural and regulatory parameters, a projected closure date may be pre-determined (e.g., one year) or may be set by user or agent specification of timeline (e.g., organizational key performance indicators may be set annually). The final mastery window may be the projected closure date minus duration. The final mastery window may represent the last window of opportunity to reach and maintain the mastery level before the goal ends.

[0057] The minimum growth line is a graphical line that runs from the baseline date and score (rating on graph) to the mastery level on the date that starts the final mastery window. The end of the minimum growth line starts the final mastery window and indicates the last possible timeframe during which the goal may be mastered before the goal expires. The minimum growth line is a reference point against which ongoing data ratings are compared to assess status and level of progress. The minimum growth line is not a prediction of how the actual data points will present, but simply a reference line against which the actual data points are compared. Assessing status is determined as data are graphed and compared with the minimum growth line. For example, the system may determine the status automatically utilizing pre-determined rules.

[0058] In one embodiment, each organization may set rules that are utilized by the system to determine whether goals and other criteria are met. For example, a client may be deemed to be progressing if when reviewing three of the most recent data points at least two of the three are better than the minimum growth line (e.g., higher than the upward-sloping minimum growth line or the mathematical indicator corresponding to the time period, lower than the downward

slanting minimum growth line, etc.) The status may also be color coded. For example, green may indicate that the client is progressing.

[0059] A client's goal may be determined to not be on track if two of the three most recent data points are worse than the minimum growth line. If three consecutive data points are worse than the minimum growth line, the third data point may have a status identified as "significant." The significant rating may be marked. For example, the significant rating may be marked in red, highlighted, flash, or so forth. In one embodiment, identification of a significant data point may trigger an AIM-review process to evaluate possible factors inhibiting progress on the goal and to identify changes to the AIM factors that are hypothesized to facilitate progress. The results of the AIM review are noted, and a phase change may be noted on the graph. In one embodiment, the phase change may be indicated by a change in a data symbol, color, background color, label, or other indicator.

[0060] In another embodiment, a status of mastered may be given when the mastery level is maintained for an amount of time specified in the duration. For example, mastery may be indicated by a purple star around the data point that meets the criteria. Once a status of mastered is given, maintained mastery is a status given for all subsequent data points that reach or are better than the mastery level. Once a status of mastered is given, all subsequent data points that fall worse than the mastery level (higher for downward-sloping minimum growth line and lower for upward-sloping minimum growth line) are given the status of regression from mastery. When three consecutive ratings are given the status of regression from mastery, the third rating is identified as regression from mastery and significant. For example, a data point associated with regression from mastery may be noted with a red circle, and an AIM review is prompted as previously cited. Each service provider may specify thresholds, criteria, or rules that are utilized to determine the differences between statuses. For example, two consecutive ratings or a specified number may be utilized to determine deviations or significance.

[0061] In one embodiment, when the goal reaches the projected closure date, the goal is given a final status based on the last status entry. Goal mastery data may be analyzed in any number of ways. Final status rates may be calculated and may be assessed by any level of the agent hierarchy (e.g., by client, by service provider, by service type, by location, organization-wide). Status reports may be generated as needed to assess the current status of goals (not yet

ended) by any level of the agent hierarchy. In one embodiment, reports may be generated to provide a listing of all goals whose current status is significant.

[0062] The illustrative embodiments may also allow multidimensional analysis of subject, goal, service, and intervention by final status outcomes to generate formulas for best practices by any of these parameters. For example, a specific subject type might be most successful with a particular goal when a specific intervention is provided. Other analyses may indicate typical timelines for reaching particular outcomes by any of these parameters.

[0063] FIG. 1 is a pictorial representation of a health system 100 in accordance with an illustrative embodiment. The health system 100 may include any number of systems, devices, or equipment. For example, the health system 100 may utilize existing medical record servers, databases, electronic files, and systems. The health system 100 may also include any number of customized or proprietary systems, software, equipment, devices, or other components that are described herein.

[0064] In one embodiment, the health system 100 may include a health network 102 and a management system 103. The health network 102 may include hardware and software components including servers 104, file servers 106, databases 108, and software 110. The health system 100 and the health network 102 are configured to serve numerous customers or providers including Provider A 112 and Provider B 114. Each of the customers may include any number of networks, servers, computing devices, wireless devices, or network equipment, systems, and so forth. In one embodiment, Provider A 112 may utilize a server 116, a computer 118 displaying a graphical user interface (GUI) 120, and an electronic medical record (EMR) 122.

[0065] The Provider A 112 may further utilize a network 124 and wireless devices 126, 128, and 130 jointly "wireless devices 132"). Provider B 114 may utilize a network 134, a computer 136, and wireless devices 138, 140, and 142 (jointly "wireless devices 144"). The wireless devices 132 and 144 may be utilized when connected to a network or offline. The information and data may be entered utilizing a keyboard, speech recognition, imaging system, microphones, or any number of other devices or peripherals known in the art.

[0066] In one embodiment, the management system 103 is one or more devices utilized to enable, initiate, route, and manage communications between one or more computing and communications devices and providers, such as Provider A 112 and Provider B 114. The

management system 103 may include one or more devices networked to manage the health network 102. For example, the management system 103 may include any number of servers, routers, switches, or advanced intelligent network devices. The health network 102 sends and receives the electronic signals through any number of transmission mediums. The health network 102 may include various fiber optics, cables, transmission towers, antennas, or other components for transmitting data, communications, information, and files.

[0067] The health network 102 may represent any number of communications networks and connections including wired or wireless networks, data or packet networks, cable networks, satellite networks, private networks, publicly switched telephone networks (PSTN), or other types of communication networks. For example, communications within the health environment 102 may occur utilizing satellite connections, Wi-Fi, WiMAX, cellular networks, and/ or hardwired connections, such as fiber optics, T1, cable, DSL, standard telephone lines, Ethernet, power line networking, or other digital or analog communications connections. Any number of communications architectures including client-server, network rings, peer-to-peer, tiered networks, application servers, distributed networks, or other network systems may be utilized.

[0068] In one embodiment, communications utilizing the wireless devices 112 and 114 may occur directly or through network devices using communications protocols, such as time division multiple access (TDMA), code division multiple access (CDMA), global systems for mobile (GSM) communications, personal communications systems (PCS), Wi-Fi, WLAN, WiMAX, or other frequently used cellular and data communications protocols and standards. The wireless devices 112 and 114 may include cellular phones, smart phones, personal digital assistants (PDA), mp3 players, laptops, the readers, evolution data optimized (EDO) cards, hybrid devices, tablets, multi-mode devices, and other wireless communication devices and components.

[0069] FIG. 2 is a block diagram of a server 200 in accordance with an illustrative embodiment. In one embodiment, the server 200 may include a processor 202, a memory 204, a database 206, logic 208, a user interface 210, system administrators 212, provider administrators 214, service providers 216, settings 218, permissions 220, users 222, clients 224, data 226, alerts and notifications 228, and reporting 230, and an interface 232. The data 226 may include service delivery 234, goals and objectives 236, recorded data 238, and general notes 240. As referenced herein clients are any individual, parties, groups, process, subject, device, or organization on which data is collected.

[0070] The server 200 may communicate with networks 242, systems 244, and electronic devices 246 utilizing applications 248. In one embodiment, the server 200 is a computing device or group of networked or distributed computing devices. The server 200 may have any number of hierarchical users including, system administrators 212, provider administrators 214, service providers 216, IT support, support staff, caregivers, and other similar users. In one embodiment, to add any of the described entities, groups, or users to the server 200, any of the following information or data may be required: name (e.g., first, last, username, nickname, etc.), email address, image, mobile telephone number, work number, role (e.g., system administrator, service providers, parent, etc.), user identification, password, designated supervisor, comments, and other related information.

[0071] The processor 202 is circuitry or logic enabled to control execution of a set of instructions. The processor 202 may be microprocessors, digital signal processors, application-specific integrated circuits (ASIC), central processing units, or other devices suitable for controlling an electronic device including one or more hardware and software elements, executing software, instructions, programs, and applications, converting and processing signals and information, and performing other related tasks. The processor 202 may be a single chip or integrated with other computing or communications elements.

[0072] The memory 204 is a hardware element, device, or recording media configured to store data for subsequent retrieval or access at a later time. The memory 204 may be static or dynamic memory. The memory 204 may include a hard disk, random access memory, cache, removable media drive, mass storage, or configuration suitable as storage for data, instructions, and information. In one embodiment, the memory 204 and processor 202 may be integrated. The memory may use any type of volatile or non-volatile storage techniques and media.

[0073] The database 206 may be utilized to store the data 226. The database 206 may include a database management system such as SQL (and variations), Access, Oracle, and DB2. In one embodiment, the interface 232 may include a transceiver configured to both transmit and receive communications for the server 200. The networks 242, systems 244, wireless devices 246 and applications 248 may represent all or a portion of the health system 100 of FIG. 1, such as Provider A 112 or client 114. The database 206 may be configured for data mining of available information and data as is known in the art.

[0074] In another embodiment, the server 200 may act as a web server hosting content that may be retrieved and managed. The illustrative embodiments may be implemented utilizing a web browser for entering, updating, and managing information, goals, activities, and other 226 data. In one embodiment, the software, information, and data utilized by the server 200 may be indexed, archived, or otherwise made available for queries and secured web-based searches. As a result, the users 222 may search the data 226 based on the applicable settings 218 and permissions 220 to determine best practices.

[0075] In one embodiment, information, settings, and data utilized by the server 200 is saved or duplicated to one or more redundant systems for backup, failover, or network purposes utilizing any number of backup standards, formats, or protocols. The various components of the server 200 may represent an application that is stored in the memory 204 and executed by the processor to perform the illustrative embodiments. The server 200 may host an application that communicates with other devices executing a local copy or version of the application (e.g., applications 248). Data may be similarly be synchronized and shared between applications in real-time or near real-time. As a result, multiple users 222 may be able to edit the data 226 simultaneously or concurrently while seeing the changes made by their counterparts.

[0076] In one embodiment, the system administrators 212 may control upload of the provider administrators 214, service providers 216 and clients 224 into the systems of the server 200. The system administrators 212 may be allowed to manage the setup of information, settings rules governing data analysis, and modules for the provider administrators 214. In one embodiment, the system administrators may be prevented from seeing specific types of data. However, in one example, general information, such as effectiveness of the service delivery 234 (e.g., a specific treatment plan) and the associated data 226 may be made available to the system administrators 212 for further enhancing the server 200 and providing additional actions and best practices to a number of clients that the system administrator 212 manages. In one embodiment, different provider administrators 214 associated with different organizations may be assigned to each of the system administrators 212 as a caseload. Service providers 216 may be similarly assigned as needed.

[0077] Provider administrators 214 may be provided unique access to the server 200 through a user interface 210. The user interface 210 may be represented by programs, applications, secure access protocols or systems made available through the server 200, such as the user

interface 210, or alternatively, the applications 248, or the systems 244. The user interface 210 may present a dashboard or portal for managing the described information and data. In one embodiment, the provider administrators 214 functions of the user interface 210 may be accessed through a desktop application interface or webpage. The provider administrators 214 may have complete read/write access to the user accounts represented by the service providers 216 including the settings 218, permissions 220, clients 224 and data 226. In one embodiment, the user interface 210 may display any number of icons, images, drop-down menus, videos, hyperlinks, internal links, scroll wheels, tabs, Windows, or other selection or display components.

[0078] The provider administrators 214 may have the capacity to add, edit, archive, and delete users 222 and the clients 224. The provider administrators 214 may have access to data 226 including service plans 234, goals and objectives 236, recorded data 238, and general notes 240. The user interface 210 may also provide user access for monitoring a patient's behavioral status. The service providers 216 may represent supervisors or may also be users 222 associated with one or more clients 224.

[0079] In one embodiment, the status may be associated with alerts or notifications 228 triggered by built-in system monitoring logic, such as reporting 230, that is intended to guide service providers 216 in their administration of service plans, tracking of recorded data 238, and service provider communications. The server 200 stores and provides access to every recorded service providers 216 interaction with the client file (e.g., updates, general notes 240, recorded data 238, event-triggered notifications, etc.) included in the data 226 or specific to the clients 224. As a result, the service providers 216 may log all activities within a file thereby allowing other service providers 216 to view the activities based on the pre-established settings 218 and permissions. For example, business, hospitals, or schools may have sharing agreements for exchanging data while still complying with the applicable laws and industry practices. Provider administrators 214 may also post public notes, comments, alerts, and notifications, associated with data 226 being recorded by the server 200 by the users 222 through the user's accounts. For example, public notes may be accessible to the related service provider 216.

[0080] Provider administrators 214 may manage their team of service providers 216 who work directly with clients 224 to administer information and data, such as goals and objectives 236. The provider administrators 214 may have complete access to the service providers 216

and the clients 224 to assign the clients 224 to individual service providers 216 through the user interface 210. In one embodiment, the service providers 216 represent authorized users able to access all or portions of the server 200 applicable to the service provider, view elements of the service plans 234, view and add goals and objectives 236 for clients 224 that are associated with the service providers 216 to enter data, information, statistics, and record audio and video permitted by the provider administrators 214.

[0081] The users 222 may utilize the applications 248 (e.g., Android, iOS, Windows, etc.) to communicate with the user interface 210 to view data 226. For example, mobile applications executed by the electronic devices 246 may communicate the data 226 that is saved to the server 600. The user interface 210 may provide an easy to navigate and user friendly interface with quick search utilities and filters (e.g., location, caseload, etc.). The user may be granted read only/write access with the capacity of adding new instances. In one embodiment, changes to the client's information, such as service plans 234, goals and objectives 236, recorded data 238, and general notes 240 may be required to be reviewed by supervisors prior to submission. The users 222 may represent support staff, parents, professionals, and in some cases the clients 224 themselves may be given full or limited access to their own data 226. In one embodiment, the users 222 may represent the full hierarchy of individuals associated with clients 224 from administrators to support staff. From each client-dashboard available through the user interface 210, the service provider 216 may have access to a log of interactions associated with the data 226 (e.g., data collection, inactivity alerts, etc.).

[0082] The communications with the server 200 are secured for sensitive electronic protected health information and to comply with applicable laws, such as HIPAA. Communications with the server 200, whether in real-time or file transfers, may be encrypted or utilize other secure data transmission protocols (e.g., SSL, https, security certificates, etc.). The server 200 may also be configured to communicate with any number of databases 206 or systems 244, internal or external, maintained or accessible by the provider administrator 214, such as electronic client records databases. The applications 248 may record information and data even if one of the networks 242 is not currently available or if the wireless devices 246 and the systems 244 are offline. Synchronization methods and modes may be utilized as necessary (e.g., cloud synchronization). In one embodiment, conflicts and synchronization of information may be presented to the service provider 216 or provider administrators 214. In one embodiment,

variance conflicts may be resolved by an automated processes or based on input from the provider administrator 214.

[0083] In one embodiment, users accessing the server 200 through the user interface 210 may be able to view clients 224 by location, caseload, or assignment. For example, the clients 224 may be associated with one or more locations, services, or programs. The locations may allow for further sub categorization, such as national, regional, or local programs. In one embodiment, provider administrators 214 may be able to see clients 224 associated with their respective service providers 216 or treatment team. In one example, the service providers 216 may be presented with a default list of clients 224 that have most recently been reviewed at login with options to search by location, client name, or other identifying information.

[0084] In one embodiment, the data 226 may further specify strengths and abilities, preferences, assistance or accommodations, such as environmental supports, activities of daily living, communication, and other, instruction and intervention strategies, and health and safety information, such as medication and special monitoring or precautions. Each of the authorized users may be able to view additional details by making further selections, such as double tapping a portion of the client data 226 presented on a touchscreen. The data 226 may be further customized or displayed in response to a user selection. For example, in an application focused on health and safety information of a client may include additional information, for example, regarding seizures, bowel movements, special diet, exercise program, and one-on-one services that may be further explored or reviewed.

[0085] In one embodiment, by choosing a heading, the service providers 216 may be presented with information for specific goals and objectives 226. For example, in a behavioral health field, the goals and objectives 226 may include areas, such as coping skills, fine motor skills, and physical aggression. The user may utilize a goal wizard or management function to be able to enter headings as well as detailed descriptions or narratives associated with each heading in a hierarchical format. For example, each of the goals and objectives 236 may include a main heading, a start date, a projected closure date, a goal description, a goal narrative, a lead service provider, a data collection method, email notifications (e.g., for individual users associated with the specific client or information for the client), function, and options. Goals may be opened and closed out at any time and may be viewed in separate files, such as active and

archived. In one embodiment, the data 226 may be associated with mastery scores, baseline information, and objectives. The information may also be prioritized or color-coded as needed.

[0086] In one embodiment, the alerts and notifications 228 may be configured to communicate information. For example, any number of alerts and notifications 228 may be communicated through the interface 232. The interface 232 may be configured to communicate with wired and wireless networks. As a result, the alerts and notifications 228 may represent emails, text messages, in-application messages or alerts, audio, video, picture, or text messages, streaming communication sessions, or other similar alerts, messages, or communications that are sent in real-time or near real-time. The alerts and notifications 228 may also include hyperlinks back to the original source of the alert or notification for easy review and to address further action that may be needed. The alerts and notifications 228 may also utilize a feed to send information to users. The feed may be similar to a newsfeed and may be organized by subject date in which users may create dialogues of streams of information related to a particular topic for a client. Individual users may add to each other's feeds or may create new ones. The user may also be able to view and re-enter the most recently accessed areas of an application utilizing a history or most recently utilized function.

[0087] In one embodiment, the alerts and notifications 228 may include a client name, goal/objective name (e.g. decrease physical aggression, 100% customer satisfaction, register balance, etc.), date of rating, name of user, and link back to the rating. If there are multiple significant ratings in a row the alert may include a note specifying how many (e.g. there are now 6 weeks of activities or data points that are off the minimum growth line). Alerts and notifications 228 are also meant to include positive information, such as a mastered rating that may include a client name, assigned providers, date of rating, name of user, and a link back to the rating. The links may represent hyperlinks or metadata for retrieving the information in a web browser application or through an electronic access system as is herein described.

[0088] Certain activities, once configured, automatically trigger the alerts and notifications 228 to send out information and request a response. For example, every time that a user is required to perform a restraint in a health facility, an alert may be sent out to a specified group of providers, users, and administrators to best care for the client restrained as well as for liability and auditing purposes. The alert may indicate the client name, time, response required, and name of the person entering information and any specific notes or comments. The alerts and

notifications 228 may also send out alerts for data exceptions. For example, if data are not received for three weeks in a row, an alert may be generated indicating the reasons for the exceptions, the user name entering the information, and a link back. The alerts may be automatically sent to supervisors, administrators, or other designated parties.

[0089] In one embodiment, the reporting 230 may be utilized to communicate charts and graphs, track and record progress, determine timeliness of data entry, and other information. The reports may be based on clients, location, service provider, region, or date ranges. The reports are configured to be customizable to track and display a variety of process mechanisms input or entered by a user or administrator based on the specific needs for which the illustrative embodiments are utilized. In one example, the reports may be selected to report, significant scores with no AIM review comment, two or more significant scores in a row, AIM distribution by a client, location, and provider, missing data for more than a time period, or other relevant information. The reports may include quick snapshot reports as well as long-term and comprehensive reports.

[0090] The reporting 230 may be configured to present information graphically utilizing bar charts, pie charts, scatter plots, line graphs, and other similar display messages. Graphical representations may include information embedded in multiple layers for automatically displaying additional information to a user (e.g., displaying identifying information and statistics when hovering over a data point). The reporting 230 may also display information statistically, utilizing percentages, in standard document formats (e.g., Word, Excel, GoogleDocs, etc.).

[0091] In one embodiment, the user may set a date range for information to be displayed and specific goals/objectives active during the date range may be automatically entered or selected by the user for display. A current status may indicate the status for a client or subject for all ongoing activities. A final status report may graphically display goals the final outcome of goals and associated activities that were closed during a specified data range.

[0092] As disclosed herein, the reports may include code categories, which may include mastered, maintained mastery, and regression from mastery. Progress toward a goal may also be displayed with information, such as progress (also progressing, or on track), not on track, and not on track/significant. Alternative reporting code categories may include “plan expired”, “achieved mastery”, “closed prior to end date”, “ready for discharge”, “premature discharge”,

"entered in error", "discontinued", "removed", or other similar codes. Some of the codes may be required by other electronic tracking systems and may be added, removed, or translated from existing code categories as is needed.

[0093] The reporting 230 may also specify an overall total based on all participating users and organizations. Overall totals may be generated by code category and by goal service type (e.g., overtime, education, etc.) as well as provider. Similarly, organization, sub-organization, and location specific reporting may also be performed by code category, goal service type, or provider. The various reporting abilities of the illustrative embodiments are configured to apply to privacy laws, such as HIPAA, and may require waivers or authorizations to share information even within an organization for treatment purposes. For example, sub-contractors or other parties may perform reporting as needed or required.

[0094] The reporting 230 may also generate reports based on an identified group of clients automatically or manually selected by a user. For example, the report for the group may show the client, service, goal/objectives, current status, and current status date. The reporting 230 may allow a user to drill down from the organization level to the client and associated goal level.

[0095] Additional information available through the reporting may include length of time of goal implementation until mastery, specified as an average time until mastery calculated from a baseline date to a mastered date and may be determined by goal service type, goal description for total, organizational, sub-organization, and location.

[0096] The reporting 230 may also allow for monitoring reports that are established to include a number of variables and may be displayed or exported in any number of formats. The monitoring reports may be automatically generated and available or communicated to the user. For example, a monitoring report may indicate goal/objectives with the most recent rating that is significant within the past x number of weeks. The reports may show sub-organization, goal/objective, provider, date of significant rating, AIM review comment associated with the significant rating, and so forth. Other monitoring reports may include goals/objectives with x number of significant ratings in a row (e.g. six consecutive points off of the minimum growth line). The monitoring reports may also retrieve all active goals/objectives organized by client, service, most recent status, and status date. Status dates that are older than two weeks old may

be indicated, such as being shown in red. The monitoring reports may also specify goals/objectives that are within x number of weeks of the final mastery period.

[0097] In one embodiment, the AIM is a process utilized to analyze the content of any outcome process. For example, AIM may represent an algorithm that is executed by the logic 208 to retrieve and analyze information as needed by any number of parties. AIM is fully customizable depending upon the content established for a group or organization. In the system administrators 212 may be able to identify key factors that most influence the outcome of the selected content. The variables may then become the different factors of AIM for that application on the server 200.

[0098] The AIM process may be used in the initial site assessment of a "client" or "subject" based on the parameters identified for the content of the client's outcome process. In one embodiment, the AIM process is smart and automated for driving questions based on answers from previous questions. As a result, various users are focused towards best practice assessments of the content. For example, AIM may also provide suggestions for goals, objectives, and interventions based on the information provided on the subject. Broad data mining may feed the AIM process based on the data 226 and other information stored by the server 200 to narrow the scope of questioning two factors found to be the most associated with positive outcomes.

[0099] The AIM process may also be used at any point during the data analysis process when the subject is not making sufficient process (e.g. a determination based on the minimum growth line line). For example, if a subject, such as a client in a behavioral health facility, has three data readings that are off the minimum growth line, the third rating is considered significant, and the user is prompted to conduct an AIM review. The AIM process may also generate suggestions for interventions to facilitate the progress of the subject.

[00100] FIG. 3 is a block diagram of a recorded data module 300 in accordance with an illustrative embodiment. The health system as is herein described includes a number of different methods of recording client data. There are a number of different data collection methods available to provide flexibility and accuracy in data collection design.

[00101] In one embodiment, the recording behavior module 300 may include task analysis 302, intensive trial teaching 304, interval recording 306, duration recording 308, frequency

recording 310, and percentage recording 312. The different aspects and features of the recording behavior module 300 may be combined in any number of combinations and formats. In one embodiment, the recorded data module 300 includes data, information, numbers, statistics, pictures, descriptions, or other content that may be received through a goal wizard or management feature.

[00102] In one embodiment, the recorded data module 300 may be presented to the user as part of a graphical user interface (GUI). The graphical user interface may be presented as part of a mobile application, web program, electronic device, or a communication session.

[00103] In one embodiment, each data collection method may include a specific set of rules related to the data entry and visual presentation of information, data, graphs, and reports available through the health system. In addition to this information, graphics, such as goal mastery graphs, may demonstrate user data results across different data collections episodes and in conjunction with each service goal. The setup and configuration of the information and graphics may be managed by the administrator. The display of the information and graphics may also take into consideration specific device orientation, display options (e.g., graph layout and corresponding information may be presented in a first configuration when viewed in a landscape mode and in a second configuration when viewed in a portrait mode), display limitations, permissions, and so forth.

[00104] In one embodiment, each graphic is the result of specific formulas and calculations. Each user may submit the features, parameters, criteria, or calculations utilized to generate graphics, such as performance measurement charts. In one embodiment, the graphs may be produced in real-time as data are entered or may be set to display historical data. A rules engine may be configured to dynamically handle information and data entered into the health system.

[00105] The recorded data 300 may be tracked to determine whether a particular goal or objective is met. In one embodiment, this option may be controlled by any number of authorized users that are assigned to a client. All or portions of the recorded data 300 may be viewed at once to make analysis accessible and thorough.

[00106] In one embodiment, the data collected in the recorded data 300 may include an antecedent trigger button (e.g., may indicate triggers for patient behavior), location, response (e.g., programmed list of responses providers and/or caregivers made, customized fields for

entries including restrictions, next actions, alerts for restricted practices, etc.), reinforcement options, severity button (e.g., ratings, description, etc.), and comments (e.g., text, audio, video, etc. The information may be presented automatically or based on the type of information presented.

[00107] Any number of data collection systems and methods may be utilized to collect patient data and measure goals and objectives. In one embodiment, all data collection options may be available to the service provider during set-up, but then only the relevant information and fields may be shown for the actual data collection.

[00108] In one embodiment, in the setup for task analysis 302 there may be two settings for that request a hierarchy and task. Task analysis 302 may also be referred to as ratings. To set up the prompt hierarchy an administrator or user may identify a field including a number of prompt types or numbers (e.g., hand over hand, touch prompt, gestural, verbal, independent, etc.), additional comments, color code or priority, and so forth. Task analysis 302 may be set up by establishing the number of tasks or steps, a narrative label for each step, optional comments for more description if needed, and scores. In one embodiment, the tasks may be associated with a particular goal or objective.

[0001] In one example, the fields included during task analysis may include any of the following:

a. What level/percent do you want (subject) to get? _____%

b. Across how many opportunities? ____ within ____ interval

c. Is there a time limit? Yes, No

- If yes, what is the time limit? _____ (interval)

d. How would you like your data calculated and graphed? Average or for each episode.

e. For how long do you want (subject) to get a score of _____ (prepopulated based on answer to a) in order to consider this goal/objective mastered? _____ out of _____ (interval) or _____ consecutive (interval)

f. Projected closure data for goal/objective (timeline to master)

g. Y axis label

h. Baseline mode – on or off

i. Tasks – number of tasks and labels for each task

j. Prompt hierarchy – level of prompt, score and color-coding

k. Option to add to goal bank

l. Instructions/Directions

m. Special permissions related to data collection

n. Alert recipients

o. Customized modification to data analysis rules if applicable

[00109] In one embodiment, task analysis 302 may specify dates or times during which data are collected each day, week, or month. For data collection, the user may be able to see each task and step paired with the prompt hierarchy. For example, the user may select a task and then a prompt level. FIG. 4 provides a chart 400 illustrating data collection in accordance with an illustrative embodiment. For example, the chart 400 illustrating levels of prompt that may be required for a patient to perform the specified tasks. Any number of tasks or objectives may be utilized and the chart 400 of FIG. 4 is given as an example.

[00110] The chart 400 may further illustrate a score 402 that may be calculated based on the level of prompts required for each task. For example, the calculation may be made by adding up the scores for the chosen prompts and dividing that number by the highest score possible. In one embodiment, the score may be reported as a percentage. For example, the score recorded may be 51%.

[00111] The illustrative embodiments may present any number of graph or chart options for the specified goal or objective. For example, by default, a percentage score may appear with the graph. The user may also be presented with the option to generate graphs for each individual task or several tasks over time to evaluate client progress. In one embodiment, the user may select the task to graph, and each graph may be generated utilizing the distinct data and formatting (e.g., color, graph type, etc.). In one embodiment, the graph schedule may be set by an administrator for graphing each entry. As a result, each data point on a graph may immediately be saved as well as displayed.

[00112] Turning again to FIG. 3, the user may be presented with additional options based on the data collection schedule. For example, the user may select to graph each entry or average the entry results. For example, if the data collection schedule is set to three times per week, then once all three data collections are made in a week, the score may be calculated and graphed. In another embodiment, weekly determinations may be made utilizing seven-day intervals starting

with a baseline date. If there are not enough data collection episodes entered to total the number identified during the data collection schedule, the calculations may not be made and an alert signal may be displayed next to the graph indicating the lack of additional data collection points.

[00113] In one embodiment, if a specified time period ends without a specific number of data collection episodes being collected, an email or other alert may be sent to the service provider and/ or the identified supervisor. In one embodiment, entries may be automatically recorded and saved as input. In another embodiment, the data collection displays may include save and edit buttons. Different versions of the recorded information may also be saved to ensure that data are not improperly overwritten. In addition, users may not be able to edit previous entries and only supervisors or administrators may be able to make such changes. The user may also be presented with a comment button to record a comment related to a data collection episode.

[00114] In one embodiment, the intensive trial teaching (ITT) 304 is a data collection module and method. Intensive trial teaching 304 may also be referred to as repeated trials. The ITT 304 and other data collection methods may have multiple modes, such as instructional and testing. While data in both modes may be viewed, in one embodiment, only data entered into the testing mode may be graphed. As previously described, the ITT 304 utilizes a prompt hierarchy, labels, fields (e.g., answer choices, yes, no, etc.), field size data collection schedules, and other options (see FIG. 4 and the associated description). The ITT 304 may also be scored as previously described.

[00115] In one example, the fields included during ITT 304 may include any of the following:

a. What percentage should be achieved? _____

b. How many trials? #_____ Randomize trial listing? Yes, No

c. Across how many episodes? _____ within _____ (interval)

d. How would you like your data calculated and graphed? Average or for each episode.

e. For how long do you want (subject) to get a score of _____ (prepopulated based on answer to a) in order to consider this goal/objective mastered? _____ out of _____ (interval) or _____ consecutive (interval)

f. Projected closure data for goal/objective (timeline to master)

g. Y axis label

h. Baseline mode – on or off

i. Trials – number of tasks and labels for each task

j. Label to identify correctness: Right/Wrong, Correct/Incorrect, Yes/No

k. Option to add to goal bank

l. Instructions/Directions

m. Special permissions related to data collection

n. Alert recipients

o. Customized modification to data analysis rules if applicable

[00116] In one embodiment, the interval recording 306 may include different types, such as whole, partial, or momentary time sampling (e.g., fixed, variable, etc.). The different types of interval recording 306 may include observation duration, length of interval (e.g., seconds, minutes, etc.), options to enter response choices (e.g., yes, no, custom label, etc.), and selection for inclusion in a score selection. In one embodiment, an alert or indicator may be made at the end of each interval. For fixed momentary time sampling, the signal may be given at the conclusion of the time. For variable momentary time sampling, the signal may be given at random times within the identified time. If the interval is specified as 30 seconds, then the signal may be given at any point between one and 30 seconds for each separate interval.

[00117] The interval recording 306 may also include other options for pausing and resuming passage of time, indicating multiple behaviors displayed at once, indicating passage of time, summary of intervals, location, save and edit options, and comment options. After setting up interval recording 306 as a data collection method, an auditory, tactile, or visual signal may be chosen to alert the user as to when to collect data. When the signal is presented, the user may rate the client based on the parameters set and enter the data.

[00118] In one example, the fields included in the interval recording 306 may include any of the following:

a. What percent of intervals are you trying to achieve? _____#

b. What type of time sampling should be used? Whole, Partial, Momentary

c. Observation duration: _____min _____sec

d. Interval duration: _____min _____sec

e. Across how many opportunities? _____ within _____ (interval)

f. How would you like your data calculated and graphed? Average or for each episode

g. For how long do you want (subject) to maintain the score in order to consider this goal/objective mastered? _____ out of ____(interval) or _____ consecutive (interval)

h. Projected closure data for goal/objective (timeline to master)

i. Y axis label

j. Baseline mode – on or off

k. Label to identify correctness: Right/Wrong, Correct/Incorrect, Yes/No

l. Option to add to goal bank

m. Instructions/Directions

n. Special permissions related to data collection

o. Alert recipients

p. Customized modification to data analysis rules if applicable

[00119] In one embodiment, the duration recording 308 may include fields for starting and stopping, a current record time, data recorded (e.g., hours, minutes, seconds to hundreds of a decimal), data collection schedule options, graph schedule options (see FIG. 4), and cumulative duration calculations. The duration recording 308 may also include a field for location and optional comments.

[00120] In one example, the fields included in the duration recording 308 may include any of the following:

a. What is your desired duration? _____# (interval)

b. How many episodes do you want to measure? All or ____ per ____ (interval)

c. How would you like your data calculated and graphed? Cumulative or Average or for Each episode

d. For how long do you want (subject) to maintain (pre-populated duration) in order to consider this goal/objective mastered? _____ out of ____ (interval) or ____ consecutive (interval)

e. Projected closure data for goal/objective (timeline to master)

f. Y axis label

g. Baseline mode – on or off

h. Option to add to goal bank

i. Instructions/Directions

j. Special permissions related to data collection

k. Alert recipients

l. Customized modification to data analysis rules if applicable

[00121] In one embodiment, the frequency recording 310 may include a number of options, such as duration of data collection. Frequency recording 310 may also be referred to as counts. In option 1, the frequency recording 310 may include a daily start time and end time. In option 2 the frequency recording 310 may include a specific interval including designations for hours and minutes, and option 3 may include a specific setting. In one embodiment, option 1 may display information that says “"Data collected from_____to_____" (times)", option 2 may display information that says "Data collected for____(minute) interval" with a displayed start time and start button, and option 3 may display information that says "Data collected in___." The frequency recording 310 and associated data collection options may allow a user to provide a user selection, voice input, or tactile input indicating the number of times a behavior or skill is shown by the client, an indication that no observed behavior was seen during the data collection, and an indication that data collection was not available and an associated comment specifying the associated reasons. Frequency counts may also show a number of items (e.g., returned retail items) or other number of times an event occurs (e.g. customer complaints). Graphing options may be presented to the user as was previously described. In addition, the user may be presented with the opportunity to utilize a scatter plot. The scatter plot may require additional information, such as a date range, time range, and time interval. The graph may then display data that are recorded within the entered specifications. If only one data point is entered on the graph, the data point may indicate the frequency of the behavior within the interval. The data point may be expanded or provide additional details to understand the specific information.

[00122] In one example, the fields included in the frequency recording 310 may include any of the following:

a. Do you want to collect data all day Yes No

If not, Data Collection from _____time to _____time

b. What is the desire score? _____#

c. Choose collection limit: Exactly At Least

d. Across how many opportunities? _____ out of ____ (interval)

e. How would you like your data calculated and graphed? Cumulative or Average

f. For how long do you want (subject) to maintain the score in order to consider this goal/ objective mastered? ____ out of _____ (interval) or _____ consecutive (interval)

g. Projected closure data for goal/objective (timeline to master)

h. Y axis label

i. Baseline mode – on or off

j. Option to add to goal bank

k. Instructions/Directions

l. Special permissions related to data collection

m. Alert recipients

n. Customized modification to data analysis rules if applicable

[00123] In one embodiment, the percentage recording 312 may be set up to include fields for the number of questions/ opportunities, number correct, and percentage correct. In one embodiment, the percentage recording 314 may include labels, number of labels, overall score (e.g., percentage, time, frequency, etc.), and individual scores for tasks. The percentage recording 314 may also be displayed as previously described.

[00124] In one example, the fields included in the percentage recording 312 may include any of the following:

a. What level/percent do you want? _____#

b. Across how many opportunities? All or _____ within ____(interval)

c. Is there a time limit per opportunity? Yes No

If yes, What is the time limit? ____# (interval)

d. How would you like your data calculated and graphed? Average or Each episode

e. For how long do you want (subject) to maintain the score in order to consider the goal/ objective mastered? ____ out of ____(interval) or ___ consecutive (interval)

f. Projected closure data for goal/objective (timeline to master)

g. Y axis label

h. Highest Possible Score

i. Baseline mode – on or off

j. Option to add to goal bank

k. Instructions/Directions

l. Special permissions related to data collection

m. Alert recipients

n. Customized modification to data analysis rules if applicable

[00125] In another embodiment, the illustrative embodiments may utilize an optional reinforcement recorder (RR) that may be utilized with any of the recording methods of FIG. 3 or the illustrative embodiments. The reinforcement recorder may be set to prompt a user to provide reinforcement to the subject on a scheduled or random basis. Two types of reinforcement recorders are provided. The first reinforcement recorder may be associated with a particular subject and goal. The user may program specific reinforcement options or procedures to be provided to the subject dependent upon performance accuracy or at a fixed or variable schedule. In one embodiment, based on the set-up of the reinforcement recorder, the user may be prompted to provide the reinforcement and may be given the options of reinforcement available to that subject. The user may then indicate which type of reinforcement was provided. Reinforcement provided dependent upon performance accuracy may be noted along with other data collection information for that episode or record. The system may log the reinforcement recorder data for analysis purposes.

[00126] In another embodiment, a second reinforcement recorder may be available for general use by the user. This reinforcement recorder may not be associated with a specific subject. The second reinforcement recorder may be programmed to provide a prompt for reinforcement on a fixed or variable schedule and provide options for reinforcement type. When the prompt is given, the user may apply the reinforcement to the subject and/or group of subjects depending upon how the user wants to apply the function. The user may be able to designate the recipient(s) of the reinforcement and the type of reinforcement provided. For example, the recorded data module 300 may log the reinforcement recorder data for analysis purposes.

[00127] In another embodiment, the data collection methods of FIG. 3 may utilize a goal bank for optional use by other users with any number of goal types. The client administrators may specify which information is placed in the goal bank. The goal bank may provide a way of retrieving goal descriptions and the associated tasks for review, modification, and acceptance by any number of users in the way to record each update to the goal.

[00128] In one embodiment, the system may have two banks or memories to store goals and associated objectives, data collection methods, and interventions. One bank may be specific to

that agency or organization and the other bank may be available to all-related organizations. For example, the banks may be used pending administrator access and permissions. Users may be given the option of placing self-created goals into the goal bank as approved by the Administrator. There is also the option for requiring Administrator approval for all suggestion goals prior to acceptance into the Bank. The AIM process may generate a list of relevant goals from the goal bank. Users may also go into the bank when setting up a goal without going through the AIM process. The Goal Bank may be sorted by Service/Type, Goal Name, and/or by typing in keywords. A generic form of the banked goal may pull in with fields requiring customization for that subject. The customizable fields may be the other fields described with respect to the goal wizard.

[00129] In one embodiment, the goal mastery graphs or other graphs may have a number of components that may be managed utilizing a goal wizard and other management feature. The user may set a number of variables during graph set-up, including the Y axis labels, baseline data and date, mastery level, mastery level duration, and projected closure date. The system may automatically calculate a final mastery period by moving back the targeted date by the target rating duration. A minimum growth line may be automatically added as a straight line from the baseline rating and date to the target rating and the beginning of the final mastery period. Ratings entered on the graphs may be colored coded to indicate their status. Data points of significance may be identified by a filled red circle. Data points that satisfy the mastery level and duration may be identified with a purple star.

[00130] The user may also be presented with options for entering other data criteria, value or number specifications, and customizations. In one embodiment, status may be automatically determined and displayed for each of the goals and objectives. The status may include any number of rules, criteria, parameters, or thresholds for calculation and display. The status may also be color-coordinated. For example, progress may be noted in green, lack of progress may be noted in orange, a significant lack of progress may be noted in red, and mastery or maintained mastery may be noted in purple. Regression from mastery may also be noted by color. Data points may be determined as significant utilizing a standardized rule of three consecutive points insufficient to the minimum growth line or a customized set of rules determined by the provider administrator.

[00131] The user may be presented with other options for picking multiple goals/ objectives to graph in a single graph, show data or hide data, view last three data points, or zoom in to a particular data point to see all enter information relevant to that data collection episode.

[00132] In one embodiment, data points of significance may be utilized to generate an alert. For example, identified users may receive a notification within the system or an email, text message, in-app message, or other alert. In one embodiment the email may include the service provider's name, client's name, goal description, reason for notification, the rating date and any review comments entered for the rating that prompted the notification. The alert may also provide a direct link back to the data collection episode entered in the system.

[00133] The illustrative embodiments may be configured to receive comments and reviews. In one embodiment, in response to determining a data point is significant, a review may be prompted or required. In one embodiment, a review may be referred to as an Analysis of Influences Matrix or "AIM Review" and prompt the user to review and document factors associated with lack of progress. The user may also be presented with options to select an intervention change or no change. Information entered in response to intervention change may be prioritized and marked for review and subsequent alerts.

[00134] The illustrative embodiments may be applied to any number of performance management methodologies, such as drug rehabilitation, smoking cessation, physical therapy, medical and behavioral treatments, weight loss, addiction recovery, hotel management, and so forth. In one embodiment, the illustrative embodiments may compile information and data from any number of clients to provide decision-support based on the compiled data. For example, based on research and development, new practices, medications, or service plans may be suggested based on the individual or aggregated recorded data. As a result, services may be adapted in real-time based on dynamic learning from aggregated data. Reporting may be performed without compromising the privacy of client information and data or violating applicable laws. For example, the identifying information, such as client name or location, may be removed from the aggregated data when compiled to provide for anonymity. In addition, the removal of identifying information may ensure that inherent biases, assumptions, inferences, or statements are not promulgated. As a result, more and more clients may utilize the systems and methods herein described increasing the amount of data and accuracy even more.

[00135] In one embodiment, the compiled data may be mined utilizing relational database management systems. The data may also be searched utilizing key word searches, Boolean searches, wild card searches or other similar search protocols, strategies, and algorithms. The generic compiled information may also be sold by a system administrator (or alternatively to service providers or other designated parties) to organizations, universities, drug manufacturers, governments, or other parties to encourage development of new treatments.

[00136] FIG. 5 is a flowchart of a process for generating a goal in accordance with an illustrative embodiment. In one embodiment, a goal manager or wizard may compile information that is utilized to generate a goal/objective. The process of FIGs. 5 and 7 may be implemented by a server, application, device, or combination of communicating elements referred to as a system. The server may be executing a client management program as is herein described. In one embodiment, the process may begin by prompting a user to enter fields and information for generating a goal, data collection method, and graphing set-up (step 502). For example, a series of probes or questions may guide the user through completing fields that may generate the goal/objective narrative, data collection method set up, and graphing setup schedule. Step 502 may help ensure all elements are included in the goal/objective narrative to make specific, objective, and measurable goals. The process may also ensure information is entered to define how the process facilitates data collection, graph set-up, graph scheduling, and alert/notifications associated with these processes. The goal wizard may distinguish between long-term and short-term goals and objectives. The goal wizard may also be referred to as goal creation and tracking software.

[00137] In one embodiment, the following fields may be included in the process of step 502: i). Service/Provider Type - customized by a user, ii). Designation of "Increase" or "Decrease" content or activity, iii). Field for entering "Condition" under which the goal/objective may be measured, iv). Field for entering content assessed (e.g., skill/behavior, actions taken, documentation, etc.). This field may captures what the goal/objective is designed to measure, and v). Field for entering data collection method. In one embodiment, a number of options are provided: Task Analysis, Intensive Trial Teaching, Interval Recording, Duration Recording, Frequency Recording, and Percentage Recording. Based on which data collection method is chosen, additional fields are generated to drive information needed for that type of data collection.

[00138] Next, the system creates a goal narrative and display fields needed for data collection (step 504). The data collection options may depend on the type of data collection method and the responses entered for the associated fields (e.g., in step 502).

[00139] Next, the system receives data from users and prompts for any required data not collected (step 506). The system may automatically score the data based on the rules associated with the data collection method and responses may automatically graph the data on the graph.

[00140] Next, the system determines whether data are collected properly (step 508). The determination of step 508 may be made based the data collection method. For example, the system may require that three entries are received per week and if only two are received, the data are not deemed to have been collected properly.

[00141] If the data are not collected properly in step 508, the system sends an alert to the service provider indicating that there are missing data (step 510). During step 508, the system may also indicate that there was insufficient data collected during a time period to the extent a graph is automatically generated or generated based on a user request. For example, any incomplete graphs may be automatically marked as such. After step 510, a user may correct the lack of data by submitting data that are received by the user. The submission may be made through a website, application, or any number of devices.

[00142] If the data are collected properly in step 508, the system analyzes the data and graphs the data for display (step 512). In one embodiment at the end of the process of FIG. 5 that may be performed by a goal wizard, the option is given to customize the data analysis fields if applicable. If this option is chosen, the user is prompted to identify the rules for determining "status" and "significance" by completing the following questions: i). Regression from Mastery: _____ consecutive data records off MGL, ii). Progress: ____ out of ____ => upward MGL / =< downward MGL, iii). Not on Track: ____ out of ____ =< upward MGL / => downward MGL, and iv). Significance: _____ consecutive points that are Regression from Mastery - _____Consecutive points that are Not on Track.

[00143] For behavioral-type goals that are marked as "decrease," in addition to the data filed associated with the type of data collection method, the following questions are provided as well: i). Severity - option for On Off (* Standard rating scale of severity is provided but may be customized), ii). Response - offers limitless number and fields for Label and Description for

each, iii). Antecedent/Triggers - offers limitless number and fields for label and description for each, iv). Function - Offers options for Obtain, Escape, Automatic, and Attention and fields to write descriptions for each.

[00144] FIG. 6 is a pictorial representation of a monitoring environment 600 in accordance with an illustrative embodiment. The monitoring environment 600 represents any number of facilities, buildings, or conditions in which the illustrative embodiments may be utilized. The monitoring environment 600 may be utilized to determine the location of any or all individuals within the facility as well as determine user and environmental conditions. For example, the monitoring environment 600 may represent a group home, a hospital, or business. The monitoring environment 600 may include any number of components including a client 602, a communications device 604, a door 606, a scanner 608, a panic button 610, a camera 612, a display 614, a user 616, speakers 618, and sensors 620.

[00145] In one embodiment, the panic button 610 is configured to set off an alarm or notify everyone or previously identified individuals in the event that there is an event that demands immediate attention. The panic button 610 may be utilized by any number of users or clients in proximity to it. The associated alert may be broadcast universally or selectively. For example, the panic button 610 may be activated in response to a heated argument between two clients and may be communicated to individuals assigned to address security issues or arguments. In another embodiment, the communications device 604 may include a panic indicator that may be relayed to the panic button 610 for communication to the designated location and parties. For example, logic may indicate specific individuals or groups of individuals that receive an alert based on a detected action, location, time of day, or so forth.

[00146] The monitoring environment 600 may include any number of rooms, furniture, separators, other individuals, or so forth that are not specifically called out. For example, the client 602 may enter the monitoring environment 600 through the door 606. In response to entering the door 606, the communications device 604 and the scanner 608 may communicate to document the location of the client 602. In one embodiment, scanners at the entryways to distinct portions of a building or room may indicate the general proximity of the client 602. The information associated with the monitoring environment 600 may be stored in any number of databases, memories, or electronic storage systems for permanent or temporary access. Positive

or negative alerts may be generated in response to criteria or parameters associated with the location of the client 602.

[00147] The communications device 604 may represent a wireless communications device or personal signaling device. The communications device 604 may be waterproof, durable, and shock resistant. The communications device 604 may be freely removable or may be secured to the client utilizing a specialized tool. In one embodiment, the communications device 604 may be a bracelet, necklace, armband, glasses, anklet, electronic sticker, headband, ornament, or other item that may be worn or integrated with the clothing or body of the client 602. The communications device 606 may communicate utilizing Wi-Fi, Bluetooth, ZigBee, global positioning system (GPS) signals, near field communications, or other existing or developing communications protocols. The communications device 604 may include a microphone, speaker, vibrator, text display, leads, biometric sensor, or other components.

[00148] The communications device 604 may also be configured to determine biometric information associated with the client 602. In one embodiment, the communications device 604 may be configured to determine a heart rate, skin response, temperature, breathing rate, blood sugar level, agitation level (e.g. voice intensity, pitch, or frequency), or other vital information associated with the client 602. The communications device 604 may also be able to determine a distance between the client 602 and one or more other clients or the user 616. For example, the communications device 604 may indicate that the client 602 is speaking to two other clients and that the client 602 and a secondary client both have elevated heart rate and are yelling at each other while the user 616 monitors the situation from approximately 20 feet away.

[00149] The communications device 604 may transmit client information and a location of the client 602 to one or more centralized systems through a wireless access point, wireless device, intercom system, or other communications points. The communications device 604 may communicate with one or more external devices to determine a location. For example, the communications device 604 may communicate with the sensors 620 indicate a room position of the client 602. In other embodiments, GPS information may be determined by the communications device 604. The GPS information may be utilized to determine the location of the client 602 as well as the communications device 604 if it is lost or otherwise removed. Any number of location generation techniques may be utilized including proximity detection, wireless triangulation, signal strength indicators, or any combination thereof. The scanner 608 and the

sensors 620 may be wireless access points, radio frequency identification (RFID) tag readers, wireless beacons, proximity sensors, or other similar devices. In one embodiment, the scanner 608 and the sensor 620 may be integrated with light fixtures, outlets, intercoms, tiles, or other components typically included in a room or facility.

[00150] In one embodiment, the communications device 604 may log activities of the client 602 throughout the day and the associated vital information to determine activities that allow the client 602 to relax and activities that may potentially agitate the client 602. The logged activities may be utilized to determine strategies and plans for any number of clients and users.

[00151] The location of the client 602 and the user 616 may also be determined utilizing the camera 612. The camera 612 may include picture, video, and audio capturing components. The camera 612 may be wireless or wired for communications with the system as herein described. In one embodiment, the camera 612 may utilize logic or algorithms to perform motion capture including detecting sudden movements, struggles, or other information that may be associated with a negative event. The camera 612 may also capture information associated with positive events for automatic or manual documentation.

[00152] Various output devices within the monitoring environment 100 may be configured to communicate auditory, video, visual, or tactile messages to the client 602 or the user 616. In one embodiment, the various communications devices and electronics within the monitoring environment 100 may be controlled through a wired or wireless communications network. As a result, communications and other messaging may be coordinated for maximum effectiveness. In one embodiment, the communications device 604, the display 614, and the speakers 618 may be configured to provide one or more of auditory output (e.g. spoken words, verbal directions, music, a calming mantra, etc.), visual output (e.g. words, pictures, videos), or tactile output (e.g. vibrations with optional speed and frequency).

[00153] The strategy may be determined based on an algorithm of the system and may be specific to the client 602. The strategies may be previously entered for the client 602 may be based on data mining for similar situations and clients. For example, a piece of music known calm client 602 may be played through the speakers 618 and the communications device 604 in response to the client 602 becoming agitated. The strategy may be implemented automatically or manually based on selection of the client 602 or a provider, administrator, or other party

authorized to implement the strategy for the client 602. For example, the communications device 604 may flash green in response to a positive action and may flash red and vibrate in response to a negative event occurring and then provide positive or negative feedback accompanying suggestions for de-escalation.

[00154] Actions performed by the different components of the monitoring environment 600 may be based on the vital information, actions, biometric readings, environmental recordings (e.g. loud noises, repeated movements, etc.) or other indicators that may indicate the behavior of concern is occurring. In one embodiment, the communications device 604 may act as a personal panic device for the client 602. For example, the client 602 may automatically request help by pressing a button on the communications device 604. The communications device 604 may also be enabled for voice communications or may include a walkie-talkie function. In one embodiment, the user 616 may include a similar communications device or may communicate with the client 602 utilizing an application run on both a communications device (not shown) controlled by the user 616 and an application run on the communications device 604 of the client 602.

[00155] The display 614 may represent a television, computer monitor, electronic glass, or other display component integrated with or attached to the floors, walls, ceiling, furniture, or other aspects of the monitoring environment 600. In one embodiment, the user 616 may utilize the camera 612 to provide audio and video feedback to the client 602 in any different room or section of the monitoring environment 600. For example, the user 616 may provide instructions for performing a calming ritual known to help the client 602 relax or face a phobia.

[00156] In one embodiment, a reinforcement recorder may be linked to the communications device 604. The communications device 604 may be utilized with the reinforcement recorder to provide the client 602 with positive reinforcement on a fixed or variable schedule. The reinforcement may be an auditory, visual, or tactile output that is automatically or manually generated. For example, if the client 602 is viewed as performing a cleaning act without prompting through the camera 612, the user 616 may utilize a cell phone to text a message that is routed to the communications device 604 telling the client 602 that he has done a good job.

[00157] The communications device 604 and the other monitoring equipment may also be utilized to monitor the health of the client 602. For example, the client 602 may have a heart

condition that may be monitored utilizing a pole, temperature, and position of the user 602. The communications device 604 may include accelerometers that may determine the location and position of the client 602. For example, the accelerometers of the communications device 604 may determine that the client 602 is lying down in a position that is not associated with his room or bed.

[00158] The communications device 604 is one example of a communications device that may record data associated with a client. Any number of communications device may be utilized simultaneously. Each communication device may be associated with a client profile or other unique identifier for distinguishing the data. As a result, any number of channels or frequencies may be utilized simultaneously. In one embodiment, the communications device 604 may include multiple transceivers for communicating utilizing a short range signal (when available) and transitioning to long distance communications (e.g., cell signals) when short range signals are unavailable. The communications device may be configured to display a time, date, text, video, audio, or tactile alerts. The communications device 604 may also be configured for simplex, half-duplex, or full duplex communications. The communications device 604 may include a touch screen, dedicated keys (e.g., panic button, voice communications, etc.), soft keys, volume indicator, and so forth. The communications device 604 may represent any number of existing or developing communications devices that interface with the system through communications and software.

[00159] The illustrative embodiments provide a number of advantages over the existing art. For example, the embodiments provide an automated AIM process for assessment that drives goals, services, and interventions. Goal management functionality allows goals to be defined, created, tracked and analyzed utilizing data. Goals may be separately stored on any number of micro and macro-levels for reference by other organizations, service providers, and individuals. The illustrative embodiments also provide a prompted data collection, calculation and analysis, and graphing process for information, such as a minimum growth line. Standardized and structured interpretations of data are presented graphically and statistically for review along with a definitive status.

[00160] The illustrative embodiments may provide an interface that displays clients assigned to a particular provider. By selecting a picture, icon, text, or avatar associated with the client 602, tracking information would be displayed for easy data entry related to one or more goals.

Data may be synched between any number of devices in response to changes saved on a single device. Similarly, alerts and notifications may be propagated through the system to applications and devices based on a user logged in or associated (permanently or temporarily) with the applications and devices. The reinforcement recorder may also be active on a device or application and may allow entry of specified reinforcement information for a client or group of clients to be entered. Medication and other sensitive or critical time-dependent information may be communicated via an audio, video, text, or tactile prompt at a set time interval prior to the event (e.g. prompt a provider to provide a client medication at a set time). All information related to an event, including the client 602, the medication with full dosage and administration instructions, and method for indicating the event is completed may be provided through the interface.

[00161] The illustrative embodiments also provide for a number of notifications and alerts. For example, real-time communications may be configured based on preset conditions and parameters (e.g., errors in user application, incomplete data collection or analysis, quality assurance audits, etc.). Stakeholder, team, or transdisciplinary communications are facilitated. For example, stakeholders may see what others have done on a case and automatic alerts are sent out to notify needed stakeholders so that the stakeholders may collaborate and form solutions. As a result, individual responsibility and ownership of issues are encouraged while increasing shared ownership and accountability. All data stored by the illustrative embodiments may be stored and analyzed through a set of standardized reports or customized reports based on user needs. Analysis of data may be utilized for individual client monitoring and may also look for trends in all levels of the hierarchy within the user and among a hierarchy of different users with similar purposes or roles. As a result, the system allows for process modifications at all levels that are associated with the most positive outcomes.

[00162] A browser, graphical user interface, or application as herein described may be utilized to provide an example of the embodiments labeled as Reliable Evidence-Based Outcomes Optimization Technologies or other applicable labels. The user interface may prompt to one or more users for logging in, creating a password, modifying a password, resetting a password, system administration for providers, searching, suggested searching, alert notification generation and display, customizing a workspace, portal, or dashboard, creating new providers, adding, modifying, and deleting providers, teams, service providers, and clients, client data, profiles, and

details, managing permissions, archiving users, creating and managing contacts, updating information, commenting, assigning caseloads, managing caseloads, establishing settings, tracking user activity, updating service information and plans, establishing, recording, tracking, and managing goals and objectives, establishing data collection methods and profiles, performing task analysis, ITT, interval recording, time recording, frequency, percentage recording data, creating episode records, indicating status and significance levels, AIM review, comments (e.g., text, audio, video, etc.), updating goals, goal activity, GMD, quick views, and data collection.

[00163] Progression towards reaching a goal and developing required skills may be broken down into manageable steps (e.g., numbered steps, labeled progression steps, etc.). In one embodiment, tips and strategies may be offered to the client, providers, administrators, parents/guardians, and other parties. Education and expectations may be managed with applicable information. The system may true up diagnosis with daily living, manage goal obtainment across the complete set of goals for the client, and automatically generate next steps or reaching the goals. During the process, the steps may create and learn what works for different clients to provide recommendations across providers, groups, organizations, businesses, government, and so forth.

[00164] As described in FIG. 6, the illustrative embodiments may be utilized with any number of imaging systems (HD cameras, infrared, multiple wavelength, etc.), medical devices, communications devices, cameras, or so forth to gather biometric feedback. The biometric feedback may be associated with one or more patients individually or as a group. In one embodiment, biometrics may include pulse rate, facial expressions, sweat analysis, retinal or pupil dilation, body heat output, galvanic skin response, respiration rate, voice stress analysis, or other indicators. In one embodiment, the patients may wear medical devices, such as bracelets, glasses, or headbands. The medical devices may be configured to determine any of the aforementioned biometrics. The biometrics may also be associated with known emotional responses or conditions, such as anger, fear, excitement, agitation, or so forth that may be utilized to intervene or take action. In one embodiment, the biometrics may be configured to generate alerts, such as an indication that a group is becoming agitated or an event may be about to occur, such as a fight or escalated argument.

[00165] As noted, the illustrative embodiments are HIPPA compliant and protect data privacy. The illustrative embodiments allow for monitoring and modification of medical and behavioral based outcomes. When used outside of a point of care or medical platform, the illustrative embodiments may utilize a HIPAA compliant client management program. The platform may represent the health system 100 and/or server 200 of FIG. 2.

[00166] In a hospital, home care, or point of care setting and account is established, and services providers and administrators establish goals for pre and post procedures, health improvement, and recovery-based goals for the client. The platform may assign and monitor client tests and teaching responses based on rules-based scoring to monitor specific thresholds and indicate when the thresholds are crossed. Alerts to the administrator or other users may serve to modify the client regimen, maintain the current course of action, or assign a new service provider to the client.

[00167] The illustrative embodiments provide the ability to monitor and modify healthcare and intervention plans, health-based goals and objectives through recorded activities, and notes from the service provider and administrator used for monitoring of healthcare and point of care outcomes for client success or failure. The client management system may help perform goal set up. For example, the goals and associated mastery level may be set or recommended based on the current status of the client. Goals may be established to be mastered through repetition and over time and not just achieved one time (e.g., exercising three times a week for 10 weeks, taking medication daily for three weeks, etc.).

[00168] The platform helps in reaching, achieving, and mastering specific health and point of care related goals by marking, measuring, and indicating the passing of specific thresholds related to health outcome mastery. The thresholds may also be used to indicate when there is a risk of not achieving a specific health related goal or outcome.

[00169] The platform monitors the time and occurrence of each client interaction and allows service providers and administrators to monitor the status of a client's goal-based outcomes progression and to establish and measure the data against a minimum growth line.

[00170] The platform may assign specific healthcare or point of care service providers to users and may modify the course of action based on thresholds, which are overseen by an

administrator who tracks and monitors the thresholds and progress of various outcome-based programs tied to user accounts.

[00171] The platform may differentiate itself by not allowing the healthcare data points to be determined by the discretion of the user alone, but rather the interaction with service providers and administrators. The interaction between the user, service providers, and administrators creates data used as a measurement tool that indicates the crossing of specific thresholds that are tracked in each interaction between the clients and the client management program or service providers. As a result, the data may be used to inform the instruction and guidance of the service providers and administrators which are weighed against specific established thresholds. These interactions are tracked via a cloud network or an internal private healthcare network.

[00172] The platform data includes healthcare and point of care goals and objectives, intervention plans, recorded activities, and general notes, which are overseen by the service provider and administrator. The data input related to the client account is measured against specific thresholds and the administrator may make recommendations to several service providers helping expand the reach and capacity of each administrator to help a greater number of clients reach a positive outcome.

[00173] The relational database management system performs data mining to analyze the data from the service providers to associate best practices with each of the individuals. This process is overseen by both the administrator and service providers.

[00174] FIG. 7 is a flowchart of a process for utilizing data in accordance with an illustrative embodiment. All or portions of the process of FIG. 7 may be implemented with the process of FIG. 5. The process of FIG. 7 may begin by tracking setup of an initial account (step 702). The initial account creation and follow-up user device interactions may be tracked by the client management program. The administrators and service providers may oversee the client management program. Each user may be provided a login for utilization over a secure network. Sometimes the login is provided through a referral for specific services. The addition of content may be performed at any time. In one embodiment, the client management system may learn from electronic medical records or electronic health records or their associated feeds. For example, external devices, systems, or software may communicate with the client management system based on permissions to compile applicable information.

[00175] Next, the system creates a client baseline (step 704). Input regarding the user (e.g., service provider) and/or patients may be received and stored as part of the initial account creation process. During account creation a client baseline may be established utilizing received data. The baseline goals may be derived from both administrator, user, and patient. For example, the user may provide input, responses, and communications through a number of devices based on questions, tests, recorded activities, notes, and assessments. The service providers and administrators receive data through a number of collection methods including task analysis, intensive trial teaching, interval recording, time recording, frequency, percentage data, and a reinforcement recorder. All of these processes for data gathering are administrator and service provider-based and the collection methods are measurable through client interaction with the system, service providers, and administrators. An assessment step may also be performed. For example, information applicable to physical, adaptive, social-emotional, cognitive, and communication domains may be performed. The system may also provide personalized recommendations. For example, applied behavior analysis (ABA) may be utilized to guide behavior and skill development for each domain, based on age equivalency, chronological age, user guidelines, practice-based evidence from treatment (e.g., in-home, educational, residential, facility-based, etc.), and other available data.

[00176] Next, the system assists creation of customized goals (step 706). In one embodiment, the client management program is used to track, tally and aid the service providers in creating customized goal-based recommendations from the user device interactions. In one embodiment, sensors (e.g., wearable, environmental, etc.) may automatically gather information for updating data, creating the client baseline (step 704) and creating customized goals (step 706). The system or administrators may recommend varied goal modules and plans of action to service providers based on the data gathered at the client management program stored in a secure server and accessed through a cloud network. During step 706, the system evaluates and analyzes the results through a threshold management tool which gives administrators and service providers the ability to tailor health and point of care outcomes to each user's interaction within the client management program.

[00177] The client responses at the device level may be based on the answers or responses to teaching, presentations, and reinforcement and may be compared against established thresholds. The thresholds may utilize predetermined scores derived from client responses and tracked at the

client management system. The data from each device interaction at the client management level may be derived from any client interactions or responses to predetermined prompts. The data for goal completion is delivered via device in computer generated from creating a visual representation report indicating the status of each goal completed, the progress and status of the current goal, and the next steps for the client to meet and reach those client-based needs. The system may facilitate easy data entry and automated status calculations. For example, push notifications may be communicated through the application for data entry. Data may be received and processed based on intervals, time periods, user requests, or based on specified events. The system may facilitate a simple response structure where possible (e.g., yes/no, numeric, etc.). Any number of soft buttons, scroll down menus, fields, or other selection components may be utilized.

[00178] Next, the system performs client services matching (step 708). Each interaction with the client management program are recorded and analyzed for establishing goals for the clients. The visual indicators of the system may show how and why changes to the goals, course of action, service providers, or services are matched to the client. Scores, compilations, or results may be utilized to perform client services matching (and may be part of step 712). The client services matching of step 708 may be performed at any time. The client may be matched to one or more new service providers that may better fit their needs at any time. For example, the client may be struggling with female service providers, and as a result, may be assigned to one or more male service providers that have a history of working well with clients with discipline issues. As noted, client services matching may be performed at any time in the best interests of the client. The system may utilize the client management system to track data points with regard to any client to determine whether changes to the client services/service providers may be required (e.g., based on tracking time of interaction, occurrences, occurrence frequency, thresholds, scores, etc.). The scores may be generated based on current and historical data. For example, artificial intelligence may utilize various rules to determine the score.

[00179] Next, the system determines whether modifications are required (step 710). The client management programs records positive, negative, and neutral client interactions to generate a score. The system may utilize visual indicators delivered to the client, service provider, and/or administrator to recommend whether modifications are required to the current course of action, goals, or so forth.

[00180] If the modifications are required in step 710, the system performs modifications for the client (step 712). In one embodiment, the system may determine modifications are required in response to passing a threshold. The threshold may be applicable to one or multiple factors, goals, parameters, or criteria. For example, when the total positive interactions have been reached and a specific threshold has been passed, a goal has been accomplished, positive encouragement may be sent to the user and the next goal may be established as part of the modifications of step 712.

[00181] If there are several negative or missed interactions with the system and the score or tall of negative interactions or missed goals has reached a specified threshold, the system may alert the administrator that the goal program and associated activities may need to be modified as part of steps 708 or 712. Any number of positive or negative modifications may be made during step 712 to help best adjust to the needs and best interests of the clients. The administrator and service providers may access the client responses to each service provider interactions at the client management system. These responses and tests may indicate a need for a change in service provider(s) based on client responses, exceeded thresholds, task analysis, intensive trial teaching, interval recording, time recording, frequency, percentage data, and/or a reinforcement recorder. The responses to the predetermined prompts are generated from device interactions or via interactions with matched service providers. The client responses at the device level may be based on the answers or responses to teaching, presentations, and reinforcement may be compared against established thresholds. The established thresholds may be based on predetermined scores derived from the client responses and tracked by the client management system.

[00182] The administrators and services providers may access client information (e.g., responses, monitoring, tests, evaluations, etc.) utilizing the client management system. The responses and tests may indicate a need for a change in service provider based on client responses, a positive or negative threshold being exceeded, task analysis, intensive trial teaching, interval recording, time recording, frequency, percentage data, a reinforcement recorder, or other applicable information and data. As noted, responses to predetermined prompts may be generated from device interactions or via interactions with matched service providers. If the modifications are not required in step 710, the process ends. In one embodiment, the modifications may not be required if the current parameters, settings, goals, and thresholds are

still functioning in the best interest of the client. For example, if the system determines there is a blend of positive and negative interactions, but the total interaction tally is not over or under a specified threshold, the system may determine there is no need for modifications to intervention efforts, goals, actions, or so forth.

[00183] In one embodiment, the system may be utilized for post-surgery outcomes for remote patient monitoring. The patient may be assigned to be monitored in the patient's home. The patient may invoke the system through a sign-up process and then may communicate at regular intervals or time periods. The client's actions may be tracked with regard to identified goals and whether those goals are met based on goal thresholds. The interactions, progress, and actions of the client are tracked by the client management program of the system for the purpose of data analysis, data collection, and data reporting. The system may utilize a rigorous evaluation process. The system may provide status updates periodically, based on events, or as needed. For example, any number of backend algorithms may be utilized to evaluate progress, lack of progress, regression, mastery, and regression from mastery. Any number of charts, spreadsheets, graphics, animations, visual aids, videos, audio files, or other content may be utilized to output the available information and data. The information and data may be displayed as part of a web portal, mobile application, program (e.g., cloud implemented, locally executed, etc.).

[00184] In one embodiment, the client may perform communications and input through their own device, such as a smart phone, tablet, or personal computer, or a provided device (e.g., facility associated, rented, leased, etc.). For example, positive indications of completed goals may record the positive progress as well as provide the client positive reinforcement. The goals may be established by the administrator and/or service providers and may range from goal-based task analysis, intensive trial teaching, interval recording, duration recording, frequency, recording, and percentage recording.

[00185] If the assigned goals are not being met and a specific threshold is not been crossed, the system may note the potential of a negative emotional or physical state. In this instant, a service provider may reach out directly to the client to address the problems or issues. If the service provider determines that there is a physical or emotional issue (e.g., depression, infection, medication complications, lack of effort, etc.), the service provider may record their observations, tests, or input in the system as part of the contact process. The data provided by the service provider may be verbal, biometric, measured, or so forth. For example, an indication

or diagnosis of depression may be performed based on a questionnaire focused on depression and observations or confirmations made by the service provider. Dates, times, and information associated each occurrence or detection of an occurrence may be saved by the client management program.

[00186] The client management program measures the client's initial response data which is matched to an initial service provider who may be the first point-of-contact. The first point-of-contact may be a key service provider or user responsible for the well-being of the client. The first-point-of-contact follows up with the client and indicates to the administrator(s) the results of follow up (e.g., depression questionnaire, testing, etc.) and recommendations for the client's goals or regimen. The administrator or service provider may then indicate to the appropriate services or departments, such as a healthcare provider, nurse, doctor, counselor, parent/guardian, or psychiatrist that there is a match for their services at the client level. The administrator or service providers may determine if the client's condition is naturally occurring or exacerbated by known or external factors, stimuli, or conditions (e.g., illegal drugs, post-traumatic stress disorder, family history, etc.). The causes of the issue affecting the client's behavior, health, or condition may affect the responses that are implemented.

[00187] The client management program may include and represent a provider interface and value-based decision-making platform. The client management program may include standardized libraries of clinical intervention content (e.g., goals, skills, thresholds, etc.). Various interventions may be selected based on outcomes and skill assessments. The client management program may provide a clear picture of client-based strengths and mastery from start to finish. Transparency is enhanced for all stakeholders that participate in a client's treatment, monitoring, and assistance. Data and applicable information may also be more seamlessly received and processed as initial input, feedback, critical updates, intervention information, and so forth for clients, providers, administrators, organizations, States, nations, and worldwide. As a result, professional and focused intervention services may be implemented. The commitment, processing, release, and discharge decision-making may be enhanced. Automated decisions regarding program and intervention may be made without administrator and provider feedback.

[00188] A detailed example of outcomes-based paths and scoring is provided for depression, but may be applicable to any number of health, behavioral, or other issues. FIGs. 8 and 9

illustrate pictorial representations of outcome-based paths and scoring for depression in accordance with illustrative embodiments. The user interface 800 illustrates a summary of outcome-based paths and scoring for depression. The user interface 800 may also be applicable to any number of conditions. In one embodiment, yes/no answers may be utilized to perform testing and scoring. For example, a yes answer may be associated with the associated points shown in the user interface 800. In another embodiment, some answers may subtract points (or add negative points).

[00189] In one embodiment, the user interface 800 may include the following questions that may be automatically posed, determined, or observed from the client: 1. Initial indication of depression at the client management program: Indicated a match for initial first points of contract consultation (+1 point); 2. Poor appetite or overeating cause of depression is dietary: Indicates the need for interaction with a Nutritionist (+ 1 point); 3. Little interest or pleasure in doing things: Indicates a match for interaction with a counselor, therapist or doctor (+1 point); 4. Feeling down, depressed, hopeless or cause of depression is unknown: Indicates a match for interaction with a counselor, therapist or doctor (+1 Point); 5. Trouble concentrating on things, such as reading the newspaper or watching television: Indicates a match for interaction with a counselor, therapist or doctor (+1 point); 6. Trouble falling or staying asleep, or sleeping too much: Indicates a match for interaction with a counselor, therapist or doctor (+1 point); 7. Feeling tired or having little energy: Indicates the need for interaction with a nutritionist (+ 1 point); 8. A family history of depression: Indicates the need for interaction with a therapist, doctor or psychologist (+2 point); 9. Feeling bad about yourself - or that you are a failure or have let yourself or your family down (+2 point); 10. Moving or speaking so slowly that other people could have noticed (+2 point); 11. Depression caused by improper medication or dosage: Indicates a match for an interaction with the clients psychiatrist, primary care physician or a match for an interaction with a pharmacist (+3 points); 12. A potential interaction with prescription medications: Indicates a match for interaction with a pharmacist and the client's doctors. (+4 points); 13. An illegal drug or Alcohol interaction: Indicates a match for interaction with a drug counselor, psychiatric care or medical intervention. (+5 points); 14. Post-Traumatic Stress Disorder (PTSD): Indicates the need for interaction with a Trauma or PTSD Specialist. (+6 points); Thoughts that you would be better off dead, or of hurting yourself (+7 points); and Suicidal thoughts: Indicate the need for interaction with Suicide Prevention or grief counselor (+7 points).

[00190] FIG. 9 is a pictorial representation of a user interface 900 for outcome-based scoring in accordance with an illustrative embodiment. The user interface 900 may request information of administrators, providers, or clients, such as the following: A. Do you want to collect data all day Yes/No; If not, Data Collection from _____ time to _____ time (9 pm daily); B. What is the desired goal and score? (_____) baseline under X); C. Choose collection limit: (Exactly) At Least; D. Across how many opportunities? ____ out of ____ (Measure baseline daily); E. How would you like your data calculated and graphed? (Cumulative and Average); F. For how long do you want (subject) to maintain the score in order to consider this goal/objective mastered? (___) out of (___) (average interval) of (___) months; G. Projected closure data for goal/objective (timeline to master or reassess) 6 months; H. Y axis label - Y/N; I. Baseline mode—(on) or off; J. Option to add to goal bank: Y/N; K. Goal Instructions/Directions; L. Special permissions related to data collection - Y/N; M. Alert recipients - Y/N; and N. Customized modification to data analysis rules if applicable Y/N. Any number of additional questions may also be posed utilizing an application, graphical user interface, or so forth.

[00191] The data and results from the system may be delivered to any number or type of care teams through systems, interfaces, or other communications interfaces, such as augmented reality, health faults, biometric displays, avatars, dashboards, health coaches, integrated platforms, education systems, applications, and so forth.

[00192] As will be appreciated by one skilled in the art, aspects of the present inventive subject matter may be embodied as a system, method or computer program product. Accordingly, aspects of the present inventive subject matter may take the form of an entirely hardware embodiment, an entirely software embodiment (including firmware, resident software, micro-code, etc.) or an embodiment combining software and hardware aspects that may all generally be referred to herein as a "circuit," "module" or "system." Furthermore, aspects of the present inventive subject matter may take the form of a computer program product embodied in one or more computer readable medium(s) having computer readable program code embodied thereon.

[00193] Any combination of one or more computer readable medium(s) may be utilized. The computer readable medium may be a computer readable signal medium or a computer readable storage medium. A computer readable storage medium may be, for example, but not limited to, an electronic, magnetic, optical, electromagnetic, infrared, or semiconductor system, apparatus,

or device, or any suitable combination of the foregoing. More specific examples (a non-exhaustive list) of the computer readable storage medium would include the following: an electrical connection having one or more wires, a portable computer diskette, a hard disk, a random access memory (RAM), a read-only memory (ROM), an erasable programmable read-only memory (EPROM or Flash memory), an optical fiber, a portable compact disc read-only memory (CD-ROM), an optical storage device, a magnetic storage device, or any suitable combination of the foregoing. In the context of this document, a computer readable storage medium may be any tangible medium that may contain, or store a program for use by or in connection with an instruction execution system, apparatus, or device.

[00194] A computer readable signal medium may include a propagated data signal with computer readable program code embodied therein, for example, in baseband or as part of a carrier wave. Such a propagated signal may take any of a variety of forms, including, but not limited to, electro-magnetic, optical, or any suitable combination thereof. A computer readable signal medium may be any computer readable medium that is not a computer readable storage medium and that can communicate, propagate, or transport a program for use by or in connection with an instruction execution system, apparatus, or device.

[00195] Program code embodied on a computer readable medium may be transmitted using any appropriate medium, including but not limited to wireless, wireline, optical fiber cable, RF, etc., or any suitable combination of the foregoing.

[00196] Computer program code for carrying out operations for aspects of the present inventive subject matter may be written in any combination of one or more programming languages, including an object-oriented programming language such as Java, Smalltalk, C++ or the like and conventional procedural programming languages, such as the "C" programming language or similar programming languages. The program code may execute entirely on the user's computer, partly on the user's computer, as a stand-alone software package, partly on the user's computer and partly on a remote computer or entirely on the remote computer or server. In the latter scenario, the remote computer may be connected to the user's computer through any type of network, including a local area network (LAN) or a wide area network (WAN), or the connection may be made to an external computer (for example, through the Internet using an Internet Service Provider).

[00197] Aspects of the present inventive subject matter are described with reference to flowchart illustrations and/or block diagrams of methods, apparatus (systems) and computer program products according to embodiments of the inventive subject matter. It will be understood that each block of the flowchart illustrations and/or block diagrams, and combinations of blocks in the flowchart illustrations and/or block diagrams, may be implemented by computer program instructions. These computer program instructions may be provided to a processor of a general-purpose computer, special purpose computer, or other programmable data processing apparatus to produce a machine, such that the instructions, which execute via the processor of the computer or other programmable data processing apparatus, create means for implementing the functions/acts specified in the flowchart and/or block diagram block or blocks.

[00198] These computer program instructions may also be stored in a computer readable medium that can direct a computer, other programmable data processing apparatus, or other devices to function in a particular manner, such that the instructions stored in the computer readable medium produce an article of manufacture including instructions which implement the function/act specified in the flowchart and/or block diagram block or blocks.

[00199] The computer program instructions may also be loaded onto a computer, other programmable data processing apparatus, or other devices to cause a series of operational steps to be performed on the computer, other programmable apparatus or other devices to produce a computer implemented process such that the instructions which execute on the computer or other programmable apparatus provide processes for implementing the functions/acts specified in the flowchart and/or block diagram block or blocks.

[00200] Figure 1 depicts an example server 106. The server and other computer systems of FIG. 1 may include a processor unit (possibly including multiple processors, multiple cores, multiple nodes, and/or implementing multi-threading, etc.). The server 106 includes a memory. The memory may be system memory (e.g., one or more of cache, SRAM, DRAM, zero capacitor RAM, Twin Transistor RAM, eDRAM, EDO RAM, DDR RAM, EEPROM, NRAM, RRAM, SONOS, PRAM, etc.) or any one or more of the above already described possible realizations of machine-readable media. The computer system also includes a bus YY03 (e.g., PCI, ISA, PCI-Express, HyperTransport®, InfiniBand®, NuBus, etc.), a network interface YY05 (e.g., an ATM interface, an Ethernet interface, a Frame Relay interface, SONET interface, wireless interface, etc.), and a storage device(s) or database (e.g., optical storage, magnetic storage, etc.). In one

embodiment, the system memory or database 108 associated with the server embodies functionality to implement embodiments described above.

[00201] In addition, any one of these functionalities may be partially (or entirely) implemented in hardware and/or on the processing unit of the server 106. For example, the functionality may be implemented with an application specific integrated circuit, in logic implemented in the processing unit, in a co-processor on a peripheral device or card, etc. Further, realizations may include fewer or additional components not illustrated in FIG. 1 (e.g., video cards, audio cards, additional network interfaces, peripheral devices, etc.).

[00202] FIG. 10 is a pictorial representation of a user interface 1000 in accordance with an illustrative embodiment. The user interface 1000 may be utilized to provide information to administrators, providers, and users. For example, the user interface 1000 may communicate goal information applicable to one or more users.

[00203] In one embodiment, the user interface 1000 may visually, textually, and/or numerically display information regarding wellness, stress, performance, sleep, blood pressure, heart rate, respiration rate, oxygen levels (e.g., SPO2), activity level, ECG, hydration, body mass index, skin temperature, altitude, steps, and fall detection. The user interface 1000 may also display an overall graphic for the goals indicating active goals and archived goals. Profile information, such as name, age, total mastered goals, and other applicable information may be displayed by the user interface 1000.

[00204] FIGs. 11-16 are pictorial representations of interfaces of a mobile application in accordance with an illustrative embodiment. In one embodiment, the interfaces of the mobile application may display information applicable to the components of the user interface 1000 of FIG 10. The various data, information, and biometrics may be determined by wearable sensors (e.g., smart watches, armbands, chest straps, hearables, smart hearing aids, smart headbands, etc.), environmental sensors, or other devices utilized by administrators, providers, or users.

[00205] Charts and graphs may be displayed for the applicable measurements per time period. For example, more detailed information may be shown by specific day, week, month, year, event, or so forth. In one embodiment, a user interface 1100 displays blood pressure information. A user interface 1200 may display heart rate information. A user interface 1300

may display respiration rate information. A user interface 1400 may display an activity level of the user.

[00206] In one embodiment, the illustrative embodiments may perform remote patient care utilizing any number of systems, devices, and methods as incorporated by reference from application number 15/876,815 filed on January 22, 2018 and the associated priority applications which are incorporated by reference in its entirety. For example, any number of devices may be utilized to capture applicable data. In one process, a system may receive a prescription from a medical professional for remote patient care. The remote patient care may be prescribed by a doctor, nurse, psychologist/psychiatrist, physician's assistant, nurse practitioner, or other authorized medical professional. The patient monitoring may be performed utilizing any number of wireless devices, wearables, hearables, smart clothing, blood pressure monitors, glucose monitors, heart rate monitors, blood oxygen monitors, or so forth whether consumer or hospital grade. The monitoring and communication of applicable patient data may be performed through any number of electronic devices to any number of networks. For example, applicable information may be captured from a weight scale and heart rate monitor without smart features.

[00207] Next, the system enables user downloads a remote monitoring application to one or more associated devices. The remote monitoring application may represent one or more mobile applications, desktop programs, or so forth. The remote monitoring application may also represent a dedicated and secured webpage for receiving information from the user/patient. In one embodiment, an identifier, pin, password, secure link, secure access process, or prescription number may be required to download the remote monitoring application. For example, a pin may be communicated to the patient through a text messaging system to ensure that the patient is authorized to download and use the remote monitoring application.

[00208] Next, the system begins remote patient monitoring. The remote patient monitoring may be performed automatically utilizing one or more sensors or monitoring components of the applicable devices. The remote patient monitoring may also be performed in response to user input to the associated device (e.g., positioning the device on or in the body of the patient, powering on the device, receiving a user selection of a button, soft button, or selection component, etc.). As previously disclosed, the remote patient monitoring may be performed utilizing a number of devices, such as image data captured by a smart phone from a weight scale and blood pressure cuff.

[00209] The intrinsic codes of the illustrative embodiments provide artificial intelligence and machine learning. The illustrative embodiments may particularly implement big data analytics, machine and deep learning, human like reasoning, continuous real-time and deep learning, traceable justification and casual reason for decision outputs, interoperability (e.g., handling logical contradictions, data incompleteness, etc.). The illustrative embodiments are utilized to perform logical and causal reasoning (e.g., inference/reasoning, multi-phase logic, conceptualization, exploration, scenarios/what-ifs, fuzzy logic, and dynamic fight/flight mitigation. The client data may be analyzed utilizing algorithms, pattern analysis, perceptions, recognition/identification, statistical co-occurrence, multi-sensor perceptions, and Bayesian/dissipative recognition.

[00210] FIGs. 14 and 15 illustrate user interfaces 1700, 1800, 1900, 2000, 2100, and 2200. The user interface 1700 may show information for a patient. In particular, the user interface 1700 may be utilized to empower and engage the patient, increase the quality of care, reduces costs, and facilitate the progress of the patient (e.g., evaluate where the patient is now, determine what is possible and how to get there, monitor and illustrate success, provide support when off-track, celebrate functional autonomy, etc.). The user interface 1700 may communicate a picture, avatar, or profile for updating or communicating assessments, goals, settings, or information (e.g., physical, adaptive, social-emotional, cognitive, communications, etc.).

[00211] The user interface 1800 may provide information for the user to with the mobile application to record information, such as exercise, medication, and communications. The user interface 1800 may be utilized to update information and send communications. For example, the user interface 1900 may track progress of taking their medication. The user interface 1900 may be utilized for guided applied behavior analysis (ABA) and skill development. The information may be used for each domain, based on age equivalency, chronological age, and other available data, using guidelines for the primary evidence-based treatment intervention, and tailored according to practice-based evidence. For example, the treatment (e.g., in-home, educational, residential, facility-based, etc.) may be performed for individuals with autism spectrum disorder.

[00212] The user interface 2000 may also be utilized to facilitate reaching specified goals. Goal setup may allow the provider to specify terms, conditions, and parameters for the goal. For

example, the user interface 2000 may track the efforts of the patient to take medications on her own and at the right time a number of times per week.

[00213] The user interface 2100 may be utilized track goals and applicable information including progress, lack of progress, mastery, and regression from mastery. The user interface 2200 may be utilized to track administrators, family members, friends, and providers that have access to the patient's information. For example, permissions may viewed or edited from the user interface 2100.

[00214] The illustrative embodiments are utilized to enhance patient engagement. The continuous engagement of the patient may be performed utilizing health data, risk analysis, risk reduction, care planning, and outcomes to ensure that the patient receives the right care at the right place and time. The illustrative embodiments utilize real time data, historical data, and intrinsic code to determine outcomes. The illustrative embodiments may also be implemented with other artificial intelligence systems, networks, equipment, devices, or algorithms to enhance performance of all or portions of the illustrative embodiments. The illustrative embodiments may utilize reasoning, expressive representation language, broad knowledge, context, and other applicable information, data, or metadata to determine applicable information. In some embodiments, the applicable data and information may be communicated transparently for administrators, providers, parents, and other stakeholders. For parties that are not authorized to receive the information, identifying for personal information may be removed. As a result, collaboration, responsibility, open evaluations, and progression become more of a focus.

[00215] While the embodiments are described with reference to various implementations and exploitations, it will be understood that these embodiments are illustrative and that the scope of the inventive subject matter is not limited to them. In general, techniques for managing goals and outcomes for organizations, groups or individuals as described herein may be implemented with facilities consistent with any hardware system or hardware systems. Many variations, modifications, additions, and improvements are possible.

[00216] Plural instances may be provided for components, operations or structures described herein as a single instance. Finally, boundaries between various components, operations and data stores are somewhat arbitrary, and particular operations are illustrated in the context of specific illustrative configurations. Other allocations of functionality are envisioned and may

fall within the scope of the inventive subject matter. In general, structures and functionality presented as separate components in the exemplary configurations may be implemented as a combined structure or component. Similarly, structures and functionality presented as a single component may be implemented as separate components. These and other variations, modifications, additions, and improvements may fall within the scope of the inventive subject matter.

WHAT IS CLAIMED IS:

1. A method for tracking goal progression, the method comprising:

receiving input establishing clients, wherein the clients are individuals receiving treatment or assistance, and wherein the data associated with the clients is stored in a server available through one or more networks;

assigning each of the clients to one or more of the providers in response to selections from an administrator, wherein the one or more providers include at least individuals available to treat or assist each of the clients and one or more biometric devices associated with each of the clients;

establishing goals for each of the clients;

compiling data associated with each of the clients received from the one or more providers in the server;

determining whether the goals are being met in response to thresholds for the compiled data; and

automatically communicating alerts in response to the compiled data varying from a threshold to become significant for one or more of the clients.

2. The method according to claim 1, wherein the server is accessed through a cloud network, and wherein a client management program is executed by communications devices utilized by the one or more providers to receive the data and track progress of the goals.

3. The method according to claim 1, further comprising:

intervening with the one or more of the clients in response to the alerts.

4. The method according to claim 3, wherein the intervening is performed by the one or more providers.

5. The method according to claim 1, wherein each of the goals is associated with a plan of action for achieving each of the goals.

6. The method according to claim 1, further comprising:

establishing a baseline for the goals of the clients.

7. The method according to claim 1, wherein the goals are established by the clients and the one or more providers.

8. The method according to claim 1, further comprising:

determining whether modifications to the goals are required in response to the compiled data.

9. The method according to claim 8, further comprising:

modifying the goals in response to the compiled data.

10. The method according to claim 8, wherein modifications are determined to be required if the one of the clients is unable to achieve the goals associated with the client.

11. A system for tracking goal progression, the system comprising:

a server communicates with communications devices through a transceiver utilizing one or more networks, the server includes a processor that executes a client management program to:

receive input establishing a client, wherein the client is a individual receiving treatment or assistance, and wherein an account associated with the client is stored in a server available through one or more networks;

assign the client to one or more of the providers in response to selections from an administrator, wherein the one or more providers include at least individuals available to treat or assist the client and one or more biometric devices associated with the client;

establish goals for the client;

compile data associated with the client received from the one or more providers in the server;

determine whether the goals are being met in response to thresholds for the compiled data; and

automatically communicate alerts in response to the compiled data varying from a threshold to become significant for the client; and

a database in communication with the server configured to store at least the data, goals, and thresholds associated with the client and the one or more providers.

12. The system according to claim 11, wherein the communications devices receive the data from the one or more providers.

13. The system according to claim 11, wherein the alerts indicate that the one or more providers are to intervene with the client.

14. The system according to claim 11, wherein each of the goals is associated with a plan of action for achieving each of the goals.

15. The system according to claim 11, wherein the goals are established by the client and the one or more providers.

16. The system according to claim 11, wherein the client management program is further executed to:

determine whether modifications to the goals are required in response to the compiled data indicating the goals are not achievable; and

modify the goals in response to the compiled data indicating the goals are not achievable.

17. A server comprising:

a processor for executing a set of instructions; and

a memory for storing the set of instructions, wherein the set of instructions are executed by the processor to:

receive input establishing clients receiving assistance, wherein the clients are individuals receiving treatment or assistance, and wherein the accounts are stored in a server available through one or more networks;

assign each of the clients to one or more of the providers in response to selections from an administrator, wherein the one or more providers

include at least individuals available to treat or assist each of the clients and one or more biometric devices associated with each of the clients;

establish goals for each of the clients;

compile data associated with each of the clients received from the one or more providers in the server;

determine whether the goals are being met in response to thresholds for the compiled data; and

automatically communicate alerts in response to the compiled data varying from a threshold to become significant for one or more of the clients.

18. The server according to claim 17, wherein the set of instructions are further executed to:

physically intervene with the one or more of the clients in response to the alerts, wherein the physical intervention is performed by the one or more providers.

19. The server according to claim 17, wherein each of the goals is associated with a plan of action for achieving each of the goals, wherein the goals are established by the client and the one or more providers.

20. The server according to claim 17, wherein the set of instructions are further executed to:

Determine whether modifications to the goals are required in response to the compiled data; and

Modify the goals in response to determining the modifications to the goals are required.

ABSTRACT OF THE DISCLOSURE

A system, method, server, and computer readable medium for tracking goal progression. Input is received establishing clients. The clients are individuals receiving treatment or assistance. Each of the clients are assigned to one or more providers in response to selections from an administrator. The one or more providers include at least individuals available to treat or assist each of the clients and one or more biometric devices associated with the clients. Goals are established for each of the clients. Data associated with each of the clients is compiled as received from the one or more providers in the server. A determination is made where the goals are being met in response to the thresholds for the compiled data. Alerts are automatically communicated in response to the compiled data varying from a threshold to become significant for one or more of the clients.

PTO/AIA/01 (06-12)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	Platform for Optimizing Goal Progression

As the below named inventor, I hereby declare that:

This declaration is directed to:

- [■] The attached application, or
- [ ] United States application or PCT international application number _____

filed on _____.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Nathaniel T. Bradley Date (Optional) :_____

Signature: Nathaniel T. Bradley

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	Platform for Optimizing Goal Progression

As the below named inventor, I hereby declare that:

This declaration is directed to:

- [■] The attached application, or
- [ ] United States application or PCT international application number _____

filed on _____.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: James Gaynor Date (Optional) :_____

Signature: _____

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	Platform for Optimizing Goal Progression

As the below named inventor, I hereby declare that:

This declaration is directed to:

- [■] The attached application, or
- [ ] United States application or PCT international application number _____

filed on _____.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Joshua S. Paugh Date (Optional) :_____

Signature: Joshua S. Paugh

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	Platform for Optimizing Goal Progression

As the below named inventor, I hereby declare that:

This declaration is directed to:

- [■] The attached application, or
- [ ] United States application or PCT international application number _____

filed on _____.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Paul Arena Date (Optional) :_____

Signature: Paul R. Arena

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/82A (07-13)
Approved for use through 03/31/2021. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FOR POWER OF ATTORNEY TO ONE OR MORE REGISTERED PRACTITIONERS

NOTE: This form is to be submitted with the Power of Attorney by Applicant form (PTO/AIA/82B) to identify the application to which the Power of Attorney is directed, in accordance with 37 CFR 1.5, unless the application number and filing date are identified in the Power of Attorney by Applicant form. If neither form PTO/AIA/82A nor form PTO/AIA82B identifies the application to which the Power of Attorney is directed, the Power of Attorney will not be recognized in the application.

Application Number	
Filing Date	
First Named Inventor	Nathaniel T. Bradley
Title	SYSTEM AND METHOD FOR ACHIEVING GOAL PROGRESSION
Art Unit	
Examiner Name	
Attorney Docket Number	PBH-P0001CIP1

SIGNATURE of Applicant or Patent Practitioner

Signature	/Brian D. Owens/	Date (Optional)	
Name	Brian Dean Owens	Registration Number	55517
Title (if Applicant is a juristic entity)			
Applicant Name (if Applicant is a juristic entity)			

NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4(d) for signature requirements and certifications. If more than one applicant, use multiple forms.

☐ *Total of _____ forms are submitted.

This collection of information is required by 37 CFR 1.131, 1.32, and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Doc Code: PA..
Document Description: Power of Attorney

PTO/AIA/82B (07-13)
Approved for use through 01/31/2018. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

POWER OF ATTORNEY BY APPLICANT

I hereby revoke all previous powers of attorney given in the application identified in either the attached transmittal letter or the boxes below.

Application Number	Filing Date

(Note: The boxes above may be left blank if information is provided on form PTO/AIA/82A.)

☑ I hereby appoint the Patent Practitioner(s) associated with the following Customer Number as my/our attorney(s) or agent(s), and to transact all business in the United States Patent and Trademark Office connected therewith for the application referenced in the attached transmittal letter (form PTO/AIA/82A) or identified above: 133690

OR

☐ I hereby appoint Practitioner(s) named in the attached list (form PTO/AIA/82C) as my/our attorney(s) or agent(s), and to transact all business in the United States Patent and Trademark Office connected therewith for the patent application referenced in the attached transmittal letter (form PTO/AIA/82A) or identified above. (Note: Complete form PTO/AIA/82C.)

Please recognize or change the correspondence address for the application identified in the attached transmittal letter or the boxes above to:

☑ The address associated with the above-mentioned Customer Number

OR

☐ The address associated with Customer Number:

OR

☐ Firm or Individual Name					
Address					
City		State		Zip	
Country					
Telephone		Email			

I am the Applicant (if the Applicant is a juristic entity, list the Applicant name in the box):

Parallax Behavioral Health, Inc.

☐ Inventor or Joint Inventor (title not required below)

☐ Legal Representative of a Deceased or Legally Incapacitated Inventor (title not required below)

☑ Assignee or Person to Whom the Inventor is Under an Obligation to Assign (provide signer's title if applicant is a juristic entity)

☐ Person Who Otherwise Shows Sufficient Proprietary Interest (e.g., a petition under 37 CFR 1.46(b)(2) was granted in the application or is concurrently being filed with this document) (provide signer's title if applicant is a juristic entity)

SIGNATURE of Applicant for Patent

The undersigned (whose title is supplied below) is authorized to act on behalf of the applicant (e.g., where the applicant is a juristic entity).

Signature	/Nathan Bradley/	Date (Optional)	
Name	Nathan Bradley		
Title	Chief Technology Officer, Parallax Behavioral Health, Inc.		

NOTE: Signature - This form must be signed by the applicant in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and certifications. If more than one applicant, use multiple forms.

☐ Total of forms are submitted.

This collection of information is required by 37 CFR 1.131, 1.32, and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



112
126
128
130
124
118
116
122
120
1/15
114
142
140
136
138
134
100
102
103
108
106
104
110

FIG. 1



Server
200
Processor
202
Memory
204
Database
206
Logic
208
User Interface
210
System Administrators
212
Provider Administrators
214
Service Providers
216
Settings
218
Permissions
220
Users
222
Clients
224
234
236
Data
226
238
240
Alerts and Notifications
228
Reporting
230
Interface
232
Networks
242
246
248
Systems
244

FIG. 2



Recorded Data Module
300
Task Analysis
302
Intensive Trial Teaching
304
Interval Recording
306
Duration Recording
308
Frequency Recording
310
Percentage Recording
312

FIG. 3

400

Task	Level of Prompt Needed					
Walk into bathroom	Refused 0	Hand-over-hand 1	Touch 2	Gestural 3	Verbal 4	Independent 5
Pick up toothbrush	Refused 0	Hand-over-hand 1	Touch 2	Gestural 3	Verbal 4	Independent 5
Put toothpaste on brush	Refused 0	Hand-over-hand 1	Touch 2	Gestural 3	Verbal 4	Independent 5
Brush teeth for 30 seconds	Refused 0	Hand-over-hand 1	Touch 2	Gestural 3	Verbal 4	Independent 5
Return brush and paste	Refused 0	Hand-over -hand 1	Touch 2	Gestural 3	Verbal 4	Independent 5
Rinse mouth	Refused 0	Hand-over-hand 1	Touch 2	Gestural 3	Verbal 4	Independent 5
Dry hands	Refused	Hand-over-hand 1	Touch 2	Gestural 3	Verbal 4	Indepen dent 5

402

Highest Possible	Obtained	Percentage
35	18	51

FIG. 4



BEGIN
Prompt a user to enter fields and information for generating a goal, data collection method, and graphing set-up
502
Create a goal narrative and display fields needed for data collection
504
Receive data from users and prompt for any required data not collected
506
DATA COLLECTED PROPERLY?
508
Send an alert to the service provider indicating there is missing data
508
Analyze the received data and graph for display
508

FIG. 5




FIG. 6



BEGIN
Track setup of initial accounts
702
Create a client baseline
704
Assist creation of customized goals
706
Perform client services matching
708
Modifications required?
710
END
Yes
Perform modifications for the client
712

FIG. 7

OUTCOME BASED PATHS AND SCORING FOR DEPRESSION	800

- Initial indication of depression at the client management program: Indicated a match for initial first points of contract consultation +1
- Poor appetite or overeating cause of depression is dietary: Indicates the need for interaction with a Nutritionist + 1
- Little interest or pleasure in doing things: Indicates a match for interaction with a counselor, therapist or doctor +1
- Feeling down, depressed, hopeless or Cause of depression is unknown: Indicates a match for interaction with a counselor, therapist or doctor +1
- Trouble concentrating on things, such as reading the newspaper or watching television: Indicates a match for interaction with a counselor, therapist or doctor +1
- Trouble falling or staying asleep, or sleeping too much: Indicates a match for interaction with a counselor, therapist or doctor +1
- Feeling tired or having little energy: Indicates the need for interaction with a Nutritionist + 1
- A family history of depression: Indicates the need for interaction with a therapist, doctor or psychologist +2
- Feeling bad about yourself - or that you are a failure or have let yourself or your family down +2
- Moving or speaking so slowly that other people could have noticed +2
- Depression caused by improper medication or dosage: Indicates a match for an interaction with the clients psychiatrist, primary care physician or a match for an interaction with a pharmacist +3
- A potential interaction with prescription medications: Indicates a match for interaction with a pharmacist and the client's doctors. +4
- An illegal drug or Alcohol interaction: Indicates a match for interaction with a drug counselor, psychiatric care or medical intervention. +5
- Post Traumatic Stress Disorder (PTSD): Indicates the need for interaction with a Trauma or PTSD Specialist. +6
- Thoughts that you would be better off dead, or of hurting yourself +7
- Suicidal thoughts: Indicate the need for interaction with Suicide Prevention or grief counselor. +7

FIG. 8

OUTCOME BASED PATHS AND SCORING FOR DEPRESSION	900

A. Do you want to collect data all day Yes/ No

If not, Data Collection from _____ time to _____ time (9pm daily)

B. What is the desired goal and score? (_____) baseline under X)

C. Choose collection limit: (Exactly) At Least

D. Across how many opportunities? _ out of _ (Measure baseline daily)

E. How would you like your data calculated and graphed? (Cumulative and Average)

F. For how long do you want (subject) to maintain the score in order to consider this goal/ objective mastered? (_) out of (_) (average interval) of (_) months

G. Projected closure data for goal/objective (timeline to master or reassess) 6 months

H. Y axis label - Y/N

I. Baseline mode—(on) or off

J. Option to add to goal bank: Y/N

K. Goal Instructions/Directions

L. Special permissions related to data collection - Y/N

M. Alert recipients - Y/N

N. Customized modification to data analysis rules if applicable Y/N

FIG. 9



Active Goals Status - My Profiles
1000
Total Goals - My Profiles
317
My Profiles

FIG. 10




FIG. 11




FIG. 12




FIG. 13


1700
Judie
1800
Next Check In
2 Hours
EXCERCISE
MEDICATION
NEED TO TALK?
1900
MEDICATION
Eliminated
LAST STEP
PROGRESS
2nd STEP
1st STEP

FIG. 14



2000
TAKES MEDICINE ON TIME
How many times a week can Judie do this now?
Judie's Goal will be to do this 5 out of 7 times per week for 1 week.
2100
ON TRACK
LABS DUE TODAY
LATE FOLLOW UP
GREAT JOB!
KEEP IT UP!
2200
Barbara
Smith
Ashley
Dr. Reeves
Dr. Sorrels

FIG. 15

SCORE Placeholder Sheet for IFW Content

Application Number: 17499725 Document Date: 10/12/2021

The presence of this form in the IFW record indicates that the following document type was received in electronic format on the date identified above. This content is stored in the SCORE database.

Since this was an electronic submission, there is no physical artifact folder, no artifact folder is recorded in PALM, and no paper documents or physical media exist. The TIFF images in the IFW record were created from the original documents that are stored in SCORE.

- Drawing

At the time of document entry (noted above):

- USPTO employees may access SCORE content via DAV or via the SCORE web page.
- External customers may access SCORE content via PAIR using the Supplemental Content tab.

Form Revision Date: March 1, 2019